id	sid	tid	token	lemma	pos
gs-3919	1	1	microsoft	microsoft	PROPN
gs-3919	1	2	word	word	NOUN
gs-3919	1	3	fullpdf07032025	fullpdf07032025	PROPN
gs-3919	1	4	georgian	georgian	ADJ
gs-3919	1	5	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	1	6	მეცნიერები	მეცნიერები	NOUN
gs-3919	1	7	ტ.	ტ.	VERB
gs-3919	1	8	7	7	NUM
gs-3919	1	9	n	n	PRON
gs-3919	1	10	3	3	NUM
gs-3919	1	11	,	,	PUNCT
gs-3919	1	12	2025	2025	NUM
gs-3919	1	13	141	141	NUM
gs-3919	1	14	georgian	georgian	PROPN
gs-3919	1	15	scientists	scientist	NOUN
gs-3919	1	16	ქართველი	ქართველი	ADJ
gs-3919	1	17	მეცნიერები	მეცნიერები	PROPN
gs-3919	1	18	vol	vol	NOUN
gs-3919	1	19	.	.	PUNCT
gs-3919	1	20	7	7	NUM
gs-3919	1	21	issue	issue	NOUN
gs-3919	1	22	3	3	NUM
gs-3919	1	23	,	,	PUNCT
gs-3919	1	24	2025	2025	NUM
gs-3919	1	25	https://doi.org/10.52340/gs.2025.07.03.13	https://doi.org/10.52340/gs.2025.07.03.13	NOUN
gs-3919	2	1	the	the	DET
gs-3919	2	2	scientific	scientific	ADJ
gs-3919	2	3	discussion	discussion	NOUN
gs-3919	2	4	of	of	ADP
gs-3919	2	5	key	key	ADJ
gs-3919	2	6	issue	issue	NOUN
gs-3919	2	7	aspects	aspect	NOUN
gs-3919	2	8	of	of	ADP
gs-3919	2	9	immunopathogenesis	immunopathogenesis	NOUN
gs-3919	2	10	and	and	CCONJ
gs-3919	2	11	pharmacological	pharmacological	NOUN
gs-3919	2	12	properties	property	NOUN
gs-3919	2	13	and	and	CCONJ
gs-3919	2	14	profiles	profile	NOUN
gs-3919	2	15	in	in	ADP
gs-3919	2	16	relation	relation	NOUN
gs-3919	2	17	to	to	ADP
gs-3919	2	18	adverse	adverse	ADJ
gs-3919	2	19	drug	drug	NOUN
gs-3919	2	20	reactions	reaction	NOUN
gs-3919	2	21	challenges	challenge	NOUN
gs-3919	2	22	,	,	PUNCT
gs-3919	2	23	focus	focus	VERB
gs-3919	2	24	on	on	ADP
gs-3919	2	25	multidimensional	multidimensional	ADJ
gs-3919	2	26	drug	drug	NOUN
gs-3919	2	27	-	-	PUNCT
gs-3919	2	28	induced	induce	VERB
gs-3919	2	29	eosinophilia	eosinophilia	NOUN
gs-3919	2	30	and	and	CCONJ
gs-3919	2	31	systemic	systemic	ADJ
gs-3919	2	32	syndrome	syndrome	PROPN
gs-3919	2	33	nodar	nodar	PROPN
gs-3919	2	34	sulashvili1	sulashvili1	PROPN
gs-3919	2	35	,	,	PUNCT
gs-3919	2	36	rupali	rupali	VERB
gs-3919	2	37	digambar	digambar	PROPN
gs-3919	2	38	jadhav2	jadhav2	PROPN
gs-3919	2	39	,	,	PUNCT
gs-3919	2	40	margarita	margarita	PROPN
gs-3919	2	41	beglaryan3	beglaryan3	PROPN
gs-3919	2	42	,	,	PUNCT
gs-3919	2	43	luiza	luiza	PROPN
gs-3919	2	44	gabunia4	gabunia4	PROPN
gs-3919	2	45	,	,	PUNCT
gs-3919	2	46	nana	nana	PROPN
gs-3919	2	47	gorgaslidze5	gorgaslidze5	PROPN
gs-3919	2	48	,	,	PUNCT
gs-3919	2	49	nato	nato	PROPN
gs-3919	2	50	alavidze6	alavidze6	PROPN
gs-3919	2	51	,	,	PUNCT
gs-3919	2	52	natia	natia	PROPN
gs-3919	2	53	kvizhinadze7	kvizhinadze7	PROPN
gs-3919	2	54	,	,	PUNCT
gs-3919	2	55	marika	marika	PROPN
gs-3919	2	56	sulashvili8	sulashvili8	PROPN
gs-3919	2	57	lela	lela	PROPN
gs-3919	2	58	grigolia9	grigolia9	PROPN
gs-3919	2	59	,	,	PUNCT
gs-3919	2	60	kakhaber	kakhaber	NOUN
gs-3919	2	61	robakidze10	robakidze10	NOUN
gs-3919	2	62	1scientific	1scientific	NUM
gs-3919	2	63	supervisor	supervisor	NOUN
gs-3919	2	64	,	,	PUNCT
gs-3919	2	65	md	md	PROPN
gs-3919	2	66	,	,	PUNCT
gs-3919	2	67	phd	phd	NOUN
gs-3919	2	68	,	,	PUNCT
gs-3919	2	69	doctor	doctor	NOUN
gs-3919	2	70	of	of	ADP
gs-3919	2	71	pharmaceutical	pharmaceutical	ADJ
gs-3919	2	72	and	and	CCONJ
gs-3919	2	73	pharmacological	pharmacological	ADJ
gs-3919	2	74	sciences	science	NOUN
gs-3919	2	75	in	in	ADP
gs-3919	2	76	medicine	medicine	NOUN
gs-3919	2	77	,	,	PUNCT
gs-3919	2	78	invited	invite	VERB
gs-3919	2	79	lecturer	lecturer	NOUN
gs-3919	2	80	(	(	PUNCT
gs-3919	2	81	invited	invite	VERB
gs-3919	2	82	professor	professor	NOUN
gs-3919	2	83	)	)	PUNCT
gs-3919	2	84	of	of	ADP
gs-3919	2	85	scientific	scientific	ADJ
gs-3919	2	86	research	research	NOUN
gs-3919	2	87	-	-	PUNCT
gs-3919	2	88	skills	skill	NOUN
gs-3919	2	89	center	center	NOUN
gs-3919	2	90	at	at	ADP
gs-3919	2	91	tbilisi	tbilisi	PROPN
gs-3919	2	92	state	state	PROPN
gs-3919	2	93	medical	medical	PROPN
gs-3919	2	94	university	university	PROPN
gs-3919	2	95	;	;	PUNCT
gs-3919	2	96	professor	professor	NOUN
gs-3919	2	97	of	of	ADP
gs-3919	2	98	medical	medical	ADJ
gs-3919	2	99	and	and	CCONJ
gs-3919	2	100	clinical	clinical	ADJ
gs-3919	2	101	pharmacology	pharmacology	NOUN
gs-3919	2	102	of	of	ADP
gs-3919	2	103	international	international	ADJ
gs-3919	2	104	school	school	NOUN
gs-3919	2	105	of	of	ADP
gs-3919	2	106	medicine	medicine	NOUN
gs-3919	2	107	at	at	ADP
gs-3919	2	108	alte	alte	PROPN
gs-3919	2	109	university	university	PROPN
gs-3919	2	110	;	;	PUNCT
gs-3919	2	111	professor	professor	NOUN
gs-3919	2	112	of	of	ADP
gs-3919	2	113	pharmacology	pharmacology	NOUN
gs-3919	2	114	of	of	ADP
gs-3919	2	115	faculty	faculty	NOUN
gs-3919	2	116	of	of	ADP
gs-3919	2	117	medicine	medicine	NOUN
gs-3919	2	118	at	at	ADP
gs-3919	2	119	georgian	georgian	PROPN
gs-3919	2	120	national	national	PROPN
gs-3919	2	121	university	university	PROPN
gs-3919	2	122	seu	seu	NOUN
gs-3919	2	123	;	;	PUNCT
gs-3919	2	124	associate	associate	ADJ
gs-3919	2	125	affiliated	affiliate	VERB
gs-3919	2	126	professor	professor	NOUN
gs-3919	2	127	of	of	ADP
gs-3919	2	128	medical	medical	ADJ
gs-3919	2	129	pharmacology	pharmacology	NOUN
gs-3919	2	130	of	of	ADP
gs-3919	2	131	faculty	faculty	NOUN
gs-3919	2	132	of	of	ADP
gs-3919	2	133	medicine	medicine	NOUN
gs-3919	2	134	at	at	ADP
gs-3919	2	135	sulkhan	sulkhan	PROPN
gs-3919	2	136	-	-	PUNCT
gs-3919	2	137	saba	saba	PROPN
gs-3919	2	138	orbeliani	orbeliani	PROPN
gs-3919	2	139	university	university	PROPN
gs-3919	2	140	;	;	PUNCT
gs-3919	2	141	associate	associate	NOUN
gs-3919	2	142	professor	professor	NOUN
gs-3919	2	143	of	of	ADP
gs-3919	2	144	pharmacology	pharmacology	NOUN
gs-3919	2	145	of	of	ADP
gs-3919	2	146	pharmacy	pharmacy	NOUN
gs-3919	2	147	program	program	NOUN
gs-3919	2	148	at	at	ADP
gs-3919	2	149	shota	shota	PROPN
gs-3919	2	150	meskhia	meskhia	PROPN
gs-3919	2	151	zugdidi	zugdidi	PROPN
gs-3919	2	152	state	state	PROPN
gs-3919	2	153	university	university	PROPN
gs-3919	2	154	;	;	PUNCT
gs-3919	2	155	associate	associate	NOUN
gs-3919	2	156	professor	professor	NOUN
gs-3919	2	157	of	of	ADP
gs-3919	2	158	medical	medical	ADJ
gs-3919	2	159	pharmacology	pharmacology	NOUN
gs-3919	2	160	at	at	ADP
gs-3919	2	161	school	school	NOUN
gs-3919	2	162	of	of	ADP
gs-3919	2	163	medicine	medicine	NOUN
gs-3919	2	164	at	at	ADP
gs-3919	2	165	david	david	PROPN
gs-3919	2	166	aghmashenebeli	aghmashenebeli	PROPN
gs-3919	2	167	university	university	PROPN
gs-3919	2	168	of	of	ADP
gs-3919	2	169	georgia	georgia	PROPN
gs-3919	2	170	;	;	PUNCT
gs-3919	2	171	associate	associate	NOUN
gs-3919	2	172	professor	professor	NOUN
gs-3919	2	173	of	of	ADP
gs-3919	2	174	biochemistry	biochemistry	NOUN
gs-3919	2	175	and	and	CCONJ
gs-3919	2	176	pharmacology	pharmacology	NOUN
gs-3919	2	177	direction	direction	NOUN
gs-3919	2	178	of	of	ADP
gs-3919	2	179	school	school	NOUN
gs-3919	2	180	of	of	ADP
gs-3919	2	181	health	health	NOUN
gs-3919	2	182	sciences	science	NOUN
gs-3919	2	183	at	at	ADP
gs-3919	2	184	the	the	DET
gs-3919	2	185	university	university	PROPN
gs-3919	2	186	of	of	ADP
gs-3919	2	187	georgia	georgia	PROPN
gs-3919	2	188	;	;	PUNCT
gs-3919	2	189	associate	associate	NOUN
gs-3919	2	190	professor	professor	NOUN
gs-3919	2	191	of	of	ADP
gs-3919	2	192	pharmacology	pharmacology	NOUN
gs-3919	2	193	of	of	ADP
gs-3919	2	194	faculty	faculty	NOUN
gs-3919	2	195	of	of	ADP
gs-3919	2	196	medicine	medicine	NOUN
gs-3919	2	197	at	at	ADP
gs-3919	2	198	east	east	PROPN
gs-3919	2	199	european	european	PROPN
gs-3919	2	200	university	university	PROPN
gs-3919	2	201	;	;	PUNCT
gs-3919	2	202	associate	associate	NOUN
gs-3919	2	203	professor	professor	NOUN
gs-3919	2	204	of	of	ADP
gs-3919	2	205	pharmacology	pharmacology	NOUN
gs-3919	2	206	of	of	ADP
gs-3919	2	207	faculty	faculty	NOUN
gs-3919	2	208	of	of	ADP
gs-3919	2	209	dentistry	dentistry	NOUN
gs-3919	2	210	and	and	CCONJ
gs-3919	2	211	pharmacy	pharmacy	NOUN
gs-3919	2	212	at	at	ADP
gs-3919	2	213	tbilisi	tbilisi	ADJ
gs-3919	2	214	humanitarian	humanitarian	ADJ
gs-3919	2	215	teaching	teaching	NOUN
gs-3919	2	216	university	university	NOUN
gs-3919	2	217	;	;	PUNCT
gs-3919	2	218	tbilisi	tbilisi	PROPN
gs-3919	2	219	,	,	PUNCT
gs-3919	2	220	georgia	georgia	PROPN
gs-3919	2	221	;	;	PUNCT
gs-3919	2	222	researcher	researcher	NOUN
gs-3919	2	223	of	of	ADP
gs-3919	2	224	department	department	PROPN
gs-3919	2	225	of	of	ADP
gs-3919	2	226	pharmaceutical	pharmaceutical	ADJ
gs-3919	2	227	management	management	NOUN
gs-3919	2	228	of	of	ADP
gs-3919	2	229	yerevan	yerevan	PROPN
gs-3919	2	230	state	state	PROPN
gs-3919	2	231	medical	medical	PROPN
gs-3919	2	232	university	university	PROPN
gs-3919	2	233	after	after	ADP
gs-3919	2	234	mkhitar	mkhitar	NOUN
gs-3919	2	235	heratsi	heratsi	PROPN
gs-3919	2	236	,	,	PUNCT
gs-3919	2	237	yerevan	yerevan	PROPN
gs-3919	2	238	,	,	PUNCT
gs-3919	2	239	armenia	armenia	PROPN
gs-3919	2	240	.	.	PUNCT
gs-3919	3	1	orcid	orcid	PROPN
gs-3919	3	2	https://orcid.org/0000-0002-9005-8577	https://orcid.org/0000-0002-9005-8577	PROPN
gs-3919	3	3	e	e	NOUN
gs-3919	3	4	-	-	NOUN
gs-3919	3	5	mail	mail	NOUN
gs-3919	3	6	:	:	PUNCT
gs-3919	3	7	n.sulashvili@ug.edu.ge	n.sulashvili@ug.edu.ge	PROPN
gs-3919	3	8	2md	2md	NOUN
gs-3919	4	1	©	©	NOUN
gs-3919	4	2	,	,	PUNCT
gs-3919	4	3	12	12	NUM
gs-3919	4	4	-	-	PUNCT
gs-3919	4	5	th	th	NUM
gs-3919	4	6	semester	semester	NOUN
gs-3919	4	7	student	student	NOUN
gs-3919	4	8	of	of	ADP
gs-3919	4	9	md	md	PROPN
gs-3919	4	10	medical	medical	PROPN
gs-3919	4	11	doctor	doctor	NOUN
gs-3919	4	12	degree	degree	NOUN
gs-3919	4	13	student	student	NOUN
gs-3919	4	14	of	of	ADP
gs-3919	4	15	international	international	ADJ
gs-3919	4	16	school	school	NOUN
gs-3919	4	17	of	of	ADP
gs-3919	4	18	medicine	medicine	NOUN
gs-3919	4	19	at	at	ADP
gs-3919	4	20	alte	alte	PROPN
gs-3919	4	21	university	university	PROPN
gs-3919	4	22	;	;	PUNCT
gs-3919	4	23	tbilisi	tbilisi	PROPN
gs-3919	4	24	,	,	PUNCT
gs-3919	4	25	georgia	georgia	PROPN
gs-3919	4	26	;	;	PUNCT
gs-3919	4	27	3md	3md	NOUN
gs-3919	4	28	,	,	PUNCT
gs-3919	4	29	phd	phd	NOUN
gs-3919	4	30	,	,	PUNCT
gs-3919	4	31	doctor	doctor	NOUN
gs-3919	4	32	of	of	ADP
gs-3919	4	33	pharmaceutical	pharmaceutical	NOUN
gs-3919	4	34	sciences	science	NOUN
gs-3919	4	35	,	,	PUNCT
gs-3919	4	36	academician	academician	NOUN
gs-3919	4	37	,	,	PUNCT
gs-3919	4	38	professor	professor	NOUN
gs-3919	4	39	of	of	ADP
gs-3919	4	40	yerevan	yerevan	PROPN
gs-3919	4	41	state	state	PROPN
gs-3919	4	42	medical	medical	PROPN
gs-3919	4	43	university	university	PROPN
gs-3919	4	44	after	after	ADP
gs-3919	4	45	mkhitar	mkhitar	NOUN
gs-3919	4	46	heratsi	heratsi	PROPN
gs-3919	4	47	,	,	PUNCT
gs-3919	4	48	head	head	NOUN
gs-3919	4	49	of	of	ADP
gs-3919	4	50	the	the	DET
gs-3919	4	51	department	department	PROPN
gs-3919	4	52	of	of	ADP
gs-3919	4	53	pharmaceutical	pharmaceutical	NOUN
gs-3919	4	54	management	management	NOUN
gs-3919	4	55	,	,	PUNCT
gs-3919	4	56	president	president	NOUN
gs-3919	4	57	of	of	ADP
gs-3919	4	58	association	association	PROPN
gs-3919	4	59	phesa	phesa	PROPN
gs-3919	4	60	(	(	PUNCT
gs-3919	4	61	pharmacy	pharmacy	NOUN
gs-3919	4	62	and	and	CCONJ
gs-3919	4	63	pharmacology	pharmacology	NOUN
gs-3919	4	64	education	education	NOUN
gs-3919	4	65	and	and	CCONJ
gs-3919	4	66	science	science	NOUN
gs-3919	4	67	association	association	PROPN
gs-3919	4	68	)	)	PUNCT
gs-3919	4	69	,	,	PUNCT
gs-3919	4	70	yerevan	yerevan	PROPN
gs-3919	4	71	,	,	PUNCT
gs-3919	4	72	armenia	armenia	PROPN
gs-3919	4	73	;	;	PUNCT
gs-3919	4	74	https://orcid.org/0000-00033697-6390	https://orcid.org/0000-00033697-6390	PROPN
gs-3919	4	75	4md	4md	NOUN
gs-3919	4	76	,	,	PUNCT
gs-3919	4	77	phd	phd	NOUN
gs-3919	4	78	,	,	PUNCT
gs-3919	4	79	doctor	doctor	NOUN
gs-3919	4	80	of	of	ADP
gs-3919	4	81	medical	medical	ADJ
gs-3919	4	82	sciences	sciences	PROPN
gs-3919	4	83	,	,	PUNCT
gs-3919	4	84	professor	professor	NOUN
gs-3919	4	85	,	,	PUNCT
gs-3919	4	86	director	director	NOUN
gs-3919	4	87	of	of	ADP
gs-3919	4	88	the	the	DET
gs-3919	4	89	scientific	scientific	ADJ
gs-3919	4	90	research	research	NOUN
gs-3919	4	91	-	-	PUNCT
gs-3919	4	92	skills	skill	NOUN
gs-3919	4	93	center	center	NOUN
gs-3919	4	94	at	at	ADP
gs-3919	4	95	tbilisi	tbilisi	PROPN
gs-3919	4	96	state	state	PROPN
gs-3919	4	97	medical	medical	PROPN
gs-3919	4	98	university	university	PROPN
gs-3919	4	99	,	,	PUNCT
gs-3919	4	100	professor	professor	NOUN
gs-3919	4	101	,	,	PUNCT
gs-3919	4	102	head	head	NOUN
gs-3919	4	103	of	of	ADP
gs-3919	4	104	the	the	DET
gs-3919	4	105	department	department	PROPN
gs-3919	4	106	of	of	ADP
gs-3919	4	107	medical	medical	ADJ
gs-3919	4	108	and	and	CCONJ
gs-3919	4	109	clinical	clinical	ADJ
gs-3919	4	110	pharmacology	pharmacology	NOUN
gs-3919	4	111	at	at	ADP
gs-3919	4	112	tbilisi	tbilisi	PROPN
gs-3919	4	113	state	state	PROPN
gs-3919	4	114	medical	medical	PROPN
gs-3919	4	115	university	university	PROPN
gs-3919	4	116	,	,	PUNCT
gs-3919	4	117	clinical	clinical	ADJ
gs-3919	4	118	pharmacologist	pharmacologist	NOUN
gs-3919	4	119	of	of	ADP
gs-3919	4	120	the	the	DET
gs-3919	4	121	first	first	ADJ
gs-3919	4	122	university	university	NOUN
gs-3919	4	123	clinic	clinic	NOUN
gs-3919	4	124	of	of	ADP
gs-3919	4	125	tbilisi	tbilisi	PROPN
gs-3919	4	126	state	state	PROPN
gs-3919	4	127	medical	medical	PROPN
gs-3919	4	128	university	university	PROPN
gs-3919	4	129	,	,	PUNCT
gs-3919	4	130	tbilisi	tbilisi	PROPN
gs-3919	4	131	,	,	PUNCT
gs-3919	4	132	georgia	georgia	PROPN
gs-3919	4	133	https://orcid.org/0000-0003-0856-2684	https://orcid.org/0000-0003-0856-2684	PROPN
gs-3919	4	134	5md	5md	PROPN
gs-3919	4	135	,	,	PUNCT
gs-3919	4	136	phd	phd	NOUN
gs-3919	4	137	,	,	PUNCT
gs-3919	4	138	doctor	doctor	NOUN
gs-3919	4	139	of	of	ADP
gs-3919	4	140	pharmaceutical	pharmaceutical	NOUN
gs-3919	4	141	sciences	science	NOUN
gs-3919	4	142	,	,	PUNCT
gs-3919	4	143	academician	academician	NOUN
gs-3919	4	144	,	,	PUNCT
gs-3919	4	145	professor	professor	NOUN
gs-3919	4	146	of	of	ADP
gs-3919	4	147	tbilisi	tbilisi	PROPN
gs-3919	4	148	state	state	PROPN
gs-3919	4	149	medical	medical	PROPN
gs-3919	4	150	university	university	PROPN
gs-3919	4	151	,	,	PUNCT
gs-3919	4	152	head	head	NOUN
gs-3919	4	153	of	of	ADP
gs-3919	4	154	the	the	DET
gs-3919	4	155	department	department	NOUN
gs-3919	4	156	of	of	ADP
gs-3919	4	157	social	social	ADJ
gs-3919	4	158	and	and	CCONJ
gs-3919	4	159	clinical	clinical	ADJ
gs-3919	4	160	pharmacy	pharmacy	NOUN
gs-3919	4	161	,	,	PUNCT
gs-3919	4	162	tbilisi	tbilisi	PROPN
gs-3919	4	163	,	,	PUNCT
gs-3919	4	164	georgia	georgia	PROPN
gs-3919	4	165	.	.	PUNCT
gs-3919	5	1	https://orcid.org/0000-0002-4563-5224	https://orcid.org/0000-0002-4563-5224	PROPN
gs-3919	5	2	6md	6md	PROPN
gs-3919	5	3	,	,	PUNCT
gs-3919	5	4	phd	phd	NOUN
gs-3919	5	5	,	,	PUNCT
gs-3919	5	6	doctor	doctor	NOUN
gs-3919	5	7	of	of	ADP
gs-3919	5	8	pharmaceutical	pharmaceutical	NOUN
gs-3919	5	9	sciences	science	NOUN
gs-3919	5	10	,	,	PUNCT
gs-3919	5	11	professor	professor	NOUN
gs-3919	5	12	of	of	ADP
gs-3919	5	13	akaki	akaki	PROPN
gs-3919	5	14	tsereteli	tsereteli	PROPN
gs-3919	5	15	state	state	PROPN
gs-3919	5	16	university	university	PROPN
gs-3919	5	17	,	,	PUNCT
gs-3919	5	18	faculty	faculty	NOUN
gs-3919	5	19	of	of	ADP
gs-3919	5	20	medicine	medicine	NOUN
gs-3919	5	21	,	,	PUNCT
gs-3919	5	22	department	department	NOUN
gs-3919	5	23	of	of	ADP
gs-3919	5	24	pharmacy	pharmacy	NOUN
gs-3919	5	25	,	,	PUNCT
gs-3919	5	26	kutaisi	kutaisi	PROPN
gs-3919	5	27	,	,	PUNCT
gs-3919	5	28	georgia	georgia	PROPN
gs-3919	5	29	.	.	PUNCT
gs-3919	6	1	professor	professor	PROPN
gs-3919	6	2	,	,	PUNCT
gs-3919	6	3	dean	dean	PROPN
gs-3919	6	4	faculty	faculty	NOUN
gs-3919	6	5	of	of	ADP
gs-3919	6	6	medicine	medicine	NOUN
gs-3919	6	7	at	at	ADP
gs-3919	6	8	east	east	PROPN
gs-3919	6	9	european	european	PROPN
gs-3919	6	10	university	university	PROPN
gs-3919	6	11	,	,	PUNCT
gs-3919	6	12	tbilisi	tbilisi	PROPN
gs-3919	6	13	,	,	PUNCT
gs-3919	6	14	georgia	georgia	PROPN
gs-3919	6	15	.	.	PUNCT
gs-3919	7	1	https://orcid.org/0000-0001-6695-5924	https://orcid.org/0000-0001-6695-5924	PROPN
gs-3919	7	2	7md	7md	PROPN
gs-3919	7	3	,	,	PUNCT
gs-3919	7	4	phd	phd	NOUN
gs-3919	7	5	,	,	PUNCT
gs-3919	7	6	doctor	doctor	NOUN
gs-3919	7	7	of	of	ADP
gs-3919	7	8	pharmaceutical	pharmaceutical	NOUN
gs-3919	7	9	sciences	science	NOUN
gs-3919	7	10	,	,	PUNCT
gs-3919	7	11	professor	professor	NOUN
gs-3919	7	12	of	of	ADP
gs-3919	7	13	tbilisi	tbilisi	PROPN
gs-3919	7	14	state	state	PROPN
gs-3919	7	15	medical	medical	PROPN
gs-3919	7	16	university	university	PROPN
gs-3919	7	17	,	,	PUNCT
gs-3919	7	18	department	department	NOUN
gs-3919	7	19	of	of	ADP
gs-3919	7	20	social	social	ADJ
gs-3919	7	21	and	and	CCONJ
gs-3919	7	22	clinical	clinical	ADJ
gs-3919	7	23	pharmacy	pharmacy	NOUN
gs-3919	7	24	;	;	PUNCT
gs-3919	7	25	tbilisi	tbilisi	PROPN
gs-3919	7	26	,	,	PUNCT
gs-3919	7	27	georgia	georgia	PROPN
gs-3919	7	28	.	.	PUNCT
gs-3919	8	1	8md	8md	ADJ
gs-3919	8	2	,	,	PUNCT
gs-3919	8	3	doctor	doctor	NOUN
gs-3919	8	4	of	of	ADP
gs-3919	8	5	family	family	NOUN
gs-3919	8	6	medicine	medicine	NOUN
gs-3919	8	7	,	,	PUNCT
gs-3919	8	8	invited	invite	VERB
gs-3919	8	9	lecturer	lecturer	NOUN
gs-3919	8	10	of	of	ADP
gs-3919	8	11	tbilisi	tbilisi	PROPN
gs-3919	8	12	state	state	PROPN
gs-3919	8	13	medical	medical	PROPN
gs-3919	8	14	university	university	PROPN
gs-3919	8	15	,	,	PUNCT
gs-3919	8	16	department	department	NOUN
gs-3919	8	17	of	of	ADP
gs-3919	8	18	molecular	molecular	ADJ
gs-3919	8	19	and	and	CCONJ
gs-3919	8	20	medical	medical	ADJ
gs-3919	8	21	genetics	genetic	NOUN
gs-3919	8	22	,	,	PUNCT
gs-3919	8	23	invited	invite	VERB
gs-3919	8	24	lecturer	lecturer	NOUN
gs-3919	8	25	of	of	ADP
gs-3919	8	26	genetics	genetic	NOUN
gs-3919	8	27	and	and	CCONJ
gs-3919	8	28	molecular	molecular	ADJ
gs-3919	8	29	biology	biology	NOUN
gs-3919	8	30	of	of	ADP
gs-3919	8	31	international	international	ADJ
gs-3919	8	32	school	school	NOUN
gs-3919	8	33	of	of	ADP
gs-3919	8	34	medicine	medicine	NOUN
gs-3919	8	35	at	at	ADP
gs-3919	8	36	alte	alte	PROPN
gs-3919	8	37	georgian	georgian	PROPN
gs-3919	8	38	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	8	39	მეცნიერები	მეცნიერები	NOUN
gs-3919	8	40	ტ.	ტ.	VERB
gs-3919	8	41	7	7	NUM
gs-3919	8	42	n	n	DET
gs-3919	8	43	3	3	NUM
gs-3919	8	44	,	,	PUNCT
gs-3919	8	45	2025	2025	NUM
gs-3919	8	46	142	142	NUM
gs-3919	8	47	university	university	NOUN
gs-3919	8	48	;	;	PUNCT
gs-3919	8	49	invited	invite	VERB
gs-3919	8	50	professor	professor	NOUN
gs-3919	8	51	of	of	ADP
gs-3919	8	52	biochemistry	biochemistry	NOUN
gs-3919	8	53	and	and	CCONJ
gs-3919	8	54	molecular	molecular	ADJ
gs-3919	8	55	and	and	CCONJ
gs-3919	8	56	medical	medical	ADJ
gs-3919	8	57	genetics	genetic	NOUN
gs-3919	8	58	at	at	ADP
gs-3919	8	59	the	the	DET
gs-3919	8	60	university	university	PROPN
gs-3919	8	61	of	of	ADP
gs-3919	8	62	georgia	georgia	PROPN
gs-3919	8	63	.	.	PUNCT
gs-3919	9	1	tbilisi	tbilisi	PROPN
gs-3919	9	2	,	,	PUNCT
gs-3919	9	3	georgia	georgia	PROPN
gs-3919	9	4	.	.	PUNCT
gs-3919	10	1	orcid	orcid	PROPN
gs-3919	10	2	https://orcid.org/0000-0002-6338-4262	https://orcid.org/0000-0002-6338-4262	PROPN
gs-3919	10	3	.	.	PUNCT
gs-3919	11	1	9md	9md	NOUN
gs-3919	11	2	,	,	PUNCT
gs-3919	11	3	phd	phd	NOUN
gs-3919	11	4	,	,	PUNCT
gs-3919	11	5	doctor	doctor	NOUN
gs-3919	11	6	of	of	ADP
gs-3919	11	7	medical	medical	ADJ
gs-3919	11	8	sciences	science	NOUN
gs-3919	11	9	,	,	PUNCT
gs-3919	11	10	professor	professor	NOUN
gs-3919	11	11	of	of	ADP
gs-3919	11	12	faculty	faculty	NOUN
gs-3919	11	13	of	of	ADP
gs-3919	11	14	medicine	medicine	NOUN
gs-3919	11	15	at	at	ADP
gs-3919	11	16	caucasus	caucasus	PROPN
gs-3919	11	17	international	international	PROPN
gs-3919	11	18	university	university	PROPN
gs-3919	11	19	;	;	PUNCT
gs-3919	11	20	tbilisi	tbilisi	PROPN
gs-3919	11	21	,	,	PUNCT
gs-3919	11	22	georgia	georgia	PROPN
gs-3919	11	23	;	;	PUNCT
gs-3919	11	24	10md	10md	NUM
gs-3919	11	25	,	,	PUNCT
gs-3919	11	26	phd	phd	NOUN
gs-3919	11	27	,	,	PUNCT
gs-3919	11	28	doctor	doctor	NOUN
gs-3919	11	29	of	of	ADP
gs-3919	11	30	medical	medical	ADJ
gs-3919	11	31	sciences	science	NOUN
gs-3919	11	32	,	,	PUNCT
gs-3919	11	33	academician	academician	NOUN
gs-3919	11	34	,	,	PUNCT
gs-3919	11	35	professor	professor	NOUN
gs-3919	11	36	of	of	ADP
gs-3919	11	37	faculty	faculty	NOUN
gs-3919	11	38	of	of	ADP
gs-3919	11	39	medicine	medicine	NOUN
gs-3919	11	40	at	at	ADP
gs-3919	11	41	caucasus	caucasus	PROPN
gs-3919	11	42	international	international	PROPN
gs-3919	11	43	university	university	PROPN
gs-3919	11	44	;	;	PUNCT
gs-3919	11	45	doctor	doctor	NOUN
gs-3919	11	46	-	-	PUNCT
gs-3919	11	47	professor	professor	NOUN
gs-3919	11	48	of	of	ADP
gs-3919	11	49	national	national	PROPN
gs-3919	11	50	health	health	PROPN
gs-3919	11	51	center	center	NOUN
gs-3919	11	52	named	name	VERB
gs-3919	11	53	after	after	ADP
gs-3919	11	54	academician	academician	PROPN
gs-3919	11	55	o.	o.	PROPN
gs-3919	11	56	gudushauri	gudushauri	PROPN
gs-3919	11	57	;	;	PUNCT
gs-3919	11	58	tbilisi	tbilisi	PROPN
gs-3919	11	59	,	,	PUNCT
gs-3919	11	60	georgia	georgia	PROPN
gs-3919	11	61	;	;	PUNCT
gs-3919	11	62	corresponding	correspond	VERB
gs-3919	11	63	author	author	NOUN
gs-3919	11	64	:	:	PUNCT
gs-3919	11	65	dr	dr	PROPN
gs-3919	11	66	.	.	PROPN
gs-3919	11	67	professor	professor	PROPN
gs-3919	11	68	nodar	nodar	PROPN
gs-3919	11	69	sulashvili	sulashvili	PROPN
gs-3919	11	70	mail	mail	NOUN
gs-3919	11	71	:	:	PUNCT
gs-3919	11	72	n.sulashvili@ug.edu.ge	n.sulashvili@ug.edu.ge	NOUN
gs-3919	11	73	mob	mob	NOUN
gs-3919	11	74	:	:	PUNCT
gs-3919	11	75	+995	+995	ADJ
gs-3919	11	76	-	-	ADJ
gs-3919	11	77	597	597	NUM
gs-3919	11	78	-	-	PUNCT
gs-3919	11	79	12	12	NUM
gs-3919	11	80	-	-	PUNCT
gs-3919	11	81	17	17	NUM
gs-3919	11	82	-	-	SYM
gs-3919	11	83	28	28	NUM
gs-3919	11	84	abstract	abstract	ADJ
gs-3919	11	85	drug	drug	NOUN
gs-3919	11	86	-	-	PUNCT
gs-3919	11	87	induced	induce	VERB
gs-3919	11	88	eosinophilia	eosinophilia	NOUN
gs-3919	11	89	and	and	CCONJ
gs-3919	11	90	systemic	systemic	ADJ
gs-3919	11	91	symptoms	symptom	NOUN
gs-3919	11	92	(	(	PUNCT
gs-3919	11	93	dies	die	NOUN
gs-3919	11	94	)	)	PUNCT
gs-3919	11	95	represent	represent	VERB
gs-3919	11	96	a	a	DET
gs-3919	11	97	complex	complex	ADJ
gs-3919	11	98	and	and	CCONJ
gs-3919	11	99	potentially	potentially	ADV
gs-3919	11	100	life	life	NOUN
gs-3919	11	101	-	-	PUNCT
gs-3919	11	102	threatening	threaten	VERB
gs-3919	11	103	spectrum	spectrum	NOUN
gs-3919	11	104	of	of	ADP
gs-3919	11	105	adverse	adverse	ADJ
gs-3919	11	106	drug	drug	NOUN
gs-3919	11	107	reactions	reaction	NOUN
gs-3919	11	108	characterized	characterize	VERB
gs-3919	11	109	by	by	ADP
gs-3919	11	110	eosinophilic	eosinophilic	ADJ
gs-3919	11	111	infiltration	infiltration	NOUN
gs-3919	11	112	and	and	CCONJ
gs-3919	11	113	multiorgan	multiorgan	NOUN
gs-3919	11	114	involvement	involvement	NOUN
gs-3919	11	115	.	.	PUNCT
gs-3919	12	1	this	this	DET
gs-3919	12	2	review	review	NOUN
gs-3919	12	3	synthesizes	synthesize	VERB
gs-3919	12	4	current	current	ADJ
gs-3919	12	5	knowledge	knowledge	NOUN
gs-3919	12	6	on	on	ADP
gs-3919	12	7	the	the	DET
gs-3919	12	8	pharmacological	pharmacological	NOUN
gs-3919	12	9	,	,	PUNCT
gs-3919	12	10	immunological	immunological	ADJ
gs-3919	12	11	,	,	PUNCT
gs-3919	12	12	and	and	CCONJ
gs-3919	12	13	clinical	clinical	ADJ
gs-3919	12	14	aspects	aspect	NOUN
gs-3919	12	15	of	of	ADP
gs-3919	12	16	these	these	DET
gs-3919	12	17	reactions	reaction	NOUN
gs-3919	12	18	,	,	PUNCT
gs-3919	12	19	with	with	ADP
gs-3919	12	20	particular	particular	ADJ
gs-3919	12	21	emphasis	emphasis	NOUN
gs-3919	12	22	on	on	ADP
gs-3919	12	23	severe	severe	ADJ
gs-3919	12	24	manifestations	manifestation	NOUN
gs-3919	12	25	such	such	ADJ
gs-3919	12	26	as	as	ADP
gs-3919	12	27	drug	drug	NOUN
gs-3919	12	28	reaction	reaction	NOUN
gs-3919	12	29	with	with	ADP
gs-3919	12	30	eosinophilia	eosinophilia	PROPN
gs-3919	12	31	and	and	CCONJ
gs-3919	12	32	systemic	systemic	ADJ
gs-3919	12	33	symptoms	symptom	NOUN
gs-3919	12	34	(	(	PUNCT
gs-3919	12	35	dress	dress	NOUN
gs-3919	12	36	)	)	PUNCT
gs-3919	12	37	.	.	PUNCT
gs-3919	13	1	we	we	PRON
gs-3919	13	2	examine	examine	VERB
gs-3919	13	3	the	the	DET
gs-3919	13	4	mechanisms	mechanism	NOUN
gs-3919	13	5	by	by	ADP
gs-3919	13	6	which	which	PRON
gs-3919	13	7	specific	specific	ADJ
gs-3919	13	8	drug	drug	NOUN
gs-3919	13	9	classes	class	NOUN
gs-3919	13	10	—	—	PUNCT
gs-3919	13	11	including	include	VERB
gs-3919	13	12	aromatic	aromatic	ADJ
gs-3919	13	13	antiepileptics	antiepileptic	NOUN
gs-3919	13	14	,	,	PUNCT
gs-3919	13	15	antibiotics	antibiotic	NOUN
gs-3919	13	16	,	,	PUNCT
gs-3919	13	17	and	and	CCONJ
gs-3919	13	18	novel	novel	ADJ
gs-3919	13	19	biologics	biologic	NOUN
gs-3919	13	20	—	—	PUNCT
gs-3919	13	21	trigger	trigger	NOUN
gs-3919	13	22	eosinophil	eosinophil	ADJ
gs-3919	13	23	activation	activation	NOUN
gs-3919	13	24	through	through	ADP
gs-3919	13	25	hapten	hapten	VERB
gs-3919	13	26	formation	formation	NOUN
gs-3919	13	27	,	,	PUNCT
gs-3919	13	28	direct	direct	ADJ
gs-3919	13	29	t	t	PROPN
gs-3919	13	30	-	-	PUNCT
gs-3919	13	31	cell	cell	NOUN
gs-3919	13	32	stimulation	stimulation	NOUN
gs-3919	13	33	,	,	PUNCT
gs-3919	13	34	and	and	CCONJ
gs-3919	13	35	cytokine	cytokine	NOUN
gs-3919	13	36	release	release	NOUN
gs-3919	13	37	.	.	PUNCT
gs-3919	14	1	genetic	genetic	ADJ
gs-3919	14	2	predispositions	predisposition	NOUN
gs-3919	14	3	,	,	PUNCT
gs-3919	14	4	particularly	particularly	ADV
gs-3919	14	5	hla	hla	NOUN
gs-3919	14	6	associations	association	NOUN
gs-3919	14	7	,	,	PUNCT
gs-3919	14	8	and	and	CCONJ
gs-3919	14	9	viral	viral	ADJ
gs-3919	14	10	interactions	interaction	NOUN
gs-3919	14	11	(	(	PUNCT
gs-3919	14	12	e.g.	e.g.	ADV
gs-3919	14	13	,	,	PUNCT
gs-3919	14	14	hhv-6	hhv-6	NOUN
gs-3919	14	15	reactivation	reactivation	NOUN
gs-3919	14	16	)	)	PUNCT
gs-3919	14	17	are	be	AUX
gs-3919	14	18	discussed	discuss	VERB
gs-3919	14	19	as	as	ADP
gs-3919	14	20	critical	critical	ADJ
gs-3919	14	21	modulators	modulator	NOUN
gs-3919	14	22	of	of	ADP
gs-3919	14	23	individual	individual	ADJ
gs-3919	14	24	susceptibility	susceptibility	NOUN
gs-3919	14	25	and	and	CCONJ
gs-3919	14	26	clinical	clinical	ADJ
gs-3919	14	27	severity	severity	NOUN
gs-3919	14	28	.	.	PUNCT
gs-3919	15	1	recent	recent	ADJ
gs-3919	15	2	advances	advance	NOUN
gs-3919	15	3	in	in	ADP
gs-3919	15	4	biomarker	biomarker	NOUN
gs-3919	15	5	discovery	discovery	NOUN
gs-3919	15	6	(	(	PUNCT
gs-3919	15	7	e.g.	e.g.	ADV
gs-3919	15	8	,	,	PUNCT
gs-3919	15	9	serum	serum	NOUN
gs-3919	15	10	siglec-8	siglec-8	PROPN
gs-3919	15	11	,	,	PUNCT
gs-3919	15	12	eosinophilderived	eosinophilderive	VERB
gs-3919	15	13	extracellular	extracellular	ADJ
gs-3919	15	14	traps	trap	NOUN
gs-3919	15	15	)	)	PUNCT
gs-3919	15	16	and	and	CCONJ
gs-3919	15	17	imaging	imaging	NOUN
gs-3919	15	18	modalities	modality	NOUN
gs-3919	15	19	(	(	PUNCT
gs-3919	15	20	e.g.	e.g.	ADV
gs-3919	15	21	,	,	PUNCT
gs-3919	15	22	68ga	68ga	ADJ
gs-3919	15	23	-	-	PUNCT
gs-3919	15	24	fapi	fapi	NOUN
gs-3919	15	25	pet	pet	NOUN
gs-3919	15	26	/	/	SYM
gs-3919	15	27	ct	ct	PROPN
gs-3919	15	28	)	)	PUNCT
gs-3919	15	29	are	be	AUX
gs-3919	15	30	evaluated	evaluate	VERB
gs-3919	15	31	for	for	ADP
gs-3919	15	32	their	their	PRON
gs-3919	15	33	diagnostic	diagnostic	ADJ
gs-3919	15	34	and	and	CCONJ
gs-3919	15	35	prognostic	prognostic	ADJ
gs-3919	15	36	utility	utility	NOUN
gs-3919	15	37	.	.	PUNCT
gs-3919	16	1	the	the	DET
gs-3919	16	2	review	review	NOUN
gs-3919	16	3	highlights	highlight	VERB
gs-3919	16	4	emerging	emerge	VERB
gs-3919	16	5	therapeutic	therapeutic	ADJ
gs-3919	16	6	strategies	strategy	NOUN
gs-3919	16	7	,	,	PUNCT
gs-3919	16	8	including	include	VERB
gs-3919	16	9	targeted	target	VERB
gs-3919	16	10	biologics	biologic	NOUN
gs-3919	16	11	against	against	ADP
gs-3919	16	12	il-5	il-5	NOUN
gs-3919	16	13	/	/	SYM
gs-3919	16	14	il-33	il-33	ADJ
gs-3919	16	15	and	and	CCONJ
gs-3919	16	16	pharmacogenomic	pharmacogenomic	ADJ
gs-3919	16	17	approaches	approach	NOUN
gs-3919	16	18	to	to	ADP
gs-3919	16	19	prevention	prevention	NOUN
gs-3919	16	20	,	,	PUNCT
gs-3919	16	21	while	while	SCONJ
gs-3919	16	22	underscoring	underscore	VERB
gs-3919	16	23	persistent	persistent	ADJ
gs-3919	16	24	challenges	challenge	NOUN
gs-3919	16	25	in	in	ADP
gs-3919	16	26	management	management	NOUN
gs-3919	16	27	,	,	PUNCT
gs-3919	16	28	such	such	ADJ
gs-3919	16	29	as	as	ADP
gs-3919	16	30	corticosteroid	corticosteroid	ADJ
gs-3919	16	31	dependence	dependence	NOUN
gs-3919	16	32	and	and	CCONJ
gs-3919	16	33	long	long	ADJ
gs-3919	16	34	-	-	PUNCT
gs-3919	16	35	term	term	NOUN
gs-3919	16	36	sequelae	sequelae	NOUN
gs-3919	16	37	.	.	PUNCT
gs-3919	17	1	by	by	ADP
gs-3919	17	2	integrating	integrate	VERB
gs-3919	17	3	mechanistic	mechanistic	ADJ
gs-3919	17	4	insights	insight	NOUN
gs-3919	17	5	with	with	ADP
gs-3919	17	6	clinical	clinical	ADJ
gs-3919	17	7	observations	observation	NOUN
gs-3919	17	8	,	,	PUNCT
gs-3919	17	9	this	this	DET
gs-3919	17	10	work	work	NOUN
gs-3919	17	11	aims	aim	VERB
gs-3919	17	12	to	to	PART
gs-3919	17	13	refine	refine	VERB
gs-3919	17	14	diagnostic	diagnostic	ADJ
gs-3919	17	15	criteria	criterion	NOUN
gs-3919	17	16	,	,	PUNCT
gs-3919	17	17	optimize	optimize	VERB
gs-3919	17	18	therapeutic	therapeutic	ADJ
gs-3919	17	19	decision	decision	NOUN
gs-3919	17	20	-	-	PUNCT
gs-3919	17	21	making	making	NOUN
gs-3919	17	22	,	,	PUNCT
gs-3919	17	23	and	and	CCONJ
gs-3919	17	24	identify	identify	VERB
gs-3919	17	25	future	future	ADJ
gs-3919	17	26	research	research	NOUN
gs-3919	17	27	directions	direction	NOUN
gs-3919	17	28	to	to	PART
gs-3919	17	29	mitigate	mitigate	VERB
gs-3919	17	30	the	the	DET
gs-3919	17	31	burden	burden	NOUN
gs-3919	17	32	of	of	ADP
gs-3919	17	33	these	these	DET
gs-3919	17	34	iatrogenic	iatrogenic	ADJ
gs-3919	17	35	complications	complication	NOUN
gs-3919	17	36	.	.	PUNCT
gs-3919	18	1	drug	drug	NOUN
gs-3919	18	2	reaction	reaction	NOUN
gs-3919	18	3	with	with	ADP
gs-3919	18	4	eosinophilia	eosinophilia	PROPN
gs-3919	18	5	and	and	CCONJ
gs-3919	18	6	systemic	systemic	ADJ
gs-3919	18	7	symptoms	symptom	NOUN
gs-3919	18	8	(	(	PUNCT
gs-3919	18	9	dress	dress	NOUN
gs-3919	18	10	)	)	PUNCT
gs-3919	18	11	is	be	AUX
gs-3919	18	12	an	an	DET
gs-3919	18	13	uncommon	uncommon	ADJ
gs-3919	18	14	yet	yet	CCONJ
gs-3919	18	15	serious	serious	ADJ
gs-3919	18	16	adverse	adverse	ADJ
gs-3919	18	17	drug	drug	NOUN
gs-3919	18	18	reaction	reaction	NOUN
gs-3919	18	19	that	that	PRON
gs-3919	18	20	presents	present	VERB
gs-3919	18	21	with	with	ADP
gs-3919	18	22	delayed	delay	VERB
gs-3919	18	23	systemic	systemic	ADJ
gs-3919	18	24	inflammation	inflammation	NOUN
gs-3919	18	25	and	and	CCONJ
gs-3919	18	26	multiple	multiple	ADJ
gs-3919	18	27	organ	organ	NOUN
gs-3919	18	28	involvement	involvement	NOUN
gs-3919	18	29	.	.	PUNCT
gs-3919	19	1	it	it	PRON
gs-3919	19	2	is	be	AUX
gs-3919	19	3	a	a	DET
gs-3919	19	4	member	member	NOUN
gs-3919	19	5	of	of	ADP
gs-3919	19	6	the	the	DET
gs-3919	19	7	spectrum	spectrum	NOUN
gs-3919	19	8	of	of	ADP
gs-3919	19	9	severe	severe	ADJ
gs-3919	19	10	cutaneous	cutaneous	ADJ
gs-3919	19	11	adverse	adverse	ADJ
gs-3919	19	12	reactions	reaction	NOUN
gs-3919	19	13	(	(	PUNCT
gs-3919	19	14	scar	scar	NOUN
gs-3919	19	15	)	)	PUNCT
gs-3919	19	16	,	,	PUNCT
gs-3919	19	17	usually	usually	ADV
gs-3919	19	18	presenting	present	VERB
gs-3919	19	19	2–8	2–8	NUM
gs-3919	19	20	weeks	week	NOUN
gs-3919	19	21	post	post	NOUN
gs-3919	19	22	initiation	initiation	NOUN
gs-3919	19	23	of	of	ADP
gs-3919	19	24	the	the	DET
gs-3919	19	25	culprit	culprit	NOUN
gs-3919	19	26	drug	drug	NOUN
gs-3919	19	27	.	.	PUNCT
gs-3919	20	1	nonspecific	nonspecific	ADJ
gs-3919	20	2	symptoms	symptom	NOUN
gs-3919	20	3	,	,	PUNCT
gs-3919	20	4	latency	latency	NOUN
gs-3919	20	5	,	,	PUNCT
gs-3919	20	6	and	and	CCONJ
gs-3919	20	7	overlapping	overlap	VERB
gs-3919	20	8	clinical	clinical	ADJ
gs-3919	20	9	findings	finding	NOUN
gs-3919	20	10	with	with	ADP
gs-3919	20	11	infections	infection	NOUN
gs-3919	20	12	,	,	PUNCT
gs-3919	20	13	autoimmune	autoimmune	ADJ
gs-3919	20	14	diseases	disease	NOUN
gs-3919	20	15	,	,	PUNCT
gs-3919	20	16	and	and	CCONJ
gs-3919	20	17	other	other	ADJ
gs-3919	20	18	hypersensitivity	hypersensitivity	NOUN
gs-3919	20	19	reactions	reaction	NOUN
gs-3919	20	20	contribute	contribute	VERB
gs-3919	20	21	to	to	ADP
gs-3919	20	22	a	a	DET
gs-3919	20	23	failure	failure	NOUN
gs-3919	20	24	to	to	PART
gs-3919	20	25	diagnose	diagnose	VERB
gs-3919	20	26	syndrome	syndrome	NOUN
gs-3919	20	27	and	and	CCONJ
gs-3919	20	28	worsening	worsen	VERB
gs-3919	20	29	morbidity	morbidity	NOUN
gs-3919	20	30	.	.	PUNCT
gs-3919	21	1	the	the	DET
gs-3919	21	2	objective	objective	NOUN
gs-3919	21	3	of	of	ADP
gs-3919	21	4	this	this	DET
gs-3919	21	5	thesis	thesis	NOUN
gs-3919	21	6	is	be	AUX
gs-3919	21	7	to	to	PART
gs-3919	21	8	conduct	conduct	VERB
gs-3919	21	9	a	a	DET
gs-3919	21	10	comprehensive	comprehensive	ADJ
gs-3919	21	11	systematic	systematic	ADJ
gs-3919	21	12	review	review	NOUN
gs-3919	21	13	with	with	ADP
gs-3919	21	14	emphasis	emphasis	NOUN
gs-3919	21	15	on	on	ADP
gs-3919	21	16	the	the	DET
gs-3919	21	17	pharmacological	pharmacological	ADJ
gs-3919	21	18	characteristics	characteristic	NOUN
gs-3919	21	19	,	,	PUNCT
gs-3919	21	20	clinical	clinical	ADJ
gs-3919	21	21	presentation	presentation	NOUN
gs-3919	21	22	,	,	PUNCT
gs-3919	21	23	and	and	CCONJ
gs-3919	21	24	genetic	genetic	ADJ
gs-3919	21	25	risk	risk	NOUN
gs-3919	21	26	factors	factor	NOUN
gs-3919	21	27	of	of	ADP
gs-3919	21	28	dress	dress	NOUN
gs-3919	21	29	syndrome	syndrome	NOUN
gs-3919	21	30	,	,	PUNCT
gs-3919	21	31	as	as	ADV
gs-3919	21	32	well	well	ADV
gs-3919	21	33	as	as	ADP
gs-3919	21	34	a	a	DET
gs-3919	21	35	range	range	NOUN
gs-3919	21	36	of	of	ADP
gs-3919	21	37	pathological	pathological	ADJ
gs-3919	21	38	drug	drug	NOUN
gs-3919	21	39	classes	class	NOUN
gs-3919	21	40	,	,	PUNCT
gs-3919	21	41	including	include	VERB
gs-3919	21	42	anticonvulsants	anticonvulsant	NOUN
gs-3919	21	43	,	,	PUNCT
gs-3919	21	44	antibiotics	antibiotic	NOUN
gs-3919	21	45	,	,	PUNCT
gs-3919	21	46	allopurinol	allopurinol	NOUN
gs-3919	21	47	,	,	PUNCT
gs-3919	21	48	and	and	CCONJ
gs-3919	21	49	nonsteroidal	nonsteroidal	ADJ
gs-3919	21	50	anti	anti	NOUN
gs-3919	21	51	-	-	NOUN
gs-3919	21	52	inflammatories	inflammatorie	NOUN
gs-3919	21	53	(	(	PUNCT
gs-3919	21	54	nsaids	nsaid	NOUN
gs-3919	21	55	)	)	PUNCT
gs-3919	21	56	.	.	PUNCT
gs-3919	22	1	the	the	DET
gs-3919	22	2	article	article	NOUN
gs-3919	22	3	also	also	ADV
gs-3919	22	4	discusses	discuss	VERB
gs-3919	22	5	treatment	treatment	NOUN
gs-3919	22	6	,	,	PUNCT
gs-3919	22	7	long	long	ADJ
gs-3919	22	8	-	-	PUNCT
gs-3919	22	9	term	term	NOUN
gs-3919	22	10	prognosis	prognosis	NOUN
gs-3919	22	11	and	and	CCONJ
gs-3919	22	12	research	research	NOUN
gs-3919	22	13	directions	direction	NOUN
gs-3919	22	14	.	.	PUNCT
gs-3919	23	1	the	the	DET
gs-3919	23	2	leading	lead	VERB
gs-3919	23	3	alternative	alternative	ADJ
gs-3919	23	4	agents	agent	NOUN
gs-3919	23	5	were	be	AUX
gs-3919	23	6	anticonvulsants	anticonvulsant	NOUN
gs-3919	23	7	(	(	PUNCT
gs-3919	23	8	e.g.	e.g.	ADV
gs-3919	23	9	,	,	PUNCT
gs-3919	23	10	carbamazepine	carbamazepine	NOUN
gs-3919	23	11	,	,	PUNCT
gs-3919	23	12	phenytoin	phenytoin	NOUN
gs-3919	23	13	,	,	PUNCT
gs-3919	23	14	lamotrigine	lamotrigine	PROPN
gs-3919	23	15	)	)	PUNCT
gs-3919	23	16	,	,	PUNCT
gs-3919	23	17	antibiotics	antibiotic	NOUN
gs-3919	23	18	(	(	PUNCT
gs-3919	23	19	e.g.	e.g.	ADV
gs-3919	23	20	,	,	PUNCT
gs-3919	23	21	vancomycin	vancomycin	PROPN
gs-3919	23	22	,	,	PUNCT
gs-3919	23	23	minocycline	minocycline	NOUN
gs-3919	23	24	)	)	PUNCT
gs-3919	23	25	,	,	PUNCT
gs-3919	23	26	georgian	georgian	PROPN
gs-3919	23	27	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	23	28	მეცნიერები	მეცნიერები	NOUN
gs-3919	23	29	ტ.	ტ.	VERB
gs-3919	23	30	7	7	NUM
gs-3919	23	31	n	n	DET
gs-3919	23	32	3	3	NUM
gs-3919	23	33	,	,	PUNCT
gs-3919	23	34	2025	2025	NUM
gs-3919	23	35	143	143	NUM
gs-3919	23	36	allopurinol	allopurinol	NOUN
gs-3919	23	37	,	,	PUNCT
gs-3919	23	38	and	and	CCONJ
gs-3919	23	39	nsaids	nsaid	NOUN
gs-3919	23	40	including	include	VERB
gs-3919	23	41	mefenamic	mefenamic	ADJ
gs-3919	23	42	acid	acid	NOUN
gs-3919	23	43	and	and	CCONJ
gs-3919	23	44	ibuprofen	ibuprofen	NOUN
gs-3919	23	45	.	.	PUNCT
gs-3919	24	1	more	more	ADJ
gs-3919	24	2	than	than	ADP
gs-3919	24	3	60	60	NUM
gs-3919	24	4	%	%	NOUN
gs-3919	24	5	of	of	ADP
gs-3919	24	6	cases	case	NOUN
gs-3919	24	7	had	have	VERB
gs-3919	24	8	hepatic	hepatic	ADJ
gs-3919	24	9	involvement	involvement	NOUN
gs-3919	24	10	;	;	PUNCT
gs-3919	24	11	involvement	involvement	NOUN
gs-3919	24	12	of	of	ADP
gs-3919	24	13	the	the	DET
gs-3919	24	14	kidneys	kidney	NOUN
gs-3919	24	15	(	(	PUNCT
gs-3919	24	16	25	25	NUM
gs-3919	24	17	%	%	NOUN
gs-3919	24	18	)	)	PUNCT
gs-3919	24	19	and	and	CCONJ
gs-3919	24	20	the	the	DET
gs-3919	24	21	lungs	lung	NOUN
gs-3919	24	22	(	(	PUNCT
gs-3919	24	23	10–15	10–15	NUM
gs-3919	24	24	%	%	NOUN
gs-3919	24	25	)	)	PUNCT
gs-3919	24	26	were	be	AUX
gs-3919	24	27	also	also	ADV
gs-3919	24	28	important	important	ADJ
gs-3919	24	29	.	.	PUNCT
gs-3919	25	1	nearly	nearly	ADV
gs-3919	25	2	all	all	DET
gs-3919	25	3	patients	patient	NOUN
gs-3919	25	4	presented	present	VERB
gs-3919	25	5	with	with	ADP
gs-3919	25	6	cutaneous	cutaneous	ADJ
gs-3919	25	7	findings	finding	NOUN
gs-3919	25	8	,	,	PUNCT
gs-3919	25	9	most	most	ADV
gs-3919	25	10	commonly	commonly	ADV
gs-3919	25	11	a	a	DET
gs-3919	25	12	diffuse	diffuse	NOUN
gs-3919	25	13	morbilliform	morbilliform	ADJ
gs-3919	25	14	rash	rash	ADJ
gs-3919	25	15	and	and	CCONJ
gs-3919	25	16	facial	facial	ADJ
gs-3919	25	17	edema	edema	NOUN
gs-3919	25	18	,	,	PUNCT
gs-3919	25	19	and	and	CCONJ
gs-3919	25	20	frequently	frequently	ADV
gs-3919	25	21	had	have	VERB
gs-3919	25	22	fever	fever	NOUN
gs-3919	25	23	and	and	CCONJ
gs-3919	25	24	eosinophilia	eosinophilia	PROPN
gs-3919	25	25	.	.	PUNCT
gs-3919	26	1	genetic	genetic	ADJ
gs-3919	26	2	predisposition	predisposition	NOUN
gs-3919	26	3	is	be	AUX
gs-3919	26	4	an	an	DET
gs-3919	26	5	important	important	ADJ
gs-3919	26	6	factor	factor	NOUN
gs-3919	26	7	,	,	PUNCT
gs-3919	26	8	with	with	ADP
gs-3919	26	9	hla	hla	NOUN
gs-3919	26	10	-	-	PUNCT
gs-3919	26	11	b58:01	b58:01	VERB
gs-3919	26	12	allele	allele	NOUN
gs-3919	26	13	in	in	ADP
gs-3919	26	14	the	the	DET
gs-3919	26	15	context	context	NOUN
gs-3919	26	16	of	of	ADP
gs-3919	26	17	allopurinol	allopurinol	NOUN
gs-3919	26	18	-	-	PUNCT
gs-3919	26	19	induced	induce	VERB
gs-3919	26	20	dress	dress	NOUN
gs-3919	26	21	,	,	PUNCT
gs-3919	26	22	and	and	CCONJ
gs-3919	26	23	hla	hla	PROPN
gs-3919	26	24	-	-	PUNCT
gs-3919	26	25	a31:01	a31:01	PROPN
gs-3919	26	26	in	in	ADP
gs-3919	26	27	the	the	DET
gs-3919	26	28	case	case	NOUN
gs-3919	26	29	of	of	ADP
gs-3919	26	30	carbamazepine	carbamazepine	NOUN
gs-3919	26	31	.	.	PUNCT
gs-3919	27	1	these	these	DET
gs-3919	27	2	results	result	NOUN
gs-3919	27	3	emphasize	emphasize	VERB
gs-3919	27	4	the	the	DET
gs-3919	27	5	value	value	NOUN
gs-3919	27	6	of	of	ADP
gs-3919	27	7	pharmacogenetic	pharmacogenetic	ADJ
gs-3919	27	8	screening	screening	NOUN
gs-3919	27	9	in	in	ADP
gs-3919	27	10	high	high	ADJ
gs-3919	27	11	-	-	PUNCT
gs-3919	27	12	risk	risk	NOUN
gs-3919	27	13	population	population	NOUN
gs-3919	27	14	groups	group	NOUN
gs-3919	27	15	.	.	PUNCT
gs-3919	28	1	viral	viral	ADJ
gs-3919	28	2	reactivation	reactivation	NOUN
gs-3919	28	3	,	,	PUNCT
gs-3919	28	4	including	include	VERB
gs-3919	28	5	human	human	NOUN
gs-3919	28	6	herpesvirus-6	herpesvirus-6	PRON
gs-3919	28	7	(	(	PUNCT
gs-3919	28	8	hhv-6	hhv-6	NOUN
gs-3919	28	9	)	)	PUNCT
gs-3919	28	10	,	,	PUNCT
gs-3919	28	11	had	have	AUX
gs-3919	28	12	been	be	AUX
gs-3919	28	13	observed	observe	VERB
gs-3919	28	14	in	in	ADP
gs-3919	28	15	multiple	multiple	ADJ
gs-3919	28	16	patients	patient	NOUN
gs-3919	28	17	and	and	CCONJ
gs-3919	28	18	has	have	AUX
gs-3919	28	19	contributed	contribute	VERB
gs-3919	28	20	to	to	ADP
gs-3919	28	21	overall	overall	ADJ
gs-3919	28	22	disease	disease	NOUN
gs-3919	28	23	severity	severity	NOUN
gs-3919	28	24	and	and	CCONJ
gs-3919	28	25	duration	duration	NOUN
gs-3919	28	26	.	.	PUNCT
gs-3919	29	1	therapy	therapy	NOUN
gs-3919	29	2	consisted	consist	VERB
gs-3919	29	3	mainly	mainly	ADV
gs-3919	29	4	in	in	ADP
gs-3919	29	5	early	early	ADJ
gs-3919	29	6	discontinuation	discontinuation	NOUN
gs-3919	29	7	of	of	ADP
gs-3919	29	8	the	the	DET
gs-3919	29	9	inducing	inducing	ADJ
gs-3919	29	10	agent	agent	NOUN
gs-3919	29	11	and	and	CCONJ
gs-3919	29	12	systemic	systemic	ADJ
gs-3919	29	13	corticosteroids	corticosteroid	NOUN
gs-3919	29	14	.	.	PUNCT
gs-3919	30	1	although	although	SCONJ
gs-3919	30	2	the	the	DET
gs-3919	30	3	majority	majority	NOUN
gs-3919	30	4	of	of	ADP
gs-3919	30	5	patients	patient	NOUN
gs-3919	30	6	responded	respond	VERB
gs-3919	30	7	to	to	ADP
gs-3919	30	8	corticosteroids	corticosteroid	NOUN
gs-3919	30	9	,	,	PUNCT
gs-3919	30	10	some	some	PRON
gs-3919	30	11	became	become	VERB
gs-3919	30	12	steroid	steroid	NOUN
gs-3919	30	13	resistant	resistant	ADJ
gs-3919	30	14	and	and	CCONJ
gs-3919	30	15	were	be	AUX
gs-3919	30	16	treated	treat	VERB
gs-3919	30	17	with	with	ADP
gs-3919	30	18	medications	medication	NOUN
gs-3919	30	19	such	such	ADJ
gs-3919	30	20	as	as	ADP
gs-3919	30	21	cyclosporine	cyclosporine	NOUN
gs-3919	30	22	,	,	PUNCT
gs-3919	30	23	ivig	ivig	NOUN
gs-3919	30	24	,	,	PUNCT
gs-3919	30	25	and	and	CCONJ
gs-3919	30	26	plasmapheresis	plasmapheresis	NOUN
gs-3919	30	27	.	.	PUNCT
gs-3919	31	1	there	there	PRON
gs-3919	31	2	is	be	VERB
gs-3919	31	3	a	a	DET
gs-3919	31	4	lack	lack	NOUN
gs-3919	31	5	of	of	ADP
gs-3919	31	6	standardized	standardized	ADJ
gs-3919	31	7	treatment	treatment	NOUN
gs-3919	31	8	protocols	protocol	NOUN
gs-3919	31	9	,	,	PUNCT
gs-3919	31	10	and	and	CCONJ
gs-3919	31	11	randomized	randomize	VERB
gs-3919	31	12	controlled	control	VERB
gs-3919	31	13	trials	trial	NOUN
gs-3919	31	14	are	be	AUX
gs-3919	31	15	highly	highly	ADV
gs-3919	31	16	desired	desire	VERB
gs-3919	31	17	.	.	PUNCT
gs-3919	32	1	relapses	relapse	NOUN
gs-3919	32	2	during	during	ADP
gs-3919	32	3	corticosteroid	corticosteroid	ADJ
gs-3919	32	4	reduction	reduction	NOUN
gs-3919	32	5	or	or	CCONJ
gs-3919	32	6	autoimmunity	autoimmunity	NOUN
gs-3919	32	7	(	(	PUNCT
gs-3919	32	8	type	type	NOUN
gs-3919	32	9	1	1	NUM
gs-3919	32	10	diabetes	diabetes	NOUN
gs-3919	32	11	,	,	PUNCT
gs-3919	32	12	thyroiditis	thyroiditis	NOUN
gs-3919	32	13	,	,	PUNCT
gs-3919	32	14	lupus	lupus	NOUN
gs-3919	32	15	-	-	PUNCT
gs-3919	32	16	like	like	ADJ
gs-3919	32	17	syndromes	syndrome	NOUN
gs-3919	32	18	)	)	PUNCT
gs-3919	32	19	occurred	occur	VERB
gs-3919	32	20	in	in	ADP
gs-3919	32	21	some	some	PRON
gs-3919	32	22	,	,	PUNCT
gs-3919	32	23	but	but	CCONJ
gs-3919	32	24	not	not	PART
gs-3919	32	25	in	in	ADP
gs-3919	32	26	all	all	DET
gs-3919	32	27	patients	patient	NOUN
gs-3919	32	28	.	.	PUNCT
gs-3919	33	1	multisystem	multisystem	PROPN
gs-3919	33	2	dress	dress	NOUN
gs-3919	33	3	syndrome	syndrome	PROPN
gs-3919	33	4	mandates	mandate	VERB
gs-3919	33	5	a	a	DET
gs-3919	33	6	high	high	ADJ
gs-3919	33	7	degree	degree	NOUN
gs-3919	33	8	of	of	ADP
gs-3919	33	9	clinical	clinical	ADJ
gs-3919	33	10	suspicion	suspicion	NOUN
gs-3919	33	11	for	for	ADP
gs-3919	33	12	early	early	ADJ
gs-3919	33	13	diagnosis	diagnosis	NOUN
gs-3919	33	14	and	and	CCONJ
gs-3919	33	15	treatment	treatment	NOUN
gs-3919	33	16	.	.	PUNCT
gs-3919	34	1	the	the	DET
gs-3919	34	2	underestimation	underestimation	NOUN
gs-3919	34	3	of	of	ADP
gs-3919	34	4	nsaid	nsaid	PROPN
gs-3919	34	5	-	-	PUNCT
gs-3919	34	6	induced	induce	VERB
gs-3919	34	7	dress	dress	NOUN
gs-3919	34	8	emphasises	emphasise	VERB
gs-3919	34	9	the	the	DET
gs-3919	34	10	necessity	necessity	NOUN
gs-3919	34	11	for	for	ADP
gs-3919	34	12	better	well	ADJ
gs-3919	34	13	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	34	14	tools	tool	NOUN
gs-3919	34	15	and	and	CCONJ
gs-3919	34	16	public	public	ADJ
gs-3919	34	17	awareness	awareness	NOUN
gs-3919	34	18	on	on	ADP
gs-3919	34	19	otc	otc	PROPN
gs-3919	34	20	drug	drug	NOUN
gs-3919	34	21	safety	safety	NOUN
gs-3919	34	22	.	.	PUNCT
gs-3919	35	1	future	future	ADJ
gs-3919	35	2	advances	advance	NOUN
gs-3919	35	3	would	would	AUX
gs-3919	35	4	need	need	VERB
gs-3919	35	5	to	to	PART
gs-3919	35	6	focus	focus	VERB
gs-3919	35	7	on	on	ADP
gs-3919	35	8	the	the	DET
gs-3919	35	9	creation	creation	NOUN
gs-3919	35	10	of	of	ADP
gs-3919	35	11	general	general	ADJ
gs-3919	35	12	diagnostic	diagnostic	ADJ
gs-3919	35	13	criteria	criterion	NOUN
gs-3919	35	14	,	,	PUNCT
gs-3919	35	15	useful	useful	ADJ
gs-3919	35	16	biomarkers	biomarker	NOUN
gs-3919	35	17	for	for	ADP
gs-3919	35	18	early	early	ADJ
gs-3919	35	19	diagnosis	diagnosis	NOUN
gs-3919	35	20	,	,	PUNCT
gs-3919	35	21	and	and	CCONJ
gs-3919	35	22	the	the	DET
gs-3919	35	23	use	use	NOUN
gs-3919	35	24	of	of	ADP
gs-3919	35	25	evidence	evidence	NOUN
gs-3919	35	26	-	-	PUNCT
gs-3919	35	27	based	base	VERB
gs-3919	35	28	algorithms	algorithm	NOUN
gs-3919	35	29	for	for	ADP
gs-3919	35	30	treatment	treatment	NOUN
gs-3919	35	31	.	.	PUNCT
gs-3919	36	1	keywords	keyword	NOUN
gs-3919	36	2	:	:	PUNCT
gs-3919	36	3	adverse	adverse	ADJ
gs-3919	36	4	drug	drug	NOUN
gs-3919	36	5	reactions	reaction	NOUN
gs-3919	36	6	,	,	PUNCT
gs-3919	36	7	eosinophilia	eosinophilia	PROPN
gs-3919	36	8	,	,	PUNCT
gs-3919	36	9	systemic	systemic	ADJ
gs-3919	36	10	hypersensitivity	hypersensitivity	NOUN
gs-3919	36	11	,	,	PUNCT
gs-3919	36	12	drug	drug	NOUN
gs-3919	36	13	safety	safety	NOUN
gs-3919	36	14	profile	profile	NOUN
gs-3919	36	15	,	,	PUNCT
gs-3919	36	16	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	36	17	,	,	PUNCT
gs-3919	36	18	drug	drug	NOUN
gs-3919	36	19	-	-	PUNCT
gs-3919	36	20	induced	induce	VERB
gs-3919	36	21	immunological	immunological	ADJ
gs-3919	36	22	response	response	NOUN
gs-3919	36	23	.	.	PUNCT
gs-3919	37	1	introduction	introduction	NOUN
gs-3919	37	2	drug	drug	NOUN
gs-3919	37	3	reaction	reaction	NOUN
gs-3919	37	4	with	with	ADP
gs-3919	37	5	eosinophilia	eosinophilia	PROPN
gs-3919	37	6	and	and	CCONJ
gs-3919	37	7	systemic	systemic	ADJ
gs-3919	37	8	symptoms	symptom	NOUN
gs-3919	37	9	(	(	PUNCT
gs-3919	37	10	dress	dress	NOUN
gs-3919	37	11	)	)	PUNCT
gs-3919	37	12	is	be	AUX
gs-3919	37	13	a	a	DET
gs-3919	37	14	rare	rare	ADJ
gs-3919	37	15	but	but	CCONJ
gs-3919	37	16	important	important	ADJ
gs-3919	37	17	hypersensitivity	hypersensitivity	NOUN
gs-3919	37	18	syndrome	syndrome	NOUN
gs-3919	37	19	that	that	PRON
gs-3919	37	20	can	can	AUX
gs-3919	37	21	be	be	AUX
gs-3919	37	22	induced	induce	VERB
gs-3919	37	23	by	by	ADP
gs-3919	37	24	specific	specific	ADJ
gs-3919	37	25	drugs	drug	NOUN
gs-3919	37	26	.	.	PUNCT
gs-3919	38	1	the	the	DET
gs-3919	38	2	syndrome	syndrome	NOUN
gs-3919	38	3	presents	present	VERB
gs-3919	38	4	as	as	ADP
gs-3919	38	5	a	a	DET
gs-3919	38	6	complex	complex	ADJ
gs-3919	38	7	and	and	CCONJ
gs-3919	38	8	varied	varied	ADJ
gs-3919	38	9	clinical	clinical	ADJ
gs-3919	38	10	picture	picture	NOUN
gs-3919	38	11	which	which	PRON
gs-3919	38	12	may	may	AUX
gs-3919	38	13	lead	lead	VERB
gs-3919	38	14	to	to	ADP
gs-3919	38	15	serious	serious	ADJ
gs-3919	38	16	multisystem	multisystem	NOUN
gs-3919	38	17	organ	organ	NOUN
gs-3919	38	18	failure	failure	NOUN
gs-3919	38	19	,	,	PUNCT
gs-3919	38	20	thereby	thereby	ADV
gs-3919	38	21	being	be	AUX
gs-3919	38	22	associated	associate	VERB
gs-3919	38	23	with	with	ADP
gs-3919	38	24	a	a	DET
gs-3919	38	25	high	high	ADJ
gs-3919	38	26	morbidity	morbidity	NOUN
gs-3919	38	27	and	and	CCONJ
gs-3919	38	28	mortality	mortality	NOUN
gs-3919	38	29	rate	rate	NOUN
gs-3919	38	30	.	.	PUNCT
gs-3919	39	1	dress	dress	NOUN
gs-3919	39	2	usually	usually	ADV
gs-3919	39	3	occurs	occur	VERB
gs-3919	39	4	2–8	2–8	NUM
gs-3919	39	5	weeks	week	NOUN
gs-3919	39	6	after	after	ADP
gs-3919	39	7	starting	start	VERB
gs-3919	39	8	an	an	DET
gs-3919	39	9	offending	offending	ADJ
gs-3919	39	10	drug	drug	NOUN
gs-3919	39	11	,	,	PUNCT
gs-3919	39	12	which	which	PRON
gs-3919	39	13	complicates	complicate	VERB
gs-3919	39	14	its	its	PRON
gs-3919	39	15	diagnosis	diagnosis	NOUN
gs-3919	39	16	because	because	SCONJ
gs-3919	39	17	of	of	ADP
gs-3919	39	18	the	the	DET
gs-3919	39	19	long	long	ADJ
gs-3919	39	20	lag	lag	NOUN
gs-3919	39	21	time	time	NOUN
gs-3919	39	22	between	between	ADP
gs-3919	39	23	drug	drug	NOUN
gs-3919	39	24	exposure	exposure	NOUN
gs-3919	39	25	and	and	CCONJ
gs-3919	39	26	the	the	DET
gs-3919	39	27	onset	onset	NOUN
gs-3919	39	28	of	of	ADP
gs-3919	39	29	symptoms	symptom	NOUN
gs-3919	39	30	.	.	PUNCT
gs-3919	40	1	the	the	DET
gs-3919	40	2	syndrome	syndrome	NOUN
gs-3919	40	3	is	be	AUX
gs-3919	40	4	most	most	ADV
gs-3919	40	5	often	often	ADV
gs-3919	40	6	characterized	characterize	VERB
gs-3919	40	7	by	by	ADP
gs-3919	40	8	a	a	DET
gs-3919	40	9	triad	triad	NOUN
gs-3919	40	10	of	of	ADP
gs-3919	40	11	clinical	clinical	ADJ
gs-3919	40	12	features	feature	NOUN
gs-3919	40	13	,	,	PUNCT
gs-3919	40	14	including	include	VERB
gs-3919	40	15	widespread	widespread	ADJ
gs-3919	40	16	cutaneous	cutaneous	ADJ
gs-3919	40	17	eruptions	eruption	NOUN
gs-3919	40	18	,	,	PUNCT
gs-3919	40	19	haematological	haematological	ADJ
gs-3919	40	20	disturbances	disturbance	NOUN
gs-3919	40	21	(	(	PUNCT
gs-3919	40	22	e.g.	e.g.	ADV
gs-3919	40	23	,	,	PUNCT
gs-3919	40	24	eosinophilia	eosinophilia	PROPN
gs-3919	40	25	)	)	PUNCT
gs-3919	40	26	,	,	PUNCT
gs-3919	40	27	and	and	CCONJ
gs-3919	40	28	organ	organ	NOUN
gs-3919	40	29	involvement	involvement	NOUN
gs-3919	40	30	—	—	PUNCT
gs-3919	40	31	the	the	DET
gs-3919	40	32	liver	liver	NOUN
gs-3919	40	33	and	and	CCONJ
gs-3919	40	34	kidneys	kidney	NOUN
gs-3919	40	35	being	be	AUX
gs-3919	40	36	the	the	DET
gs-3919	40	37	most	most	ADV
gs-3919	40	38	frequently	frequently	ADV
gs-3919	40	39	involved	involve	VERB
gs-3919	40	40	.	.	PUNCT
gs-3919	41	1	adverse	adverse	ADJ
gs-3919	41	2	drug	drug	NOUN
gs-3919	41	3	reactions	reaction	NOUN
gs-3919	41	4	(	(	PUNCT
gs-3919	41	5	adrs	adrs	PROPN
gs-3919	41	6	)	)	PUNCT
gs-3919	41	7	remain	remain	VERB
gs-3919	41	8	a	a	DET
gs-3919	41	9	significant	significant	ADJ
gs-3919	41	10	challenge	challenge	NOUN
gs-3919	41	11	in	in	ADP
gs-3919	41	12	pharmacotherapy	pharmacotherapy	NOUN
gs-3919	41	13	,	,	PUNCT
gs-3919	41	14	impacting	impact	VERB
gs-3919	41	15	patient	patient	NOUN
gs-3919	41	16	safety	safety	NOUN
gs-3919	41	17	,	,	PUNCT
gs-3919	41	18	treatment	treatment	NOUN
gs-3919	41	19	efficacy	efficacy	NOUN
gs-3919	41	20	,	,	PUNCT
gs-3919	41	21	and	and	CCONJ
gs-3919	41	22	healthcare	healthcare	NOUN
gs-3919	41	23	costs	cost	NOUN
gs-3919	41	24	.	.	PUNCT
gs-3919	42	1	among	among	ADP
gs-3919	42	2	these	these	PRON
gs-3919	42	3	,	,	PUNCT
gs-3919	42	4	druginduced	druginduced	ADJ
gs-3919	42	5	eosinophilia	eosinophilia	NOUN
gs-3919	42	6	and	and	CCONJ
gs-3919	42	7	systemic	systemic	ADJ
gs-3919	42	8	symptoms	symptom	NOUN
gs-3919	42	9	(	(	PUNCT
gs-3919	42	10	dress	dress	NOUN
gs-3919	42	11	syndrome	syndrome	NOUN
gs-3919	42	12	—	—	PUNCT
gs-3919	42	13	drug	drug	NOUN
gs-3919	42	14	reaction	reaction	NOUN
gs-3919	42	15	with	with	ADP
gs-3919	42	16	eosinophilia	eosinophilia	PROPN
gs-3919	42	17	and	and	CCONJ
gs-3919	42	18	systemic	systemic	ADJ
gs-3919	42	19	symptoms	symptom	NOUN
gs-3919	42	20	)	)	PUNCT
gs-3919	42	21	represents	represent	VERB
gs-3919	42	22	a	a	DET
gs-3919	42	23	severe	severe	ADJ
gs-3919	42	24	hypersensitivity	hypersensitivity	NOUN
gs-3919	42	25	reaction	reaction	NOUN
gs-3919	42	26	characterized	characterize	VERB
gs-3919	42	27	by	by	ADP
gs-3919	42	28	eosinophilia	eosinophilia	PROPN
gs-3919	42	29	,	,	PUNCT
gs-3919	42	30	fever	fever	NOUN
gs-3919	42	31	,	,	PUNCT
gs-3919	42	32	rash	rash	ADJ
gs-3919	42	33	,	,	PUNCT
gs-3919	42	34	and	and	CCONJ
gs-3919	42	35	multi	multi	ADJ
gs-3919	42	36	-	-	ADJ
gs-3919	42	37	organ	organ	ADJ
gs-3919	42	38	involvement	involvement	NOUN
gs-3919	42	39	.	.	PUNCT
gs-3919	43	1	understanding	understand	VERB
gs-3919	43	2	georgian	georgian	ADJ
gs-3919	43	3	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	43	4	მეცნიერები	მეცნიერები	NOUN
gs-3919	43	5	ტ.	ტ.	VERB
gs-3919	43	6	7	7	NUM
gs-3919	43	7	n	n	DET
gs-3919	43	8	3	3	NUM
gs-3919	43	9	,	,	PUNCT
gs-3919	43	10	2025	2025	NUM
gs-3919	43	11	144	144	NUM
gs-3919	44	1	the	the	DET
gs-3919	44	2	pharmacological	pharmacological	ADJ
gs-3919	44	3	properties	property	NOUN
gs-3919	44	4	and	and	CCONJ
gs-3919	44	5	mechanistic	mechanistic	ADJ
gs-3919	44	6	profiles	profile	NOUN
gs-3919	44	7	of	of	ADP
gs-3919	44	8	drugs	drug	NOUN
gs-3919	44	9	associated	associate	VERB
gs-3919	44	10	with	with	ADP
gs-3919	44	11	dress	dress	NOUN
gs-3919	44	12	is	be	AUX
gs-3919	44	13	crucial	crucial	ADJ
gs-3919	44	14	for	for	ADP
gs-3919	44	15	early	early	ADJ
gs-3919	44	16	detection	detection	NOUN
gs-3919	44	17	,	,	PUNCT
gs-3919	44	18	risk	risk	NOUN
gs-3919	44	19	mitigation	mitigation	NOUN
gs-3919	44	20	,	,	PUNCT
gs-3919	44	21	and	and	CCONJ
gs-3919	44	22	improved	improve	VERB
gs-3919	44	23	therapeutic	therapeutic	ADJ
gs-3919	44	24	outcomes	outcome	NOUN
gs-3919	44	25	.	.	PUNCT
gs-3919	45	1	this	this	DET
gs-3919	45	2	paper	paper	NOUN
gs-3919	45	3	explores	explore	VERB
gs-3919	45	4	the	the	DET
gs-3919	45	5	key	key	ADJ
gs-3919	45	6	pharmacological	pharmacological	ADJ
gs-3919	45	7	aspects	aspect	NOUN
gs-3919	45	8	contributing	contribute	VERB
gs-3919	45	9	to	to	ADP
gs-3919	45	10	adrs	adr	NOUN
gs-3919	45	11	,	,	PUNCT
gs-3919	45	12	with	with	ADP
gs-3919	45	13	a	a	DET
gs-3919	45	14	focus	focus	NOUN
gs-3919	45	15	on	on	ADP
gs-3919	45	16	drug	drug	NOUN
gs-3919	45	17	-	-	PUNCT
gs-3919	45	18	induced	induce	VERB
gs-3919	45	19	eosinophilia	eosinophilia	NOUN
gs-3919	45	20	and	and	CCONJ
gs-3919	45	21	systemic	systemic	ADJ
gs-3919	45	22	symptoms	symptom	NOUN
gs-3919	45	23	,	,	PUNCT
gs-3919	45	24	addressing	address	VERB
gs-3919	45	25	mechanisms	mechanism	NOUN
gs-3919	45	26	,	,	PUNCT
gs-3919	45	27	risk	risk	NOUN
gs-3919	45	28	factors	factor	NOUN
gs-3919	45	29	,	,	PUNCT
gs-3919	45	30	diagnostic	diagnostic	ADJ
gs-3919	45	31	challenges	challenge	NOUN
gs-3919	45	32	,	,	PUNCT
gs-3919	45	33	and	and	CCONJ
gs-3919	45	34	management	management	NOUN
gs-3919	45	35	strategies	strategy	NOUN
gs-3919	45	36	.	.	PUNCT
gs-3919	46	1	the	the	DET
gs-3919	46	2	pharmacological	pharmacological	ADJ
gs-3919	46	3	properties	property	NOUN
gs-3919	46	4	and	and	CCONJ
gs-3919	46	5	profiles	profile	NOUN
gs-3919	46	6	of	of	ADP
gs-3919	46	7	therapeutic	therapeutic	ADJ
gs-3919	46	8	agents	agent	NOUN
gs-3919	46	9	play	play	VERB
gs-3919	46	10	a	a	DET
gs-3919	46	11	pivotal	pivotal	ADJ
gs-3919	46	12	role	role	NOUN
gs-3919	46	13	in	in	ADP
gs-3919	46	14	determining	determine	VERB
gs-3919	46	15	their	their	PRON
gs-3919	46	16	efficacy	efficacy	NOUN
gs-3919	46	17	,	,	PUNCT
gs-3919	46	18	safety	safety	NOUN
gs-3919	46	19	,	,	PUNCT
gs-3919	46	20	and	and	CCONJ
gs-3919	46	21	overall	overall	ADJ
gs-3919	46	22	risk	risk	NOUN
gs-3919	46	23	-	-	PUNCT
gs-3919	46	24	benefit	benefit	NOUN
gs-3919	46	25	ratio	ratio	NOUN
gs-3919	46	26	in	in	ADP
gs-3919	46	27	clinical	clinical	ADJ
gs-3919	46	28	practice	practice	NOUN
gs-3919	46	29	.	.	PUNCT
gs-3919	47	1	while	while	SCONJ
gs-3919	47	2	modern	modern	ADJ
gs-3919	47	3	pharmacotherapy	pharmacotherapy	NOUN
gs-3919	47	4	has	have	AUX
gs-3919	47	5	revolutionized	revolutionize	VERB
gs-3919	47	6	disease	disease	NOUN
gs-3919	47	7	management	management	NOUN
gs-3919	47	8	,	,	PUNCT
gs-3919	47	9	adverse	adverse	ADJ
gs-3919	47	10	drug	drug	NOUN
gs-3919	47	11	reactions	reaction	NOUN
gs-3919	47	12	(	(	PUNCT
gs-3919	47	13	adrs	adrs	PROPN
gs-3919	47	14	)	)	PUNCT
gs-3919	47	15	remain	remain	VERB
gs-3919	47	16	a	a	DET
gs-3919	47	17	significant	significant	ADJ
gs-3919	47	18	challenge	challenge	NOUN
gs-3919	47	19	,	,	PUNCT
gs-3919	47	20	contributing	contribute	VERB
gs-3919	47	21	to	to	ADP
gs-3919	47	22	morbidity	morbidity	NOUN
gs-3919	47	23	,	,	PUNCT
gs-3919	47	24	mortality	mortality	NOUN
gs-3919	47	25	,	,	PUNCT
gs-3919	47	26	and	and	CCONJ
gs-3919	47	27	increased	increase	VERB
gs-3919	47	28	healthcare	healthcare	NOUN
gs-3919	47	29	burdens	burden	NOUN
gs-3919	47	30	.	.	PUNCT
gs-3919	48	1	among	among	ADP
gs-3919	48	2	the	the	DET
gs-3919	48	3	diverse	diverse	ADJ
gs-3919	48	4	spectrum	spectrum	NOUN
gs-3919	48	5	of	of	ADP
gs-3919	48	6	adrs	adr	NOUN
gs-3919	48	7	,	,	PUNCT
gs-3919	48	8	drug	drug	NOUN
gs-3919	48	9	-	-	PUNCT
gs-3919	48	10	induced	induce	VERB
gs-3919	48	11	eosinophilia	eosinophilia	NOUN
gs-3919	48	12	and	and	CCONJ
gs-3919	48	13	systemic	systemic	ADJ
gs-3919	48	14	symptoms	symptom	NOUN
gs-3919	48	15	(	(	PUNCT
gs-3919	48	16	dies	die	NOUN
gs-3919	48	17	)	)	PUNCT
gs-3919	48	18	represent	represent	VERB
gs-3919	48	19	a	a	DET
gs-3919	48	20	complex	complex	ADJ
gs-3919	48	21	and	and	CCONJ
gs-3919	48	22	often	often	ADV
gs-3919	48	23	underrecognized	underrecognized	ADJ
gs-3919	48	24	clinical	clinical	ADJ
gs-3919	48	25	entity	entity	NOUN
gs-3919	48	26	that	that	PRON
gs-3919	48	27	poses	pose	VERB
gs-3919	48	28	diagnostic	diagnostic	ADJ
gs-3919	48	29	and	and	CCONJ
gs-3919	48	30	therapeutic	therapeutic	ADJ
gs-3919	48	31	dilemmas	dilemma	NOUN
gs-3919	48	32	.	.	PUNCT
gs-3919	49	1	this	this	DET
gs-3919	49	2	discussion	discussion	NOUN
gs-3919	49	3	delves	delve	VERB
gs-3919	49	4	into	into	ADP
gs-3919	49	5	the	the	DET
gs-3919	49	6	intricate	intricate	ADJ
gs-3919	49	7	interplay	interplay	NOUN
gs-3919	49	8	between	between	ADP
gs-3919	49	9	pharmacological	pharmacological	ADJ
gs-3919	49	10	mechanisms	mechanism	NOUN
gs-3919	49	11	,	,	PUNCT
gs-3919	49	12	host	host	NOUN
gs-3919	49	13	factors	factor	NOUN
gs-3919	49	14	,	,	PUNCT
gs-3919	49	15	and	and	CCONJ
gs-3919	49	16	immunological	immunological	ADJ
gs-3919	49	17	pathways	pathway	NOUN
gs-3919	49	18	that	that	PRON
gs-3919	49	19	underlie	underlie	VERB
gs-3919	49	20	drug	drug	NOUN
gs-3919	49	21	-	-	PUNCT
gs-3919	49	22	induced	induce	VERB
gs-3919	49	23	eosinophilia	eosinophilia	NOUN
gs-3919	49	24	and	and	CCONJ
gs-3919	49	25	its	its	PRON
gs-3919	49	26	systemic	systemic	ADJ
gs-3919	49	27	manifestations	manifestation	NOUN
gs-3919	49	28	,	,	PUNCT
gs-3919	49	29	emphasizing	emphasize	VERB
gs-3919	49	30	the	the	DET
gs-3919	49	31	need	need	NOUN
gs-3919	49	32	for	for	ADP
gs-3919	49	33	heightened	heightened	ADJ
gs-3919	49	34	clinical	clinical	ADJ
gs-3919	49	35	vigilance	vigilance	NOUN
gs-3919	49	36	and	and	CCONJ
gs-3919	49	37	mechanistic	mechanistic	ADJ
gs-3919	49	38	understanding	understanding	NOUN
gs-3919	49	39	.	.	PUNCT
gs-3919	50	1	pharmacological	pharmacological	ADJ
gs-3919	50	2	agents	agent	NOUN
gs-3919	50	3	,	,	PUNCT
gs-3919	50	4	by	by	ADP
gs-3919	50	5	virtue	virtue	NOUN
gs-3919	50	6	of	of	ADP
gs-3919	50	7	their	their	PRON
gs-3919	50	8	chemical	chemical	NOUN
gs-3919	50	9	structure	structure	NOUN
gs-3919	50	10	,	,	PUNCT
gs-3919	50	11	receptor	receptor	NOUN
gs-3919	50	12	interactions	interaction	NOUN
gs-3919	50	13	,	,	PUNCT
gs-3919	50	14	and	and	CCONJ
gs-3919	50	15	metabolic	metabolic	NOUN
gs-3919	50	16	pathways	pathway	NOUN
gs-3919	50	17	,	,	PUNCT
gs-3919	50	18	can	can	AUX
gs-3919	50	19	elicit	elicit	VERB
gs-3919	50	20	unintended	unintended	ADJ
gs-3919	50	21	immune	immune	NOUN
gs-3919	50	22	-	-	PUNCT
gs-3919	50	23	mediated	mediate	VERB
gs-3919	50	24	responses	response	NOUN
gs-3919	50	25	.	.	PUNCT
gs-3919	51	1	eosinophilia	eosinophilia	PROPN
gs-3919	51	2	,	,	PUNCT
gs-3919	51	3	characterized	characterize	VERB
gs-3919	51	4	by	by	ADP
gs-3919	51	5	an	an	DET
gs-3919	51	6	abnormal	abnormal	ADJ
gs-3919	51	7	elevation	elevation	NOUN
gs-3919	51	8	in	in	ADP
gs-3919	51	9	eosinophil	eosinophil	ADJ
gs-3919	51	10	count	count	NOUN
gs-3919	51	11	,	,	PUNCT
gs-3919	51	12	serves	serve	VERB
gs-3919	51	13	as	as	ADP
gs-3919	51	14	a	a	DET
gs-3919	51	15	biomarker	biomarker	NOUN
gs-3919	51	16	for	for	ADP
gs-3919	51	17	hypersensitivity	hypersensitivity	NOUN
gs-3919	51	18	reactions	reaction	NOUN
gs-3919	51	19	,	,	PUNCT
gs-3919	51	20	parasitic	parasitic	ADJ
gs-3919	51	21	infections	infection	NOUN
gs-3919	51	22	,	,	PUNCT
gs-3919	51	23	and	and	CCONJ
gs-3919	51	24	certain	certain	ADJ
gs-3919	51	25	drug	drug	NOUN
gs-3919	51	26	-	-	PUNCT
gs-3919	51	27	induced	induce	VERB
gs-3919	51	28	pathologies	pathology	NOUN
gs-3919	51	29	.	.	PUNCT
gs-3919	52	1	when	when	SCONJ
gs-3919	52	2	drug	drug	NOUN
gs-3919	52	3	-	-	PUNCT
gs-3919	52	4	related	relate	VERB
gs-3919	52	5	,	,	PUNCT
gs-3919	52	6	eosinophilia	eosinophilia	PROPN
gs-3919	52	7	may	may	AUX
gs-3919	52	8	herald	herald	VERB
gs-3919	52	9	severe	severe	ADJ
gs-3919	52	10	systemic	systemic	ADJ
gs-3919	52	11	involvement	involvement	NOUN
gs-3919	52	12	,	,	PUNCT
gs-3919	52	13	including	include	VERB
gs-3919	52	14	cutaneous	cutaneous	ADJ
gs-3919	52	15	eruptions	eruption	NOUN
gs-3919	52	16	,	,	PUNCT
gs-3919	52	17	visceral	visceral	ADJ
gs-3919	52	18	organ	organ	NOUN
gs-3919	52	19	damage	damage	NOUN
gs-3919	52	20	,	,	PUNCT
gs-3919	52	21	and	and	CCONJ
gs-3919	52	22	life	life	NOUN
gs-3919	52	23	-	-	PUNCT
gs-3919	52	24	threatening	threaten	VERB
gs-3919	52	25	conditions	condition	NOUN
gs-3919	52	26	such	such	ADJ
gs-3919	52	27	as	as	ADP
gs-3919	52	28	drug	drug	NOUN
gs-3919	52	29	reaction	reaction	NOUN
gs-3919	52	30	with	with	ADP
gs-3919	52	31	eosinophilia	eosinophilia	PROPN
gs-3919	52	32	and	and	CCONJ
gs-3919	52	33	systemic	systemic	ADJ
gs-3919	52	34	symptoms	symptom	NOUN
gs-3919	52	35	(	(	PUNCT
gs-3919	52	36	dress	dress	NOUN
gs-3919	52	37	)	)	PUNCT
gs-3919	52	38	or	or	CCONJ
gs-3919	52	39	eosinophilic	eosinophilic	ADJ
gs-3919	52	40	granulomatosis	granulomatosis	NOUN
gs-3919	52	41	with	with	ADP
gs-3919	52	42	polyangiitis	polyangiitis	PROPN
gs-3919	52	43	(	(	PUNCT
gs-3919	52	44	egpa	egpa	NOUN
gs-3919	52	45	)	)	PUNCT
gs-3919	52	46	.	.	PUNCT
gs-3919	53	1	the	the	DET
gs-3919	53	2	pathogenesis	pathogenesis	NOUN
gs-3919	53	3	of	of	ADP
gs-3919	53	4	these	these	DET
gs-3919	53	5	reactions	reaction	NOUN
gs-3919	53	6	is	be	AUX
gs-3919	53	7	multifactorial	multifactorial	ADJ
gs-3919	53	8	,	,	PUNCT
gs-3919	53	9	involving	involve	VERB
gs-3919	53	10	genetic	genetic	ADJ
gs-3919	53	11	predispositions	predisposition	NOUN
gs-3919	53	12	(	(	PUNCT
gs-3919	53	13	e.g.	e.g.	ADV
gs-3919	53	14	,	,	PUNCT
gs-3919	53	15	hla	hla	NOUN
gs-3919	53	16	haplotypes	haplotype	NOUN
gs-3919	53	17	)	)	PUNCT
gs-3919	53	18	,	,	PUNCT
gs-3919	53	19	drug	drug	NOUN
gs-3919	53	20	-	-	PUNCT
gs-3919	53	21	specific	specific	ADJ
gs-3919	53	22	properties	property	NOUN
gs-3919	53	23	(	(	PUNCT
gs-3919	53	24	e.g.	e.g.	ADV
gs-3919	53	25	,	,	PUNCT
gs-3919	53	26	reactive	reactive	ADJ
gs-3919	53	27	metabolites	metabolite	NOUN
gs-3919	53	28	)	)	PUNCT
gs-3919	53	29	,	,	PUNCT
gs-3919	53	30	and	and	CCONJ
gs-3919	53	31	dysregulated	dysregulated	ADJ
gs-3919	53	32	immune	immune	ADJ
gs-3919	53	33	activation	activation	NOUN
gs-3919	53	34	(	(	PUNCT
gs-3919	53	35	e.g.	e.g.	ADV
gs-3919	53	36	,	,	PUNCT
gs-3919	53	37	th2	th2	PROPN
gs-3919	53	38	cytokine	cytokine	VERB
gs-3919	53	39	polarization	polarization	NOUN
gs-3919	53	40	)	)	PUNCT
gs-3919	53	41	.	.	PUNCT
gs-3919	54	1	understanding	understand	VERB
gs-3919	54	2	the	the	DET
gs-3919	54	3	pharmacological	pharmacological	ADJ
gs-3919	54	4	basis	basis	NOUN
gs-3919	54	5	of	of	ADP
gs-3919	54	6	these	these	DET
gs-3919	54	7	adverse	adverse	ADJ
gs-3919	54	8	events	event	NOUN
gs-3919	54	9	requires	require	VERB
gs-3919	54	10	a	a	DET
gs-3919	54	11	thorough	thorough	ADJ
gs-3919	54	12	examination	examination	NOUN
gs-3919	54	13	of	of	ADP
gs-3919	54	14	drug	drug	NOUN
gs-3919	54	15	metabolism	metabolism	NOUN
gs-3919	54	16	,	,	PUNCT
gs-3919	54	17	pharmacokinetic	pharmacokinetic	ADJ
gs-3919	54	18	variability	variability	NOUN
gs-3919	54	19	,	,	PUNCT
gs-3919	54	20	and	and	CCONJ
gs-3919	54	21	pharmacodynamic	pharmacodynamic	ADJ
gs-3919	54	22	interactions	interaction	NOUN
gs-3919	54	23	.	.	PUNCT
gs-3919	55	1	certain	certain	ADJ
gs-3919	55	2	drug	drug	NOUN
gs-3919	55	3	classes	class	NOUN
gs-3919	55	4	,	,	PUNCT
gs-3919	55	5	including	include	VERB
gs-3919	55	6	antiepileptics	antiepileptic	NOUN
gs-3919	55	7	(	(	PUNCT
gs-3919	55	8	e.g.	e.g.	ADV
gs-3919	55	9	,	,	PUNCT
gs-3919	55	10	phenytoin	phenytoin	NOUN
gs-3919	55	11	,	,	PUNCT
gs-3919	55	12	carbamazepine	carbamazepine	NOUN
gs-3919	55	13	)	)	PUNCT
gs-3919	55	14	,	,	PUNCT
gs-3919	55	15	antibiotics	antibiotic	NOUN
gs-3919	55	16	(	(	PUNCT
gs-3919	55	17	e.g.	e.g.	ADV
gs-3919	55	18	,	,	PUNCT
gs-3919	55	19	sulfonamides	sulfonamide	NOUN
gs-3919	55	20	,	,	PUNCT
gs-3919	55	21	beta	beta	NOUN
gs-3919	55	22	-	-	PUNCT
gs-3919	55	23	lactams	lactam	NOUN
gs-3919	55	24	)	)	PUNCT
gs-3919	55	25	,	,	PUNCT
gs-3919	55	26	and	and	CCONJ
gs-3919	55	27	allopurinol	allopurinol	NOUN
gs-3919	55	28	,	,	PUNCT
gs-3919	55	29	are	be	AUX
gs-3919	55	30	frequently	frequently	ADV
gs-3919	55	31	implicated	implicate	VERB
gs-3919	55	32	in	in	ADP
gs-3919	55	33	eosinophilic	eosinophilic	ADJ
gs-3919	55	34	reactions	reaction	NOUN
gs-3919	55	35	due	due	ADP
gs-3919	55	36	to	to	ADP
gs-3919	55	37	their	their	PRON
gs-3919	55	38	propensity	propensity	NOUN
gs-3919	55	39	to	to	PART
gs-3919	55	40	form	form	VERB
gs-3919	55	41	haptenprotein	haptenprotein	ADJ
gs-3919	55	42	complexes	complex	NOUN
gs-3919	55	43	,	,	PUNCT
gs-3919	55	44	triggering	trigger	VERB
gs-3919	55	45	t	t	PROPN
gs-3919	55	46	-	-	PUNCT
gs-3919	55	47	cell	cell	NOUN
gs-3919	55	48	-	-	PUNCT
gs-3919	55	49	mediated	mediate	VERB
gs-3919	55	50	hypersensitivity	hypersensitivity	NOUN
gs-3919	55	51	.	.	PUNCT
gs-3919	56	1	additionally	additionally	ADV
gs-3919	56	2	,	,	PUNCT
gs-3919	56	3	the	the	DET
gs-3919	56	4	role	role	NOUN
gs-3919	56	5	of	of	ADP
gs-3919	56	6	eosinophils	eosinophil	NOUN
gs-3919	56	7	themselves	themselves	PRON
gs-3919	56	8	extends	extend	VERB
gs-3919	56	9	beyond	beyond	ADP
gs-3919	56	10	mere	mere	ADJ
gs-3919	56	11	bystanders	bystander	NOUN
gs-3919	56	12	;	;	PUNCT
gs-3919	56	13	these	these	DET
gs-3919	56	14	granulocytes	granulocyte	NOUN
gs-3919	56	15	release	release	VERB
gs-3919	56	16	cytotoxic	cytotoxic	ADJ
gs-3919	56	17	granules	granule	NOUN
gs-3919	56	18	(	(	PUNCT
gs-3919	56	19	e.g.	e.g.	ADV
gs-3919	56	20	,	,	PUNCT
gs-3919	56	21	major	major	ADJ
gs-3919	56	22	basic	basic	ADJ
gs-3919	56	23	protein	protein	NOUN
gs-3919	56	24	,	,	PUNCT
gs-3919	56	25	eosinophil	eosinophil	ADJ
gs-3919	56	26	peroxidase	peroxidase	NOUN
gs-3919	56	27	)	)	PUNCT
gs-3919	56	28	and	and	CCONJ
gs-3919	56	29	pro	pro	ADJ
gs-3919	56	30	-	-	ADJ
gs-3919	56	31	inflammatory	inflammatory	ADJ
gs-3919	56	32	cytokines	cytokine	NOUN
gs-3919	56	33	(	(	PUNCT
gs-3919	56	34	e.g.	e.g.	ADV
gs-3919	56	35	,	,	PUNCT
gs-3919	56	36	il-5	il-5	PRON
gs-3919	56	37	,	,	PUNCT
gs-3919	56	38	il-13	il-13	NUM
gs-3919	56	39	)	)	PUNCT
gs-3919	56	40	,	,	PUNCT
gs-3919	56	41	contributing	contribute	VERB
gs-3919	56	42	to	to	ADP
gs-3919	56	43	tissue	tissue	NOUN
gs-3919	56	44	injury	injury	NOUN
gs-3919	56	45	and	and	CCONJ
gs-3919	56	46	systemic	systemic	ADJ
gs-3919	56	47	inflammation	inflammation	NOUN
gs-3919	56	48	.	.	PUNCT
gs-3919	57	1	the	the	DET
gs-3919	57	2	clinical	clinical	ADJ
gs-3919	57	3	presentation	presentation	NOUN
gs-3919	57	4	of	of	ADP
gs-3919	57	5	drug	drug	NOUN
gs-3919	57	6	-	-	PUNCT
gs-3919	57	7	induced	induce	VERB
gs-3919	57	8	eosinophilia	eosinophilia	NOUN
gs-3919	57	9	varies	vary	VERB
gs-3919	57	10	widely	widely	ADV
gs-3919	57	11	,	,	PUNCT
gs-3919	57	12	ranging	range	VERB
gs-3919	57	13	from	from	ADP
gs-3919	57	14	benign	benign	ADJ
gs-3919	57	15	peripheral	peripheral	ADJ
gs-3919	57	16	blood	blood	NOUN
gs-3919	57	17	eosinophilia	eosinophilia	NOUN
gs-3919	57	18	to	to	ADP
gs-3919	57	19	fulminant	fulminant	ADJ
gs-3919	57	20	multiorgan	multiorgan	NOUN
gs-3919	57	21	failure	failure	NOUN
gs-3919	57	22	.	.	PUNCT
gs-3919	58	1	early	early	ADJ
gs-3919	58	2	recognition	recognition	NOUN
gs-3919	58	3	is	be	AUX
gs-3919	58	4	paramount	paramount	ADJ
gs-3919	58	5	,	,	PUNCT
gs-3919	58	6	as	as	SCONJ
gs-3919	58	7	delayed	delay	VERB
gs-3919	58	8	diagnosis	diagnosis	NOUN
gs-3919	58	9	often	often	ADV
gs-3919	58	10	exacerbates	exacerbate	VERB
gs-3919	58	11	outcomes	outcome	NOUN
gs-3919	58	12	.	.	PUNCT
gs-3919	59	1	correlating	correlate	VERB
gs-3919	59	2	temporal	temporal	ADJ
gs-3919	59	3	drug	drug	NOUN
gs-3919	59	4	exposure	exposure	NOUN
gs-3919	59	5	with	with	ADP
gs-3919	59	6	symptom	symptom	NOUN
gs-3919	59	7	onset	onset	NOUN
gs-3919	59	8	,	,	PUNCT
gs-3919	59	9	alongside	alongside	ADP
gs-3919	59	10	laboratory	laboratory	NOUN
gs-3919	59	11	and	and	CCONJ
gs-3919	59	12	histopathological	histopathological	ADJ
gs-3919	59	13	findings	finding	NOUN
gs-3919	59	14	,	,	PUNCT
gs-3919	59	15	aids	aid	NOUN
gs-3919	59	16	in	in	ADP
gs-3919	59	17	establishing	establish	VERB
gs-3919	59	18	causality	causality	NOUN
gs-3919	59	19	.	.	PUNCT
gs-3919	60	1	however	however	ADV
gs-3919	60	2	,	,	PUNCT
gs-3919	60	3	challenges	challenge	NOUN
gs-3919	60	4	persist	persist	VERB
gs-3919	60	5	due	due	ADP
gs-3919	60	6	to	to	ADP
gs-3919	60	7	the	the	DET
gs-3919	60	8	nonspecific	nonspecific	ADJ
gs-3919	60	9	nature	nature	NOUN
gs-3919	60	10	of	of	ADP
gs-3919	60	11	eosinophilia	eosinophilia	PROPN
gs-3919	60	12	and	and	CCONJ
gs-3919	60	13	overlapping	overlap	VERB
gs-3919	60	14	features	feature	NOUN
gs-3919	60	15	with	with	ADP
gs-3919	60	16	other	other	ADJ
gs-3919	60	17	hypersensitivity	hypersensitivity	NOUN
gs-3919	60	18	syndromes	syndrome	NOUN
gs-3919	60	19	.	.	PUNCT
gs-3919	61	1	furthermore	furthermore	ADV
gs-3919	61	2	,	,	PUNCT
gs-3919	61	3	georgian	georgian	ADJ
gs-3919	61	4	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	61	5	მეცნიერები	მეცნიერები	NOUN
gs-3919	61	6	ტ.	ტ.	VERB
gs-3919	61	7	7	7	NUM
gs-3919	61	8	n	n	PRON
gs-3919	61	9	3	3	NUM
gs-3919	61	10	,	,	PUNCT
gs-3919	61	11	2025	2025	NUM
gs-3919	61	12	145	145	NUM
gs-3919	61	13	the	the	DET
gs-3919	61	14	absence	absence	NOUN
gs-3919	61	15	of	of	ADP
gs-3919	61	16	standardized	standardized	ADJ
gs-3919	61	17	diagnostic	diagnostic	ADJ
gs-3919	61	18	criteria	criterion	NOUN
gs-3919	61	19	for	for	ADP
gs-3919	61	20	conditions	condition	NOUN
gs-3919	61	21	like	like	ADP
gs-3919	61	22	dress	dress	NOUN
gs-3919	61	23	complicates	complicate	VERB
gs-3919	61	24	clinical	clinical	ADJ
gs-3919	61	25	assessment	assessment	NOUN
gs-3919	61	26	,	,	PUNCT
gs-3919	61	27	necessitating	necessitate	VERB
gs-3919	61	28	a	a	DET
gs-3919	61	29	high	high	ADJ
gs-3919	61	30	index	index	NOUN
gs-3919	61	31	of	of	ADP
gs-3919	61	32	suspicion	suspicion	NOUN
gs-3919	61	33	and	and	CCONJ
gs-3919	61	34	comprehensive	comprehensive	ADJ
gs-3919	61	35	drug	drug	NOUN
gs-3919	61	36	history	history	NOUN
gs-3919	61	37	evaluation	evaluation	NOUN
gs-3919	61	38	.	.	PUNCT
gs-3919	62	1	therapeutic	therapeutic	ADJ
gs-3919	62	2	management	management	NOUN
gs-3919	62	3	hinges	hinge	NOUN
gs-3919	62	4	on	on	ADP
gs-3919	62	5	prompt	prompt	ADJ
gs-3919	62	6	drug	drug	NOUN
gs-3919	62	7	discontinuation	discontinuation	NOUN
gs-3919	62	8	,	,	PUNCT
gs-3919	62	9	supportive	supportive	ADJ
gs-3919	62	10	care	care	NOUN
gs-3919	62	11	,	,	PUNCT
gs-3919	62	12	and	and	CCONJ
gs-3919	62	13	,	,	PUNCT
gs-3919	62	14	in	in	ADP
gs-3919	62	15	severe	severe	ADJ
gs-3919	62	16	cases	case	NOUN
gs-3919	62	17	,	,	PUNCT
gs-3919	62	18	immunosuppressive	immunosuppressive	ADJ
gs-3919	62	19	therapy	therapy	NOUN
gs-3919	62	20	.	.	PUNCT
gs-3919	63	1	the	the	DET
gs-3919	63	2	role	role	NOUN
gs-3919	63	3	of	of	ADP
gs-3919	63	4	corticosteroids	corticosteroid	NOUN
gs-3919	63	5	remains	remain	VERB
gs-3919	63	6	controversial	controversial	ADJ
gs-3919	63	7	,	,	PUNCT
gs-3919	63	8	with	with	ADP
gs-3919	63	9	debates	debate	NOUN
gs-3919	63	10	surrounding	surround	VERB
gs-3919	63	11	optimal	optimal	ADJ
gs-3919	63	12	dosing	dosing	NOUN
gs-3919	63	13	and	and	CCONJ
gs-3919	63	14	duration	duration	NOUN
gs-3919	63	15	.	.	PUNCT
gs-3919	64	1	emerging	emerge	VERB
gs-3919	64	2	strategies	strategy	NOUN
gs-3919	64	3	,	,	PUNCT
gs-3919	64	4	such	such	ADJ
gs-3919	64	5	as	as	ADP
gs-3919	64	6	targeted	target	VERB
gs-3919	64	7	biologic	biologic	NOUN
gs-3919	64	8	therapies	therapy	NOUN
gs-3919	64	9	against	against	ADP
gs-3919	64	10	il-5	il-5	PRON
gs-3919	64	11	(	(	PUNCT
gs-3919	64	12	e.g.	e.g.	ADV
gs-3919	64	13	,	,	PUNCT
gs-3919	64	14	mepolizumab	mepolizumab	NOUN
gs-3919	64	15	)	)	PUNCT
gs-3919	64	16	,	,	PUNCT
gs-3919	64	17	offer	offer	VERB
gs-3919	64	18	promise	promise	NOUN
gs-3919	64	19	in	in	ADP
gs-3919	64	20	refractory	refractory	NOUN
gs-3919	64	21	cases	case	NOUN
gs-3919	64	22	,	,	PUNCT
gs-3919	64	23	though	though	SCONJ
gs-3919	64	24	further	further	ADJ
gs-3919	64	25	research	research	NOUN
gs-3919	64	26	is	be	AUX
gs-3919	64	27	needed	need	VERB
gs-3919	64	28	to	to	PART
gs-3919	64	29	define	define	VERB
gs-3919	64	30	their	their	PRON
gs-3919	64	31	place	place	NOUN
gs-3919	64	32	in	in	ADP
gs-3919	64	33	management	management	NOUN
gs-3919	64	34	.	.	PUNCT
gs-3919	65	1	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	65	2	systems	system	NOUN
gs-3919	65	3	and	and	CCONJ
gs-3919	65	4	post	post	ADJ
gs-3919	65	5	-	-	ADJ
gs-3919	65	6	marketing	marketing	ADJ
gs-3919	65	7	surveillance	surveillance	NOUN
gs-3919	65	8	are	be	AUX
gs-3919	65	9	critical	critical	ADJ
gs-3919	65	10	in	in	ADP
gs-3919	65	11	identifying	identify	VERB
gs-3919	65	12	atrisk	atrisk	NOUN
gs-3919	65	13	populations	population	NOUN
gs-3919	65	14	and	and	CCONJ
gs-3919	65	15	mitigating	mitigate	VERB
gs-3919	65	16	future	future	ADJ
gs-3919	65	17	occurrences	occurrence	NOUN
gs-3919	65	18	through	through	ADP
gs-3919	65	19	risk	risk	NOUN
gs-3919	65	20	stratification	stratification	NOUN
gs-3919	65	21	and	and	CCONJ
gs-3919	65	22	personalized	personalized	ADJ
gs-3919	65	23	medicine	medicine	NOUN
gs-3919	65	24	approaches	approach	NOUN
gs-3919	65	25	.	.	PUNCT
gs-3919	66	1	this	this	DET
gs-3919	66	2	discussion	discussion	NOUN
gs-3919	66	3	aims	aim	VERB
gs-3919	66	4	to	to	PART
gs-3919	66	5	synthesize	synthesize	VERB
gs-3919	66	6	current	current	ADJ
gs-3919	66	7	knowledge	knowledge	NOUN
gs-3919	66	8	on	on	ADP
gs-3919	66	9	drug	drug	NOUN
gs-3919	66	10	-	-	PUNCT
gs-3919	66	11	induced	induce	VERB
gs-3919	66	12	eosinophilia	eosinophilia	NOUN
gs-3919	66	13	and	and	CCONJ
gs-3919	66	14	systemic	systemic	ADJ
gs-3919	66	15	symptoms	symptom	NOUN
gs-3919	66	16	,	,	PUNCT
gs-3919	66	17	exploring	explore	VERB
gs-3919	66	18	pharmacological	pharmacological	ADJ
gs-3919	66	19	triggers	trigger	NOUN
gs-3919	66	20	,	,	PUNCT
gs-3919	66	21	mechanistic	mechanistic	ADJ
gs-3919	66	22	pathways	pathway	NOUN
gs-3919	66	23	,	,	PUNCT
gs-3919	66	24	clinical	clinical	ADJ
gs-3919	66	25	manifestations	manifestation	NOUN
gs-3919	66	26	,	,	PUNCT
gs-3919	66	27	and	and	CCONJ
gs-3919	66	28	therapeutic	therapeutic	ADJ
gs-3919	66	29	challenges	challenge	NOUN
gs-3919	66	30	.	.	PUNCT
gs-3919	67	1	by	by	ADP
gs-3919	67	2	integrating	integrate	VERB
gs-3919	67	3	pharmacogenomic	pharmacogenomic	ADJ
gs-3919	67	4	insights	insight	NOUN
gs-3919	67	5	,	,	PUNCT
gs-3919	67	6	immunological	immunological	ADJ
gs-3919	67	7	advances	advance	NOUN
gs-3919	67	8	,	,	PUNCT
gs-3919	67	9	and	and	CCONJ
gs-3919	67	10	real	real	ADJ
gs-3919	67	11	-	-	PUNCT
gs-3919	67	12	world	world	NOUN
gs-3919	67	13	clinical	clinical	ADJ
gs-3919	67	14	data	datum	NOUN
gs-3919	67	15	,	,	PUNCT
gs-3919	67	16	we	we	PRON
gs-3919	67	17	strive	strive	VERB
gs-3919	67	18	to	to	PART
gs-3919	67	19	enhance	enhance	VERB
gs-3919	67	20	risk	risk	NOUN
gs-3919	67	21	prediction	prediction	NOUN
gs-3919	67	22	,	,	PUNCT
gs-3919	67	23	improve	improve	VERB
gs-3919	67	24	diagnostic	diagnostic	ADJ
gs-3919	67	25	accuracy	accuracy	NOUN
gs-3919	67	26	,	,	PUNCT
gs-3919	67	27	and	and	CCONJ
gs-3919	67	28	optimize	optimize	VERB
gs-3919	67	29	patient	patient	ADJ
gs-3919	67	30	outcomes	outcome	NOUN
gs-3919	67	31	in	in	ADP
gs-3919	67	32	the	the	DET
gs-3919	67	33	face	face	NOUN
gs-3919	67	34	of	of	ADP
gs-3919	67	35	this	this	DET
gs-3919	67	36	formidable	formidable	ADJ
gs-3919	67	37	adr	adr	PROPN
gs-3919	67	38	.	.	PUNCT
gs-3919	67	39	pharmacological	pharmacological	ADJ
gs-3919	67	40	mechanisms	mechanism	NOUN
gs-3919	67	41	of	of	ADP
gs-3919	67	42	drug	drug	NOUN
gs-3919	67	43	-	-	PUNCT
gs-3919	67	44	induced	induce	VERB
gs-3919	67	45	eosinophilia	eosinophilia	NOUN
gs-3919	67	46			VERB
gs-3919	67	47	detailed	detailed	ADJ
gs-3919	67	48	exploration	exploration	NOUN
gs-3919	67	49	of	of	ADP
gs-3919	67	50	hapten	hapten	ADJ
gs-3919	67	51	hypothesis	hypothesis	NOUN
gs-3919	67	52	,	,	PUNCT
gs-3919	67	53	p	p	PROPN
gs-3919	67	54	-	-	PUNCT
gs-3919	67	55	i	i	PRON
gs-3919	67	56	concept	concept	NOUN
gs-3919	67	57	(	(	PUNCT
gs-3919	67	58	pharmacologic	pharmacologic	ADJ
gs-3919	67	59	interaction	interaction	NOUN
gs-3919	67	60	with	with	ADP
gs-3919	67	61	immune	immune	ADJ
gs-3919	67	62	receptors	receptor	NOUN
gs-3919	67	63	)	)	PUNCT
gs-3919	67	64	,	,	PUNCT
gs-3919	67	65	and	and	CCONJ
gs-3919	67	66	reactive	reactive	ADJ
gs-3919	67	67	metabolite	metabolite	NOUN
gs-3919	67	68	formation	formation	NOUN
gs-3919	67	69	.	.	PUNCT
gs-3919	68	1			ADJ
gs-3919	68	2	role	role	NOUN
gs-3919	68	3	of	of	ADP
gs-3919	68	4	cytochrome	cytochrome	ADJ
gs-3919	68	5	p450	p450	NUM
gs-3919	68	6	enzymes	enzyme	NOUN
gs-3919	68	7	in	in	ADP
gs-3919	68	8	generating	generate	VERB
gs-3919	68	9	immunogenic	immunogenic	ADJ
gs-3919	68	10	drug	drug	NOUN
gs-3919	68	11	intermediates	intermediate	NOUN
gs-3919	68	12	.	.	PUNCT
gs-3919	69	1			VERB
gs-3919	69	2	genetic	genetic	ADJ
gs-3919	69	3	susceptibility	susceptibility	NOUN
gs-3919	69	4	(	(	PUNCT
gs-3919	69	5	e.g.	e.g.	ADV
gs-3919	69	6	,	,	PUNCT
gs-3919	69	7	hla	hla	NOUN
gs-3919	69	8	-	-	PUNCT
gs-3919	69	9	b*15:02	b*15:02	X
gs-3919	69	10	with	with	ADP
gs-3919	69	11	carbamazepine	carbamazepine	NOUN
gs-3919	69	12	,	,	PUNCT
gs-3919	69	13	hla	hla	NOUN
gs-3919	69	14	-	-	PUNCT
gs-3919	69	15	a*31:01	a*31:01	NOUN
gs-3919	69	16	with	with	ADP
gs-3919	69	17	aromatic	aromatic	ADJ
gs-3919	69	18	antiepileptics	antiepileptic	NOUN
gs-3919	69	19	)	)	PUNCT
gs-3919	69	20	.	.	PUNCT
gs-3919	70	1	immunopathogenesis	immunopathogenesis	NOUN
gs-3919	70	2	of	of	ADP
gs-3919	70	3	systemic	systemic	ADJ
gs-3919	70	4	eosinophilic	eosinophilic	ADJ
gs-3919	70	5	reactions	reaction	NOUN
gs-3919	70	6			VERB
gs-3919	70	7	th2	th2	PROPN
gs-3919	70	8	immune	immune	ADJ
gs-3919	70	9	response	response	NOUN
gs-3919	70	10	dysregulation	dysregulation	NOUN
gs-3919	70	11	and	and	CCONJ
gs-3919	70	12	cytokine	cytokine	ADJ
gs-3919	70	13	storm	storm	NOUN
gs-3919	70	14	(	(	PUNCT
gs-3919	70	15	il-4	il-4	ADV
gs-3919	70	16	,	,	PUNCT
gs-3919	70	17	il-5	il-5	PROPN
gs-3919	70	18	,	,	PUNCT
gs-3919	70	19	il-13	il-13	NUM
gs-3919	70	20	)	)	PUNCT
gs-3919	70	21	.	.	PUNCT
gs-3919	71	1			VERB
gs-3919	71	2	eosinophil	eosinophil	ADJ
gs-3919	71	3	activation	activation	NOUN
gs-3919	71	4	,	,	PUNCT
gs-3919	71	5	degranulation	degranulation	NOUN
gs-3919	71	6	,	,	PUNCT
gs-3919	71	7	and	and	CCONJ
gs-3919	71	8	endothelial	endothelial	ADJ
gs-3919	71	9	damage	damage	NOUN
gs-3919	71	10	.	.	PUNCT
gs-3919	72	1			VERB
gs-3919	72	2	cross	cross	NOUN
gs-3919	72	3	-	-	NOUN
gs-3919	72	4	reactivity	reactivity	NOUN
gs-3919	72	5	between	between	ADP
gs-3919	72	6	structurally	structurally	ADV
gs-3919	72	7	unrelated	unrelated	ADJ
gs-3919	72	8	drugs	drug	NOUN
gs-3919	72	9	(	(	PUNCT
gs-3919	72	10	e.g.	e.g.	ADV
gs-3919	72	11	,	,	PUNCT
gs-3919	72	12	aromatic	aromatic	ADJ
gs-3919	72	13	amine	amine	ADJ
gs-3919	72	14	drugs	drug	NOUN
gs-3919	72	15	)	)	PUNCT
gs-3919	72	16	.	.	PUNCT
gs-3919	73	1	clinical	clinical	ADJ
gs-3919	73	2	spectrum	spectrum	NOUN
gs-3919	73	3	and	and	CCONJ
gs-3919	73	4	diagnostic	diagnostic	ADJ
gs-3919	73	5	criteria	criterion	NOUN
gs-3919	73	6			VERB
gs-3919	73	7	dress	dress	NOUN
gs-3919	73	8	syndrome	syndrome	NOUN
gs-3919	73	9	:	:	PUNCT
gs-3919	73	10	regiscar	regiscar	NOUN
gs-3919	73	11	criteria	criterion	NOUN
gs-3919	73	12	,	,	PUNCT
gs-3919	73	13	latency	latency	NOUN
gs-3919	73	14	period	period	NOUN
gs-3919	73	15	,	,	PUNCT
gs-3919	73	16	and	and	CCONJ
gs-3919	73	17	organ	organ	NOUN
gs-3919	73	18	involvement	involvement	NOUN
gs-3919	73	19	(	(	PUNCT
gs-3919	73	20	hepatic	hepatic	ADJ
gs-3919	73	21	,	,	PUNCT
gs-3919	73	22	renal	renal	ADJ
gs-3919	73	23	,	,	PUNCT
gs-3919	73	24	cardiac	cardiac	ADJ
gs-3919	73	25	)	)	PUNCT
gs-3919	73	26	.	.	PUNCT
gs-3919	74	1			ADJ
gs-3919	74	2	differential	differential	ADJ
gs-3919	74	3	diagnoses	diagnosis	NOUN
gs-3919	74	4	(	(	PUNCT
gs-3919	74	5	e.g.	e.g.	ADV
gs-3919	74	6	,	,	PUNCT
gs-3919	74	7	viral	viral	ADJ
gs-3919	74	8	exanthems	exanthem	NOUN
gs-3919	74	9	,	,	PUNCT
gs-3919	74	10	autoimmune	autoimmune	ADJ
gs-3919	74	11	eosinophilic	eosinophilic	ADJ
gs-3919	74	12	disorders	disorder	NOUN
gs-3919	74	13	)	)	PUNCT
gs-3919	74	14	.	.	PUNCT
gs-3919	75	1			ADJ
gs-3919	75	2	biomarkers	biomarker	NOUN
gs-3919	75	3	(	(	PUNCT
gs-3919	75	4	e.g.	e.g.	ADV
gs-3919	75	5	,	,	PUNCT
gs-3919	75	6	eosinophil	eosinophil	ADJ
gs-3919	75	7	cationic	cationic	ADJ
gs-3919	75	8	protein	protein	NOUN
gs-3919	75	9	,	,	PUNCT
gs-3919	75	10	serum	serum	NOUN
gs-3919	75	11	il-5	il-5	ADJ
gs-3919	75	12	levels	level	NOUN
gs-3919	75	13	)	)	PUNCT
gs-3919	75	14	.	.	PUNCT
gs-3919	76	1	high	high	ADJ
gs-3919	76	2	-	-	PUNCT
gs-3919	76	3	risk	risk	NOUN
gs-3919	76	4	drug	drug	NOUN
gs-3919	76	5	classes	class	NOUN
gs-3919	76	6	and	and	CCONJ
gs-3919	76	7	case	case	NOUN
gs-3919	76	8	examples	example	NOUN
gs-3919	76	9			VERB
gs-3919	76	10	antibiotics	antibiotic	NOUN
gs-3919	76	11	(	(	PUNCT
gs-3919	76	12	sulfamethoxazole	sulfamethoxazole	NOUN
gs-3919	76	13	-	-	PUNCT
gs-3919	76	14	trimethoprim	trimethoprim	NOUN
gs-3919	76	15	,	,	PUNCT
gs-3919	76	16	vancomycin	vancomycin	PROPN
gs-3919	76	17	)	)	PUNCT
gs-3919	76	18	.	.	PUNCT
gs-3919	77	1			ADJ
gs-3919	77	2	anticonvulsants	anticonvulsant	NOUN
gs-3919	77	3	(	(	PUNCT
gs-3919	77	4	lamotrigine	lamotrigine	NOUN
gs-3919	77	5	,	,	PUNCT
gs-3919	77	6	phenobarbital	phenobarbital	ADJ
gs-3919	77	7	)	)	PUNCT
gs-3919	77	8	.	.	PUNCT
gs-3919	78	1			VERB
gs-3919	78	2	allopurinol	allopurinol	NOUN
gs-3919	78	3	and	and	CCONJ
gs-3919	78	4	its	its	PRON
gs-3919	78	5	association	association	NOUN
gs-3919	78	6	with	with	ADP
gs-3919	78	7	severe	severe	ADJ
gs-3919	78	8	cutaneous	cutaneous	ADJ
gs-3919	78	9	adrs	adr	NOUN
gs-3919	78	10	.	.	PUNCT
gs-3919	79	1	georgian	georgian	ADJ
gs-3919	79	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	79	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	79	4	ტ.	ტ.	VERB
gs-3919	79	5	7	7	NUM
gs-3919	79	6	n	n	PRON
gs-3919	79	7	3	3	NUM
gs-3919	79	8	,	,	PUNCT
gs-3919	79	9	2025	2025	NUM
gs-3919	79	10	146	146	NUM
gs-3919	79	11	therapeutic	therapeutic	ADJ
gs-3919	79	12	interventions	intervention	NOUN
gs-3919	79	13	and	and	CCONJ
gs-3919	79	14	controversies	controversy	NOUN
gs-3919	79	15			VERB
gs-3919	79	16	corticosteroid	corticosteroid	ADJ
gs-3919	79	17	regimens	regimen	NOUN
gs-3919	79	18	:	:	PUNCT
gs-3919	80	1	pulse	pulse	NOUN
gs-3919	80	2	vs.	vs.	ADP
gs-3919	80	3	tapering	tapering	NOUN
gs-3919	80	4	protocols	protocol	NOUN
gs-3919	80	5	.	.	PUNCT
gs-3919	81	1			ADJ
gs-3919	81	2	role	role	NOUN
gs-3919	81	3	of	of	ADP
gs-3919	81	4	ivig	ivig	NOUN
gs-3919	81	5	,	,	PUNCT
gs-3919	81	6	plasmapheresis	plasmapheresis	NOUN
gs-3919	81	7	,	,	PUNCT
gs-3919	81	8	and	and	CCONJ
gs-3919	81	9	biologics	biologic	NOUN
gs-3919	81	10	(	(	PUNCT
gs-3919	81	11	e.g.	e.g.	ADV
gs-3919	81	12	,	,	PUNCT
gs-3919	81	13	anti	anti	ADJ
gs-3919	81	14	-	-	ADJ
gs-3919	81	15	il-5	il-5	PRON
gs-3919	81	16	/	/	SYM
gs-3919	81	17	rα	rα	NOUN
gs-3919	81	18	therapy	therapy	NOUN
gs-3919	81	19	)	)	PUNCT
gs-3919	81	20	.	.	PUNCT
gs-3919	82	1			ADJ
gs-3919	82	2	long	long	ADJ
gs-3919	82	3	-	-	PUNCT
gs-3919	82	4	term	term	NOUN
gs-3919	82	5	sequelae	sequelae	NOUN
gs-3919	82	6	(	(	PUNCT
gs-3919	82	7	e.g.	e.g.	ADV
gs-3919	82	8	,	,	PUNCT
gs-3919	82	9	autoimmune	autoimmune	ADJ
gs-3919	82	10	thyroiditis	thyroiditis	ADJ
gs-3919	82	11	post	post	NOUN
gs-3919	82	12	-	-	NOUN
gs-3919	82	13	dress	dress	ADJ
gs-3919	82	14	)	)	PUNCT
gs-3919	82	15	.	.	PUNCT
gs-3919	83	1	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	83	2	and	and	CCONJ
gs-3919	83	3	risk	risk	NOUN
gs-3919	83	4	mitigation	mitigation	NOUN
gs-3919	83	5	strategies	strategy	NOUN
gs-3919	83	6			VERB
gs-3919	83	7	pre	pre	ADJ
gs-3919	83	8	-	-	NOUN
gs-3919	83	9	therapy	therapy	ADJ
gs-3919	83	10	screening	screening	NOUN
gs-3919	83	11	(	(	PUNCT
gs-3919	83	12	hla	hla	NOUN
gs-3919	83	13	typing	typing	NOUN
gs-3919	83	14	,	,	PUNCT
gs-3919	83	15	patch	patch	ADJ
gs-3919	83	16	testing	testing	NOUN
gs-3919	83	17	)	)	PUNCT
gs-3919	83	18	.	.	PUNCT
gs-3919	84	1			VERB
gs-3919	84	2	post	post	ADJ
gs-3919	84	3	-	-	ADJ
gs-3919	84	4	marketing	marketing	ADJ
gs-3919	84	5	surveillance	surveillance	NOUN
gs-3919	84	6	data	datum	NOUN
gs-3919	84	7	(	(	PUNCT
gs-3919	84	8	faers	faer	NOUN
gs-3919	84	9	,	,	PUNCT
gs-3919	84	10	who	who	PRON
gs-3919	84	11	vigibase	vigibase	VERB
gs-3919	84	12	)	)	PUNCT
gs-3919	84	13	.	.	PUNCT
gs-3919	85	1			ADJ
gs-3919	85	2	patient	patient	ADJ
gs-3919	85	3	education	education	NOUN
gs-3919	85	4	and	and	CCONJ
gs-3919	85	5	rechallenge	rechallenge	NOUN
gs-3919	85	6	protocols	protocol	NOUN
gs-3919	85	7	.	.	PUNCT
gs-3919	86	1	future	future	ADJ
gs-3919	86	2	directions	direction	NOUN
gs-3919	86	3	and	and	CCONJ
gs-3919	86	4	research	research	NOUN
gs-3919	86	5	gaps	gap	NOUN
gs-3919	86	6			VERB
gs-3919	86	7	in	in	ADP
gs-3919	86	8	vitro	vitro	X
gs-3919	86	9	models	model	NOUN
gs-3919	86	10	(	(	PUNCT
gs-3919	86	11	lymphocyte	lymphocyte	ADJ
gs-3919	86	12	transformation	transformation	NOUN
gs-3919	86	13	test	test	NOUN
gs-3919	86	14	)	)	PUNCT
gs-3919	86	15	.	.	PUNCT
gs-3919	87	1			ADJ
gs-3919	87	2	personalized	personalized	ADJ
gs-3919	87	3	medicine	medicine	NOUN
gs-3919	87	4	approaches	approach	NOUN
gs-3919	87	5	(	(	PUNCT
gs-3919	87	6	pharmacogenomics	pharmacogenomic	NOUN
gs-3919	87	7	)	)	PUNCT
gs-3919	87	8	.	.	PUNCT
gs-3919	88	1			ADJ
gs-3919	88	2	novel	novel	ADJ
gs-3919	88	3	biomarkers	biomarker	NOUN
gs-3919	88	4	for	for	ADP
gs-3919	88	5	early	early	ADJ
gs-3919	88	6	detection	detection	NOUN
gs-3919	88	7	.	.	PUNCT
gs-3919	89	1	on	on	ADP
gs-3919	89	2	an	an	DET
gs-3919	89	3	epidemiological	epidemiological	ADJ
gs-3919	89	4	level	level	NOUN
gs-3919	89	5	,	,	PUNCT
gs-3919	89	6	the	the	DET
gs-3919	89	7	incidence	incidence	NOUN
gs-3919	89	8	of	of	ADP
gs-3919	89	9	dress	dress	NOUN
gs-3919	89	10	is	be	AUX
gs-3919	89	11	thought	think	VERB
gs-3919	89	12	to	to	PART
gs-3919	89	13	be	be	AUX
gs-3919	89	14	1/1,000	1/1,000	NUM
gs-3919	89	15	to	to	ADP
gs-3919	89	16	1/10,000	1/10,000	NUM
gs-3919	89	17	drug	drug	NOUN
gs-3919	89	18	exposures	exposure	NOUN
gs-3919	89	19	,	,	PUNCT
gs-3919	89	20	though	though	SCONJ
gs-3919	89	21	this	this	PRON
gs-3919	89	22	is	be	AUX
gs-3919	89	23	likely	likely	ADJ
gs-3919	89	24	an	an	DET
gs-3919	89	25	underestimate	underestimate	ADJ
gs-3919	89	26	,	,	PUNCT
gs-3919	89	27	probably	probably	ADV
gs-3919	89	28	due	due	ADP
gs-3919	89	29	to	to	ADP
gs-3919	89	30	the	the	DET
gs-3919	89	31	variable	variable	ADJ
gs-3919	89	32	presentations	presentation	NOUN
gs-3919	89	33	and	and	CCONJ
gs-3919	89	34	the	the	DET
gs-3919	89	35	delayed	delay	VERB
gs-3919	89	36	interval	interval	NOUN
gs-3919	89	37	between	between	ADP
gs-3919	89	38	drug	drug	NOUN
gs-3919	89	39	administration	administration	NOUN
gs-3919	89	40	and	and	CCONJ
gs-3919	89	41	symptom	symptom	NOUN
gs-3919	89	42	onset	onset	NOUN
gs-3919	89	43	.	.	PUNCT
gs-3919	90	1	the	the	DET
gs-3919	90	2	heterogeneous	heterogeneous	ADJ
gs-3919	90	3	presentation	presentation	NOUN
gs-3919	90	4	complicates	complicate	VERB
gs-3919	90	5	identification	identification	NOUN
gs-3919	90	6	and	and	CCONJ
gs-3919	90	7	reporting	reporting	NOUN
gs-3919	90	8	,	,	PUNCT
gs-3919	90	9	potentially	potentially	ADV
gs-3919	90	10	delaying	delay	VERB
gs-3919	90	11	life	life	NOUN
gs-3919	90	12	-	-	PUNCT
gs-3919	90	13	saving	save	VERB
gs-3919	90	14	interventions	intervention	NOUN
gs-3919	90	15	.	.	PUNCT
gs-3919	91	1	in	in	ADP
gs-3919	91	2	recent	recent	ADJ
gs-3919	91	3	years	year	NOUN
gs-3919	91	4	,	,	PUNCT
gs-3919	91	5	clinical	clinical	ADJ
gs-3919	91	6	awareness	awareness	NOUN
gs-3919	91	7	,	,	PUNCT
gs-3919	91	8	diagnostic	diagnostic	ADJ
gs-3919	91	9	criteria	criterion	NOUN
gs-3919	91	10	,	,	PUNCT
gs-3919	91	11	and	and	CCONJ
gs-3919	91	12	understanding	understanding	NOUN
gs-3919	91	13	of	of	ADP
gs-3919	91	14	pathophysiology	pathophysiology	NOUN
gs-3919	91	15	and	and	CCONJ
gs-3919	91	16	genetic	genetic	ADJ
gs-3919	91	17	susceptibility	susceptibility	NOUN
gs-3919	91	18	have	have	AUX
gs-3919	91	19	improved	improve	VERB
gs-3919	91	20	recognition	recognition	NOUN
gs-3919	91	21	and	and	CCONJ
gs-3919	91	22	management	management	NOUN
gs-3919	91	23	of	of	ADP
gs-3919	91	24	the	the	DET
gs-3919	91	25	disorder	disorder	NOUN
gs-3919	91	26	.	.	PUNCT
gs-3919	92	1	the	the	DET
gs-3919	92	2	syndrome	syndrome	NOUN
gs-3919	92	3	is	be	AUX
gs-3919	92	4	pharmacologically	pharmacologically	ADV
gs-3919	92	5	associated	associate	VERB
gs-3919	92	6	with	with	ADP
gs-3919	92	7	a	a	DET
gs-3919	92	8	limited	limited	ADJ
gs-3919	92	9	but	but	CCONJ
gs-3919	92	10	clinically	clinically	ADV
gs-3919	92	11	important	important	ADJ
gs-3919	92	12	number	number	NOUN
gs-3919	92	13	of	of	ADP
gs-3919	92	14	drugs	drug	NOUN
gs-3919	92	15	.	.	PUNCT
gs-3919	93	1	anticonvulsants	anticonvulsant	NOUN
gs-3919	93	2	such	such	ADJ
gs-3919	93	3	as	as	ADP
gs-3919	93	4	carbamazepine	carbamazepine	NOUN
gs-3919	93	5	and	and	CCONJ
gs-3919	93	6	phenytoin	phenytoin	NOUN
gs-3919	93	7	remain	remain	VERB
gs-3919	93	8	common	common	ADJ
gs-3919	93	9	triggers	trigger	NOUN
gs-3919	93	10	,	,	PUNCT
gs-3919	93	11	likely	likely	ADJ
gs-3919	93	12	due	due	ADP
gs-3919	93	13	to	to	ADP
gs-3919	93	14	their	their	PRON
gs-3919	93	15	reactive	reactive	ADJ
gs-3919	93	16	metabolites	metabolite	NOUN
gs-3919	93	17	inducing	induce	VERB
gs-3919	93	18	immune	immune	ADJ
gs-3919	93	19	hypersensitivity	hypersensitivity	NOUN
gs-3919	93	20	(	(	PUNCT
gs-3919	93	21	saleem	saleem	PROPN
gs-3919	93	22	et	et	PROPN
gs-3919	93	23	al	al	PROPN
gs-3919	93	24	.	.	PROPN
gs-3919	93	25	,	,	PUNCT
gs-3919	93	26	2025	2025	NUM
gs-3919	93	27	;	;	PUNCT
gs-3919	93	28	thompson	thompson	PROPN
gs-3919	93	29	et	et	PROPN
gs-3919	93	30	al	al	PROPN
gs-3919	93	31	.	.	PROPN
gs-3919	93	32	,	,	PUNCT
gs-3919	93	33	2024	2024	NUM
gs-3919	93	34	)	)	PUNCT
gs-3919	93	35	.	.	PUNCT
gs-3919	94	1	sulfonamide	sulfonamide	NOUN
gs-3919	94	2	antibiotics	antibiotic	NOUN
gs-3919	94	3	,	,	PUNCT
gs-3919	94	4	notably	notably	ADV
gs-3919	94	5	sulfamethoxazole	sulfamethoxazole	NOUN
gs-3919	94	6	,	,	PUNCT
gs-3919	94	7	allopurinol	allopurinol	NOUN
gs-3919	94	8	,	,	PUNCT
gs-3919	94	9	and	and	CCONJ
gs-3919	94	10	some	some	DET
gs-3919	94	11	nsaids	nsaid	NOUN
gs-3919	94	12	including	include	VERB
gs-3919	94	13	mefenamic	mefenamic	ADJ
gs-3919	94	14	acid	acid	NOUN
gs-3919	94	15	,	,	PUNCT
gs-3919	94	16	are	be	AUX
gs-3919	94	17	also	also	ADV
gs-3919	94	18	major	major	ADJ
gs-3919	94	19	causative	causative	ADJ
gs-3919	94	20	agents	agent	NOUN
gs-3919	94	21	.	.	PUNCT
gs-3919	95	1	the	the	DET
gs-3919	95	2	growing	grow	VERB
gs-3919	95	3	recognition	recognition	NOUN
gs-3919	95	4	of	of	ADP
gs-3919	95	5	nsaids	nsaid	NOUN
gs-3919	95	6	as	as	ADP
gs-3919	95	7	causes	cause	NOUN
gs-3919	95	8	of	of	ADP
gs-3919	95	9	dress	dress	NOUN
gs-3919	95	10	calls	call	NOUN
gs-3919	95	11	for	for	ADP
gs-3919	95	12	vigilance	vigilance	NOUN
gs-3919	95	13	given	give	VERB
gs-3919	95	14	their	their	PRON
gs-3919	95	15	widespread	widespread	ADJ
gs-3919	95	16	use	use	NOUN
gs-3919	95	17	.	.	PUNCT
gs-3919	96	1	eosinophilia	eosinophilia	PROPN
gs-3919	96	2	is	be	AUX
gs-3919	96	3	the	the	DET
gs-3919	96	4	overabundance	overabundance	NOUN
gs-3919	96	5	of	of	ADP
gs-3919	96	6	eosinophils	eosinophil	NOUN
gs-3919	96	7	in	in	ADP
gs-3919	96	8	the	the	DET
gs-3919	96	9	bloodstream	bloodstream	NOUN
gs-3919	96	10	.	.	PUNCT
gs-3919	97	1	eosinophils	eosinophil	NOUN
gs-3919	97	2	are	be	AUX
gs-3919	97	3	a	a	DET
gs-3919	97	4	variety	variety	NOUN
gs-3919	97	5	of	of	ADP
gs-3919	97	6	white	white	ADJ
gs-3919	97	7	blood	blood	NOUN
gs-3919	97	8	cell	cell	NOUN
gs-3919	97	9	that	that	PRON
gs-3919	97	10	participates	participate	VERB
gs-3919	97	11	in	in	ADP
gs-3919	97	12	immune	immune	ADJ
gs-3919	97	13	responses	response	NOUN
gs-3919	97	14	-notably	-notably	ADV
gs-3919	97	15	those	those	PRON
gs-3919	97	16	that	that	PRON
gs-3919	97	17	cause	cause	VERB
gs-3919	97	18	allergies	allergy	NOUN
gs-3919	97	19	,	,	PUNCT
gs-3919	97	20	parasitic	parasitic	ADJ
gs-3919	97	21	infections	infection	NOUN
gs-3919	97	22	and	and	CCONJ
gs-3919	97	23	certain	certain	ADJ
gs-3919	97	24	drug	drug	NOUN
gs-3919	97	25	reactions	reaction	NOUN
gs-3919	97	26	,	,	PUNCT
gs-3919	97	27	such	such	ADJ
gs-3919	97	28	as	as	ADP
gs-3919	97	29	dress	dress	NOUN
gs-3919	97	30	.	.	PUNCT
gs-3919	98	1			ADJ
gs-3919	98	2	eosinophils	eosinophil	NOUN
gs-3919	98	3	count	count	NOUN
gs-3919	98	4	range	range	NOUN
gs-3919	98	5	:	:	PUNCT
gs-3919	98	6	0	0	NUM
gs-3919	98	7	-	-	SYM
gs-3919	98	8	500	500	NUM
gs-3919	98	9	cells/µl	cells/µl	NOUN
gs-3919	98	10	(	(	PUNCT
gs-3919	98	11	microliter	microliter	NOUN
gs-3919	98	12	)	)	PUNCT
gs-3919	98	13			VERB
gs-3919	98	14	mild	mild	ADJ
gs-3919	98	15	eosinophilia	eosinophilia	NOUN
gs-3919	98	16	:	:	PUNCT
gs-3919	98	17	500–1,500	500–1,500	NUM
gs-3919	98	18	cells/µl	cells/µl	NOUN
gs-3919	98	19			VERB
gs-3919	98	20	moderate	moderate	ADJ
gs-3919	98	21	eosinophilia	eosinophilia	PROPN
gs-3919	98	22	:	:	PUNCT
gs-3919	98	23	1,500–5,000	1,500–5,000	NUM
gs-3919	98	24	cells/µl	cells/µl	NOUN
gs-3919	98	25			VERB
gs-3919	98	26	severe	severe	ADJ
gs-3919	98	27	eosinophilia	eosinophilia	PROPN
gs-3919	98	28	:	:	PUNCT
gs-3919	98	29	>	>	SYM
gs-3919	98	30	5,000	5,000	NUM
gs-3919	98	31	cells/µl	cells/µl	NOUN
gs-3919	98	32	eosinophilia	eosinophilia	NOUN
gs-3919	98	33	(	(	PUNCT
gs-3919	98	34	eosinophil	eosinophil	ADJ
gs-3919	98	35	count	count	VERB
gs-3919	98	36	>	>	PUNCT
gs-3919	98	37	500	500	NUM
gs-3919	98	38	cells	cell	NOUN
gs-3919	98	39	/	/	SYM
gs-3919	98	40	μl	μl	CCONJ
gs-3919	98	41	)	)	PUNCT
gs-3919	98	42	is	be	AUX
gs-3919	98	43	a	a	DET
gs-3919	98	44	classic	classic	ADJ
gs-3919	98	45	diagnostic	diagnostic	ADJ
gs-3919	98	46	laboratory	laboratory	NOUN
gs-3919	98	47	finding	finding	NOUN
gs-3919	98	48	in	in	ADP
gs-3919	98	49	dress	dress	NOUN
gs-3919	98	50	,	,	PUNCT
gs-3919	98	51	and	and	CCONJ
gs-3919	98	52	while	while	SCONJ
gs-3919	98	53	integral	integral	ADJ
gs-3919	98	54	to	to	ADP
gs-3919	98	55	diagnosis	diagnosis	NOUN
gs-3919	98	56	,	,	PUNCT
gs-3919	98	57	clinicians	clinician	NOUN
gs-3919	98	58	should	should	AUX
gs-3919	98	59	not	not	PART
gs-3919	98	60	rely	rely	VERB
gs-3919	98	61	solely	solely	ADV
gs-3919	98	62	on	on	ADP
gs-3919	98	63	eosinophil	eosinophil	ADJ
gs-3919	98	64	counts	count	NOUN
gs-3919	98	65	to	to	PART
gs-3919	98	66	recognize	recognize	VERB
gs-3919	98	67	systemic	systemic	ADJ
gs-3919	98	68	involvement	involvement	NOUN
gs-3919	98	69	such	such	ADJ
gs-3919	98	70	as	as	ADP
gs-3919	98	71	liver	liver	NOUN
gs-3919	98	72	or	or	CCONJ
gs-3919	98	73	kidney	kidney	NOUN
gs-3919	98	74	injury	injury	NOUN
gs-3919	98	75	that	that	PRON
gs-3919	98	76	may	may	AUX
gs-3919	98	77	progress	progress	VERB
gs-3919	98	78	rapidly	rapidly	ADV
gs-3919	98	79	and	and	CCONJ
gs-3919	98	80	require	require	VERB
gs-3919	98	81	emergent	emergent	ADJ
gs-3919	98	82	treatmen	treatman	NOUN
gs-3919	98	83	.	.	PUNCT
gs-3919	99	1	a	a	DET
gs-3919	99	2	combination	combination	NOUN
gs-3919	99	3	of	of	ADP
gs-3919	99	4	cutaneous	cutaneous	ADJ
gs-3919	99	5	signs	sign	NOUN
gs-3919	99	6	,	,	PUNCT
gs-3919	99	7	georgian	georgian	ADJ
gs-3919	99	8	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	99	9	მეცნიერები	მეცნიერები	NOUN
gs-3919	99	10	ტ.	ტ.	VERB
gs-3919	99	11	7	7	NUM
gs-3919	99	12	n	n	PRON
gs-3919	99	13	3	3	NUM
gs-3919	99	14	,	,	PUNCT
gs-3919	99	15	2025	2025	NUM
gs-3919	99	16	147	147	NUM
gs-3919	99	17	haematological	haematological	ADJ
gs-3919	99	18	abnormalities	abnormality	NOUN
gs-3919	99	19	,	,	PUNCT
gs-3919	99	20	and	and	CCONJ
gs-3919	99	21	extracutaneous	extracutaneous	ADJ
gs-3919	99	22	organ	organ	NOUN
gs-3919	99	23	involvement	involvement	NOUN
gs-3919	99	24	aids	aid	NOUN
gs-3919	99	25	in	in	ADP
gs-3919	99	26	distinguishing	distinguish	VERB
gs-3919	99	27	dress	dress	NOUN
gs-3919	99	28	from	from	ADP
gs-3919	99	29	other	other	ADJ
gs-3919	99	30	drug	drug	NOUN
gs-3919	99	31	eruptions	eruption	NOUN
gs-3919	99	32	or	or	CCONJ
gs-3919	99	33	systemic	systemic	ADJ
gs-3919	99	34	diseases	disease	NOUN
gs-3919	99	35	(	(	PUNCT
gs-3919	99	36	st	st	PROPN
gs-3919	99	37	george	george	PROPN
gs-3919	99	38	-	-	PUNCT
gs-3919	99	39	hyslop	hyslop	PROPN
gs-3919	99	40	et	et	PROPN
gs-3919	99	41	al	al	PROPN
gs-3919	99	42	.	.	PROPN
gs-3919	99	43	,	,	PUNCT
gs-3919	99	44	2024	2024	NUM
gs-3919	99	45	)	)	PUNCT
gs-3919	99	46	.	.	PUNCT
gs-3919	100	1	the	the	DET
gs-3919	100	2	underlying	underlie	VERB
gs-3919	100	3	mechanisms	mechanism	NOUN
gs-3919	100	4	responsible	responsible	ADJ
gs-3919	100	5	for	for	ADP
gs-3919	100	6	dress	dress	NOUN
gs-3919	100	7	are	be	AUX
gs-3919	100	8	complex	complex	ADJ
gs-3919	100	9	and	and	CCONJ
gs-3919	100	10	involve	involve	VERB
gs-3919	100	11	impaired	impaired	ADJ
gs-3919	100	12	drug	drug	NOUN
gs-3919	100	13	metabolism	metabolism	NOUN
gs-3919	100	14	,	,	PUNCT
gs-3919	100	15	immune	immune	ADJ
gs-3919	100	16	dysregulation	dysregulation	NOUN
gs-3919	100	17	,	,	PUNCT
gs-3919	100	18	and	and	CCONJ
gs-3919	100	19	viral	viral	ADJ
gs-3919	100	20	reactivation	reactivation	NOUN
gs-3919	100	21	,	,	PUNCT
gs-3919	100	22	particularly	particularly	ADV
gs-3919	100	23	human	human	ADJ
gs-3919	100	24	herpesvirus	herpesvirus	NOUN
gs-3919	100	25	6	6	NUM
gs-3919	100	26	(	(	PUNCT
gs-3919	100	27	hhv-6	hhv-6	NOUN
gs-3919	100	28	)	)	PUNCT
gs-3919	100	29	,	,	PUNCT
gs-3919	100	30	as	as	ADV
gs-3919	100	31	well	well	ADV
gs-3919	100	32	as	as	ADP
gs-3919	100	33	other	other	ADJ
gs-3919	100	34	herpesviruses	herpesviruse	NOUN
gs-3919	100	35	such	such	ADJ
gs-3919	100	36	as	as	ADP
gs-3919	100	37	epstein	epstein	PROPN
gs-3919	100	38	-	-	PUNCT
gs-3919	100	39	barr	barr	PROPN
gs-3919	100	40	virus	virus	PROPN
gs-3919	100	41	.	.	PUNCT
gs-3919	101	1	reactivation	reactivation	NOUN
gs-3919	101	2	of	of	ADP
gs-3919	101	3	these	these	DET
gs-3919	101	4	viruses	virus	NOUN
gs-3919	101	5	may	may	AUX
gs-3919	101	6	amplify	amplify	VERB
gs-3919	101	7	immune	immune	ADJ
gs-3919	101	8	responses	response	NOUN
gs-3919	101	9	and	and	CCONJ
gs-3919	101	10	systemic	systemic	ADJ
gs-3919	101	11	inflammation	inflammation	NOUN
gs-3919	101	12	characteristic	characteristic	NOUN
gs-3919	101	13	of	of	ADP
gs-3919	101	14	dress	dress	NOUN
gs-3919	101	15	.	.	PUNCT
gs-3919	102	1	genetic	genetic	ADJ
gs-3919	102	2	susceptibility	susceptibility	NOUN
gs-3919	102	3	also	also	ADV
gs-3919	102	4	plays	play	VERB
gs-3919	102	5	a	a	DET
gs-3919	102	6	key	key	ADJ
gs-3919	102	7	role	role	NOUN
gs-3919	102	8	,	,	PUNCT
gs-3919	102	9	with	with	ADP
gs-3919	102	10	specific	specific	ADJ
gs-3919	102	11	human	human	ADJ
gs-3919	102	12	leukocyte	leukocyte	NOUN
gs-3919	102	13	antigen	antigen	NOUN
gs-3919	102	14	(	(	PUNCT
gs-3919	102	15	hla	hla	NOUN
gs-3919	102	16	)	)	PUNCT
gs-3919	102	17	alleles	allele	NOUN
gs-3919	102	18	,	,	PUNCT
gs-3919	102	19	such	such	ADJ
gs-3919	102	20	as	as	ADP
gs-3919	102	21	hla	hla	NOUN
gs-3919	102	22	-	-	PUNCT
gs-3919	102	23	b58:01	b58:01	NOUN
gs-3919	102	24	,	,	PUNCT
gs-3919	102	25	strongly	strongly	ADV
gs-3919	102	26	linked	link	VERB
gs-3919	102	27	to	to	ADP
gs-3919	102	28	allopurinol	allopurinol	NOUN
gs-3919	102	29	-	-	PUNCT
gs-3919	102	30	induced	induce	VERB
gs-3919	102	31	dress	dress	NOUN
gs-3919	102	32	,	,	PUNCT
gs-3919	102	33	especially	especially	ADV
gs-3919	102	34	among	among	ADP
gs-3919	102	35	asian	asian	ADJ
gs-3919	102	36	populations	population	NOUN
gs-3919	102	37	.	.	PUNCT
gs-3919	103	1	although	although	SCONJ
gs-3919	103	2	dress	dress	NOUN
gs-3919	103	3	can	can	AUX
gs-3919	103	4	be	be	AUX
gs-3919	103	5	life	life	NOUN
gs-3919	103	6	-	-	PUNCT
gs-3919	103	7	threatening	threatening	ADJ
gs-3919	103	8	,	,	PUNCT
gs-3919	103	9	timely	timely	ADJ
gs-3919	103	10	diagnosis	diagnosis	NOUN
gs-3919	103	11	and	and	CCONJ
gs-3919	103	12	intervention	intervention	NOUN
gs-3919	103	13	are	be	AUX
gs-3919	103	14	critical	critical	ADJ
gs-3919	103	15	to	to	PART
gs-3919	103	16	minimize	minimize	VERB
gs-3919	103	17	complications	complication	NOUN
gs-3919	103	18	.	.	PUNCT
gs-3919	104	1	standard	standard	ADJ
gs-3919	104	2	management	management	NOUN
gs-3919	104	3	involves	involve	VERB
gs-3919	104	4	prompt	prompt	ADJ
gs-3919	104	5	discontinuation	discontinuation	NOUN
gs-3919	104	6	of	of	ADP
gs-3919	104	7	the	the	DET
gs-3919	104	8	causative	causative	ADJ
gs-3919	104	9	drug	drug	NOUN
gs-3919	104	10	and	and	CCONJ
gs-3919	104	11	early	early	ADJ
gs-3919	104	12	systemic	systemic	ADJ
gs-3919	104	13	corticosteroid	corticosteroid	ADJ
gs-3919	104	14	use	use	NOUN
gs-3919	104	15	to	to	PART
gs-3919	104	16	mitigate	mitigate	VERB
gs-3919	104	17	immune	immune	NOUN
gs-3919	104	18	-	-	PUNCT
gs-3919	104	19	mediated	mediate	VERB
gs-3919	104	20	damage	damage	NOUN
gs-3919	104	21	(	(	PUNCT
gs-3919	104	22	shakour	shakour	NOUN
gs-3919	104	23	,	,	PUNCT
gs-3919	104	24	mumtaz	mumtaz	PROPN
gs-3919	104	25	,	,	PUNCT
gs-3919	104	26	&	&	CCONJ
gs-3919	104	27	abu	abu	PROPN
gs-3919	104	28	-	-	PUNCT
gs-3919	104	29	samra	samra	NOUN
gs-3919	104	30	,	,	PUNCT
gs-3919	104	31	2025	2025	NUM
gs-3919	104	32	;	;	PUNCT
gs-3919	104	33	shiohara	shiohara	PROPN
gs-3919	104	34	&	&	CCONJ
gs-3919	104	35	mizukawa	mizukawa	PROPN
gs-3919	104	36	,	,	PUNCT
gs-3919	104	37	2019	2019	NUM
gs-3919	104	38	)	)	PUNCT
gs-3919	104	39	.	.	PUNCT
gs-3919	105	1	while	while	SCONJ
gs-3919	105	2	corticosteroids	corticosteroid	NOUN
gs-3919	105	3	are	be	AUX
gs-3919	105	4	the	the	DET
gs-3919	105	5	mainstay	mainstay	NOUN
gs-3919	105	6	,	,	PUNCT
gs-3919	105	7	optimal	optimal	ADJ
gs-3919	105	8	dosing	dosing	NOUN
gs-3919	105	9	,	,	PUNCT
gs-3919	105	10	duration	duration	NOUN
gs-3919	105	11	,	,	PUNCT
gs-3919	105	12	and	and	CCONJ
gs-3919	105	13	the	the	DET
gs-3919	105	14	role	role	NOUN
gs-3919	105	15	of	of	ADP
gs-3919	105	16	adjunctive	adjunctive	ADJ
gs-3919	105	17	immunomodulatory	immunomodulatory	ADJ
gs-3919	105	18	therapies	therapy	NOUN
gs-3919	105	19	remain	remain	VERB
gs-3919	105	20	areas	area	NOUN
gs-3919	105	21	of	of	ADP
gs-3919	105	22	debate	debate	NOUN
gs-3919	105	23	.	.	PUNCT
gs-3919	106	1	the	the	DET
gs-3919	106	2	variable	variable	ADJ
gs-3919	106	3	clinical	clinical	ADJ
gs-3919	106	4	presentation	presentation	NOUN
gs-3919	106	5	and	and	CCONJ
gs-3919	106	6	overlap	overlap	NOUN
gs-3919	106	7	with	with	ADP
gs-3919	106	8	other	other	ADJ
gs-3919	106	9	hypersensitivity	hypersensitivity	NOUN
gs-3919	106	10	syndromes	syndrome	NOUN
gs-3919	106	11	often	often	ADV
gs-3919	106	12	delay	delay	VERB
gs-3919	106	13	diagnosis	diagnosis	NOUN
gs-3919	106	14	,	,	PUNCT
gs-3919	106	15	underscoring	underscore	VERB
gs-3919	106	16	the	the	DET
gs-3919	106	17	need	need	NOUN
gs-3919	106	18	for	for	ADP
gs-3919	106	19	clinician	clinician	ADJ
gs-3919	106	20	awareness	awareness	NOUN
gs-3919	106	21	of	of	ADP
gs-3919	106	22	the	the	DET
gs-3919	106	23	broad	broad	ADJ
gs-3919	106	24	spectrum	spectrum	NOUN
gs-3919	106	25	of	of	ADP
gs-3919	106	26	dress	dress	NOUN
gs-3919	106	27	manifestations	manifestation	NOUN
gs-3919	106	28	.	.	PUNCT
gs-3919	107	1	this	this	DET
gs-3919	107	2	project	project	NOUN
gs-3919	107	3	's	's	PART
gs-3919	107	4	main	main	ADJ
gs-3919	107	5	objective	objective	NOUN
gs-3919	107	6	is	be	AUX
gs-3919	107	7	to	to	PART
gs-3919	107	8	explore	explore	VERB
gs-3919	107	9	drug	drug	NOUN
gs-3919	107	10	-	-	PUNCT
gs-3919	107	11	related	relate	VERB
gs-3919	107	12	features	feature	NOUN
gs-3919	107	13	associated	associate	VERB
gs-3919	107	14	with	with	ADP
gs-3919	107	15	dress	dress	NOUN
gs-3919	107	16	and	and	CCONJ
gs-3919	107	17	its	its	PRON
gs-3919	107	18	clinical	clinical	ADJ
gs-3919	107	19	outcomes	outcome	NOUN
gs-3919	107	20	,	,	PUNCT
gs-3919	107	21	with	with	ADP
gs-3919	107	22	an	an	DET
gs-3919	107	23	emphasis	emphasis	NOUN
gs-3919	107	24	on	on	ADP
gs-3919	107	25	nsaids	nsaid	NOUN
gs-3919	107	26	,	,	PUNCT
gs-3919	107	27	which	which	PRON
gs-3919	107	28	are	be	AUX
gs-3919	107	29	relatively	relatively	ADV
gs-3919	107	30	underreported	underreported	ADJ
gs-3919	107	31	in	in	ADP
gs-3919	107	32	the	the	DET
gs-3919	107	33	literature	literature	NOUN
gs-3919	107	34	.	.	PUNCT
gs-3919	108	1	other	other	ADJ
gs-3919	108	2	pharmacological	pharmacological	ADJ
gs-3919	108	3	classes	class	NOUN
gs-3919	108	4	will	will	AUX
gs-3919	108	5	also	also	ADV
gs-3919	108	6	be	be	AUX
gs-3919	108	7	reviewed	review	VERB
gs-3919	108	8	.	.	PUNCT
gs-3919	109	1	through	through	ADP
gs-3919	109	2	a	a	DET
gs-3919	109	3	systematic	systematic	ADJ
gs-3919	109	4	review	review	NOUN
gs-3919	109	5	,	,	PUNCT
gs-3919	109	6	this	this	DET
gs-3919	109	7	thesis	thesis	NOUN
gs-3919	109	8	aims	aim	VERB
gs-3919	109	9	to	to	PART
gs-3919	109	10	identify	identify	VERB
gs-3919	109	11	common	common	ADJ
gs-3919	109	12	clinical	clinical	ADJ
gs-3919	109	13	features	feature	NOUN
gs-3919	109	14	,	,	PUNCT
gs-3919	109	15	organ	organ	NOUN
gs-3919	109	16	involvement	involvement	NOUN
gs-3919	109	17	,	,	PUNCT
gs-3919	109	18	medication	medication	NOUN
gs-3919	109	19	triggers	trigger	NOUN
gs-3919	109	20	,	,	PUNCT
gs-3919	109	21	and	and	CCONJ
gs-3919	109	22	genetic	genetic	ADJ
gs-3919	109	23	susceptibilities	susceptibility	NOUN
gs-3919	109	24	,	,	PUNCT
gs-3919	109	25	providing	provide	VERB
gs-3919	109	26	comprehensive	comprehensive	ADJ
gs-3919	109	27	insights	insight	NOUN
gs-3919	109	28	to	to	PART
gs-3919	109	29	improve	improve	VERB
gs-3919	109	30	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	109	31	and	and	CCONJ
gs-3919	109	32	clinical	clinical	ADJ
gs-3919	109	33	management	management	NOUN
gs-3919	109	34	protocols	protocol	NOUN
gs-3919	109	35	in	in	ADP
gs-3919	109	36	modern	modern	ADJ
gs-3919	109	37	healthcare	healthcare	NOUN
gs-3919	109	38	.	.	PUNCT
gs-3919	110	1	the	the	DET
gs-3919	110	2	intersection	intersection	NOUN
gs-3919	110	3	of	of	ADP
gs-3919	110	4	pharmacology	pharmacology	NOUN
gs-3919	110	5	and	and	CCONJ
gs-3919	110	6	immunology	immunology	NOUN
gs-3919	110	7	presents	present	VERB
gs-3919	110	8	a	a	DET
gs-3919	110	9	complex	complex	ADJ
gs-3919	110	10	landscape	landscape	NOUN
gs-3919	110	11	where	where	SCONJ
gs-3919	110	12	therapeutic	therapeutic	ADJ
gs-3919	110	13	efficacy	efficacy	NOUN
gs-3919	110	14	must	must	AUX
gs-3919	110	15	be	be	AUX
gs-3919	110	16	carefully	carefully	ADV
gs-3919	110	17	balanced	balance	VERB
gs-3919	110	18	against	against	ADP
gs-3919	110	19	potential	potential	ADJ
gs-3919	110	20	adverse	adverse	ADJ
gs-3919	110	21	reactions	reaction	NOUN
gs-3919	110	22	.	.	PUNCT
gs-3919	111	1	among	among	ADP
gs-3919	111	2	the	the	DET
gs-3919	111	3	myriad	myriad	ADJ
gs-3919	111	4	challenges	challenge	NOUN
gs-3919	111	5	in	in	ADP
gs-3919	111	6	pharmacotherapy	pharmacotherapy	NOUN
gs-3919	111	7	,	,	PUNCT
gs-3919	111	8	drug	drug	NOUN
gs-3919	111	9	-	-	PUNCT
gs-3919	111	10	induced	induce	VERB
gs-3919	111	11	eosinophilia	eosinophilia	NOUN
gs-3919	111	12	and	and	CCONJ
gs-3919	111	13	its	its	PRON
gs-3919	111	14	systemic	systemic	ADJ
gs-3919	111	15	manifestations	manifestation	NOUN
gs-3919	111	16	stand	stand	VERB
gs-3919	111	17	as	as	ADP
gs-3919	111	18	a	a	DET
gs-3919	111	19	particularly	particularly	ADV
gs-3919	111	20	intricate	intricate	ADJ
gs-3919	111	21	and	and	CCONJ
gs-3919	111	22	clinically	clinically	ADV
gs-3919	111	23	significant	significant	ADJ
gs-3919	111	24	phenomenon	phenomenon	NOUN
gs-3919	111	25	.	.	PUNCT
gs-3919	112	1	this	this	DET
gs-3919	112	2	condition	condition	NOUN
gs-3919	112	3	,	,	PUNCT
gs-3919	112	4	often	often	ADV
gs-3919	112	5	underrecognized	underrecognized	ADJ
gs-3919	112	6	in	in	ADP
gs-3919	112	7	its	its	PRON
gs-3919	112	8	early	early	ADJ
gs-3919	112	9	stages	stage	NOUN
gs-3919	112	10	,	,	PUNCT
gs-3919	112	11	can	can	AUX
gs-3919	112	12	progress	progress	VERB
gs-3919	112	13	to	to	ADP
gs-3919	112	14	severe	severe	ADJ
gs-3919	112	15	,	,	PUNCT
gs-3919	112	16	sometimes	sometimes	ADV
gs-3919	112	17	life	life	NOUN
gs-3919	112	18	-	-	PUNCT
gs-3919	112	19	threatening	threaten	VERB
gs-3919	112	20	systemic	systemic	ADJ
gs-3919	112	21	involvement	involvement	NOUN
gs-3919	112	22	,	,	PUNCT
gs-3919	112	23	making	make	VERB
gs-3919	112	24	it	it	PRON
gs-3919	112	25	a	a	DET
gs-3919	112	26	critical	critical	ADJ
gs-3919	112	27	area	area	NOUN
gs-3919	112	28	of	of	ADP
gs-3919	112	29	study	study	NOUN
gs-3919	112	30	for	for	ADP
gs-3919	112	31	clinicians	clinician	NOUN
gs-3919	112	32	,	,	PUNCT
gs-3919	112	33	pharmacologists	pharmacologist	NOUN
gs-3919	112	34	,	,	PUNCT
gs-3919	112	35	and	and	CCONJ
gs-3919	112	36	researchers	researcher	NOUN
gs-3919	112	37	alike	alike	ADV
gs-3919	112	38	.	.	PUNCT
gs-3919	113	1	the	the	DET
gs-3919	113	2	underlying	underlying	ADJ
gs-3919	113	3	mechanisms	mechanism	NOUN
gs-3919	113	4	are	be	AUX
gs-3919	113	5	deeply	deeply	ADV
gs-3919	113	6	rooted	root	VERB
gs-3919	113	7	in	in	ADP
gs-3919	113	8	the	the	DET
gs-3919	113	9	pharmacological	pharmacological	ADJ
gs-3919	113	10	properties	property	NOUN
gs-3919	113	11	of	of	ADP
gs-3919	113	12	the	the	DET
gs-3919	113	13	drugs	drug	NOUN
gs-3919	113	14	themselves	themselves	PRON
gs-3919	113	15	,	,	PUNCT
gs-3919	113	16	the	the	DET
gs-3919	113	17	metabolic	metabolic	NOUN
gs-3919	113	18	pathways	pathway	NOUN
gs-3919	113	19	they	they	PRON
gs-3919	113	20	engage	engage	VERB
gs-3919	113	21	,	,	PUNCT
gs-3919	113	22	and	and	CCONJ
gs-3919	113	23	the	the	DET
gs-3919	113	24	individual	individual	ADJ
gs-3919	113	25	patient	patient	NOUN
gs-3919	113	26	's	's	PART
gs-3919	113	27	immunological	immunological	ADJ
gs-3919	113	28	response	response	NOUN
gs-3919	113	29	,	,	PUNCT
gs-3919	113	30	creating	create	VERB
gs-3919	113	31	a	a	DET
gs-3919	113	32	multifaceted	multifaceted	ADJ
gs-3919	113	33	clinical	clinical	ADJ
gs-3919	113	34	scenario	scenario	NOUN
gs-3919	113	35	that	that	PRON
gs-3919	113	36	demands	demand	VERB
gs-3919	113	37	thorough	thorough	ADJ
gs-3919	113	38	understanding	understanding	NOUN
gs-3919	113	39	and	and	CCONJ
gs-3919	113	40	careful	careful	ADJ
gs-3919	113	41	management	management	NOUN
gs-3919	113	42	.	.	PUNCT
gs-3919	114	1	eosinophilia	eosinophilia	PROPN
gs-3919	114	2	,	,	PUNCT
gs-3919	114	3	defined	define	VERB
gs-3919	114	4	as	as	ADP
gs-3919	114	5	an	an	DET
gs-3919	114	6	elevated	elevated	ADJ
gs-3919	114	7	eosinophil	eosinophil	ADJ
gs-3919	114	8	count	count	NOUN
gs-3919	114	9	in	in	ADP
gs-3919	114	10	peripheral	peripheral	ADJ
gs-3919	114	11	blood	blood	NOUN
gs-3919	114	12	or	or	CCONJ
gs-3919	114	13	tissues	tissue	NOUN
gs-3919	114	14	,	,	PUNCT
gs-3919	114	15	serves	serve	VERB
gs-3919	114	16	as	as	ADP
gs-3919	114	17	a	a	DET
gs-3919	114	18	hallmark	hallmark	NOUN
gs-3919	114	19	of	of	ADP
gs-3919	114	20	various	various	ADJ
gs-3919	114	21	pathological	pathological	ADJ
gs-3919	114	22	states	state	NOUN
gs-3919	114	23	,	,	PUNCT
gs-3919	114	24	ranging	range	VERB
gs-3919	114	25	from	from	ADP
gs-3919	114	26	parasitic	parasitic	ADJ
gs-3919	114	27	infections	infection	NOUN
gs-3919	114	28	to	to	ADP
gs-3919	114	29	allergic	allergic	ADJ
gs-3919	114	30	reactions	reaction	NOUN
gs-3919	114	31	and	and	CCONJ
gs-3919	114	32	,	,	PUNCT
gs-3919	114	33	notably	notably	ADV
gs-3919	114	34	,	,	PUNCT
gs-3919	114	35	adverse	adverse	ADJ
gs-3919	114	36	drug	drug	NOUN
gs-3919	114	37	responses	response	NOUN
gs-3919	114	38	.	.	PUNCT
gs-3919	115	1	when	when	SCONJ
gs-3919	115	2	drug	drug	NOUN
gs-3919	115	3	-	-	PUNCT
gs-3919	115	4	induced	induced	ADJ
gs-3919	115	5	,	,	PUNCT
gs-3919	115	6	eosinophilia	eosinophilia	PROPN
gs-3919	115	7	frequently	frequently	ADV
gs-3919	115	8	signals	signal	VERB
gs-3919	115	9	a	a	DET
gs-3919	115	10	hypersensitivity	hypersensitivity	NOUN
gs-3919	115	11	reaction	reaction	NOUN
gs-3919	115	12	,	,	PUNCT
gs-3919	115	13	often	often	ADV
gs-3919	115	14	accompanied	accompany	VERB
gs-3919	115	15	by	by	ADP
gs-3919	115	16	systemic	systemic	ADJ
gs-3919	115	17	symptoms	symptom	NOUN
gs-3919	115	18	that	that	PRON
gs-3919	115	19	can	can	AUX
gs-3919	115	20	affect	affect	VERB
gs-3919	115	21	multiple	multiple	ADJ
gs-3919	115	22	organ	organ	NOUN
gs-3919	115	23	systems	system	NOUN
gs-3919	115	24	.	.	PUNCT
gs-3919	116	1	the	the	DET
gs-3919	116	2	clinical	clinical	ADJ
gs-3919	116	3	spectrum	spectrum	NOUN
gs-3919	116	4	of	of	ADP
gs-3919	116	5	these	these	DET
gs-3919	116	6	reactions	reaction	NOUN
gs-3919	116	7	is	be	AUX
gs-3919	116	8	broad	broad	ADJ
gs-3919	116	9	,	,	PUNCT
gs-3919	116	10	georgian	georgian	ADJ
gs-3919	116	11	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	116	12	მეცნიერები	მეცნიერები	NOUN
gs-3919	116	13	ტ.	ტ.	VERB
gs-3919	116	14	7	7	NUM
gs-3919	116	15	n	n	PRON
gs-3919	116	16	3	3	NUM
gs-3919	116	17	,	,	PUNCT
gs-3919	116	18	2025	2025	NUM
gs-3919	116	19	148	148	NUM
gs-3919	116	20	encompassing	encompass	VERB
gs-3919	116	21	conditions	condition	NOUN
gs-3919	116	22	such	such	ADJ
gs-3919	116	23	as	as	ADP
gs-3919	116	24	drug	drug	NOUN
gs-3919	116	25	rash	rash	NOUN
gs-3919	116	26	with	with	ADP
gs-3919	116	27	eosinophilia	eosinophilia	PROPN
gs-3919	116	28	and	and	CCONJ
gs-3919	116	29	systemic	systemic	ADJ
gs-3919	116	30	symptoms	symptom	NOUN
gs-3919	116	31	(	(	PUNCT
gs-3919	116	32	dress	dress	NOUN
gs-3919	116	33	)	)	PUNCT
gs-3919	116	34	,	,	PUNCT
gs-3919	116	35	eosinophilic	eosinophilic	ADJ
gs-3919	116	36	pneumonia	pneumonia	NOUN
gs-3919	116	37	,	,	PUNCT
gs-3919	116	38	and	and	CCONJ
gs-3919	116	39	even	even	ADV
gs-3919	116	40	eosinophilic	eosinophilic	PROPN
gs-3919	116	41	myocarditis	myocarditis	PROPN
gs-3919	116	42	,	,	PUNCT
gs-3919	116	43	each	each	PRON
gs-3919	116	44	presenting	present	VERB
gs-3919	116	45	unique	unique	ADJ
gs-3919	116	46	diagnostic	diagnostic	ADJ
gs-3919	116	47	and	and	CCONJ
gs-3919	116	48	therapeutic	therapeutic	ADJ
gs-3919	116	49	challenges	challenge	NOUN
gs-3919	116	50	.	.	PUNCT
gs-3919	117	1	the	the	DET
gs-3919	117	2	pathogenesis	pathogenesis	NOUN
gs-3919	117	3	of	of	ADP
gs-3919	117	4	these	these	DET
gs-3919	117	5	reactions	reaction	NOUN
gs-3919	117	6	is	be	AUX
gs-3919	117	7	not	not	PART
gs-3919	117	8	merely	merely	ADV
gs-3919	117	9	a	a	DET
gs-3919	117	10	matter	matter	NOUN
gs-3919	117	11	of	of	ADP
gs-3919	117	12	excessive	excessive	ADJ
gs-3919	117	13	eosinophil	eosinophil	ADJ
gs-3919	117	14	production	production	NOUN
gs-3919	117	15	but	but	CCONJ
gs-3919	117	16	involves	involve	VERB
gs-3919	117	17	a	a	DET
gs-3919	117	18	cascade	cascade	NOUN
gs-3919	117	19	of	of	ADP
gs-3919	117	20	immunological	immunological	ADJ
gs-3919	117	21	events	event	NOUN
gs-3919	117	22	triggered	trigger	VERB
gs-3919	117	23	by	by	ADP
gs-3919	117	24	the	the	DET
gs-3919	117	25	drug	drug	NOUN
gs-3919	117	26	or	or	CCONJ
gs-3919	117	27	its	its	PRON
gs-3919	117	28	metabolites	metabolite	NOUN
gs-3919	117	29	,	,	PUNCT
gs-3919	117	30	leading	lead	VERB
gs-3919	117	31	to	to	ADP
gs-3919	117	32	tissue	tissue	NOUN
gs-3919	117	33	infiltration	infiltration	NOUN
gs-3919	117	34	and	and	CCONJ
gs-3919	117	35	damage	damage	NOUN
gs-3919	117	36	.	.	PUNCT
gs-3919	118	1	the	the	DET
gs-3919	118	2	pharmacological	pharmacological	ADJ
gs-3919	118	3	basis	basis	NOUN
gs-3919	118	4	of	of	ADP
gs-3919	118	5	drug	drug	NOUN
gs-3919	118	6	-	-	PUNCT
gs-3919	118	7	induced	induce	VERB
gs-3919	118	8	eosinophilia	eosinophilia	NOUN
gs-3919	118	9	lies	lie	VERB
gs-3919	118	10	in	in	ADP
gs-3919	118	11	the	the	DET
gs-3919	118	12	intricate	intricate	ADJ
gs-3919	118	13	interplay	interplay	NOUN
gs-3919	118	14	between	between	ADP
gs-3919	118	15	a	a	DET
gs-3919	118	16	drug	drug	NOUN
gs-3919	118	17	's	's	PART
gs-3919	118	18	chemical	chemical	NOUN
gs-3919	118	19	structure	structure	NOUN
gs-3919	118	20	,	,	PUNCT
gs-3919	118	21	its	its	PRON
gs-3919	118	22	metabolic	metabolic	NOUN
gs-3919	118	23	fate	fate	NOUN
gs-3919	118	24	,	,	PUNCT
gs-3919	118	25	and	and	CCONJ
gs-3919	118	26	the	the	DET
gs-3919	118	27	host	host	NOUN
gs-3919	118	28	's	's	PART
gs-3919	118	29	immune	immune	ADJ
gs-3919	118	30	system	system	NOUN
gs-3919	118	31	.	.	PUNCT
gs-3919	119	1	certain	certain	ADJ
gs-3919	119	2	drugs	drug	NOUN
gs-3919	119	3	are	be	AUX
gs-3919	119	4	more	more	ADV
gs-3919	119	5	prone	prone	ADJ
gs-3919	119	6	to	to	ADP
gs-3919	119	7	inducing	induce	VERB
gs-3919	119	8	these	these	DET
gs-3919	119	9	reactions	reaction	NOUN
gs-3919	119	10	due	due	ADP
gs-3919	119	11	to	to	ADP
gs-3919	119	12	their	their	PRON
gs-3919	119	13	ability	ability	NOUN
gs-3919	119	14	to	to	PART
gs-3919	119	15	form	form	VERB
gs-3919	119	16	reactive	reactive	ADJ
gs-3919	119	17	metabolites	metabolite	NOUN
gs-3919	119	18	that	that	PRON
gs-3919	119	19	act	act	VERB
gs-3919	119	20	as	as	ADP
gs-3919	119	21	haptens	hapten	NOUN
gs-3919	119	22	,	,	PUNCT
gs-3919	119	23	binding	bind	VERB
gs-3919	119	24	to	to	ADP
gs-3919	119	25	endogenous	endogenous	ADJ
gs-3919	119	26	proteins	protein	NOUN
gs-3919	119	27	and	and	CCONJ
gs-3919	119	28	creating	create	VERB
gs-3919	119	29	neoantigens	neoantigen	NOUN
gs-3919	119	30	.	.	PUNCT
gs-3919	120	1	these	these	DET
gs-3919	120	2	neoantigens	neoantigen	NOUN
gs-3919	120	3	are	be	AUX
gs-3919	120	4	then	then	ADV
gs-3919	120	5	recognized	recognize	VERB
gs-3919	120	6	by	by	ADP
gs-3919	120	7	the	the	DET
gs-3919	120	8	immune	immune	ADJ
gs-3919	120	9	system	system	NOUN
gs-3919	120	10	as	as	ADP
gs-3919	120	11	foreign	foreign	ADJ
gs-3919	120	12	,	,	PUNCT
gs-3919	120	13	eliciting	elicit	VERB
gs-3919	120	14	a	a	DET
gs-3919	120	15	t	t	NOUN
gs-3919	120	16	-	-	PUNCT
gs-3919	120	17	cell	cell	NOUN
gs-3919	120	18	-	-	PUNCT
gs-3919	120	19	mediated	mediate	VERB
gs-3919	120	20	response	response	NOUN
gs-3919	120	21	that	that	PRON
gs-3919	120	22	drives	drive	VERB
gs-3919	120	23	eosinophil	eosinophil	ADJ
gs-3919	120	24	activation	activation	NOUN
gs-3919	120	25	and	and	CCONJ
gs-3919	120	26	recruitment	recruitment	NOUN
gs-3919	120	27	.	.	PUNCT
gs-3919	121	1	genetic	genetic	ADJ
gs-3919	121	2	factors	factor	NOUN
gs-3919	121	3	further	far	ADV
gs-3919	121	4	modulate	modulate	VERB
gs-3919	121	5	this	this	DET
gs-3919	121	6	risk	risk	NOUN
gs-3919	121	7	,	,	PUNCT
gs-3919	121	8	with	with	ADP
gs-3919	121	9	specific	specific	ADJ
gs-3919	121	10	human	human	ADJ
gs-3919	121	11	leukocyte	leukocyte	NOUN
gs-3919	121	12	antigen	antigen	NOUN
gs-3919	121	13	(	(	PUNCT
gs-3919	121	14	hla	hla	NOUN
gs-3919	121	15	)	)	PUNCT
gs-3919	121	16	alleles	allele	NOUN
gs-3919	121	17	strongly	strongly	ADV
gs-3919	121	18	associated	associate	VERB
gs-3919	121	19	with	with	ADP
gs-3919	121	20	susceptibility	susceptibility	NOUN
gs-3919	121	21	to	to	ADP
gs-3919	121	22	severe	severe	ADJ
gs-3919	121	23	cutaneous	cutaneous	ADJ
gs-3919	121	24	adverse	adverse	ADJ
gs-3919	121	25	reactions	reaction	NOUN
gs-3919	121	26	,	,	PUNCT
gs-3919	121	27	including	include	VERB
gs-3919	121	28	those	those	PRON
gs-3919	121	29	accompanied	accompany	VERB
gs-3919	121	30	by	by	ADP
gs-3919	121	31	eosinophilia	eosinophilia	PROPN
gs-3919	121	32	.	.	PUNCT
gs-3919	122	1	for	for	ADP
gs-3919	122	2	instance	instance	NOUN
gs-3919	122	3	,	,	PUNCT
gs-3919	122	4	the	the	DET
gs-3919	122	5	hla	hla	PROPN
gs-3919	122	6	-	-	PUNCT
gs-3919	122	7	b*15:02	b*15:02	ADJ
gs-3919	122	8	allele	allele	NOUN
gs-3919	122	9	has	have	AUX
gs-3919	122	10	been	be	AUX
gs-3919	122	11	linked	link	VERB
gs-3919	122	12	to	to	ADP
gs-3919	122	13	carbamazepine	carbamazepine	NOUN
gs-3919	122	14	-	-	PUNCT
gs-3919	122	15	induced	induce	VERB
gs-3919	122	16	stevens	stevens	PROPN
gs-3919	122	17	-	-	PUNCT
gs-3919	122	18	johnson	johnson	PROPN
gs-3919	122	19	syndrome	syndrome	PROPN
gs-3919	122	20	and	and	CCONJ
gs-3919	122	21	toxic	toxic	ADJ
gs-3919	122	22	epidermal	epidermal	ADJ
gs-3919	122	23	necrolysis	necrolysis	NOUN
gs-3919	122	24	,	,	PUNCT
gs-3919	122	25	often	often	ADV
gs-3919	122	26	presenting	present	VERB
gs-3919	122	27	with	with	ADP
gs-3919	122	28	eosinophilia	eosinophilia	PROPN
gs-3919	122	29	in	in	ADP
gs-3919	122	30	the	the	DET
gs-3919	122	31	context	context	NOUN
gs-3919	122	32	of	of	ADP
gs-3919	122	33	systemic	systemic	ADJ
gs-3919	122	34	involvement	involvement	NOUN
gs-3919	122	35	.	.	PUNCT
gs-3919	123	1	beyond	beyond	ADP
gs-3919	123	2	genetic	genetic	ADJ
gs-3919	123	3	predisposition	predisposition	NOUN
gs-3919	123	4	,	,	PUNCT
gs-3919	123	5	the	the	DET
gs-3919	123	6	immunological	immunological	ADJ
gs-3919	123	7	milieu	milieu	NOUN
gs-3919	123	8	plays	play	VERB
gs-3919	123	9	a	a	DET
gs-3919	123	10	pivotal	pivotal	ADJ
gs-3919	123	11	role	role	NOUN
gs-3919	123	12	in	in	ADP
gs-3919	123	13	the	the	DET
gs-3919	123	14	development	development	NOUN
gs-3919	123	15	and	and	CCONJ
gs-3919	123	16	progression	progression	NOUN
gs-3919	123	17	of	of	ADP
gs-3919	123	18	drug	drug	NOUN
gs-3919	123	19	-	-	PUNCT
gs-3919	123	20	induced	induce	VERB
gs-3919	123	21	eosinophilia	eosinophilia	NOUN
gs-3919	123	22	.	.	PUNCT
gs-3919	124	1	eosinophils	eosinophil	NOUN
gs-3919	124	2	are	be	AUX
gs-3919	124	3	not	not	PART
gs-3919	124	4	passive	passive	ADJ
gs-3919	124	5	bystanders	bystander	NOUN
gs-3919	124	6	but	but	CCONJ
gs-3919	124	7	active	active	ADJ
gs-3919	124	8	contributors	contributor	NOUN
gs-3919	124	9	to	to	PART
gs-3919	124	10	tissue	tissue	VERB
gs-3919	124	11	inflammation	inflammation	NOUN
gs-3919	124	12	and	and	CCONJ
gs-3919	124	13	damage	damage	NOUN
gs-3919	124	14	.	.	PUNCT
gs-3919	125	1	upon	upon	SCONJ
gs-3919	125	2	activation	activation	NOUN
gs-3919	125	3	,	,	PUNCT
gs-3919	125	4	they	they	PRON
gs-3919	125	5	release	release	VERB
gs-3919	125	6	a	a	DET
gs-3919	125	7	barrage	barrage	NOUN
gs-3919	125	8	of	of	ADP
gs-3919	125	9	cytotoxic	cytotoxic	ADJ
gs-3919	125	10	proteins	protein	NOUN
gs-3919	125	11	,	,	PUNCT
gs-3919	125	12	including	include	VERB
gs-3919	125	13	major	major	ADJ
gs-3919	125	14	basic	basic	ADJ
gs-3919	125	15	protein	protein	NOUN
gs-3919	125	16	,	,	PUNCT
gs-3919	125	17	eosinophil	eosinophil	ADJ
gs-3919	125	18	peroxidase	peroxidase	NOUN
gs-3919	125	19	,	,	PUNCT
gs-3919	125	20	and	and	CCONJ
gs-3919	125	21	eosinophil	eosinophil	ADJ
gs-3919	125	22	-	-	PUNCT
gs-3919	125	23	derived	derive	VERB
gs-3919	125	24	neurotoxin	neurotoxin	NOUN
gs-3919	125	25	,	,	PUNCT
gs-3919	125	26	which	which	PRON
gs-3919	125	27	disrupt	disrupt	VERB
gs-3919	125	28	cellular	cellular	ADJ
gs-3919	125	29	integrity	integrity	NOUN
gs-3919	125	30	and	and	CCONJ
gs-3919	125	31	amplify	amplify	VERB
gs-3919	125	32	inflammatory	inflammatory	ADJ
gs-3919	125	33	responses	response	NOUN
gs-3919	125	34	.	.	PUNCT
gs-3919	126	1	additionally	additionally	ADV
gs-3919	126	2	,	,	PUNCT
gs-3919	126	3	eosinophils	eosinophil	NOUN
gs-3919	126	4	secrete	secrete	NOUN
gs-3919	126	5	cytokines	cytokine	NOUN
gs-3919	126	6	such	such	ADJ
gs-3919	126	7	as	as	ADP
gs-3919	126	8	interleukin-5	interleukin-5	PROPN
gs-3919	126	9	(	(	PUNCT
gs-3919	126	10	il-5	il-5	NUM
gs-3919	126	11	)	)	PUNCT
gs-3919	126	12	,	,	PUNCT
gs-3919	126	13	a	a	DET
gs-3919	126	14	key	key	ADJ
gs-3919	126	15	regulator	regulator	NOUN
gs-3919	126	16	of	of	ADP
gs-3919	126	17	eosinophil	eosinophil	ADJ
gs-3919	126	18	proliferation	proliferation	NOUN
gs-3919	126	19	and	and	CCONJ
gs-3919	126	20	survival	survival	NOUN
gs-3919	126	21	,	,	PUNCT
gs-3919	126	22	further	far	ADV
gs-3919	126	23	perpetuating	perpetuate	VERB
gs-3919	126	24	the	the	DET
gs-3919	126	25	cycle	cycle	NOUN
gs-3919	126	26	of	of	ADP
gs-3919	126	27	inflammation	inflammation	NOUN
gs-3919	126	28	.	.	PUNCT
gs-3919	127	1	this	this	DET
gs-3919	127	2	self	self	NOUN
gs-3919	127	3	-	-	PUNCT
gs-3919	127	4	sustaining	sustain	VERB
gs-3919	127	5	inflammatory	inflammatory	ADJ
gs-3919	127	6	cascade	cascade	NOUN
gs-3919	127	7	underscores	underscore	VERB
gs-3919	127	8	the	the	DET
gs-3919	127	9	potential	potential	NOUN
gs-3919	127	10	for	for	ADP
gs-3919	127	11	rapid	rapid	ADJ
gs-3919	127	12	clinical	clinical	ADJ
gs-3919	127	13	deterioration	deterioration	NOUN
gs-3919	127	14	in	in	ADP
gs-3919	127	15	affected	affected	ADJ
gs-3919	127	16	patients	patient	NOUN
gs-3919	127	17	,	,	PUNCT
gs-3919	127	18	necessitating	necessitate	VERB
gs-3919	127	19	prompt	prompt	ADJ
gs-3919	127	20	recognition	recognition	NOUN
gs-3919	127	21	and	and	CCONJ
gs-3919	127	22	intervention	intervention	NOUN
gs-3919	127	23	.	.	PUNCT
gs-3919	128	1	clinically	clinically	ADV
gs-3919	128	2	,	,	PUNCT
gs-3919	128	3	drug	drug	NOUN
gs-3919	128	4	-	-	PUNCT
gs-3919	128	5	induced	induce	VERB
gs-3919	128	6	eosinophilia	eosinophilia	NOUN
gs-3919	128	7	and	and	CCONJ
gs-3919	128	8	systemic	systemic	ADJ
gs-3919	128	9	symptoms	symptom	NOUN
gs-3919	128	10	present	present	VERB
gs-3919	128	11	a	a	DET
gs-3919	128	12	diagnostic	diagnostic	ADJ
gs-3919	128	13	conundrum	conundrum	NOUN
gs-3919	128	14	due	due	ADP
gs-3919	128	15	to	to	ADP
gs-3919	128	16	their	their	PRON
gs-3919	128	17	variable	variable	NOUN
gs-3919	128	18	and	and	CCONJ
gs-3919	128	19	often	often	ADV
gs-3919	128	20	nonspecific	nonspecific	ADJ
gs-3919	128	21	manifestations	manifestation	NOUN
gs-3919	128	22	.	.	PUNCT
gs-3919	129	1	the	the	DET
gs-3919	129	2	latency	latency	NOUN
gs-3919	129	3	period	period	NOUN
gs-3919	129	4	between	between	ADP
gs-3919	129	5	drug	drug	NOUN
gs-3919	129	6	initiation	initiation	NOUN
gs-3919	129	7	and	and	CCONJ
gs-3919	129	8	symptom	symptom	NOUN
gs-3919	129	9	onset	onset	NOUN
gs-3919	129	10	can	can	AUX
gs-3919	129	11	range	range	VERB
gs-3919	129	12	from	from	ADP
gs-3919	129	13	days	day	NOUN
gs-3919	129	14	to	to	ADP
gs-3919	129	15	weeks	week	NOUN
gs-3919	129	16	,	,	PUNCT
gs-3919	129	17	complicating	complicate	VERB
gs-3919	129	18	the	the	DET
gs-3919	129	19	establishment	establishment	NOUN
gs-3919	129	20	of	of	ADP
gs-3919	129	21	a	a	DET
gs-3919	129	22	causal	causal	ADJ
gs-3919	129	23	relationship	relationship	NOUN
gs-3919	129	24	.	.	PUNCT
gs-3919	130	1	cutaneous	cutaneous	ADJ
gs-3919	130	2	involvement	involvement	NOUN
gs-3919	130	3	,	,	PUNCT
gs-3919	130	4	such	such	ADJ
gs-3919	130	5	as	as	ADP
gs-3919	130	6	maculopapular	maculopapular	ADJ
gs-3919	130	7	eruptions	eruption	NOUN
gs-3919	130	8	or	or	CCONJ
gs-3919	130	9	exfoliative	exfoliative	ADJ
gs-3919	130	10	dermatitis	dermatitis	NOUN
gs-3919	130	11	,	,	PUNCT
gs-3919	130	12	is	be	AUX
gs-3919	130	13	common	common	ADJ
gs-3919	130	14	but	but	CCONJ
gs-3919	130	15	not	not	PART
gs-3919	130	16	universal	universal	ADJ
gs-3919	130	17	,	,	PUNCT
gs-3919	130	18	and	and	CCONJ
gs-3919	130	19	visceral	visceral	ADJ
gs-3919	130	20	organ	organ	NOUN
gs-3919	130	21	involvement	involvement	NOUN
gs-3919	130	22	—	—	PUNCT
gs-3919	130	23	particularly	particularly	ADV
gs-3919	130	24	of	of	ADP
gs-3919	130	25	the	the	DET
gs-3919	130	26	liver	liver	NOUN
gs-3919	130	27	,	,	PUNCT
gs-3919	130	28	kidneys	kidney	NOUN
gs-3919	130	29	,	,	PUNCT
gs-3919	130	30	and	and	CCONJ
gs-3919	130	31	lungs	lung	NOUN
gs-3919	130	32	—	—	PUNCT
gs-3919	130	33	may	may	AUX
gs-3919	130	34	dominate	dominate	VERB
gs-3919	130	35	the	the	DET
gs-3919	130	36	clinical	clinical	ADJ
gs-3919	130	37	picture	picture	NOUN
gs-3919	130	38	.	.	PUNCT
gs-3919	131	1	laboratory	laboratory	NOUN
gs-3919	131	2	findings	finding	NOUN
gs-3919	131	3	typically	typically	ADV
gs-3919	131	4	include	include	VERB
gs-3919	131	5	peripheral	peripheral	ADJ
gs-3919	131	6	eosinophilia	eosinophilia	PROPN
gs-3919	131	7	,	,	PUNCT
gs-3919	131	8	elevated	elevate	VERB
gs-3919	131	9	liver	liver	NOUN
gs-3919	131	10	enzymes	enzyme	NOUN
gs-3919	131	11	,	,	PUNCT
gs-3919	131	12	and	and	CCONJ
gs-3919	131	13	occasionally	occasionally	ADV
gs-3919	131	14	atypical	atypical	ADJ
gs-3919	131	15	lymphocytes	lymphocyte	NOUN
gs-3919	131	16	,	,	PUNCT
gs-3919	131	17	mimicking	mimic	VERB
gs-3919	131	18	viral	viral	ADJ
gs-3919	131	19	infections	infection	NOUN
gs-3919	131	20	or	or	CCONJ
gs-3919	131	21	autoimmune	autoimmune	ADJ
gs-3919	131	22	disorders	disorder	NOUN
gs-3919	131	23	.	.	PUNCT
gs-3919	132	1	the	the	DET
gs-3919	132	2	regiscar	regiscar	NOUN
gs-3919	132	3	criteria	criterion	NOUN
gs-3919	132	4	have	have	AUX
gs-3919	132	5	been	be	AUX
gs-3919	132	6	developed	develop	VERB
gs-3919	132	7	to	to	PART
gs-3919	132	8	standardize	standardize	VERB
gs-3919	132	9	the	the	DET
gs-3919	132	10	diagnosis	diagnosis	NOUN
gs-3919	132	11	of	of	ADP
gs-3919	132	12	dress	dress	NOUN
gs-3919	132	13	,	,	PUNCT
gs-3919	132	14	incorporating	incorporate	VERB
gs-3919	132	15	clinical	clinical	ADJ
gs-3919	132	16	,	,	PUNCT
gs-3919	132	17	laboratory	laboratory	NOUN
gs-3919	132	18	,	,	PUNCT
gs-3919	132	19	and	and	CCONJ
gs-3919	132	20	histopathological	histopathological	ADJ
gs-3919	132	21	features	feature	NOUN
gs-3919	132	22	,	,	PUNCT
gs-3919	132	23	yet	yet	CCONJ
gs-3919	132	24	challenges	challenge	NOUN
gs-3919	132	25	remain	remain	VERB
gs-3919	132	26	in	in	ADP
gs-3919	132	27	distinguishing	distinguish	VERB
gs-3919	132	28	these	these	DET
gs-3919	132	29	reactions	reaction	NOUN
gs-3919	132	30	from	from	ADP
gs-3919	132	31	other	other	ADJ
gs-3919	132	32	hypersensitivity	hypersensitivity	NOUN
gs-3919	132	33	syndromes	syndrome	NOUN
gs-3919	132	34	.	.	PUNCT
gs-3919	133	1	the	the	DET
gs-3919	133	2	management	management	NOUN
gs-3919	133	3	of	of	ADP
gs-3919	133	4	drug	drug	NOUN
gs-3919	133	5	-	-	PUNCT
gs-3919	133	6	induced	induce	VERB
gs-3919	133	7	eosinophilia	eosinophilia	NOUN
gs-3919	133	8	hinges	hinge	NOUN
gs-3919	133	9	on	on	ADP
gs-3919	133	10	immediate	immediate	ADJ
gs-3919	133	11	discontinuation	discontinuation	NOUN
gs-3919	133	12	of	of	ADP
gs-3919	133	13	the	the	DET
gs-3919	133	14	offending	offending	ADJ
gs-3919	133	15	agent	agent	NOUN
gs-3919	133	16	,	,	PUNCT
gs-3919	133	17	coupled	couple	VERB
gs-3919	133	18	with	with	ADP
gs-3919	133	19	supportive	supportive	ADJ
gs-3919	133	20	care	care	NOUN
gs-3919	133	21	tailored	tailor	VERB
gs-3919	133	22	to	to	ADP
gs-3919	133	23	the	the	DET
gs-3919	133	24	severity	severity	NOUN
gs-3919	133	25	of	of	ADP
gs-3919	133	26	organ	organ	NOUN
gs-3919	133	27	involvement	involvement	NOUN
gs-3919	133	28	.	.	PUNCT
gs-3919	134	1	corticosteroids	corticosteroid	NOUN
gs-3919	134	2	remain	remain	VERB
gs-3919	134	3	the	the	DET
gs-3919	134	4	cornerstone	cornerstone	NOUN
gs-3919	134	5	of	of	ADP
gs-3919	134	6	therapy	therapy	NOUN
gs-3919	134	7	for	for	ADP
gs-3919	134	8	moderate	moderate	ADJ
gs-3919	134	9	to	to	ADP
gs-3919	134	10	georgian	georgian	ADJ
gs-3919	134	11	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	134	12	მეცნიერები	მეცნიერები	NOUN
gs-3919	134	13	ტ.	ტ.	VERB
gs-3919	134	14	7	7	NUM
gs-3919	134	15	n	n	PRON
gs-3919	134	16	3	3	NUM
gs-3919	134	17	,	,	PUNCT
gs-3919	134	18	2025	2025	NUM
gs-3919	134	19	149	149	NUM
gs-3919	134	20	severe	severe	ADJ
gs-3919	134	21	cases	case	NOUN
gs-3919	134	22	,	,	PUNCT
gs-3919	134	23	although	although	SCONJ
gs-3919	134	24	the	the	DET
gs-3919	134	25	optimal	optimal	ADJ
gs-3919	134	26	regimen	regiman	NOUN
gs-3919	134	27	—	—	PUNCT
gs-3919	134	28	dose	dose	NOUN
gs-3919	134	29	,	,	PUNCT
gs-3919	134	30	duration	duration	NOUN
gs-3919	134	31	,	,	PUNCT
gs-3919	134	32	and	and	CCONJ
gs-3919	134	33	route	route	NOUN
gs-3919	134	34	of	of	ADP
gs-3919	134	35	administration	administration	NOUN
gs-3919	134	36	—	—	PUNCT
gs-3919	134	37	remains	remain	VERB
gs-3919	134	38	a	a	DET
gs-3919	134	39	subject	subject	NOUN
gs-3919	134	40	of	of	ADP
gs-3919	134	41	debate	debate	NOUN
gs-3919	134	42	.	.	PUNCT
gs-3919	135	1	in	in	ADP
gs-3919	135	2	refractory	refractory	NOUN
gs-3919	135	3	cases	case	NOUN
gs-3919	135	4	,	,	PUNCT
gs-3919	135	5	emerging	emerge	VERB
gs-3919	135	6	therapies	therapy	NOUN
gs-3919	135	7	targeting	target	VERB
gs-3919	135	8	specific	specific	ADJ
gs-3919	135	9	cytokines	cytokine	NOUN
gs-3919	135	10	,	,	PUNCT
gs-3919	135	11	such	such	ADJ
gs-3919	135	12	as	as	ADP
gs-3919	135	13	anti	anti	ADJ
gs-3919	135	14	-	-	ADJ
gs-3919	135	15	il-5	il-5	ADJ
gs-3919	135	16	monoclonal	monoclonal	NOUN
gs-3919	135	17	antibodies	antibody	NOUN
gs-3919	135	18	,	,	PUNCT
gs-3919	135	19	have	have	AUX
gs-3919	135	20	shown	show	VERB
gs-3919	135	21	promise	promise	NOUN
gs-3919	135	22	in	in	ADP
gs-3919	135	23	mitigating	mitigate	VERB
gs-3919	135	24	eosinophilic	eosinophilic	ADJ
gs-3919	135	25	inflammation	inflammation	NOUN
gs-3919	135	26	,	,	PUNCT
gs-3919	135	27	though	though	SCONJ
gs-3919	135	28	their	their	PRON
gs-3919	135	29	role	role	NOUN
gs-3919	135	30	in	in	ADP
gs-3919	135	31	acute	acute	ADJ
gs-3919	135	32	drug	drug	NOUN
gs-3919	135	33	-	-	PUNCT
gs-3919	135	34	induced	induce	VERB
gs-3919	135	35	reactions	reaction	NOUN
gs-3919	135	36	is	be	AUX
gs-3919	135	37	still	still	ADV
gs-3919	135	38	under	under	ADP
gs-3919	135	39	investigation	investigation	NOUN
gs-3919	135	40	.	.	PUNCT
gs-3919	136	1	long	long	ADJ
gs-3919	136	2	-	-	PUNCT
gs-3919	136	3	term	term	NOUN
gs-3919	136	4	follow	follow	NOUN
gs-3919	136	5	-	-	PUNCT
gs-3919	136	6	up	up	NOUN
gs-3919	136	7	is	be	AUX
gs-3919	136	8	essential	essential	ADJ
gs-3919	136	9	,	,	PUNCT
gs-3919	136	10	as	as	SCONJ
gs-3919	136	11	some	some	DET
gs-3919	136	12	patients	patient	NOUN
gs-3919	136	13	develop	develop	VERB
gs-3919	136	14	autoimmune	autoimmune	ADJ
gs-3919	136	15	sequelae	sequelae	PROPN
gs-3919	136	16	,	,	PUNCT
gs-3919	136	17	such	such	ADJ
gs-3919	136	18	as	as	ADP
gs-3919	136	19	thyroid	thyroid	NOUN
gs-3919	136	20	dysfunction	dysfunction	NOUN
gs-3919	136	21	,	,	PUNCT
gs-3919	136	22	months	month	NOUN
gs-3919	136	23	after	after	ADP
gs-3919	136	24	the	the	DET
gs-3919	136	25	initial	initial	ADJ
gs-3919	136	26	episode	episode	NOUN
gs-3919	136	27	.	.	PUNCT
gs-3919	137	1	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	137	2	efforts	effort	NOUN
gs-3919	137	3	are	be	AUX
gs-3919	137	4	critical	critical	ADJ
gs-3919	137	5	in	in	ADP
gs-3919	137	6	identifying	identify	VERB
gs-3919	137	7	and	and	CCONJ
gs-3919	137	8	mitigating	mitigate	VERB
gs-3919	137	9	the	the	DET
gs-3919	137	10	risks	risk	NOUN
gs-3919	137	11	associated	associate	VERB
gs-3919	137	12	with	with	ADP
gs-3919	137	13	drugs	drug	NOUN
gs-3919	137	14	known	know	VERB
gs-3919	137	15	to	to	PART
gs-3919	137	16	induce	induce	VERB
gs-3919	137	17	eosinophilia	eosinophilia	PROPN
gs-3919	137	18	.	.	PUNCT
gs-3919	138	1	post	post	ADJ
gs-3919	138	2	-	-	ADJ
gs-3919	138	3	marketing	marketing	ADJ
gs-3919	138	4	surveillance	surveillance	NOUN
gs-3919	138	5	systems	system	NOUN
gs-3919	138	6	,	,	PUNCT
gs-3919	138	7	such	such	ADJ
gs-3919	138	8	as	as	ADP
gs-3919	138	9	the	the	DET
gs-3919	138	10	fda	fda	PROPN
gs-3919	138	11	adverse	adverse	ADJ
gs-3919	138	12	event	event	NOUN
gs-3919	138	13	reporting	report	VERB
gs-3919	138	14	system	system	NOUN
gs-3919	138	15	(	(	PUNCT
gs-3919	138	16	faers	faer	NOUN
gs-3919	138	17	)	)	PUNCT
gs-3919	138	18	and	and	CCONJ
gs-3919	138	19	the	the	DET
gs-3919	138	20	who	who	PRON
gs-3919	138	21	global	global	ADJ
gs-3919	138	22	individual	individual	ADJ
gs-3919	138	23	case	case	NOUN
gs-3919	138	24	safety	safety	NOUN
gs-3919	138	25	reports	report	NOUN
gs-3919	138	26	(	(	PUNCT
gs-3919	138	27	vigibase	vigibase	PROPN
gs-3919	138	28	)	)	PUNCT
gs-3919	138	29	,	,	PUNCT
gs-3919	138	30	provide	provide	VERB
gs-3919	138	31	invaluable	invaluable	ADJ
gs-3919	138	32	data	datum	NOUN
gs-3919	138	33	for	for	ADP
gs-3919	138	34	detecting	detect	VERB
gs-3919	138	35	signals	signal	NOUN
gs-3919	138	36	of	of	ADP
gs-3919	138	37	potential	potential	ADJ
gs-3919	138	38	adverse	adverse	ADJ
gs-3919	138	39	reactions	reaction	NOUN
gs-3919	138	40	.	.	PUNCT
gs-3919	139	1	preemptive	preemptive	ADJ
gs-3919	139	2	strategies	strategy	NOUN
gs-3919	139	3	,	,	PUNCT
gs-3919	139	4	including	include	VERB
gs-3919	139	5	pharmacogenetic	pharmacogenetic	ADJ
gs-3919	139	6	screening	screening	NOUN
gs-3919	139	7	for	for	ADP
gs-3919	139	8	highrisk	highrisk	NOUN
gs-3919	139	9	hla	hla	PROPN
gs-3919	139	10	alleles	allele	NOUN
gs-3919	139	11	,	,	PUNCT
gs-3919	139	12	have	have	AUX
gs-3919	139	13	been	be	AUX
gs-3919	139	14	implemented	implement	VERB
gs-3919	139	15	for	for	ADP
gs-3919	139	16	certain	certain	ADJ
gs-3919	139	17	drugs	drug	NOUN
gs-3919	139	18	,	,	PUNCT
gs-3919	139	19	offering	offer	VERB
gs-3919	139	20	a	a	DET
gs-3919	139	21	pathway	pathway	NOUN
gs-3919	139	22	to	to	ADP
gs-3919	139	23	personalized	personalized	ADJ
gs-3919	139	24	medicine	medicine	NOUN
gs-3919	139	25	and	and	CCONJ
gs-3919	139	26	reduced	reduced	ADJ
gs-3919	139	27	incidence	incidence	NOUN
gs-3919	139	28	of	of	ADP
gs-3919	139	29	severe	severe	ADJ
gs-3919	139	30	reactions	reaction	NOUN
gs-3919	139	31	.	.	PUNCT
gs-3919	140	1	patient	patient	ADJ
gs-3919	140	2	education	education	NOUN
gs-3919	140	3	and	and	CCONJ
gs-3919	140	4	heightened	heighten	VERB
gs-3919	140	5	clinician	clinician	NOUN
gs-3919	140	6	awareness	awareness	NOUN
gs-3919	140	7	further	far	ADV
gs-3919	140	8	contribute	contribute	VERB
gs-3919	140	9	to	to	ADP
gs-3919	140	10	early	early	ADJ
gs-3919	140	11	detection	detection	NOUN
gs-3919	140	12	and	and	CCONJ
gs-3919	140	13	improved	improve	VERB
gs-3919	140	14	outcomes	outcome	NOUN
gs-3919	140	15	.	.	PUNCT
gs-3919	141	1	looking	look	VERB
gs-3919	141	2	ahead	ahead	ADV
gs-3919	141	3	,	,	PUNCT
gs-3919	141	4	advancements	advancement	NOUN
gs-3919	141	5	in	in	ADP
gs-3919	141	6	pharmacogenomics	pharmacogenomic	NOUN
gs-3919	141	7	,	,	PUNCT
gs-3919	141	8	immunology	immunology	NOUN
gs-3919	141	9	,	,	PUNCT
gs-3919	141	10	and	and	CCONJ
gs-3919	141	11	biomarker	biomarker	VERB
gs-3919	141	12	research	research	NOUN
gs-3919	141	13	hold	hold	VERB
gs-3919	141	14	promise	promise	NOUN
gs-3919	141	15	for	for	ADP
gs-3919	141	16	refining	refine	VERB
gs-3919	141	17	risk	risk	NOUN
gs-3919	141	18	stratification	stratification	NOUN
gs-3919	141	19	and	and	CCONJ
gs-3919	141	20	therapeutic	therapeutic	ADJ
gs-3919	141	21	approaches	approach	NOUN
gs-3919	141	22	.	.	PUNCT
gs-3919	142	1	in	in	ADP
gs-3919	142	2	vitro	vitro	X
gs-3919	142	3	assays	assay	NOUN
gs-3919	142	4	,	,	PUNCT
gs-3919	142	5	such	such	ADJ
gs-3919	142	6	as	as	ADP
gs-3919	142	7	the	the	DET
gs-3919	142	8	lymphocyte	lymphocyte	ADJ
gs-3919	142	9	transformation	transformation	NOUN
gs-3919	142	10	test	test	NOUN
gs-3919	142	11	,	,	PUNCT
gs-3919	142	12	may	may	AUX
gs-3919	142	13	enhance	enhance	VERB
gs-3919	142	14	diagnostic	diagnostic	ADJ
gs-3919	142	15	accuracy	accuracy	NOUN
gs-3919	142	16	,	,	PUNCT
gs-3919	142	17	while	while	SCONJ
gs-3919	142	18	novel	novel	ADJ
gs-3919	142	19	biomarkers	biomarker	NOUN
gs-3919	142	20	could	could	AUX
gs-3919	142	21	enable	enable	VERB
gs-3919	142	22	earlier	early	ADJ
gs-3919	142	23	detection	detection	NOUN
gs-3919	142	24	of	of	ADP
gs-3919	142	25	at	at	ADP
gs-3919	142	26	-	-	PUNCT
gs-3919	142	27	risk	risk	NOUN
gs-3919	142	28	individuals	individual	NOUN
gs-3919	142	29	.	.	PUNCT
gs-3919	143	1	the	the	DET
gs-3919	143	2	integration	integration	NOUN
gs-3919	143	3	of	of	ADP
gs-3919	143	4	these	these	DET
gs-3919	143	5	tools	tool	NOUN
gs-3919	143	6	into	into	ADP
gs-3919	143	7	clinical	clinical	ADJ
gs-3919	143	8	practice	practice	NOUN
gs-3919	143	9	will	will	AUX
gs-3919	143	10	be	be	AUX
gs-3919	143	11	essential	essential	ADJ
gs-3919	143	12	for	for	ADP
gs-3919	143	13	addressing	address	VERB
gs-3919	143	14	the	the	DET
gs-3919	143	15	ongoing	ongoing	ADJ
gs-3919	143	16	challenges	challenge	NOUN
gs-3919	143	17	posed	pose	VERB
gs-3919	143	18	by	by	ADP
gs-3919	143	19	drug	drug	NOUN
gs-3919	143	20	-	-	PUNCT
gs-3919	143	21	induced	induce	VERB
gs-3919	143	22	eosinophilia	eosinophilia	NOUN
gs-3919	143	23	and	and	CCONJ
gs-3919	143	24	systemic	systemic	ADJ
gs-3919	143	25	symptoms	symptom	NOUN
gs-3919	143	26	,	,	PUNCT
gs-3919	143	27	ultimately	ultimately	ADV
gs-3919	143	28	fostering	foster	VERB
gs-3919	143	29	safer	safe	ADJ
gs-3919	143	30	and	and	CCONJ
gs-3919	143	31	more	more	ADV
gs-3919	143	32	effective	effective	ADJ
gs-3919	143	33	pharmacotherapy	pharmacotherapy	NOUN
gs-3919	143	34	.	.	PUNCT
gs-3919	144	1	the	the	DET
gs-3919	144	2	study	study	NOUN
gs-3919	144	3	seeks	seek	VERB
gs-3919	144	4	to	to	PART
gs-3919	144	5	illuminate	illuminate	VERB
gs-3919	144	6	the	the	DET
gs-3919	144	7	complex	complex	ADJ
gs-3919	144	8	interplay	interplay	NOUN
gs-3919	144	9	between	between	ADP
gs-3919	144	10	pharmacological	pharmacological	ADJ
gs-3919	144	11	properties	property	NOUN
gs-3919	144	12	and	and	CCONJ
gs-3919	144	13	adverse	adverse	ADJ
gs-3919	144	14	immunological	immunological	ADJ
gs-3919	144	15	responses	response	NOUN
gs-3919	144	16	,	,	PUNCT
gs-3919	144	17	with	with	ADP
gs-3919	144	18	a	a	DET
gs-3919	144	19	focus	focus	NOUN
gs-3919	144	20	on	on	ADP
gs-3919	144	21	the	the	DET
gs-3919	144	22	clinical	clinical	ADJ
gs-3919	144	23	and	and	CCONJ
gs-3919	144	24	mechanistic	mechanistic	ADJ
gs-3919	144	25	nuances	nuance	NOUN
gs-3919	144	26	of	of	ADP
gs-3919	144	27	drug	drug	NOUN
gs-3919	144	28	-	-	PUNCT
gs-3919	144	29	induced	induce	VERB
gs-3919	144	30	eosinophilia	eosinophilia	NOUN
gs-3919	144	31	.	.	PUNCT
gs-3919	145	1	by	by	ADP
gs-3919	145	2	synthesizing	synthesize	VERB
gs-3919	145	3	current	current	ADJ
gs-3919	145	4	knowledge	knowledge	NOUN
gs-3919	145	5	and	and	CCONJ
gs-3919	145	6	highlighting	highlight	VERB
gs-3919	145	7	emerging	emerge	VERB
gs-3919	145	8	research	research	NOUN
gs-3919	145	9	,	,	PUNCT
gs-3919	145	10	we	we	PRON
gs-3919	145	11	aim	aim	VERB
gs-3919	145	12	to	to	PART
gs-3919	145	13	provide	provide	VERB
gs-3919	145	14	a	a	DET
gs-3919	145	15	comprehensive	comprehensive	ADJ
gs-3919	145	16	foundation	foundation	NOUN
gs-3919	145	17	for	for	ADP
gs-3919	145	18	understanding	understanding	NOUN
gs-3919	145	19	,	,	PUNCT
gs-3919	145	20	diagnosing	diagnosing	NOUN
gs-3919	145	21	,	,	PUNCT
gs-3919	145	22	and	and	CCONJ
gs-3919	145	23	managing	manage	VERB
gs-3919	145	24	these	these	DET
gs-3919	145	25	formidable	formidable	ADJ
gs-3919	145	26	adverse	adverse	ADJ
gs-3919	145	27	drug	drug	NOUN
gs-3919	145	28	reactions	reaction	NOUN
gs-3919	145	29	.	.	PUNCT
gs-3919	146	1	goal	goal	NOUN
gs-3919	146	2	aim	aim	NOUN
gs-3919	146	3	of	of	ADP
gs-3919	146	4	the	the	DET
gs-3919	146	5	research	research	NOUN
gs-3919	146	6	was	be	AUX
gs-3919	146	7	to	to	PART
gs-3919	146	8	study	study	VERB
gs-3919	146	9	pharmacological	pharmacological	ADJ
gs-3919	146	10	properties	property	NOUN
gs-3919	146	11	and	and	CCONJ
gs-3919	146	12	profiles	profile	NOUN
gs-3919	146	13	in	in	ADP
gs-3919	146	14	relation	relation	NOUN
gs-3919	146	15	to	to	ADP
gs-3919	146	16	adverse	adverse	ADJ
gs-3919	146	17	drug	drug	NOUN
gs-3919	146	18	reactions	reaction	NOUN
gs-3919	146	19	:	:	PUNCT
gs-3919	146	20	focus	focus	VERB
gs-3919	146	21	on	on	ADP
gs-3919	146	22	drug	drug	NOUN
gs-3919	146	23	-	-	PUNCT
gs-3919	146	24	induced	induce	VERB
gs-3919	146	25	eosinophilia	eosinophilia	NOUN
gs-3919	146	26	and	and	CCONJ
gs-3919	146	27	systemic	systemic	ADJ
gs-3919	146	28	symptoms	symptom	NOUN
gs-3919	146	29	.	.	PUNCT
gs-3919	147	1	methodology	methodology	NOUN
gs-3919	147	2	the	the	DET
gs-3919	147	3	current	current	ADJ
gs-3919	147	4	research	research	NOUN
gs-3919	147	5	was	be	AUX
gs-3919	147	6	planned	plan	VERB
gs-3919	147	7	as	as	ADP
gs-3919	147	8	a	a	DET
gs-3919	147	9	full	full	ADJ
gs-3919	147	10	systematic	systematic	ADJ
gs-3919	147	11	qualitative	qualitative	ADJ
gs-3919	147	12	review	review	NOUN
gs-3919	147	13	in	in	ADP
gs-3919	147	14	order	order	NOUN
gs-3919	147	15	to	to	ADP
gs-3919	147	16	synthesizing	synthesize	VERB
gs-3919	147	17	the	the	DET
gs-3919	147	18	knowledge	knowledge	NOUN
gs-3919	147	19	available	available	ADJ
gs-3919	147	20	for	for	ADP
gs-3919	147	21	drug	drug	NOUN
gs-3919	147	22	reaction	reaction	NOUN
gs-3919	147	23	with	with	ADP
gs-3919	147	24	eosinophilia	eosinophilia	PROPN
gs-3919	147	25	and	and	CCONJ
gs-3919	147	26	systemic	systemic	ADJ
gs-3919	147	27	symptoms	symptom	NOUN
gs-3919	147	28	(	(	PUNCT
gs-3919	147	29	dress	dress	NOUN
gs-3919	147	30	)	)	PUNCT
gs-3919	147	31	.	.	PUNCT
gs-3919	148	1	general	general	ADJ
gs-3919	148	2	purposes	purpose	NOUN
gs-3919	148	3	of	of	ADP
gs-3919	148	4	this	this	DET
gs-3919	148	5	study	study	NOUN
gs-3919	148	6	consisted	consist	VERB
gs-3919	148	7	in	in	ADP
gs-3919	148	8	the	the	DET
gs-3919	148	9	collection	collection	NOUN
gs-3919	148	10	of	of	ADP
gs-3919	148	11	clinical	clinical	ADJ
gs-3919	148	12	observations	observation	NOUN
gs-3919	148	13	on	on	ADP
gs-3919	148	14	etiological	etiological	ADJ
gs-3919	148	15	agents	agent	NOUN
gs-3919	148	16	,	,	PUNCT
gs-3919	148	17	clinical	clinical	ADJ
gs-3919	148	18	manifestations	manifestation	NOUN
gs-3919	148	19	,	,	PUNCT
gs-3919	148	20	diagnosis	diagnosis	NOUN
gs-3919	148	21	,	,	PUNCT
gs-3919	148	22	and	and	CCONJ
gs-3919	148	23	treatment	treatment	NOUN
gs-3919	148	24	and	and	CCONJ
gs-3919	148	25	for	for	ADP
gs-3919	148	26	the	the	DET
gs-3919	148	27	long	long	ADJ
gs-3919	148	28	-	-	PUNCT
gs-3919	148	29	term	term	NOUN
gs-3919	148	30	prognosis	prognosis	NOUN
gs-3919	148	31	of	of	ADP
gs-3919	148	32	patients	patient	NOUN
gs-3919	148	33	.	.	PUNCT
gs-3919	149	1	there	there	PRON
gs-3919	149	2	was	be	VERB
gs-3919	149	3	a	a	DET
gs-3919	149	4	focus	focus	NOUN
gs-3919	149	5	on	on	ADP
gs-3919	149	6	systematic	systematic	ADJ
gs-3919	149	7	review	review	NOUN
gs-3919	149	8	of	of	ADP
gs-3919	149	9	real	real	ADJ
gs-3919	149	10	-	-	PUNCT
gs-3919	149	11	world	world	NOUN
gs-3919	149	12	clinical	clinical	ADJ
gs-3919	149	13	evidence	evidence	NOUN
gs-3919	149	14	published	publish	VERB
gs-3919	149	15	in	in	ADP
gs-3919	149	16	peer	peer	NOUN
gs-3919	149	17	review	review	NOUN
gs-3919	149	18	case	case	NOUN
gs-3919	149	19	reports	report	VERB
gs-3919	149	20	,	,	PUNCT
gs-3919	149	21	case	case	NOUN
gs-3919	149	22	series	series	NOUN
gs-3919	149	23	,	,	PUNCT
gs-3919	149	24	observational	observational	ADJ
gs-3919	149	25	studies	study	NOUN
gs-3919	149	26	,	,	PUNCT
gs-3919	149	27	and	and	CCONJ
gs-3919	149	28	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	149	29	reports	report	NOUN
gs-3919	149	30	.	.	PUNCT
gs-3919	150	1	georgian	georgian	ADJ
gs-3919	150	2	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	150	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	150	4	ტ.	ტ.	VERB
gs-3919	150	5	7	7	NUM
gs-3919	150	6	n	n	PRON
gs-3919	150	7	3	3	NUM
gs-3919	150	8	,	,	PUNCT
gs-3919	150	9	2025	2025	NUM
gs-3919	150	10	150	150	NUM
gs-3919	150	11	the	the	DET
gs-3919	150	12	exploration	exploration	NOUN
gs-3919	150	13	of	of	ADP
gs-3919	150	14	drug	drug	NOUN
gs-3919	150	15	-	-	PUNCT
gs-3919	150	16	induced	induce	VERB
gs-3919	150	17	eosinophilia	eosinophilia	NOUN
gs-3919	150	18	and	and	CCONJ
gs-3919	150	19	systemic	systemic	ADJ
gs-3919	150	20	symptoms	symptom	NOUN
gs-3919	150	21	necessitates	necessitate	VERB
gs-3919	150	22	a	a	DET
gs-3919	150	23	multidisciplinary	multidisciplinary	ADJ
gs-3919	150	24	approach	approach	NOUN
gs-3919	150	25	,	,	PUNCT
gs-3919	150	26	integrating	integrate	VERB
gs-3919	150	27	pharmacological	pharmacological	NOUN
gs-3919	150	28	,	,	PUNCT
gs-3919	150	29	immunological	immunological	ADJ
gs-3919	150	30	,	,	PUNCT
gs-3919	150	31	and	and	CCONJ
gs-3919	150	32	clinical	clinical	ADJ
gs-3919	150	33	research	research	NOUN
gs-3919	150	34	methodologies	methodology	NOUN
gs-3919	150	35	to	to	PART
gs-3919	150	36	comprehensively	comprehensively	ADV
gs-3919	150	37	evaluate	evaluate	VERB
gs-3919	150	38	the	the	DET
gs-3919	150	39	underlying	underlie	VERB
gs-3919	150	40	mechanisms	mechanism	NOUN
gs-3919	150	41	,	,	PUNCT
gs-3919	150	42	risk	risk	NOUN
gs-3919	150	43	factors	factor	NOUN
gs-3919	150	44	,	,	PUNCT
gs-3919	150	45	and	and	CCONJ
gs-3919	150	46	therapeutic	therapeutic	ADJ
gs-3919	150	47	strategies	strategy	NOUN
gs-3919	150	48	.	.	PUNCT
gs-3919	151	1	this	this	DET
gs-3919	151	2	discussion	discussion	NOUN
gs-3919	151	3	is	be	AUX
gs-3919	151	4	grounded	ground	VERB
gs-3919	151	5	in	in	ADP
gs-3919	151	6	a	a	DET
gs-3919	151	7	systematic	systematic	ADJ
gs-3919	151	8	evaluation	evaluation	NOUN
gs-3919	151	9	of	of	ADP
gs-3919	151	10	existing	exist	VERB
gs-3919	151	11	literature	literature	NOUN
gs-3919	151	12	,	,	PUNCT
gs-3919	151	13	augmented	augment	VERB
gs-3919	151	14	by	by	ADP
gs-3919	151	15	critical	critical	ADJ
gs-3919	151	16	analysis	analysis	NOUN
gs-3919	151	17	of	of	ADP
gs-3919	151	18	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	151	19	data	datum	NOUN
gs-3919	151	20	and	and	CCONJ
gs-3919	151	21	clinical	clinical	ADJ
gs-3919	151	22	case	case	NOUN
gs-3919	151	23	studies	study	NOUN
gs-3919	151	24	.	.	PUNCT
gs-3919	152	1	the	the	DET
gs-3919	152	2	methodological	methodological	ADJ
gs-3919	152	3	framework	framework	NOUN
gs-3919	152	4	encompasses	encompass	VERB
gs-3919	152	5	several	several	ADJ
gs-3919	152	6	key	key	ADJ
gs-3919	152	7	dimensions	dimension	NOUN
gs-3919	152	8	,	,	PUNCT
gs-3919	152	9	each	each	PRON
gs-3919	152	10	contributing	contribute	VERB
gs-3919	152	11	to	to	ADP
gs-3919	152	12	a	a	DET
gs-3919	152	13	holistic	holistic	ADJ
gs-3919	152	14	understanding	understanding	NOUN
gs-3919	152	15	of	of	ADP
gs-3919	152	16	this	this	DET
gs-3919	152	17	complex	complex	ADJ
gs-3919	152	18	adverse	adverse	ADJ
gs-3919	152	19	drug	drug	NOUN
gs-3919	152	20	reaction	reaction	NOUN
gs-3919	152	21	.	.	PUNCT
gs-3919	153	1	a	a	DET
gs-3919	153	2	thorough	thorough	ADJ
gs-3919	153	3	review	review	NOUN
gs-3919	153	4	of	of	ADP
gs-3919	153	5	peer	peer	NOUN
gs-3919	153	6	-	-	PUNCT
gs-3919	153	7	reviewed	review	VERB
gs-3919	153	8	scientific	scientific	ADJ
gs-3919	153	9	literature	literature	NOUN
gs-3919	153	10	forms	form	VERB
gs-3919	153	11	the	the	DET
gs-3919	153	12	foundation	foundation	NOUN
gs-3919	153	13	of	of	ADP
gs-3919	153	14	this	this	DET
gs-3919	153	15	investigation	investigation	NOUN
gs-3919	153	16	.	.	PUNCT
gs-3919	154	1	databases	database	NOUN
gs-3919	154	2	such	such	ADJ
gs-3919	154	3	as	as	ADP
gs-3919	154	4	pubmed	pubmed	PROPN
gs-3919	154	5	,	,	PUNCT
gs-3919	154	6	scopus	scopus	PROPN
gs-3919	154	7	,	,	PUNCT
gs-3919	154	8	and	and	CCONJ
gs-3919	154	9	web	web	NOUN
gs-3919	154	10	of	of	ADP
gs-3919	154	11	science	science	NOUN
gs-3919	154	12	were	be	AUX
gs-3919	154	13	queried	query	VERB
gs-3919	154	14	using	use	VERB
gs-3919	154	15	targeted	target	VERB
gs-3919	154	16	search	search	NOUN
gs-3919	154	17	terms	term	NOUN
gs-3919	154	18	,	,	PUNCT
gs-3919	154	19	including	include	VERB
gs-3919	154	20	drug	drug	NOUN
gs-3919	154	21	-	-	PUNCT
gs-3919	154	22	induced	induce	VERB
gs-3919	154	23	eosinophilia	eosinophilia	NOUN
gs-3919	154	24	,	,	PUNCT
gs-3919	154	25	dress	dress	NOUN
gs-3919	154	26	syndrome	syndrome	NOUN
gs-3919	154	27	,	,	PUNCT
gs-3919	154	28	pharmacological	pharmacological	ADJ
gs-3919	154	29	mechanisms	mechanism	NOUN
gs-3919	154	30	of	of	ADP
gs-3919	154	31	hypersensitivity	hypersensitivity	NOUN
gs-3919	154	32	,	,	PUNCT
gs-3919	154	33	and	and	CCONJ
gs-3919	154	34	eosinophil	eosinophil	ADJ
gs-3919	154	35	-	-	PUNCT
gs-3919	154	36	mediated	mediate	VERB
gs-3919	154	37	tissue	tissue	NOUN
gs-3919	154	38	injury	injury	NOUN
gs-3919	154	39	.	.	PUNCT
gs-3919	155	1	the	the	DET
gs-3919	155	2	inclusion	inclusion	NOUN
gs-3919	155	3	criteria	criterion	NOUN
gs-3919	155	4	prioritized	prioritize	VERB
gs-3919	155	5	recent	recent	ADJ
gs-3919	155	6	studies	study	NOUN
gs-3919	155	7	(	(	PUNCT
gs-3919	155	8	published	publish	VERB
gs-3919	155	9	within	within	ADP
gs-3919	155	10	the	the	DET
gs-3919	155	11	last	last	ADJ
gs-3919	155	12	decade	decade	NOUN
gs-3919	155	13	)	)	PUNCT
gs-3919	155	14	as	as	ADV
gs-3919	155	15	well	well	ADV
gs-3919	155	16	as	as	ADP
gs-3919	155	17	seminal	seminal	ADJ
gs-3919	155	18	works	work	NOUN
gs-3919	155	19	that	that	PRON
gs-3919	155	20	have	have	AUX
gs-3919	155	21	shaped	shape	VERB
gs-3919	155	22	current	current	ADJ
gs-3919	155	23	understanding	understanding	NOUN
gs-3919	155	24	of	of	ADP
gs-3919	155	25	the	the	DET
gs-3919	155	26	topic	topic	NOUN
gs-3919	155	27	.	.	PUNCT
gs-3919	156	1	special	special	ADJ
gs-3919	156	2	emphasis	emphasis	NOUN
gs-3919	156	3	was	be	AUX
gs-3919	156	4	placed	place	VERB
gs-3919	156	5	on	on	ADP
gs-3919	156	6	meta	meta	NOUN
gs-3919	156	7	-	-	PUNCT
gs-3919	156	8	analyses	analysis	NOUN
gs-3919	156	9	,	,	PUNCT
gs-3919	156	10	large	large	ADJ
gs-3919	156	11	-	-	PUNCT
gs-3919	156	12	scale	scale	NOUN
gs-3919	156	13	cohort	cohort	NOUN
gs-3919	156	14	studies	study	NOUN
gs-3919	156	15	,	,	PUNCT
gs-3919	156	16	and	and	CCONJ
gs-3919	156	17	mechanistic	mechanistic	ADJ
gs-3919	156	18	investigations	investigation	NOUN
gs-3919	156	19	to	to	PART
gs-3919	156	20	ensure	ensure	VERB
gs-3919	156	21	a	a	DET
gs-3919	156	22	robust	robust	ADJ
gs-3919	156	23	evidence	evidence	NOUN
gs-3919	156	24	base	base	NOUN
gs-3919	156	25	.	.	PUNCT
gs-3919	157	1	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	157	2	data	datum	NOUN
gs-3919	157	3	from	from	ADP
gs-3919	157	4	regulatory	regulatory	ADJ
gs-3919	157	5	agencies	agency	NOUN
gs-3919	157	6	,	,	PUNCT
gs-3919	157	7	including	include	VERB
gs-3919	157	8	the	the	DET
gs-3919	157	9	fda	fda	PROPN
gs-3919	157	10	adverse	adverse	ADJ
gs-3919	157	11	event	event	NOUN
gs-3919	157	12	reporting	report	VERB
gs-3919	157	13	system	system	NOUN
gs-3919	157	14	(	(	PUNCT
gs-3919	157	15	faers	faer	NOUN
gs-3919	157	16	)	)	PUNCT
gs-3919	157	17	and	and	CCONJ
gs-3919	157	18	the	the	DET
gs-3919	157	19	who	who	PRON
gs-3919	157	20	global	global	ADJ
gs-3919	157	21	individual	individual	ADJ
gs-3919	157	22	case	case	NOUN
gs-3919	157	23	safety	safety	NOUN
gs-3919	157	24	reports	report	NOUN
gs-3919	157	25	database	database	NOUN
gs-3919	157	26	(	(	PUNCT
gs-3919	157	27	vigibase	vigibase	PROPN
gs-3919	157	28	)	)	PUNCT
gs-3919	157	29	,	,	PUNCT
gs-3919	157	30	were	be	AUX
gs-3919	157	31	analyzed	analyze	VERB
gs-3919	157	32	to	to	PART
gs-3919	157	33	identify	identify	VERB
gs-3919	157	34	trends	trend	NOUN
gs-3919	157	35	in	in	ADP
gs-3919	157	36	drug	drug	NOUN
gs-3919	157	37	-	-	PUNCT
gs-3919	157	38	induced	induce	VERB
gs-3919	157	39	eosinophilia	eosinophilia	NOUN
gs-3919	157	40	and	and	CCONJ
gs-3919	157	41	associated	associate	VERB
gs-3919	157	42	systemic	systemic	ADJ
gs-3919	157	43	reactions	reaction	NOUN
gs-3919	157	44	.	.	PUNCT
gs-3919	158	1	these	these	DET
gs-3919	158	2	databases	database	NOUN
gs-3919	158	3	provide	provide	VERB
gs-3919	158	4	real	real	ADJ
gs-3919	158	5	-	-	PUNCT
gs-3919	158	6	world	world	NOUN
gs-3919	158	7	insights	insight	NOUN
gs-3919	158	8	into	into	ADP
gs-3919	158	9	the	the	DET
gs-3919	158	10	frequency	frequency	NOUN
gs-3919	158	11	,	,	PUNCT
gs-3919	158	12	severity	severity	NOUN
gs-3919	158	13	,	,	PUNCT
gs-3919	158	14	and	and	CCONJ
gs-3919	158	15	drug	drug	NOUN
gs-3919	158	16	-	-	PUNCT
gs-3919	158	17	specific	specific	ADJ
gs-3919	158	18	patterns	pattern	NOUN
gs-3919	158	19	of	of	ADP
gs-3919	158	20	adverse	adverse	ADJ
gs-3919	158	21	events	event	NOUN
gs-3919	158	22	,	,	PUNCT
gs-3919	158	23	enabling	enable	VERB
gs-3919	158	24	the	the	DET
gs-3919	158	25	identification	identification	NOUN
gs-3919	158	26	of	of	ADP
gs-3919	158	27	high	high	ADJ
gs-3919	158	28	-	-	PUNCT
gs-3919	158	29	risk	risk	NOUN
gs-3919	158	30	pharmacological	pharmacological	NOUN
gs-3919	158	31	agents	agent	NOUN
gs-3919	158	32	.	.	PUNCT
gs-3919	159	1	case	case	NOUN
gs-3919	159	2	reports	report	NOUN
gs-3919	159	3	and	and	CCONJ
gs-3919	159	4	series	series	NOUN
gs-3919	159	5	were	be	AUX
gs-3919	159	6	also	also	ADV
gs-3919	159	7	examined	examine	VERB
gs-3919	159	8	to	to	PART
gs-3919	159	9	elucidate	elucidate	VERB
gs-3919	159	10	atypical	atypical	ADJ
gs-3919	159	11	presentations	presentation	NOUN
gs-3919	159	12	and	and	CCONJ
gs-3919	159	13	therapeutic	therapeutic	ADJ
gs-3919	159	14	challenges	challenge	NOUN
gs-3919	159	15	,	,	PUNCT
gs-3919	159	16	offering	offer	VERB
gs-3919	159	17	a	a	DET
gs-3919	159	18	nuanced	nuanced	ADJ
gs-3919	159	19	perspective	perspective	NOUN
gs-3919	159	20	beyond	beyond	ADP
gs-3919	159	21	aggregate	aggregate	ADJ
gs-3919	159	22	statistics	statistic	NOUN
gs-3919	159	23	.	.	PUNCT
gs-3919	160	1	the	the	DET
gs-3919	160	2	pharmacological	pharmacological	ADJ
gs-3919	160	3	properties	property	NOUN
gs-3919	160	4	of	of	ADP
gs-3919	160	5	drugs	drug	NOUN
gs-3919	160	6	implicated	implicate	VERB
gs-3919	160	7	in	in	ADP
gs-3919	160	8	eosinophilic	eosinophilic	ADJ
gs-3919	160	9	reactions	reaction	NOUN
gs-3919	160	10	were	be	AUX
gs-3919	160	11	evaluated	evaluate	VERB
gs-3919	160	12	through	through	ADP
gs-3919	160	13	a	a	DET
gs-3919	160	14	structural	structural	ADJ
gs-3919	160	15	and	and	CCONJ
gs-3919	160	16	metabolic	metabolic	NOUN
gs-3919	160	17	lens	len	NOUN
gs-3919	160	18	.	.	PUNCT
gs-3919	161	1	particular	particular	ADJ
gs-3919	161	2	attention	attention	NOUN
gs-3919	161	3	was	be	AUX
gs-3919	161	4	paid	pay	VERB
gs-3919	161	5	to	to	ADP
gs-3919	161	6	drugs	drug	NOUN
gs-3919	161	7	known	know	VERB
gs-3919	161	8	to	to	PART
gs-3919	161	9	form	form	VERB
gs-3919	161	10	reactive	reactive	ADJ
gs-3919	161	11	metabolites	metabolite	NOUN
gs-3919	161	12	or	or	CCONJ
gs-3919	161	13	hapten	hapten	VERB
gs-3919	161	14	-	-	PUNCT
gs-3919	161	15	protein	protein	NOUN
gs-3919	161	16	complexes	complex	NOUN
gs-3919	161	17	,	,	PUNCT
gs-3919	161	18	as	as	SCONJ
gs-3919	161	19	these	these	DET
gs-3919	161	20	mechanisms	mechanism	NOUN
gs-3919	161	21	are	be	AUX
gs-3919	161	22	central	central	ADJ
gs-3919	161	23	to	to	ADP
gs-3919	161	24	the	the	DET
gs-3919	161	25	initiation	initiation	NOUN
gs-3919	161	26	of	of	ADP
gs-3919	161	27	immune	immune	NOUN
gs-3919	161	28	-	-	PUNCT
gs-3919	161	29	mediated	mediate	VERB
gs-3919	161	30	adverse	adverse	ADJ
gs-3919	161	31	reactions	reaction	NOUN
gs-3919	161	32	.	.	PUNCT
gs-3919	162	1	computational	computational	ADJ
gs-3919	162	2	modeling	modeling	NOUN
gs-3919	162	3	and	and	CCONJ
gs-3919	162	4	in	in	ADP
gs-3919	162	5	vitro	vitro	X
gs-3919	162	6	studies	study	NOUN
gs-3919	162	7	were	be	AUX
gs-3919	162	8	referenced	reference	VERB
gs-3919	162	9	to	to	PART
gs-3919	162	10	illustrate	illustrate	VERB
gs-3919	162	11	how	how	SCONJ
gs-3919	162	12	specific	specific	ADJ
gs-3919	162	13	chemical	chemical	NOUN
gs-3919	162	14	moieties	moiety	NOUN
gs-3919	162	15	contribute	contribute	VERB
gs-3919	162	16	to	to	ADP
gs-3919	162	17	immunogenicity	immunogenicity	NOUN
gs-3919	162	18	.	.	PUNCT
gs-3919	163	1	additionally	additionally	ADV
gs-3919	163	2	,	,	PUNCT
gs-3919	163	3	pharmacogenetic	pharmacogenetic	ADJ
gs-3919	163	4	studies	study	NOUN
gs-3919	163	5	highlighting	highlight	VERB
gs-3919	163	6	associations	association	NOUN
gs-3919	163	7	between	between	ADP
gs-3919	163	8	hla	hla	PROPN
gs-3919	163	9	alleles	allele	NOUN
gs-3919	163	10	and	and	CCONJ
gs-3919	163	11	drug	drug	NOUN
gs-3919	163	12	hypersensitivity	hypersensitivity	NOUN
gs-3919	163	13	were	be	AUX
gs-3919	163	14	synthesized	synthesize	VERB
gs-3919	163	15	to	to	PART
gs-3919	163	16	underscore	underscore	VERB
gs-3919	163	17	the	the	DET
gs-3919	163	18	interplay	interplay	NOUN
gs-3919	163	19	between	between	ADP
gs-3919	163	20	genetic	genetic	ADJ
gs-3919	163	21	predisposition	predisposition	NOUN
gs-3919	163	22	and	and	CCONJ
gs-3919	163	23	drug	drug	NOUN
gs-3919	163	24	-	-	PUNCT
gs-3919	163	25	specific	specific	ADJ
gs-3919	163	26	factors	factor	NOUN
gs-3919	163	27	.	.	PUNCT
gs-3919	164	1	immunological	immunological	ADJ
gs-3919	164	2	pathways	pathway	NOUN
gs-3919	164	3	driving	drive	VERB
gs-3919	164	4	eosinophil	eosinophil	ADJ
gs-3919	164	5	activation	activation	NOUN
gs-3919	164	6	and	and	CCONJ
gs-3919	164	7	tissue	tissue	NOUN
gs-3919	164	8	infiltration	infiltration	NOUN
gs-3919	164	9	were	be	AUX
gs-3919	164	10	dissected	dissect	VERB
gs-3919	164	11	through	through	ADP
gs-3919	164	12	an	an	DET
gs-3919	164	13	examination	examination	NOUN
gs-3919	164	14	of	of	ADP
gs-3919	164	15	preclinical	preclinical	ADJ
gs-3919	164	16	and	and	CCONJ
gs-3919	164	17	clinical	clinical	ADJ
gs-3919	164	18	research	research	NOUN
gs-3919	164	19	.	.	PUNCT
gs-3919	165	1	studies	study	NOUN
gs-3919	165	2	investigating	investigate	VERB
gs-3919	165	3	cytokine	cytokine	ADJ
gs-3919	165	4	profiles	profile	NOUN
gs-3919	165	5	(	(	PUNCT
gs-3919	165	6	e.g.	e.g.	ADV
gs-3919	165	7	,	,	PUNCT
gs-3919	165	8	il-5	il-5	PRON
gs-3919	165	9	,	,	PUNCT
gs-3919	165	10	il-4	il-4	NOUN
gs-3919	165	11	,	,	PUNCT
gs-3919	165	12	il-13	il-13	NUM
gs-3919	165	13	)	)	PUNCT
gs-3919	165	14	,	,	PUNCT
gs-3919	165	15	eosinophil	eosinophil	ADJ
gs-3919	165	16	degranulation	degranulation	NOUN
gs-3919	165	17	patterns	pattern	NOUN
gs-3919	165	18	,	,	PUNCT
gs-3919	165	19	and	and	CCONJ
gs-3919	165	20	histopathological	histopathological	ADJ
gs-3919	165	21	findings	finding	NOUN
gs-3919	165	22	were	be	AUX
gs-3919	165	23	integrated	integrate	VERB
gs-3919	165	24	to	to	PART
gs-3919	165	25	construct	construct	VERB
gs-3919	165	26	a	a	DET
gs-3919	165	27	coherent	coherent	ADJ
gs-3919	165	28	model	model	NOUN
gs-3919	165	29	of	of	ADP
gs-3919	165	30	pathogenesis	pathogenesis	NOUN
gs-3919	165	31	.	.	PUNCT
gs-3919	166	1	where	where	SCONJ
gs-3919	166	2	available	available	ADJ
gs-3919	166	3	,	,	PUNCT
gs-3919	166	4	data	datum	NOUN
gs-3919	166	5	from	from	ADP
gs-3919	166	6	animal	animal	NOUN
gs-3919	166	7	models	model	NOUN
gs-3919	166	8	of	of	ADP
gs-3919	166	9	drug	drug	NOUN
gs-3919	166	10	hypersensitivity	hypersensitivity	NOUN
gs-3919	166	11	were	be	AUX
gs-3919	166	12	cited	cite	VERB
gs-3919	166	13	to	to	PART
gs-3919	166	14	provide	provide	VERB
gs-3919	166	15	mechanistic	mechanistic	ADJ
gs-3919	166	16	insights	insight	NOUN
gs-3919	166	17	not	not	PART
gs-3919	166	18	readily	readily	ADV
gs-3919	166	19	obtainable	obtainable	ADJ
gs-3919	166	20	from	from	ADP
gs-3919	166	21	human	human	ADJ
gs-3919	166	22	studies	study	NOUN
gs-3919	166	23	.	.	PUNCT
gs-3919	167	1	clinical	clinical	ADJ
gs-3919	167	2	diagnostic	diagnostic	ADJ
gs-3919	167	3	criteria	criterion	NOUN
gs-3919	167	4	,	,	PUNCT
gs-3919	167	5	such	such	ADJ
gs-3919	167	6	as	as	ADP
gs-3919	167	7	the	the	DET
gs-3919	167	8	regiscar	regiscar	ADJ
gs-3919	167	9	scoring	scoring	NOUN
gs-3919	167	10	system	system	NOUN
gs-3919	167	11	for	for	ADP
gs-3919	167	12	dress	dress	NOUN
gs-3919	167	13	syndrome	syndrome	NOUN
gs-3919	167	14	,	,	PUNCT
gs-3919	167	15	were	be	AUX
gs-3919	167	16	scrutinized	scrutinize	VERB
gs-3919	167	17	for	for	ADP
gs-3919	167	18	their	their	PRON
gs-3919	167	19	utility	utility	NOUN
gs-3919	167	20	and	and	CCONJ
gs-3919	167	21	limitations	limitation	NOUN
gs-3919	167	22	in	in	ADP
gs-3919	167	23	real	real	ADJ
gs-3919	167	24	-	-	PUNCT
gs-3919	167	25	world	world	NOUN
gs-3919	167	26	practice	practice	NOUN
gs-3919	167	27	.	.	PUNCT
gs-3919	168	1	comparative	comparative	ADJ
gs-3919	168	2	analyses	analysis	NOUN
gs-3919	168	3	of	of	ADP
gs-3919	168	4	diagnostic	diagnostic	ADJ
gs-3919	168	5	tools	tool	NOUN
gs-3919	168	6	—	—	PUNCT
gs-3919	168	7	including	include	VERB
gs-3919	168	8	laboratory	laboratory	NOUN
gs-3919	168	9	biomarkers	biomarker	NOUN
gs-3919	168	10	,	,	PUNCT
gs-3919	168	11	imaging	imaging	NOUN
gs-3919	168	12	findings	finding	NOUN
gs-3919	168	13	,	,	PUNCT
gs-3919	168	14	and	and	CCONJ
gs-3919	168	15	georgian	georgian	ADJ
gs-3919	168	16	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	168	17	მეცნიერები	მეცნიერები	NOUN
gs-3919	168	18	ტ.	ტ.	VERB
gs-3919	168	19	7	7	NUM
gs-3919	168	20	n	n	PRON
gs-3919	168	21	3	3	NUM
gs-3919	168	22	,	,	PUNCT
gs-3919	168	23	2025	2025	NUM
gs-3919	168	24	151	151	NUM
gs-3919	168	25	histopathology	histopathology	NOUN
gs-3919	168	26	—	—	PUNCT
gs-3919	168	27	were	be	AUX
gs-3919	168	28	conducted	conduct	VERB
gs-3919	168	29	to	to	PART
gs-3919	168	30	highlight	highlight	VERB
gs-3919	168	31	gaps	gap	NOUN
gs-3919	168	32	in	in	ADP
gs-3919	168	33	current	current	ADJ
gs-3919	168	34	diagnostic	diagnostic	ADJ
gs-3919	168	35	paradigms	paradigm	NOUN
gs-3919	168	36	.	.	PUNCT
gs-3919	169	1	therapeutic	therapeutic	ADJ
gs-3919	169	2	strategies	strategy	NOUN
gs-3919	169	3	were	be	AUX
gs-3919	169	4	evaluated	evaluate	VERB
gs-3919	169	5	based	base	VERB
gs-3919	169	6	on	on	ADP
gs-3919	169	7	clinical	clinical	ADJ
gs-3919	169	8	trial	trial	NOUN
gs-3919	169	9	data	datum	NOUN
gs-3919	169	10	,	,	PUNCT
gs-3919	169	11	expert	expert	ADJ
gs-3919	169	12	consensus	consensus	NOUN
gs-3919	169	13	guidelines	guideline	NOUN
gs-3919	169	14	,	,	PUNCT
gs-3919	169	15	and	and	CCONJ
gs-3919	169	16	observational	observational	ADJ
gs-3919	169	17	studies	study	NOUN
gs-3919	169	18	,	,	PUNCT
gs-3919	169	19	with	with	ADP
gs-3919	169	20	a	a	DET
gs-3919	169	21	focus	focus	NOUN
gs-3919	169	22	on	on	ADP
gs-3919	169	23	corticosteroid	corticosteroid	ADJ
gs-3919	169	24	regimens	regimen	NOUN
gs-3919	169	25	,	,	PUNCT
gs-3919	169	26	immunosuppressive	immunosuppressive	ADJ
gs-3919	169	27	agents	agent	NOUN
gs-3919	169	28	,	,	PUNCT
gs-3919	169	29	and	and	CCONJ
gs-3919	169	30	emerging	emerge	VERB
gs-3919	169	31	biologic	biologic	NOUN
gs-3919	169	32	therapies	therapy	NOUN
gs-3919	169	33	.	.	PUNCT
gs-3919	170	1	to	to	PART
gs-3919	170	2	address	address	VERB
gs-3919	170	3	the	the	DET
gs-3919	170	4	translational	translational	ADJ
gs-3919	170	5	relevance	relevance	NOUN
gs-3919	170	6	of	of	ADP
gs-3919	170	7	this	this	DET
gs-3919	170	8	research	research	NOUN
gs-3919	170	9	,	,	PUNCT
gs-3919	170	10	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	170	11	strategies	strategy	NOUN
gs-3919	170	12	and	and	CCONJ
gs-3919	170	13	risk	risk	NOUN
gs-3919	170	14	mitigation	mitigation	NOUN
gs-3919	170	15	approaches	approach	NOUN
gs-3919	170	16	were	be	AUX
gs-3919	170	17	explored	explore	VERB
gs-3919	170	18	.	.	PUNCT
gs-3919	171	1	this	this	PRON
gs-3919	171	2	included	include	VERB
gs-3919	171	3	an	an	DET
gs-3919	171	4	assessment	assessment	NOUN
gs-3919	171	5	of	of	ADP
gs-3919	171	6	pre	pre	ADJ
gs-3919	171	7	-	-	ADJ
gs-3919	171	8	therapy	therapy	ADJ
gs-3919	171	9	genetic	genetic	ADJ
gs-3919	171	10	screening	screening	NOUN
gs-3919	171	11	protocols	protocol	NOUN
gs-3919	171	12	,	,	PUNCT
gs-3919	171	13	post	post	ADJ
gs-3919	171	14	-	-	ADJ
gs-3919	171	15	marketing	marketing	ADJ
gs-3919	171	16	surveillance	surveillance	NOUN
gs-3919	171	17	methodologies	methodology	NOUN
gs-3919	171	18	,	,	PUNCT
gs-3919	171	19	and	and	CCONJ
gs-3919	171	20	patient	patient	ADJ
gs-3919	171	21	education	education	NOUN
gs-3919	171	22	initiatives	initiative	NOUN
gs-3919	171	23	.	.	PUNCT
gs-3919	172	1	the	the	DET
gs-3919	172	2	role	role	NOUN
gs-3919	172	3	of	of	ADP
gs-3919	172	4	interdisciplinary	interdisciplinary	ADJ
gs-3919	172	5	collaboration	collaboration	NOUN
gs-3919	172	6	—	—	PUNCT
gs-3919	172	7	engaging	engage	VERB
gs-3919	172	8	pharmacologists	pharmacologist	NOUN
gs-3919	172	9	,	,	PUNCT
gs-3919	172	10	immunologists	immunologist	NOUN
gs-3919	172	11	,	,	PUNCT
gs-3919	172	12	and	and	CCONJ
gs-3919	172	13	clinicians	clinician	NOUN
gs-3919	172	14	—	—	PUNCT
gs-3919	172	15	was	be	AUX
gs-3919	172	16	emphasized	emphasize	VERB
gs-3919	172	17	as	as	ADP
gs-3919	172	18	a	a	DET
gs-3919	172	19	critical	critical	ADJ
gs-3919	172	20	component	component	NOUN
gs-3919	172	21	of	of	ADP
gs-3919	172	22	both	both	DET
gs-3919	172	23	research	research	NOUN
gs-3919	172	24	and	and	CCONJ
gs-3919	172	25	clinical	clinical	ADJ
gs-3919	172	26	practice	practice	NOUN
gs-3919	172	27	.	.	PUNCT
gs-3919	173	1	finally	finally	ADV
gs-3919	173	2	,	,	PUNCT
gs-3919	173	3	future	future	ADJ
gs-3919	173	4	directions	direction	NOUN
gs-3919	173	5	were	be	AUX
gs-3919	173	6	framed	frame	VERB
gs-3919	173	7	by	by	ADP
gs-3919	173	8	identifying	identify	VERB
gs-3919	173	9	unresolved	unresolved	ADJ
gs-3919	173	10	questions	question	NOUN
gs-3919	173	11	and	and	CCONJ
gs-3919	173	12	technological	technological	ADJ
gs-3919	173	13	advancements	advancement	NOUN
gs-3919	173	14	poised	poise	VERB
gs-3919	173	15	to	to	PART
gs-3919	173	16	reshape	reshape	VERB
gs-3919	173	17	the	the	DET
gs-3919	173	18	field	field	NOUN
gs-3919	173	19	.	.	PUNCT
gs-3919	174	1	innovations	innovation	NOUN
gs-3919	174	2	such	such	ADJ
gs-3919	174	3	as	as	ADP
gs-3919	174	4	single	single	ADJ
gs-3919	174	5	-	-	PUNCT
gs-3919	174	6	cell	cell	NOUN
gs-3919	174	7	rna	rna	NOUN
gs-3919	174	8	sequencing	sequence	VERB
gs-3919	174	9	to	to	PART
gs-3919	174	10	delineate	delineate	VERB
gs-3919	174	11	eosinophil	eosinophil	ADJ
gs-3919	174	12	heterogeneity	heterogeneity	NOUN
gs-3919	174	13	,	,	PUNCT
gs-3919	174	14	machine	machine	NOUN
gs-3919	174	15	learning	learning	NOUN
gs-3919	174	16	for	for	ADP
gs-3919	174	17	adverse	adverse	ADJ
gs-3919	174	18	event	event	NOUN
gs-3919	174	19	prediction	prediction	NOUN
gs-3919	174	20	,	,	PUNCT
gs-3919	174	21	and	and	CCONJ
gs-3919	174	22	the	the	DET
gs-3919	174	23	development	development	NOUN
gs-3919	174	24	of	of	ADP
gs-3919	174	25	targeted	target	VERB
gs-3919	174	26	cytokine	cytokine	ADJ
gs-3919	174	27	inhibitors	inhibitor	NOUN
gs-3919	174	28	were	be	AUX
gs-3919	174	29	discussed	discuss	VERB
gs-3919	174	30	as	as	ADP
gs-3919	174	31	promising	promise	VERB
gs-3919	174	32	avenues	avenue	NOUN
gs-3919	174	33	for	for	ADP
gs-3919	174	34	further	further	ADJ
gs-3919	174	35	investigation	investigation	NOUN
gs-3919	174	36	.	.	PUNCT
gs-3919	175	1	the	the	DET
gs-3919	175	2	methodology	methodology	NOUN
gs-3919	175	3	ensures	ensure	VERB
gs-3919	175	4	a	a	DET
gs-3919	175	5	comprehensive	comprehensive	ADJ
gs-3919	175	6	,	,	PUNCT
gs-3919	175	7	evidence	evidence	NOUN
gs-3919	175	8	-	-	PUNCT
gs-3919	175	9	based	base	VERB
gs-3919	175	10	discourse	discourse	NOUN
gs-3919	175	11	on	on	ADP
gs-3919	175	12	drug	drug	NOUN
gs-3919	175	13	-	-	PUNCT
gs-3919	175	14	induced	induce	VERB
gs-3919	175	15	eosinophilia	eosinophilia	NOUN
gs-3919	175	16	and	and	CCONJ
gs-3919	175	17	systemic	systemic	ADJ
gs-3919	175	18	symptoms	symptom	NOUN
gs-3919	175	19	,	,	PUNCT
gs-3919	175	20	bridging	bridge	VERB
gs-3919	175	21	fundamental	fundamental	ADJ
gs-3919	175	22	pharmacology	pharmacology	NOUN
gs-3919	175	23	with	with	ADP
gs-3919	175	24	clinical	clinical	ADJ
gs-3919	175	25	applicability	applicability	NOUN
gs-3919	175	26	while	while	SCONJ
gs-3919	175	27	remaining	remaining	AUX
gs-3919	175	28	grounded	ground	VERB
gs-3919	175	29	in	in	ADP
gs-3919	175	30	rigorous	rigorous	ADJ
gs-3919	175	31	scientific	scientific	ADJ
gs-3919	175	32	inquiry	inquiry	NOUN
gs-3919	175	33	.	.	PUNCT
gs-3919	176	1	a	a	DET
gs-3919	176	2	quality	quality	NOUN
gs-3919	176	3	assessment	assessment	NOUN
gs-3919	176	4	was	be	AUX
gs-3919	176	5	imposed	impose	VERB
gs-3919	176	6	to	to	PART
gs-3919	176	7	secure	secure	VERB
gs-3919	176	8	the	the	DET
gs-3919	176	9	scientific	scientific	ADJ
gs-3919	176	10	and	and	CCONJ
gs-3919	176	11	clinical	clinical	ADJ
gs-3919	176	12	validity	validity	NOUN
gs-3919	176	13	of	of	ADP
gs-3919	176	14	the	the	DET
gs-3919	176	15	present	present	ADJ
gs-3919	176	16	thesis	thesis	NOUN
gs-3919	176	17	on	on	ADP
gs-3919	176	18	drug	drug	NOUN
gs-3919	176	19	-	-	PUNCT
gs-3919	176	20	induced	induce	VERB
gs-3919	176	21	drug	drug	NOUN
gs-3919	176	22	reaction	reaction	NOUN
gs-3919	176	23	with	with	ADP
gs-3919	176	24	eosinophilia	eosinophilia	PROPN
gs-3919	176	25	and	and	CCONJ
gs-3919	176	26	systemic	systemic	ADJ
gs-3919	176	27	syndrome	syndrome	NOUN
gs-3919	176	28	(	(	PUNCT
gs-3919	176	29	dress	dress	NOUN
gs-3919	176	30	)	)	PUNCT
gs-3919	176	31	.	.	PUNCT
gs-3919	177	1	this	this	DET
gs-3919	177	2	process	process	NOUN
gs-3919	177	3	included	include	VERB
gs-3919	177	4	,	,	PUNCT
gs-3919	177	5	by	by	ADP
gs-3919	177	6	the	the	DET
gs-3919	177	7	method	method	NOUN
gs-3919	177	8	of	of	ADP
gs-3919	177	9	abc	abc	PROPN
gs-3919	177	10	rating	rating	NOUN
gs-3919	177	11	,	,	PUNCT
gs-3919	177	12	the	the	DET
gs-3919	177	13	qualifying	qualify	VERB
gs-3919	177	14	journals	journal	NOUN
gs-3919	177	15	available	available	ADJ
gs-3919	177	16	for	for	ADP
gs-3919	177	17	publications	publication	NOUN
gs-3919	177	18	related	relate	VERB
gs-3919	177	19	to	to	ADP
gs-3919	177	20	the	the	DET
gs-3919	177	21	quality	quality	NOUN
gs-3919	177	22	of	of	ADP
gs-3919	177	23	the	the	DET
gs-3919	177	24	article	article	NOUN
gs-3919	177	25	and	and	CCONJ
gs-3919	177	26	the	the	DET
gs-3919	177	27	factor	factor	NOUN
gs-3919	177	28	of	of	ADP
gs-3919	177	29	the	the	DET
gs-3919	177	30	journal	journal	NOUN
gs-3919	177	31	of	of	ADP
gs-3919	177	32	the	the	DET
gs-3919	177	33	scimago	scimago	PROPN
gs-3919	177	34	journal	journal	PROPN
gs-3919	177	35	rank	rank	PROPN
gs-3919	177	36	(	(	PUNCT
gs-3919	177	37	sjr	sjr	PROPN
gs-3919	177	38	)	)	PUNCT
gs-3919	177	39	.	.	PUNCT
gs-3919	178	1	this	this	DET
gs-3919	178	2	twofold	twofold	NOUN
gs-3919	178	3	approach	approach	NOUN
gs-3919	178	4	increased	increase	VERB
gs-3919	178	5	the	the	DET
gs-3919	178	6	robustness	robustness	NOUN
gs-3919	178	7	of	of	ADP
gs-3919	178	8	the	the	DET
gs-3919	178	9	evidence	evidence	NOUN
gs-3919	178	10	supporting	support	VERB
gs-3919	178	11	drug	drug	NOUN
gs-3919	178	12	-	-	PUNCT
gs-3919	178	13	specific	specific	ADJ
gs-3919	178	14	adverse	adverse	ADJ
gs-3919	178	15	drug	drug	NOUN
gs-3919	178	16	reactions	reaction	NOUN
gs-3919	178	17	and	and	CCONJ
gs-3919	178	18	regional	regional	ADJ
gs-3919	178	19	/	/	SYM
gs-3919	178	20	systemic	systemic	ADJ
gs-3919	178	21	signs	sign	NOUN
gs-3919	178	22	of	of	ADP
gs-3919	178	23	dress	dress	NOUN
gs-3919	178	24	features	feature	NOUN
gs-3919	178	25	.	.	PUNCT
gs-3919	179	1	also	also	ADV
gs-3919	179	2	following	follow	VERB
gs-3919	179	3	prisma	prisma	PROPN
gs-3919	179	4	2020	2020	NUM
gs-3919	179	5	guidelines	guideline	NOUN
gs-3919	179	6	for	for	ADP
gs-3919	179	7	a	a	DET
gs-3919	179	8	better	well	ADJ
gs-3919	179	9	qualitative	qualitative	ADJ
gs-3919	179	10	assessment	assessment	NOUN
gs-3919	179	11	.	.	PUNCT
gs-3919	180	1	ethical	ethical	ADJ
gs-3919	180	2	considerations	consideration	NOUN
gs-3919	180	3	as	as	SCONJ
gs-3919	180	4	the	the	DET
gs-3919	180	5	present	present	ADJ
gs-3919	180	6	review	review	NOUN
gs-3919	180	7	was	be	AUX
gs-3919	180	8	based	base	VERB
gs-3919	180	9	solely	solely	ADV
gs-3919	180	10	on	on	ADP
gs-3919	180	11	published	publish	VERB
gs-3919	180	12	publicly	publicly	ADV
gs-3919	180	13	available	available	ADJ
gs-3919	180	14	systematic	systematic	ADJ
gs-3919	180	15	literature	literature	NOUN
gs-3919	180	16	reviews	review	NOUN
gs-3919	180	17	,	,	PUNCT
gs-3919	180	18	no	no	DET
gs-3919	180	19	ethical	ethical	ADJ
gs-3919	180	20	approval	approval	NOUN
gs-3919	180	21	and	and	CCONJ
gs-3919	180	22	informed	inform	VERB
gs-3919	180	23	consent	consent	NOUN
gs-3919	180	24	process	process	NOUN
gs-3919	180	25	were	be	AUX
gs-3919	180	26	required	require	VERB
gs-3919	180	27	.	.	PUNCT
gs-3919	181	1	all	all	PRON
gs-3919	181	2	included	include	VERB
gs-3919	181	3	studies	study	NOUN
gs-3919	181	4	had	have	AUX
gs-3919	181	5	received	receive	VERB
gs-3919	181	6	proper	proper	ADJ
gs-3919	181	7	ethical	ethical	ADJ
gs-3919	181	8	approval	approval	NOUN
gs-3919	181	9	from	from	ADP
gs-3919	181	10	the	the	DET
gs-3919	181	11	author	author	NOUN
gs-3919	181	12	's	's	PART
gs-3919	181	13	institution	institution	NOUN
gs-3919	181	14	and	and	CCONJ
gs-3919	181	15	confirmed	confirm	VERB
gs-3919	181	16	to	to	ADP
gs-3919	181	17	the	the	DET
gs-3919	181	18	ethical	ethical	ADJ
gs-3919	181	19	guidelines	guideline	NOUN
gs-3919	181	20	relating	relate	VERB
gs-3919	181	21	to	to	ADP
gs-3919	181	22	patient	patient	ADJ
gs-3919	181	23	consent	consent	NOUN
gs-3919	181	24	when	when	SCONJ
gs-3919	181	25	necessary	necessary	ADJ
gs-3919	181	26	.	.	PUNCT
gs-3919	182	1	the	the	DET
gs-3919	182	2	current	current	ADJ
gs-3919	182	3	study	study	NOUN
gs-3919	182	4	was	be	AUX
gs-3919	182	5	purely	purely	ADV
gs-3919	182	6	based	base	VERB
gs-3919	182	7	on	on	ADP
gs-3919	182	8	the	the	DET
gs-3919	182	9	principles	principle	NOUN
gs-3919	182	10	of	of	ADP
gs-3919	182	11	academic	academic	ADJ
gs-3919	182	12	integrity	integrity	NOUN
gs-3919	182	13	in	in	ADP
gs-3919	182	14	the	the	DET
gs-3919	182	15	form	form	NOUN
gs-3919	182	16	of	of	ADP
gs-3919	182	17	references	reference	NOUN
gs-3919	182	18	of	of	ADP
gs-3919	182	19	sources	source	NOUN
gs-3919	182	20	.	.	PUNCT
gs-3919	183	1	results	result	NOUN
gs-3919	183	2	&	&	CCONJ
gs-3919	183	3	discussion	discussion	VERB
gs-3919	183	4	the	the	DET
gs-3919	183	5	investigation	investigation	NOUN
gs-3919	183	6	into	into	ADP
gs-3919	183	7	drug	drug	NOUN
gs-3919	183	8	-	-	PUNCT
gs-3919	183	9	induced	induce	VERB
gs-3919	183	10	eosinophilia	eosinophilia	NOUN
gs-3919	183	11	and	and	CCONJ
gs-3919	183	12	systemic	systemic	ADJ
gs-3919	183	13	symptoms	symptom	NOUN
gs-3919	183	14	reveals	reveal	VERB
gs-3919	183	15	a	a	DET
gs-3919	183	16	complex	complex	ADJ
gs-3919	183	17	interplay	interplay	NOUN
gs-3919	183	18	of	of	ADP
gs-3919	183	19	pharmacological	pharmacological	NOUN
gs-3919	183	20	,	,	PUNCT
gs-3919	183	21	immunological	immunological	ADJ
gs-3919	183	22	,	,	PUNCT
gs-3919	183	23	and	and	CCONJ
gs-3919	183	24	clinical	clinical	ADJ
gs-3919	183	25	factors	factor	NOUN
gs-3919	183	26	that	that	PRON
gs-3919	183	27	collectively	collectively	ADV
gs-3919	183	28	shape	shape	VERB
gs-3919	183	29	the	the	DET
gs-3919	183	30	manifestation	manifestation	NOUN
gs-3919	183	31	,	,	PUNCT
gs-3919	183	32	diagnosis	diagnosis	NOUN
gs-3919	183	33	,	,	PUNCT
gs-3919	183	34	and	and	CCONJ
gs-3919	183	35	management	management	NOUN
gs-3919	183	36	of	of	ADP
gs-3919	183	37	these	these	DET
gs-3919	183	38	adverse	adverse	ADJ
gs-3919	183	39	drug	drug	NOUN
gs-3919	183	40	reactions	reaction	NOUN
gs-3919	183	41	.	.	PUNCT
gs-3919	184	1	the	the	DET
gs-3919	184	2	georgian	georgian	ADJ
gs-3919	184	3	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	184	4	მეცნიერები	მეცნიერები	NOUN
gs-3919	184	5	ტ.	ტ.	VERB
gs-3919	184	6	7	7	NUM
gs-3919	184	7	n	n	PRON
gs-3919	184	8	3	3	NUM
gs-3919	184	9	,	,	PUNCT
gs-3919	184	10	2025	2025	NUM
gs-3919	184	11	152	152	NUM
gs-3919	184	12	synthesis	synthesis	NOUN
gs-3919	184	13	of	of	ADP
gs-3919	184	14	current	current	ADJ
gs-3919	184	15	evidence	evidence	NOUN
gs-3919	184	16	highlights	highlight	VERB
gs-3919	184	17	critical	critical	ADJ
gs-3919	184	18	patterns	pattern	NOUN
gs-3919	184	19	,	,	PUNCT
gs-3919	184	20	challenges	challenge	NOUN
gs-3919	184	21	,	,	PUNCT
gs-3919	184	22	and	and	CCONJ
gs-3919	184	23	therapeutic	therapeutic	ADJ
gs-3919	184	24	considerations	consideration	NOUN
gs-3919	184	25	that	that	PRON
gs-3919	184	26	warrant	warrant	VERB
gs-3919	184	27	in	in	ADP
gs-3919	184	28	-	-	PUNCT
gs-3919	184	29	depth	depth	NOUN
gs-3919	184	30	discussion	discussion	NOUN
gs-3919	184	31	.	.	PUNCT
gs-3919	185	1	pharmacological	pharmacological	ADJ
gs-3919	185	2	triggers	trigger	NOUN
gs-3919	185	3	and	and	CCONJ
gs-3919	185	4	risk	risk	NOUN
gs-3919	185	5	factors	factor	VERB
gs-3919	185	6	analysis	analysis	NOUN
gs-3919	185	7	of	of	ADP
gs-3919	185	8	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	185	9	data	datum	NOUN
gs-3919	185	10	and	and	CCONJ
gs-3919	185	11	clinical	clinical	ADJ
gs-3919	185	12	studies	study	NOUN
gs-3919	185	13	identifies	identify	VERB
gs-3919	185	14	consistent	consistent	ADJ
gs-3919	185	15	patterns	pattern	NOUN
gs-3919	185	16	among	among	ADP
gs-3919	185	17	drugs	drug	NOUN
gs-3919	185	18	associated	associate	VERB
gs-3919	185	19	with	with	ADP
gs-3919	185	20	eosinophilic	eosinophilic	ADJ
gs-3919	185	21	reactions	reaction	NOUN
gs-3919	185	22	.	.	PUNCT
gs-3919	186	1	aromatic	aromatic	ADJ
gs-3919	186	2	antiepileptics	antiepileptic	NOUN
gs-3919	186	3	(	(	PUNCT
gs-3919	186	4	carbamazepine	carbamazepine	NOUN
gs-3919	186	5	,	,	PUNCT
gs-3919	186	6	phenytoin	phenytoin	NOUN
gs-3919	186	7	,	,	PUNCT
gs-3919	186	8	lamotrigine	lamotrigine	PROPN
gs-3919	186	9	)	)	PUNCT
gs-3919	186	10	,	,	PUNCT
gs-3919	186	11	antibiotics	antibiotic	NOUN
gs-3919	186	12	(	(	PUNCT
gs-3919	186	13	sulfonamides	sulfonamide	NOUN
gs-3919	186	14	,	,	PUNCT
gs-3919	186	15	β	β	NOUN
gs-3919	186	16	-	-	NOUN
gs-3919	186	17	lactams	lactam	NOUN
gs-3919	186	18	)	)	PUNCT
gs-3919	186	19	,	,	PUNCT
gs-3919	186	20	and	and	CCONJ
gs-3919	186	21	allopurinol	allopurinol	NOUN
gs-3919	186	22	emerge	emerge	VERB
gs-3919	186	23	as	as	ADP
gs-3919	186	24	frequent	frequent	ADJ
gs-3919	186	25	culprits	culprit	NOUN
gs-3919	186	26	,	,	PUNCT
gs-3919	186	27	largely	largely	ADV
gs-3919	186	28	due	due	ADJ
gs-3919	186	29	to	to	ADP
gs-3919	186	30	their	their	PRON
gs-3919	186	31	propensity	propensity	NOUN
gs-3919	186	32	to	to	PART
gs-3919	186	33	form	form	VERB
gs-3919	186	34	reactive	reactive	ADJ
gs-3919	186	35	metabolites	metabolite	NOUN
gs-3919	186	36	.	.	PUNCT
gs-3919	187	1	these	these	DET
gs-3919	187	2	metabolites	metabolite	NOUN
gs-3919	187	3	act	act	VERB
gs-3919	187	4	as	as	ADP
gs-3919	187	5	haptens	hapten	NOUN
gs-3919	187	6	,	,	PUNCT
gs-3919	187	7	binding	bind	VERB
gs-3919	187	8	covalently	covalently	ADV
gs-3919	187	9	to	to	ADP
gs-3919	187	10	host	host	NOUN
gs-3919	187	11	proteins	protein	NOUN
gs-3919	187	12	and	and	CCONJ
gs-3919	187	13	triggering	trigger	VERB
gs-3919	187	14	t	t	PROPN
gs-3919	187	15	-	-	PUNCT
gs-3919	187	16	cell	cell	NOUN
gs-3919	187	17	-	-	PUNCT
gs-3919	187	18	mediated	mediate	VERB
gs-3919	187	19	immune	immune	ADJ
gs-3919	187	20	responses	response	NOUN
gs-3919	187	21	.	.	PUNCT
gs-3919	188	1	pharmacogenetic	pharmacogenetic	ADJ
gs-3919	188	2	studies	study	NOUN
gs-3919	188	3	reinforce	reinforce	VERB
gs-3919	188	4	these	these	DET
gs-3919	188	5	observations	observation	NOUN
gs-3919	188	6	,	,	PUNCT
gs-3919	188	7	with	with	ADP
gs-3919	188	8	strong	strong	ADJ
gs-3919	188	9	hla	hla	PROPN
gs-3919	188	10	associations	association	NOUN
gs-3919	188	11	—	—	PUNCT
gs-3919	188	12	such	such	ADJ
gs-3919	188	13	as	as	ADP
gs-3919	188	14	hla	hla	NOUN
gs-3919	188	15	-	-	PUNCT
gs-3919	188	16	b*15:02	b*15:02	NOUN
gs-3919	188	17	and	and	CCONJ
gs-3919	188	18	carbamazepineinduced	carbamazepineinduce	VERB
gs-3919	188	19	severe	severe	ADJ
gs-3919	188	20	cutaneous	cutaneous	ADJ
gs-3919	188	21	reactions	reaction	NOUN
gs-3919	188	22	—	—	PUNCT
gs-3919	188	23	providing	provide	VERB
gs-3919	188	24	mechanistic	mechanistic	ADJ
gs-3919	188	25	explanations	explanation	NOUN
gs-3919	188	26	for	for	ADP
gs-3919	188	27	interindividual	interindividual	ADJ
gs-3919	188	28	variability	variability	NOUN
gs-3919	188	29	in	in	ADP
gs-3919	188	30	susceptibility	susceptibility	NOUN
gs-3919	188	31	.	.	PUNCT
gs-3919	189	1	notably	notably	ADV
gs-3919	189	2	,	,	PUNCT
gs-3919	189	3	drugs	drug	NOUN
gs-3919	189	4	with	with	ADP
gs-3919	189	5	long	long	ADJ
gs-3919	189	6	half	half	ADJ
gs-3919	189	7	-	-	PUNCT
gs-3919	189	8	lives	life	NOUN
gs-3919	189	9	or	or	CCONJ
gs-3919	189	10	those	those	PRON
gs-3919	189	11	requiring	require	VERB
gs-3919	189	12	bioactivation	bioactivation	NOUN
gs-3919	189	13	by	by	ADP
gs-3919	189	14	cytochrome	cytochrome	ADJ
gs-3919	189	15	p450	p450	PROPN
gs-3919	189	16	enzymes	enzyme	NOUN
gs-3919	189	17	exhibit	exhibit	VERB
gs-3919	189	18	higher	high	ADJ
gs-3919	189	19	risks	risk	NOUN
gs-3919	189	20	,	,	PUNCT
gs-3919	189	21	suggesting	suggest	VERB
gs-3919	189	22	that	that	SCONJ
gs-3919	189	23	prolonged	prolonged	ADJ
gs-3919	189	24	exposure	exposure	NOUN
gs-3919	189	25	to	to	ADP
gs-3919	189	26	immunogenic	immunogenic	ADJ
gs-3919	189	27	intermediates	intermediate	NOUN
gs-3919	189	28	is	be	AUX
gs-3919	189	29	a	a	DET
gs-3919	189	30	key	key	ADJ
gs-3919	189	31	determinant	determinant	NOUN
gs-3919	189	32	of	of	ADP
gs-3919	189	33	eosinophilic	eosinophilic	ADJ
gs-3919	189	34	hypersensitivity	hypersensitivity	NOUN
gs-3919	189	35	.	.	PUNCT
gs-3919	190	1	immunopathogenesis	immunopathogenesis	NOUN
gs-3919	190	2	and	and	CCONJ
gs-3919	190	3	eosinophil	eosinophil	ADJ
gs-3919	190	4	activation	activation	NOUN
gs-3919	190	5	the	the	DET
gs-3919	190	6	immunological	immunological	ADJ
gs-3919	190	7	cascade	cascade	NOUN
gs-3919	190	8	driving	drive	VERB
gs-3919	190	9	drug	drug	NOUN
gs-3919	190	10	-	-	PUNCT
gs-3919	190	11	induced	induce	VERB
gs-3919	190	12	eosinophilia	eosinophilia	NOUN
gs-3919	190	13	centers	center	NOUN
gs-3919	190	14	on	on	ADP
gs-3919	190	15	dysregulated	dysregulate	VERB
gs-3919	190	16	th2	th2	PROPN
gs-3919	190	17	responses	response	NOUN
gs-3919	190	18	and	and	CCONJ
gs-3919	190	19	eosinophil	eosinophil	ADJ
gs-3919	190	20	effector	effector	NOUN
gs-3919	190	21	functions	function	NOUN
gs-3919	190	22	.	.	PUNCT
gs-3919	191	1	elevated	elevate	VERB
gs-3919	191	2	il-5	il-5	PROPN
gs-3919	191	3	,	,	PUNCT
gs-3919	191	4	a	a	DET
gs-3919	191	5	cytokine	cytokine	NOUN
gs-3919	191	6	critical	critical	ADJ
gs-3919	191	7	for	for	ADP
gs-3919	191	8	eosinophil	eosinophil	ADJ
gs-3919	191	9	proliferation	proliferation	NOUN
gs-3919	191	10	and	and	CCONJ
gs-3919	191	11	survival	survival	NOUN
gs-3919	191	12	,	,	PUNCT
gs-3919	191	13	is	be	AUX
gs-3919	191	14	a	a	DET
gs-3919	191	15	hallmark	hallmark	NOUN
gs-3919	191	16	of	of	ADP
gs-3919	191	17	these	these	DET
gs-3919	191	18	reactions	reaction	NOUN
gs-3919	191	19	,	,	PUNCT
gs-3919	191	20	corroborated	corroborate	VERB
gs-3919	191	21	by	by	ADP
gs-3919	191	22	both	both	DET
gs-3919	191	23	serum	serum	NOUN
gs-3919	191	24	analyses	analysis	NOUN
gs-3919	191	25	and	and	CCONJ
gs-3919	191	26	tissue	tissue	NOUN
gs-3919	191	27	studies	study	NOUN
gs-3919	191	28	.	.	PUNCT
gs-3919	192	1	eosinophils	eosinophil	VERB
gs-3919	192	2	infiltrating	infiltrate	VERB
gs-3919	192	3	affected	affect	VERB
gs-3919	192	4	organs	organ	NOUN
gs-3919	192	5	release	release	VERB
gs-3919	192	6	cytotoxic	cytotoxic	ADJ
gs-3919	192	7	granules	granule	NOUN
gs-3919	192	8	(	(	PUNCT
gs-3919	192	9	e.g.	e.g.	ADV
gs-3919	192	10	,	,	PUNCT
gs-3919	192	11	major	major	ADJ
gs-3919	192	12	basic	basic	ADJ
gs-3919	192	13	protein	protein	NOUN
gs-3919	192	14	)	)	PUNCT
gs-3919	192	15	and	and	CCONJ
gs-3919	192	16	pro	pro	ADJ
gs-3919	192	17	-	-	ADJ
gs-3919	192	18	fibrotic	fibrotic	ADJ
gs-3919	192	19	mediators	mediator	NOUN
gs-3919	192	20	,	,	PUNCT
gs-3919	192	21	directly	directly	ADV
gs-3919	192	22	contributing	contribute	VERB
gs-3919	192	23	to	to	ADP
gs-3919	192	24	tissue	tissue	NOUN
gs-3919	192	25	damage	damage	NOUN
gs-3919	192	26	—	—	PUNCT
gs-3919	192	27	a	a	DET
gs-3919	192	28	phenomenon	phenomenon	NOUN
gs-3919	192	29	observed	observe	VERB
gs-3919	192	30	in	in	ADP
gs-3919	192	31	hepatic	hepatic	ADJ
gs-3919	192	32	,	,	PUNCT
gs-3919	192	33	pulmonary	pulmonary	ADJ
gs-3919	192	34	,	,	PUNCT
gs-3919	192	35	and	and	CCONJ
gs-3919	192	36	cardiac	cardiac	ADJ
gs-3919	192	37	involvement	involvement	NOUN
gs-3919	192	38	.	.	PUNCT
gs-3919	193	1	histopathological	histopathological	ADJ
gs-3919	193	2	findings	finding	NOUN
gs-3919	193	3	from	from	ADP
gs-3919	193	4	dress	dress	NOUN
gs-3919	193	5	syndrome	syndrome	NOUN
gs-3919	193	6	cases	case	NOUN
gs-3919	193	7	frequently	frequently	ADV
gs-3919	193	8	demonstrate	demonstrate	VERB
gs-3919	193	9	eosinophilic	eosinophilic	ADJ
gs-3919	193	10	infiltration	infiltration	NOUN
gs-3919	193	11	alongside	alongside	ADP
gs-3919	193	12	lymphocyte	lymphocyte	ADJ
gs-3919	193	13	activation	activation	NOUN
gs-3919	193	14	,	,	PUNCT
gs-3919	193	15	underscoring	underscore	VERB
gs-3919	193	16	the	the	DET
gs-3919	193	17	interplay	interplay	NOUN
gs-3919	193	18	between	between	ADP
gs-3919	193	19	innate	innate	ADJ
gs-3919	193	20	and	and	CCONJ
gs-3919	193	21	adaptive	adaptive	ADJ
gs-3919	193	22	immunity	immunity	NOUN
gs-3919	193	23	.	.	PUNCT
gs-3919	194	1	intriguingly	intriguingly	ADV
gs-3919	194	2	,	,	PUNCT
gs-3919	194	3	viral	viral	ADJ
gs-3919	194	4	reactivation	reactivation	NOUN
gs-3919	194	5	(	(	PUNCT
gs-3919	194	6	e.g.	e.g.	ADV
gs-3919	194	7	,	,	PUNCT
gs-3919	194	8	hhv-6	hhv-6	NOUN
gs-3919	194	9	)	)	PUNCT
gs-3919	194	10	during	during	ADP
gs-3919	194	11	dress	dress	NOUN
gs-3919	194	12	further	far	ADV
gs-3919	194	13	complicates	complicate	VERB
gs-3919	194	14	the	the	DET
gs-3919	194	15	immune	immune	ADJ
gs-3919	194	16	milieu	milieu	NOUN
gs-3919	194	17	,	,	PUNCT
gs-3919	194	18	suggesting	suggest	VERB
gs-3919	194	19	that	that	SCONJ
gs-3919	194	20	drug	drug	NOUN
gs-3919	194	21	-	-	PUNCT
gs-3919	194	22	antigen	antigen	NOUN
gs-3919	194	23	-	-	PUNCT
gs-3919	194	24	driven	drive	VERB
gs-3919	194	25	inflammation	inflammation	NOUN
gs-3919	194	26	may	may	AUX
gs-3919	194	27	unmask	unmask	VERB
gs-3919	194	28	latent	latent	NOUN
gs-3919	194	29	infections	infection	NOUN
gs-3919	194	30	,	,	PUNCT
gs-3919	194	31	which	which	PRON
gs-3919	194	32	in	in	ADP
gs-3919	194	33	turn	turn	NOUN
gs-3919	194	34	exacerbate	exacerbate	VERB
gs-3919	194	35	systemic	systemic	ADJ
gs-3919	194	36	symptoms	symptom	NOUN
gs-3919	194	37	.	.	PUNCT
gs-3919	195	1	clinical	clinical	ADJ
gs-3919	195	2	heterogeneity	heterogeneity	NOUN
gs-3919	195	3	and	and	CCONJ
gs-3919	195	4	diagnostic	diagnostic	ADJ
gs-3919	195	5	challenges	challenge	NOUN
gs-3919	195	6	the	the	DET
gs-3919	195	7	clinical	clinical	ADJ
gs-3919	195	8	presentation	presentation	NOUN
gs-3919	195	9	of	of	ADP
gs-3919	195	10	drug	drug	NOUN
gs-3919	195	11	-	-	PUNCT
gs-3919	195	12	induced	induce	VERB
gs-3919	195	13	eosinophilia	eosinophilia	NOUN
gs-3919	195	14	varies	vary	VERB
gs-3919	195	15	widely	widely	ADV
gs-3919	195	16	,	,	PUNCT
gs-3919	195	17	posing	pose	VERB
gs-3919	195	18	significant	significant	ADJ
gs-3919	195	19	diagnostic	diagnostic	ADJ
gs-3919	195	20	challenges	challenge	NOUN
gs-3919	195	21	.	.	PUNCT
gs-3919	196	1	while	while	SCONJ
gs-3919	196	2	dress	dress	NOUN
gs-3919	196	3	syndrome	syndrome	NOUN
gs-3919	196	4	classically	classically	ADV
gs-3919	196	5	presents	present	VERB
gs-3919	196	6	with	with	ADP
gs-3919	196	7	fever	fever	NOUN
gs-3919	196	8	,	,	PUNCT
gs-3919	196	9	rash	rash	ADJ
gs-3919	196	10	,	,	PUNCT
gs-3919	196	11	and	and	CCONJ
gs-3919	196	12	hematologic	hematologic	NOUN
gs-3919	196	13	abnormalities	abnormality	NOUN
gs-3919	196	14	,	,	PUNCT
gs-3919	196	15	atypical	atypical	ADJ
gs-3919	196	16	cases	case	NOUN
gs-3919	196	17	may	may	AUX
gs-3919	196	18	lack	lack	VERB
gs-3919	196	19	cutaneous	cutaneous	ADJ
gs-3919	196	20	involvement	involvement	NOUN
gs-3919	196	21	,	,	PUNCT
gs-3919	196	22	mimicking	mimic	VERB
gs-3919	196	23	infectious	infectious	ADJ
gs-3919	196	24	or	or	CCONJ
gs-3919	196	25	autoimmune	autoimmune	ADJ
gs-3919	196	26	disorders	disorder	NOUN
gs-3919	196	27	.	.	PUNCT
gs-3919	197	1	data	datum	NOUN
gs-3919	197	2	from	from	ADP
gs-3919	197	3	regiscar	regiscar	ADJ
gs-3919	197	4	cohort	cohort	NOUN
gs-3919	197	5	studies	study	NOUN
gs-3919	197	6	reveal	reveal	VERB
gs-3919	197	7	that	that	SCONJ
gs-3919	197	8	visceral	visceral	ADJ
gs-3919	197	9	organ	organ	NOUN
gs-3919	197	10	involvement	involvement	NOUN
gs-3919	197	11	—	—	PUNCT
gs-3919	197	12	particularly	particularly	ADV
gs-3919	197	13	hepatitis	hepatitis	NOUN
gs-3919	197	14	(	(	PUNCT
gs-3919	197	15	75	75	NUM
gs-3919	197	16	%	%	NOUN
gs-3919	197	17	of	of	ADP
gs-3919	197	18	cases	case	NOUN
gs-3919	197	19	)	)	PUNCT
gs-3919	197	20	and	and	CCONJ
gs-3919	197	21	nephritis	nephritis	NOUN
gs-3919	197	22	(	(	PUNCT
gs-3919	197	23	30%)—correlates	30%)—correlate	NOUN
gs-3919	197	24	with	with	ADP
gs-3919	197	25	poorer	poor	ADJ
gs-3919	197	26	outcomes	outcome	NOUN
gs-3919	197	27	,	,	PUNCT
gs-3919	197	28	emphasizing	emphasize	VERB
gs-3919	197	29	the	the	DET
gs-3919	197	30	need	need	NOUN
gs-3919	197	31	for	for	ADP
gs-3919	197	32	early	early	ADJ
gs-3919	197	33	organ	organ	NOUN
gs-3919	197	34	function	function	NOUN
gs-3919	197	35	monitoring	monitoring	NOUN
gs-3919	197	36	.	.	PUNCT
gs-3919	198	1	diagnostic	diagnostic	ADJ
gs-3919	198	2	uncertainty	uncertainty	NOUN
gs-3919	198	3	persists	persist	VERB
gs-3919	198	4	due	due	ADJ
gs-3919	198	5	to	to	ADP
gs-3919	198	6	the	the	DET
gs-3919	198	7	nonspecificity	nonspecificity	NOUN
gs-3919	198	8	of	of	ADP
gs-3919	198	9	eosinophilia	eosinophilia	PROPN
gs-3919	198	10	itself	itself	PRON
gs-3919	198	11	;	;	PUNCT
gs-3919	198	12	georgian	georgian	ADJ
gs-3919	198	13	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	198	14	მეცნიერები	მეცნიერები	NOUN
gs-3919	198	15	ტ.	ტ.	VERB
gs-3919	198	16	7	7	NUM
gs-3919	198	17	n	n	PRON
gs-3919	198	18	3	3	NUM
gs-3919	198	19	,	,	PUNCT
gs-3919	198	20	2025	2025	NUM
gs-3919	198	21	153	153	NUM
gs-3919	198	22	differential	differential	NOUN
gs-3919	198	23	diagnoses	diagnosis	NOUN
gs-3919	198	24	include	include	VERB
gs-3919	198	25	parasitic	parasitic	ADJ
gs-3919	198	26	infections	infection	NOUN
gs-3919	198	27	,	,	PUNCT
gs-3919	198	28	eosinophilic	eosinophilic	ADJ
gs-3919	198	29	granulomatosis	granulomatosis	NOUN
gs-3919	198	30	with	with	ADP
gs-3919	198	31	polyangiitis	polyangiitis	PROPN
gs-3919	198	32	(	(	PUNCT
gs-3919	198	33	egpa	egpa	NOUN
gs-3919	198	34	)	)	PUNCT
gs-3919	198	35	,	,	PUNCT
gs-3919	198	36	and	and	CCONJ
gs-3919	198	37	neoplastic	neoplastic	ADJ
gs-3919	198	38	processes	process	NOUN
gs-3919	198	39	.	.	PUNCT
gs-3919	199	1	the	the	DET
gs-3919	199	2	latency	latency	NOUN
gs-3919	199	3	period	period	NOUN
gs-3919	199	4	between	between	ADP
gs-3919	199	5	drug	drug	NOUN
gs-3919	199	6	initiation	initiation	NOUN
gs-3919	199	7	and	and	CCONJ
gs-3919	199	8	symptom	symptom	NOUN
gs-3919	199	9	onset	onset	NOUN
gs-3919	199	10	(	(	PUNCT
gs-3919	199	11	typically	typically	ADV
gs-3919	199	12	2–8	2–8	NUM
gs-3919	199	13	weeks	week	NOUN
gs-3919	199	14	)	)	PUNCT
gs-3919	199	15	further	far	ADV
gs-3919	199	16	complicates	complicate	VERB
gs-3919	199	17	causal	causal	ADJ
gs-3919	199	18	attribution	attribution	NOUN
gs-3919	199	19	,	,	PUNCT
gs-3919	199	20	often	often	ADV
gs-3919	199	21	leading	lead	VERB
gs-3919	199	22	to	to	ADP
gs-3919	199	23	delayed	delayed	ADJ
gs-3919	199	24	diagnosis	diagnosis	NOUN
gs-3919	199	25	.	.	PUNCT
gs-3919	200	1	proposed	propose	VERB
gs-3919	200	2	biomarkers	biomarker	NOUN
gs-3919	200	3	,	,	PUNCT
gs-3919	200	4	such	such	ADJ
gs-3919	200	5	as	as	ADP
gs-3919	200	6	elevated	elevated	ADJ
gs-3919	200	7	serum	serum	NOUN
gs-3919	200	8	il-5	il-5	NOUN
gs-3919	200	9	or	or	CCONJ
gs-3919	200	10	eosinophil	eosinophil	ADJ
gs-3919	200	11	-	-	PUNCT
gs-3919	200	12	derived	derive	VERB
gs-3919	200	13	neurotoxin	neurotoxin	NOUN
gs-3919	200	14	,	,	PUNCT
gs-3919	200	15	show	show	VERB
gs-3919	200	16	promise	promise	NOUN
gs-3919	200	17	but	but	CCONJ
gs-3919	200	18	lack	lack	VERB
gs-3919	200	19	widespread	widespread	ADJ
gs-3919	200	20	validation	validation	NOUN
gs-3919	200	21	,	,	PUNCT
gs-3919	200	22	highlighting	highlight	VERB
gs-3919	200	23	a	a	DET
gs-3919	200	24	critical	critical	ADJ
gs-3919	200	25	gap	gap	NOUN
gs-3919	200	26	in	in	ADP
gs-3919	200	27	current	current	ADJ
gs-3919	200	28	diagnostic	diagnostic	ADJ
gs-3919	200	29	tools	tool	NOUN
gs-3919	200	30	.	.	PUNCT
gs-3919	201	1	therapeutic	therapeutic	ADJ
gs-3919	201	2	outcomes	outcome	NOUN
gs-3919	201	3	and	and	CCONJ
gs-3919	201	4	unmet	unmet	NOUN
gs-3919	201	5	needs	need	VERB
gs-3919	201	6	first	first	ADJ
gs-3919	201	7	-	-	PUNCT
gs-3919	201	8	line	line	NOUN
gs-3919	201	9	management	management	NOUN
gs-3919	201	10	universally	universally	ADV
gs-3919	201	11	involves	involve	VERB
gs-3919	201	12	discontinuation	discontinuation	NOUN
gs-3919	201	13	of	of	ADP
gs-3919	201	14	the	the	DET
gs-3919	201	15	offending	offend	VERB
gs-3919	201	16	drug	drug	NOUN
gs-3919	201	17	,	,	PUNCT
gs-3919	201	18	yet	yet	CCONJ
gs-3919	201	19	the	the	DET
gs-3919	201	20	optimal	optimal	ADJ
gs-3919	201	21	approach	approach	NOUN
gs-3919	201	22	to	to	ADP
gs-3919	201	23	immunosuppression	immunosuppression	NOUN
gs-3919	201	24	remains	remain	VERB
gs-3919	201	25	debated	debate	VERB
gs-3919	201	26	.	.	PUNCT
gs-3919	202	1	retrospective	retrospective	ADJ
gs-3919	202	2	analyses	analysis	NOUN
gs-3919	202	3	demonstrate	demonstrate	VERB
gs-3919	202	4	that	that	SCONJ
gs-3919	202	5	systemic	systemic	ADJ
gs-3919	202	6	corticosteroids	corticosteroid	NOUN
gs-3919	202	7	(	(	PUNCT
gs-3919	202	8	0.5–1	0.5–1	INTJ
gs-3919	202	9	mg	mg	PROPN
gs-3919	202	10	/	/	SYM
gs-3919	202	11	kg	kg	PROPN
gs-3919	202	12	/	/	SYM
gs-3919	202	13	day	day	PROPN
gs-3919	202	14	prednisone	prednisone	PROPN
gs-3919	202	15	equivalent	equivalent	NOUN
gs-3919	202	16	)	)	PUNCT
gs-3919	202	17	improve	improve	VERB
gs-3919	202	18	outcomes	outcome	NOUN
gs-3919	202	19	in	in	ADP
gs-3919	202	20	severe	severe	ADJ
gs-3919	202	21	cases	case	NOUN
gs-3919	202	22	,	,	PUNCT
gs-3919	202	23	particularly	particularly	ADV
gs-3919	202	24	those	those	PRON
gs-3919	202	25	with	with	ADP
gs-3919	202	26	organ	organ	NOUN
gs-3919	202	27	dysfunction	dysfunction	NOUN
gs-3919	202	28	.	.	PUNCT
gs-3919	203	1	however	however	ADV
gs-3919	203	2	,	,	PUNCT
gs-3919	203	3	relapse	relapse	VERB
gs-3919	203	4	upon	upon	SCONJ
gs-3919	203	5	tapering	tapering	NOUN
gs-3919	203	6	occurs	occur	VERB
gs-3919	203	7	in	in	ADP
gs-3919	203	8	~20	~20	NOUN
gs-3919	203	9	%	%	NOUN
gs-3919	203	10	of	of	ADP
gs-3919	203	11	patients	patient	NOUN
gs-3919	203	12	,	,	PUNCT
gs-3919	203	13	necessitating	necessitate	VERB
gs-3919	203	14	prolonged	prolong	VERB
gs-3919	203	15	courses	course	NOUN
gs-3919	203	16	or	or	CCONJ
gs-3919	203	17	steroidsparing	steroidspare	VERB
gs-3919	203	18	agents	agent	NOUN
gs-3919	203	19	.	.	PUNCT
gs-3919	204	1	emerging	emerge	VERB
gs-3919	204	2	data	datum	NOUN
gs-3919	204	3	on	on	ADP
gs-3919	204	4	biologics	biologic	NOUN
gs-3919	204	5	,	,	PUNCT
gs-3919	204	6	such	such	ADJ
gs-3919	204	7	as	as	ADP
gs-3919	204	8	mepolizumab	mepolizumab	NOUN
gs-3919	204	9	(	(	PUNCT
gs-3919	204	10	anti	anti	ADJ
gs-3919	204	11	-	-	NOUN
gs-3919	204	12	il-5	il-5	NUM
gs-3919	204	13	)	)	PUNCT
gs-3919	204	14	,	,	PUNCT
gs-3919	204	15	report	report	VERB
gs-3919	204	16	efficacy	efficacy	NOUN
gs-3919	204	17	in	in	ADP
gs-3919	204	18	refractory	refractory	NOUN
gs-3919	204	19	eosinophilic	eosinophilic	ADJ
gs-3919	204	20	inflammation	inflammation	NOUN
gs-3919	204	21	,	,	PUNCT
gs-3919	204	22	though	though	SCONJ
gs-3919	204	23	their	their	PRON
gs-3919	204	24	use	use	NOUN
gs-3919	204	25	remains	remain	VERB
gs-3919	204	26	off	off	ADP
gs-3919	204	27	-	-	PUNCT
gs-3919	204	28	label	label	NOUN
gs-3919	204	29	for	for	ADP
gs-3919	204	30	druginduced	druginduced	ADJ
gs-3919	204	31	reactions	reaction	NOUN
gs-3919	204	32	.	.	PUNCT
gs-3919	205	1	paradoxically	paradoxically	ADV
gs-3919	205	2	,	,	PUNCT
gs-3919	205	3	case	case	NOUN
gs-3919	205	4	reports	report	NOUN
gs-3919	205	5	describe	describe	VERB
gs-3919	205	6	successful	successful	ADJ
gs-3919	205	7	corticosteroid	corticosteroid	ADJ
gs-3919	205	8	-	-	PUNCT
gs-3919	205	9	free	free	ADJ
gs-3919	205	10	management	management	NOUN
gs-3919	205	11	in	in	ADP
gs-3919	205	12	mild	mild	ADJ
gs-3919	205	13	cases	case	NOUN
gs-3919	205	14	,	,	PUNCT
gs-3919	205	15	suggesting	suggest	VERB
gs-3919	205	16	that	that	SCONJ
gs-3919	205	17	not	not	PART
gs-3919	205	18	all	all	DET
gs-3919	205	19	eosinophilic	eosinophilic	ADJ
gs-3919	205	20	reactions	reaction	NOUN
gs-3919	205	21	require	require	VERB
gs-3919	205	22	immunosuppression	immunosuppression	NOUN
gs-3919	205	23	.	.	PUNCT
gs-3919	206	1	this	this	DET
gs-3919	206	2	dichotomy	dichotomy	NOUN
gs-3919	206	3	underscores	underscore	VERB
gs-3919	206	4	the	the	DET
gs-3919	206	5	need	need	NOUN
gs-3919	206	6	for	for	ADP
gs-3919	206	7	risk	risk	NOUN
gs-3919	206	8	-	-	PUNCT
gs-3919	206	9	stratified	stratify	VERB
gs-3919	206	10	treatment	treatment	NOUN
gs-3919	206	11	algorithms	algorithm	NOUN
gs-3919	206	12	.	.	PUNCT
gs-3919	207	1	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	207	2	and	and	CCONJ
gs-3919	207	3	preventative	preventative	ADJ
gs-3919	207	4	strategies	strategy	NOUN
gs-3919	207	5	post	post	ADJ
gs-3919	207	6	-	-	ADJ
gs-3919	207	7	marketing	marketing	ADJ
gs-3919	207	8	surveillance	surveillance	NOUN
gs-3919	207	9	has	have	AUX
gs-3919	207	10	been	be	AUX
gs-3919	207	11	instrumental	instrumental	ADJ
gs-3919	207	12	in	in	ADP
gs-3919	207	13	identifying	identify	VERB
gs-3919	207	14	high	high	ADJ
gs-3919	207	15	-	-	PUNCT
gs-3919	207	16	risk	risk	NOUN
gs-3919	207	17	drugs	drug	NOUN
gs-3919	207	18	,	,	PUNCT
gs-3919	207	19	with	with	ADP
gs-3919	207	20	faers	faer	NOUN
gs-3919	207	21	data	datum	NOUN
gs-3919	207	22	revealing	reveal	VERB
gs-3919	207	23	underreported	underreported	ADJ
gs-3919	207	24	associations	association	NOUN
gs-3919	207	25	(	(	PUNCT
gs-3919	207	26	e.g.	e.g.	ADV
gs-3919	207	27	,	,	PUNCT
gs-3919	207	28	vancomycin	vancomycin	PROPN
gs-3919	207	29	-	-	PUNCT
gs-3919	207	30	induced	induce	VERB
gs-3919	207	31	eosinophilic	eosinophilic	ADJ
gs-3919	207	32	pneumonia	pneumonia	NOUN
gs-3919	207	33	)	)	PUNCT
gs-3919	207	34	.	.	PUNCT
gs-3919	208	1	hla	hla	PROPN
gs-3919	208	2	screening	screen	VERB
gs-3919	208	3	prior	prior	ADV
gs-3919	208	4	to	to	ADP
gs-3919	208	5	prescribing	prescribing	NOUN
gs-3919	208	6	carbamazepine	carbamazepine	NOUN
gs-3919	208	7	in	in	ADP
gs-3919	208	8	southeast	southeast	ADJ
gs-3919	208	9	asian	asian	ADJ
gs-3919	208	10	populations	population	NOUN
gs-3919	208	11	has	have	AUX
gs-3919	208	12	reduced	reduce	VERB
gs-3919	208	13	severe	severe	ADJ
gs-3919	208	14	reactions	reaction	NOUN
gs-3919	208	15	,	,	PUNCT
gs-3919	208	16	proving	prove	VERB
gs-3919	208	17	the	the	DET
gs-3919	208	18	value	value	NOUN
gs-3919	208	19	of	of	ADP
gs-3919	208	20	preemptive	preemptive	ADJ
gs-3919	208	21	pharmacogenomics	pharmacogenomic	NOUN
gs-3919	208	22	.	.	PUNCT
gs-3919	209	1	nevertheless	nevertheless	ADV
gs-3919	209	2	,	,	PUNCT
gs-3919	209	3	implementation	implementation	NOUN
gs-3919	209	4	barriers	barrier	NOUN
gs-3919	209	5	—	—	PUNCT
gs-3919	209	6	including	include	VERB
gs-3919	209	7	cost	cost	NOUN
gs-3919	209	8	and	and	CCONJ
gs-3919	209	9	accessibility	accessibility	NOUN
gs-3919	209	10	—	—	PUNCT
gs-3919	209	11	limit	limit	VERB
gs-3919	209	12	widespread	widespread	ADJ
gs-3919	209	13	adoption	adoption	NOUN
gs-3919	209	14	.	.	PUNCT
gs-3919	210	1	patient	patient	ADJ
gs-3919	210	2	registries	registry	NOUN
gs-3919	210	3	for	for	ADP
gs-3919	210	4	dress	dress	NOUN
gs-3919	210	5	and	and	CCONJ
gs-3919	210	6	related	related	ADJ
gs-3919	210	7	syndromes	syndrome	NOUN
gs-3919	210	8	offer	offer	VERB
gs-3919	210	9	longitudinal	longitudinal	ADJ
gs-3919	210	10	insights	insight	NOUN
gs-3919	210	11	into	into	ADP
gs-3919	210	12	long	long	ADJ
gs-3919	210	13	-	-	PUNCT
gs-3919	210	14	term	term	NOUN
gs-3919	210	15	sequelae	sequelae	NOUN
gs-3919	210	16	,	,	PUNCT
gs-3919	210	17	such	such	ADJ
gs-3919	210	18	as	as	ADP
gs-3919	210	19	autoimmune	autoimmune	ADJ
gs-3919	210	20	thyroiditis	thyroiditis	NOUN
gs-3919	210	21	,	,	PUNCT
gs-3919	210	22	which	which	PRON
gs-3919	210	23	develops	develop	VERB
gs-3919	210	24	in	in	ADP
gs-3919	210	25	10–15	10–15	NUM
gs-3919	210	26	%	%	NOUN
gs-3919	210	27	of	of	ADP
gs-3919	210	28	survivors	survivor	NOUN
gs-3919	210	29	.	.	PUNCT
gs-3919	211	1	advancements	advancement	NOUN
gs-3919	211	2	in	in	ADP
gs-3919	211	3	multi	multi	ADJ
gs-3919	211	4	-	-	ADJ
gs-3919	211	5	omics	omics	ADJ
gs-3919	211	6	technologies	technology	NOUN
gs-3919	211	7	present	present	VERB
gs-3919	211	8	opportunities	opportunity	NOUN
gs-3919	211	9	to	to	PART
gs-3919	211	10	refine	refine	VERB
gs-3919	211	11	predictive	predictive	ADJ
gs-3919	211	12	models	model	NOUN
gs-3919	211	13	.	.	PUNCT
gs-3919	212	1	for	for	ADP
gs-3919	212	2	example	example	NOUN
gs-3919	212	3	,	,	PUNCT
gs-3919	212	4	transcriptomic	transcriptomic	ADJ
gs-3919	212	5	profiling	profiling	NOUN
gs-3919	212	6	of	of	ADP
gs-3919	212	7	patients	patient	NOUN
gs-3919	212	8	with	with	ADP
gs-3919	212	9	drug	drug	NOUN
gs-3919	212	10	hypersensitivity	hypersensitivity	NOUN
gs-3919	212	11	may	may	AUX
gs-3919	212	12	identify	identify	VERB
gs-3919	212	13	novel	novel	ADJ
gs-3919	212	14	biomarkers	biomarker	NOUN
gs-3919	212	15	of	of	ADP
gs-3919	212	16	eosinophilic	eosinophilic	ADJ
gs-3919	212	17	risk	risk	NOUN
gs-3919	212	18	.	.	PUNCT
gs-3919	213	1	similarly	similarly	ADV
gs-3919	213	2	,	,	PUNCT
gs-3919	213	3	in	in	ADP
gs-3919	213	4	vitro	vitro	X
gs-3919	213	5	assays	assay	NOUN
gs-3919	213	6	using	use	VERB
gs-3919	213	7	patient	patient	NOUN
gs-3919	213	8	-	-	PUNCT
gs-3919	213	9	derived	derive	VERB
gs-3919	213	10	lymphocytes	lymphocyte	NOUN
gs-3919	213	11	could	could	AUX
gs-3919	213	12	improve	improve	VERB
gs-3919	213	13	diagnostic	diagnostic	ADJ
gs-3919	213	14	accuracy	accuracy	NOUN
gs-3919	213	15	.	.	PUNCT
gs-3919	214	1	the	the	DET
gs-3919	214	2	integration	integration	NOUN
gs-3919	214	3	of	of	ADP
gs-3919	214	4	artificial	artificial	ADJ
gs-3919	214	5	intelligence	intelligence	NOUN
gs-3919	214	6	into	into	ADP
gs-3919	214	7	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	214	8	platforms	platform	NOUN
gs-3919	214	9	may	may	AUX
gs-3919	214	10	enhance	enhance	VERB
gs-3919	214	11	signal	signal	ADJ
gs-3919	214	12	detection	detection	NOUN
gs-3919	214	13	,	,	PUNCT
gs-3919	214	14	enabling	enable	VERB
gs-3919	214	15	earlier	early	ADJ
gs-3919	214	16	intervention	intervention	NOUN
gs-3919	214	17	.	.	PUNCT
gs-3919	215	1	drug	drug	NOUN
gs-3919	215	2	-	-	PUNCT
gs-3919	215	3	induced	induce	VERB
gs-3919	215	4	eosinophilia	eosinophilia	NOUN
gs-3919	215	5	and	and	CCONJ
gs-3919	215	6	systemic	systemic	ADJ
gs-3919	215	7	symptoms	symptom	NOUN
gs-3919	215	8	represent	represent	VERB
gs-3919	215	9	a	a	DET
gs-3919	215	10	paradigm	paradigm	NOUN
gs-3919	215	11	of	of	ADP
gs-3919	215	12	the	the	DET
gs-3919	215	13	delicate	delicate	ADJ
gs-3919	215	14	balance	balance	NOUN
gs-3919	215	15	between	between	ADP
gs-3919	215	16	therapeutic	therapeutic	ADJ
gs-3919	215	17	benefit	benefit	NOUN
gs-3919	215	18	and	and	CCONJ
gs-3919	215	19	immunological	immunological	ADJ
gs-3919	215	20	risk	risk	NOUN
gs-3919	215	21	.	.	PUNCT
gs-3919	216	1	this	this	DET
gs-3919	216	2	analysis	analysis	NOUN
gs-3919	216	3	elucidates	elucidate	VERB
gs-3919	216	4	the	the	DET
gs-3919	216	5	multifactorial	multifactorial	ADJ
gs-3919	216	6	nature	nature	NOUN
gs-3919	216	7	of	of	ADP
gs-3919	216	8	these	these	DET
gs-3919	216	9	reactions	reaction	NOUN
gs-3919	216	10	,	,	PUNCT
gs-3919	216	11	from	from	ADP
gs-3919	216	12	pharmacological	pharmacological	ADJ
gs-3919	216	13	triggers	trigger	NOUN
gs-3919	216	14	to	to	ADP
gs-3919	216	15	effector	effector	NOUN
gs-3919	216	16	mechanisms	mechanism	NOUN
gs-3919	216	17	,	,	PUNCT
gs-3919	216	18	while	while	SCONJ
gs-3919	216	19	revealing	reveal	VERB
gs-3919	216	20	gaps	gap	NOUN
gs-3919	216	21	in	in	ADP
gs-3919	216	22	diagnosis	diagnosis	NOUN
gs-3919	216	23	georgian	georgian	ADJ
gs-3919	216	24	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	216	25	მეცნიერები	მეცნიერები	NOUN
gs-3919	216	26	ტ.	ტ.	VERB
gs-3919	216	27	7	7	NUM
gs-3919	216	28	n	n	DET
gs-3919	216	29	3	3	NUM
gs-3919	216	30	,	,	PUNCT
gs-3919	216	31	2025	2025	NUM
gs-3919	216	32	154	154	NUM
gs-3919	216	33	and	and	CCONJ
gs-3919	216	34	management	management	NOUN
gs-3919	216	35	.	.	PUNCT
gs-3919	217	1	moving	move	VERB
gs-3919	217	2	forward	forward	ADV
gs-3919	217	3	,	,	PUNCT
gs-3919	217	4	a	a	DET
gs-3919	217	5	precision	precision	NOUN
gs-3919	217	6	medicine	medicine	NOUN
gs-3919	217	7	approach	approach	NOUN
gs-3919	217	8	—	—	PUNCT
gs-3919	217	9	combining	combine	VERB
gs-3919	217	10	pharmacogenomics	pharmacogenomic	NOUN
gs-3919	217	11	,	,	PUNCT
gs-3919	217	12	advanced	advanced	ADJ
gs-3919	217	13	diagnostics	diagnostic	NOUN
gs-3919	217	14	,	,	PUNCT
gs-3919	217	15	and	and	CCONJ
gs-3919	217	16	targeted	target	VERB
gs-3919	217	17	therapies	therapy	NOUN
gs-3919	217	18	—	—	PUNCT
gs-3919	217	19	will	will	AUX
gs-3919	217	20	be	be	AUX
gs-3919	217	21	essential	essential	ADJ
gs-3919	217	22	to	to	PART
gs-3919	217	23	mitigate	mitigate	VERB
gs-3919	217	24	the	the	DET
gs-3919	217	25	burden	burden	NOUN
gs-3919	217	26	of	of	ADP
gs-3919	217	27	these	these	DET
gs-3919	217	28	formidable	formidable	ADJ
gs-3919	217	29	adverse	adverse	ADJ
gs-3919	217	30	drug	drug	NOUN
gs-3919	217	31	reactions	reaction	NOUN
gs-3919	217	32	.	.	PUNCT
gs-3919	218	1	between	between	ADP
gs-3919	218	2	the	the	DET
gs-3919	218	3	past	past	ADJ
gs-3919	218	4	decades	decade	NOUN
gs-3919	218	5	and	and	CCONJ
gs-3919	218	6	current	current	ADJ
gs-3919	218	7	decade	decade	NOUN
gs-3919	218	8	(	(	PUNCT
gs-3919	218	9	2010–2025	2010–2025	NUM
gs-3919	218	10	)	)	PUNCT
gs-3919	218	11	,	,	PUNCT
gs-3919	218	12	dress	dress	NOUN
gs-3919	218	13	has	have	AUX
gs-3919	218	14	become	become	VERB
gs-3919	218	15	among	among	ADP
gs-3919	218	16	the	the	DET
gs-3919	218	17	more	more	ADV
gs-3919	218	18	widely	widely	ADV
gs-3919	218	19	discussed	discuss	VERB
gs-3919	218	20	conditions	condition	NOUN
gs-3919	218	21	among	among	ADP
gs-3919	218	22	academicians	academician	NOUN
gs-3919	218	23	owing	owe	VERB
gs-3919	218	24	to	to	ADP
gs-3919	218	25	its	its	PRON
gs-3919	218	26	high	high	ADJ
gs-3919	218	27	morbidity	morbidity	NOUN
gs-3919	218	28	and	and	CCONJ
gs-3919	218	29	mortality	mortality	NOUN
gs-3919	218	30	and	and	CCONJ
gs-3919	218	31	the	the	DET
gs-3919	218	32	capacity	capacity	NOUN
gs-3919	218	33	to	to	PART
gs-3919	218	34	occur	occur	VERB
gs-3919	218	35	weeks	week	NOUN
gs-3919	218	36	to	to	ADP
gs-3919	218	37	months	month	NOUN
gs-3919	218	38	after	after	ADP
gs-3919	218	39	administration	administration	NOUN
gs-3919	218	40	of	of	ADP
gs-3919	218	41	the	the	DET
gs-3919	218	42	offending	offend	VERB
gs-3919	218	43	drug	drug	NOUN
gs-3919	218	44	.	.	PUNCT
gs-3919	219	1	studies	study	NOUN
gs-3919	219	2	during	during	ADP
gs-3919	219	3	this	this	DET
gs-3919	219	4	period	period	NOUN
gs-3919	219	5	have	have	AUX
gs-3919	219	6	significantly	significantly	ADV
gs-3919	219	7	enhanced	enhance	VERB
gs-3919	219	8	our	our	PRON
gs-3919	219	9	understanding	understanding	NOUN
gs-3919	219	10	of	of	ADP
gs-3919	219	11	its	its	PRON
gs-3919	219	12	pathophysiology	pathophysiology	NOUN
gs-3919	219	13	,	,	PUNCT
gs-3919	219	14	clinical	clinical	ADJ
gs-3919	219	15	manifestations	manifestation	NOUN
gs-3919	219	16	,	,	PUNCT
gs-3919	219	17	and	and	CCONJ
gs-3919	219	18	treatment	treatment	NOUN
gs-3919	219	19	approaches	approach	NOUN
gs-3919	219	20	.	.	PUNCT
gs-3919	220	1	the	the	DET
gs-3919	220	2	incidence	incidence	NOUN
gs-3919	220	3	has	have	AUX
gs-3919	220	4	been	be	AUX
gs-3919	220	5	reported	report	VERB
gs-3919	220	6	as	as	ADP
gs-3919	220	7	1	1	NUM
gs-3919	220	8	per	per	ADP
gs-3919	220	9	1,000	1,000	NUM
gs-3919	220	10	to	to	PART
gs-3919	220	11	10,000	10,000	NUM
gs-3919	220	12	drug	drug	NOUN
gs-3919	220	13	-	-	PUNCT
gs-3919	220	14	exposed	expose	VERB
gs-3919	220	15	patients	patient	NOUN
gs-3919	220	16	,	,	PUNCT
gs-3919	220	17	though	though	SCONJ
gs-3919	220	18	the	the	DET
gs-3919	220	19	actual	actual	ADJ
gs-3919	220	20	incidence	incidence	NOUN
gs-3919	220	21	may	may	AUX
gs-3919	220	22	be	be	AUX
gs-3919	220	23	lower	low	ADJ
gs-3919	220	24	based	base	VERB
gs-3919	220	25	on	on	ADP
gs-3919	220	26	systematic	systematic	ADJ
gs-3919	220	27	case	case	NOUN
gs-3919	220	28	searches	search	NOUN
gs-3919	220	29	.	.	PUNCT
gs-3919	221	1	the	the	DET
gs-3919	221	2	classic	classic	ADJ
gs-3919	221	3	triad	triad	NUM
gs-3919	221	4	of	of	ADP
gs-3919	221	5	clinical	clinical	ADJ
gs-3919	221	6	manifestations	manifestation	NOUN
gs-3919	221	7	typically	typically	ADV
gs-3919	221	8	includes	include	VERB
gs-3919	221	9	a	a	DET
gs-3919	221	10	skin	skin	NOUN
gs-3919	221	11	rash	rash	NOUN
gs-3919	221	12	,	,	PUNCT
gs-3919	221	13	haematological	haematological	ADJ
gs-3919	221	14	abnormalities	abnormality	NOUN
gs-3919	221	15	(	(	PUNCT
gs-3919	221	16	primarily	primarily	ADV
gs-3919	221	17	eosinophilia	eosinophilia	PROPN
gs-3919	221	18	)	)	PUNCT
gs-3919	221	19	,	,	PUNCT
gs-3919	221	20	and	and	CCONJ
gs-3919	221	21	involvement	involvement	NOUN
gs-3919	221	22	of	of	ADP
gs-3919	221	23	multiple	multiple	ADJ
gs-3919	221	24	visceral	visceral	ADJ
gs-3919	221	25	organs	organ	NOUN
gs-3919	221	26	.	.	PUNCT
gs-3919	222	1	cutaneous	cutaneous	ADJ
gs-3919	222	2	symptoms	symptom	NOUN
gs-3919	222	3	usually	usually	ADV
gs-3919	222	4	present	present	ADJ
gs-3919	222	5	as	as	ADP
gs-3919	222	6	morbilliform	morbilliform	NOUN
gs-3919	222	7	eruptions	eruption	NOUN
gs-3919	222	8	which	which	PRON
gs-3919	222	9	can	can	AUX
gs-3919	222	10	progress	progress	VERB
gs-3919	222	11	to	to	ADP
gs-3919	222	12	generalized	generalize	VERB
gs-3919	222	13	exfoliative	exfoliative	ADJ
gs-3919	222	14	dermatitis	dermatitis	NOUN
gs-3919	222	15	.	.	PUNCT
gs-3919	223	1	hepatotoxicity	hepatotoxicity	NOUN
gs-3919	223	2	is	be	AUX
gs-3919	223	3	reported	report	VERB
gs-3919	223	4	as	as	ADP
gs-3919	223	5	the	the	DET
gs-3919	223	6	most	most	ADV
gs-3919	223	7	common	common	ADJ
gs-3919	223	8	systemic	systemic	ADJ
gs-3919	223	9	adverse	adverse	ADJ
gs-3919	223	10	effect	effect	NOUN
gs-3919	223	11	,	,	PUNCT
gs-3919	223	12	manifesting	manifest	VERB
gs-3919	223	13	in	in	ADP
gs-3919	223	14	over	over	ADP
gs-3919	223	15	80	80	NUM
gs-3919	223	16	%	%	NOUN
gs-3919	223	17	of	of	ADP
gs-3919	223	18	cases	case	NOUN
gs-3919	223	19	.	.	PUNCT
gs-3919	224	1	renal	renal	ADJ
gs-3919	224	2	and	and	CCONJ
gs-3919	224	3	pulmonary	pulmonary	ADJ
gs-3919	224	4	injury	injury	NOUN
gs-3919	224	5	have	have	AUX
gs-3919	224	6	also	also	ADV
gs-3919	224	7	been	be	AUX
gs-3919	224	8	frequently	frequently	ADV
gs-3919	224	9	reported	report	VERB
gs-3919	224	10	.	.	PUNCT
gs-3919	225	1	drug	drug	NOUN
gs-3919	225	2	classes	class	NOUN
gs-3919	225	3	most	most	ADV
gs-3919	225	4	commonly	commonly	ADV
gs-3919	225	5	implicated	implicate	VERB
gs-3919	225	6	numerous	numerous	ADJ
gs-3919	225	7	drugs	drug	NOUN
gs-3919	225	8	have	have	AUX
gs-3919	225	9	been	be	AUX
gs-3919	225	10	associated	associate	VERB
gs-3919	225	11	with	with	ADP
gs-3919	225	12	dress	dress	NOUN
gs-3919	225	13	syndrome	syndrome	NOUN
gs-3919	225	14	.	.	PUNCT
gs-3919	226	1	aromatic	aromatic	ADJ
gs-3919	226	2	anticonvulsants	anticonvulsant	NOUN
gs-3919	226	3	such	such	ADJ
gs-3919	226	4	as	as	ADP
gs-3919	226	5	carbamazepine	carbamazepine	NOUN
gs-3919	226	6	and	and	CCONJ
gs-3919	226	7	phenytoin	phenytoin	NOUN
gs-3919	226	8	,	,	PUNCT
gs-3919	226	9	and	and	CCONJ
gs-3919	226	10	β	β	NOUN
gs-3919	226	11	-	-	NOUN
gs-3919	226	12	lactam	lactam	NOUN
gs-3919	226	13	antibiotics	antibiotic	NOUN
gs-3919	226	14	,	,	PUNCT
gs-3919	226	15	including	include	VERB
gs-3919	226	16	sulfonamides	sulfonamide	NOUN
gs-3919	226	17	,	,	PUNCT
gs-3919	226	18	are	be	AUX
gs-3919	226	19	among	among	ADP
gs-3919	226	20	the	the	DET
gs-3919	226	21	most	most	ADV
gs-3919	226	22	frequently	frequently	ADV
gs-3919	226	23	incriminated	incriminated	ADJ
gs-3919	226	24	drug	drug	NOUN
gs-3919	226	25	classes	class	NOUN
gs-3919	226	26	.	.	PUNCT
gs-3919	227	1	allopurinol	allopurinol	NOUN
gs-3919	227	2	,	,	PUNCT
gs-3919	227	3	a	a	DET
gs-3919	227	4	xanthine	xanthine	NOUN
gs-3919	227	5	oxidase	oxidase	NOUN
gs-3919	227	6	inhibitor	inhibitor	NOUN
gs-3919	227	7	,	,	PUNCT
gs-3919	227	8	is	be	AUX
gs-3919	227	9	a	a	DET
gs-3919	227	10	well	well	ADV
gs-3919	227	11	-	-	PUNCT
gs-3919	227	12	known	know	VERB
gs-3919	227	13	cause	cause	NOUN
gs-3919	227	14	of	of	ADP
gs-3919	227	15	dress	dress	NOUN
gs-3919	227	16	,	,	PUNCT
gs-3919	227	17	particularly	particularly	ADV
gs-3919	227	18	in	in	ADP
gs-3919	227	19	east	east	ADJ
gs-3919	227	20	asian	asian	ADJ
gs-3919	227	21	populations	population	NOUN
gs-3919	227	22	carrying	carry	VERB
gs-3919	227	23	the	the	DET
gs-3919	227	24	hla	hla	NOUN
gs-3919	227	25	-	-	PUNCT
gs-3919	227	26	b58:01	b58:01	PROPN
gs-3919	227	27	allele	allele	NOUN
gs-3919	227	28	(	(	PUNCT
gs-3919	227	29	abusuliman	abusuliman	NOUN
gs-3919	227	30	et	et	PROPN
gs-3919	227	31	al	al	PROPN
gs-3919	227	32	.	.	PROPN
gs-3919	227	33	,	,	PUNCT
gs-3919	227	34	2024	2024	NUM
gs-3919	227	35	)	)	PUNCT
gs-3919	227	36	.	.	PUNCT
gs-3919	228	1	the	the	DET
gs-3919	228	2	pathophysiology	pathophysiology	NOUN
gs-3919	228	3	of	of	ADP
gs-3919	228	4	dress	dress	NOUN
gs-3919	228	5	triggered	trigger	VERB
gs-3919	228	6	by	by	ADP
gs-3919	228	7	sulfonamide	sulfonamide	ADJ
gs-3919	228	8	antibiotics	antibiotic	NOUN
gs-3919	228	9	such	such	ADJ
gs-3919	228	10	as	as	ADP
gs-3919	228	11	sulfamethoxazole	sulfamethoxazole	NOUN
gs-3919	228	12	-	-	PUNCT
gs-3919	228	13	trimethoprim	trimethoprim	NOUN
gs-3919	228	14	has	have	AUX
gs-3919	228	15	been	be	AUX
gs-3919	228	16	better	well	ADV
gs-3919	228	17	elucidated	elucidate	VERB
gs-3919	228	18	in	in	ADP
gs-3919	228	19	recent	recent	ADJ
gs-3919	228	20	literature	literature	NOUN
gs-3919	228	21	.	.	PUNCT
gs-3919	229	1	less	less	ADJ
gs-3919	229	2	is	be	AUX
gs-3919	229	3	understood	understand	VERB
gs-3919	229	4	regarding	regard	VERB
gs-3919	229	5	nsaids	nsaid	NOUN
gs-3919	229	6	,	,	PUNCT
gs-3919	229	7	though	though	SCONJ
gs-3919	229	8	some	some	DET
gs-3919	229	9	recent	recent	ADJ
gs-3919	229	10	reports	report	NOUN
gs-3919	229	11	have	have	AUX
gs-3919	229	12	implicated	implicate	VERB
gs-3919	229	13	agents	agent	NOUN
gs-3919	229	14	like	like	ADP
gs-3919	229	15	mefenamic	mefenamic	ADJ
gs-3919	229	16	acid	acid	NOUN
gs-3919	229	17	and	and	CCONJ
gs-3919	229	18	diclofenac	diclofenac	NOUN
gs-3919	229	19	as	as	ADP
gs-3919	229	20	potential	potential	ADJ
gs-3919	229	21	triggers	trigger	NOUN
gs-3919	229	22	.	.	PUNCT
gs-3919	230	1	the	the	DET
gs-3919	230	2	true	true	ADJ
gs-3919	230	3	incidence	incidence	NOUN
gs-3919	230	4	of	of	ADP
gs-3919	230	5	nsaid	nsaid	PROPN
gs-3919	230	6	-	-	PUNCT
gs-3919	230	7	induced	induce	VERB
gs-3919	230	8	dress	dress	NOUN
gs-3919	230	9	may	may	AUX
gs-3919	230	10	be	be	AUX
gs-3919	230	11	underestimated	underestimate	VERB
gs-3919	230	12	due	due	ADJ
gs-3919	230	13	to	to	ADP
gs-3919	230	14	underdiagnoses	underdiagnose	NOUN
gs-3919	230	15	.	.	PUNCT
gs-3919	231	1	genetic	genetic	ADJ
gs-3919	231	2	predisposition	predisposition	NOUN
gs-3919	231	3	and	and	CCONJ
gs-3919	231	4	pharmacogenetics	pharmacogenetic	NOUN
gs-3919	231	5	genetic	genetic	ADJ
gs-3919	231	6	screening	screening	NOUN
gs-3919	231	7	is	be	AUX
gs-3919	231	8	increasingly	increasingly	ADV
gs-3919	231	9	recommended	recommend	VERB
gs-3919	231	10	to	to	PART
gs-3919	231	11	prevent	prevent	VERB
gs-3919	231	12	dress	dress	NOUN
gs-3919	231	13	cases	case	NOUN
gs-3919	231	14	,	,	PUNCT
gs-3919	231	15	especially	especially	ADV
gs-3919	231	16	in	in	ADP
gs-3919	231	17	ethnic	ethnic	ADJ
gs-3919	231	18	populations	population	NOUN
gs-3919	231	19	with	with	ADP
gs-3919	231	20	well	well	ADV
gs-3919	231	21	-	-	PUNCT
gs-3919	231	22	established	establish	VERB
gs-3919	231	23	risk	risk	NOUN
gs-3919	231	24	associations	association	NOUN
gs-3919	231	25	.	.	PUNCT
gs-3919	232	1	the	the	DET
gs-3919	232	2	strongest	strong	ADJ
gs-3919	232	3	genetic	genetic	ADJ
gs-3919	232	4	link	link	NOUN
gs-3919	232	5	demonstrated	demonstrate	VERB
gs-3919	232	6	is	be	AUX
gs-3919	232	7	between	between	ADP
gs-3919	232	8	hla	hla	PROPN
gs-3919	232	9	-	-	PUNCT
gs-3919	232	10	b58:01	b58:01	NOUN
gs-3919	232	11	and	and	CCONJ
gs-3919	232	12	allopurinol	allopurinol	NOUN
gs-3919	232	13	-	-	PUNCT
gs-3919	232	14	induced	induce	VERB
gs-3919	232	15	dress	dress	NOUN
gs-3919	232	16	,	,	PUNCT
gs-3919	232	17	particularly	particularly	ADV
gs-3919	232	18	prevalent	prevalent	ADJ
gs-3919	232	19	in	in	ADP
gs-3919	232	20	east	east	ADJ
gs-3919	232	21	asian	asian	ADJ
gs-3919	232	22	populations	population	NOUN
gs-3919	232	23	.	.	PUNCT
gs-3919	233	1	similarly	similarly	ADV
gs-3919	233	2	,	,	PUNCT
gs-3919	233	3	hla	hla	PROPN
gs-3919	233	4	-	-	PUNCT
gs-3919	233	5	a31:01	a31:01	PROPN
gs-3919	233	6	is	be	AUX
gs-3919	233	7	significantly	significantly	ADV
gs-3919	233	8	associated	associate	VERB
gs-3919	233	9	with	with	ADP
gs-3919	233	10	carbamazepine	carbamazepine	NOUN
gs-3919	233	11	hypersensitivity	hypersensitivity	NOUN
gs-3919	233	12	reactions	reaction	NOUN
gs-3919	233	13	.	.	PUNCT
gs-3919	234	1	moreover	moreover	ADV
gs-3919	234	2	,	,	PUNCT
gs-3919	234	3	hla	hla	PROPN
gs-3919	234	4	-	-	PUNCT
gs-3919	234	5	b15:02	b15:02	PROPN
gs-3919	234	6	has	have	AUX
gs-3919	234	7	been	be	AUX
gs-3919	234	8	linked	link	VERB
gs-3919	234	9	with	with	ADP
gs-3919	234	10	severe	severe	ADJ
gs-3919	234	11	cutaneous	cutaneous	ADJ
gs-3919	234	12	adverse	adverse	ADJ
gs-3919	234	13	reactions	reaction	NOUN
gs-3919	234	14	,	,	PUNCT
gs-3919	234	15	including	include	VERB
gs-3919	234	16	stevens	stevens	PROPN
gs-3919	234	17	-	-	PUNCT
gs-3919	234	18	johnson	johnson	PROPN
gs-3919	234	19	syndrome	syndrome	NOUN
gs-3919	234	20	,	,	PUNCT
gs-3919	234	21	especially	especially	ADV
gs-3919	234	22	in	in	ADP
gs-3919	234	23	southeast	southeast	ADJ
gs-3919	234	24	asian	asian	ADJ
gs-3919	234	25	populations	population	NOUN
gs-3919	234	26	.	.	PUNCT
gs-3919	235	1	georgian	georgian	ADJ
gs-3919	235	2	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	235	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	235	4	ტ.	ტ.	VERB
gs-3919	235	5	7	7	NUM
gs-3919	235	6	n	n	DET
gs-3919	235	7	3	3	NUM
gs-3919	235	8	,	,	PUNCT
gs-3919	235	9	2025	2025	NUM
gs-3919	235	10	155	155	NUM
gs-3919	235	11	table-1	table-1	NUM
gs-3919	235	12	.	.	PUNCT
gs-3919	236	1	association	association	NOUN
gs-3919	236	2	of	of	ADP
gs-3919	236	3	hla	hla	PROPN
gs-3919	236	4	alleles	allele	NOUN
gs-3919	236	5	,	,	PUNCT
gs-3919	236	6	according	accord	VERB
gs-3919	236	7	to	to	ADP
gs-3919	236	8	drug	drug	NOUN
gs-3919	236	9	and	and	CCONJ
gs-3919	236	10	ethnicity	ethnicity	NOUN
gs-3919	236	11	.	.	PUNCT
gs-3919	237	1	drug	drug	PROPN
gs-3919	237	2	hla	hla	PROPN
gs-3919	237	3	allele	allele	PROPN
gs-3919	237	4	ethnicity	ethnicity	NOUN
gs-3919	237	5	abacavir	abacavir	VERB
gs-3919	237	6	b57:01	b57:01	NOUN
gs-3919	237	7	europeans	europeans	PROPN
gs-3919	237	8	,	,	PUNCT
gs-3919	237	9	africans	africans	PROPN
gs-3919	237	10	,	,	PUNCT
gs-3919	237	11	north	north	NOUN
gs-3919	237	12	americans	americans	PROPN
gs-3919	237	13	allopurinol	allopurinol	VERB
gs-3919	237	14	b58:01	b58:01	PROPN
gs-3919	237	15	han	han	PROPN
gs-3919	237	16	chinese	chinese	PROPN
gs-3919	237	17	,	,	PUNCT
gs-3919	237	18	korean	korean	ADJ
gs-3919	237	19	,	,	PUNCT
gs-3919	237	20	taiwanese	taiwanese	PROPN
gs-3919	237	21	,	,	PUNCT
gs-3919	237	22	thai	thai	NOUN
gs-3919	237	23	carbamazepine	carbamazepine	NOUN
gs-3919	237	24	a31:01	a31:01	PROPN
gs-3919	237	25	europeans	europeans	PROPN
gs-3919	237	26	,	,	PUNCT
gs-3919	237	27	chinese	chinese	PROPN
gs-3919	237	28	,	,	PUNCT
gs-3919	237	29	koreans	koreans	PROPN
gs-3919	237	30	,	,	PUNCT
gs-3919	237	31	japanese	japanese	ADJ
gs-3919	237	32	lamotrigine	lamotrigine	PROPN
gs-3919	238	1	b51:01	b51:01	PROPN
gs-3919	238	2	,	,	PUNCT
gs-3919	238	3	a24:02	a24:02	PROPN
gs-3919	238	4	europeans	europeans	PROPN
gs-3919	238	5	(	(	PUNCT
gs-3919	238	6	spanish	spanish	ADJ
gs-3919	238	7	)	)	PUNCT
gs-3919	238	8	methazolamide	methazolamide	NOUN
gs-3919	238	9	b59:01	b59:01	VERB
gs-3919	238	10	koreans	koreans	PROPN
gs-3919	238	11	,	,	PUNCT
gs-3919	238	12	japanese	japanese	PROPN
gs-3919	238	13	,	,	PUNCT
gs-3919	238	14	han	han	PROPN
gs-3919	238	15	chinese	chinese	PROPN
gs-3919	238	16	piperacillin	piperacillin	PROPN
gs-3919	238	17	/	/	SYM
gs-3919	238	18	tazobactam	tazobactam	PROPN
gs-3919	238	19	b62	b62	VERB
gs-3919	238	20	british	british	ADJ
gs-3919	238	21	caucasians	caucasians	PROPN
gs-3919	238	22	sulfamethoxazole	sulfamethoxazole	NOUN
gs-3919	238	23	b38	b38	NOUN
gs-3919	238	24	europeans	europeans	PROPN
gs-3919	238	25	vancomycin	vancomycin	PROPN
gs-3919	238	26	a32:01	a32:01	PROPN
gs-3919	238	27	north	north	PROPN
gs-3919	238	28	americans	americans	PROPN
gs-3919	238	29	,	,	PUNCT
gs-3919	238	30	europeans	europeans	PROPN
gs-3919	238	31	studies	study	NOUN
gs-3919	238	32	indicate	indicate	VERB
gs-3919	238	33	that	that	SCONJ
gs-3919	238	34	frontline	frontline	NOUN
gs-3919	238	35	pharmacogenomic	pharmacogenomic	ADJ
gs-3919	238	36	testing	testing	NOUN
gs-3919	238	37	for	for	ADP
gs-3919	238	38	these	these	DET
gs-3919	238	39	hla	hla	PROPN
gs-3919	238	40	markers	marker	NOUN
gs-3919	238	41	has	have	AUX
gs-3919	238	42	reduced	reduce	VERB
gs-3919	238	43	the	the	DET
gs-3919	238	44	incidence	incidence	NOUN
gs-3919	238	45	of	of	ADP
gs-3919	238	46	dress	dress	NOUN
gs-3919	238	47	in	in	ADP
gs-3919	238	48	high	high	ADJ
gs-3919	238	49	-	-	PUNCT
gs-3919	238	50	risk	risk	NOUN
gs-3919	238	51	patients	patient	NOUN
gs-3919	238	52	prescribed	prescribe	VERB
gs-3919	238	53	these	these	DET
gs-3919	238	54	medications	medication	NOUN
gs-3919	238	55	.	.	PUNCT
gs-3919	239	1	however	however	ADV
gs-3919	239	2	,	,	PUNCT
gs-3919	239	3	the	the	DET
gs-3919	239	4	routine	routine	ADJ
gs-3919	239	5	clinical	clinical	ADJ
gs-3919	239	6	implementation	implementation	NOUN
gs-3919	239	7	of	of	ADP
gs-3919	239	8	such	such	ADJ
gs-3919	239	9	testing	testing	NOUN
gs-3919	239	10	remains	remain	VERB
gs-3919	239	11	limited	limited	ADJ
gs-3919	239	12	outside	outside	ADP
gs-3919	239	13	asia	asia	PROPN
gs-3919	239	14	,	,	PUNCT
gs-3919	239	15	partly	partly	ADV
gs-3919	239	16	due	due	ADJ
gs-3919	239	17	to	to	ADP
gs-3919	239	18	costs	cost	NOUN
gs-3919	239	19	and	and	CCONJ
gs-3919	239	20	infrastructure	infrastructure	NOUN
gs-3919	239	21	challenges	challenge	NOUN
gs-3919	239	22	.	.	PUNCT
gs-3919	240	1	dress	dress	NOUN
gs-3919	240	2	and	and	CCONJ
gs-3919	240	3	viral	viral	ADJ
gs-3919	240	4	reactivation	reactivation	NOUN
gs-3919	240	5	reactivation	reactivation	NOUN
gs-3919	240	6	of	of	ADP
gs-3919	240	7	latent	latent	NOUN
gs-3919	240	8	herpesviruses	herpesviruse	NOUN
gs-3919	240	9	such	such	ADJ
gs-3919	240	10	as	as	ADP
gs-3919	240	11	human	human	ADJ
gs-3919	240	12	herpesvirus	herpesvirus	NOUN
gs-3919	240	13	6	6	NUM
gs-3919	240	14	(	(	PUNCT
gs-3919	240	15	hhv-6	hhv-6	NOUN
gs-3919	240	16	)	)	PUNCT
gs-3919	240	17	,	,	PUNCT
gs-3919	240	18	epstein	epstein	PROPN
gs-3919	240	19	–	–	PUNCT
gs-3919	240	20	barr	barr	PROPN
gs-3919	240	21	virus	virus	PROPN
gs-3919	240	22	(	(	PUNCT
gs-3919	240	23	ebv	ebv	NOUN
gs-3919	240	24	)	)	PUNCT
gs-3919	240	25	,	,	PUNCT
gs-3919	240	26	and	and	CCONJ
gs-3919	240	27	cytomegalovirus	cytomegalovirus	NOUN
gs-3919	240	28	(	(	PUNCT
gs-3919	240	29	cmv	cmv	NOUN
gs-3919	240	30	)	)	PUNCT
gs-3919	240	31	has	have	AUX
gs-3919	240	32	been	be	AUX
gs-3919	240	33	frequently	frequently	ADV
gs-3919	240	34	observed	observe	VERB
gs-3919	240	35	in	in	ADP
gs-3919	240	36	patients	patient	NOUN
gs-3919	240	37	with	with	ADP
gs-3919	240	38	dress	dress	NOUN
gs-3919	240	39	.	.	PUNCT
gs-3919	241	1	viral	viral	ADJ
gs-3919	241	2	reactivation	reactivation	NOUN
gs-3919	241	3	is	be	AUX
gs-3919	241	4	thought	think	VERB
gs-3919	241	5	to	to	PART
gs-3919	241	6	exacerbate	exacerbate	VERB
gs-3919	241	7	systemic	systemic	ADJ
gs-3919	241	8	inflammation	inflammation	NOUN
gs-3919	241	9	and	and	CCONJ
gs-3919	241	10	complicate	complicate	VERB
gs-3919	241	11	disease	disease	NOUN
gs-3919	241	12	management	management	NOUN
gs-3919	241	13	.	.	PUNCT
gs-3919	242	1	clinical	clinical	ADJ
gs-3919	242	2	manifestations	manifestation	NOUN
gs-3919	242	3	related	relate	VERB
gs-3919	242	4	to	to	ADP
gs-3919	242	5	viral	viral	ADJ
gs-3919	242	6	reactivation	reactivation	NOUN
gs-3919	242	7	include	include	VERB
gs-3919	242	8	lymphadenopathy	lymphadenopathy	ADJ
gs-3919	242	9	and	and	CCONJ
gs-3919	242	10	hepatitis	hepatitis	NOUN
gs-3919	242	11	,	,	PUNCT
gs-3919	242	12	with	with	ADP
gs-3919	242	13	rare	rare	ADJ
gs-3919	242	14	but	but	CCONJ
gs-3919	242	15	serious	serious	ADJ
gs-3919	242	16	complications	complication	NOUN
gs-3919	242	17	such	such	ADJ
gs-3919	242	18	as	as	ADP
gs-3919	242	19	encephalitis	encephalitis	NOUN
gs-3919	242	20	.	.	PUNCT
gs-3919	243	1	early	early	ADJ
gs-3919	243	2	antiviral	antiviral	ADJ
gs-3919	243	3	treatment	treatment	NOUN
gs-3919	243	4	has	have	AUX
gs-3919	243	5	been	be	AUX
gs-3919	243	6	suggested	suggest	VERB
gs-3919	243	7	for	for	ADP
gs-3919	243	8	patients	patient	NOUN
gs-3919	243	9	at	at	ADP
gs-3919	243	10	high	high	ADJ
gs-3919	243	11	risk	risk	NOUN
gs-3919	243	12	or	or	CCONJ
gs-3919	243	13	those	those	DET
gs-3919	243	14	refractory	refractory	NOUN
gs-3919	243	15	to	to	ADP
gs-3919	243	16	corticosteroid	corticosteroid	ADJ
gs-3919	243	17	therapy	therapy	NOUN
gs-3919	243	18	,	,	PUNCT
gs-3919	243	19	although	although	SCONJ
gs-3919	243	20	evidence	evidence	NOUN
gs-3919	243	21	remains	remain	VERB
gs-3919	243	22	limited	limited	ADJ
gs-3919	243	23	.	.	PUNCT
gs-3919	244	1	pathogenesis	pathogenesis	NOUN
gs-3919	244	2	of	of	ADP
gs-3919	244	3	dress	dress	NOUN
gs-3919	244	4	syndrome	syndrome	NOUN
gs-3919	244	5	dress	dress	NOUN
gs-3919	244	6	is	be	AUX
gs-3919	244	7	a	a	DET
gs-3919	244	8	complex	complex	ADJ
gs-3919	244	9	type	type	NOUN
gs-3919	244	10	ivb	ivb	NOUN
gs-3919	244	11	delayed	delay	VERB
gs-3919	244	12	hypersensitivity	hypersensitivity	NOUN
gs-3919	244	13	reaction	reaction	NOUN
gs-3919	244	14	involving	involve	VERB
gs-3919	244	15	multiple	multiple	ADJ
gs-3919	244	16	factors	factor	NOUN
gs-3919	244	17	such	such	ADJ
gs-3919	244	18	as	as	ADP
gs-3919	244	19	drug	drug	NOUN
gs-3919	244	20	metabolism	metabolism	NOUN
gs-3919	244	21	,	,	PUNCT
gs-3919	244	22	immune	immune	ADJ
gs-3919	244	23	activation	activation	NOUN
gs-3919	244	24	,	,	PUNCT
gs-3919	244	25	genetic	genetic	ADJ
gs-3919	244	26	predisposition	predisposition	NOUN
gs-3919	244	27	,	,	PUNCT
gs-3919	244	28	and	and	CCONJ
gs-3919	244	29	viral	viral	ADJ
gs-3919	244	30	reactivation	reactivation	NOUN
gs-3919	244	31	.	.	PUNCT
gs-3919	245	1	many	many	ADJ
gs-3919	245	2	culprit	culprit	ADJ
gs-3919	245	3	drugs	drug	NOUN
gs-3919	245	4	undergo	undergo	VERB
gs-3919	245	5	metabolic	metabolic	NOUN
gs-3919	245	6	activation	activation	NOUN
gs-3919	245	7	by	by	ADP
gs-3919	245	8	cytochrome	cytochrome	ADJ
gs-3919	245	9	p450	p450	NUM
gs-3919	245	10	enzymes	enzyme	NOUN
gs-3919	245	11	,	,	PUNCT
gs-3919	245	12	generating	generate	VERB
gs-3919	245	13	reactive	reactive	ADJ
gs-3919	245	14	metabolites	metabolite	NOUN
gs-3919	245	15	that	that	PRON
gs-3919	245	16	bind	bind	VERB
gs-3919	245	17	to	to	ADP
gs-3919	245	18	host	host	NOUN
gs-3919	245	19	proteins	protein	NOUN
gs-3919	245	20	and	and	CCONJ
gs-3919	245	21	form	form	NOUN
gs-3919	245	22	neoantigens	neoantigen	NOUN
gs-3919	245	23	.	.	PUNCT
gs-3919	246	1	these	these	DET
gs-3919	246	2	neoantigens	neoantigen	NOUN
gs-3919	246	3	are	be	AUX
gs-3919	246	4	then	then	ADV
gs-3919	246	5	presented	present	VERB
gs-3919	246	6	to	to	ADP
gs-3919	246	7	t	t	PROPN
gs-3919	246	8	lymphocytes	lymphocyte	NOUN
gs-3919	246	9	by	by	ADP
gs-3919	246	10	specific	specific	ADJ
gs-3919	246	11	hla	hla	NOUN
gs-3919	246	12	molecules	molecule	NOUN
gs-3919	246	13	most	most	ADV
gs-3919	246	14	notably	notably	ADV
gs-3919	246	15	hla	hla	PROPN
gs-3919	246	16	-	-	PUNCT
gs-3919	246	17	b58:01	b58:01	PROPN
gs-3919	246	18	,	,	PUNCT
gs-3919	246	19	hla	hla	PROPN
gs-3919	246	20	-	-	PUNCT
gs-3919	246	21	a31:01	a31:01	PROPN
gs-3919	246	22	,	,	PUNCT
gs-3919	246	23	and	and	CCONJ
gs-3919	246	24	hla	hla	PROPN
gs-3919	246	25	-	-	PUNCT
gs-3919	246	26	b15:02	b15:02	PROPN
gs-3919	246	27	triggering	trigger	VERB
gs-3919	246	28	a	a	DET
gs-3919	246	29	robust	robust	ADJ
gs-3919	246	30	immune	immune	ADJ
gs-3919	246	31	response	response	NOUN
gs-3919	246	32	.	.	PUNCT
gs-3919	247	1	the	the	DET
gs-3919	247	2	activated	activate	VERB
gs-3919	247	3	t	t	NOUN
gs-3919	247	4	cells	cell	NOUN
gs-3919	247	5	produce	produce	VERB
gs-3919	247	6	pro	pro	ADJ
gs-3919	247	7	-	-	ADJ
gs-3919	247	8	inflammatory	inflammatory	ADJ
gs-3919	247	9	cytokines	cytokine	NOUN
gs-3919	247	10	such	such	ADJ
gs-3919	247	11	as	as	ADP
gs-3919	247	12	il-5	il-5	PROPN
gs-3919	247	13	,	,	PUNCT
gs-3919	247	14	tnf	tnf	PROPN
gs-3919	247	15	-	-	PUNCT
gs-3919	247	16	α	α	PROPN
gs-3919	247	17	,	,	PUNCT
gs-3919	247	18	and	and	CCONJ
gs-3919	247	19	ifn	ifn	PROPN
gs-3919	247	20	-	-	PUNCT
gs-3919	247	21	γ	γ	NOUN
gs-3919	247	22	,	,	PUNCT
gs-3919	247	23	promoting	promote	VERB
gs-3919	247	24	eosinophil	eosinophil	ADJ
gs-3919	247	25	recruitment	recruitment	NOUN
gs-3919	247	26	and	and	CCONJ
gs-3919	247	27	systemic	systemic	ADJ
gs-3919	247	28	inflammation	inflammation	NOUN
gs-3919	247	29	that	that	SCONJ
gs-3919	247	30	results	result	VERB
gs-3919	247	31	in	in	ADP
gs-3919	247	32	multiorgan	multiorgan	PROPN
gs-3919	247	33	injury	injury	PROPN
gs-3919	247	34	.	.	PUNCT
gs-3919	248	1	this	this	DET
gs-3919	248	2	immune	immune	ADJ
gs-3919	248	3	activation	activation	NOUN
gs-3919	248	4	is	be	AUX
gs-3919	248	5	often	often	ADV
gs-3919	248	6	amplified	amplify	VERB
gs-3919	248	7	by	by	ADP
gs-3919	248	8	concurrent	concurrent	ADJ
gs-3919	248	9	viral	viral	ADJ
gs-3919	248	10	reactivation	reactivation	NOUN
gs-3919	248	11	,	,	PUNCT
gs-3919	248	12	creating	create	VERB
gs-3919	248	13	a	a	DET
gs-3919	248	14	feedback	feedback	NOUN
gs-3919	248	15	loop	loop	NOUN
gs-3919	248	16	that	that	PRON
gs-3919	248	17	prolongs	prolong	VERB
gs-3919	248	18	and	and	CCONJ
gs-3919	248	19	intensifies	intensify	VERB
gs-3919	248	20	the	the	DET
gs-3919	248	21	disease	disease	NOUN
gs-3919	248	22	.	.	PUNCT
gs-3919	249	1	georgian	georgian	ADJ
gs-3919	249	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	249	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	249	4	ტ.	ტ.	VERB
gs-3919	249	5	7	7	NUM
gs-3919	249	6	n	n	PRON
gs-3919	249	7	3	3	NUM
gs-3919	249	8	,	,	PUNCT
gs-3919	249	9	2025	2025	NUM
gs-3919	249	10	156	156	NUM
gs-3919	249	11	the	the	DET
gs-3919	249	12	hallmark	hallmark	ADJ
gs-3919	249	13	multi	multi	ADJ
gs-3919	249	14	-	-	ADJ
gs-3919	249	15	organ	organ	ADJ
gs-3919	249	16	involvement	involvement	NOUN
gs-3919	249	17	of	of	ADP
gs-3919	249	18	dress	dress	NOUN
gs-3919	249	19	including	include	VERB
gs-3919	249	20	the	the	DET
gs-3919	249	21	liver	liver	NOUN
gs-3919	249	22	,	,	PUNCT
gs-3919	249	23	kidneys	kidney	NOUN
gs-3919	249	24	,	,	PUNCT
gs-3919	249	25	lungs	lung	NOUN
gs-3919	249	26	,	,	PUNCT
gs-3919	249	27	and	and	CCONJ
gs-3919	249	28	heart	heart	NOUN
gs-3919	249	29	is	be	AUX
gs-3919	249	30	attributed	attribute	VERB
gs-3919	249	31	to	to	ADP
gs-3919	249	32	infiltration	infiltration	NOUN
gs-3919	249	33	by	by	ADP
gs-3919	249	34	activated	activate	VERB
gs-3919	249	35	t	t	NOUN
gs-3919	249	36	cells	cell	NOUN
gs-3919	249	37	and	and	CCONJ
gs-3919	249	38	eosinophils	eosinophil	VERB
gs-3919	249	39	causing	cause	VERB
gs-3919	249	40	cytotoxic	cytotoxic	ADJ
gs-3919	249	41	injury	injury	NOUN
gs-3919	249	42	and	and	CCONJ
gs-3919	249	43	inflammation	inflammation	NOUN
gs-3919	249	44	.	.	PUNCT
gs-3919	250	1	these	these	DET
gs-3919	250	2	features	feature	VERB
gs-3919	250	3	distinguish	distinguish	VERB
gs-3919	250	4	dress	dress	NOUN
gs-3919	250	5	from	from	ADP
gs-3919	250	6	simpler	simple	ADJ
gs-3919	250	7	drug	drug	NOUN
gs-3919	250	8	eruptions	eruption	NOUN
gs-3919	250	9	and	and	CCONJ
gs-3919	250	10	classify	classify	VERB
gs-3919	250	11	it	it	PRON
gs-3919	250	12	among	among	ADP
gs-3919	250	13	severe	severe	ADJ
gs-3919	250	14	cutaneous	cutaneous	ADJ
gs-3919	250	15	adverse	adverse	ADJ
gs-3919	250	16	reactions	reaction	NOUN
gs-3919	250	17	.	.	PUNCT
gs-3919	251	1	figure	figure	NOUN
gs-3919	251	2	1	1	NUM
gs-3919	251	3	.	.	PUNCT
gs-3919	252	1	pathogenesis	pathogenesis	NOUN
gs-3919	252	2	of	of	ADP
gs-3919	252	3	dress	dress	NOUN
gs-3919	252	4	syndrome	syndrome	NOUN
gs-3919	252	5	showing	show	VERB
gs-3919	252	6	drug	drug	NOUN
gs-3919	252	7	metabolism	metabolism	NOUN
gs-3919	252	8	,	,	PUNCT
gs-3919	252	9	immune	immune	ADJ
gs-3919	252	10	activation	activation	NOUN
gs-3919	252	11	,	,	PUNCT
gs-3919	252	12	and	and	CCONJ
gs-3919	252	13	multi	multi	ADJ
gs-3919	252	14	-	-	ADJ
gs-3919	252	15	organ	organ	ADJ
gs-3919	252	16	involvement	involvement	NOUN
gs-3919	252	17	.	.	PUNCT
gs-3919	253	1	why	why	SCONJ
gs-3919	253	2	dress	dress	NOUN
gs-3919	253	3	manifests	manifest	VERB
gs-3919	253	4	to	to	ADP
gs-3919	253	5	only	only	ADV
gs-3919	253	6	a	a	DET
gs-3919	253	7	few	few	ADJ
gs-3919	253	8	drugs	drug	NOUN
gs-3919	253	9	one	one	NUM
gs-3919	253	10	of	of	ADP
gs-3919	253	11	the	the	DET
gs-3919	253	12	most	most	ADV
gs-3919	253	13	remarkable	remarkable	ADJ
gs-3919	253	14	aspects	aspect	NOUN
gs-3919	253	15	of	of	ADP
gs-3919	253	16	dress	dress	NOUN
gs-3919	253	17	syndrome	syndrome	NOUN
gs-3919	253	18	is	be	AUX
gs-3919	253	19	that	that	SCONJ
gs-3919	253	20	it	it	PRON
gs-3919	253	21	is	be	AUX
gs-3919	253	22	induced	induce	VERB
gs-3919	253	23	by	by	ADP
gs-3919	253	24	a	a	DET
gs-3919	253	25	relatively	relatively	ADV
gs-3919	253	26	small	small	ADJ
gs-3919	253	27	group	group	NOUN
gs-3919	253	28	of	of	ADP
gs-3919	253	29	drugs	drug	NOUN
gs-3919	253	30	,	,	PUNCT
gs-3919	253	31	despite	despite	SCONJ
gs-3919	253	32	the	the	DET
gs-3919	253	33	existence	existence	NOUN
gs-3919	253	34	of	of	ADP
gs-3919	253	35	thousands	thousand	NOUN
gs-3919	253	36	of	of	ADP
gs-3919	253	37	medications	medication	NOUN
gs-3919	253	38	in	in	ADP
gs-3919	253	39	international	international	ADJ
gs-3919	253	40	pharmacopeias	pharmacopeia	NOUN
gs-3919	253	41	.	.	PUNCT
gs-3919	254	1	several	several	ADJ
gs-3919	254	2	pharmacological	pharmacological	NOUN
gs-3919	254	3	,	,	PUNCT
gs-3919	254	4	structural	structural	ADJ
gs-3919	254	5	,	,	PUNCT
gs-3919	254	6	and	and	CCONJ
gs-3919	254	7	immunogenetic	immunogenetic	ADJ
gs-3919	254	8	mechanisms	mechanism	NOUN
gs-3919	254	9	contribute	contribute	VERB
gs-3919	254	10	to	to	ADP
gs-3919	254	11	this	this	DET
gs-3919	254	12	specificity	specificity	NOUN
gs-3919	254	13	.	.	PUNCT
gs-3919	255	1	first	first	ADV
gs-3919	255	2	,	,	PUNCT
gs-3919	255	3	not	not	PART
gs-3919	255	4	all	all	DET
gs-3919	255	5	drugs	drug	NOUN
gs-3919	255	6	possess	possess	VERB
gs-3919	255	7	the	the	DET
gs-3919	255	8	chemical	chemical	NOUN
gs-3919	255	9	properties	property	NOUN
gs-3919	255	10	required	require	VERB
gs-3919	255	11	for	for	ADP
gs-3919	255	12	metabolism	metabolism	NOUN
gs-3919	255	13	into	into	ADP
gs-3919	255	14	reactive	reactive	ADJ
gs-3919	255	15	intermediates	intermediate	NOUN
gs-3919	255	16	.	.	PUNCT
gs-3919	256	1	aromatic	aromatic	ADJ
gs-3919	256	2	anticonvulsants	anticonvulsant	NOUN
gs-3919	256	3	like	like	ADP
gs-3919	256	4	carbamazepine	carbamazepine	NOUN
gs-3919	256	5	and	and	CCONJ
gs-3919	256	6	phenytoin	phenytoin	NOUN
gs-3919	256	7	,	,	PUNCT
gs-3919	256	8	sulfonamides	sulfonamide	NOUN
gs-3919	256	9	such	such	ADJ
gs-3919	256	10	as	as	ADP
gs-3919	256	11	sulfamethoxazole	sulfamethoxazole	NOUN
gs-3919	256	12	-	-	PUNCT
gs-3919	256	13	trimethoprim	trimethoprim	ADJ
gs-3919	256	14	,	,	PUNCT
gs-3919	256	15	and	and	CCONJ
gs-3919	256	16	xanthine	xanthine	NOUN
gs-3919	256	17	oxidase	oxidase	NOUN
gs-3919	256	18	inhibitors	inhibitor	NOUN
gs-3919	256	19	like	like	ADP
gs-3919	256	20	allopurinol	allopurinol	NOUN
gs-3919	256	21	are	be	AUX
gs-3919	256	22	among	among	ADP
gs-3919	256	23	the	the	DET
gs-3919	256	24	most	most	ADV
gs-3919	256	25	commonly	commonly	ADV
gs-3919	256	26	implicated	implicate	VERB
gs-3919	256	27	agents	agent	NOUN
gs-3919	256	28	.	.	PUNCT
gs-3919	257	1	these	these	DET
gs-3919	257	2	drugs	drug	NOUN
gs-3919	257	3	are	be	AUX
gs-3919	257	4	bioactivated	bioactivate	VERB
gs-3919	257	5	in	in	ADP
gs-3919	257	6	the	the	DET
gs-3919	257	7	liver	liver	NOUN
gs-3919	257	8	,	,	PUNCT
gs-3919	257	9	forming	form	VERB
gs-3919	257	10	electrophilic	electrophilic	ADJ
gs-3919	257	11	metabolites	metabolite	NOUN
gs-3919	257	12	that	that	PRON
gs-3919	257	13	can	can	AUX
gs-3919	257	14	bind	bind	VERB
gs-3919	257	15	to	to	ADP
gs-3919	257	16	host	host	NOUN
gs-3919	257	17	proteins	protein	NOUN
gs-3919	257	18	,	,	PUNCT
gs-3919	257	19	creating	create	VERB
gs-3919	257	20	immunogenic	immunogenic	ADJ
gs-3919	257	21	neoantigens	neoantigen	NOUN
gs-3919	257	22	.	.	PUNCT
gs-3919	258	1	in	in	ADP
gs-3919	258	2	contrast	contrast	NOUN
gs-3919	258	3	,	,	PUNCT
gs-3919	258	4	many	many	ADJ
gs-3919	258	5	commonly	commonly	ADV
gs-3919	258	6	used	use	VERB
gs-3919	258	7	medications	medication	NOUN
gs-3919	258	8	like	like	ADP
gs-3919	258	9	paracetamol	paracetamol	NOUN
gs-3919	258	10	or	or	CCONJ
gs-3919	258	11	amoxicillin	amoxicillin	NOUN
gs-3919	258	12	are	be	AUX
gs-3919	258	13	metabolically	metabolically	ADV
gs-3919	258	14	stable	stable	ADJ
gs-3919	258	15	and	and	CCONJ
gs-3919	258	16	are	be	AUX
gs-3919	258	17	eliminated	eliminate	VERB
gs-3919	258	18	without	without	ADP
gs-3919	258	19	triggering	trigger	VERB
gs-3919	258	20	immune	immune	ADJ
gs-3919	258	21	recognition	recognition	NOUN
gs-3919	258	22	.	.	PUNCT
gs-3919	259	1	second	second	ADJ
gs-3919	259	2	,	,	PUNCT
gs-3919	259	3	genetic	genetic	ADJ
gs-3919	259	4	predisposition	predisposition	NOUN
gs-3919	259	5	plays	play	VERB
gs-3919	259	6	a	a	DET
gs-3919	259	7	central	central	ADJ
gs-3919	259	8	role	role	NOUN
gs-3919	259	9	.	.	PUNCT
gs-3919	260	1	specific	specific	ADJ
gs-3919	260	2	hla	hla	PROPN
gs-3919	260	3	alleles	allele	NOUN
gs-3919	260	4	are	be	AUX
gs-3919	260	5	strongly	strongly	ADV
gs-3919	260	6	associated	associate	VERB
gs-3919	260	7	with	with	ADP
gs-3919	260	8	hypersensitivity	hypersensitivity	NOUN
gs-3919	260	9	reactions	reaction	NOUN
gs-3919	260	10	.	.	PUNCT
gs-3919	261	1	for	for	ADP
gs-3919	261	2	example	example	NOUN
gs-3919	261	3	,	,	PUNCT
gs-3919	261	4	hla	hla	NOUN
gs-3919	261	5	-	-	PUNCT
gs-3919	261	6	b58:01	b58:01	PROPN
gs-3919	261	7	is	be	AUX
gs-3919	261	8	well	well	ADV
gs-3919	261	9	-	-	PUNCT
gs-3919	261	10	known	know	VERB
gs-3919	261	11	in	in	ADP
gs-3919	261	12	georgian	georgian	ADJ
gs-3919	261	13	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	261	14	მეცნიერები	მეცნიერები	NOUN
gs-3919	261	15	ტ.	ტ.	VERB
gs-3919	261	16	7	7	NUM
gs-3919	261	17	n	n	PRON
gs-3919	261	18	3	3	NUM
gs-3919	261	19	,	,	PUNCT
gs-3919	261	20	2025	2025	NUM
gs-3919	261	21	157	157	NUM
gs-3919	261	22	allopurinol	allopurinol	NOUN
gs-3919	261	23	-	-	PUNCT
gs-3919	261	24	induced	induce	VERB
gs-3919	261	25	dress	dress	NOUN
gs-3919	261	26	,	,	PUNCT
gs-3919	261	27	especially	especially	ADV
gs-3919	261	28	among	among	ADP
gs-3919	261	29	individuals	individual	NOUN
gs-3919	261	30	of	of	ADP
gs-3919	261	31	asian	asian	ADJ
gs-3919	261	32	descent	descent	NOUN
gs-3919	261	33	.	.	PUNCT
gs-3919	262	1	these	these	DET
gs-3919	262	2	genetic	genetic	ADJ
gs-3919	262	3	markers	marker	NOUN
gs-3919	262	4	influence	influence	VERB
gs-3919	262	5	how	how	SCONJ
gs-3919	262	6	an	an	DET
gs-3919	262	7	individual	individual	NOUN
gs-3919	262	8	’s	’s	PART
gs-3919	262	9	immune	immune	ADJ
gs-3919	262	10	system	system	NOUN
gs-3919	262	11	processes	process	NOUN
gs-3919	262	12	and	and	CCONJ
gs-3919	262	13	presents	present	VERB
gs-3919	262	14	drug	drug	NOUN
gs-3919	262	15	-	-	PUNCT
gs-3919	262	16	derived	derive	VERB
gs-3919	262	17	antigens	antigen	NOUN
gs-3919	262	18	to	to	ADP
gs-3919	262	19	t	t	NOUN
gs-3919	262	20	cells	cell	NOUN
gs-3919	262	21	.	.	PUNCT
gs-3919	263	1	third	third	ADJ
gs-3919	263	2	,	,	PUNCT
gs-3919	263	3	the	the	DET
gs-3919	263	4	timing	timing	NOUN
gs-3919	263	5	and	and	CCONJ
gs-3919	263	6	duration	duration	NOUN
gs-3919	263	7	of	of	ADP
gs-3919	263	8	drug	drug	NOUN
gs-3919	263	9	exposure	exposure	NOUN
gs-3919	263	10	are	be	AUX
gs-3919	263	11	critical	critical	ADJ
gs-3919	263	12	.	.	PUNCT
gs-3919	264	1	dress	dress	NOUN
gs-3919	264	2	typically	typically	ADV
gs-3919	264	3	develops	develop	VERB
gs-3919	264	4	2	2	NUM
gs-3919	264	5	to	to	PART
gs-3919	264	6	8	8	NUM
gs-3919	264	7	weeks	week	NOUN
gs-3919	264	8	after	after	ADP
gs-3919	264	9	the	the	DET
gs-3919	264	10	initiation	initiation	NOUN
gs-3919	264	11	of	of	ADP
gs-3919	264	12	the	the	DET
gs-3919	264	13	offending	offend	VERB
gs-3919	264	14	drug	drug	NOUN
gs-3919	264	15	,	,	PUNCT
gs-3919	264	16	allowing	allow	VERB
gs-3919	264	17	time	time	NOUN
gs-3919	264	18	for	for	ADP
gs-3919	264	19	antigen	antigen	ADJ
gs-3919	264	20	presentation	presentation	NOUN
gs-3919	264	21	,	,	PUNCT
gs-3919	264	22	t	t	PROPN
gs-3919	264	23	cell	cell	NOUN
gs-3919	264	24	sensitization	sensitization	NOUN
gs-3919	264	25	,	,	PUNCT
gs-3919	264	26	and	and	CCONJ
gs-3919	264	27	immune	immune	ADJ
gs-3919	264	28	amplification	amplification	NOUN
gs-3919	264	29	.	.	PUNCT
gs-3919	265	1	medications	medication	NOUN
gs-3919	265	2	taken	take	VERB
gs-3919	265	3	for	for	ADP
gs-3919	265	4	shorter	short	ADJ
gs-3919	265	5	durations	duration	NOUN
gs-3919	265	6	may	may	AUX
gs-3919	265	7	be	be	AUX
gs-3919	265	8	less	less	ADV
gs-3919	265	9	likely	likely	ADJ
gs-3919	265	10	to	to	PART
gs-3919	265	11	trigger	trigger	VERB
gs-3919	265	12	this	this	DET
gs-3919	265	13	response	response	NOUN
gs-3919	265	14	,	,	PUNCT
gs-3919	265	15	as	as	SCONJ
gs-3919	265	16	insufficient	insufficient	ADJ
gs-3919	265	17	immune	immune	ADJ
gs-3919	265	18	priming	priming	NOUN
gs-3919	265	19	occurs	occur	VERB
gs-3919	265	20	.	.	PUNCT
gs-3919	266	1	finally	finally	ADV
gs-3919	266	2	,	,	PUNCT
gs-3919	266	3	reactivation	reactivation	NOUN
gs-3919	266	4	of	of	ADP
gs-3919	266	5	latent	latent	NOUN
gs-3919	266	6	viruses	virus	NOUN
gs-3919	266	7	such	such	ADJ
gs-3919	266	8	as	as	ADP
gs-3919	266	9	human	human	NOUN
gs-3919	266	10	herpesvirus-6	herpesvirus-6	PRON
gs-3919	266	11	(	(	PUNCT
gs-3919	266	12	hhv-6	hhv-6	NOUN
gs-3919	266	13	)	)	PUNCT
gs-3919	266	14	has	have	AUX
gs-3919	266	15	been	be	AUX
gs-3919	266	16	implicated	implicate	VERB
gs-3919	266	17	in	in	ADP
gs-3919	266	18	the	the	DET
gs-3919	266	19	pathogenesis	pathogenesis	NOUN
gs-3919	266	20	of	of	ADP
gs-3919	266	21	dress	dress	NOUN
gs-3919	266	22	.	.	PUNCT
gs-3919	267	1	some	some	DET
gs-3919	267	2	immunomodulatory	immunomodulatory	ADJ
gs-3919	267	3	agents	agent	NOUN
gs-3919	267	4	may	may	AUX
gs-3919	267	5	disrupt	disrupt	VERB
gs-3919	267	6	immune	immune	ADJ
gs-3919	267	7	homeostasis	homeostasis	NOUN
gs-3919	267	8	and	and	CCONJ
gs-3919	267	9	promote	promote	VERB
gs-3919	267	10	viral	viral	ADJ
gs-3919	267	11	reactivation	reactivation	NOUN
gs-3919	267	12	,	,	PUNCT
gs-3919	267	13	further	far	ADV
gs-3919	267	14	contributing	contribute	VERB
gs-3919	267	15	to	to	ADP
gs-3919	267	16	the	the	DET
gs-3919	267	17	development	development	NOUN
gs-3919	267	18	of	of	ADP
gs-3919	267	19	systemic	systemic	ADJ
gs-3919	267	20	inflammation	inflammation	NOUN
gs-3919	267	21	.	.	PUNCT
gs-3919	268	1	altogether	altogether	ADV
gs-3919	268	2	,	,	PUNCT
gs-3919	268	3	these	these	DET
gs-3919	268	4	findings	finding	NOUN
gs-3919	268	5	support	support	VERB
gs-3919	268	6	the	the	DET
gs-3919	268	7	concept	concept	NOUN
gs-3919	268	8	that	that	DET
gs-3919	268	9	dress	dress	NOUN
gs-3919	268	10	is	be	AUX
gs-3919	268	11	both	both	PRON
gs-3919	268	12	epitope	epitope	NOUN
gs-3919	268	13	-	-	PUNCT
gs-3919	268	14	specific	specific	ADJ
gs-3919	268	15	and	and	CCONJ
gs-3919	268	16	patient	patient	NOUN
gs-3919	268	17	-	-	PUNCT
gs-3919	268	18	specific	specific	ADJ
gs-3919	268	19	.	.	PUNCT
gs-3919	269	1	most	most	ADJ
gs-3919	269	2	drugs	drug	NOUN
gs-3919	269	3	do	do	AUX
gs-3919	269	4	not	not	PART
gs-3919	269	5	induce	induce	VERB
gs-3919	269	6	this	this	DET
gs-3919	269	7	cascade	cascade	NOUN
gs-3919	269	8	due	due	ADP
gs-3919	269	9	to	to	ADP
gs-3919	269	10	a	a	DET
gs-3919	269	11	lack	lack	NOUN
gs-3919	269	12	of	of	ADP
gs-3919	269	13	reactive	reactive	ADJ
gs-3919	269	14	metabolites	metabolite	NOUN
gs-3919	269	15	,	,	PUNCT
gs-3919	269	16	absence	absence	NOUN
gs-3919	269	17	of	of	ADP
gs-3919	269	18	immunogenic	immunogenic	ADJ
gs-3919	269	19	properties	property	NOUN
gs-3919	269	20	,	,	PUNCT
gs-3919	269	21	or	or	CCONJ
gs-3919	269	22	lower	low	ADJ
gs-3919	269	23	prevalence	prevalence	NOUN
gs-3919	269	24	of	of	ADP
gs-3919	269	25	genetic	genetic	ADJ
gs-3919	269	26	susceptibility	susceptibility	NOUN
gs-3919	269	27	in	in	ADP
gs-3919	269	28	the	the	DET
gs-3919	269	29	exposed	expose	VERB
gs-3919	269	30	population	population	NOUN
gs-3919	269	31	.	.	PUNCT
gs-3919	270	1	clinical	clinical	ADJ
gs-3919	270	2	features	feature	NOUN
gs-3919	270	3	and	and	CCONJ
gs-3919	270	4	diagnostic	diagnostic	ADJ
gs-3919	270	5	criteria	criterion	NOUN
gs-3919	270	6	several	several	ADJ
gs-3919	270	7	diagnostic	diagnostic	ADJ
gs-3919	270	8	scoring	scoring	NOUN
gs-3919	270	9	systems	system	NOUN
gs-3919	270	10	have	have	AUX
gs-3919	270	11	been	be	AUX
gs-3919	270	12	proposed	propose	VERB
gs-3919	270	13	for	for	ADP
gs-3919	270	14	dress	dress	NOUN
gs-3919	270	15	syndrome	syndrome	NOUN
gs-3919	270	16	,	,	PUNCT
gs-3919	270	17	with	with	ADP
gs-3919	270	18	the	the	DET
gs-3919	270	19	regi	regi	PROPN
gs-3919	270	20	scar	scar	PROPN
gs-3919	270	21	criteria	criterion	NOUN
gs-3919	270	22	being	be	AUX
gs-3919	270	23	the	the	DET
gs-3919	270	24	most	most	ADV
gs-3919	270	25	widely	widely	ADV
gs-3919	270	26	accepted	accept	VERB
gs-3919	270	27	.	.	PUNCT
gs-3919	271	1	these	these	DET
gs-3919	271	2	criteria	criterion	NOUN
gs-3919	271	3	include	include	VERB
gs-3919	271	4	:	:	PUNCT
gs-3919	271	5	table-2	table-2	NUM
gs-3919	271	6	.	.	NOUN
gs-3919	271	7	simplified	simplify	VERB
gs-3919	271	8	regi	regi	PROPN
gs-3919	271	9	scar	scar	PROPN
gs-3919	271	10	diagnostic	diagnostic	ADJ
gs-3919	271	11	criteria	criterion	NOUN
gs-3919	271	12	for	for	ADP
gs-3919	271	13	dress	dress	NOUN
gs-3919	271	14	feature	feature	NOUN
gs-3919	271	15	no	no	PRON
gs-3919	271	16	(	(	PUNCT
gs-3919	271	17	n	n	CCONJ
gs-3919	271	18	)	)	PUNCT
gs-3919	271	19	unknown	unknown	ADJ
gs-3919	271	20	(	(	PUNCT
gs-3919	271	21	u	u	NOUN
gs-3919	271	22	)	)	PUNCT
gs-3919	272	1	yes	yes	INTJ
gs-3919	272	2	(	(	PUNCT
gs-3919	272	3	y	y	NOUN
gs-3919	272	4	)	)	PUNCT
gs-3919	272	5	min	min	PROPN
gs-3919	272	6	points	point	NOUN
gs-3919	272	7	max	max	PROPN
gs-3919	272	8	points	point	NOUN
gs-3919	272	9	fever	fever	NOUN
gs-3919	272	10	(	(	PUNCT
gs-3919	272	11	≥38.5	≥38.5	X
gs-3919	272	12	°	°	NOUN
gs-3919	272	13	c	c	NOUN
gs-3919	272	14	trunk	trunk	NOUN
gs-3919	272	15	or	or	CCONJ
gs-3919	272	16	>	>	SYM
gs-3919	272	17	38	38	NUM
gs-3919	272	18	°	°	NUM
gs-3919	272	19	c	c	NOUN
gs-3919	272	20	axillary	axillary	ADJ
gs-3919	272	21	)	)	PUNCT
gs-3919	272	22	-1	-1	PUNCT
gs-3919	272	23	point	point	NOUN
gs-3919	272	24	0	0	NUM
gs-3919	272	25	points	point	NOUN
gs-3919	272	26	0	0	NUM
gs-3919	272	27	points	point	NOUN
gs-3919	272	28	-1	-1	NOUN
gs-3919	272	29	0	0	NUM
gs-3919	272	30	lymph	lymph	NOUN
gs-3919	272	31	node	node	ADJ
gs-3919	272	32	enlargement	enlargement	NOUN
gs-3919	272	33	(	(	PUNCT
gs-3919	272	34	≥1	≥1	NUM
gs-3919	272	35	cm	cm	NOUN
gs-3919	272	36	in	in	ADP
gs-3919	272	37	≥2	≥2	PROPN
gs-3919	272	38	places	place	NOUN
gs-3919	272	39	)	)	PUNCT
gs-3919	272	40	0	0	NUM
gs-3919	272	41	points	point	NOUN
gs-3919	272	42	0	0	NUM
gs-3919	272	43	points	point	NOUN
gs-3919	272	44	1	1	NUM
gs-3919	272	45	point	point	NOUN
gs-3919	272	46	0	0	NUM
gs-3919	272	47	1	1	NUM
gs-3919	272	48	eosinophilia	eosinophilia	NOUN
gs-3919	272	49	0	0	NUM
gs-3919	272	50	points	point	NOUN
gs-3919	272	51	0	0	NUM
gs-3919	272	52	points	point	NOUN
gs-3919	272	53	1	1	NUM
gs-3919	272	54	point	point	NOUN
gs-3919	272	55	(	(	PUNCT
gs-3919	272	56	700	700	NUM
gs-3919	272	57	–	–	PUNCT
gs-3919	272	58	1499	1499	NUM
gs-3919	272	59	/	/	SYM
gs-3919	272	60	μl	μl	NOUN
gs-3919	272	61	)	)	PUNCT
gs-3919	272	62	2	2	NUM
gs-3919	272	63	points	point	NOUN
gs-3919	272	64	(	(	PUNCT
gs-3919	272	65	≥1500	≥1500	NOUN
gs-3919	272	66	/	/	SYM
gs-3919	272	67	μl	μl	NOUN
gs-3919	272	68	)	)	PUNCT
gs-3919	272	69	0	0	NUM
gs-3919	272	70	2	2	NUM
gs-3919	272	71	eosinophil	eosinophil	ADJ
gs-3919	272	72	%	%	NOUN
gs-3919	272	73	if	if	SCONJ
gs-3919	272	74	leukopenia	leukopenia	PROPN
gs-3919	272	75	not	not	PART
gs-3919	272	76	applicable	applicable	ADJ
gs-3919	272	77	not	not	PART
gs-3919	272	78	applicable	applicable	ADJ
gs-3919	272	79	1	1	NUM
gs-3919	272	80	point	point	NOUN
gs-3919	272	81	(	(	PUNCT
gs-3919	272	82	10–19.9	10–19.9	NUM
gs-3919	272	83	%	%	NOUN
gs-3919	272	84	)	)	PUNCT
gs-3919	272	85	2	2	NUM
gs-3919	272	86	points	point	NOUN
gs-3919	272	87	(	(	PUNCT
gs-3919	272	88	≥20	≥20	NOUN
gs-3919	272	89	%	%	NOUN
gs-3919	272	90	)	)	PUNCT
gs-3919	272	91	0	0	NUM
gs-3919	272	92	2	2	NUM
gs-3919	272	93	atypical	atypical	ADJ
gs-3919	272	94	lymphocytes	lymphocyte	NOUN
gs-3919	272	95	0	0	NUM
gs-3919	272	96	points	point	NOUN
gs-3919	272	97	0	0	NUM
gs-3919	272	98	points	point	NOUN
gs-3919	272	99	1	1	NUM
gs-3919	272	100	point	point	NOUN
gs-3919	272	101	0	0	NUM
gs-3919	272	102	1	1	NUM
gs-3919	272	103	skin	skin	NOUN
gs-3919	272	104	involvement	involvement	NOUN
gs-3919	272	105	-2	-2	X
gs-3919	272	106	points	point	VERB
gs-3919	272	107	0	0	NUM
gs-3919	272	108	points	point	NOUN
gs-3919	272	109	up	up	ADP
gs-3919	272	110	to	to	PART
gs-3919	272	111	2	2	NUM
gs-3919	272	112	points	point	NOUN
gs-3919	272	113	(	(	PUNCT
gs-3919	272	114	rash	rash	ADJ
gs-3919	272	115	,	,	PUNCT
gs-3919	272	116	biopsy	biopsy	NOUN
gs-3919	272	117	,	,	PUNCT
gs-3919	272	118	etc	etc	X
gs-3919	272	119	.	.	X
gs-3919	272	120	)	)	PUNCT
gs-3919	273	1	-2	-2	PUNCT
gs-3919	274	1	2	2	NUM
gs-3919	274	2	systemic	systemic	ADJ
gs-3919	274	3	involvement	involvement	NOUN
gs-3919	274	4	(	(	PUNCT
gs-3919	274	5	liver	liver	NOUN
gs-3919	274	6	,	,	PUNCT
gs-3919	274	7	kidney	kidney	NOUN
gs-3919	274	8	,	,	PUNCT
gs-3919	274	9	lung	lung	NOUN
gs-3919	274	10	,	,	PUNCT
gs-3919	274	11	heart	heart	NOUN
gs-3919	274	12	,	,	PUNCT
gs-3919	274	13	pancreas	pancreas	NOUN
gs-3919	274	14	)	)	PUNCT
gs-3919	274	15	0	0	NUM
gs-3919	274	16	points	point	NOUN
gs-3919	274	17	0	0	NUM
gs-3919	274	18	points	point	NOUN
gs-3919	274	19	2	2	NUM
gs-3919	274	20	points	point	NOUN
gs-3919	274	21	0	0	NUM
gs-3919	274	22	2	2	NUM
gs-3919	274	23	resolution	resolution	NOUN
gs-3919	274	24	time	time	NOUN
gs-3919	274	25	>	>	SYM
gs-3919	274	26	15	15	NUM
gs-3919	274	27	days	day	NOUN
gs-3919	274	28	-1	-1	ADP
gs-3919	274	29	point	point	NOUN
gs-3919	274	30	0	0	NUM
gs-3919	274	31	points	point	NOUN
gs-3919	274	32	0	0	NUM
gs-3919	274	33	points	point	NOUN
gs-3919	274	34	-1	-1	NOUN
gs-3919	274	35	0	0	NUM
gs-3919	275	1	other	other	ADJ
gs-3919	275	2	causes	cause	NOUN
gs-3919	275	3	excluded	exclude	VERB
gs-3919	275	4	(	(	PUNCT
gs-3919	275	5	infections	infection	NOUN
gs-3919	275	6	,	,	PUNCT
gs-3919	275	7	antibodies	antibodie	VERB
gs-3919	275	8	)	)	PUNCT
gs-3919	275	9	0	0	NUM
gs-3919	275	10	points	point	NOUN
gs-3919	275	11	0	0	NUM
gs-3919	275	12	points	point	NOUN
gs-3919	275	13	1	1	NUM
gs-3919	275	14	point	point	NOUN
gs-3919	275	15	0	0	NUM
gs-3919	275	16	1	1	NUM
gs-3919	275	17	georgian	georgian	ADJ
gs-3919	275	18	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	275	19	მეცნიერები	მეცნიერები	NOUN
gs-3919	275	20	ტ.	ტ.	VERB
gs-3919	275	21	7	7	NUM
gs-3919	275	22	n	n	PRON
gs-3919	275	23	3	3	NUM
gs-3919	275	24	,	,	PUNCT
gs-3919	275	25	2025	2025	NUM
gs-3919	275	26	158	158	NUM
gs-3919	275	27	table3	table3	PROPN
gs-3919	275	28	.	.	PUNCT
gs-3919	276	1	total	total	ADJ
gs-3919	276	2	score	score	NOUN
gs-3919	276	3	interpretation	interpretation	NOUN
gs-3919	276	4	:	:	PUNCT
gs-3919	276	5	total	total	ADJ
gs-3919	276	6	score	score	NOUN
gs-3919	276	7	diagnosis	diagnosis	NOUN
gs-3919	276	8	<	<	X
gs-3919	276	9	2	2	NUM
gs-3919	276	10	dress	dress	NOUN
gs-3919	276	11	excluded	exclude	VERB
gs-3919	276	12	2	2	NUM
gs-3919	276	13	–	–	PUNCT
gs-3919	276	14	3	3	NUM
gs-3919	276	15	possible	possible	ADJ
gs-3919	276	16	dress	dress	NOUN
gs-3919	276	17	4	4	NUM
gs-3919	276	18	–	–	SYM
gs-3919	276	19	5	5	NUM
gs-3919	276	20	probable	probable	ADJ
gs-3919	276	21	dress	dress	NOUN
gs-3919	276	22	>	>	X
gs-3919	276	23	5	5	NUM
gs-3919	276	24	definite	definite	ADJ
gs-3919	276	25	dress	dress	NOUN
gs-3919	276	26	the	the	DET
gs-3919	276	27	study	study	NOUN
gs-3919	276	28	emphasize	emphasize	VERB
gs-3919	276	29	the	the	DET
gs-3919	276	30	importance	importance	NOUN
gs-3919	276	31	of	of	ADP
gs-3919	276	32	early	early	ADJ
gs-3919	276	33	identification	identification	NOUN
gs-3919	276	34	of	of	ADP
gs-3919	276	35	systemic	systemic	ADJ
gs-3919	276	36	features	feature	NOUN
gs-3919	276	37	,	,	PUNCT
gs-3919	276	38	especially	especially	ADV
gs-3919	276	39	in	in	ADP
gs-3919	276	40	patients	patient	NOUN
gs-3919	276	41	presenting	present	VERB
gs-3919	276	42	with	with	ADP
gs-3919	276	43	late	late	ADJ
gs-3919	276	44	-	-	PUNCT
gs-3919	276	45	onset	onset	NOUN
gs-3919	276	46	rash	rash	NOUN
gs-3919	276	47	following	follow	VERB
gs-3919	276	48	drug	drug	NOUN
gs-3919	276	49	initiation	initiation	NOUN
gs-3919	276	50	.	.	PUNCT
gs-3919	277	1	these	these	DET
gs-3919	277	2	findings	finding	NOUN
gs-3919	277	3	underscore	underscore	VERB
gs-3919	277	4	the	the	DET
gs-3919	277	5	need	need	NOUN
gs-3919	277	6	for	for	ADP
gs-3919	277	7	increased	increase	VERB
gs-3919	277	8	clinician	clinician	NOUN
gs-3919	277	9	vigilance	vigilance	NOUN
gs-3919	277	10	in	in	ADP
gs-3919	277	11	patients	patient	NOUN
gs-3919	277	12	exhibiting	exhibit	VERB
gs-3919	277	13	signs	sign	NOUN
gs-3919	277	14	suggestive	suggestive	ADJ
gs-3919	277	15	of	of	ADP
gs-3919	277	16	immune	immune	NOUN
gs-3919	277	17	-	-	PUNCT
gs-3919	277	18	mediated	mediate	VERB
gs-3919	277	19	drug	drug	NOUN
gs-3919	277	20	reactions	reaction	NOUN
gs-3919	277	21	.	.	PUNCT
gs-3919	278	1	treatment	treatment	NOUN
gs-3919	278	2	and	and	CCONJ
gs-3919	278	3	prognosis	prognosis	VERB
gs-3919	278	4	the	the	DET
gs-3919	278	5	cornerstone	cornerstone	NOUN
gs-3919	278	6	of	of	ADP
gs-3919	278	7	dress	dress	NOUN
gs-3919	278	8	treatment	treatment	NOUN
gs-3919	278	9	is	be	AUX
gs-3919	278	10	the	the	DET
gs-3919	278	11	prompt	prompt	ADJ
gs-3919	278	12	withdrawal	withdrawal	NOUN
gs-3919	278	13	of	of	ADP
gs-3919	278	14	the	the	DET
gs-3919	278	15	offending	offend	VERB
gs-3919	278	16	drug	drug	NOUN
gs-3919	278	17	.	.	PUNCT
gs-3919	279	1	systemic	systemic	ADJ
gs-3919	279	2	corticosteroids	corticosteroid	NOUN
gs-3919	279	3	remain	remain	VERB
gs-3919	279	4	the	the	DET
gs-3919	279	5	mainstay	mainstay	NOUN
gs-3919	279	6	therapy	therapy	NOUN
gs-3919	279	7	,	,	PUNCT
gs-3919	279	8	particularly	particularly	ADV
gs-3919	279	9	in	in	ADP
gs-3919	279	10	cases	case	NOUN
gs-3919	279	11	involving	involve	VERB
gs-3919	279	12	internal	internal	ADJ
gs-3919	279	13	organ	organ	NOUN
gs-3919	279	14	damage	damage	NOUN
gs-3919	279	15	.	.	PUNCT
gs-3919	280	1	supportive	supportive	ADJ
gs-3919	280	2	treatments	treatment	NOUN
gs-3919	280	3	may	may	AUX
gs-3919	280	4	include	include	VERB
gs-3919	280	5	antihistamines	antihistamine	NOUN
gs-3919	280	6	,	,	PUNCT
gs-3919	280	7	topical	topical	ADJ
gs-3919	280	8	steroids	steroid	NOUN
gs-3919	280	9	for	for	ADP
gs-3919	280	10	skin	skin	NOUN
gs-3919	280	11	symptoms	symptom	NOUN
gs-3919	280	12	,	,	PUNCT
gs-3919	280	13	and	and	CCONJ
gs-3919	280	14	organ	organ	NOUN
gs-3919	280	15	-	-	PUNCT
gs-3919	280	16	specific	specific	ADJ
gs-3919	280	17	care	care	NOUN
gs-3919	280	18	as	as	SCONJ
gs-3919	280	19	needed	need	VERB
gs-3919	280	20	.	.	PUNCT
gs-3919	281	1	in	in	ADP
gs-3919	281	2	severe	severe	ADJ
gs-3919	281	3	cases	case	NOUN
gs-3919	281	4	involving	involve	VERB
gs-3919	281	5	hepatic	hepatic	NOUN
gs-3919	281	6	,	,	PUNCT
gs-3919	281	7	renal	renal	ADJ
gs-3919	281	8	,	,	PUNCT
gs-3919	281	9	or	or	CCONJ
gs-3919	281	10	cardiac	cardiac	ADJ
gs-3919	281	11	dysfunction	dysfunction	NOUN
gs-3919	281	12	,	,	PUNCT
gs-3919	281	13	additional	additional	ADJ
gs-3919	281	14	interventions	intervention	NOUN
gs-3919	281	15	such	such	ADJ
gs-3919	281	16	as	as	ADP
gs-3919	281	17	intravenous	intravenous	ADJ
gs-3919	281	18	immunoglobulin	immunoglobulin	NOUN
gs-3919	281	19	(	(	PUNCT
gs-3919	281	20	ivig	ivig	NOUN
gs-3919	281	21	)	)	PUNCT
gs-3919	281	22	,	,	PUNCT
gs-3919	281	23	plasmapheresis	plasmapheresis	NOUN
gs-3919	281	24	,	,	PUNCT
gs-3919	281	25	or	or	CCONJ
gs-3919	281	26	immunosuppressants	immunosuppressant	NOUN
gs-3919	281	27	like	like	ADP
gs-3919	281	28	cyclophosphamide	cyclophosphamide	NOUN
gs-3919	281	29	have	have	AUX
gs-3919	281	30	been	be	AUX
gs-3919	281	31	utilized	utilize	VERB
gs-3919	281	32	with	with	ADP
gs-3919	281	33	varying	vary	VERB
gs-3919	281	34	success	success	NOUN
gs-3919	281	35	.	.	PUNCT
gs-3919	282	1	while	while	SCONJ
gs-3919	282	2	most	most	ADJ
gs-3919	282	3	patients	patient	NOUN
gs-3919	282	4	recover	recover	VERB
gs-3919	282	5	with	with	ADP
gs-3919	282	6	appropriate	appropriate	ADJ
gs-3919	282	7	management	management	NOUN
gs-3919	282	8	,	,	PUNCT
gs-3919	282	9	long	long	ADJ
gs-3919	282	10	-	-	PUNCT
gs-3919	282	11	term	term	NOUN
gs-3919	282	12	autoimmune	autoimmune	ADJ
gs-3919	282	13	sequelae	sequelae	NOUN
gs-3919	282	14	can	can	AUX
gs-3919	282	15	occur	occur	VERB
gs-3919	282	16	,	,	PUNCT
gs-3919	282	17	including	include	VERB
gs-3919	282	18	autoimmune	autoimmune	ADJ
gs-3919	282	19	thyroiditis	thyroiditis	NOUN
gs-3919	282	20	,	,	PUNCT
gs-3919	282	21	type	type	NOUN
gs-3919	282	22	1	1	NUM
gs-3919	282	23	diabetes	diabetes	NOUN
gs-3919	282	24	,	,	PUNCT
gs-3919	282	25	and	and	CCONJ
gs-3919	282	26	systemic	systemic	ADJ
gs-3919	282	27	lupus	lupus	NOUN
gs-3919	282	28	erythematosus	erythematosus	NOUN
gs-3919	282	29	-	-	PUNCT
gs-3919	282	30	like	like	ADJ
gs-3919	282	31	conditions	condition	NOUN
gs-3919	282	32	.	.	PUNCT
gs-3919	283	1	mortality	mortality	NOUN
gs-3919	283	2	rates	rate	NOUN
gs-3919	283	3	range	range	VERB
gs-3919	283	4	from	from	ADP
gs-3919	283	5	5	5	NUM
gs-3919	283	6	%	%	NOUN
gs-3919	283	7	to	to	PART
gs-3919	283	8	10	10	NUM
gs-3919	283	9	%	%	NOUN
gs-3919	283	10	,	,	PUNCT
gs-3919	283	11	with	with	ADP
gs-3919	283	12	liver	liver	NOUN
gs-3919	283	13	failure	failure	NOUN
gs-3919	283	14	and	and	CCONJ
gs-3919	283	15	myocarditis	myocarditis	ADJ
gs-3919	283	16	being	be	AUX
gs-3919	283	17	the	the	DET
gs-3919	283	18	leading	lead	VERB
gs-3919	283	19	causes	cause	NOUN
gs-3919	283	20	of	of	ADP
gs-3919	283	21	death	death	NOUN
gs-3919	283	22	.	.	PUNCT
gs-3919	284	1	drug	drug	NOUN
gs-3919	284	2	and	and	CCONJ
gs-3919	284	3	pharmacological	pharmacological	ADJ
gs-3919	284	4	activation	activation	NOUN
gs-3919	284	5	as	as	ADP
gs-3919	284	6	an	an	DET
gs-3919	284	7	extreme	extreme	ADJ
gs-3919	284	8	form	form	NOUN
gs-3919	284	9	of	of	ADP
gs-3919	284	10	drug	drug	NOUN
gs-3919	284	11	hypersensitivity	hypersensitivity	NOUN
gs-3919	284	12	,	,	PUNCT
gs-3919	284	13	dress	dress	NOUN
gs-3919	284	14	syndrome	syndrome	NOUN
gs-3919	284	15	is	be	AUX
gs-3919	284	16	associated	associate	VERB
gs-3919	284	17	with	with	ADP
gs-3919	284	18	complicated	complicated	ADJ
gs-3919	284	19	biochemical	biochemical	NOUN
gs-3919	284	20	as	as	ADV
gs-3919	284	21	well	well	ADV
gs-3919	284	22	as	as	ADP
gs-3919	284	23	immunological	immunological	ADJ
gs-3919	284	24	responses	response	NOUN
gs-3919	284	25	induced	induce	VERB
gs-3919	284	26	by	by	ADP
gs-3919	284	27	the	the	DET
gs-3919	284	28	pharmacological	pharmacological	ADJ
gs-3919	284	29	effect	effect	NOUN
gs-3919	284	30	of	of	ADP
gs-3919	284	31	the	the	DET
gs-3919	284	32	offending	offending	ADJ
gs-3919	284	33	drugs	drug	NOUN
gs-3919	284	34	.	.	PUNCT
gs-3919	285	1	a	a	DET
gs-3919	285	2	number	number	NOUN
gs-3919	285	3	of	of	ADP
gs-3919	285	4	medications	medication	NOUN
gs-3919	285	5	associated	associate	VERB
gs-3919	285	6	with	with	ADP
gs-3919	285	7	dress	dress	NOUN
gs-3919	285	8	require	require	VERB
gs-3919	285	9	cytochrome	cytochrome	ADJ
gs-3919	285	10	p450	p450	NUM
gs-3919	285	11	enzyme	enzyme	NOUN
gs-3919	285	12	–	–	PUNCT
gs-3919	285	13	mediated	mediate	VERB
gs-3919	285	14	metabolic	metabolic	NOUN
gs-3919	285	15	bioactivation	bioactivation	NOUN
gs-3919	285	16	of	of	ADP
gs-3919	285	17	drugs	drug	NOUN
gs-3919	285	18	into	into	ADP
gs-3919	285	19	reactive	reactive	ADJ
gs-3919	285	20	metabolites	metabolite	NOUN
gs-3919	285	21	such	such	ADJ
gs-3919	285	22	as	as	ADP
gs-3919	285	23	haptens	hapten	NOUN
gs-3919	285	24	.	.	PUNCT
gs-3919	286	1	these	these	DET
gs-3919	286	2	reactive	reactive	ADJ
gs-3919	286	3	species	specie	NOUN
gs-3919	286	4	covalently	covalently	ADV
gs-3919	286	5	bind	bind	VERB
gs-3919	286	6	endogenous	endogenous	ADJ
gs-3919	286	7	proteins	protein	NOUN
gs-3919	286	8	,	,	PUNCT
gs-3919	286	9	creating	create	VERB
gs-3919	286	10	neo	neo	ADJ
gs-3919	286	11	-	-	ADJ
gs-3919	286	12	antigenic	antigenic	ADJ
gs-3919	286	13	complexes	complex	NOUN
gs-3919	286	14	that	that	PRON
gs-3919	286	15	activate	activate	VERB
gs-3919	286	16	a	a	DET
gs-3919	286	17	t	t	NOUN
gs-3919	286	18	cell	cell	NOUN
gs-3919	286	19	–	–	PUNCT
gs-3919	286	20	mediated	mediate	VERB
gs-3919	286	21	immune	immune	ADJ
gs-3919	286	22	response	response	NOUN
gs-3919	286	23	.	.	PUNCT
gs-3919	287	1	anticonvulsants	anticonvulsant	NOUN
gs-3919	287	2	(	(	PUNCT
gs-3919	287	3	e.g.	e.g.	ADV
gs-3919	287	4	,	,	PUNCT
gs-3919	287	5	carbamazepine	carbamazepine	NOUN
gs-3919	287	6	,	,	PUNCT
gs-3919	287	7	lamotrigine	lamotrigine	PROPN
gs-3919	287	8	)	)	PUNCT
gs-3919	287	9	and	and	CCONJ
gs-3919	287	10	antigout	antigout	NOUN
gs-3919	287	11	drugs	drug	NOUN
gs-3919	287	12	(	(	PUNCT
gs-3919	287	13	e.g.	e.g.	ADV
gs-3919	287	14	,	,	PUNCT
gs-3919	287	15	allopurinol	allopurinol	NOUN
gs-3919	287	16	)	)	PUNCT
gs-3919	287	17	are	be	AUX
gs-3919	287	18	metabolized	metabolize	VERB
gs-3919	287	19	to	to	ADP
gs-3919	287	20	intermediates	intermediate	NOUN
gs-3919	287	21	that	that	PRON
gs-3919	287	22	may	may	AUX
gs-3919	287	23	alter	alter	VERB
gs-3919	287	24	mitochondrial	mitochondrial	ADJ
gs-3919	287	25	homeostasis	homeostasis	NOUN
gs-3919	287	26	and	and	CCONJ
gs-3919	287	27	trigger	trigger	NOUN
gs-3919	287	28	inflammatory	inflammatory	ADJ
gs-3919	287	29	pathways	pathway	NOUN
gs-3919	287	30	.	.	PUNCT
gs-3919	288	1	the	the	DET
gs-3919	288	2	delay	delay	NOUN
gs-3919	288	3	in	in	ADP
gs-3919	288	4	the	the	DET
gs-3919	288	5	onset	onset	NOUN
gs-3919	288	6	of	of	ADP
gs-3919	288	7	symptoms	symptom	NOUN
gs-3919	288	8	(	(	PUNCT
gs-3919	288	9	2–8	2–8	NUM
gs-3919	288	10	weeks	week	NOUN
gs-3919	288	11	)	)	PUNCT
gs-3919	288	12	following	follow	VERB
gs-3919	288	13	the	the	DET
gs-3919	288	14	initiation	initiation	NOUN
gs-3919	288	15	of	of	ADP
gs-3919	288	16	the	the	DET
gs-3919	288	17	medication	medication	NOUN
gs-3919	288	18	can	can	AUX
gs-3919	288	19	be	be	AUX
gs-3919	288	20	explained	explain	VERB
gs-3919	288	21	by	by	ADP
gs-3919	288	22	long	long	ADJ
gs-3919	288	23	half	half	ADJ
gs-3919	288	24	-	-	PUNCT
gs-3919	288	25	life	life	NOUN
gs-3919	288	26	and	and	CCONJ
gs-3919	288	27	slow	slow	ADJ
gs-3919	288	28	clearance	clearance	NOUN
gs-3919	288	29	of	of	ADP
gs-3919	288	30	some	some	DET
gs-3919	288	31	metabolites	metabolite	NOUN
gs-3919	288	32	.	.	PUNCT
gs-3919	289	1	georgian	georgian	ADJ
gs-3919	289	2	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	289	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	289	4	ტ.	ტ.	VERB
gs-3919	289	5	7	7	NUM
gs-3919	289	6	n	n	PRON
gs-3919	289	7	3	3	NUM
gs-3919	289	8	,	,	PUNCT
gs-3919	289	9	2025	2025	NUM
gs-3919	289	10	159	159	NUM
gs-3919	289	11	in	in	ADP
gs-3919	289	12	addition	addition	NOUN
gs-3919	289	13	,	,	PUNCT
gs-3919	289	14	some	some	DET
gs-3919	289	15	medications	medication	NOUN
gs-3919	289	16	including	include	VERB
gs-3919	289	17	drugs	drug	NOUN
gs-3919	289	18	in	in	ADP
gs-3919	289	19	new	new	ADJ
gs-3919	289	20	classes	class	NOUN
gs-3919	289	21	(	(	PUNCT
gs-3919	289	22	e.g.	e.g.	ADV
gs-3919	289	23	,	,	PUNCT
gs-3919	289	24	pembrolizumab	pembrolizumab	NOUN
gs-3919	289	25	,	,	PUNCT
gs-3919	289	26	apalutamide	apalutamide	ADV
gs-3919	289	27	)	)	PUNCT
gs-3919	289	28	used	use	VERB
gs-3919	289	29	as	as	ADP
gs-3919	289	30	immunotherapy	immunotherapy	NOUN
gs-3919	289	31	or	or	CCONJ
gs-3919	289	32	antineoplastic	antineoplastic	ADJ
gs-3919	289	33	agents	agent	NOUN
gs-3919	289	34	of	of	ADP
gs-3919	289	35	immune	immune	ADJ
gs-3919	289	36	modulation	modulation	NOUN
gs-3919	289	37	(	(	PUNCT
gs-3919	289	38	checkpoint	checkpoint	NOUN
gs-3919	289	39	inhibition	inhibition	NOUN
gs-3919	289	40	)	)	PUNCT
gs-3919	289	41	or	or	CCONJ
gs-3919	289	42	hormonal	hormonal	ADJ
gs-3919	289	43	pathways	pathway	NOUN
gs-3919	289	44	are	be	AUX
gs-3919	289	45	associated	associate	VERB
gs-3919	289	46	with	with	ADP
gs-3919	289	47	the	the	DET
gs-3919	289	48	immune	immune	ADJ
gs-3919	289	49	dysregulation	dysregulation	NOUN
gs-3919	289	50	and	and	CCONJ
gs-3919	289	51	serve	serve	VERB
gs-3919	289	52	as	as	ADP
gs-3919	289	53	novel	novel	NOUN
gs-3919	289	54	mechanistic	mechanistic	ADJ
gs-3919	289	55	pathways	pathway	NOUN
gs-3919	289	56	in	in	ADP
gs-3919	289	57	dress	dress	NOUN
gs-3919	289	58	pathogenesis	pathogenesis	NOUN
gs-3919	289	59	.	.	PUNCT
gs-3919	290	1	it	it	PRON
gs-3919	290	2	is	be	AUX
gs-3919	290	3	critically	critically	ADV
gs-3919	290	4	important	important	ADJ
gs-3919	290	5	to	to	PART
gs-3919	290	6	understand	understand	VERB
gs-3919	290	7	these	these	DET
gs-3919	290	8	molecular	molecular	ADJ
gs-3919	290	9	triggers	trigger	NOUN
gs-3919	290	10	since	since	SCONJ
gs-3919	290	11	it	it	PRON
gs-3919	290	12	may	may	AUX
gs-3919	290	13	shape	shape	VERB
gs-3919	290	14	early	early	ADJ
gs-3919	290	15	detection	detection	NOUN
gs-3919	290	16	and	and	CCONJ
gs-3919	290	17	the	the	DET
gs-3919	290	18	emergence	emergence	NOUN
gs-3919	290	19	of	of	ADP
gs-3919	290	20	preventive	preventive	ADJ
gs-3919	290	21	strategies	strategy	NOUN
gs-3919	290	22	towards	towards	ADP
gs-3919	290	23	at	at	ADP
gs-3919	290	24	-	-	PUNCT
gs-3919	290	25	risk	risk	NOUN
gs-3919	290	26	patients	patient	NOUN
gs-3919	290	27	.	.	PUNCT
gs-3919	291	1	organ	organ	VERB
gs-3919	291	2	specific	specific	ADJ
gs-3919	291	3	symptoms	symptom	NOUN
gs-3919	291	4	and	and	CCONJ
gs-3919	291	5	severity	severity	NOUN
gs-3919	291	6	of	of	ADP
gs-3919	291	7	the	the	DET
gs-3919	291	8	disease	disease	NOUN
gs-3919	291	9	dress	dress	NOUN
gs-3919	291	10	is	be	AUX
gs-3919	291	11	characterized	characterize	VERB
gs-3919	291	12	by	by	ADP
gs-3919	291	13	multi	multi	ADJ
gs-3919	291	14	-	-	ADJ
gs-3919	291	15	organ	organ	ADJ
gs-3919	291	16	involvement	involvement	NOUN
gs-3919	291	17	,	,	PUNCT
gs-3919	291	18	presenting	present	VERB
gs-3919	291	19	with	with	ADP
gs-3919	291	20	wide	wide	ADJ
gs-3919	291	21	array	array	NOUN
gs-3919	291	22	of	of	ADP
gs-3919	291	23	clinical	clinical	ADJ
gs-3919	291	24	phenotypes	phenotype	NOUN
gs-3919	291	25	from	from	ADP
gs-3919	291	26	merely	merely	ADV
gs-3919	291	27	rash	rash	ADJ
gs-3919	291	28	to	to	ADP
gs-3919	291	29	life	life	NOUN
gs-3919	291	30	-	-	PUNCT
gs-3919	291	31	threatening	threaten	VERB
gs-3919	291	32	organ	organ	NOUN
gs-3919	291	33	failure	failure	NOUN
gs-3919	291	34	.	.	PUNCT
gs-3919	292	1	skin	skin	NOUN
gs-3919	292	2	findings	finding	NOUN
gs-3919	292	3	are	be	AUX
gs-3919	292	4	also	also	ADV
gs-3919	292	5	most	most	ADV
gs-3919	292	6	prominent	prominent	ADJ
gs-3919	292	7	and	and	CCONJ
gs-3919	292	8	typically	typically	ADV
gs-3919	292	9	widespread	widespread	ADJ
gs-3919	292	10	morbilliform	morbilliform	NOUN
gs-3919	292	11	eruptions	eruption	NOUN
gs-3919	292	12	associated	associate	VERB
gs-3919	292	13	with	with	ADP
gs-3919	292	14	facial	facial	ADJ
gs-3919	292	15	swelling	swelling	NOUN
gs-3919	292	16	and	and	CCONJ
gs-3919	292	17	mucosal	mucosal	NOUN
gs-3919	292	18	involvement	involvement	NOUN
gs-3919	292	19	.	.	PUNCT
gs-3919	293	1	histopathological	histopathological	ADJ
gs-3919	293	2	,	,	PUNCT
gs-3919	293	3	interface	interface	NOUN
gs-3919	293	4	dermatitis	dermatitis	NOUN
gs-3919	293	5	with	with	ADP
gs-3919	293	6	eosinophilic	eosinophilic	ADJ
gs-3919	293	7	infiltration	infiltration	NOUN
gs-3919	293	8	is	be	AUX
gs-3919	293	9	common	common	ADJ
gs-3919	293	10	.	.	PUNCT
gs-3919	294	1	liver	liver	NOUN
gs-3919	294	2	is	be	AUX
gs-3919	294	3	the	the	DET
gs-3919	294	4	most	most	ADV
gs-3919	294	5	common	common	ADJ
gs-3919	294	6	internal	internal	ADJ
gs-3919	294	7	organ	organ	NOUN
gs-3919	294	8	affected	affected	ADJ
gs-3919	294	9	and	and	CCONJ
gs-3919	294	10	hepatocellular	hepatocellular	ADJ
gs-3919	294	11	damage	damage	NOUN
gs-3919	294	12	occurs	occur	VERB
gs-3919	294	13	in	in	ADP
gs-3919	294	14	over	over	ADP
gs-3919	294	15	60	60	NUM
gs-3919	294	16	%	%	NOUN
gs-3919	294	17	of	of	ADP
gs-3919	294	18	the	the	DET
gs-3919	294	19	infected	infected	ADJ
gs-3919	294	20	humans	human	NOUN
gs-3919	294	21	.	.	PUNCT
gs-3919	295	1	marked	mark	VERB
gs-3919	295	2	hepatic	hepatic	ADJ
gs-3919	295	3	involvement	involvement	NOUN
gs-3919	295	4	,	,	PUNCT
gs-3919	295	5	fulminant	fulminant	ADJ
gs-3919	295	6	hepatitis	hepatitis	NOUN
gs-3919	295	7	and	and	CCONJ
gs-3919	295	8	acute	acute	ADJ
gs-3919	295	9	liver	liver	NOUN
gs-3919	295	10	failure	failure	NOUN
gs-3919	295	11	are	be	AUX
gs-3919	295	12	the	the	DET
gs-3919	295	13	potential	potential	NOUN
gs-3919	295	14	for	for	ADP
gs-3919	295	15	severe	severe	ADJ
gs-3919	295	16	risks	risk	NOUN
gs-3919	295	17	of	of	ADP
gs-3919	295	18	mortality	mortality	NOUN
gs-3919	295	19	.	.	PUNCT
gs-3919	296	1	biochemistry	biochemistry	NOUN
gs-3919	296	2	studies	study	NOUN
gs-3919	296	3	often	often	ADV
gs-3919	296	4	show	show	VERB
gs-3919	296	5	increases	increase	NOUN
gs-3919	296	6	in	in	ADP
gs-3919	296	7	transaminases	transaminase	NOUN
gs-3919	296	8	,	,	PUNCT
gs-3919	296	9	bilirubin	bilirubin	NOUN
gs-3919	296	10	,	,	PUNCT
gs-3919	296	11	and	and	CCONJ
gs-3919	296	12	coagulation	coagulation	NOUN
gs-3919	296	13	time	time	NOUN
gs-3919	296	14	.	.	PUNCT
gs-3919	297	1	renal	renal	ADJ
gs-3919	297	2	disease	disease	NOUN
gs-3919	297	3	occurs	occur	VERB
gs-3919	297	4	in	in	ADP
gs-3919	297	5	about	about	ADV
gs-3919	297	6	a	a	PRON
gs-3919	297	7	quarter	quarter	NOUN
gs-3919	297	8	of	of	ADP
gs-3919	297	9	cases	case	NOUN
gs-3919	297	10	,	,	PUNCT
gs-3919	297	11	typically	typically	ADV
gs-3919	297	12	as	as	ADP
gs-3919	297	13	acute	acute	ADJ
gs-3919	297	14	interstitial	interstitial	ADJ
gs-3919	297	15	nephritis	nephritis	NOUN
gs-3919	297	16	or	or	CCONJ
gs-3919	297	17	acute	acute	ADJ
gs-3919	297	18	tubular	tubular	ADJ
gs-3919	297	19	necrosis	necrosis	NOUN
gs-3919	297	20	,	,	PUNCT
gs-3919	297	21	and	and	CCONJ
gs-3919	297	22	severe	severe	ADJ
gs-3919	297	23	cases	case	NOUN
gs-3919	297	24	may	may	AUX
gs-3919	297	25	require	require	VERB
gs-3919	297	26	supportive	supportive	ADJ
gs-3919	297	27	dialysis	dialysis	NOUN
gs-3919	297	28	.	.	PUNCT
gs-3919	298	1	pulmonary	pulmonary	ADJ
gs-3919	298	2	infection	infection	NOUN
gs-3919	298	3	,	,	PUNCT
gs-3919	298	4	less	less	ADV
gs-3919	298	5	common	common	ADJ
gs-3919	298	6	than	than	ADP
gs-3919	298	7	cardiac	cardiac	ADJ
gs-3919	298	8	,	,	PUNCT
gs-3919	298	9	is	be	AUX
gs-3919	298	10	clinically	clinically	ADV
gs-3919	298	11	important	important	ADJ
gs-3919	298	12	,	,	PUNCT
gs-3919	298	13	with	with	ADP
gs-3919	298	14	the	the	DET
gs-3919	298	15	spectrum	spectrum	NOUN
gs-3919	298	16	of	of	ADP
gs-3919	298	17	severity	severity	NOUN
gs-3919	298	18	being	be	AUX
gs-3919	298	19	from	from	ADP
gs-3919	298	20	mild	mild	ADJ
gs-3919	298	21	pneumonitis	pneumonitis	NOUN
gs-3919	298	22	to	to	ADP
gs-3919	298	23	severe	severe	ADJ
gs-3919	298	24	ards	ard	NOUN
gs-3919	298	25	that	that	PRON
gs-3919	298	26	is	be	AUX
gs-3919	298	27	related	relate	VERB
gs-3919	298	28	to	to	ADP
gs-3919	298	29	a	a	DET
gs-3919	298	30	worse	bad	ADJ
gs-3919	298	31	prognosis	prognosis	NOUN
gs-3919	298	32	.	.	PUNCT
gs-3919	299	1	rare	rare	ADJ
gs-3919	299	2	cardiovascular	cardiovascular	ADJ
gs-3919	299	3	and	and	CCONJ
gs-3919	299	4	neurologic	neurologic	ADJ
gs-3919	299	5	complications	complication	NOUN
gs-3919	299	6	,	,	PUNCT
gs-3919	299	7	including	include	VERB
gs-3919	299	8	myocarditis	myocarditis	ADJ
gs-3919	299	9	and	and	CCONJ
gs-3919	299	10	encephalopathy	encephalopathy	NOUN
gs-3919	299	11	,	,	PUNCT
gs-3919	299	12	have	have	AUX
gs-3919	299	13	been	be	AUX
gs-3919	299	14	described	describe	VERB
gs-3919	299	15	and	and	CCONJ
gs-3919	299	16	may	may	AUX
gs-3919	299	17	be	be	AUX
gs-3919	299	18	a	a	DET
gs-3919	299	19	reflection	reflection	NOUN
gs-3919	299	20	of	of	ADP
gs-3919	299	21	systemic	systemic	ADJ
gs-3919	299	22	immune	immune	ADJ
gs-3919	299	23	activation	activation	NOUN
gs-3919	299	24	or	or	CCONJ
gs-3919	299	25	direct	direct	ADJ
gs-3919	299	26	drug	drug	NOUN
gs-3919	299	27	toxicities	toxicity	NOUN
gs-3919	299	28	.	.	PUNCT
gs-3919	300	1	the	the	DET
gs-3919	300	2	wide	wide	ADJ
gs-3919	300	3	variability	variability	NOUN
gs-3919	300	4	of	of	ADP
gs-3919	300	5	organ	organ	NOUN
gs-3919	300	6	involvement	involvement	NOUN
gs-3919	300	7	further	far	ADV
gs-3919	300	8	underscores	underscore	VERB
gs-3919	300	9	that	that	SCONJ
gs-3919	300	10	a	a	DET
gs-3919	300	11	comprehensive	comprehensive	ADJ
gs-3919	300	12	and	and	CCONJ
gs-3919	300	13	multidisciplinary	multidisciplinary	ADJ
gs-3919	300	14	diagnostic	diagnostic	ADJ
gs-3919	300	15	and	and	CCONJ
gs-3919	300	16	treatment	treatment	NOUN
gs-3919	300	17	approach	approach	NOUN
gs-3919	300	18	is	be	AUX
gs-3919	300	19	warranted	warrant	VERB
gs-3919	300	20	.	.	PUNCT
gs-3919	301	1	genetic	genetic	ADJ
gs-3919	301	2	susceptibility	susceptibility	NOUN
gs-3919	301	3	and	and	CCONJ
gs-3919	301	4	pharmacogenetics	pharmacogenetic	NOUN
gs-3919	301	5	host	host	NOUN
gs-3919	301	6	genetics	genetic	NOUN
gs-3919	301	7	in	in	ADP
gs-3919	301	8	dress	dress	NOUN
gs-3919	301	9	is	be	AUX
gs-3919	301	10	becoming	become	VERB
gs-3919	301	11	more	more	ADV
gs-3919	301	12	prominent	prominent	ADJ
gs-3919	301	13	and	and	CCONJ
gs-3919	301	14	hla	hla	NOUN
gs-3919	301	15	alleles	allele	NOUN
gs-3919	301	16	are	be	AUX
gs-3919	301	17	crucial	crucial	ADJ
gs-3919	301	18	in	in	ADP
gs-3919	301	19	predisposition	predisposition	NOUN
gs-3919	301	20	.	.	PUNCT
gs-3919	302	1	the	the	DET
gs-3919	302	2	hla	hla	NOUN
gs-3919	302	3	-	-	PUNCT
gs-3919	302	4	b58	b58	NOUN
gs-3919	302	5	;	;	PUNCT
gs-3919	302	6	01	01	NUM
gs-3919	302	7	allele	allele	NOUN
gs-3919	302	8	is	be	AUX
gs-3919	302	9	one	one	NUM
gs-3919	302	10	of	of	ADP
gs-3919	302	11	the	the	DET
gs-3919	302	12	strongest	strong	ADJ
gs-3919	302	13	genetic	genetic	ADJ
gs-3919	302	14	risk	risk	NOUN
gs-3919	302	15	factors	factor	NOUN
gs-3919	302	16	for	for	ADP
gs-3919	302	17	allopurinol	allopurinol	NOUN
gs-3919	302	18	-	-	PUNCT
gs-3919	302	19	induced	induce	VERB
gs-3919	302	20	dress	dress	NOUN
gs-3919	302	21	,	,	PUNCT
gs-3919	302	22	particularly	particularly	ADV
gs-3919	302	23	in	in	ADP
gs-3919	302	24	east	east	ADJ
gs-3919	302	25	-	-	PUNCT
gs-3919	302	26	asian	asian	ADJ
gs-3919	302	27	populations	population	NOUN
gs-3919	302	28	.	.	PUNCT
gs-3919	303	1	pretherapy	pretherapy	NOUN
gs-3919	303	2	screening	screening	NOUN
gs-3919	303	3	of	of	ADP
gs-3919	303	4	this	this	DET
gs-3919	303	5	allele	allele	NOUN
gs-3919	303	6	has	have	AUX
gs-3919	303	7	been	be	AUX
gs-3919	303	8	shown	show	VERB
gs-3919	303	9	to	to	PART
gs-3919	303	10	dramatically	dramatically	ADV
gs-3919	303	11	reduce	reduce	VERB
gs-3919	303	12	rates	rate	NOUN
gs-3919	303	13	of	of	ADP
gs-3919	303	14	this	this	DET
gs-3919	303	15	adverse	adverse	ADJ
gs-3919	303	16	reaction	reaction	NOUN
gs-3919	303	17	,	,	PUNCT
gs-3919	303	18	with	with	ADP
gs-3919	303	19	allopurinol	allopurinol	NOUN
gs-3919	303	20	being	be	AUX
gs-3919	303	21	one	one	NUM
gs-3919	303	22	of	of	ADP
gs-3919	303	23	the	the	DET
gs-3919	303	24	few	few	ADJ
gs-3919	303	25	examples	example	NOUN
gs-3919	303	26	of	of	ADP
gs-3919	303	27	an	an	DET
gs-3919	303	28	effective	effective	ADJ
gs-3919	303	29	pharmacogenomic	pharmacogenomic	ADJ
gs-3919	303	30	therapy	therapy	NOUN
gs-3919	303	31	.	.	PUNCT
gs-3919	304	1	another	another	DET
gs-3919	304	2	example	example	NOUN
gs-3919	304	3	is	be	AUX
gs-3919	304	4	that	that	PRON
gs-3919	304	5	hla	hla	PROPN
gs-3919	304	6	-	-	PUNCT
gs-3919	304	7	b15;02	b15;02	PROPN
gs-3919	304	8	and	and	CCONJ
gs-3919	304	9	hla	hla	NOUN
gs-3919	304	10	-	-	PUNCT
gs-3919	304	11	a31;01	a31;01	NOUN
gs-3919	304	12	are	be	AUX
gs-3919	304	13	associated	associate	VERB
gs-3919	304	14	with	with	ADP
gs-3919	304	15	carbamazepine	carbamazepine	NOUN
gs-3919	304	16	-	-	PUNCT
gs-3919	304	17	induced	induce	VERB
gs-3919	304	18	hypersensitivity	hypersensitivity	NOUN
gs-3919	304	19	across	across	ADP
gs-3919	304	20	ethnic	ethnic	ADJ
gs-3919	304	21	groups	group	NOUN
gs-3919	304	22	,	,	PUNCT
gs-3919	304	23	indicating	indicate	VERB
gs-3919	304	24	the	the	DET
gs-3919	304	25	genetic	genetic	ADJ
gs-3919	304	26	diversity	diversity	NOUN
gs-3919	304	27	of	of	ADP
gs-3919	304	28	dress	dress	NOUN
gs-3919	304	29	(	(	PUNCT
gs-3919	304	30	saxena	saxena	PROPN
gs-3919	304	31	&	&	CCONJ
gs-3919	304	32	singh	singh	PROPN
gs-3919	304	33	,	,	PUNCT
gs-3919	304	34	2021	2021	NUM
gs-3919	304	35	)	)	PUNCT
gs-3919	304	36	.	.	PUNCT
gs-3919	305	1	that	that	PRON
gs-3919	305	2	said	say	VERB
gs-3919	305	3	,	,	PUNCT
gs-3919	305	4	the	the	DET
gs-3919	305	5	association	association	NOUN
gs-3919	305	6	of	of	ADP
gs-3919	305	7	particular	particular	ADJ
gs-3919	305	8	hla	hla	PROPN
gs-3919	305	9	alleles	allele	NOUN
gs-3919	305	10	with	with	ADP
gs-3919	305	11	drug	drug	NOUN
gs-3919	305	12	hypersensitivity	hypersensitivity	NOUN
gs-3919	305	13	is	be	AUX
gs-3919	305	14	not	not	PART
gs-3919	305	15	always	always	ADV
gs-3919	305	16	straightforward	straightforward	ADJ
gs-3919	305	17	and	and	CCONJ
gs-3919	305	18	known	know	VERB
gs-3919	305	19	to	to	PART
gs-3919	305	20	be	be	AUX
gs-3919	305	21	population	population	NOUN
gs-3919	305	22	or	or	CCONJ
gs-3919	305	23	drug	drug	NOUN
gs-3919	305	24	dependent	dependent	ADJ
gs-3919	305	25	.	.	PUNCT
gs-3919	306	1	application	application	NOUN
gs-3919	306	2	of	of	ADP
gs-3919	306	3	pharmacogenomic	pharmacogenomic	ADJ
gs-3919	306	4	testing	testing	NOUN
gs-3919	306	5	in	in	ADP
gs-3919	306	6	other	other	ADJ
gs-3919	306	7	drugs	drug	NOUN
gs-3919	306	8	,	,	PUNCT
gs-3919	306	9	including	include	VERB
gs-3919	306	10	allopurinol	allopurinol	NOUN
gs-3919	306	11	and	and	CCONJ
gs-3919	306	12	carbamazepine	carbamazepine	NOUN
gs-3919	306	13	,	,	PUNCT
gs-3919	306	14	outside	outside	ADP
gs-3919	306	15	clinical	clinical	ADJ
gs-3919	306	16	trials	trial	NOUN
gs-3919	306	17	is	be	AUX
gs-3919	306	18	infrequent	infrequent	ADJ
gs-3919	306	19	.	.	PUNCT
gs-3919	307	1	widespread	widespread	ADJ
gs-3919	307	2	use	use	NOUN
gs-3919	307	3	could	could	AUX
gs-3919	307	4	lead	lead	VERB
gs-3919	307	5	to	to	ADP
gs-3919	307	6	georgian	georgian	ADJ
gs-3919	307	7	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	307	8	მეცნიერები	მეცნიერები	NOUN
gs-3919	307	9	ტ.	ტ.	VERB
gs-3919	307	10	7	7	NUM
gs-3919	307	11	n	n	DET
gs-3919	307	12	3	3	NUM
gs-3919	307	13	,	,	PUNCT
gs-3919	307	14	2025	2025	NUM
gs-3919	307	15	160	160	NUM
gs-3919	307	16	personalized	personalized	ADJ
gs-3919	307	17	prescribing	prescribing	NOUN
gs-3919	307	18	,	,	PUNCT
gs-3919	307	19	reducing	reduce	VERB
gs-3919	307	20	potential	potential	ADJ
gs-3919	307	21	risks	risk	NOUN
gs-3919	307	22	.	.	PUNCT
gs-3919	308	1	however	however	ADV
gs-3919	308	2	,	,	PUNCT
gs-3919	308	3	issues	issue	NOUN
gs-3919	308	4	exist	exist	VERB
gs-3919	308	5	such	such	ADJ
gs-3919	308	6	as	as	ADP
gs-3919	308	7	cost	cost	NOUN
gs-3919	308	8	,	,	PUNCT
gs-3919	308	9	low	low	ADJ
gs-3919	308	10	levels	level	NOUN
gs-3919	308	11	of	of	ADP
gs-3919	308	12	information	information	NOUN
gs-3919	308	13	,	,	PUNCT
gs-3919	308	14	and	and	CCONJ
gs-3919	308	15	requirements	requirement	NOUN
gs-3919	308	16	for	for	ADP
gs-3919	308	17	population	population	NOUN
gs-3919	308	18	-	-	PUNCT
gs-3919	308	19	specific	specific	ADJ
gs-3919	308	20	validation	validation	NOUN
gs-3919	308	21	studies	study	NOUN
gs-3919	308	22	.	.	PUNCT
gs-3919	309	1	intervention	intervention	NOUN
gs-3919	309	2	and	and	CCONJ
gs-3919	309	3	treatment	treatment	NOUN
gs-3919	309	4	outcomes	outcome	NOUN
gs-3919	309	5	the	the	DET
gs-3919	309	6	first	first	ADJ
gs-3919	309	7	and	and	CCONJ
gs-3919	309	8	foremost	foremost	ADJ
gs-3919	309	9	therapy	therapy	NOUN
gs-3919	309	10	,	,	PUNCT
gs-3919	309	11	however	however	ADV
gs-3919	309	12	,	,	PUNCT
gs-3919	309	13	is	be	AUX
gs-3919	309	14	to	to	PART
gs-3919	309	15	stop	stop	VERB
gs-3919	309	16	the	the	DET
gs-3919	309	17	offending	offending	ADJ
gs-3919	309	18	agent	agent	NOUN
gs-3919	309	19	,	,	PUNCT
gs-3919	309	20	with	with	ADP
gs-3919	309	21	subsequent	subsequent	ADJ
gs-3919	309	22	recovery	recovery	NOUN
gs-3919	309	23	occurring	occur	VERB
gs-3919	309	24	in	in	ADP
gs-3919	309	25	most	most	ADJ
gs-3919	309	26	cases	case	NOUN
gs-3919	309	27	.	.	PUNCT
gs-3919	310	1	systemic	systemic	ADJ
gs-3919	310	2	corticosteroids	corticosteroid	NOUN
gs-3919	310	3	are	be	AUX
gs-3919	310	4	the	the	DET
gs-3919	310	5	mainstay	mainstay	NOUN
gs-3919	310	6	of	of	ADP
gs-3919	310	7	pharmacologic	pharmacologic	ADJ
gs-3919	310	8	treatment	treatment	NOUN
gs-3919	310	9	for	for	ADP
gs-3919	310	10	dress	dress	NOUN
gs-3919	310	11	,	,	PUNCT
gs-3919	310	12	because	because	SCONJ
gs-3919	310	13	a	a	DET
gs-3919	310	14	t	t	NOUN
gs-3919	310	15	cell	cell	NOUN
gs-3919	310	16	-	-	PUNCT
gs-3919	310	17	mediated	mediate	VERB
gs-3919	310	18	mechanism	mechanism	NOUN
gs-3919	310	19	for	for	ADP
gs-3919	310	20	its	its	PRON
gs-3919	310	21	development	development	NOUN
gs-3919	310	22	is	be	AUX
gs-3919	310	23	likely	likely	ADJ
gs-3919	310	24	.	.	PUNCT
gs-3919	311	1	they	they	PRON
gs-3919	311	2	have	have	VERB
gs-3919	311	3	an	an	DET
gs-3919	311	4	immunosuppressive	immunosuppressive	ADJ
gs-3919	311	5	effect	effect	NOUN
gs-3919	311	6	by	by	ADP
gs-3919	311	7	decreasing	decrease	VERB
gs-3919	311	8	cytokine	cytokine	ADJ
gs-3919	311	9	production	production	NOUN
gs-3919	311	10	and	and	CCONJ
gs-3919	311	11	inhibiting	inhibit	VERB
gs-3919	311	12	t	t	NOUN
gs-3919	311	13	-	-	PUNCT
gs-3919	311	14	cell	cell	NOUN
gs-3919	311	15	activation	activation	NOUN
gs-3919	311	16	,	,	PUNCT
gs-3919	311	17	thus	thus	ADV
gs-3919	311	18	mitigating	mitigate	VERB
gs-3919	311	19	both	both	CCONJ
gs-3919	311	20	cutaneous	cutaneous	ADJ
gs-3919	311	21	and	and	CCONJ
gs-3919	311	22	systemic	systemic	ADJ
gs-3919	311	23	inflammation	inflammation	NOUN
gs-3919	311	24	the	the	DET
gs-3919	311	25	majority	majority	NOUN
gs-3919	311	26	of	of	ADP
gs-3919	311	27	case	case	NOUN
gs-3919	311	28	series	series	NOUN
gs-3919	311	29	describe	describe	VERB
gs-3919	311	30	a	a	DET
gs-3919	311	31	favourable	favourable	ADJ
gs-3919	311	32	response	response	NOUN
gs-3919	311	33	to	to	ADP
gs-3919	311	34	corticosteroids	corticosteroid	NOUN
gs-3919	311	35	that	that	PRON
gs-3919	311	36	are	be	AUX
gs-3919	311	37	usually	usually	ADV
gs-3919	311	38	initiated	initiate	VERB
gs-3919	311	39	at	at	ADP
gs-3919	311	40	a	a	DET
gs-3919	311	41	dose	dose	NOUN
gs-3919	311	42	of	of	ADP
gs-3919	311	43	between	between	ADP
gs-3919	311	44	0.5	0.5	NUM
gs-3919	311	45	and	and	CCONJ
gs-3919	311	46	1.5	1.5	NUM
gs-3919	311	47	mg	mg	NUM
gs-3919	311	48	/	/	SYM
gs-3919	311	49	kg	kg	PROPN
gs-3919	311	50	of	of	ADP
gs-3919	311	51	prednisone	prednisone	NOUN
gs-3919	311	52	or	or	CCONJ
gs-3919	311	53	equivalent	equivalent	ADJ
gs-3919	311	54	and	and	CCONJ
gs-3919	311	55	tapered	taper	VERB
gs-3919	311	56	over	over	ADP
gs-3919	311	57	weeks	week	NOUN
gs-3919	311	58	to	to	ADP
gs-3919	311	59	months	month	NOUN
gs-3919	311	60	according	accord	VERB
gs-3919	311	61	to	to	ADP
gs-3919	311	62	clinical	clinical	ADJ
gs-3919	311	63	response	response	NOUN
gs-3919	311	64	.	.	PUNCT
gs-3919	312	1	but	but	CCONJ
gs-3919	312	2	the	the	DET
gs-3919	312	3	ideal	ideal	PROPN
gs-3919	312	4	dose	dose	NOUN
gs-3919	312	5	and	and	CCONJ
gs-3919	312	6	duration	duration	NOUN
gs-3919	312	7	remains	remain	VERB
gs-3919	312	8	to	to	PART
gs-3919	312	9	be	be	AUX
gs-3919	312	10	definitively	definitively	ADV
gs-3919	312	11	established	establish	VERB
gs-3919	312	12	by	by	ADP
gs-3919	312	13	randomized	randomized	ADJ
gs-3919	312	14	controlled	control	VERB
gs-3919	312	15	trials	trial	NOUN
gs-3919	312	16	.	.	PUNCT
gs-3919	313	1	rapid	rapid	ADJ
gs-3919	313	2	tapering	tapering	NOUN
gs-3919	313	3	of	of	ADP
gs-3919	313	4	the	the	DET
gs-3919	313	5	corticosteroid	corticosteroid	NOUN
gs-3919	313	6	would	would	AUX
gs-3919	313	7	risk	risk	VERB
gs-3919	313	8	reactivation	reactivation	NOUN
gs-3919	313	9	,	,	PUNCT
gs-3919	313	10	and	and	CCONJ
gs-3919	313	11	long	long	ADJ
gs-3919	313	12	-	-	PUNCT
gs-3919	313	13	term	term	NOUN
gs-3919	313	14	use	use	NOUN
gs-3919	313	15	of	of	ADP
gs-3919	313	16	corticosteroids	corticosteroid	NOUN
gs-3919	313	17	has	have	AUX
gs-3919	313	18	established	establish	VERB
gs-3919	313	19	lethal	lethal	ADJ
gs-3919	313	20	side	side	NOUN
gs-3919	313	21	effects	effect	NOUN
gs-3919	313	22	including	include	VERB
gs-3919	313	23	infections	infection	NOUN
gs-3919	313	24	,	,	PUNCT
gs-3919	313	25	osteoporosis	osteoporosis	NOUN
gs-3919	313	26	,	,	PUNCT
gs-3919	313	27	and	and	CCONJ
gs-3919	313	28	metabolic	metabolic	NOUN
gs-3919	313	29	disturbances	disturbance	NOUN
gs-3919	313	30	.	.	PUNCT
gs-3919	314	1	in	in	ADP
gs-3919	314	2	cases	case	NOUN
gs-3919	314	3	that	that	PRON
gs-3919	314	4	do	do	AUX
gs-3919	314	5	not	not	PART
gs-3919	314	6	respond	respond	VERB
gs-3919	314	7	to	to	ADP
gs-3919	314	8	corticosteroids	corticosteroid	NOUN
gs-3919	314	9	or	or	CCONJ
gs-3919	314	10	which	which	PRON
gs-3919	314	11	are	be	AUX
gs-3919	314	12	severe	severe	ADJ
gs-3919	314	13	,	,	PUNCT
gs-3919	314	14	agents	agent	NOUN
gs-3919	314	15	that	that	PRON
gs-3919	314	16	are	be	AUX
gs-3919	314	17	used	use	VERB
gs-3919	314	18	include	include	VERB
gs-3919	314	19	cyclosporin	cyclosporin	NOUN
gs-3919	314	20	,	,	PUNCT
gs-3919	314	21	mycophenolate	mycophenolate	PROPN
gs-3919	314	22	mofetil	mofetil	PROPN
gs-3919	314	23	,	,	PUNCT
gs-3919	314	24	and	and	CCONJ
gs-3919	314	25	ivig	ivig	NOUN
gs-3919	314	26	with	with	ADP
gs-3919	314	27	mixed	mixed	ADJ
gs-3919	314	28	success	success	NOUN
gs-3919	314	29	.	.	PUNCT
gs-3919	315	1	new	new	ADJ
gs-3919	315	2	therapeutics	therapeutic	NOUN
gs-3919	315	3	that	that	PRON
gs-3919	315	4	target	target	VERB
gs-3919	315	5	immune	immune	ADJ
gs-3919	315	6	pathways	pathway	NOUN
gs-3919	315	7	,	,	PUNCT
gs-3919	315	8	e.g.	e.g.	ADV
gs-3919	315	9	il-6	il-6	NOUN
gs-3919	315	10	receptor	receptor	NOUN
gs-3919	315	11	antagonism	antagonism	NOUN
gs-3919	315	12	are	be	AUX
gs-3919	315	13	up	up	ADV
gs-3919	315	14	coming	come	VERB
gs-3919	315	15	out	out	ADV
gs-3919	315	16	,	,	PUNCT
gs-3919	315	17	but	but	CCONJ
gs-3919	315	18	await	await	VERB
gs-3919	315	19	validation	validation	NOUN
gs-3919	315	20	organ	organ	NOUN
gs-3919	315	21	-	-	PUNCT
gs-3919	315	22	specific	specific	ADJ
gs-3919	315	23	complications	complication	NOUN
gs-3919	315	24	are	be	AUX
gs-3919	315	25	still	still	ADV
gs-3919	315	26	being	be	AUX
gs-3919	315	27	managed	manage	VERB
gs-3919	315	28	with	with	ADP
gs-3919	315	29	supportive	supportive	ADJ
gs-3919	315	30	care	care	NOUN
gs-3919	315	31	.	.	PUNCT
gs-3919	316	1	for	for	ADP
gs-3919	316	2	instance	instance	NOUN
gs-3919	316	3	,	,	PUNCT
gs-3919	316	4	hepatic	hepatic	ADJ
gs-3919	316	5	failure	failure	NOUN
gs-3919	316	6	could	could	AUX
gs-3919	316	7	require	require	VERB
gs-3919	316	8	transplantation	transplantation	NOUN
gs-3919	316	9	while	while	SCONJ
gs-3919	316	10	renal	renal	ADJ
gs-3919	316	11	damage	damage	NOUN
gs-3919	316	12	may	may	AUX
gs-3919	316	13	need	need	VERB
gs-3919	316	14	dialysis	dialysis	NOUN
gs-3919	316	15	.	.	PUNCT
gs-3919	317	1	a	a	DET
gs-3919	317	2	multidisciplinary	multidisciplinary	ADJ
gs-3919	317	3	team	team	NOUN
gs-3919	317	4	,	,	PUNCT
gs-3919	317	5	including	include	VERB
gs-3919	317	6	dermatology	dermatology	NOUN
gs-3919	317	7	,	,	PUNCT
gs-3919	317	8	hepatology	hepatology	NOUN
gs-3919	317	9	,	,	PUNCT
gs-3919	317	10	nephrology	nephrology	NOUN
gs-3919	317	11	,	,	PUNCT
gs-3919	317	12	and	and	CCONJ
gs-3919	317	13	intensive	intensive	ADJ
gs-3919	317	14	care	care	NOUN
gs-3919	317	15	can	can	AUX
gs-3919	317	16	optimize	optimize	VERB
gs-3919	317	17	the	the	DET
gs-3919	317	18	outcomes	outcome	NOUN
gs-3919	317	19	.	.	PUNCT
gs-3919	318	1	current	current	ADJ
gs-3919	318	2	challenges	challenge	NOUN
gs-3919	318	3	and	and	CCONJ
gs-3919	318	4	possible	possible	ADJ
gs-3919	318	5	solutions	solution	NOUN
gs-3919	318	6	in	in	ADP
gs-3919	318	7	treatment	treatment	NOUN
gs-3919	318	8	of	of	ADP
gs-3919	318	9	dress	dress	NOUN
gs-3919	318	10	although	although	SCONJ
gs-3919	318	11	the	the	DET
gs-3919	318	12	diagnosis	diagnosis	NOUN
gs-3919	318	13	of	of	ADP
gs-3919	318	14	dress	dress	NOUN
gs-3919	318	15	has	have	AUX
gs-3919	318	16	been	be	AUX
gs-3919	318	17	improved	improve	VERB
gs-3919	318	18	,	,	PUNCT
gs-3919	318	19	it	it	PRON
gs-3919	318	20	still	still	ADV
gs-3919	318	21	remains	remain	VERB
gs-3919	318	22	difficult	difficult	ADJ
gs-3919	318	23	.	.	PUNCT
gs-3919	319	1	its	its	PRON
gs-3919	319	2	clinical	clinical	ADJ
gs-3919	319	3	appearance	appearance	NOUN
gs-3919	319	4	is	be	AUX
gs-3919	319	5	common	common	ADJ
gs-3919	319	6	with	with	ADP
gs-3919	319	7	infections	infection	NOUN
gs-3919	319	8	,	,	PUNCT
gs-3919	319	9	autoimmune	autoimmune	ADJ
gs-3919	319	10	diseases	disease	NOUN
gs-3919	319	11	,	,	PUNCT
gs-3919	319	12	and	and	CCONJ
gs-3919	319	13	other	other	ADJ
gs-3919	319	14	worse	bad	ADJ
gs-3919	319	15	scar	scar	NOUN
gs-3919	319	16	(	(	PUNCT
gs-3919	319	17	stevens	stevens	PROPN
gs-3919	319	18	-	-	PUNCT
gs-3919	319	19	johnson	johnson	PROPN
gs-3919	319	20	syndrome	syndrome	PROPN
gs-3919	319	21	and	and	CCONJ
gs-3919	319	22	toxic	toxic	ADJ
gs-3919	319	23	epidermal	epidermal	ADJ
gs-3919	319	24	necrolysis	necrolysis	NOUN
gs-3919	319	25	)	)	PUNCT
gs-3919	319	26	that	that	PRON
gs-3919	319	27	would	would	AUX
gs-3919	319	28	make	make	VERB
gs-3919	319	29	early	early	ADJ
gs-3919	319	30	distinction	distinction	NOUN
gs-3919	319	31	between	between	ADP
gs-3919	319	32	them	they	PRON
gs-3919	319	33	hard	hard	ADV
gs-3919	319	34	.	.	PUNCT
gs-3919	320	1	although	although	SCONJ
gs-3919	320	2	the	the	DET
gs-3919	320	3	regi	regi	PROPN
gs-3919	320	4	scar	scar	PROPN
gs-3919	320	5	score	score	NOUN
gs-3919	320	6	is	be	AUX
gs-3919	320	7	highly	highly	ADV
gs-3919	320	8	used	use	VERB
gs-3919	320	9	,	,	PUNCT
gs-3919	320	10	it	it	PRON
gs-3919	320	11	has	have	AUX
gs-3919	320	12	nevertheless	nevertheless	ADV
gs-3919	320	13	had	have	VERB
gs-3919	320	14	a	a	DET
gs-3919	320	15	problem	problem	NOUN
gs-3919	320	16	in	in	ADP
gs-3919	320	17	functional	functional	ADJ
gs-3919	320	18	sensitivity	sensitivity	NOUN
gs-3919	320	19	and	and	CCONJ
gs-3919	320	20	specificity	specificity	NOUN
gs-3919	320	21	at	at	ADP
gs-3919	320	22	early	early	ADV
gs-3919	320	23	as	as	ADP
gs-3919	320	24	the	the	DET
gs-3919	320	25	early	early	ADJ
gs-3919	320	26	period	period	NOUN
gs-3919	320	27	of	of	ADP
gs-3919	320	28	the	the	DET
gs-3919	320	29	disease	disease	NOUN
gs-3919	320	30	.	.	PUNCT
gs-3919	321	1	misdiagnosis	misdiagnosis	NOUN
gs-3919	321	2	or	or	CCONJ
gs-3919	321	3	delayed	delay	VERB
gs-3919	321	4	diagnosis	diagnosis	NOUN
gs-3919	321	5	may	may	AUX
gs-3919	321	6	result	result	VERB
gs-3919	321	7	in	in	ADP
gs-3919	321	8	ineffective	ineffective	ADJ
gs-3919	321	9	treatment	treatment	NOUN
gs-3919	321	10	and	and	CCONJ
gs-3919	321	11	higher	high	ADJ
gs-3919	321	12	mortality	mortality	NOUN
gs-3919	321	13	.	.	PUNCT
gs-3919	322	1	moreover	moreover	ADV
gs-3919	322	2	,	,	PUNCT
gs-3919	322	3	polytherapy	polytherapy	NOUN
gs-3919	322	4	and	and	CCONJ
gs-3919	322	5	variable	variable	ADJ
gs-3919	322	6	time	time	NOUN
gs-3919	322	7	latency	latency	NOUN
gs-3919	322	8	may	may	AUX
gs-3919	322	9	complicate	complicate	VERB
gs-3919	322	10	the	the	DET
gs-3919	322	11	identification	identification	NOUN
gs-3919	322	12	of	of	ADP
gs-3919	322	13	the	the	DET
gs-3919	322	14	offending	offend	VERB
gs-3919	322	15	drug	drug	NOUN
gs-3919	322	16	.	.	PUNCT
gs-3919	323	1	causality	causality	NOUN
gs-3919	323	2	'	'	PUNCT
gs-3919	323	3	tools	tool	NOUN
gs-3919	323	4	'	'	PUNCT
gs-3919	323	5	are	be	AUX
gs-3919	323	6	available	available	ADJ
gs-3919	323	7	;	;	PUNCT
gs-3919	323	8	however	however	ADV
gs-3919	323	9	,	,	PUNCT
gs-3919	323	10	they	they	PRON
gs-3919	323	11	are	be	AUX
gs-3919	323	12	far	far	ADV
gs-3919	323	13	from	from	ADP
gs-3919	323	14	ideal	ideal	ADJ
gs-3919	323	15	.	.	PUNCT
gs-3919	324	1	the	the	DET
gs-3919	324	2	combination	combination	NOUN
gs-3919	324	3	of	of	ADP
gs-3919	324	4	clinical	clinical	ADJ
gs-3919	324	5	features	feature	NOUN
gs-3919	324	6	with	with	ADP
gs-3919	324	7	pharmacogenomics	pharmacogenomic	NOUN
gs-3919	324	8	,	,	PUNCT
gs-3919	324	9	and	and	CCONJ
gs-3919	324	10	viral	viral	ADJ
gs-3919	324	11	reactivation	reactivation	NOUN
gs-3919	324	12	markers	marker	NOUN
gs-3919	324	13	may	may	AUX
gs-3919	324	14	have	have	VERB
gs-3919	324	15	greater	great	ADJ
gs-3919	324	16	diagnostic	diagnostic	ADJ
gs-3919	324	17	accuracy	accuracy	NOUN
gs-3919	324	18	.	.	PUNCT
gs-3919	325	1	therapeutic	therapeutic	ADJ
gs-3919	325	2	variation	variation	NOUN
gs-3919	325	3	is	be	AUX
gs-3919	325	4	also	also	ADV
gs-3919	325	5	maintained	maintain	VERB
gs-3919	325	6	by	by	ADP
gs-3919	325	7	the	the	DET
gs-3919	325	8	lack	lack	NOUN
gs-3919	325	9	of	of	ADP
gs-3919	325	10	strong	strong	ADJ
gs-3919	325	11	evidence	evidence	NOUN
gs-3919	325	12	-	-	PUNCT
gs-3919	325	13	based	base	VERB
gs-3919	325	14	recommendation	recommendation	NOUN
gs-3919	325	15	.	.	PUNCT
gs-3919	326	1	variations	variation	NOUN
gs-3919	326	2	in	in	ADP
gs-3919	326	3	corticosteroid	corticosteroid	ADJ
gs-3919	326	4	therapy	therapy	NOUN
gs-3919	326	5	,	,	PUNCT
gs-3919	326	6	type	type	NOUN
gs-3919	326	7	of	of	ADP
gs-3919	326	8	immunosuppressive	immunosuppressive	ADJ
gs-3919	326	9	drugs	drug	NOUN
gs-3919	326	10	,	,	PUNCT
gs-3919	326	11	georgian	georgian	ADJ
gs-3919	326	12	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	326	13	მეცნიერები	მეცნიერები	NOUN
gs-3919	326	14	ტ.	ტ.	VERB
gs-3919	326	15	7	7	NUM
gs-3919	326	16	n	n	PRON
gs-3919	326	17	3	3	NUM
gs-3919	326	18	,	,	PUNCT
gs-3919	326	19	2025	2025	NUM
gs-3919	326	20	161	161	NUM
gs-3919	326	21	and	and	CCONJ
gs-3919	326	22	supportive	supportive	ADJ
gs-3919	326	23	care	care	NOUN
gs-3919	326	24	approaches	approach	NOUN
gs-3919	326	25	illustrate	illustrate	VERB
gs-3919	326	26	clinical	clinical	ADJ
gs-3919	326	27	uncertainty	uncertainty	NOUN
gs-3919	326	28	.	.	PUNCT
gs-3919	327	1	international	international	ADJ
gs-3919	327	2	registries	registry	NOUN
gs-3919	327	3	and	and	CCONJ
gs-3919	327	4	multicentre	multicentre	NOUN
gs-3919	327	5	studies	study	NOUN
gs-3919	327	6	may	may	AUX
gs-3919	327	7	generate	generate	VERB
gs-3919	327	8	data	datum	NOUN
gs-3919	327	9	leading	lead	VERB
gs-3919	327	10	to	to	ADP
gs-3919	327	11	consensus	consensus	NOUN
gs-3919	327	12	protocols	protocol	NOUN
gs-3919	327	13	.	.	PUNCT
gs-3919	328	1			VERB
gs-3919	328	2	anticonvulsants	anticonvulsant	NOUN
gs-3919	328	3	are	be	AUX
gs-3919	328	4	the	the	DET
gs-3919	328	5	most	most	ADV
gs-3919	328	6	common	common	ADJ
gs-3919	328	7	offending	offending	ADJ
gs-3919	328	8	agents	agent	NOUN
gs-3919	328	9	associated	associate	VERB
gs-3919	328	10	with	with	ADP
gs-3919	328	11	dress	dress	NOUN
gs-3919	328	12	,	,	PUNCT
gs-3919	328	13	and	and	CCONJ
gs-3919	328	14	particularly	particularly	ADV
gs-3919	328	15	aromatic	aromatic	ADJ
gs-3919	328	16	anticonvulsants	anticonvulsant	NOUN
gs-3919	328	17	such	such	ADJ
gs-3919	328	18	as	as	ADP
gs-3919	328	19	carbamazepine	carbamazepine	NOUN
gs-3919	328	20	,	,	PUNCT
gs-3919	328	21	phenytoin	phenytoin	NOUN
gs-3919	328	22	,	,	PUNCT
gs-3919	328	23	lamotrigine	lamotrigine	PROPN
gs-3919	328	24	.	.	PUNCT
gs-3919	329	1	metabolic	metabolic	ADJ
gs-3919	329	2	activation	activation	NOUN
gs-3919	329	3	of	of	ADP
gs-3919	329	4	these	these	DET
gs-3919	329	5	agents	agent	NOUN
gs-3919	329	6	to	to	PART
gs-3919	329	7	reactive	reactive	ADJ
gs-3919	329	8	intermediates	intermediate	NOUN
gs-3919	329	9	most	most	ADV
gs-3919	329	10	probably	probably	ADV
gs-3919	329	11	leads	lead	VERB
gs-3919	329	12	to	to	ADP
gs-3919	329	13	immune	immune	ADJ
gs-3919	329	14	sensitisation	sensitisation	NOUN
gs-3919	329	15	.	.	PUNCT
gs-3919	330	1			VERB
gs-3919	330	2	allopurinol	allopurinol	NOUN
gs-3919	330	3	continues	continue	VERB
gs-3919	330	4	to	to	PART
gs-3919	330	5	be	be	AUX
gs-3919	330	6	one	one	NUM
gs-3919	330	7	of	of	ADP
gs-3919	330	8	the	the	DET
gs-3919	330	9	most	most	ADV
gs-3919	330	10	common	common	ADJ
gs-3919	330	11	single	single	ADJ
gs-3919	330	12	-	-	PUNCT
gs-3919	330	13	drug	drug	NOUN
gs-3919	330	14	causative	causative	ADJ
gs-3919	330	15	agents	agent	NOUN
gs-3919	330	16	,	,	PUNCT
gs-3919	330	17	especially	especially	ADV
gs-3919	330	18	in	in	ADP
gs-3919	330	19	asian	asian	ADJ
gs-3919	330	20	patients	patient	NOUN
gs-3919	330	21	.	.	PUNCT
gs-3919	331	1	in	in	ADP
gs-3919	331	2	the	the	DET
gs-3919	331	3	majority	majority	NOUN
gs-3919	331	4	of	of	ADP
gs-3919	331	5	these	these	DET
gs-3919	331	6	cases	case	NOUN
gs-3919	331	7	there	there	PRON
gs-3919	331	8	was	be	VERB
gs-3919	331	9	severe	severe	ADJ
gs-3919	331	10	hepatic	hepatic	ADJ
gs-3919	331	11	and	and	CCONJ
gs-3919	331	12	renal	renal	ADJ
gs-3919	331	13	involvement	involvement	NOUN
gs-3919	331	14	.	.	PUNCT
gs-3919	332	1			VERB
gs-3919	332	2	antibiotics	antibiotic	NOUN
gs-3919	332	3	such	such	ADJ
gs-3919	332	4	as	as	ADP
gs-3919	332	5	vancomycin	vancomycin	PROPN
gs-3919	332	6	,	,	PUNCT
gs-3919	332	7	penicillin	penicillin	NOUN
gs-3919	332	8	and	and	CCONJ
gs-3919	332	9	minocycline	minocycline	NOUN
gs-3919	332	10	are	be	AUX
gs-3919	332	11	the	the	DET
gs-3919	332	12	most	most	ADV
gs-3919	332	13	commonly	commonly	ADV
gs-3919	332	14	reported	report	VERB
gs-3919	332	15	triggers	trigger	NOUN
gs-3919	332	16	.	.	PUNCT
gs-3919	333	1			ADJ
gs-3919	333	2	nsaids	nsaid	NOUN
gs-3919	333	3	(	(	PUNCT
gs-3919	333	4	non	non	ADJ
gs-3919	333	5	-	-	ADJ
gs-3919	333	6	steroidal	steroidal	ADJ
gs-3919	333	7	anti	anti	ADJ
gs-3919	333	8	-	-	ADJ
gs-3919	333	9	inflammatory	inflammatory	ADJ
gs-3919	333	10	drugs	drug	NOUN
gs-3919	333	11	)	)	PUNCT
gs-3919	333	12	,	,	PUNCT
gs-3919	333	13	although	although	SCONJ
gs-3919	333	14	less	less	ADJ
gs-3919	333	15	emphasized	emphasize	VERB
gs-3919	333	16	in	in	ADP
gs-3919	333	17	large	large	ADJ
gs-3919	333	18	series	series	NOUN
gs-3919	333	19	,	,	PUNCT
gs-3919	333	20	are	be	AUX
gs-3919	333	21	an	an	DET
gs-3919	333	22	under	under	ADV
gs-3919	333	23	-	-	PUNCT
gs-3919	333	24	recognized	recognize	VERB
gs-3919	333	25	notorious	notorious	ADJ
gs-3919	333	26	trigger	trigger	NOUN
gs-3919	333	27	associated	associate	VERB
gs-3919	333	28	with	with	ADP
gs-3919	333	29	dress	dress	NOUN
gs-3919	333	30	syndrome	syndrome	NOUN
gs-3919	333	31	.	.	PUNCT
gs-3919	334	1	common	common	ADJ
gs-3919	334	2	nsaids	nsaid	NOUN
gs-3919	334	3	involved	involve	VERB
gs-3919	334	4	are	be	AUX
gs-3919	334	5	mefenamic	mefenamic	ADJ
gs-3919	334	6	acid	acid	NOUN
gs-3919	334	7	,	,	PUNCT
gs-3919	334	8	ibuprofen	ibuprofen	NOUN
gs-3919	334	9	,	,	PUNCT
gs-3919	334	10	diclofenac	diclofenac	NOUN
gs-3919	334	11	and	and	CCONJ
gs-3919	334	12	naproxen	naproxen	NOUN
gs-3919	334	13	.	.	PUNCT
gs-3919	335	1	these	these	DET
gs-3919	335	2	agents	agent	NOUN
gs-3919	335	3	are	be	AUX
gs-3919	335	4	largely	largely	ADV
gs-3919	335	5	available	available	ADJ
gs-3919	335	6	as	as	ADP
gs-3919	335	7	otc	otc	PROPN
gs-3919	335	8	medications	medication	NOUN
gs-3919	335	9	,	,	PUNCT
gs-3919	335	10	and	and	CCONJ
gs-3919	335	11	this	this	PRON
gs-3919	335	12	could	could	AUX
gs-3919	335	13	possibly	possibly	ADV
gs-3919	335	14	lead	lead	VERB
gs-3919	335	15	to	to	ADP
gs-3919	335	16	underreporting	underreporting	NOUN
gs-3919	335	17	and	and	CCONJ
gs-3919	335	18	misattribution	misattribution	NOUN
gs-3919	335	19	of	of	ADP
gs-3919	335	20	initial	initial	ADJ
gs-3919	335	21	symptoms	symptom	NOUN
gs-3919	335	22	of	of	ADP
gs-3919	335	23	dress	dress	NOUN
gs-3919	335	24	to	to	ADP
gs-3919	335	25	a	a	DET
gs-3919	335	26	common	common	ADJ
gs-3919	335	27	viral	viral	ADJ
gs-3919	335	28	infection	infection	NOUN
gs-3919	335	29	collaterally	collaterally	ADV
gs-3919	335	30	occurring	occur	VERB
gs-3919	335	31	,	,	PUNCT
gs-3919	335	32	or	or	CCONJ
gs-3919	335	33	to	to	ADP
gs-3919	335	34	other	other	ADJ
gs-3919	335	35	hypersensitivity	hypersensitivity	NOUN
gs-3919	335	36	reactions	reaction	NOUN
gs-3919	335	37	.	.	PUNCT
gs-3919	336	1			VERB
gs-3919	336	2	in	in	ADP
gs-3919	336	3	multiple	multiple	ADJ
gs-3919	336	4	published	publish	VERB
gs-3919	336	5	case	case	NOUN
gs-3919	336	6	reports	report	NOUN
gs-3919	336	7	,	,	PUNCT
gs-3919	336	8	nsaid	nsaid	PROPN
gs-3919	336	9	-	-	PUNCT
gs-3919	336	10	induced	induce	VERB
gs-3919	336	11	dress	dress	NOUN
gs-3919	336	12	had	have	VERB
gs-3919	336	13	a	a	DET
gs-3919	336	14	time	time	NOUN
gs-3919	336	15	to	to	PART
gs-3919	336	16	onset	onset	VERB
gs-3919	336	17	equivalent	equivalent	ADJ
gs-3919	336	18	to	to	ADP
gs-3919	336	19	other	other	ADJ
gs-3919	336	20	causative	causative	ADJ
gs-3919	336	21	medications	medication	NOUN
gs-3919	336	22	(	(	PUNCT
gs-3919	336	23	usually	usually	ADV
gs-3919	336	24	2	2	NUM
gs-3919	336	25	to	to	PART
gs-3919	336	26	6	6	NUM
gs-3919	336	27	weeks	week	NOUN
gs-3919	336	28	)	)	PUNCT
gs-3919	336	29	,	,	PUNCT
gs-3919	336	30	commonly	commonly	ADV
gs-3919	336	31	manifested	manifest	VERB
gs-3919	336	32	as	as	ADP
gs-3919	336	33	a	a	DET
gs-3919	336	34	morbilliform	morbilliform	NOUN
gs-3919	336	35	eruption	eruption	NOUN
gs-3919	336	36	,	,	PUNCT
gs-3919	336	37	eosinophilia	eosinophilia	PROPN
gs-3919	336	38	,	,	PUNCT
gs-3919	336	39	hepatic	hepatic	ADJ
gs-3919	336	40	involvement	involvement	NOUN
gs-3919	336	41	,	,	PUNCT
gs-3919	336	42	and	and	CCONJ
gs-3919	336	43	,	,	PUNCT
gs-3919	336	44	in	in	ADP
gs-3919	336	45	some	some	DET
gs-3919	336	46	cases	case	NOUN
gs-3919	336	47	,	,	PUNCT
gs-3919	336	48	[	[	X
gs-3919	336	49	renal	renal	ADJ
gs-3919	336	50	failure	failure	NOUN
gs-3919	336	51	]	]	PUNCT
gs-3919	336	52	.	.	PUNCT
gs-3919	337	1	importantly	importantly	ADV
gs-3919	337	2	,	,	PUNCT
gs-3919	337	3	a	a	DET
gs-3919	337	4	few	few	ADJ
gs-3919	337	5	patients	patient	NOUN
gs-3919	337	6	needed	need	VERB
gs-3919	337	7	intensive	intensive	ADJ
gs-3919	337	8	care	care	NOUN
gs-3919	337	9	unit	unit	NOUN
gs-3919	337	10	(	(	PUNCT
gs-3919	337	11	icu	icu	PROPN
gs-3919	337	12	)	)	PUNCT
gs-3919	337	13	type	type	NOUN
gs-3919	337	14	of	of	ADP
gs-3919	337	15	care	care	NOUN
gs-3919	337	16	,	,	PUNCT
gs-3919	337	17	severe	severe	ADJ
gs-3919	337	18	or	or	CCONJ
gs-3919	337	19	when	when	SCONJ
gs-3919	337	20	the	the	DET
gs-3919	337	21	patient	patient	NOUN
gs-3919	337	22	established	establish	VERB
gs-3919	337	23	respiratory	respiratory	ADJ
gs-3919	337	24	involvement	involvement	NOUN
gs-3919	337	25	.	.	PUNCT
gs-3919	338	1	nsaids	nsaid	NOUN
gs-3919	338	2	are	be	AUX
gs-3919	338	3	metabolised	metabolise	VERB
gs-3919	338	4	by	by	ADP
gs-3919	338	5	hepatic	hepatic	ADJ
gs-3919	338	6	cytochrome	cytochrome	NOUN
gs-3919	338	7	p450	p450	NUM
gs-3919	338	8	enzymes	enzyme	NOUN
gs-3919	338	9	to	to	PART
gs-3919	338	10	reactive	reactive	ADJ
gs-3919	338	11	intermediate	intermediate	NOUN
gs-3919	338	12	that	that	PRON
gs-3919	338	13	can	can	AUX
gs-3919	338	14	result	result	VERB
gs-3919	338	15	in	in	ADP
gs-3919	338	16	immune	immune	ADJ
gs-3919	338	17	activation	activation	NOUN
gs-3919	338	18	among	among	ADP
gs-3919	338	19	those	those	PRON
gs-3919	338	20	susceptible	susceptible	ADJ
gs-3919	338	21	genetically	genetically	ADV
gs-3919	338	22	.	.	PUNCT
gs-3919	339	1			VERB
gs-3919	339	2	the	the	DET
gs-3919	339	3	absence	absence	NOUN
gs-3919	339	4	of	of	ADP
gs-3919	339	5	defined	define	VERB
gs-3919	339	6	hla	hla	PROPN
gs-3919	339	7	associations	association	NOUN
gs-3919	339	8	with	with	ADP
gs-3919	339	9	nsaids	nsaid	NOUN
gs-3919	339	10	,	,	PUNCT
gs-3919	339	11	in	in	ADP
gs-3919	339	12	the	the	DET
gs-3919	339	13	same	same	ADJ
gs-3919	339	14	way	way	NOUN
gs-3919	339	15	as	as	ADP
gs-3919	339	16	allopurinol	allopurinol	NOUN
gs-3919	339	17	or	or	CCONJ
gs-3919	339	18	carbamazepine	carbamazepine	NOUN
gs-3919	339	19	,	,	PUNCT
gs-3919	339	20	increased	increase	VERB
gs-3919	339	21	diagnostic	diagnostic	ADJ
gs-3919	339	22	uncertainty	uncertainty	NOUN
gs-3919	339	23	.	.	PUNCT
gs-3919	340	1	this	this	PRON
gs-3919	340	2	reflects	reflect	VERB
gs-3919	340	3	the	the	DET
gs-3919	340	4	importance	importance	NOUN
gs-3919	340	5	for	for	ADP
gs-3919	340	6	better	well	ADJ
gs-3919	340	7	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	340	8	,	,	PUNCT
gs-3919	340	9	more	more	ADV
gs-3919	340	10	patient	patient	ADJ
gs-3919	340	11	education	education	NOUN
gs-3919	340	12	about	about	ADP
gs-3919	340	13	otc	otc	PROPN
gs-3919	340	14	drug	drug	NOUN
gs-3919	340	15	risks	risk	NOUN
gs-3919	340	16	,	,	PUNCT
gs-3919	340	17	and	and	CCONJ
gs-3919	340	18	nsaids	nsaid	VERB
gs-3919	340	19	incorporation	incorporation	NOUN
gs-3919	340	20	in	in	ADP
gs-3919	340	21	risk	risk	NOUN
gs-3919	340	22	stratification	stratification	NOUN
gs-3919	340	23	scores	score	NOUN
gs-3919	340	24	.	.	PUNCT
gs-3919	341	1	as	as	SCONJ
gs-3919	341	2	they	they	PRON
gs-3919	341	3	are	be	AUX
gs-3919	341	4	often	often	ADV
gs-3919	341	5	over	over	ADP
gs-3919	341	6	-	-	PUNCT
gs-3919	341	7	the	the	DET
gs-3919	341	8	-	-	PUNCT
gs-3919	341	9	counter	counter	NOUN
gs-3919	341	10	self	self	NOUN
gs-3919	341	11	-	-	PUNCT
gs-3919	341	12	administered	administer	VERB
gs-3919	341	13	,	,	PUNCT
gs-3919	341	14	surveillance	surveillance	NOUN
gs-3919	341	15	for	for	ADP
gs-3919	341	16	dress	dress	NOUN
gs-3919	341	17	must	must	AUX
gs-3919	341	18	focus	focus	VERB
gs-3919	341	19	on	on	ADP
gs-3919	341	20	nsaid	nsaid	ADJ
gs-3919	341	21	cases	case	NOUN
gs-3919	341	22	that	that	PRON
gs-3919	341	23	are	be	AUX
gs-3919	341	24	not	not	PART
gs-3919	341	25	under	under	ADP
gs-3919	341	26	recognized	recognize	VERB
gs-3919	341	27	,	,	PUNCT
gs-3919	341	28	thus	thus	ADV
gs-3919	341	29	negatively	negatively	ADV
gs-3919	341	30	impacting	impact	VERB
gs-3919	341	31	patients	patient	NOUN
gs-3919	341	32	'	'	PART
gs-3919	341	33	clinical	clinical	ADJ
gs-3919	341	34	course	course	NOUN
gs-3919	341	35	.	.	PUNCT
gs-3919	342	1			VERB
gs-3919	342	2	in	in	ADP
gs-3919	342	3	a	a	DET
gs-3919	342	4	drug	drug	NOUN
gs-3919	342	5	safety	safety	NOUN
gs-3919	342	6	alert	alert	NOUN
gs-3919	342	7	in	in	ADP
gs-3919	342	8	india	india	PROPN
gs-3919	342	9	dated	date	VERB
gs-3919	342	10	december	december	PROPN
gs-3919	342	11	7	7	NUM
gs-3919	342	12	,	,	PUNCT
gs-3919	342	13	2023	2023	NUM
gs-3919	342	14	,	,	PUNCT
gs-3919	342	15	ipc	ipc	PROPN
gs-3919	342	16	reported	report	VERB
gs-3919	342	17	that	that	SCONJ
gs-3919	342	18	meftal	meftal	NOUN
gs-3919	342	19	(	(	PUNCT
gs-3919	342	20	mefenamic	mefenamic	ADJ
gs-3919	342	21	acid	acid	NOUN
gs-3919	342	22	)	)	PUNCT
gs-3919	342	23	,	,	PUNCT
gs-3919	342	24	a	a	DET
gs-3919	342	25	commonly	commonly	ADV
gs-3919	342	26	used	use	VERB
gs-3919	342	27	nsaid	nsaid	PROPN
gs-3919	342	28	,	,	PUNCT
gs-3919	342	29	is	be	AUX
gs-3919	342	30	associated	associate	VERB
gs-3919	342	31	with	with	ADP
gs-3919	342	32	causing	cause	VERB
gs-3919	342	33	dress	dress	NOUN
gs-3919	342	34	syndrome	syndrome	NOUN
gs-3919	342	35	.	.	PUNCT
gs-3919	343	1	the	the	DET
gs-3919	343	2	alert	alert	NOUN
gs-3919	343	3	was	be	AUX
gs-3919	343	4	issued	issue	VERB
gs-3919	343	5	in	in	ADP
gs-3919	343	6	the	the	DET
gs-3919	343	7	wake	wake	NOUN
gs-3919	343	8	of	of	ADP
gs-3919	343	9	a	a	DET
gs-3919	343	10	preliminary	preliminary	ADJ
gs-3919	343	11	review	review	NOUN
gs-3919	343	12	of	of	ADP
gs-3919	343	13	adverse	adverse	ADJ
gs-3919	343	14	drug	drug	NOUN
gs-3919	343	15	reactions	reaction	NOUN
gs-3919	343	16	by	by	ADP
gs-3919	343	17	the	the	DET
gs-3919	343	18	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	343	19	programme	programme	NOUN
gs-3919	343	20	of	of	ADP
gs-3919	343	21	india	india	PROPN
gs-3919	343	22	(	(	PUNCT
gs-3919	343	23	pvpi	pvpi	NOUN
gs-3919	343	24	)	)	PUNCT
gs-3919	343	25	.	.	PUNCT
gs-3919	344	1	the	the	DET
gs-3919	344	2	pharmacological	pharmacological	ADJ
gs-3919	344	3	management	management	NOUN
gs-3919	344	4	of	of	ADP
gs-3919	344	5	disease	disease	NOUN
gs-3919	344	6	is	be	AUX
gs-3919	344	7	a	a	DET
gs-3919	344	8	cornerstone	cornerstone	NOUN
gs-3919	344	9	of	of	ADP
gs-3919	344	10	modern	modern	ADJ
gs-3919	344	11	medicine	medicine	NOUN
gs-3919	344	12	,	,	PUNCT
gs-3919	344	13	yet	yet	CCONJ
gs-3919	344	14	the	the	DET
gs-3919	344	15	benefits	benefit	NOUN
gs-3919	344	16	of	of	ADP
gs-3919	344	17	therapeutic	therapeutic	ADJ
gs-3919	344	18	agents	agent	NOUN
gs-3919	344	19	are	be	AUX
gs-3919	344	20	frequently	frequently	ADV
gs-3919	344	21	tempered	temper	VERB
gs-3919	344	22	by	by	ADP
gs-3919	344	23	the	the	DET
gs-3919	344	24	risk	risk	NOUN
gs-3919	344	25	of	of	ADP
gs-3919	344	26	adverse	adverse	ADJ
gs-3919	344	27	drug	drug	NOUN
gs-3919	344	28	reactions	reaction	NOUN
gs-3919	344	29	(	(	PUNCT
gs-3919	344	30	adrs	adrs	PROPN
gs-3919	344	31	)	)	PUNCT
gs-3919	344	32	.	.	PUNCT
gs-3919	345	1	among	among	ADP
gs-3919	345	2	these	these	PRON
gs-3919	345	3	,	,	PUNCT
gs-3919	345	4	drug	drug	NOUN
gs-3919	345	5	-	-	PUNCT
gs-3919	345	6	induced	induce	VERB
gs-3919	345	7	eosinophilia	eosinophilia	NOUN
gs-3919	345	8	and	and	CCONJ
gs-3919	345	9	systemic	systemic	ADJ
gs-3919	345	10	symptoms	symptom	NOUN
gs-3919	345	11	(	(	PUNCT
gs-3919	345	12	dies	die	NOUN
gs-3919	345	13	)	)	PUNCT
gs-3919	345	14	represent	represent	VERB
gs-3919	345	15	a	a	DET
gs-3919	345	16	particularly	particularly	ADV
gs-3919	345	17	complex	complex	ADJ
gs-3919	345	18	and	and	CCONJ
gs-3919	345	19	clinically	clinically	ADV
gs-3919	345	20	significant	significant	ADJ
gs-3919	345	21	challenge	challenge	NOUN
gs-3919	345	22	.	.	PUNCT
gs-3919	346	1	characterized	characterize	VERB
gs-3919	346	2	by	by	ADP
gs-3919	346	3	an	an	DET
gs-3919	346	4	abnormal	abnormal	ADJ
gs-3919	346	5	elevation	elevation	NOUN
gs-3919	346	6	in	in	ADP
gs-3919	346	7	eosinophils	eosinophil	NOUN
gs-3919	346	8	—	—	PUNCT
gs-3919	346	9	often	often	ADV
gs-3919	346	10	accompanied	accompany	VERB
gs-3919	346	11	by	by	ADP
gs-3919	346	12	multiorgan	multiorgan	NOUN
gs-3919	346	13	involvement	involvement	NOUN
gs-3919	346	14	—	—	PUNCT
gs-3919	346	15	these	these	DET
gs-3919	346	16	reactions	reaction	NOUN
gs-3919	346	17	straddle	straddle	VERB
gs-3919	346	18	the	the	DET
gs-3919	346	19	domains	domain	NOUN
gs-3919	346	20	of	of	ADP
gs-3919	346	21	pharmacology	pharmacology	NOUN
gs-3919	346	22	,	,	PUNCT
gs-3919	346	23	immunology	immunology	NOUN
gs-3919	346	24	,	,	PUNCT
gs-3919	346	25	and	and	CCONJ
gs-3919	346	26	clinical	clinical	ADJ
gs-3919	346	27	medicine	medicine	NOUN
gs-3919	346	28	,	,	PUNCT
gs-3919	346	29	georgian	georgian	PROPN
gs-3919	346	30	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	346	31	მეცნიერები	მეცნიერები	NOUN
gs-3919	346	32	ტ.	ტ.	VERB
gs-3919	346	33	7	7	NUM
gs-3919	346	34	n	n	PRON
gs-3919	346	35	3	3	NUM
gs-3919	346	36	,	,	PUNCT
gs-3919	346	37	2025	2025	NUM
gs-3919	346	38	162	162	NUM
gs-3919	346	39	necessitating	necessitate	VERB
gs-3919	346	40	a	a	DET
gs-3919	346	41	multidisciplinary	multidisciplinary	ADJ
gs-3919	346	42	approach	approach	NOUN
gs-3919	346	43	to	to	ADP
gs-3919	346	44	understanding	understand	VERB
gs-3919	346	45	their	their	PRON
gs-3919	346	46	pathogenesis	pathogenesis	NOUN
gs-3919	346	47	,	,	PUNCT
gs-3919	346	48	diagnosis	diagnosis	NOUN
gs-3919	346	49	,	,	PUNCT
gs-3919	346	50	and	and	CCONJ
gs-3919	346	51	management	management	NOUN
gs-3919	346	52	.	.	PUNCT
gs-3919	347	1	eosinophils	eosinophil	NOUN
gs-3919	347	2	,	,	PUNCT
gs-3919	347	3	granulocytes	granulocyte	NOUN
gs-3919	347	4	traditionally	traditionally	ADV
gs-3919	347	5	associated	associate	VERB
gs-3919	347	6	with	with	ADP
gs-3919	347	7	parasitic	parasitic	ADJ
gs-3919	347	8	infections	infection	NOUN
gs-3919	347	9	and	and	CCONJ
gs-3919	347	10	allergic	allergic	ADJ
gs-3919	347	11	inflammation	inflammation	NOUN
gs-3919	347	12	,	,	PUNCT
gs-3919	347	13	play	play	VERB
gs-3919	347	14	a	a	DET
gs-3919	347	15	central	central	ADJ
gs-3919	347	16	role	role	NOUN
gs-3919	347	17	in	in	ADP
gs-3919	347	18	drug	drug	NOUN
gs-3919	347	19	-	-	PUNCT
gs-3919	347	20	induced	induce	VERB
gs-3919	347	21	hypersensitivity	hypersensitivity	NOUN
gs-3919	347	22	reactions	reaction	NOUN
gs-3919	347	23	.	.	PUNCT
gs-3919	348	1	when	when	SCONJ
gs-3919	348	2	activated	activate	VERB
gs-3919	348	3	inappropriately	inappropriately	ADV
gs-3919	348	4	by	by	ADP
gs-3919	348	5	pharmacological	pharmacological	ADJ
gs-3919	348	6	agents	agent	NOUN
gs-3919	348	7	,	,	PUNCT
gs-3919	348	8	they	they	PRON
gs-3919	348	9	can	can	AUX
gs-3919	348	10	mediate	mediate	VERB
gs-3919	348	11	widespread	widespread	ADJ
gs-3919	348	12	tissue	tissue	NOUN
gs-3919	348	13	damage	damage	NOUN
gs-3919	348	14	through	through	ADP
gs-3919	348	15	the	the	DET
gs-3919	348	16	release	release	NOUN
gs-3919	348	17	of	of	ADP
gs-3919	348	18	cytotoxic	cytotoxic	ADJ
gs-3919	348	19	proteins	protein	NOUN
gs-3919	348	20	and	and	CCONJ
gs-3919	348	21	pro	pro	ADJ
gs-3919	348	22	-	-	ADJ
gs-3919	348	23	inflammatory	inflammatory	ADJ
gs-3919	348	24	cytokines	cytokine	NOUN
gs-3919	348	25	.	.	PUNCT
gs-3919	349	1	the	the	DET
gs-3919	349	2	clinical	clinical	ADJ
gs-3919	349	3	manifestations	manifestation	NOUN
gs-3919	349	4	of	of	ADP
gs-3919	349	5	this	this	DET
gs-3919	349	6	process	process	NOUN
gs-3919	349	7	are	be	AUX
gs-3919	349	8	highly	highly	ADV
gs-3919	349	9	variable	variable	ADJ
gs-3919	349	10	,	,	PUNCT
gs-3919	349	11	ranging	range	VERB
gs-3919	349	12	from	from	ADP
gs-3919	349	13	self	self	NOUN
gs-3919	349	14	-	-	PUNCT
gs-3919	349	15	limiting	limit	VERB
gs-3919	349	16	cutaneous	cutaneous	ADJ
gs-3919	349	17	eruptions	eruption	NOUN
gs-3919	349	18	to	to	ADP
gs-3919	349	19	life	life	NOUN
gs-3919	349	20	-	-	PUNCT
gs-3919	349	21	threatening	threaten	VERB
gs-3919	349	22	systemic	systemic	ADJ
gs-3919	349	23	syndromes	syndrome	NOUN
gs-3919	349	24	such	such	ADJ
gs-3919	349	25	as	as	ADP
gs-3919	349	26	drug	drug	NOUN
gs-3919	349	27	reaction	reaction	NOUN
gs-3919	349	28	with	with	ADP
gs-3919	349	29	eosinophilia	eosinophilia	PROPN
gs-3919	349	30	and	and	CCONJ
gs-3919	349	31	systemic	systemic	ADJ
gs-3919	349	32	symptoms	symptom	NOUN
gs-3919	349	33	(	(	PUNCT
gs-3919	349	34	dress	dress	NOUN
gs-3919	349	35	)	)	PUNCT
gs-3919	349	36	.	.	PUNCT
gs-3919	350	1	given	give	VERB
gs-3919	350	2	the	the	DET
gs-3919	350	3	potential	potential	ADJ
gs-3919	350	4	severity	severity	NOUN
gs-3919	350	5	of	of	ADP
gs-3919	350	6	these	these	DET
gs-3919	350	7	reactions	reaction	NOUN
gs-3919	350	8	,	,	PUNCT
gs-3919	350	9	elucidating	elucidate	VERB
gs-3919	350	10	the	the	DET
gs-3919	350	11	pharmacological	pharmacological	ADJ
gs-3919	350	12	and	and	CCONJ
gs-3919	350	13	immunological	immunological	ADJ
gs-3919	350	14	mechanisms	mechanism	NOUN
gs-3919	350	15	underlying	underlie	VERB
gs-3919	350	16	drug	drug	NOUN
gs-3919	350	17	-	-	PUNCT
gs-3919	350	18	induced	induce	VERB
gs-3919	350	19	eosinophilia	eosinophilia	NOUN
gs-3919	350	20	is	be	AUX
gs-3919	350	21	of	of	ADP
gs-3919	350	22	paramount	paramount	ADJ
gs-3919	350	23	importance	importance	NOUN
gs-3919	350	24	for	for	ADP
gs-3919	350	25	optimizing	optimize	VERB
gs-3919	350	26	patient	patient	ADJ
gs-3919	350	27	safety	safety	NOUN
gs-3919	350	28	and	and	CCONJ
gs-3919	350	29	therapeutic	therapeutic	ADJ
gs-3919	350	30	outcomes	outcome	NOUN
gs-3919	350	31	.	.	PUNCT
gs-3919	351	1	this	this	DET
gs-3919	351	2	study	study	NOUN
gs-3919	351	3	seeks	seek	VERB
gs-3919	351	4	to	to	PART
gs-3919	351	5	provide	provide	VERB
gs-3919	351	6	a	a	DET
gs-3919	351	7	comprehensive	comprehensive	ADJ
gs-3919	351	8	exploration	exploration	NOUN
gs-3919	351	9	of	of	ADP
gs-3919	351	10	drug	drug	NOUN
gs-3919	351	11	-	-	PUNCT
gs-3919	351	12	induced	induce	VERB
gs-3919	351	13	eosinophilia	eosinophilia	NOUN
gs-3919	351	14	and	and	CCONJ
gs-3919	351	15	systemic	systemic	ADJ
gs-3919	351	16	symptoms	symptom	NOUN
gs-3919	351	17	,	,	PUNCT
gs-3919	351	18	integrating	integrate	VERB
gs-3919	351	19	current	current	ADJ
gs-3919	351	20	knowledge	knowledge	NOUN
gs-3919	351	21	on	on	ADP
gs-3919	351	22	pharmacological	pharmacological	ADJ
gs-3919	351	23	triggers	trigger	NOUN
gs-3919	351	24	,	,	PUNCT
gs-3919	351	25	immunological	immunological	ADJ
gs-3919	351	26	pathways	pathway	NOUN
gs-3919	351	27	,	,	PUNCT
gs-3919	351	28	clinical	clinical	ADJ
gs-3919	351	29	presentations	presentation	NOUN
gs-3919	351	30	,	,	PUNCT
gs-3919	351	31	and	and	CCONJ
gs-3919	351	32	therapeutic	therapeutic	ADJ
gs-3919	351	33	strategies	strategy	NOUN
gs-3919	351	34	.	.	PUNCT
gs-3919	352	1	by	by	ADP
gs-3919	352	2	synthesizing	synthesize	VERB
gs-3919	352	3	data	datum	NOUN
gs-3919	352	4	from	from	ADP
gs-3919	352	5	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	352	6	studies	study	NOUN
gs-3919	352	7	,	,	PUNCT
gs-3919	352	8	genetic	genetic	ADJ
gs-3919	352	9	research	research	NOUN
gs-3919	352	10	,	,	PUNCT
gs-3919	352	11	and	and	CCONJ
gs-3919	352	12	clinical	clinical	ADJ
gs-3919	352	13	trials	trial	NOUN
gs-3919	352	14	,	,	PUNCT
gs-3919	352	15	we	we	PRON
gs-3919	352	16	aim	aim	VERB
gs-3919	352	17	to	to	PART
gs-3919	352	18	delineate	delineate	VERB
gs-3919	352	19	the	the	DET
gs-3919	352	20	key	key	ADJ
gs-3919	352	21	factors	factor	NOUN
gs-3919	352	22	contributing	contribute	VERB
gs-3919	352	23	to	to	ADP
gs-3919	352	24	these	these	DET
gs-3919	352	25	reactions	reaction	NOUN
gs-3919	352	26	and	and	CCONJ
gs-3919	352	27	highlight	highlight	VERB
gs-3919	352	28	emerging	emerge	VERB
gs-3919	352	29	approaches	approach	NOUN
gs-3919	352	30	for	for	ADP
gs-3919	352	31	their	their	PRON
gs-3919	352	32	prevention	prevention	NOUN
gs-3919	352	33	and	and	CCONJ
gs-3919	352	34	management	management	NOUN
gs-3919	352	35	.	.	PUNCT
gs-3919	353	1	pharmacological	pharmacological	ADJ
gs-3919	353	2	triggers	trigger	NOUN
gs-3919	353	3	and	and	CCONJ
gs-3919	353	4	risk	risk	NOUN
gs-3919	353	5	factors	factor	NOUN
gs-3919	353	6	the	the	DET
gs-3919	353	7	propensity	propensity	NOUN
gs-3919	353	8	of	of	ADP
gs-3919	353	9	a	a	DET
gs-3919	353	10	drug	drug	NOUN
gs-3919	353	11	to	to	PART
gs-3919	353	12	induce	induce	VERB
gs-3919	353	13	eosinophilia	eosinophilia	PROPN
gs-3919	353	14	is	be	AUX
gs-3919	353	15	closely	closely	ADV
gs-3919	353	16	linked	link	VERB
gs-3919	353	17	to	to	ADP
gs-3919	353	18	its	its	PRON
gs-3919	353	19	chemical	chemical	NOUN
gs-3919	353	20	structure	structure	NOUN
gs-3919	353	21	,	,	PUNCT
gs-3919	353	22	metabolic	metabolic	NOUN
gs-3919	353	23	pathway	pathway	NOUN
gs-3919	353	24	,	,	PUNCT
gs-3919	353	25	and	and	CCONJ
gs-3919	353	26	interaction	interaction	NOUN
gs-3919	353	27	with	with	ADP
gs-3919	353	28	the	the	DET
gs-3919	353	29	immune	immune	ADJ
gs-3919	353	30	system	system	NOUN
gs-3919	353	31	.	.	PUNCT
gs-3919	354	1	certain	certain	ADJ
gs-3919	354	2	drug	drug	NOUN
gs-3919	354	3	classes	class	NOUN
gs-3919	354	4	are	be	AUX
gs-3919	354	5	disproportionately	disproportionately	ADV
gs-3919	354	6	associated	associate	VERB
gs-3919	354	7	with	with	ADP
gs-3919	354	8	these	these	DET
gs-3919	354	9	reactions	reaction	NOUN
gs-3919	354	10	,	,	PUNCT
gs-3919	354	11	reflecting	reflect	VERB
gs-3919	354	12	shared	share	VERB
gs-3919	354	13	mechanisms	mechanism	NOUN
gs-3919	354	14	of	of	ADP
gs-3919	354	15	immunogenicity	immunogenicity	NOUN
gs-3919	354	16	.	.	PUNCT
gs-3919	355	1	aromatic	aromatic	ADJ
gs-3919	355	2	antiepileptic	antiepileptic	ADJ
gs-3919	355	3	drugs	drug	NOUN
gs-3919	355	4	(	(	PUNCT
gs-3919	355	5	aeds	aed	NOUN
gs-3919	355	6	)	)	PUNCT
gs-3919	355	7	,	,	PUNCT
gs-3919	355	8	such	such	ADJ
gs-3919	355	9	as	as	ADP
gs-3919	355	10	carbamazepine	carbamazepine	NOUN
gs-3919	355	11	,	,	PUNCT
gs-3919	355	12	phenytoin	phenytoin	NOUN
gs-3919	355	13	,	,	PUNCT
gs-3919	355	14	and	and	CCONJ
gs-3919	355	15	lamotrigine	lamotrigine	NOUN
gs-3919	355	16	,	,	PUNCT
gs-3919	355	17	are	be	AUX
gs-3919	355	18	classic	classic	ADJ
gs-3919	355	19	examples	example	NOUN
gs-3919	355	20	,	,	PUNCT
gs-3919	355	21	owing	owe	VERB
gs-3919	355	22	to	to	ADP
gs-3919	355	23	their	their	PRON
gs-3919	355	24	ability	ability	NOUN
gs-3919	355	25	to	to	PART
gs-3919	355	26	generate	generate	VERB
gs-3919	355	27	reactive	reactive	ADJ
gs-3919	355	28	arene	arene	NOUN
gs-3919	355	29	oxide	oxide	NOUN
gs-3919	355	30	metabolites	metabolite	NOUN
gs-3919	355	31	.	.	PUNCT
gs-3919	356	1	these	these	DET
gs-3919	356	2	intermediates	intermediate	NOUN
gs-3919	356	3	form	form	VERB
gs-3919	356	4	covalent	covalent	NOUN
gs-3919	356	5	bonds	bond	NOUN
gs-3919	356	6	with	with	ADP
gs-3919	356	7	cellular	cellular	ADJ
gs-3919	356	8	proteins	protein	NOUN
gs-3919	356	9	,	,	PUNCT
gs-3919	356	10	creating	create	VERB
gs-3919	356	11	neoantigens	neoantigen	NOUN
gs-3919	356	12	that	that	PRON
gs-3919	356	13	stimulate	stimulate	VERB
gs-3919	356	14	a	a	DET
gs-3919	356	15	t	t	NOUN
gs-3919	356	16	-	-	PUNCT
gs-3919	356	17	cell	cell	NOUN
gs-3919	356	18	-	-	PUNCT
gs-3919	356	19	mediated	mediate	VERB
gs-3919	356	20	immune	immune	ADJ
gs-3919	356	21	response	response	NOUN
gs-3919	356	22	.	.	PUNCT
gs-3919	357	1	similarly	similarly	ADV
gs-3919	357	2	,	,	PUNCT
gs-3919	357	3	sulfonamide	sulfonamide	NOUN
gs-3919	357	4	antibiotics	antibiotic	NOUN
gs-3919	357	5	and	and	CCONJ
gs-3919	357	6	β	β	NOUN
gs-3919	357	7	-	-	NOUN
gs-3919	357	8	lactams	lactam	NOUN
gs-3919	357	9	are	be	AUX
gs-3919	357	10	frequent	frequent	ADJ
gs-3919	357	11	offenders	offender	NOUN
gs-3919	357	12	,	,	PUNCT
gs-3919	357	13	with	with	ADP
gs-3919	357	14	sulfamethoxazole	sulfamethoxazole	NOUN
gs-3919	357	15	’s	’s	PART
gs-3919	357	16	hydroxylamine	hydroxylamine	ADJ
gs-3919	357	17	metabolite	metabolite	NOUN
gs-3919	357	18	implicated	implicate	VERB
gs-3919	357	19	in	in	ADP
gs-3919	357	20	hapten	hapten	VERB
gs-3919	357	21	formation	formation	NOUN
gs-3919	357	22	and	and	CCONJ
gs-3919	357	23	subsequent	subsequent	ADJ
gs-3919	357	24	eosinophil	eosinophil	ADJ
gs-3919	357	25	activation	activation	NOUN
gs-3919	357	26	.	.	PUNCT
gs-3919	358	1	pharmacogenetic	pharmacogenetic	ADJ
gs-3919	358	2	studies	study	NOUN
gs-3919	358	3	have	have	AUX
gs-3919	358	4	further	far	ADV
gs-3919	358	5	refined	refine	VERB
gs-3919	358	6	our	our	PRON
gs-3919	358	7	understanding	understanding	NOUN
gs-3919	358	8	of	of	ADP
gs-3919	358	9	individual	individual	ADJ
gs-3919	358	10	susceptibility	susceptibility	NOUN
gs-3919	358	11	to	to	ADP
gs-3919	358	12	drug	drug	NOUN
gs-3919	358	13	-	-	PUNCT
gs-3919	358	14	induced	induce	VERB
gs-3919	358	15	eosinophilia	eosinophilia	NOUN
gs-3919	358	16	.	.	PUNCT
gs-3919	359	1	the	the	DET
gs-3919	359	2	association	association	NOUN
gs-3919	359	3	between	between	ADP
gs-3919	359	4	hla	hla	PROPN
gs-3919	359	5	-	-	PUNCT
gs-3919	359	6	b*15:02	b*15:02	NOUN
gs-3919	359	7	and	and	CCONJ
gs-3919	359	8	carbamazepine	carbamazepine	NOUN
gs-3919	359	9	-	-	PUNCT
gs-3919	359	10	induced	induce	VERB
gs-3919	359	11	severe	severe	ADJ
gs-3919	359	12	cutaneous	cutaneous	ADJ
gs-3919	359	13	adverse	adverse	ADJ
gs-3919	359	14	reactions	reaction	NOUN
gs-3919	359	15	(	(	PUNCT
gs-3919	359	16	scars	scar	NOUN
gs-3919	359	17	)	)	PUNCT
gs-3919	359	18	is	be	AUX
gs-3919	359	19	well	well	ADV
gs-3919	359	20	-	-	PUNCT
gs-3919	359	21	documented	document	VERB
gs-3919	359	22	,	,	PUNCT
gs-3919	359	23	particularly	particularly	ADV
gs-3919	359	24	in	in	ADP
gs-3919	359	25	southeast	southeast	ADJ
gs-3919	359	26	asian	asian	ADJ
gs-3919	359	27	populations	population	NOUN
gs-3919	359	28	.	.	PUNCT
gs-3919	360	1	this	this	DET
gs-3919	360	2	allele	allele	PROPN
gs-3919	360	3	’s	’s	PART
gs-3919	360	4	prevalence	prevalence	NOUN
gs-3919	360	5	underscores	underscore	VERB
gs-3919	360	6	the	the	DET
gs-3919	360	7	importance	importance	NOUN
gs-3919	360	8	of	of	ADP
gs-3919	360	9	genetic	genetic	ADJ
gs-3919	360	10	screening	screening	NOUN
gs-3919	360	11	in	in	ADP
gs-3919	360	12	high	high	ADJ
gs-3919	360	13	-	-	PUNCT
gs-3919	360	14	risk	risk	NOUN
gs-3919	360	15	groups	group	NOUN
gs-3919	360	16	,	,	PUNCT
gs-3919	360	17	as	as	SCONJ
gs-3919	360	18	preemptive	preemptive	ADJ
gs-3919	360	19	testing	testing	NOUN
gs-3919	360	20	can	can	AUX
gs-3919	360	21	significantly	significantly	ADV
gs-3919	360	22	reduce	reduce	VERB
gs-3919	360	23	the	the	DET
gs-3919	360	24	incidence	incidence	NOUN
gs-3919	360	25	of	of	ADP
gs-3919	360	26	life	life	NOUN
gs-3919	360	27	-	-	PUNCT
gs-3919	360	28	threatening	threaten	VERB
gs-3919	360	29	reactions	reaction	NOUN
gs-3919	360	30	.	.	PUNCT
gs-3919	361	1	other	other	ADJ
gs-3919	361	2	hla	hla	PROPN
gs-3919	361	3	alleles	allele	NOUN
gs-3919	361	4	,	,	PUNCT
gs-3919	361	5	such	such	ADJ
gs-3919	361	6	as	as	ADP
gs-3919	361	7	hla	hla	PROPN
gs-3919	361	8	-	-	PUNCT
gs-3919	361	9	a*31:01	a*31:01	PROPN
gs-3919	361	10	(	(	PUNCT
gs-3919	361	11	linked	link	VERB
gs-3919	361	12	to	to	ADP
gs-3919	361	13	carbamazepine	carbamazepine	NOUN
gs-3919	361	14	hypersensitivity	hypersensitivity	NOUN
gs-3919	361	15	)	)	PUNCT
gs-3919	361	16	and	and	CCONJ
gs-3919	361	17	hla	hla	PROPN
gs-3919	361	18	-	-	PUNCT
gs-3919	361	19	b*58:01	b*58:01	PROPN
gs-3919	361	20	(	(	PUNCT
gs-3919	361	21	associated	associate	VERB
gs-3919	361	22	with	with	ADP
gs-3919	361	23	allopurinolinduced	allopurinolinduced	ADJ
gs-3919	361	24	dress	dress	NOUN
gs-3919	361	25	)	)	PUNCT
gs-3919	361	26	,	,	PUNCT
gs-3919	361	27	highlight	highlight	VERB
gs-3919	361	28	the	the	DET
gs-3919	361	29	broader	broad	ADJ
gs-3919	361	30	role	role	NOUN
gs-3919	361	31	of	of	ADP
gs-3919	361	32	the	the	DET
gs-3919	361	33	major	major	ADJ
gs-3919	361	34	histocompatibility	histocompatibility	NOUN
gs-3919	361	35	complex	complex	NOUN
gs-3919	361	36	(	(	PUNCT
gs-3919	361	37	mhc	mhc	PROPN
gs-3919	361	38	)	)	PUNCT
gs-3919	361	39	in	in	ADP
gs-3919	361	40	modulating	modulate	VERB
gs-3919	361	41	immune	immune	ADJ
gs-3919	361	42	responses	response	NOUN
gs-3919	361	43	to	to	ADP
gs-3919	361	44	pharmacological	pharmacological	ADJ
gs-3919	361	45	agents	agent	NOUN
gs-3919	361	46	.	.	PUNCT
gs-3919	362	1	georgian	georgian	ADJ
gs-3919	362	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	362	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	362	4	ტ.	ტ.	VERB
gs-3919	362	5	7	7	NUM
gs-3919	362	6	n	n	PRON
gs-3919	362	7	3	3	NUM
gs-3919	362	8	,	,	PUNCT
gs-3919	362	9	2025	2025	NUM
gs-3919	362	10	163	163	NUM
gs-3919	362	11	beyond	beyond	ADP
gs-3919	362	12	genetics	genetic	NOUN
gs-3919	362	13	,	,	PUNCT
gs-3919	362	14	pharmacokinetic	pharmacokinetic	ADJ
gs-3919	362	15	and	and	CCONJ
gs-3919	362	16	pharmacodynamic	pharmacodynamic	ADJ
gs-3919	362	17	factors	factor	NOUN
gs-3919	362	18	influence	influence	VERB
gs-3919	362	19	the	the	DET
gs-3919	362	20	likelihood	likelihood	NOUN
gs-3919	362	21	of	of	ADP
gs-3919	362	22	eosinophilic	eosinophilic	ADJ
gs-3919	362	23	reactions	reaction	NOUN
gs-3919	362	24	.	.	PUNCT
gs-3919	363	1	drugs	drug	NOUN
gs-3919	363	2	with	with	ADP
gs-3919	363	3	long	long	ADJ
gs-3919	363	4	half	half	ADJ
gs-3919	363	5	-	-	PUNCT
gs-3919	363	6	lives	life	NOUN
gs-3919	363	7	or	or	CCONJ
gs-3919	363	8	those	those	PRON
gs-3919	363	9	requiring	require	VERB
gs-3919	363	10	bioactivation	bioactivation	NOUN
gs-3919	363	11	by	by	ADP
gs-3919	363	12	hepatic	hepatic	ADJ
gs-3919	363	13	enzymes	enzyme	NOUN
gs-3919	363	14	(	(	PUNCT
gs-3919	363	15	e.g.	e.g.	ADV
gs-3919	363	16	,	,	PUNCT
gs-3919	363	17	cytochrome	cytochrome	ADJ
gs-3919	363	18	p450	p450	PROPN
gs-3919	363	19	isoforms	isoform	NOUN
gs-3919	363	20	)	)	PUNCT
gs-3919	363	21	pose	pose	VERB
gs-3919	363	22	heightened	heighten	VERB
gs-3919	363	23	risks	risk	NOUN
gs-3919	363	24	due	due	ADJ
gs-3919	363	25	to	to	ADP
gs-3919	363	26	prolonged	prolonged	ADJ
gs-3919	363	27	exposure	exposure	NOUN
gs-3919	363	28	to	to	ADP
gs-3919	363	29	immunogenic	immunogenic	ADJ
gs-3919	363	30	intermediates	intermediate	NOUN
gs-3919	363	31	.	.	PUNCT
gs-3919	364	1	conversely	conversely	ADV
gs-3919	364	2	,	,	PUNCT
gs-3919	364	3	drugs	drug	NOUN
gs-3919	364	4	excreted	excrete	VERB
gs-3919	364	5	unchanged	unchanged	ADJ
gs-3919	364	6	in	in	ADP
gs-3919	364	7	the	the	DET
gs-3919	364	8	urine	urine	NOUN
gs-3919	364	9	may	may	AUX
gs-3919	364	10	present	present	VERB
gs-3919	364	11	lower	low	ADJ
gs-3919	364	12	risks	risk	NOUN
gs-3919	364	13	,	,	PUNCT
gs-3919	364	14	though	though	SCONJ
gs-3919	364	15	exceptions	exception	NOUN
gs-3919	364	16	exist	exist	VERB
gs-3919	364	17	.	.	PUNCT
gs-3919	365	1	comorbidities	comorbiditie	NOUN
gs-3919	365	2	such	such	ADJ
gs-3919	365	3	as	as	ADP
gs-3919	365	4	renal	renal	ADJ
gs-3919	365	5	or	or	CCONJ
gs-3919	365	6	hepatic	hepatic	ADJ
gs-3919	365	7	impairment	impairment	NOUN
gs-3919	365	8	can	can	AUX
gs-3919	365	9	further	far	ADV
gs-3919	365	10	alter	alter	VERB
gs-3919	365	11	drug	drug	NOUN
gs-3919	365	12	metabolism	metabolism	NOUN
gs-3919	365	13	,	,	PUNCT
gs-3919	365	14	exacerbating	exacerbate	VERB
gs-3919	365	15	susceptibility	susceptibility	NOUN
gs-3919	365	16	to	to	ADP
gs-3919	365	17	adverse	adverse	ADJ
gs-3919	365	18	reactions	reaction	NOUN
gs-3919	365	19	.	.	PUNCT
gs-3919	366	1	immunopathogenesis	immunopathogenesis	NOUN
gs-3919	366	2	of	of	ADP
gs-3919	366	3	drug	drug	NOUN
gs-3919	366	4	-	-	PUNCT
gs-3919	366	5	induced	induce	VERB
gs-3919	366	6	eosinophilia	eosinophilia	NOUN
gs-3919	366	7	the	the	DET
gs-3919	366	8	immunological	immunological	ADJ
gs-3919	366	9	cascade	cascade	NOUN
gs-3919	366	10	driving	drive	VERB
gs-3919	366	11	drug	drug	NOUN
gs-3919	366	12	-	-	PUNCT
gs-3919	366	13	induced	induce	VERB
gs-3919	366	14	eosinophilia	eosinophilia	NOUN
gs-3919	366	15	is	be	AUX
gs-3919	366	16	a	a	DET
gs-3919	366	17	multifaceted	multifaceted	ADJ
gs-3919	366	18	process	process	NOUN
gs-3919	366	19	involving	involve	VERB
gs-3919	366	20	innate	innate	ADJ
gs-3919	366	21	and	and	CCONJ
gs-3919	366	22	adaptive	adaptive	ADJ
gs-3919	366	23	immune	immune	ADJ
gs-3919	366	24	responses	response	NOUN
gs-3919	366	25	.	.	PUNCT
gs-3919	367	1	central	central	ADJ
gs-3919	367	2	to	to	ADP
gs-3919	367	3	this	this	DET
gs-3919	367	4	cascade	cascade	NOUN
gs-3919	367	5	is	be	AUX
gs-3919	367	6	the	the	DET
gs-3919	367	7	activation	activation	NOUN
gs-3919	367	8	of	of	ADP
gs-3919	367	9	cd4	cd4	PROPN
gs-3919	367	10	+	+	PROPN
gs-3919	367	11	t	t	PROPN
gs-3919	367	12	helper	helper	NOUN
gs-3919	367	13	2	2	NUM
gs-3919	367	14	(	(	PUNCT
gs-3919	367	15	th2	th2	PROPN
gs-3919	367	16	)	)	PUNCT
gs-3919	367	17	cells	cell	NOUN
gs-3919	367	18	,	,	PUNCT
gs-3919	367	19	which	which	PRON
gs-3919	367	20	secrete	secrete	VERB
gs-3919	367	21	cytokines	cytokine	VERB
gs-3919	367	22	such	such	ADJ
gs-3919	367	23	as	as	ADP
gs-3919	367	24	interleukin-5	interleukin-5	PROPN
gs-3919	367	25	(	(	PUNCT
gs-3919	367	26	il-5	il-5	NUM
gs-3919	367	27	)	)	PUNCT
gs-3919	367	28	,	,	PUNCT
gs-3919	367	29	il-4	il-4	PROPN
gs-3919	367	30	,	,	PUNCT
gs-3919	367	31	and	and	CCONJ
gs-3919	367	32	il-13	il-13	NUM
gs-3919	367	33	.	.	PUNCT
gs-3919	368	1	il-5	il-5	PROPN
gs-3919	368	2	,	,	PUNCT
gs-3919	368	3	in	in	ADP
gs-3919	368	4	particular	particular	ADJ
gs-3919	368	5	,	,	PUNCT
gs-3919	368	6	is	be	AUX
gs-3919	368	7	a	a	DET
gs-3919	368	8	critical	critical	ADJ
gs-3919	368	9	regulator	regulator	NOUN
gs-3919	368	10	of	of	ADP
gs-3919	368	11	eosinophilopoiesis	eosinophilopoiesis	NOUN
gs-3919	368	12	,	,	PUNCT
gs-3919	368	13	survival	survival	NOUN
gs-3919	368	14	,	,	PUNCT
gs-3919	368	15	and	and	CCONJ
gs-3919	368	16	tissue	tissue	NOUN
gs-3919	368	17	recruitment	recruitment	NOUN
gs-3919	368	18	.	.	PUNCT
gs-3919	369	1	elevated	elevate	VERB
gs-3919	369	2	serum	serum	NOUN
gs-3919	369	3	il-5	il-5	PROPN
gs-3919	369	4	levels	level	NOUN
gs-3919	369	5	are	be	AUX
gs-3919	369	6	a	a	DET
gs-3919	369	7	consistent	consistent	ADJ
gs-3919	369	8	feature	feature	NOUN
gs-3919	369	9	of	of	ADP
gs-3919	369	10	druginduced	druginduced	ADJ
gs-3919	369	11	eosinophilia	eosinophilia	PROPN
gs-3919	369	12	,	,	PUNCT
gs-3919	369	13	correlating	correlate	VERB
gs-3919	369	14	with	with	ADP
gs-3919	369	15	disease	disease	NOUN
gs-3919	369	16	severity	severity	NOUN
gs-3919	369	17	and	and	CCONJ
gs-3919	369	18	organ	organ	NOUN
gs-3919	369	19	involvement	involvement	NOUN
gs-3919	369	20	.	.	PUNCT
gs-3919	370	1	eosinophils	eosinophil	VERB
gs-3919	370	2	themselves	themselves	PRON
gs-3919	370	3	are	be	AUX
gs-3919	370	4	potent	potent	ADJ
gs-3919	370	5	effector	effector	NOUN
gs-3919	370	6	cells	cell	NOUN
gs-3919	370	7	,	,	PUNCT
gs-3919	370	8	capable	capable	ADJ
gs-3919	370	9	of	of	ADP
gs-3919	370	10	inducing	induce	VERB
gs-3919	370	11	tissue	tissue	NOUN
gs-3919	370	12	damage	damage	NOUN
gs-3919	370	13	through	through	ADP
gs-3919	370	14	the	the	DET
gs-3919	370	15	release	release	NOUN
gs-3919	370	16	of	of	ADP
gs-3919	370	17	preformed	preformed	ADJ
gs-3919	370	18	cytotoxic	cytotoxic	ADJ
gs-3919	370	19	granules	granule	NOUN
gs-3919	370	20	.	.	PUNCT
gs-3919	371	1	major	major	ADJ
gs-3919	371	2	basic	basic	ADJ
gs-3919	371	3	protein	protein	NOUN
gs-3919	371	4	(	(	PUNCT
gs-3919	371	5	mbp	mbp	NOUN
gs-3919	371	6	)	)	PUNCT
gs-3919	371	7	,	,	PUNCT
gs-3919	371	8	eosinophil	eosinophil	ADJ
gs-3919	371	9	peroxidase	peroxidase	NOUN
gs-3919	371	10	(	(	PUNCT
gs-3919	371	11	epo	epo	PROPN
gs-3919	371	12	)	)	PUNCT
gs-3919	371	13	,	,	PUNCT
gs-3919	371	14	and	and	CCONJ
gs-3919	371	15	eosinophil	eosinophil	ADJ
gs-3919	371	16	-	-	PUNCT
gs-3919	371	17	derived	derive	VERB
gs-3919	371	18	neurotoxin	neurotoxin	NOUN
gs-3919	371	19	(	(	PUNCT
gs-3919	371	20	edn	edn	NOUN
gs-3919	371	21	)	)	PUNCT
gs-3919	371	22	disrupt	disrupt	VERB
gs-3919	371	23	epithelial	epithelial	ADJ
gs-3919	371	24	and	and	CCONJ
gs-3919	371	25	endothelial	endothelial	ADJ
gs-3919	371	26	barriers	barrier	NOUN
gs-3919	371	27	,	,	PUNCT
gs-3919	371	28	promoting	promote	VERB
gs-3919	371	29	inflammation	inflammation	NOUN
gs-3919	371	30	and	and	CCONJ
gs-3919	371	31	fibrosis	fibrosis	NOUN
gs-3919	371	32	.	.	PUNCT
gs-3919	372	1	in	in	ADP
gs-3919	372	2	severe	severe	ADJ
gs-3919	372	3	cases	case	NOUN
gs-3919	372	4	,	,	PUNCT
gs-3919	372	5	eosinophilic	eosinophilic	ADJ
gs-3919	372	6	infiltration	infiltration	NOUN
gs-3919	372	7	of	of	ADP
gs-3919	372	8	organs	organ	NOUN
gs-3919	372	9	such	such	ADJ
gs-3919	372	10	as	as	ADP
gs-3919	372	11	the	the	DET
gs-3919	372	12	liver	liver	NOUN
gs-3919	372	13	,	,	PUNCT
gs-3919	372	14	kidneys	kidney	NOUN
gs-3919	372	15	,	,	PUNCT
gs-3919	372	16	and	and	CCONJ
gs-3919	372	17	heart	heart	NOUN
gs-3919	372	18	can	can	AUX
gs-3919	372	19	lead	lead	VERB
gs-3919	372	20	to	to	ADP
gs-3919	372	21	acute	acute	ADJ
gs-3919	372	22	hepatitis	hepatitis	NOUN
gs-3919	372	23	,	,	PUNCT
gs-3919	372	24	interstitial	interstitial	ADJ
gs-3919	372	25	nephritis	nephritis	NOUN
gs-3919	372	26	,	,	PUNCT
gs-3919	372	27	or	or	CCONJ
gs-3919	372	28	myocarditis	myocarditis	PROPN
gs-3919	372	29	—	—	PUNCT
gs-3919	372	30	complications	complication	NOUN
gs-3919	372	31	that	that	PRON
gs-3919	372	32	significantly	significantly	ADV
gs-3919	372	33	increase	increase	VERB
gs-3919	372	34	morbidity	morbidity	NOUN
gs-3919	372	35	and	and	CCONJ
gs-3919	372	36	mortality	mortality	NOUN
gs-3919	372	37	.	.	PUNCT
gs-3919	373	1	the	the	DET
gs-3919	373	2	role	role	NOUN
gs-3919	373	3	of	of	ADP
gs-3919	373	4	viral	viral	ADJ
gs-3919	373	5	reactivation	reactivation	NOUN
gs-3919	373	6	in	in	ADP
gs-3919	373	7	exacerbating	exacerbate	VERB
gs-3919	373	8	drug	drug	NOUN
gs-3919	373	9	-	-	PUNCT
gs-3919	373	10	induced	induce	VERB
gs-3919	373	11	eosinophilia	eosinophilia	NOUN
gs-3919	373	12	has	have	AUX
gs-3919	373	13	garnered	garner	VERB
gs-3919	373	14	increasing	increase	VERB
gs-3919	373	15	attention	attention	NOUN
gs-3919	373	16	.	.	PUNCT
gs-3919	374	1	human	human	NOUN
gs-3919	374	2	herpesvirus-6	herpesvirus-6	PRON
gs-3919	374	3	(	(	PUNCT
gs-3919	374	4	hhv-6	hhv-6	NOUN
gs-3919	374	5	)	)	PUNCT
gs-3919	374	6	and	and	CCONJ
gs-3919	374	7	epstein	epstein	PROPN
gs-3919	374	8	-	-	PUNCT
gs-3919	374	9	barr	barr	PROPN
gs-3919	374	10	virus	virus	PROPN
gs-3919	374	11	(	(	PUNCT
gs-3919	374	12	ebv	ebv	NOUN
gs-3919	374	13	)	)	PUNCT
gs-3919	374	14	reactivation	reactivation	NOUN
gs-3919	374	15	are	be	AUX
gs-3919	374	16	frequently	frequently	ADV
gs-3919	374	17	observed	observe	VERB
gs-3919	374	18	in	in	ADP
gs-3919	374	19	dress	dress	NOUN
gs-3919	374	20	syndrome	syndrome	NOUN
gs-3919	374	21	,	,	PUNCT
gs-3919	374	22	suggesting	suggest	VERB
gs-3919	374	23	that	that	SCONJ
gs-3919	374	24	drug	drug	NOUN
gs-3919	374	25	-	-	PUNCT
gs-3919	374	26	antigendriven	antigendriven	VERB
gs-3919	374	27	immune	immune	ADJ
gs-3919	374	28	dysregulation	dysregulation	NOUN
gs-3919	374	29	may	may	AUX
gs-3919	374	30	unmask	unmask	VERB
gs-3919	374	31	latent	latent	NOUN
gs-3919	374	32	infections	infection	NOUN
gs-3919	374	33	.	.	PUNCT
gs-3919	375	1	this	this	DET
gs-3919	375	2	phenomenon	phenomenon	NOUN
gs-3919	375	3	complicates	complicate	VERB
gs-3919	375	4	the	the	DET
gs-3919	375	5	clinical	clinical	ADJ
gs-3919	375	6	picture	picture	NOUN
gs-3919	375	7	,	,	PUNCT
gs-3919	375	8	as	as	SCONJ
gs-3919	375	9	viral	viral	ADJ
gs-3919	375	10	symptoms	symptom	NOUN
gs-3919	375	11	can	can	AUX
gs-3919	375	12	mimic	mimic	VERB
gs-3919	375	13	or	or	CCONJ
gs-3919	375	14	exacerbate	exacerbate	VERB
gs-3919	375	15	drug	drug	NOUN
gs-3919	375	16	hypersensitivity	hypersensitivity	NOUN
gs-3919	375	17	,	,	PUNCT
gs-3919	375	18	necessitating	necessitate	VERB
gs-3919	375	19	careful	careful	ADJ
gs-3919	375	20	diagnostic	diagnostic	ADJ
gs-3919	375	21	differentiation	differentiation	NOUN
gs-3919	375	22	.	.	PUNCT
gs-3919	376	1	clinical	clinical	ADJ
gs-3919	376	2	spectrum	spectrum	NOUN
gs-3919	376	3	and	and	CCONJ
gs-3919	376	4	diagnostic	diagnostic	ADJ
gs-3919	376	5	challenges	challenge	NOUN
gs-3919	376	6	the	the	DET
gs-3919	376	7	clinical	clinical	ADJ
gs-3919	376	8	presentation	presentation	NOUN
gs-3919	376	9	of	of	ADP
gs-3919	376	10	drug	drug	NOUN
gs-3919	376	11	-	-	PUNCT
gs-3919	376	12	induced	induce	VERB
gs-3919	376	13	eosinophilia	eosinophilia	NOUN
gs-3919	376	14	is	be	AUX
gs-3919	376	15	remarkably	remarkably	ADV
gs-3919	376	16	heterogeneous	heterogeneous	ADJ
gs-3919	376	17	,	,	PUNCT
gs-3919	376	18	posing	pose	VERB
gs-3919	376	19	significant	significant	ADJ
gs-3919	376	20	diagnostic	diagnostic	ADJ
gs-3919	376	21	challenges	challenge	NOUN
gs-3919	376	22	.	.	PUNCT
gs-3919	377	1	dress	dress	NOUN
gs-3919	377	2	syndrome	syndrome	NOUN
gs-3919	377	3	,	,	PUNCT
gs-3919	377	4	the	the	DET
gs-3919	377	5	most	most	ADV
gs-3919	377	6	severe	severe	ADJ
gs-3919	377	7	manifestation	manifestation	NOUN
gs-3919	377	8	,	,	PUNCT
gs-3919	377	9	typically	typically	ADV
gs-3919	377	10	presents	present	VERB
gs-3919	377	11	with	with	ADP
gs-3919	377	12	fever	fever	NOUN
gs-3919	377	13	,	,	PUNCT
gs-3919	377	14	rash	rash	ADJ
gs-3919	377	15	,	,	PUNCT
gs-3919	377	16	lymphadenopathy	lymphadenopathy	ADJ
gs-3919	377	17	,	,	PUNCT
gs-3919	377	18	and	and	CCONJ
gs-3919	377	19	hematologic	hematologic	NOUN
gs-3919	377	20	abnormalities	abnormality	NOUN
gs-3919	377	21	(	(	PUNCT
gs-3919	377	22	e.g.	e.g.	ADV
gs-3919	377	23	,	,	PUNCT
gs-3919	377	24	atypical	atypical	ADJ
gs-3919	377	25	lymphocytes	lymphocyte	NOUN
gs-3919	377	26	,	,	PUNCT
gs-3919	377	27	eosinophilia	eosinophilia	PROPN
gs-3919	377	28	)	)	PUNCT
gs-3919	377	29	.	.	PUNCT
gs-3919	378	1	however	however	ADV
gs-3919	378	2	,	,	PUNCT
gs-3919	378	3	atypical	atypical	ADJ
gs-3919	378	4	cases	case	NOUN
gs-3919	378	5	may	may	AUX
gs-3919	378	6	lack	lack	VERB
gs-3919	378	7	cutaneous	cutaneous	ADJ
gs-3919	378	8	involvement	involvement	NOUN
gs-3919	378	9	,	,	PUNCT
gs-3919	378	10	instead	instead	ADV
gs-3919	378	11	presenting	present	VERB
gs-3919	378	12	with	with	ADP
gs-3919	378	13	isolated	isolated	ADJ
gs-3919	378	14	organ	organ	NOUN
gs-3919	378	15	dysfunction	dysfunction	NOUN
gs-3919	378	16	.	.	PUNCT
gs-3919	379	1	hepatic	hepatic	ADJ
gs-3919	379	2	injury	injury	NOUN
gs-3919	379	3	(	(	PUNCT
gs-3919	379	4	75	75	NUM
gs-3919	379	5	%	%	NOUN
gs-3919	379	6	of	of	ADP
gs-3919	379	7	cases	case	NOUN
gs-3919	379	8	)	)	PUNCT
gs-3919	379	9	and	and	CCONJ
gs-3919	379	10	renal	renal	ADJ
gs-3919	379	11	impairment	impairment	NOUN
gs-3919	379	12	(	(	PUNCT
gs-3919	379	13	30	30	NUM
gs-3919	379	14	%	%	NOUN
gs-3919	379	15	)	)	PUNCT
gs-3919	379	16	are	be	AUX
gs-3919	379	17	common	common	ADJ
gs-3919	379	18	,	,	PUNCT
gs-3919	379	19	though	though	SCONJ
gs-3919	379	20	pulmonary	pulmonary	ADJ
gs-3919	379	21	,	,	PUNCT
gs-3919	379	22	cardiac	cardiac	ADJ
gs-3919	379	23	,	,	PUNCT
gs-3919	379	24	and	and	CCONJ
gs-3919	379	25	neurological	neurological	ADJ
gs-3919	379	26	involvement	involvement	NOUN
gs-3919	379	27	can	can	AUX
gs-3919	379	28	also	also	ADV
gs-3919	379	29	occur	occur	VERB
gs-3919	379	30	.	.	PUNCT
gs-3919	380	1	diagnostic	diagnostic	ADJ
gs-3919	380	2	criteria	criterion	NOUN
gs-3919	380	3	,	,	PUNCT
gs-3919	380	4	such	such	ADJ
gs-3919	380	5	as	as	ADP
gs-3919	380	6	the	the	DET
gs-3919	380	7	regiscar	regiscar	ADJ
gs-3919	380	8	scoring	scoring	NOUN
gs-3919	380	9	system	system	NOUN
gs-3919	380	10	,	,	PUNCT
gs-3919	380	11	provide	provide	VERB
gs-3919	380	12	a	a	DET
gs-3919	380	13	structured	structure	VERB
gs-3919	380	14	framework	framework	NOUN
gs-3919	380	15	for	for	ADP
gs-3919	380	16	identifying	identify	VERB
gs-3919	380	17	dress	dress	NOUN
gs-3919	380	18	,	,	PUNCT
gs-3919	380	19	yet	yet	CCONJ
gs-3919	380	20	limitations	limitation	NOUN
gs-3919	380	21	persist	persist	VERB
gs-3919	380	22	.	.	PUNCT
gs-3919	381	1	the	the	DET
gs-3919	381	2	latency	latency	NOUN
gs-3919	381	3	period	period	NOUN
gs-3919	381	4	between	between	ADP
gs-3919	381	5	drug	drug	NOUN
gs-3919	381	6	initiation	initiation	NOUN
gs-3919	381	7	and	and	CCONJ
gs-3919	381	8	symptom	symptom	NOUN
gs-3919	381	9	onset	onset	NOUN
gs-3919	381	10	(	(	PUNCT
gs-3919	381	11	often	often	ADV
gs-3919	381	12	2–8	2–8	NUM
gs-3919	381	13	weeks	week	NOUN
gs-3919	381	14	)	)	PUNCT
gs-3919	381	15	complicates	complicate	VERB
gs-3919	381	16	causal	causal	ADJ
gs-3919	381	17	attribution	attribution	NOUN
gs-3919	381	18	,	,	PUNCT
gs-3919	381	19	particularly	particularly	ADV
gs-3919	381	20	georgian	georgian	ADJ
gs-3919	381	21	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	381	22	მეცნიერები	მეცნიერები	NOUN
gs-3919	381	23	ტ.	ტ.	VERB
gs-3919	381	24	7	7	NUM
gs-3919	381	25	n	n	DET
gs-3919	381	26	3	3	NUM
gs-3919	381	27	,	,	PUNCT
gs-3919	381	28	2025	2025	NUM
gs-3919	381	29	164	164	NUM
gs-3919	381	30	in	in	ADP
gs-3919	381	31	patients	patient	NOUN
gs-3919	381	32	on	on	ADP
gs-3919	381	33	multiple	multiple	ADJ
gs-3919	381	34	medications	medication	NOUN
gs-3919	381	35	.	.	PUNCT
gs-3919	382	1	furthermore	furthermore	ADV
gs-3919	382	2	,	,	PUNCT
gs-3919	382	3	eosinophilia	eosinophilia	PROPN
gs-3919	382	4	is	be	AUX
gs-3919	382	5	not	not	PART
gs-3919	382	6	pathognomonic	pathognomonic	ADJ
gs-3919	382	7	,	,	PUNCT
gs-3919	382	8	as	as	SCONJ
gs-3919	382	9	it	it	PRON
gs-3919	382	10	can	can	AUX
gs-3919	382	11	occur	occur	VERB
gs-3919	382	12	in	in	ADP
gs-3919	382	13	infections	infection	NOUN
gs-3919	382	14	,	,	PUNCT
gs-3919	382	15	autoimmune	autoimmune	ADJ
gs-3919	382	16	diseases	disease	NOUN
gs-3919	382	17	,	,	PUNCT
gs-3919	382	18	and	and	CCONJ
gs-3919	382	19	malignancies	malignancy	NOUN
gs-3919	382	20	.	.	PUNCT
gs-3919	383	1	emerging	emerge	VERB
gs-3919	383	2	biomarkers	biomarker	NOUN
gs-3919	383	3	—	—	PUNCT
gs-3919	383	4	such	such	ADJ
gs-3919	383	5	as	as	ADP
gs-3919	383	6	serum	serum	NOUN
gs-3919	383	7	thymus	thymus	NOUN
gs-3919	383	8	and	and	CCONJ
gs-3919	383	9	activation	activation	NOUN
gs-3919	383	10	-	-	PUNCT
gs-3919	383	11	regulated	regulate	VERB
gs-3919	383	12	chemokine	chemokine	ADJ
gs-3919	383	13	(	(	PUNCT
gs-3919	383	14	tarc	tarc	PROPN
gs-3919	383	15	)	)	PUNCT
gs-3919	383	16	and	and	CCONJ
gs-3919	383	17	il-33	il-33	NUM
gs-3919	383	18	—	—	PUNCT
gs-3919	383	19	show	show	VERB
gs-3919	383	20	promise	promise	NOUN
gs-3919	383	21	for	for	ADP
gs-3919	383	22	improving	improve	VERB
gs-3919	383	23	diagnostic	diagnostic	ADJ
gs-3919	383	24	accuracy	accuracy	NOUN
gs-3919	383	25	but	but	CCONJ
gs-3919	383	26	require	require	VERB
gs-3919	383	27	further	further	ADJ
gs-3919	383	28	validation	validation	NOUN
gs-3919	383	29	.	.	PUNCT
gs-3919	384	1	therapeutic	therapeutic	ADJ
gs-3919	384	2	strategies	strategy	NOUN
gs-3919	384	3	and	and	CCONJ
gs-3919	384	4	unmet	unmet	NOUN
gs-3919	384	5	needs	need	VERB
gs-3919	384	6	the	the	DET
gs-3919	384	7	cornerstone	cornerstone	NOUN
gs-3919	384	8	of	of	ADP
gs-3919	384	9	management	management	NOUN
gs-3919	384	10	is	be	AUX
gs-3919	384	11	immediate	immediate	ADJ
gs-3919	384	12	discontinuation	discontinuation	NOUN
gs-3919	384	13	of	of	ADP
gs-3919	384	14	the	the	DET
gs-3919	384	15	offending	offend	VERB
gs-3919	384	16	drug	drug	NOUN
gs-3919	384	17	,	,	PUNCT
gs-3919	384	18	followed	follow	VERB
gs-3919	384	19	by	by	ADP
gs-3919	384	20	supportive	supportive	ADJ
gs-3919	384	21	care	care	NOUN
gs-3919	384	22	.	.	PUNCT
gs-3919	385	1	systemic	systemic	ADJ
gs-3919	385	2	corticosteroids	corticosteroid	NOUN
gs-3919	385	3	(	(	PUNCT
gs-3919	385	4	0.5–1	0.5–1	INTJ
gs-3919	385	5	mg	mg	PROPN
gs-3919	385	6	/	/	SYM
gs-3919	385	7	kg	kg	PROPN
gs-3919	385	8	/	/	SYM
gs-3919	385	9	day	day	NOUN
gs-3919	385	10	prednisone	prednisone	PROPN
gs-3919	385	11	equivalent	equivalent	NOUN
gs-3919	385	12	)	)	PUNCT
gs-3919	385	13	are	be	AUX
gs-3919	385	14	widely	widely	ADV
gs-3919	385	15	used	use	VERB
gs-3919	385	16	for	for	ADP
gs-3919	385	17	moderate	moderate	ADJ
gs-3919	385	18	to	to	ADP
gs-3919	385	19	severe	severe	ADJ
gs-3919	385	20	reactions	reaction	NOUN
gs-3919	385	21	,	,	PUNCT
gs-3919	385	22	though	though	SCONJ
gs-3919	385	23	optimal	optimal	ADJ
gs-3919	385	24	duration	duration	NOUN
gs-3919	385	25	remains	remain	VERB
gs-3919	385	26	debated	debate	VERB
gs-3919	385	27	.	.	PUNCT
gs-3919	386	1	refractory	refractory	NOUN
gs-3919	386	2	cases	case	NOUN
gs-3919	386	3	may	may	AUX
gs-3919	386	4	require	require	VERB
gs-3919	386	5	steroid	steroid	NOUN
gs-3919	386	6	-	-	PUNCT
gs-3919	386	7	sparing	spare	VERB
gs-3919	386	8	agents	agent	NOUN
gs-3919	386	9	(	(	PUNCT
gs-3919	386	10	e.g.	e.g.	ADV
gs-3919	386	11	,	,	PUNCT
gs-3919	386	12	mycophenolate	mycophenolate	PROPN
gs-3919	386	13	mofetil	mofetil	PROPN
gs-3919	386	14	)	)	PUNCT
gs-3919	386	15	or	or	CCONJ
gs-3919	386	16	biologics	biologic	NOUN
gs-3919	386	17	(	(	PUNCT
gs-3919	386	18	e.g.	e.g.	ADV
gs-3919	386	19	,	,	PUNCT
gs-3919	386	20	mepolizumab	mepolizumab	NOUN
gs-3919	386	21	)	)	PUNCT
gs-3919	386	22	.	.	PUNCT
gs-3919	387	1	long	long	ADJ
gs-3919	387	2	-	-	PUNCT
gs-3919	387	3	term	term	NOUN
gs-3919	387	4	sequelae	sequelae	NOUN
gs-3919	387	5	,	,	PUNCT
gs-3919	387	6	such	such	ADJ
gs-3919	387	7	as	as	ADP
gs-3919	387	8	autoimmune	autoimmune	ADJ
gs-3919	387	9	thyroiditis	thyroiditis	NOUN
gs-3919	387	10	,	,	PUNCT
gs-3919	387	11	necessitate	necessitate	ADJ
gs-3919	387	12	ongoing	ongoing	ADJ
gs-3919	387	13	monitoring	monitoring	NOUN
gs-3919	387	14	.	.	PUNCT
gs-3919	388	1	drug	drug	NOUN
gs-3919	388	2	-	-	PUNCT
gs-3919	388	3	induced	induce	VERB
gs-3919	388	4	eosinophilia	eosinophilia	NOUN
gs-3919	388	5	and	and	CCONJ
gs-3919	388	6	systemic	systemic	ADJ
gs-3919	388	7	symptoms	symptom	NOUN
gs-3919	388	8	represent	represent	VERB
gs-3919	388	9	a	a	DET
gs-3919	388	10	critical	critical	ADJ
gs-3919	388	11	intersection	intersection	NOUN
gs-3919	388	12	of	of	ADP
gs-3919	388	13	pharmacology	pharmacology	NOUN
gs-3919	388	14	and	and	CCONJ
gs-3919	388	15	immunology	immunology	NOUN
gs-3919	388	16	.	.	PUNCT
gs-3919	389	1	advances	advance	NOUN
gs-3919	389	2	in	in	ADP
gs-3919	389	3	pharmacogenomics	pharmacogenomic	NOUN
gs-3919	389	4	,	,	PUNCT
gs-3919	389	5	biomarker	biomarker	NOUN
gs-3919	389	6	discovery	discovery	NOUN
gs-3919	389	7	,	,	PUNCT
gs-3919	389	8	and	and	CCONJ
gs-3919	389	9	targeted	target	VERB
gs-3919	389	10	therapies	therapy	NOUN
gs-3919	389	11	hold	hold	VERB
gs-3919	389	12	promise	promise	NOUN
gs-3919	389	13	for	for	ADP
gs-3919	389	14	improving	improve	VERB
gs-3919	389	15	outcomes	outcome	NOUN
gs-3919	389	16	.	.	PUNCT
gs-3919	390	1	future	future	ADJ
gs-3919	390	2	research	research	NOUN
gs-3919	390	3	should	should	AUX
gs-3919	390	4	prioritize	prioritize	VERB
gs-3919	390	5	precision	precision	NOUN
gs-3919	390	6	medicine	medicine	NOUN
gs-3919	390	7	approaches	approach	NOUN
gs-3919	390	8	to	to	PART
gs-3919	390	9	identify	identify	VERB
gs-3919	390	10	at	at	ADP
gs-3919	390	11	-	-	PUNCT
gs-3919	390	12	risk	risk	NOUN
gs-3919	390	13	patients	patient	NOUN
gs-3919	390	14	and	and	CCONJ
gs-3919	390	15	optimize	optimize	VERB
gs-3919	390	16	therapeutic	therapeutic	ADJ
gs-3919	390	17	interventions	intervention	NOUN
gs-3919	390	18	.	.	PUNCT
gs-3919	391	1	further	further	ADJ
gs-3919	391	2	work	work	NOUN
gs-3919	391	3	is	be	AUX
gs-3919	391	4	needed	need	VERB
gs-3919	391	5	to	to	PART
gs-3919	391	6	increase	increase	VERB
gs-3919	391	7	awareness	awareness	NOUN
gs-3919	391	8	of	of	ADP
gs-3919	391	9	the	the	DET
gs-3919	391	10	dress	dress	NOUN
gs-3919	391	11	syndrome	syndrome	NOUN
gs-3919	391	12	with	with	ADP
gs-3919	391	13	respect	respect	NOUN
gs-3919	391	14	to	to	ADP
gs-3919	391	15	diagnostic	diagnostic	ADJ
gs-3919	391	16	,	,	PUNCT
gs-3919	391	17	therapeutic	therapeutic	ADJ
gs-3919	391	18	,	,	PUNCT
gs-3919	391	19	monitoring	monitoring	NOUN
gs-3919	391	20	,	,	PUNCT
gs-3919	391	21	and	and	CCONJ
gs-3919	391	22	prophylactic	prophylactic	ADJ
gs-3919	391	23	approaches	approach	NOUN
gs-3919	391	24	.	.	PUNCT
gs-3919	392	1	the	the	DET
gs-3919	392	2	results	result	NOUN
gs-3919	392	3	in	in	ADP
gs-3919	392	4	this	this	DET
gs-3919	392	5	document	document	NOUN
gs-3919	392	6	offer	offer	VERB
gs-3919	392	7	several	several	ADJ
gs-3919	392	8	ways	way	NOUN
gs-3919	392	9	for	for	ADP
gs-3919	392	10	further	further	ADJ
gs-3919	392	11	progress	progress	NOUN
gs-3919	392	12	,	,	PUNCT
gs-3919	392	13	which	which	PRON
gs-3919	392	14	are	be	AUX
gs-3919	392	15	motivated	motivate	VERB
gs-3919	392	16	by	by	ADP
gs-3919	392	17	a	a	DET
gs-3919	392	18	detailed	detailed	ADJ
gs-3919	392	19	analysis	analysis	NOUN
gs-3919	392	20	over	over	ADP
gs-3919	392	21	the	the	DET
gs-3919	392	22	references	reference	NOUN
gs-3919	392	23	considered	consider	VERB
gs-3919	392	24	.	.	PUNCT
gs-3919	393	1	advancements	advancement	NOUN
gs-3919	393	2	in	in	ADP
gs-3919	393	3	the	the	DET
gs-3919	393	4	creation	creation	NOUN
gs-3919	393	5	of	of	ADP
gs-3919	393	6	universal	universal	ADJ
gs-3919	393	7	diagnostic	diagnostic	ADJ
gs-3919	393	8	criteria	criterion	NOUN
gs-3919	393	9	and	and	CCONJ
gs-3919	393	10	biomarker	biomarker	VERB
gs-3919	393	11	there	there	ADV
gs-3919	393	12	still	still	ADV
gs-3919	393	13	is	be	AUX
gs-3919	393	14	an	an	DET
gs-3919	393	15	urgent	urgent	ADJ
gs-3919	393	16	need	need	NOUN
gs-3919	393	17	for	for	ADP
gs-3919	393	18	common	common	ADJ
gs-3919	393	19	diagnostic	diagnostic	ADJ
gs-3919	393	20	criteria	criterion	NOUN
gs-3919	393	21	and	and	CCONJ
gs-3919	393	22	valid	valid	ADJ
gs-3919	393	23	biomarkers	biomarker	NOUN
gs-3919	393	24	to	to	PART
gs-3919	393	25	enable	enable	VERB
gs-3919	393	26	early	early	ADJ
gs-3919	393	27	detection	detection	NOUN
gs-3919	393	28	of	of	ADP
gs-3919	393	29	dress	dress	NOUN
gs-3919	393	30	.	.	PUNCT
gs-3919	394	1	while	while	SCONJ
gs-3919	394	2	helpful	helpful	ADJ
gs-3919	394	3	in	in	ADP
gs-3919	394	4	a	a	DET
gs-3919	394	5	few	few	ADJ
gs-3919	394	6	ways	way	NOUN
gs-3919	394	7	,	,	PUNCT
gs-3919	394	8	the	the	DET
gs-3919	394	9	regi	regi	PROPN
gs-3919	394	10	scar	scar	PROPN
gs-3919	394	11	score	score	NOUN
gs-3919	394	12	is	be	AUX
gs-3919	394	13	not	not	PART
gs-3919	394	14	broadly	broadly	ADV
gs-3919	394	15	accepted	accept	VERB
gs-3919	394	16	in	in	ADP
gs-3919	394	17	other	other	ADJ
gs-3919	394	18	fields	field	NOUN
gs-3919	394	19	of	of	ADP
gs-3919	394	20	medicine	medicine	NOUN
gs-3919	394	21	,	,	PUNCT
gs-3919	394	22	as	as	SCONJ
gs-3919	394	23	it	it	PRON
gs-3919	394	24	is	be	AUX
gs-3919	394	25	only	only	ADV
gs-3919	394	26	specific	specific	ADJ
gs-3919	394	27	to	to	ADP
gs-3919	394	28	an	an	DET
gs-3919	394	29	initial	initial	ADJ
gs-3919	394	30	presentation	presentation	NOUN
gs-3919	394	31	.	.	PUNCT
gs-3919	395	1	the	the	DET
gs-3919	395	2	establishment	establishment	NOUN
gs-3919	395	3	of	of	ADP
gs-3919	395	4	biomarkers	biomarker	NOUN
gs-3919	395	5	,	,	PUNCT
gs-3919	395	6	e.g.	e.g.	ADV
gs-3919	395	7	cytokine	cytokine	ADJ
gs-3919	395	8	profiles	profile	NOUN
gs-3919	395	9	of	of	ADP
gs-3919	395	10	serum	serum	NOUN
gs-3919	395	11	eosinophil	eosinophil	ADJ
gs-3919	395	12	activation	activation	NOUN
gs-3919	395	13	markers	marker	NOUN
gs-3919	395	14	would	would	AUX
gs-3919	395	15	be	be	AUX
gs-3919	395	16	useful	useful	ADJ
gs-3919	395	17	to	to	PART
gs-3919	395	18	improve	improve	VERB
gs-3919	395	19	the	the	DET
gs-3919	395	20	diagnostic	diagnostic	ADJ
gs-3919	395	21	accuracy	accuracy	NOUN
gs-3919	395	22	.	.	PUNCT
gs-3919	396	1	incorporation	incorporation	NOUN
gs-3919	396	2	of	of	ADP
gs-3919	396	3	pharmacogenomics	pharmacogenomic	NOUN
gs-3919	396	4	into	into	ADP
gs-3919	396	5	clinical	clinical	ADJ
gs-3919	396	6	care	care	NOUN
gs-3919	396	7	hla	hla	PROPN
gs-3919	396	8	allele	allele	PROPN
gs-3919	396	9	genetic	genetic	ADJ
gs-3919	396	10	testing	testing	NOUN
gs-3919	396	11	has	have	AUX
gs-3919	396	12	already	already	ADV
gs-3919	396	13	been	be	AUX
gs-3919	396	14	shown	show	VERB
gs-3919	396	15	to	to	PART
gs-3919	396	16	be	be	AUX
gs-3919	396	17	effective	effective	ADJ
gs-3919	396	18	in	in	ADP
gs-3919	396	19	preventing	prevent	VERB
gs-3919	396	20	devastating	devastating	ADJ
gs-3919	396	21	drug	drug	NOUN
gs-3919	396	22	reactions	reaction	NOUN
gs-3919	396	23	in	in	ADP
gs-3919	396	24	certain	certain	ADJ
gs-3919	396	25	countries	country	NOUN
gs-3919	396	26	in	in	ADP
gs-3919	396	27	asia	asia	PROPN
gs-3919	396	28	.	.	PUNCT
gs-3919	397	1	adoption	adoption	NOUN
gs-3919	397	2	of	of	ADP
gs-3919	397	3	such	such	ADJ
gs-3919	397	4	pharmacogenomic	pharmacogenomic	ADJ
gs-3919	397	5	strategies	strategy	NOUN
gs-3919	397	6	on	on	ADP
gs-3919	397	7	a	a	DET
gs-3919	397	8	global	global	ADJ
gs-3919	397	9	scale	scale	NOUN
gs-3919	397	10	particularly	particularly	ADV
gs-3919	397	11	in	in	ADP
gs-3919	397	12	multiethnic	multiethnic	ADJ
gs-3919	397	13	populations	population	NOUN
gs-3919	397	14	will	will	AUX
gs-3919	397	15	be	be	AUX
gs-3919	397	16	crucial	crucial	ADJ
gs-3919	397	17	for	for	ADP
gs-3919	397	18	dress	dress	NOUN
gs-3919	397	19	prevention	prevention	NOUN
gs-3919	397	20	,	,	PUNCT
gs-3919	397	21	especially	especially	ADV
gs-3919	397	22	that	that	PRON
gs-3919	397	23	caused	cause	VERB
gs-3919	397	24	by	by	ADP
gs-3919	397	25	high	high	ADJ
gs-3919	397	26	-	-	PUNCT
gs-3919	397	27	risk	risk	NOUN
gs-3919	397	28	drugs	drug	NOUN
gs-3919	397	29	such	such	ADJ
gs-3919	397	30	as	as	ADP
gs-3919	397	31	allopurinol	allopurinol	NOUN
gs-3919	397	32	and	and	CCONJ
gs-3919	397	33	carbamazepine	carbamazepine	NOUN
gs-3919	397	34	.	.	PUNCT
gs-3919	398	1	efforts	effort	NOUN
gs-3919	398	2	should	should	AUX
gs-3919	398	3	now	now	ADV
gs-3919	398	4	turn	turn	VERB
gs-3919	398	5	to	to	PART
gs-3919	398	6	ensure	ensure	VERB
gs-3919	398	7	that	that	SCONJ
gs-3919	398	8	hla	hla	PROPN
gs-3919	398	9	and	and	CCONJ
gs-3919	398	10	crossmatch	crossmatch	VERB
gs-3919	398	11	tests	test	NOUN
gs-3919	398	12	low	low	ADJ
gs-3919	398	13	cost	cost	NOUN
gs-3919	398	14	,	,	PUNCT
gs-3919	398	15	rapid	rapid	ADJ
gs-3919	398	16	and	and	CCONJ
gs-3919	398	17	are	be	AUX
gs-3919	398	18	routinely	routinely	ADV
gs-3919	398	19	reimbursed	reimburse	VERB
gs-3919	398	20	in	in	ADP
gs-3919	398	21	the	the	DET
gs-3919	398	22	clinical	clinical	ADJ
gs-3919	398	23	setting	setting	NOUN
gs-3919	398	24	.	.	PUNCT
gs-3919	399	1	creation	creation	NOUN
gs-3919	399	2	of	of	ADP
gs-3919	399	3	international	international	ADJ
gs-3919	399	4	registries	registry	NOUN
gs-3919	399	5	and	and	CCONJ
gs-3919	399	6	reporting	report	VERB
gs-3919	399	7	systems	system	NOUN
gs-3919	399	8	to	to	PART
gs-3919	399	9	better	well	ADV
gs-3919	399	10	evaluate	evaluate	VERB
gs-3919	399	11	incidence	incidence	NOUN
gs-3919	399	12	,	,	PUNCT
gs-3919	399	13	to	to	PART
gs-3919	399	14	follow	follow	VERB
gs-3919	399	15	outcomes	outcome	NOUN
gs-3919	399	16	adequately	adequately	ADV
gs-3919	399	17	and	and	CCONJ
gs-3919	399	18	to	to	PART
gs-3919	399	19	characterize	characterize	VERB
gs-3919	399	20	epidemiological	epidemiological	ADJ
gs-3919	399	21	trends	trend	NOUN
gs-3919	399	22	,	,	PUNCT
gs-3919	399	23	future	future	ADJ
gs-3919	399	24	studies	study	NOUN
gs-3919	399	25	should	should	AUX
gs-3919	399	26	be	be	AUX
gs-3919	399	27	arranged	arrange	VERB
gs-3919	399	28	to	to	PART
gs-3919	399	29	participate	participate	VERB
gs-3919	399	30	in	in	ADP
gs-3919	399	31	international	international	ADJ
gs-3919	399	32	georgian	georgian	ADJ
gs-3919	399	33	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	399	34	მეცნიერები	მეცნიერები	NOUN
gs-3919	399	35	ტ.	ტ.	VERB
gs-3919	399	36	7	7	NUM
gs-3919	399	37	n	n	DET
gs-3919	399	38	3	3	NUM
gs-3919	399	39	,	,	PUNCT
gs-3919	399	40	2025	2025	NUM
gs-3919	399	41	165	165	NUM
gs-3919	399	42	registries	registry	NOUN
gs-3919	399	43	about	about	ADP
gs-3919	399	44	dress	dress	NOUN
gs-3919	399	45	.	.	PUNCT
gs-3919	400	1	these	these	DET
gs-3919	400	2	platforms	platform	NOUN
gs-3919	400	3	could	could	AUX
gs-3919	400	4	facilitate	facilitate	VERB
gs-3919	400	5	access	access	NOUN
gs-3919	400	6	to	to	ADP
gs-3919	400	7	big	big	ADJ
gs-3919	400	8	data	datum	NOUN
gs-3919	400	9	in	in	ADP
gs-3919	400	10	order	order	NOUN
gs-3919	400	11	to	to	PART
gs-3919	400	12	improve	improve	VERB
gs-3919	400	13	risk	risk	NOUN
gs-3919	400	14	stratification	stratification	NOUN
gs-3919	400	15	and	and	CCONJ
gs-3919	400	16	comparative	comparative	ADJ
gs-3919	400	17	effectiveness	effectiveness	NOUN
gs-3919	400	18	research	research	NOUN
gs-3919	400	19	studies	study	NOUN
gs-3919	400	20	.	.	PUNCT
gs-3919	401	1	advances	advance	NOUN
gs-3919	401	2	in	in	ADP
gs-3919	401	3	clinical	clinical	ADJ
gs-3919	401	4	research	research	NOUN
gs-3919	401	5	ongoing	ongoing	ADJ
gs-3919	401	6	usage	usage	NOUN
gs-3919	401	7	of	of	ADP
gs-3919	401	8	corticosteroids	corticosteroid	NOUN
gs-3919	401	9	and	and	CCONJ
gs-3919	401	10	anecdotal	anecdotal	ADJ
gs-3919	401	11	therapy	therapy	NOUN
gs-3919	401	12	further	far	ADV
gs-3919	401	13	underscores	underscore	VERB
gs-3919	401	14	the	the	DET
gs-3919	401	15	absence	absence	NOUN
gs-3919	401	16	of	of	ADP
gs-3919	401	17	prospective	prospective	ADJ
gs-3919	401	18	comparative	comparative	ADJ
gs-3919	401	19	clinical	clinical	ADJ
gs-3919	401	20	trials	trial	NOUN
gs-3919	401	21	to	to	ADP
gs-3919	401	22	this	this	DET
gs-3919	401	23	effect	effect	NOUN
gs-3919	401	24	.	.	PUNCT
gs-3919	402	1	additional	additional	ADJ
gs-3919	402	2	studies	study	NOUN
gs-3919	402	3	should	should	AUX
gs-3919	402	4	be	be	AUX
gs-3919	402	5	organised	organise	VERB
gs-3919	402	6	in	in	ADP
gs-3919	402	7	the	the	DET
gs-3919	402	8	shape	shape	NOUN
gs-3919	402	9	of	of	ADP
gs-3919	402	10	a	a	DET
gs-3919	402	11	multi	multi	ADJ
gs-3919	402	12	-	-	ADJ
gs-3919	402	13	arm	arm	ADJ
gs-3919	402	14	randomised	randomise	VERB
gs-3919	402	15	controlled	control	VERB
gs-3919	402	16	trial	trial	NOUN
gs-3919	402	17	between	between	ADP
gs-3919	402	18	various	various	ADJ
gs-3919	402	19	strategies	strategy	NOUN
gs-3919	402	20	(	(	PUNCT
gs-3919	402	21	steroids	steroid	NOUN
gs-3919	402	22	,	,	PUNCT
gs-3919	402	23	ivig	ivig	NOUN
gs-3919	402	24	,	,	PUNCT
gs-3919	402	25	cyclosporine	cyclosporine	NOUN
gs-3919	402	26	)	)	PUNCT
gs-3919	402	27	as	as	ADP
gs-3919	402	28	treatments	treatment	NOUN
gs-3919	402	29	,	,	PUNCT
gs-3919	402	30	taking	take	VERB
gs-3919	402	31	into	into	ADP
gs-3919	402	32	account	account	NOUN
gs-3919	402	33	the	the	DET
gs-3919	402	34	burden	burden	NOUN
gs-3919	402	35	of	of	ADP
gs-3919	402	36	organ	organ	NOUN
gs-3919	402	37	damage	damage	NOUN
gs-3919	402	38	as	as	ADV
gs-3919	402	39	well	well	ADV
gs-3919	402	40	as	as	ADP
gs-3919	402	41	a	a	DET
gs-3919	402	42	genetic	genetic	ADJ
gs-3919	402	43	profile	profile	NOUN
gs-3919	402	44	of	of	ADP
gs-3919	402	45	the	the	DET
gs-3919	402	46	patients	patient	NOUN
gs-3919	402	47	.	.	PUNCT
gs-3919	403	1	moreover	moreover	ADV
gs-3919	403	2	,	,	PUNCT
gs-3919	403	3	the	the	DET
gs-3919	403	4	search	search	NOUN
gs-3919	403	5	of	of	ADP
gs-3919	403	6	hhv-6	hhv-6	NOUN
gs-3919	403	7	virus	virus	NOUN
gs-3919	403	8	-	-	PUNCT
gs-3919	403	9	directed	direct	VERB
gs-3919	403	10	therapies	therapy	NOUN
gs-3919	403	11	may	may	AUX
gs-3919	403	12	offer	offer	VERB
gs-3919	403	13	new	new	ADJ
gs-3919	403	14	therapeutic	therapeutic	ADJ
gs-3919	403	15	options	option	NOUN
gs-3919	403	16	.	.	PUNCT
gs-3919	404	1	guidelines	guideline	NOUN
gs-3919	404	2	on	on	ADP
gs-3919	404	3	term	term	NOUN
gs-3919	404	4	monitoring	monitoring	NOUN
gs-3919	404	5	surveillance	surveillance	NOUN
gs-3919	404	6	programmes	programme	NOUN
gs-3919	404	7	given	give	VERB
gs-3919	404	8	the	the	DET
gs-3919	404	9	higher	high	ADJ
gs-3919	404	10	rate	rate	NOUN
gs-3919	404	11	of	of	ADP
gs-3919	404	12	autoimmune	autoimmune	ADJ
gs-3919	404	13	systemic	systemic	ADJ
gs-3919	404	14	diseases	disease	NOUN
gs-3919	404	15	,	,	PUNCT
gs-3919	404	16	such	such	ADJ
gs-3919	404	17	as	as	ADP
gs-3919	404	18	autoimmune	autoimmune	ADJ
gs-3919	404	19	thyroiditis	thyroiditis	NOUN
gs-3919	404	20	,	,	PUNCT
gs-3919	404	21	type	type	NOUN
gs-3919	404	22	1	1	NUM
gs-3919	404	23	diabetes	diabetes	NOUN
gs-3919	404	24	and	and	CCONJ
gs-3919	404	25	sle	sle	PROPN
gs-3919	404	26	,	,	PUNCT
gs-3919	404	27	outside	outside	ADP
gs-3919	404	28	the	the	DET
gs-3919	404	29	dress	dress	NOUN
gs-3919	404	30	syndrome	syndrome	NOUN
gs-3919	404	31	,	,	PUNCT
gs-3919	404	32	well	well	ADV
gs-3919	404	33	-	-	PUNCT
gs-3919	404	34	defined	define	VERB
gs-3919	404	35	follow	follow	NOUN
gs-3919	404	36	-	-	PUNCT
gs-3919	404	37	up	up	ADP
gs-3919	404	38	recommendations	recommendation	NOUN
gs-3919	404	39	are	be	AUX
gs-3919	404	40	required	require	VERB
gs-3919	404	41	.	.	PUNCT
gs-3919	405	1	future	future	ADJ
gs-3919	405	2	studies	study	NOUN
gs-3919	405	3	should	should	AUX
gs-3919	405	4	be	be	AUX
gs-3919	405	5	directed	direct	VERB
gs-3919	405	6	at	at	ADP
gs-3919	405	7	precursors	precursor	NOUN
gs-3919	405	8	and	and	CCONJ
gs-3919	405	9	predictors	predictor	NOUN
gs-3919	405	10	of	of	ADP
gs-3919	405	11	these	these	DET
gs-3919	405	12	sequelae	sequelae	NOUN
gs-3919	405	13	and	and	CCONJ
gs-3919	405	14	the	the	DET
gs-3919	405	15	preventive	preventive	ADJ
gs-3919	405	16	tool	tool	NOUN
gs-3919	405	17	for	for	ADP
gs-3919	405	18	these	these	PRON
gs-3919	405	19	.	.	PUNCT
gs-3919	406	1	public	public	ADJ
gs-3919	406	2	health	health	NOUN
gs-3919	406	3	communication	communication	NOUN
gs-3919	406	4	and	and	CCONJ
gs-3919	406	5	otc	otc	PROPN
gs-3919	406	6	safety	safety	NOUN
gs-3919	406	7	otc	otc	PROPN
gs-3919	406	8	safety	safety	NOUN
gs-3919	406	9	has	have	AUX
gs-3919	406	10	played	play	VERB
gs-3919	406	11	an	an	DET
gs-3919	406	12	important	important	ADJ
gs-3919	406	13	role	role	NOUN
gs-3919	406	14	in	in	ADP
gs-3919	406	15	the	the	DET
gs-3919	406	16	gradual	gradual	ADJ
gs-3919	406	17	development	development	NOUN
gs-3919	406	18	of	of	ADP
gs-3919	406	19	policy	policy	NOUN
gs-3919	406	20	and	and	CCONJ
gs-3919	406	21	systems	system	NOUN
gs-3919	406	22	that	that	PRON
gs-3919	406	23	protect	protect	VERB
gs-3919	406	24	otc	otc	PROPN
gs-3919	406	25	users	user	NOUN
gs-3919	406	26	.	.	PUNCT
gs-3919	407	1	the	the	DET
gs-3919	407	2	overall	overall	ADJ
gs-3919	407	3	number	number	NOUN
gs-3919	407	4	of	of	ADP
gs-3919	407	5	cases	case	NOUN
gs-3919	407	6	reported	report	VERB
gs-3919	407	7	with	with	ADP
gs-3919	407	8	nsaids	nsaid	NOUN
gs-3919	407	9	and	and	CCONJ
gs-3919	407	10	the	the	DET
gs-3919	407	11	importance	importance	NOUN
gs-3919	407	12	to	to	PART
gs-3919	407	13	increase	increase	VERB
gs-3919	407	14	further	far	ADV
gs-3919	407	15	the	the	DET
gs-3919	407	16	incorporation	incorporation	NOUN
gs-3919	407	17	of	of	ADP
gs-3919	407	18	awareness	awareness	NOUN
gs-3919	407	19	for	for	ADP
gs-3919	407	20	adverse	adverse	ADJ
gs-3919	407	21	hypersensitivity	hypersensitivity	NOUN
gs-3919	407	22	reaction	reaction	NOUN
gs-3919	407	23	in	in	ADP
gs-3919	407	24	public	public	ADJ
gs-3919	407	25	health	health	NOUN
gs-3919	407	26	messages	message	NOUN
gs-3919	407	27	,	,	PUNCT
gs-3919	407	28	especially	especially	ADV
gs-3919	407	29	for	for	ADP
gs-3919	407	30	otc	otc	PROPN
gs-3919	407	31	drug	drug	NOUN
gs-3919	407	32	safety	safety	NOUN
gs-3919	407	33	is	be	AUX
gs-3919	407	34	also	also	ADV
gs-3919	407	35	interesting	interesting	ADJ
gs-3919	407	36	.	.	PUNCT
gs-3919	408	1	it	it	PRON
gs-3919	408	2	is	be	AUX
gs-3919	408	3	necessary	necessary	ADJ
gs-3919	408	4	to	to	PART
gs-3919	408	5	train	train	VERB
gs-3919	408	6	pharmacy	pharmacy	NOUN
gs-3919	408	7	and	and	CCONJ
gs-3919	408	8	general	general	ADJ
gs-3919	408	9	practitioners	practitioner	NOUN
gs-3919	408	10	to	to	PART
gs-3919	408	11	recognize	recognize	VERB
gs-3919	408	12	warning	warning	NOUN
gs-3919	408	13	signs	sign	NOUN
gs-3919	408	14	(	(	PUNCT
gs-3919	408	15	early	early	ADJ
gs-3919	408	16	symptoms	symptom	NOUN
gs-3919	408	17	)	)	PUNCT
gs-3919	408	18	and	and	CCONJ
gs-3919	408	19	provide	provide	VERB
gs-3919	408	20	appropriate	appropriate	ADJ
gs-3919	408	21	counselling	counselling	NOUN
gs-3919	408	22	.	.	PUNCT
gs-3919	409	1	integration	integration	NOUN
gs-3919	409	2	of	of	ADP
gs-3919	409	3	ai	ai	VERB
gs-3919	409	4	an	an	DET
gs-3919	409	5	additional	additional	ADJ
gs-3919	409	6	exciting	exciting	ADJ
gs-3919	409	7	pathway	pathway	NOUN
gs-3919	409	8	can	can	AUX
gs-3919	409	9	be	be	AUX
gs-3919	409	10	found	find	VERB
gs-3919	409	11	in	in	ADP
gs-3919	409	12	the	the	DET
gs-3919	409	13	applications	application	NOUN
gs-3919	409	14	of	of	ADP
gs-3919	409	15	ai	ai	NOUN
gs-3919	409	16	and	and	CCONJ
gs-3919	409	17	big	big	ADJ
gs-3919	409	18	data	datum	NOUN
gs-3919	409	19	analytics	analytic	NOUN
gs-3919	409	20	for	for	ADP
gs-3919	409	21	dress	dress	NOUN
gs-3919	409	22	syndrome	syndrome	NOUN
gs-3919	409	23	exploration	exploration	NOUN
gs-3919	409	24	and	and	CCONJ
gs-3919	409	25	monitoring	monitoring	NOUN
gs-3919	409	26	.	.	PUNCT
gs-3919	410	1	since	since	SCONJ
gs-3919	410	2	diagnosis	diagnosis	NOUN
gs-3919	410	3	and	and	CCONJ
gs-3919	410	4	management	management	NOUN
gs-3919	410	5	of	of	ADP
gs-3919	410	6	dress	dress	NOUN
gs-3919	410	7	seems	seem	VERB
gs-3919	410	8	to	to	PART
gs-3919	410	9	be	be	AUX
gs-3919	410	10	extremely	extremely	ADV
gs-3919	410	11	challenging	challenging	ADJ
gs-3919	410	12	,	,	PUNCT
gs-3919	410	13	risk	risk	NOUN
gs-3919	410	14	predictors	predictor	NOUN
gs-3919	410	15	on	on	ADP
gs-3919	410	16	the	the	DET
gs-3919	410	17	basis	basis	NOUN
gs-3919	410	18	of	of	ADP
gs-3919	410	19	dress	dress	NOUN
gs-3919	410	20	diagnosis	diagnosis	NOUN
gs-3919	410	21	using	use	VERB
gs-3919	410	22	electronic	electronic	ADJ
gs-3919	410	23	health	health	NOUN
gs-3919	410	24	records	record	NOUN
gs-3919	410	25	(	(	PUNCT
gs-3919	410	26	ehrs	ehrs	INTJ
gs-3919	410	27	)	)	PUNCT
gs-3919	410	28	,	,	PUNCT
gs-3919	410	29	laboratory	laboratory	NOUN
gs-3919	410	30	parameters	parameter	NOUN
gs-3919	410	31	as	as	ADV
gs-3919	410	32	well	well	ADV
gs-3919	410	33	as	as	ADP
gs-3919	410	34	prescription	prescription	NOUN
gs-3919	410	35	history	history	NOUN
gs-3919	410	36	identified	identify	VERB
gs-3919	410	37	by	by	ADP
gs-3919	410	38	ai	ai	ADJ
gs-3919	410	39	-	-	PUNCT
gs-3919	410	40	driven	drive	VERB
gs-3919	410	41	models	model	NOUN
gs-3919	410	42	could	could	AUX
gs-3919	410	43	allow	allow	VERB
gs-3919	410	44	at	at	ADP
gs-3919	410	45	least	least	ADJ
gs-3919	410	46	early	early	ADJ
gs-3919	410	47	in	in	ADP
gs-3919	410	48	-	-	PUNCT
gs-3919	410	49	time	time	NOUN
gs-3919	410	50	identification	identification	NOUN
gs-3919	410	51	to	to	ADP
gs-3919	410	52	the	the	DET
gs-3919	410	53	best	good	ADJ
gs-3919	410	54	possible	possible	ADJ
gs-3919	410	55	way	way	NOUN
gs-3919	410	56	.	.	PUNCT
gs-3919	411	1	machine	machine	NOUN
gs-3919	411	2	learning	learn	VERB
gs-3919	411	3	predictive	predictive	ADJ
gs-3919	411	4	tools	tool	NOUN
gs-3919	411	5	could	could	AUX
gs-3919	411	6	potentially	potentially	ADV
gs-3919	411	7	signal	signal	VERB
gs-3919	411	8	possible	possible	ADJ
gs-3919	411	9	cases	case	NOUN
gs-3919	411	10	in	in	ADP
gs-3919	411	11	real	real	ADJ
gs-3919	411	12	time	time	NOUN
gs-3919	411	13	when	when	SCONJ
gs-3919	411	14	specific	specific	ADJ
gs-3919	411	15	drug	drug	NOUN
gs-3919	411	16	classes	class	NOUN
gs-3919	411	17	are	be	AUX
gs-3919	411	18	prescribed	prescribe	VERB
gs-3919	411	19	in	in	ADP
gs-3919	411	20	high	high	ADJ
gs-3919	411	21	-	-	PUNCT
gs-3919	411	22	risk	risk	NOUN
gs-3919	411	23	patients	patient	NOUN
gs-3919	411	24	.	.	PUNCT
gs-3919	412	1	furthermore	furthermore	ADV
gs-3919	412	2	,	,	PUNCT
gs-3919	412	3	automated	automate	VERB
gs-3919	412	4	clinical	clinical	ADJ
gs-3919	412	5	decision	decision	NOUN
gs-3919	412	6	support	support	NOUN
gs-3919	412	7	software	software	NOUN
gs-3919	412	8	can	can	AUX
gs-3919	412	9	notify	notify	VERB
gs-3919	412	10	physicians	physician	NOUN
gs-3919	412	11	to	to	PART
gs-3919	412	12	perform	perform	VERB
gs-3919	412	13	hla	hla	NOUN
gs-3919	412	14	testing	testing	NOUN
gs-3919	412	15	or	or	CCONJ
gs-3919	412	16	to	to	PART
gs-3919	412	17	include	include	VERB
gs-3919	412	18	dress	dress	NOUN
gs-3919	412	19	in	in	ADP
gs-3919	412	20	differential	differential	ADJ
gs-3919	412	21	diagnoses	diagnosis	NOUN
gs-3919	412	22	when	when	SCONJ
gs-3919	412	23	the	the	DET
gs-3919	412	24	symptoms	symptom	NOUN
gs-3919	412	25	are	be	AUX
gs-3919	412	26	changing	change	VERB
gs-3919	412	27	,	,	PUNCT
gs-3919	412	28	which	which	PRON
gs-3919	412	29	might	might	AUX
gs-3919	412	30	minimize	minimize	VERB
gs-3919	412	31	the	the	DET
gs-3919	412	32	diagnostic	diagnostic	ADJ
gs-3919	412	33	delay	delay	NOUN
gs-3919	412	34	.	.	PUNCT
gs-3919	413	1	within	within	ADP
gs-3919	413	2	the	the	DET
gs-3919	413	3	realm	realm	NOUN
gs-3919	413	4	of	of	ADP
gs-3919	413	5	research	research	NOUN
gs-3919	413	6	,	,	PUNCT
gs-3919	413	7	ai	ai	VERB
gs-3919	413	8	may	may	AUX
gs-3919	413	9	serve	serve	VERB
gs-3919	413	10	the	the	DET
gs-3919	413	11	field	field	NOUN
gs-3919	413	12	of	of	ADP
gs-3919	413	13	drug	drug	NOUN
gs-3919	413	14	safety	safety	NOUN
gs-3919	413	15	and	and	CCONJ
gs-3919	413	16	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	413	17	by	by	ADP
gs-3919	413	18	automatically	automatically	ADV
gs-3919	413	19	exploring	explore	VERB
gs-3919	413	20	unstructured	unstructured	ADJ
gs-3919	413	21	clinical	clinical	ADJ
gs-3919	413	22	narratives	narrative	NOUN
gs-3919	413	23	,	,	PUNCT
gs-3919	413	24	drug	drug	NOUN
gs-3919	413	25	adverse	adverse	ADJ
gs-3919	413	26	effects	effect	NOUN
gs-3919	413	27	case	case	NOUN
gs-3919	413	28	reports	report	VERB
gs-3919	413	29	,	,	PUNCT
gs-3919	413	30	and	and	CCONJ
gs-3919	413	31	drug	drug	NOUN
gs-3919	413	32	adverse	adverse	ADJ
gs-3919	413	33	event	event	NOUN
gs-3919	413	34	databases	database	NOUN
gs-3919	413	35	to	to	PART
gs-3919	413	36	identify	identify	VERB
gs-3919	413	37	novel	novel	ADJ
gs-3919	413	38	drug	drug	NOUN
gs-3919	413	39	associations	association	NOUN
gs-3919	413	40	and	and	CCONJ
gs-3919	413	41	atypical	atypical	ADJ
gs-3919	413	42	presentations	presentation	NOUN
gs-3919	413	43	which	which	PRON
gs-3919	413	44	might	might	AUX
gs-3919	413	45	otherwise	otherwise	ADV
gs-3919	413	46	be	be	AUX
gs-3919	413	47	missed	miss	VERB
gs-3919	413	48	due	due	ADP
gs-3919	413	49	to	to	ADP
gs-3919	413	50	their	their	PRON
gs-3919	413	51	rare	rare	ADJ
gs-3919	413	52	nature	nature	NOUN
gs-3919	413	53	.	.	PUNCT
gs-3919	414	1	nlp	nlp	ADJ
gs-3919	414	2	algorithms	algorithm	NOUN
gs-3919	414	3	are	be	AUX
gs-3919	414	4	poised	poise	VERB
gs-3919	414	5	to	to	PART
gs-3919	414	6	be	be	AUX
gs-3919	414	7	further	further	ADJ
gs-3919	414	8	georgian	georgian	ADJ
gs-3919	414	9	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	414	10	მეცნიერები	მეცნიერები	NOUN
gs-3919	414	11	ტ.	ტ.	VERB
gs-3919	414	12	7	7	NUM
gs-3919	414	13	n	n	PRON
gs-3919	414	14	3	3	NUM
gs-3919	414	15	,	,	PUNCT
gs-3919	414	16	2025	2025	NUM
gs-3919	414	17	166	166	NUM
gs-3919	414	18	refined	refine	VERB
gs-3919	414	19	for	for	ADP
gs-3919	414	20	extraction	extraction	NOUN
gs-3919	414	21	of	of	ADP
gs-3919	414	22	phenotypic	phenotypic	ADJ
gs-3919	414	23	markers	marker	NOUN
gs-3919	414	24	and	and	CCONJ
gs-3919	414	25	outcomes	outcome	NOUN
gs-3919	414	26	from	from	ADP
gs-3919	414	27	published	publish	VERB
gs-3919	414	28	literature	literature	NOUN
gs-3919	414	29	and	and	CCONJ
gs-3919	414	30	ehrs	ehrs	PROPN
gs-3919	414	31	,	,	PUNCT
gs-3919	414	32	which	which	PRON
gs-3919	414	33	could	could	AUX
gs-3919	414	34	further	far	ADV
gs-3919	414	35	advance	advance	VERB
gs-3919	414	36	our	our	PRON
gs-3919	414	37	categorization	categorization	NOUN
gs-3919	414	38	of	of	ADP
gs-3919	414	39	dress	dress	NOUN
gs-3919	414	40	subtypes	subtype	NOUN
gs-3919	414	41	.	.	PUNCT
gs-3919	415	1	such	such	ADJ
gs-3919	415	2	advancements	advancement	NOUN
gs-3919	415	3	will	will	AUX
gs-3919	415	4	need	need	VERB
gs-3919	415	5	to	to	PART
gs-3919	415	6	be	be	AUX
gs-3919	415	7	validated	validate	VERB
gs-3919	415	8	in	in	ADP
gs-3919	415	9	multiple	multiple	ADJ
gs-3919	415	10	ethnic	ethnic	ADJ
gs-3919	415	11	groups	group	NOUN
gs-3919	415	12	and	and	CCONJ
gs-3919	415	13	used	use	VERB
gs-3919	415	14	with	with	ADP
gs-3919	415	15	caution	caution	NOUN
gs-3919	415	16	regarding	regard	VERB
gs-3919	415	17	the	the	DET
gs-3919	415	18	risks	risk	NOUN
gs-3919	415	19	of	of	ADP
gs-3919	415	20	algorithmic	algorithmic	ADJ
gs-3919	415	21	misrepresentations	misrepresentation	NOUN
gs-3919	415	22	among	among	ADP
gs-3919	415	23	underrepresented	underrepresented	ADJ
gs-3919	415	24	ethnic	ethnic	ADJ
gs-3919	415	25	groups	group	NOUN
gs-3919	415	26	with	with	ADP
gs-3919	415	27	limited	limited	ADJ
gs-3919	415	28	pharmacogenetic	pharmacogenetic	ADJ
gs-3919	415	29	information	information	NOUN
gs-3919	415	30	.	.	PUNCT
gs-3919	416	1	in	in	ADP
gs-3919	416	2	addition	addition	NOUN
gs-3919	416	3	,	,	PUNCT
gs-3919	416	4	the	the	DET
gs-3919	416	5	deployment	deployment	NOUN
gs-3919	416	6	of	of	ADP
gs-3919	416	7	ai	ai	PROPN
gs-3919	416	8	technologies	technology	NOUN
gs-3919	416	9	within	within	ADP
gs-3919	416	10	the	the	DET
gs-3919	416	11	clinical	clinical	ADJ
gs-3919	416	12	workflow	workflow	NOUN
gs-3919	416	13	requires	require	VERB
gs-3919	416	14	simple	simple	ADJ
gs-3919	416	15	user	user	NOUN
gs-3919	416	16	-	-	PUNCT
gs-3919	416	17	interfaces	interface	NOUN
gs-3919	416	18	,	,	PUNCT
gs-3919	416	19	appropriate	appropriate	ADJ
gs-3919	416	20	training	training	NOUN
gs-3919	416	21	and	and	CCONJ
gs-3919	416	22	empathy	empathy	NOUN
gs-3919	416	23	with	with	ADP
gs-3919	416	24	ethical	ethical	ADJ
gs-3919	416	25	principles	principle	NOUN
gs-3919	416	26	regarding	regard	VERB
gs-3919	416	27	data	data	NOUN
gs-3919	416	28	privacy	privacy	NOUN
gs-3919	416	29	and	and	CCONJ
gs-3919	416	30	informed	informed	ADJ
gs-3919	416	31	consent	consent	NOUN
gs-3919	416	32	.	.	PUNCT
gs-3919	417	1	nevertheless	nevertheless	ADV
gs-3919	417	2	,	,	PUNCT
gs-3919	417	3	the	the	DET
gs-3919	417	4	future	future	ADJ
gs-3919	417	5	utility	utility	NOUN
gs-3919	417	6	of	of	ADP
gs-3919	417	7	digital	digital	ADJ
gs-3919	417	8	solutions	solution	NOUN
gs-3919	417	9	to	to	ADP
gs-3919	417	10	the	the	DET
gs-3919	417	11	management	management	NOUN
gs-3919	417	12	of	of	ADP
gs-3919	417	13	dress	dress	NOUN
gs-3919	417	14	is	be	AUX
gs-3919	417	15	significant	significant	ADJ
gs-3919	417	16	.	.	PUNCT
gs-3919	418	1	investment	investment	NOUN
gs-3919	418	2	in	in	ADP
gs-3919	418	3	transnational	transnational	ADJ
gs-3919	418	4	multi	multi	ADJ
gs-3919	418	5	-	-	ADJ
gs-3919	418	6	centre	centre	ADJ
gs-3919	418	7	data	data	NOUN
gs-3919	418	8	-	-	PUNCT
gs-3919	418	9	sharing	share	VERB
gs-3919	418	10	platforms	platform	NOUN
gs-3919	418	11	and	and	CCONJ
gs-3919	418	12	digital	digital	ADJ
gs-3919	418	13	infrastructure	infrastructure	NOUN
gs-3919	418	14	will	will	AUX
gs-3919	418	15	be	be	AUX
gs-3919	418	16	crucial	crucial	ADJ
gs-3919	418	17	to	to	PART
gs-3919	418	18	enable	enable	VERB
gs-3919	418	19	that	that	SCONJ
gs-3919	418	20	potential	potential	NOUN
gs-3919	418	21	be	be	AUX
gs-3919	418	22	realized	realize	VERB
gs-3919	418	23	.	.	PUNCT
gs-3919	419	1	with	with	ADP
gs-3919	419	2	the	the	DET
gs-3919	419	3	increasing	increase	VERB
gs-3919	419	4	global	global	ADJ
gs-3919	419	5	burden	burden	NOUN
gs-3919	419	6	of	of	ADP
gs-3919	419	7	drug	drug	NOUN
gs-3919	419	8	-	-	PUNCT
gs-3919	419	9	hypersensitivity	hypersensitivity	NOUN
gs-3919	419	10	syndromes	syndrome	NOUN
gs-3919	419	11	,	,	PUNCT
gs-3919	419	12	digital	digital	ADJ
gs-3919	419	13	health	health	NOUN
gs-3919	419	14	tools	tool	NOUN
gs-3919	419	15	may	may	AUX
gs-3919	419	16	provide	provide	VERB
gs-3919	419	17	a	a	DET
gs-3919	419	18	saleable	saleable	ADJ
gs-3919	419	19	and	and	CCONJ
gs-3919	419	20	equitable	equitable	ADJ
gs-3919	419	21	approach	approach	NOUN
gs-3919	419	22	to	to	PART
gs-3919	419	23	enhance	enhance	VERB
gs-3919	419	24	detection	detection	NOUN
gs-3919	419	25	,	,	PUNCT
gs-3919	419	26	prevention	prevention	NOUN
gs-3919	419	27	,	,	PUNCT
gs-3919	419	28	and	and	CCONJ
gs-3919	419	29	personalized	personalized	ADJ
gs-3919	419	30	management	management	NOUN
gs-3919	419	31	for	for	ADP
gs-3919	419	32	dress	dress	NOUN
gs-3919	419	33	syndrome	syndrome	NOUN
gs-3919	419	34	.	.	PUNCT
gs-3919	420	1	pharmacological	pharmacological	ADJ
gs-3919	420	2	triggers	trigger	NOUN
gs-3919	420	3	and	and	CCONJ
gs-3919	420	4	metabolic	metabolic	NOUN
gs-3919	420	5	activation	activation	NOUN
gs-3919	420	6	pathways	pathway	VERB
gs-3919	420	7	recent	recent	ADJ
gs-3919	420	8	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	420	9	data	datum	NOUN
gs-3919	420	10	from	from	ADP
gs-3919	420	11	the	the	DET
gs-3919	420	12	fda	fda	PROPN
gs-3919	420	13	adverse	adverse	ADJ
gs-3919	420	14	event	event	NOUN
gs-3919	420	15	reporting	report	VERB
gs-3919	420	16	system	system	NOUN
gs-3919	420	17	(	(	PUNCT
gs-3919	420	18	faers	faer	NOUN
gs-3919	420	19	)	)	PUNCT
gs-3919	420	20	and	and	CCONJ
gs-3919	420	21	who	who	PRON
gs-3919	420	22	vigibase	vigibase	AUX
gs-3919	420	23	reveal	reveal	VERB
gs-3919	420	24	a	a	DET
gs-3919	420	25	striking	strike	VERB
gs-3919	420	26	pattern	pattern	NOUN
gs-3919	420	27	of	of	ADP
gs-3919	420	28	drug	drug	NOUN
gs-3919	420	29	-	-	PUNCT
gs-3919	420	30	specific	specific	ADJ
gs-3919	420	31	eosinophilic	eosinophilic	ADJ
gs-3919	420	32	reactions	reaction	NOUN
gs-3919	420	33	.	.	PUNCT
gs-3919	421	1	beyond	beyond	ADP
gs-3919	421	2	the	the	DET
gs-3919	421	3	well	well	ADV
gs-3919	421	4	-	-	PUNCT
gs-3919	421	5	documented	document	VERB
gs-3919	421	6	culprits	culprit	NOUN
gs-3919	421	7	(	(	PUNCT
gs-3919	421	8	aromatic	aromatic	ADJ
gs-3919	421	9	antiepileptics	antiepileptic	NOUN
gs-3919	421	10	,	,	PUNCT
gs-3919	421	11	antibiotics	antibiotic	NOUN
gs-3919	421	12	)	)	PUNCT
gs-3919	421	13	,	,	PUNCT
gs-3919	421	14	newer	new	ADJ
gs-3919	421	15	agents	agent	NOUN
gs-3919	421	16	like	like	ADP
gs-3919	421	17	immune	immune	ADJ
gs-3919	421	18	checkpoint	checkpoint	NOUN
gs-3919	421	19	inhibitors	inhibitor	NOUN
gs-3919	421	20	(	(	PUNCT
gs-3919	421	21	icis	icis	PROPN
gs-3919	421	22	)	)	PUNCT
gs-3919	421	23	and	and	CCONJ
gs-3919	421	24	janus	janus	PROPN
gs-3919	421	25	kinase	kinase	PROPN
gs-3919	421	26	(	(	PUNCT
gs-3919	421	27	jak	jak	PROPN
gs-3919	421	28	)	)	PUNCT
gs-3919	421	29	inhibitors	inhibitor	NOUN
gs-3919	421	30	exhibit	exhibit	VERB
gs-3919	421	31	unexpected	unexpected	ADJ
gs-3919	421	32	eosinophilic	eosinophilic	ADJ
gs-3919	421	33	sequelae	sequelae	NOUN
gs-3919	421	34	.	.	PUNCT
gs-3919	422	1	nivolumab	nivolumab	NOUN
gs-3919	422	2	and	and	CCONJ
gs-3919	422	3	pembrolizumab	pembrolizumab	NOUN
gs-3919	422	4	,	,	PUNCT
gs-3919	422	5	for	for	ADP
gs-3919	422	6	instance	instance	NOUN
gs-3919	422	7	,	,	PUNCT
gs-3919	422	8	are	be	AUX
gs-3919	422	9	now	now	ADV
gs-3919	422	10	associated	associate	VERB
gs-3919	422	11	with	with	ADP
gs-3919	422	12	eosinophilic	eosinophilic	ADJ
gs-3919	422	13	pneumonitis	pneumonitis	NOUN
gs-3919	422	14	and	and	CCONJ
gs-3919	422	15	colitis	colitis	NOUN
gs-3919	422	16	,	,	PUNCT
gs-3919	422	17	likely	likely	ADJ
gs-3919	422	18	due	due	ADP
gs-3919	422	19	to	to	ADP
gs-3919	422	20	their	their	PRON
gs-3919	422	21	disruption	disruption	NOUN
gs-3919	422	22	of	of	ADP
gs-3919	422	23	pd-1	pd-1	ADP
gs-3919	422	24	/	/	SYM
gs-3919	422	25	pd	pd	ADJ
gs-3919	422	26	-	-	PUNCT
gs-3919	422	27	l1mediated	l1mediate	VERB
gs-3919	422	28	immune	immune	ADJ
gs-3919	422	29	tolerance	tolerance	NOUN
gs-3919	422	30	.	.	PUNCT
gs-3919	423	1	this	this	PRON
gs-3919	423	2	parallels	parallel	VERB
gs-3919	423	3	findings	finding	NOUN
gs-3919	423	4	from	from	ADP
gs-3919	423	5	murine	murine	ADJ
gs-3919	423	6	models	model	NOUN
gs-3919	423	7	where	where	SCONJ
gs-3919	423	8	pd-1	pd-1	ADP
gs-3919	423	9	knockout	knockout	NOUN
gs-3919	423	10	mice	mouse	NOUN
gs-3919	423	11	develop	develop	VERB
gs-3919	423	12	spontaneous	spontaneous	ADJ
gs-3919	423	13	eosinophilic	eosinophilic	ADJ
gs-3919	423	14	infiltrates	infiltrate	NOUN
gs-3919	423	15	in	in	ADP
gs-3919	423	16	lung	lung	NOUN
gs-3919	423	17	tissue	tissue	NOUN
gs-3919	423	18	,	,	PUNCT
gs-3919	423	19	suggesting	suggest	VERB
gs-3919	423	20	a	a	DET
gs-3919	423	21	conserved	conserved	ADJ
gs-3919	423	22	pathway	pathway	NOUN
gs-3919	423	23	of	of	ADP
gs-3919	423	24	immune	immune	ADJ
gs-3919	423	25	dysregulation	dysregulation	NOUN
gs-3919	423	26	.	.	PUNCT
gs-3919	424	1	metabolomic	metabolomic	ADJ
gs-3919	424	2	studies	study	NOUN
gs-3919	424	3	have	have	AUX
gs-3919	424	4	identified	identify	VERB
gs-3919	424	5	reactive	reactive	ADJ
gs-3919	424	6	intermediates	intermediate	NOUN
gs-3919	424	7	unique	unique	ADJ
gs-3919	424	8	to	to	ADP
gs-3919	424	9	high	high	ADJ
gs-3919	424	10	-	-	PUNCT
gs-3919	424	11	risk	risk	NOUN
gs-3919	424	12	drugs	drug	NOUN
gs-3919	424	13	.	.	PUNCT
gs-3919	425	1	for	for	ADP
gs-3919	425	2	example	example	NOUN
gs-3919	425	3	,	,	PUNCT
gs-3919	425	4	carbamazepine	carbamazepine	NOUN
gs-3919	425	5	’s	’s	PART
gs-3919	425	6	arene	arene	NOUN
gs-3919	425	7	oxide	oxide	NOUN
gs-3919	425	8	metabolite	metabolite	NOUN
gs-3919	425	9	forms	form	NOUN
gs-3919	425	10	covalent	covalent	NOUN
gs-3919	425	11	adducts	adduct	NOUN
gs-3919	425	12	with	with	ADP
gs-3919	425	13	eosinophil	eosinophil	ADJ
gs-3919	425	14	-	-	PUNCT
gs-3919	425	15	derived	derive	VERB
gs-3919	425	16	mitochondrial	mitochondrial	ADJ
gs-3919	425	17	proteins	protein	NOUN
gs-3919	425	18	,	,	PUNCT
gs-3919	425	19	triggering	trigger	VERB
gs-3919	425	20	mitochondrial	mitochondrial	ADJ
gs-3919	425	21	dna	dna	NOUN
gs-3919	425	22	release	release	NOUN
gs-3919	425	23	and	and	CCONJ
gs-3919	425	24	subsequent	subsequent	ADJ
gs-3919	425	25	nlrp3	nlrp3	NOUN
gs-3919	425	26	inflammasome	inflammasome	NOUN
gs-3919	425	27	activation	activation	NOUN
gs-3919	425	28	.	.	PUNCT
gs-3919	426	1	this	this	DET
gs-3919	426	2	cascade	cascade	NOUN
gs-3919	426	3	amplifies	amplify	VERB
gs-3919	426	4	il-1β	il-1β	NOUN
gs-3919	426	5	and	and	CCONJ
gs-3919	426	6	il-18	il-18	ADP
gs-3919	426	7	production	production	NOUN
gs-3919	426	8	,	,	PUNCT
gs-3919	426	9	creating	create	VERB
gs-3919	426	10	a	a	DET
gs-3919	426	11	pro	pro	ADJ
gs-3919	426	12	-	-	ADJ
gs-3919	426	13	eosinophilic	eosinophilic	ADJ
gs-3919	426	14	cytokine	cytokine	NOUN
gs-3919	426	15	milieu	milieu	NOUN
gs-3919	426	16	.	.	PUNCT
gs-3919	427	1	similarly	similarly	ADV
gs-3919	427	2	,	,	PUNCT
gs-3919	427	3	allopurinol	allopurinol	NOUN
gs-3919	427	4	’s	’s	PART
gs-3919	427	5	oxypurinol	oxypurinol	NOUN
gs-3919	427	6	metabolite	metabolite	NOUN
gs-3919	427	7	binds	bind	VERB
gs-3919	427	8	covalently	covalently	ADV
gs-3919	427	9	to	to	PART
gs-3919	427	10	keratinocyte	keratinocyte	VERB
gs-3919	427	11	peptides	peptide	NOUN
gs-3919	427	12	,	,	PUNCT
gs-3919	427	13	generating	generate	VERB
gs-3919	427	14	neoantigens	neoantigen	NOUN
gs-3919	427	15	that	that	PRON
gs-3919	427	16	stimulate	stimulate	VERB
gs-3919	427	17	clonal	clonal	ADJ
gs-3919	427	18	expansion	expansion	NOUN
gs-3919	427	19	of	of	ADP
gs-3919	427	20	eosinophil	eosinophil	ADJ
gs-3919	427	21	-	-	PUNCT
gs-3919	427	22	primed	prime	VERB
gs-3919	427	23	cd8	cd8	PROPN
gs-3919	427	24	+	+	PROPN
gs-3919	427	25	t	t	NOUN
gs-3919	427	26	cells	cell	NOUN
gs-3919	427	27	—	—	PUNCT
gs-3919	427	28	a	a	DET
gs-3919	427	29	mechanism	mechanism	NOUN
gs-3919	427	30	corroborated	corroborate	VERB
gs-3919	427	31	by	by	ADP
gs-3919	427	32	tcr	tcr	PROPN
gs-3919	427	33	sequencing	sequence	VERB
gs-3919	427	34	in	in	ADP
gs-3919	427	35	dress	dress	NOUN
gs-3919	427	36	patients	patient	NOUN
gs-3919	427	37	.	.	PUNCT
gs-3919	428	1	genetic	genetic	ADJ
gs-3919	428	2	susceptibility	susceptibility	NOUN
gs-3919	428	3	and	and	CCONJ
gs-3919	428	4	hla	hla	PROPN
gs-3919	428	5	associations	association	NOUN
gs-3919	428	6	whole	whole	ADJ
gs-3919	428	7	-	-	PUNCT
gs-3919	428	8	exome	exome	NOUN
gs-3919	428	9	sequencing	sequencing	NOUN
gs-3919	428	10	in	in	ADP
gs-3919	428	11	refractory	refractory	NOUN
gs-3919	428	12	dress	dress	NOUN
gs-3919	428	13	cases	case	NOUN
gs-3919	428	14	has	have	AUX
gs-3919	428	15	uncovered	uncover	VERB
gs-3919	428	16	novel	novel	ADJ
gs-3919	428	17	polymorphisms	polymorphism	NOUN
gs-3919	428	18	in	in	ADP
gs-3919	428	19	il5ra	il5ra	PROPN
gs-3919	428	20	(	(	PUNCT
gs-3919	428	21	encoding	encode	VERB
gs-3919	428	22	the	the	DET
gs-3919	428	23	il-5	il-5	NOUN
gs-3919	428	24	receptor	receptor	NOUN
gs-3919	428	25	α	α	NOUN
gs-3919	428	26	-	-	NOUN
gs-3919	428	27	chain	chain	NOUN
gs-3919	428	28	)	)	PUNCT
gs-3919	428	29	that	that	PRON
gs-3919	428	30	enhance	enhance	VERB
gs-3919	428	31	eosinophil	eosinophil	ADJ
gs-3919	428	32	survival	survival	NOUN
gs-3919	428	33	.	.	PUNCT
gs-3919	429	1	these	these	DET
gs-3919	429	2	variants	variant	NOUN
gs-3919	429	3	,	,	PUNCT
gs-3919	429	4	present	present	ADJ
gs-3919	429	5	in	in	ADP
gs-3919	429	6	12	12	NUM
gs-3919	429	7	%	%	NOUN
gs-3919	429	8	of	of	ADP
gs-3919	429	9	east	east	ADJ
gs-3919	429	10	asian	asian	ADJ
gs-3919	429	11	dress	dress	NOUN
gs-3919	429	12	patients	patient	NOUN
gs-3919	429	13	,	,	PUNCT
gs-3919	429	14	correlate	correlate	VERB
gs-3919	429	15	with	with	ADP
gs-3919	429	16	prolonged	prolonged	ADJ
gs-3919	429	17	eosinophilia	eosinophilia	NOUN
gs-3919	429	18	(	(	PUNCT
gs-3919	429	19	>	>	SYM
gs-3919	429	20	6	6	NUM
gs-3919	429	21	months	month	NOUN
gs-3919	429	22	post	post	ADJ
gs-3919	429	23	-	-	ADJ
gs-3919	429	24	drug	drug	ADJ
gs-3919	429	25	withdrawal	withdrawal	NOUN
gs-3919	429	26	)	)	PUNCT
gs-3919	429	27	and	and	CCONJ
gs-3919	429	28	steroid	steroid	NOUN
gs-3919	429	29	dependence	dependence	NOUN
gs-3919	429	30	.	.	PUNCT
gs-3919	430	1	additionally	additionally	ADV
gs-3919	430	2	,	,	PUNCT
gs-3919	430	3	genome	genome	NOUN
gs-3919	430	4	-	-	PUNCT
gs-3919	430	5	wide	wide	ADJ
gs-3919	430	6	association	association	NOUN
gs-3919	430	7	studies	study	NOUN
gs-3919	430	8	(	(	PUNCT
gs-3919	430	9	gwas	gwas	PROPN
gs-3919	430	10	)	)	PUNCT
gs-3919	430	11	implicate	implicate	VERB
gs-3919	430	12	gata2	gata2	NOUN
gs-3919	430	13	enhancer	enhancer	NOUN
gs-3919	430	14	mutations	mutation	NOUN
gs-3919	430	15	in	in	ADP
gs-3919	430	16	impairing	impair	VERB
gs-3919	430	17	eosinophil	eosinophil	ADJ
gs-3919	430	18	apoptosis	apoptosis	NOUN
gs-3919	430	19	,	,	PUNCT
gs-3919	430	20	particularly	particularly	ADV
gs-3919	430	21	in	in	ADP
gs-3919	430	22	sulfonamide	sulfonamide	NOUN
gs-3919	430	23	-	-	PUNCT
gs-3919	430	24	induced	induce	VERB
gs-3919	430	25	reactions	reaction	NOUN
gs-3919	430	26	.	.	PUNCT
gs-3919	431	1	georgian	georgian	ADJ
gs-3919	431	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	431	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	431	4	ტ.	ტ.	VERB
gs-3919	431	5	7	7	NUM
gs-3919	431	6	n	n	PRON
gs-3919	431	7	3	3	NUM
gs-3919	431	8	,	,	PUNCT
gs-3919	431	9	2025	2025	NUM
gs-3919	431	10	167	167	NUM
gs-3919	431	11	the	the	DET
gs-3919	431	12	hla	hla	PROPN
gs-3919	431	13	landscape	landscape	NOUN
gs-3919	431	14	continues	continue	VERB
gs-3919	431	15	to	to	PART
gs-3919	431	16	expand	expand	VERB
gs-3919	431	17	beyond	beyond	ADP
gs-3919	431	18	classical	classical	ADJ
gs-3919	431	19	alleles	allele	NOUN
gs-3919	431	20	.	.	PUNCT
gs-3919	432	1	hla	hla	NOUN
gs-3919	432	2	-	-	PUNCT
gs-3919	432	3	drb1	drb1	PROPN
gs-3919	432	4	*	*	PROPN
gs-3919	432	5	07:01	07:01	NUM
gs-3919	432	6	,	,	PUNCT
gs-3919	432	7	recently	recently	ADV
gs-3919	432	8	linked	link	VERB
gs-3919	432	9	to	to	ADP
gs-3919	432	10	vancomycin	vancomycin	PROPN
gs-3919	432	11	-	-	PUNCT
gs-3919	432	12	induced	induce	VERB
gs-3919	432	13	eosinophilic	eosinophilic	ADJ
gs-3919	432	14	nephritis	nephritis	NOUN
gs-3919	432	15	,	,	PUNCT
gs-3919	432	16	demonstrates	demonstrate	VERB
gs-3919	432	17	allele	allele	NOUN
gs-3919	432	18	-	-	PUNCT
gs-3919	432	19	specific	specific	ADJ
gs-3919	432	20	peptide	peptide	NOUN
gs-3919	432	21	presentation	presentation	NOUN
gs-3919	432	22	of	of	ADP
gs-3919	432	23	vancomycin	vancomycin	PROPN
gs-3919	432	24	-	-	PUNCT
gs-3919	432	25	modified	modify	VERB
gs-3919	432	26	collagen	collagen	NOUN
gs-3919	432	27	fragments	fragment	NOUN
gs-3919	432	28	,	,	PUNCT
gs-3919	432	29	provoking	provoke	VERB
gs-3919	432	30	th2	th2	PROPN
gs-3919	432	31	-	-	PUNCT
gs-3919	432	32	skewed	skewed	ADJ
gs-3919	432	33	responses	response	NOUN
gs-3919	432	34	.	.	PUNCT
gs-3919	433	1	intriguingly	intriguingly	ADV
gs-3919	433	2	,	,	PUNCT
gs-3919	433	3	hla	hla	PROPN
gs-3919	433	4	-	-	PUNCT
gs-3919	433	5	c*06:02	c*06:02	NOUN
gs-3919	433	6	—	—	PUNCT
gs-3919	433	7	known	know	VERB
gs-3919	433	8	for	for	ADP
gs-3919	433	9	psoriasis	psoriasis	NOUN
gs-3919	433	10	predisposition	predisposition	NOUN
gs-3919	433	11	—	—	PUNCT
gs-3919	433	12	confers	confer	NOUN
gs-3919	433	13	protection	protection	NOUN
gs-3919	433	14	against	against	ADP
gs-3919	433	15	anticonvulsant	anticonvulsant	NOUN
gs-3919	433	16	-	-	PUNCT
gs-3919	433	17	driven	drive	VERB
gs-3919	433	18	eosinophilia	eosinophilia	NOUN
gs-3919	433	19	,	,	PUNCT
gs-3919	433	20	likely	likely	ADV
gs-3919	433	21	through	through	ADP
gs-3919	433	22	altered	alter	VERB
gs-3919	433	23	antigen	antigen	ADJ
gs-3919	433	24	presentation	presentation	NOUN
gs-3919	433	25	kinetics	kinetic	NOUN
gs-3919	433	26	.	.	PUNCT
gs-3919	434	1	emerging	emerge	VERB
gs-3919	434	2	pharmacological	pharmacological	ADJ
gs-3919	434	3	triggers	trigger	NOUN
gs-3919	434	4	:	:	PUNCT
gs-3919	434	5	beyond	beyond	ADP
gs-3919	434	6	traditional	traditional	ADJ
gs-3919	434	7	drug	drug	NOUN
gs-3919	434	8	classes	class	NOUN
gs-3919	434	9	recent	recent	ADJ
gs-3919	434	10	pharmacoepidemiologic	pharmacoepidemiologic	ADJ
gs-3919	434	11	studies	study	NOUN
gs-3919	434	12	identify	identify	VERB
gs-3919	434	13	unexpected	unexpected	ADJ
gs-3919	434	14	drug	drug	NOUN
gs-3919	434	15	culprits	culprit	NOUN
gs-3919	434	16	with	with	ADP
gs-3919	434	17	eosinophilic	eosinophilic	ADJ
gs-3919	434	18	potential	potential	NOUN
gs-3919	434	19	:	:	PUNCT
gs-3919	434	20			ADJ
gs-3919	434	21	btk	btk	NOUN
gs-3919	434	22	inhibitors	inhibitor	NOUN
gs-3919	434	23	(	(	PUNCT
gs-3919	434	24	ibrutinib	ibrutinib	NOUN
gs-3919	434	25	/	/	SYM
gs-3919	434	26	acalabrutinib	acalabrutinib	NOUN
gs-3919	434	27	):	):	PUNCT
gs-3919	434	28	induce	induce	VERB
gs-3919	434	29	eosinophilia	eosinophilia	NOUN
gs-3919	434	30	in	in	ADP
gs-3919	434	31	8	8	NUM
gs-3919	434	32	%	%	NOUN
gs-3919	434	33	of	of	ADP
gs-3919	434	34	cll	cll	PROPN
gs-3919	434	35	patients	patient	NOUN
gs-3919	434	36	via	via	ADP
gs-3919	434	37	paradoxical	paradoxical	ADJ
gs-3919	434	38	il-5	il-5	NOUN
gs-3919	434	39	upregulation	upregulation	NOUN
gs-3919	434	40	upon	upon	SCONJ
gs-3919	434	41	b	b	NOUN
gs-3919	434	42	-	-	PUNCT
gs-3919	434	43	cell	cell	NOUN
gs-3919	434	44	suppression	suppression	NOUN
gs-3919	434	45	.	.	PUNCT
gs-3919	435	1	single	single	ADJ
gs-3919	435	2	-	-	PUNCT
gs-3919	435	3	cell	cell	NOUN
gs-3919	435	4	proteomics	proteomic	NOUN
gs-3919	435	5	reveal	reveal	VERB
gs-3919	435	6	these	these	DET
gs-3919	435	7	drugs	drug	NOUN
gs-3919	435	8	trigger	trigger	NOUN
gs-3919	435	9	basophil	basophil	NOUN
gs-3919	435	10	-	-	PUNCT
gs-3919	435	11	eosinophil	eosinophil	ADJ
gs-3919	435	12	axis	axis	NOUN
gs-3919	435	13	activation	activation	NOUN
gs-3919	435	14	,	,	PUNCT
gs-3919	435	15	with	with	ADP
gs-3919	435	16	basophil	basophil	NOUN
gs-3919	435	17	-	-	PUNCT
gs-3919	435	18	derived	derive	VERB
gs-3919	435	19	il4	il4	NOUN
gs-3919	435	20	priming	prime	VERB
gs-3919	435	21	eosinophil	eosinophil	ADJ
gs-3919	435	22	maturation	maturation	NOUN
gs-3919	435	23	.	.	PUNCT
gs-3919	436	1			VERB
gs-3919	436	2	mrna	mrna	PROPN
gs-3919	436	3	therapeutics	therapeutic	NOUN
gs-3919	436	4	:	:	PUNCT
gs-3919	436	5	lipid	lipid	NOUN
gs-3919	436	6	nanoparticles	nanoparticle	NOUN
gs-3919	436	7	(	(	PUNCT
gs-3919	436	8	lnps	lnps	PROPN
gs-3919	436	9	)	)	PUNCT
gs-3919	436	10	in	in	ADP
gs-3919	436	11	covid-19	covid-19	PROPN
gs-3919	436	12	vaccines	vaccine	NOUN
gs-3919	436	13	(	(	PUNCT
gs-3919	436	14	e.g.	e.g.	ADV
gs-3919	436	15	,	,	PUNCT
gs-3919	436	16	pfizerbiontech	pfizerbiontech	NOUN
gs-3919	436	17	)	)	PUNCT
gs-3919	436	18	are	be	AUX
gs-3919	436	19	linked	link	VERB
gs-3919	436	20	to	to	PART
gs-3919	436	21	transient	transient	VERB
gs-3919	436	22	eosinophilic	eosinophilic	ADJ
gs-3919	436	23	myocarditis	myocarditis	NOUN
gs-3919	436	24	in	in	ADP
gs-3919	436	25	adolescents	adolescent	NOUN
gs-3919	436	26	.	.	PUNCT
gs-3919	437	1	cryo	cryo	PROPN
gs-3919	437	2	-	-	PUNCT
gs-3919	437	3	em	em	PRON
gs-3919	437	4	studies	study	NOUN
gs-3919	437	5	show	show	VERB
gs-3919	437	6	lnps	lnps	PROPN
gs-3919	437	7	activate	activate	VERB
gs-3919	437	8	*	*	PUNCT
gs-3919	437	9	tlr7/8	tlr7/8	NOUN
gs-3919	437	10	*	*	NOUN
gs-3919	437	11	in	in	ADP
gs-3919	437	12	plasmacytoid	plasmacytoid	NOUN
gs-3919	437	13	dendritic	dendritic	ADJ
gs-3919	437	14	cells	cell	NOUN
gs-3919	437	15	,	,	PUNCT
gs-3919	437	16	driving	drive	VERB
gs-3919	437	17	il33	il33	PROPN
gs-3919	437	18	/	/	SYM
gs-3919	437	19	tslp	tslp	VERB
gs-3919	437	20	release	release	NOUN
gs-3919	437	21	and	and	CCONJ
gs-3919	437	22	eosinophil	eosinophil	ADJ
gs-3919	437	23	recruitment	recruitment	NOUN
gs-3919	437	24	—	—	PUNCT
gs-3919	437	25	a	a	DET
gs-3919	437	26	mechanism	mechanism	NOUN
gs-3919	437	27	distinct	distinct	ADJ
gs-3919	437	28	from	from	ADP
gs-3919	437	29	classical	classical	ADJ
gs-3919	437	30	haptenization	haptenization	NOUN
gs-3919	437	31	.	.	PUNCT
gs-3919	438	1			VERB
gs-3919	438	2	metabolic	metabolic	NOUN
gs-3919	438	3	profiling	profiling	NOUN
gs-3919	438	4	revelations	revelation	NOUN
gs-3919	438	5	:	:	PUNCT
gs-3919	438	6	lc	lc	PROPN
gs-3919	438	7	-	-	PUNCT
gs-3919	438	8	ms	ms	PROPN
gs-3919	438	9	/	/	SYM
gs-3919	438	10	ms	ms	NOUN
gs-3919	438	11	analyses	analysis	NOUN
gs-3919	438	12	of	of	ADP
gs-3919	438	13	dress	dress	NOUN
gs-3919	438	14	patient	patient	ADJ
gs-3919	438	15	sera	sera	NOUN
gs-3919	438	16	uncover	uncover	NOUN
gs-3919	438	17	kynurenine	kynurenine	PROPN
gs-3919	438	18	pathway	pathway	NOUN
gs-3919	438	19	dysregulation	dysregulation	NOUN
gs-3919	438	20	:	:	PUNCT
gs-3919	438	21			ADJ
gs-3919	438	22	quinolinic	quinolinic	ADJ
gs-3919	438	23	acid	acid	NOUN
gs-3919	438	24	levels	level	NOUN
gs-3919	438	25	rise	rise	VERB
gs-3919	438	26	15	15	NUM
gs-3919	438	27	-	-	NOUN
gs-3919	438	28	fold	fold	ADJ
gs-3919	438	29	in	in	ADP
gs-3919	438	30	severe	severe	ADJ
gs-3919	438	31	cases	case	NOUN
gs-3919	438	32	,	,	PUNCT
gs-3919	438	33	correlating	correlate	VERB
gs-3919	438	34	with	with	ADP
gs-3919	438	35	eosinophil	eosinophil	ADJ
gs-3919	438	36	extracellular	extracellular	ADJ
gs-3919	438	37	trap	trap	NOUN
gs-3919	438	38	(	(	PUNCT
gs-3919	438	39	eet	eet	NOUN
gs-3919	438	40	)	)	PUNCT
gs-3919	438	41	formation	formation	NOUN
gs-3919	438	42	and	and	CCONJ
gs-3919	438	43	renal	renal	ADJ
gs-3919	438	44	fibrosis	fibrosis	NOUN
gs-3919	438	45	.	.	PUNCT
gs-3919	439	1			VERB
gs-3919	439	2	3	3	NUM
gs-3919	439	3	-	-	PUNCT
gs-3919	439	4	hydroxykynurenine	hydroxykynurenine	NOUN
gs-3919	439	5	,	,	PUNCT
gs-3919	439	6	a	a	DET
gs-3919	439	7	tryptophan	tryptophan	NOUN
gs-3919	439	8	metabolite	metabolite	NOUN
gs-3919	439	9	,	,	PUNCT
gs-3919	439	10	directly	directly	ADV
gs-3919	439	11	chelates	chelate	VERB
gs-3919	439	12	iron	iron	NOUN
gs-3919	439	13	in	in	ADP
gs-3919	439	14	eosinophil	eosinophil	ADJ
gs-3919	439	15	mitochondria	mitochondria	NOUN
gs-3919	439	16	,	,	PUNCT
gs-3919	439	17	inducing	induce	VERB
gs-3919	439	18	ferroptosis	ferroptosis	NOUN
gs-3919	439	19	and	and	CCONJ
gs-3919	439	20	amplifying	amplifying	ADJ
gs-3919	439	21	tissue	tissue	NOUN
gs-3919	439	22	damage	damage	NOUN
gs-3919	439	23	(	(	PUNCT
gs-3919	439	24	p<0.001	p<0.001	VERB
gs-3919	439	25	in	in	ADP
gs-3919	439	26	murine	murine	ADJ
gs-3919	439	27	models	model	NOUN
gs-3919	439	28	)	)	PUNCT
gs-3919	439	29	.	.	PUNCT
gs-3919	440	1	genomic	genomic	NOUN
gs-3919	440	2	and	and	CCONJ
gs-3919	440	3	epigenetic	epigenetic	ADJ
gs-3919	440	4	drivers	driver	NOUN
gs-3919	440	5	of	of	ADP
gs-3919	440	6	susceptibility	susceptibility	NOUN
gs-3919	440	7			PROPN
gs-3919	440	8	non	non	ADJ
gs-3919	440	9	-	-	ADJ
gs-3919	440	10	hla	hla	ADJ
gs-3919	440	11	genetic	genetic	ADJ
gs-3919	440	12	risks	risk	NOUN
gs-3919	440	13			VERB
gs-3919	440	14	gsdmb	gsdmb	ADJ
gs-3919	440	15	variants	variant	NOUN
gs-3919	440	16	:	:	PUNCT
gs-3919	440	17	gwas	gwas	NOUN
gs-3919	440	18	of	of	ADP
gs-3919	440	19	1,243	1,243	NUM
gs-3919	440	20	dress	dress	NOUN
gs-3919	440	21	cases	case	NOUN
gs-3919	440	22	implicate	implicate	VERB
gs-3919	440	23	gsdmb	gsdmb	NOUN
gs-3919	440	24	(	(	PUNCT
gs-3919	440	25	gasdermin	gasdermin	NOUN
gs-3919	440	26	b	b	NOUN
gs-3919	440	27	)	)	PUNCT
gs-3919	440	28	polymorphisms	polymorphism	NOUN
gs-3919	440	29	in	in	ADP
gs-3919	440	30	18q12	18q12	NUM
gs-3919	440	31	.	.	PUNCT
gs-3919	441	1	risk	risk	NOUN
gs-3919	441	2	alleles	allele	NOUN
gs-3919	441	3	enhance	enhance	VERB
gs-3919	441	4	eosinophil	eosinophil	ADJ
gs-3919	441	5	pyroptosis	pyroptosis	NOUN
gs-3919	441	6	,	,	PUNCT
gs-3919	441	7	releasing	release	VERB
gs-3919	441	8	il-1α	il-1α	PROPN
gs-3919	441	9	and	and	CCONJ
gs-3919	441	10	perpetuating	perpetuate	VERB
gs-3919	441	11	inflammation	inflammation	NOUN
gs-3919	441	12	.	.	PUNCT
gs-3919	442	1			ADJ
gs-3919	442	2	tet2	tet2	NOUN
gs-3919	442	3	mutations	mutation	NOUN
gs-3919	442	4	:	:	PUNCT
gs-3919	442	5	clonal	clonal	ADJ
gs-3919	442	6	hematopoiesis	hematopoiesis	NOUN
gs-3919	442	7	of	of	ADP
gs-3919	442	8	indeterminate	indeterminate	ADJ
gs-3919	442	9	potential	potential	ADJ
gs-3919	442	10	(	(	PUNCT
gs-3919	442	11	chip	chip	NOUN
gs-3919	442	12	)	)	PUNCT
gs-3919	442	13	with	with	ADP
gs-3919	442	14	tet2	tet2	PROPN
gs-3919	442	15	loss	loss	NOUN
gs-3919	442	16	-	-	PUNCT
gs-3919	442	17	of	of	ADP
gs-3919	442	18	-	-	PUNCT
gs-3919	442	19	function	function	NOUN
gs-3919	442	20	increases	increase	NOUN
gs-3919	442	21	eosinophil	eosinophil	ADJ
gs-3919	442	22	lifespan	lifespan	NOUN
gs-3919	442	23	by	by	ADP
gs-3919	442	24	40	40	NUM
gs-3919	442	25	%	%	NOUN
gs-3919	442	26	in	in	ADP
gs-3919	442	27	elderly	elderly	ADJ
gs-3919	442	28	patients	patient	NOUN
gs-3919	442	29	on	on	ADP
gs-3919	442	30	sulfamethoxazole	sulfamethoxazole	NOUN
gs-3919	442	31	(	(	PUNCT
gs-3919	442	32	hr	hr	NOUN
gs-3919	442	33	3.2	3.2	NUM
gs-3919	442	34	for	for	ADP
gs-3919	442	35	severe	severe	ADJ
gs-3919	442	36	reactions	reaction	NOUN
gs-3919	442	37	)	)	PUNCT
gs-3919	442	38	.	.	PUNCT
gs-3919	443	1			ADJ
gs-3919	443	2	epigenetic	epigenetic	ADJ
gs-3919	443	3	modifications	modification	NOUN
gs-3919	443	4			VERB
gs-3919	443	5	dna	dna	PROPN
gs-3919	443	6	methylation	methylation	NOUN
gs-3919	443	7	:	:	PUNCT
gs-3919	443	8	hypomethylation	hypomethylation	NOUN
gs-3919	443	9	at	at	ADP
gs-3919	443	10	the	the	DET
gs-3919	443	11	il5	il5	NOUN
gs-3919	443	12	promoter	promoter	NOUN
gs-3919	443	13	in	in	ADP
gs-3919	443	14	cd4	cd4	PROPN
gs-3919	443	15	+	+	PROPN
gs-3919	443	16	t	t	NOUN
gs-3919	443	17	cells	cell	NOUN
gs-3919	443	18	precedes	precede	VERB
gs-3919	443	19	eosinophilia	eosinophilia	PROPN
gs-3919	443	20	onset	onset	VERB
gs-3919	443	21	by	by	ADP
gs-3919	443	22	4	4	NUM
gs-3919	443	23	weeks	week	NOUN
gs-3919	443	24	(	(	PUNCT
gs-3919	443	25	auc	auc	NOUN
gs-3919	443	26	0.89	0.89	NUM
gs-3919	443	27	for	for	ADP
gs-3919	443	28	prediction	prediction	NOUN
gs-3919	443	29	)	)	PUNCT
gs-3919	443	30	.	.	PUNCT
gs-3919	444	1			PROPN
gs-3919	444	2	mirna	mirna	PROPN
gs-3919	444	3	networks	network	NOUN
gs-3919	444	4	:	:	PUNCT
gs-3919	444	5	mir-223	mir-223	NOUN
gs-3919	444	6	-	-	PUNCT
gs-3919	444	7	3p	3p	NUM
gs-3919	444	8	,	,	PUNCT
gs-3919	444	9	packaged	package	VERB
gs-3919	444	10	in	in	ADP
gs-3919	444	11	eosinophil	eosinophil	ADJ
gs-3919	444	12	-	-	PUNCT
gs-3919	444	13	derived	derive	VERB
gs-3919	444	14	exosomes	exosome	NOUN
gs-3919	444	15	,	,	PUNCT
gs-3919	444	16	silences	silence	VERB
gs-3919	444	17	foxp3	foxp3	NOUN
gs-3919	444	18	in	in	ADP
gs-3919	444	19	tregs	treg	NOUN
gs-3919	444	20	,	,	PUNCT
gs-3919	444	21	reducing	reduce	VERB
gs-3919	444	22	immune	immune	ADJ
gs-3919	444	23	tolerance	tolerance	NOUN
gs-3919	444	24	in	in	ADP
gs-3919	444	25	dress	dress	NOUN
gs-3919	444	26	(	(	PUNCT
gs-3919	444	27	confirmed	confirm	VERB
gs-3919	444	28	by	by	ADP
gs-3919	444	29	luciferase	luciferase	ADJ
gs-3919	444	30	reporter	reporter	NOUN
gs-3919	444	31	assays	assay	NOUN
gs-3919	444	32	)	)	PUNCT
gs-3919	444	33	.	.	PUNCT
gs-3919	445	1	georgian	georgian	ADJ
gs-3919	445	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	445	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	445	4	ტ.	ტ.	VERB
gs-3919	445	5	7	7	NUM
gs-3919	445	6	n	n	PRON
gs-3919	445	7	3	3	NUM
gs-3919	445	8	,	,	PUNCT
gs-3919	445	9	2025	2025	NUM
gs-3919	445	10	168	168	NUM
gs-3919	445	11	single	single	ADJ
gs-3919	445	12	-	-	PUNCT
gs-3919	445	13	cell	cell	NOUN
gs-3919	445	14	dissection	dissection	NOUN
gs-3919	445	15	of	of	ADP
gs-3919	445	16	eosinophil	eosinophil	ADJ
gs-3919	445	17	heterogeneity	heterogeneity	NOUN
gs-3919	445	18	mass	mass	NOUN
gs-3919	445	19	cytometry	cytometry	NOUN
gs-3919	445	20	(	(	PUNCT
gs-3919	445	21	cytof	cytof	NOUN
gs-3919	445	22	)	)	PUNCT
gs-3919	445	23	of	of	ADP
gs-3919	445	24	drug	drug	NOUN
gs-3919	445	25	-	-	PUNCT
gs-3919	445	26	reactive	reactive	ADJ
gs-3919	445	27	eosinophils	eosinophil	NOUN
gs-3919	445	28	identifies	identifie	NOUN
gs-3919	445	29	:	:	PUNCT
gs-3919	445	30			ADJ
gs-3919	445	31	eos	eo	NOUN
gs-3919	445	32	-	-	NOUN
gs-3919	445	33	ifnγ	ifnγ	NOUN
gs-3919	445	34	:	:	PUNCT
gs-3919	445	35	a	a	DET
gs-3919	445	36	novel	novel	NOUN
gs-3919	445	37	subset	subset	NOUN
gs-3919	445	38	expressing	express	VERB
gs-3919	445	39	tbx21	tbx21	PROPN
gs-3919	445	40	and	and	CCONJ
gs-3919	445	41	secreting	secrete	VERB
gs-3919	445	42	ifnγ	ifnγ	NOUN
gs-3919	445	43	,	,	PUNCT
gs-3919	445	44	dominant	dominant	ADJ
gs-3919	445	45	in	in	ADP
gs-3919	445	46	checkpoint	checkpoint	NOUN
gs-3919	445	47	inhibitor	inhibitor	NOUN
gs-3919	445	48	reactions	reaction	NOUN
gs-3919	445	49	.	.	PUNCT
gs-3919	446	1	these	these	DET
gs-3919	446	2	cells	cell	NOUN
gs-3919	446	3	exhibit	exhibit	VERB
gs-3919	446	4	enhanced	enhance	VERB
gs-3919	446	5	mhc	mhc	PROPN
gs-3919	446	6	-	-	PUNCT
gs-3919	446	7	ii	ii	PROPN
gs-3919	446	8	presentation	presentation	NOUN
gs-3919	446	9	,	,	PUNCT
gs-3919	446	10	directly	directly	ADV
gs-3919	446	11	activating	activate	VERB
gs-3919	446	12	cd8	cd8	PROPN
gs-3919	446	13	+	+	PROPN
gs-3919	446	14	t	t	NOUN
gs-3919	446	15	cells	cell	NOUN
gs-3919	446	16	.	.	PUNCT
gs-3919	447	1			VERB
gs-3919	447	2	eos	eos	PROPN
gs-3919	447	3	-	-	PUNCT
gs-3919	447	4	memory	memory	NOUN
gs-3919	447	5	:	:	PUNCT
gs-3919	447	6	long	long	ADJ
gs-3919	447	7	-	-	PUNCT
gs-3919	447	8	lived	live	VERB
gs-3919	447	9	eosinophils	eosinophil	NOUN
gs-3919	447	10	with	with	ADP
gs-3919	447	11	tcf7	tcf7	NOUN
gs-3919	447	12	expression	expression	NOUN
gs-3919	447	13	,	,	PUNCT
gs-3919	447	14	persisting	persist	VERB
gs-3919	447	15	>	>	ADP
gs-3919	447	16	1	1	NUM
gs-3919	447	17	year	year	NOUN
gs-3919	447	18	postreaction	postreaction	NOUN
gs-3919	447	19	and	and	CCONJ
gs-3919	447	20	driving	drive	VERB
gs-3919	447	21	relapses	relapse	NOUN
gs-3919	447	22	upon	upon	SCONJ
gs-3919	447	23	drug	drug	NOUN
gs-3919	447	24	re	re	NOUN
gs-3919	447	25	-	-	NOUN
gs-3919	447	26	exposure	exposure	NOUN
gs-3919	447	27	.	.	PUNCT
gs-3919	448	1			VERB
gs-3919	448	2	spatial	spatial	ADJ
gs-3919	448	3	transcriptomics	transcriptomic	NOUN
gs-3919	448	4			VERB
gs-3919	448	5	in	in	ADP
gs-3919	448	6	dress	dress	NOUN
gs-3919	448	7	skin	skin	NOUN
gs-3919	448	8	lesions	lesion	NOUN
gs-3919	448	9	,	,	PUNCT
gs-3919	448	10	*	*	PUNCT
gs-3919	448	11	col17a1	col17a1	PROPN
gs-3919	448	12	+	+	ADJ
gs-3919	448	13	-eosinophil	-eosinophil	ADJ
gs-3919	448	14	*	*	VERB
gs-3919	448	15	clusters	cluster	NOUN
gs-3919	448	16	colocalize	colocalize	VERB
gs-3919	448	17	with	with	ADP
gs-3919	448	18	cd8	cd8	PROPN
gs-3919	448	19	+	+	CCONJ
gs-3919	448	20	trm	trm	ADJ
gs-3919	448	21	cells	cell	NOUN
gs-3919	448	22	,	,	PUNCT
gs-3919	448	23	forming	form	VERB
gs-3919	448	24	"	"	PUNCT
gs-3919	448	25	eosinophilic	eosinophilic	ADJ
gs-3919	448	26	synapses	synapsis	NOUN
gs-3919	448	27	"	"	PUNCT
gs-3919	448	28	that	that	PRON
gs-3919	448	29	sustain	sustain	VERB
gs-3919	448	30	chronic	chronic	ADJ
gs-3919	448	31	inflammation	inflammation	NOUN
gs-3919	448	32	.	.	PUNCT
gs-3919	449	1	viral	viral	ADJ
gs-3919	449	2	mimicry	mimicry	ADJ
gs-3919	449	3	and	and	CCONJ
gs-3919	449	4	molecular	molecular	ADJ
gs-3919	449	5	trojan	trojan	NOUN
gs-3919	449	6	horses	horse	NOUN
gs-3919	449	7	proteomic	proteomic	ADJ
gs-3919	449	8	studies	study	NOUN
gs-3919	449	9	reveal	reveal	VERB
gs-3919	449	10	:	:	PUNCT
gs-3919	449	11			ADJ
gs-3919	449	12	hhv-6	hhv-6	ADJ
gs-3919	449	13	u54	u54	ADJ
gs-3919	449	14	protein	protein	NOUN
gs-3919	449	15	:	:	PUNCT
gs-3919	449	16	structurally	structurally	ADV
gs-3919	449	17	mimics	mimic	VERB
gs-3919	449	18	carbamazepine	carbamazepine	NOUN
gs-3919	449	19	-	-	PUNCT
gs-3919	449	20	metabolite	metabolite	NOUN
gs-3919	449	21	complexes	complex	NOUN
gs-3919	449	22	,	,	PUNCT
gs-3919	449	23	crossactivating	crossactivate	VERB
gs-3919	449	24	drug	drug	NOUN
gs-3919	449	25	-	-	PUNCT
gs-3919	449	26	specific	specific	ADJ
gs-3919	449	27	tcrs	tcrs	NOUN
gs-3919	449	28	(	(	PUNCT
gs-3919	449	29	tetramer	tetramer	ADJ
gs-3919	449	30	staining	stain	VERB
gs-3919	449	31	confirms	confirm	VERB
gs-3919	449	32	23	23	NUM
gs-3919	449	33	%	%	NOUN
gs-3919	449	34	tcr	tcr	PROPN
gs-3919	449	35	overlap	overlap	NOUN
gs-3919	449	36	)	)	PUNCT
gs-3919	449	37	.	.	PUNCT
gs-3919	450	1			ADJ
gs-3919	450	2	endogenous	endogenous	ADJ
gs-3919	450	3	retroviruses	retrovirus	NOUN
gs-3919	450	4	(	(	PUNCT
gs-3919	450	5	ervs	ervs	NOUN
gs-3919	450	6	):	):	PUNCT
gs-3919	450	7	drug	drug	NOUN
gs-3919	450	8	-	-	PUNCT
gs-3919	450	9	induced	induce	VERB
gs-3919	450	10	hypomethylation	hypomethylation	NOUN
gs-3919	450	11	reactivate	reactivate	VERB
gs-3919	450	12	erv-3	erv-3	ADP
gs-3919	450	13	,	,	PUNCT
gs-3919	450	14	whose	whose	DET
gs-3919	450	15	envelope	envelope	NOUN
gs-3919	450	16	protein	protein	NOUN
gs-3919	450	17	triggers	trigger	VERB
gs-3919	450	18	mda5	mda5	NOUN
gs-3919	450	19	-	-	PUNCT
gs-3919	450	20	dependent	dependent	ADJ
gs-3919	450	21	ifnβ	ifnβ	ADJ
gs-3919	450	22	production	production	NOUN
gs-3919	450	23	—	—	PUNCT
gs-3919	450	24	amplifying	amplifying	ADJ
gs-3919	450	25	eosinophil	eosinophil	ADJ
gs-3919	450	26	chemotaxis	chemotaxis	ADJ
gs-3919	450	27	.	.	PUNCT
gs-3919	451	1	clinical	clinical	ADJ
gs-3919	451	2	innovations	innovation	NOUN
gs-3919	451	3	:	:	PUNCT
gs-3919	451	4	from	from	ADP
gs-3919	451	5	bedside	bedside	NOUN
gs-3919	451	6	to	to	PART
gs-3919	451	7	bench	bench	VERB
gs-3919	451	8	and	and	CCONJ
gs-3919	451	9	dynamic	dynamic	ADJ
gs-3919	451	10	biomarkers	biomarker	NOUN
gs-3919	451	11			VERB
gs-3919	451	12	fecal	fecal	ADJ
gs-3919	451	13	ecp	ecp	NOUN
gs-3919	451	14	:	:	PUNCT
gs-3919	451	15	elevated	elevate	VERB
gs-3919	451	16	in	in	ADP
gs-3919	451	17	drug	drug	NOUN
gs-3919	451	18	-	-	PUNCT
gs-3919	451	19	induced	induce	VERB
gs-3919	451	20	eosinophilic	eosinophilic	ADJ
gs-3919	451	21	colitis	colitis	NOUN
gs-3919	451	22	(	(	PUNCT
gs-3919	451	23	>	>	X
gs-3919	451	24	200	200	NUM
gs-3919	451	25	μg	μg	PROPN
gs-3919	451	26	/	/	SYM
gs-3919	451	27	g	g	PROPN
gs-3919	451	28	predicts	predict	VERB
gs-3919	451	29	steroid	steroid	NOUN
gs-3919	451	30	resistance	resistance	NOUN
gs-3919	451	31	;	;	PUNCT
gs-3919	451	32	sensitivity	sensitivity	NOUN
gs-3919	451	33	94	94	NUM
gs-3919	451	34	%	%	NOUN
gs-3919	451	35	)	)	PUNCT
gs-3919	451	36	.	.	PUNCT
gs-3919	452	1			PROPN
gs-3919	452	2	eets	eet	NOUN
gs-3919	452	3	in	in	ADP
gs-3919	452	4	plasma	plasma	NOUN
gs-3919	452	5	:	:	PUNCT
gs-3919	452	6	quantified	quantify	VERB
gs-3919	452	7	by	by	ADP
gs-3919	452	8	*	*	PROPN
gs-3919	452	9	cith3	cith3	PROPN
gs-3919	452	10	-	-	NOUN
gs-3919	452	11	dna	dna	PROPN
gs-3919	452	12	*	*	NOUN
gs-3919	452	13	elisa	elisa	PROPN
gs-3919	452	14	,	,	PUNCT
gs-3919	452	15	levels	level	NOUN
gs-3919	452	16	>	>	X
gs-3919	452	17	8	8	NUM
gs-3919	452	18	ng	ng	NOUN
gs-3919	452	19	/	/	SYM
gs-3919	452	20	ml	ml	AUX
gs-3919	452	21	indicate	indicate	VERB
gs-3919	452	22	progressive	progressive	ADJ
gs-3919	452	23	organ	organ	NOUN
gs-3919	452	24	involvement	involvement	NOUN
gs-3919	452	25	.	.	PUNCT
gs-3919	453	1			ADJ
gs-3919	453	2	imaging	imaging	NOUN
gs-3919	453	3	breakthroughs	breakthrough	NOUN
gs-3919	453	4	:	:	PUNCT
gs-3919	453	5	68ga	68ga	ADJ
gs-3919	453	6	-	-	PUNCT
gs-3919	453	7	fapi	fapi	NOUN
gs-3919	453	8	pet	pet	NOUN
gs-3919	453	9	/	/	SYM
gs-3919	453	10	ctvisualizes	ctvisualize	NOUN
gs-3919	453	11	eosinophil	eosinophil	ADJ
gs-3919	453	12	-	-	PUNCT
gs-3919	453	13	mediated	mediate	VERB
gs-3919	453	14	fibrosis	fibrosis	NOUN
gs-3919	453	15	(	(	PUNCT
gs-3919	453	16	suvmax	suvmax	ADV
gs-3919	453	17	>	>	X
gs-3919	453	18	6.5	6.5	NUM
gs-3919	453	19	in	in	ADP
gs-3919	453	20	dress	dress	NOUN
gs-3919	453	21	-	-	PUNCT
gs-3919	453	22	associated	associate	VERB
gs-3919	453	23	myocarditis	myocarditis	PROPN
gs-3919	453	24	)	)	PUNCT
gs-3919	453	25	.	.	PUNCT
gs-3919	454	1			ADJ
gs-3919	454	2	eosinophil	eosinophil	ADJ
gs-3919	454	3	-	-	PUNCT
gs-3919	454	4	specific	specific	ADJ
gs-3919	454	5	mri	mri	NOUN
gs-3919	454	6	:	:	PUNCT
gs-3919	454	7	ferumoxytol	ferumoxytol	NOUN
gs-3919	454	8	-	-	PUNCT
gs-3919	454	9	enhanced	enhance	VERB
gs-3919	454	10	t2	t2	NOUN
gs-3919	454	11	*	*	SYM
gs-3919	454	12	mapping	mapping	NOUN
gs-3919	454	13	detects	detect	NOUN
gs-3919	454	14	cardiac	cardiac	ADJ
gs-3919	454	15	eosinophilic	eosinophilic	NOUN
gs-3919	454	16	infiltrates	infiltrate	NOUN
gs-3919	454	17	with	with	ADP
gs-3919	454	18	92	92	NUM
gs-3919	454	19	%	%	NOUN
gs-3919	454	20	concordance	concordance	NOUN
gs-3919	454	21	to	to	PART
gs-3919	454	22	biopsy	biopsy	VERB
gs-3919	454	23	.	.	PUNCT
gs-3919	455	1	therapeutic	therapeutic	ADJ
gs-3919	455	2	frontiers	frontier	NOUN
gs-3919	455	3			VERB
gs-3919	455	4	anti	anti	ADJ
gs-3919	455	5	-	-	ADJ
gs-3919	455	6	il-33	il-33	ADJ
gs-3919	455	7	(	(	PUNCT
gs-3919	455	8	etokimab	etokimab	NOUN
gs-3919	455	9	):	):	PUNCT
gs-3919	455	10	phase	phase	NOUN
gs-3919	455	11	ii	ii	PROPN
gs-3919	455	12	trials	trial	NOUN
gs-3919	455	13	show	show	VERB
gs-3919	455	14	72	72	NUM
gs-3919	455	15	%	%	NOUN
gs-3919	455	16	reduction	reduction	NOUN
gs-3919	455	17	in	in	ADP
gs-3919	455	18	eosinophil	eosinophil	ADJ
gs-3919	455	19	counts	count	NOUN
gs-3919	455	20	within	within	ADP
gs-3919	455	21	48	48	NUM
gs-3919	455	22	hours	hour	NOUN
gs-3919	455	23	for	for	ADP
gs-3919	455	24	dress	dress	NOUN
gs-3919	455	25	(	(	PUNCT
gs-3919	455	26	vs.	vs.	NOUN
gs-3919	455	27	31	31	NUM
gs-3919	455	28	%	%	NOUN
gs-3919	455	29	placebo	placebo	NOUN
gs-3919	455	30	;	;	PUNCT
gs-3919	455	31	p=0.008	p=0.008	NOUN
gs-3919	455	32	)	)	PUNCT
gs-3919	455	33	.	.	PUNCT
gs-3919	456	1			ADJ
gs-3919	456	2	btk	btk	NOUN
gs-3919	456	3	inhibitor	inhibitor	NOUN
gs-3919	456	4	switch	switch	NOUN
gs-3919	456	5	:	:	PUNCT
gs-3919	456	6	transitioning	transition	VERB
gs-3919	456	7	ibrutinib	ibrutinib	NOUN
gs-3919	456	8	to	to	ADP
gs-3919	456	9	zanubrutinib	zanubrutinib	PROPN
gs-3919	456	10	(	(	PUNCT
gs-3919	456	11	lower	low	ADJ
gs-3919	456	12	il-5	il-5	ADJ
gs-3919	456	13	induction	induction	NOUN
gs-3919	456	14	)	)	PUNCT
gs-3919	456	15	resolves	resolve	VERB
gs-3919	456	16	eosinophilia	eosinophilia	PROPN
gs-3919	456	17	in	in	ADP
gs-3919	456	18	89	89	NUM
gs-3919	456	19	%	%	NOUN
gs-3919	456	20	of	of	ADP
gs-3919	456	21	cases	case	NOUN
gs-3919	456	22	.	.	PUNCT
gs-3919	457	1			ADJ
gs-3919	457	2	microbiome	microbiome	ADJ
gs-3919	457	3	manipulation	manipulation	NOUN
gs-3919	457	4			VERB
gs-3919	457	5	fmt	fmt	NOUN
gs-3919	457	6	in	in	ADP
gs-3919	457	7	recurrent	recurrent	ADJ
gs-3919	457	8	cases	case	NOUN
gs-3919	457	9	:	:	PUNCT
gs-3919	457	10	fecal	fecal	ADJ
gs-3919	457	11	microbiota	microbiota	NOUN
gs-3919	457	12	transplantation	transplantation	NOUN
gs-3919	457	13	restores	restore	VERB
gs-3919	457	14	bacteroidesdominant	bacteroidesdominant	NOUN
gs-3919	457	15	profiles	profile	NOUN
gs-3919	457	16	,	,	PUNCT
gs-3919	457	17	reducing	reduce	VERB
gs-3919	457	18	il-25	il-25	NOUN
gs-3919	457	19	-	-	PUNCT
gs-3919	457	20	driven	drive	VERB
gs-3919	457	21	eosinophilia	eosinophilia	NOUN
gs-3919	457	22	(	(	PUNCT
gs-3919	457	23	n=12	n=12	PROPN
gs-3919	457	24	,	,	PUNCT
gs-3919	457	25	remission	remission	NOUN
gs-3919	457	26	duration	duration	NOUN
gs-3919	457	27	14±3	14±3	NUM
gs-3919	457	28	months	month	NOUN
gs-3919	457	29	)	)	PUNCT
gs-3919	457	30	.	.	PUNCT
gs-3919	458	1	georgian	georgian	ADJ
gs-3919	458	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	458	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	458	4	ტ.	ტ.	VERB
gs-3919	458	5	7	7	NUM
gs-3919	458	6	n	n	PRON
gs-3919	458	7	3	3	NUM
gs-3919	458	8	,	,	PUNCT
gs-3919	458	9	2025	2025	NUM
gs-3919	458	10	169	169	NUM
gs-3919	458	11			VERB
gs-3919	458	12	deepeos	deepeo	NOUN
gs-3919	458	13	model	model	NOUN
gs-3919	458	14	:	:	PUNCT
gs-3919	458	15	trained	train	VERB
gs-3919	458	16	on	on	ADP
gs-3919	458	17	45,000	45,000	NUM
gs-3919	458	18	faers	faer	NOUN
gs-3919	458	19	reports	report	NOUN
gs-3919	458	20	,	,	PUNCT
gs-3919	458	21	predicts	predict	VERB
gs-3919	458	22	eosinophilia	eosinophilia	PROPN
gs-3919	458	23	risk	risk	NOUN
gs-3919	458	24	for	for	ADP
gs-3919	458	25	investigational	investigational	ADJ
gs-3919	458	26	drugs	drug	NOUN
gs-3919	458	27	with	with	ADP
gs-3919	458	28	87	87	NUM
gs-3919	458	29	%	%	NOUN
gs-3919	458	30	accuracy	accuracy	NOUN
gs-3919	458	31	(	(	PUNCT
gs-3919	458	32	e.g.	e.g.	ADV
gs-3919	458	33	,	,	PUNCT
gs-3919	458	34	correctly	correctly	ADV
gs-3919	458	35	flagged	flag	VERB
gs-3919	458	36	tezepelumab	tezepelumab	NOUN
gs-3919	458	37	prelaunch	prelaunch	NOUN
gs-3919	458	38	)	)	PUNCT
gs-3919	458	39	.	.	PUNCT
gs-3919	459	1			VERB
gs-3919	459	2	digital	digital	ADJ
gs-3919	459	3	twins	twin	NOUN
gs-3919	459	4	:	:	PUNCT
gs-3919	459	5	patient	patient	NOUN
gs-3919	459	6	-	-	PUNCT
gs-3919	459	7	specific	specific	NOUN
gs-3919	459	8	in	in	ADP
gs-3919	459	9	silico	silico	NOUN
gs-3919	459	10	models	model	NOUN
gs-3919	459	11	incorporating	incorporate	VERB
gs-3919	459	12	hla	hla	PROPN
gs-3919	459	13	,	,	PUNCT
gs-3919	459	14	metabolome	metabolome	NOUN
gs-3919	459	15	,	,	PUNCT
gs-3919	459	16	and	and	CCONJ
gs-3919	459	17	microbiome	microbiome	ADJ
gs-3919	459	18	data	datum	NOUN
gs-3919	459	19	simulate	simulate	VERB
gs-3919	459	20	reaction	reaction	NOUN
gs-3919	459	21	trajectories	trajectory	NOUN
gs-3919	459	22	(	(	PUNCT
gs-3919	459	23	pilot	pilot	NOUN
gs-3919	459	24	study	study	NOUN
gs-3919	459	25	reduced	reduce	VERB
gs-3919	459	26	icu	icu	PROPN
gs-3919	459	27	admissions	admission	NOUN
gs-3919	459	28	by	by	ADP
gs-3919	459	29	33	33	NUM
gs-3919	459	30	%	%	NOUN
gs-3919	459	31	)	)	PUNCT
gs-3919	459	32	.	.	PUNCT
gs-3919	460	1	immunological	immunological	ADJ
gs-3919	460	2	mechanisms	mechanism	NOUN
gs-3919	460	3	:	:	PUNCT
gs-3919	460	4	beyond	beyond	ADP
gs-3919	460	5	th2	th2	PROPN
gs-3919	460	6	dominance	dominance	NOUN
gs-3919	460	7	single	single	ADJ
gs-3919	460	8	-	-	PUNCT
gs-3919	460	9	cell	cell	NOUN
gs-3919	460	10	rna	rna	NOUN
gs-3919	460	11	sequencing	sequence	VERB
gs-3919	460	12	(	(	PUNCT
gs-3919	460	13	scrna	scrna	NOUN
gs-3919	460	14	-	-	PUNCT
gs-3919	460	15	seq	seq	NOUN
gs-3919	460	16	)	)	PUNCT
gs-3919	460	17	of	of	ADP
gs-3919	460	18	dress	dress	NOUN
gs-3919	460	19	skin	skin	NOUN
gs-3919	460	20	biopsies	biopsy	NOUN
gs-3919	460	21	has	have	AUX
gs-3919	460	22	redefined	redefine	VERB
gs-3919	460	23	eosinophil	eosinophil	ADJ
gs-3919	460	24	heterogeneity	heterogeneity	NOUN
gs-3919	460	25	in	in	ADP
gs-3919	460	26	drug	drug	NOUN
gs-3919	460	27	reactions	reaction	NOUN
gs-3919	460	28	.	.	PUNCT
gs-3919	461	1	three	three	NUM
gs-3919	461	2	distinct	distinct	ADJ
gs-3919	461	3	subsets	subset	NOUN
gs-3919	461	4	emerge	emerge	VERB
gs-3919	461	5	:	:	PUNCT
gs-3919	461	6			ADJ
gs-3919	461	7	cytotoxic	cytotoxic	ADJ
gs-3919	461	8	eosinophils	eosinophil	NOUN
gs-3919	461	9	(	(	PUNCT
gs-3919	461	10	eos	eos	PROPN
gs-3919	461	11	-	-	PUNCT
gs-3919	461	12	cyt	cyt	PROPN
gs-3919	461	13	):	):	PUNCT
gs-3919	461	14	express	express	VERB
gs-3919	461	15	high	high	ADJ
gs-3919	461	16	levels	level	NOUN
gs-3919	461	17	of	of	ADP
gs-3919	461	18	prg2	prg2	PROPN
gs-3919	461	19	(	(	PUNCT
gs-3919	461	20	major	major	ADJ
gs-3919	461	21	basic	basic	ADJ
gs-3919	461	22	protein	protein	NOUN
gs-3919	461	23	)	)	PUNCT
gs-3919	461	24	and	and	CCONJ
gs-3919	461	25	epx	epx	VERB
gs-3919	461	26	(	(	PUNCT
gs-3919	461	27	eosinophil	eosinophil	ADJ
gs-3919	461	28	peroxidase	peroxidase	NOUN
gs-3919	461	29	)	)	PUNCT
gs-3919	461	30	,	,	PUNCT
gs-3919	461	31	infiltrating	infiltrate	VERB
gs-3919	461	32	organs	organ	NOUN
gs-3919	461	33	like	like	ADP
gs-3919	461	34	the	the	DET
gs-3919	461	35	liver	liver	NOUN
gs-3919	461	36	and	and	CCONJ
gs-3919	461	37	heart	heart	NOUN
gs-3919	461	38	.	.	PUNCT
gs-3919	462	1			ADJ
gs-3919	462	2	regulatory	regulatory	ADJ
gs-3919	462	3	eosinophils	eosinophil	NOUN
gs-3919	462	4	(	(	PUNCT
gs-3919	462	5	eos	eos	PROPN
gs-3919	462	6	-	-	PUNCT
gs-3919	462	7	reg	reg	NOUN
gs-3919	462	8	):	):	PUNCT
gs-3919	462	9	enriched	enrich	VERB
gs-3919	462	10	in	in	ADP
gs-3919	462	11	alox15	alox15	ADJ
gs-3919	462	12	(	(	PUNCT
gs-3919	462	13	15	15	NUM
gs-3919	462	14	-	-	PUNCT
gs-3919	462	15	lipoxygenase	lipoxygenase	NOUN
gs-3919	462	16	)	)	PUNCT
gs-3919	462	17	,	,	PUNCT
gs-3919	462	18	resolving	resolve	VERB
gs-3919	462	19	inflammation	inflammation	NOUN
gs-3919	462	20	via	via	ADP
gs-3919	462	21	specialized	specialized	ADJ
gs-3919	462	22	pro	pro	ADJ
gs-3919	462	23	-	-	ADJ
gs-3919	462	24	resolving	resolving	ADJ
gs-3919	462	25	mediators	mediator	NOUN
gs-3919	462	26	(	(	PUNCT
gs-3919	462	27	spms	spms	NOUN
gs-3919	462	28	)	)	PUNCT
gs-3919	462	29	.	.	PUNCT
gs-3919	463	1			VERB
gs-3919	463	2	antigen	antigen	NOUN
gs-3919	463	3	-	-	PUNCT
gs-3919	463	4	presenting	present	VERB
gs-3919	463	5	eosinophils	eosinophil	NOUN
gs-3919	463	6	(	(	PUNCT
gs-3919	463	7	eos	eos	PROPN
gs-3919	463	8	-	-	PUNCT
gs-3919	463	9	apc	apc	PROPN
gs-3919	463	10	):	):	PUNCT
gs-3919	463	11	upregulate	upregulate	ADJ
gs-3919	463	12	hla	hla	PROPN
gs-3919	463	13	-	-	PUNCT
gs-3919	463	14	dr	dr	PROPN
gs-3919	463	15	and	and	CCONJ
gs-3919	463	16	co	co	ADJ
gs-3919	463	17	-	-	ADJ
gs-3919	463	18	stimulatory	stimulatory	ADJ
gs-3919	463	19	molecules	molecule	NOUN
gs-3919	463	20	,	,	PUNCT
gs-3919	463	21	directly	directly	ADV
gs-3919	463	22	activating	activate	VERB
gs-3919	463	23	drug	drug	NOUN
gs-3919	463	24	-	-	PUNCT
gs-3919	463	25	specific	specific	NOUN
gs-3919	463	26	cd4	cd4	PROPN
gs-3919	463	27	+	+	PROPN
gs-3919	463	28	t	t	NOUN
gs-3919	463	29	cells	cell	NOUN
gs-3919	463	30	.	.	PUNCT
gs-3919	464	1	this	this	DET
gs-3919	464	2	subset	subset	ADJ
gs-3919	464	3	diversity	diversity	NOUN
gs-3919	464	4	explains	explain	VERB
gs-3919	464	5	clinical	clinical	ADJ
gs-3919	464	6	variability	variability	NOUN
gs-3919	464	7	—	—	PUNCT
gs-3919	464	8	eos	eos	PROPN
gs-3919	464	9	-	-	PUNCT
gs-3919	464	10	cyt	cyt	PROPN
gs-3919	464	11	dominance	dominance	NOUN
gs-3919	464	12	predicts	predict	VERB
gs-3919	464	13	fulminant	fulminant	ADJ
gs-3919	464	14	myocarditis	myocarditis	PROPN
gs-3919	464	15	,	,	PUNCT
gs-3919	464	16	while	while	SCONJ
gs-3919	464	17	eos	eos	PROPN
gs-3919	464	18	-	-	PUNCT
gs-3919	464	19	reg	reg	NOUN
gs-3919	464	20	predominance	predominance	NOUN
gs-3919	464	21	associates	associate	NOUN
gs-3919	464	22	with	with	ADP
gs-3919	464	23	self	self	NOUN
gs-3919	464	24	-	-	PUNCT
gs-3919	464	25	limited	limit	VERB
gs-3919	464	26	reactions	reaction	NOUN
gs-3919	464	27	.	.	PUNCT
gs-3919	465	1	viral	viral	ADJ
gs-3919	465	2	reactivation	reactivation	NOUN
gs-3919	465	3	and	and	CCONJ
gs-3919	465	4	the	the	DET
gs-3919	465	5	“	"	PUNCT
gs-3919	465	6	hapten	hapten	VERB
gs-3919	465	7	-	-	PUNCT
gs-3919	465	8	viral	viral	ADJ
gs-3919	465	9	”	"	PUNCT
gs-3919	465	10	hypothesis	hypothesis	NOUN
gs-3919	465	11	longitudinal	longitudinal	ADJ
gs-3919	465	12	metagenomic	metagenomic	ADJ
gs-3919	465	13	sequencing	sequencing	NOUN
gs-3919	465	14	in	in	ADP
gs-3919	465	15	dress	dress	NOUN
gs-3919	465	16	patients	patient	NOUN
gs-3919	465	17	confirms	confirm	VERB
gs-3919	465	18	hhv-6b	hhv-6b	ADJ
gs-3919	465	19	reactivation	reactivation	NOUN
gs-3919	465	20	in	in	ADP
gs-3919	465	21	89	89	NUM
gs-3919	465	22	%	%	NOUN
gs-3919	465	23	of	of	ADP
gs-3919	465	24	cases	case	NOUN
gs-3919	465	25	,	,	PUNCT
gs-3919	465	26	but	but	CCONJ
gs-3919	465	27	with	with	ADP
gs-3919	465	28	a	a	DET
gs-3919	465	29	twist	twist	NOUN
gs-3919	465	30	:	:	PUNCT
gs-3919	465	31	viral	viral	ADJ
gs-3919	465	32	loads	load	NOUN
gs-3919	465	33	peak	peak	NOUN
gs-3919	465	34	after	after	ADP
gs-3919	465	35	eosinophil	eosinophil	ADJ
gs-3919	465	36	expansion	expansion	NOUN
gs-3919	465	37	,	,	PUNCT
gs-3919	465	38	suggesting	suggest	VERB
gs-3919	465	39	eosinophil	eosinophil	ADJ
gs-3919	465	40	-	-	PUNCT
gs-3919	465	41	derived	derive	VERB
gs-3919	465	42	granules	granule	NOUN
gs-3919	465	43	(	(	PUNCT
gs-3919	465	44	e.g.	e.g.	ADV
gs-3919	465	45	,	,	PUNCT
gs-3919	465	46	edn	edn	NOUN
gs-3919	465	47	)	)	PUNCT
gs-3919	465	48	directly	directly	ADV
gs-3919	465	49	lyse	lyse	X
gs-3919	465	50	latently	latently	ADV
gs-3919	465	51	infected	infect	VERB
gs-3919	465	52	cells	cell	NOUN
gs-3919	465	53	.	.	PUNCT
gs-3919	466	1	this	this	PRON
gs-3919	466	2	creates	create	VERB
gs-3919	466	3	a	a	DET
gs-3919	466	4	feedforward	feedforward	NOUN
gs-3919	466	5	loop	loop	NOUN
gs-3919	466	6	where	where	SCONJ
gs-3919	466	7	viral	viral	ADJ
gs-3919	466	8	antigens	antigen	NOUN
gs-3919	466	9	amplify	amplify	VERB
gs-3919	466	10	drug	drug	NOUN
gs-3919	466	11	-	-	PUNCT
gs-3919	466	12	specific	specific	ADJ
gs-3919	466	13	t	t	NOUN
gs-3919	466	14	-	-	PUNCT
gs-3919	466	15	cell	cell	NOUN
gs-3919	466	16	responses	response	NOUN
gs-3919	466	17	.	.	PUNCT
gs-3919	467	1	supporting	support	VERB
gs-3919	467	2	this	this	PRON
gs-3919	467	3	,	,	PUNCT
gs-3919	467	4	in	in	ADP
gs-3919	467	5	vitro	vitro	X
gs-3919	467	6	co	co	NOUN
gs-3919	467	7	-	-	NOUN
gs-3919	467	8	cultures	culture	NOUN
gs-3919	467	9	show	show	VERB
gs-3919	467	10	carbamazepine	carbamazepine	NOUN
gs-3919	467	11	-	-	PUNCT
gs-3919	467	12	treated	treat	VERB
gs-3919	467	13	dendritic	dendritic	ADJ
gs-3919	467	14	cells	cell	NOUN
gs-3919	467	15	stimulate	stimulate	VERB
gs-3919	467	16	hhv-6	hhv-6	NOUN
gs-3919	467	17	-	-	PUNCT
gs-3919	467	18	specific	specific	ADJ
gs-3919	467	19	cd4	cd4	PROPN
gs-3919	467	20	+	+	PROPN
gs-3919	467	21	t	t	NOUN
gs-3919	467	22	cells	cell	NOUN
gs-3919	467	23	only	only	ADV
gs-3919	467	24	in	in	ADP
gs-3919	467	25	the	the	DET
gs-3919	467	26	presence	presence	NOUN
gs-3919	467	27	of	of	ADP
gs-3919	467	28	eosinophil	eosinophil	ADJ
gs-3919	467	29	supernatants	supernatant	NOUN
gs-3919	467	30	.	.	PUNCT
gs-3919	468	1	clinical	clinical	ADJ
gs-3919	468	2	phenotypes	phenotype	NOUN
gs-3919	468	3	and	and	CCONJ
gs-3919	468	4	biomarker	biomarker	NOUN
gs-3919	468	5	advancements	advancement	NOUN
gs-3919	468	6	novel	novel	ADJ
gs-3919	468	7	subtypes	subtype	NOUN
gs-3919	468	8	of	of	ADP
gs-3919	468	9	drug	drug	NOUN
gs-3919	468	10	-	-	PUNCT
gs-3919	468	11	induced	induce	VERB
gs-3919	468	12	eosinophilia	eosinophilia	NOUN
gs-3919	468	13			VERB
gs-3919	468	14	eosinophilic	eosinophilic	ADJ
gs-3919	468	15	enterocolitis	enterocolitis	NOUN
gs-3919	468	16	:	:	PUNCT
gs-3919	468	17	seen	see	VERB
gs-3919	468	18	with	with	ADP
gs-3919	468	19	icis	icis	PROPN
gs-3919	468	20	,	,	PUNCT
gs-3919	468	21	characterized	characterize	VERB
gs-3919	468	22	by	by	ADP
gs-3919	468	23	duodenal	duodenal	ADJ
gs-3919	468	24	eosinophil	eosinophil	ADJ
gs-3919	468	25	counts	count	NOUN
gs-3919	468	26	>	>	X
gs-3919	468	27	50	50	NUM
gs-3919	468	28	/	/	SYM
gs-3919	468	29	hpf	hpf	NOUN
gs-3919	468	30	and	and	CCONJ
gs-3919	468	31	fecal	fecal	ADJ
gs-3919	468	32	calprotectin	calprotectin	NOUN
gs-3919	468	33	>	>	X
gs-3919	468	34	500	500	NUM
gs-3919	468	35	μg	μg	PROPN
gs-3919	468	36	/	/	SYM
gs-3919	468	37	g.	g.	PROPN
gs-3919	468	38			VERB
gs-3919	468	39	neurologic	neurologic	ADJ
gs-3919	468	40	eosinophilic	eosinophilic	ADJ
gs-3919	468	41	syndrome	syndrome	NOUN
gs-3919	468	42	:	:	PUNCT
gs-3919	468	43	reported	report	VERB
gs-3919	468	44	with	with	ADP
gs-3919	468	45	clozapine	clozapine	NOUN
gs-3919	468	46	,	,	PUNCT
gs-3919	468	47	featuring	feature	VERB
gs-3919	468	48	csf	csf	ADJ
gs-3919	468	49	eosinophilia	eosinophilia	NOUN
gs-3919	468	50	and	and	CCONJ
gs-3919	468	51	mri	mri	NOUN
gs-3919	468	52	-	-	PUNCT
gs-3919	468	53	documented	document	VERB
gs-3919	468	54	meningeal	meningeal	ADJ
gs-3919	468	55	enhancement	enhancement	NOUN
gs-3919	468	56	.	.	PUNCT
gs-3919	469	1	biomarkers	biomarker	NOUN
gs-3919	469	2	:	:	PUNCT
gs-3919	469	3			VERB
gs-3919	469	4	serum	serum	NOUN
gs-3919	469	5	siglec-8	siglec-8	NOUN
gs-3919	469	6	:	:	PUNCT
gs-3919	469	7	elevated	elevate	VERB
gs-3919	469	8	in	in	ADP
gs-3919	469	9	progressive	progressive	ADJ
gs-3919	469	10	eosinophilic	eosinophilic	ADJ
gs-3919	469	11	organ	organ	NOUN
gs-3919	469	12	infiltration	infiltration	NOUN
gs-3919	469	13	(	(	PUNCT
gs-3919	469	14	auc	auc	ADP
gs-3919	469	15	0.92	0.92	NUM
gs-3919	469	16	for	for	ADP
gs-3919	469	17	predicting	predict	VERB
gs-3919	469	18	cardiac	cardiac	ADJ
gs-3919	469	19	involvement	involvement	NOUN
gs-3919	469	20	)	)	PUNCT
gs-3919	469	21	.	.	PUNCT
gs-3919	470	1			ADJ
gs-3919	470	2	plasma	plasma	NOUN
gs-3919	470	3	mtdna	mtdna	ADV
gs-3919	470	4	:	:	PUNCT
gs-3919	470	5	surrogate	surrogate	VERB
gs-3919	470	6	for	for	ADP
gs-3919	470	7	eosinophil	eosinophil	ADJ
gs-3919	470	8	extracellular	extracellular	ADJ
gs-3919	470	9	traps	trap	NOUN
gs-3919	470	10	(	(	PUNCT
gs-3919	470	11	etosis	etosis	NOUN
gs-3919	470	12	)	)	PUNCT
gs-3919	470	13	,	,	PUNCT
gs-3919	470	14	levels	level	NOUN
gs-3919	470	15	>	>	PUNCT
gs-3919	470	16	5,000	5,000	NUM
gs-3919	470	17	copies	copy	NOUN
gs-3919	470	18	/	/	SYM
gs-3919	470	19	μl	μl	NUM
gs-3919	470	20	correlate	correlate	VERB
gs-3919	470	21	with	with	ADP
gs-3919	470	22	mortality	mortality	NOUN
gs-3919	470	23	in	in	ADP
gs-3919	470	24	dress	dress	NOUN
gs-3919	470	25	.	.	PUNCT
gs-3919	471	1	georgian	georgian	ADJ
gs-3919	471	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	471	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	471	4	ტ.	ტ.	VERB
gs-3919	471	5	7	7	NUM
gs-3919	471	6	n	n	PRON
gs-3919	471	7	3	3	NUM
gs-3919	471	8	,	,	PUNCT
gs-3919	471	9	2025	2025	NUM
gs-3919	471	10	170	170	NUM
gs-3919	471	11	therapeutic	therapeutic	ADJ
gs-3919	471	12	breakthroughs	breakthrough	NOUN
gs-3919	471	13	and	and	CCONJ
gs-3919	471	14	trials	trial	NOUN
gs-3919	471	15	:	:	PUNCT
gs-3919	471	16	targeted	target	VERB
gs-3919	471	17	biologics	biologic	NOUN
gs-3919	471	18			VERB
gs-3919	471	19	mepolizumab	mepolizumab	NOUN
gs-3919	471	20	(	(	PUNCT
gs-3919	471	21	anti	anti	ADJ
gs-3919	471	22	-	-	NOUN
gs-3919	471	23	il-5	il-5	NUM
gs-3919	471	24	):	):	PUNCT
gs-3919	471	25	in	in	ADP
gs-3919	471	26	the	the	DET
gs-3919	471	27	phase	phase	NOUN
gs-3919	471	28	iib	iib	PROPN
gs-3919	471	29	medea	medea	PROPN
gs-3919	471	30	trial	trial	NOUN
gs-3919	471	31	,	,	PUNCT
gs-3919	471	32	reduced	reduce	VERB
gs-3919	471	33	steroid	steroid	NOUN
gs-3919	471	34	duration	duration	NOUN
gs-3919	471	35	by	by	ADP
gs-3919	471	36	14	14	NUM
gs-3919	471	37	days	day	NOUN
gs-3919	471	38	in	in	ADP
gs-3919	471	39	dress	dress	NOUN
gs-3919	471	40	(	(	PUNCT
gs-3919	471	41	p=0.003	p=0.003	NOUN
gs-3919	471	42	)	)	PUNCT
gs-3919	471	43	.	.	PUNCT
gs-3919	472	1			ADJ
gs-3919	472	2	lirentelimab	lirentelimab	NOUN
gs-3919	472	3	(	(	PUNCT
gs-3919	472	4	anti	anti	ADJ
gs-3919	472	5	-	-	ADJ
gs-3919	472	6	siglec-8	siglec-8	ADJ
gs-3919	472	7	):	):	PUNCT
gs-3919	472	8	induces	induce	VERB
gs-3919	472	9	eosinophil	eosinophil	ADJ
gs-3919	472	10	apoptosis	apoptosis	NOUN
gs-3919	472	11	;	;	PUNCT
gs-3919	472	12	78	78	NUM
gs-3919	472	13	%	%	NOUN
gs-3919	472	14	achieved	achieve	VERB
gs-3919	472	15	histologic	histologic	ADJ
gs-3919	472	16	remission	remission	NOUN
gs-3919	472	17	in	in	ADP
gs-3919	472	18	eosinophilic	eosinophilic	ADJ
gs-3919	472	19	gastritis	gastritis	NOUN
gs-3919	472	20	trials	trial	NOUN
gs-3919	472	21	—	—	PUNCT
gs-3919	472	22	potential	potential	ADJ
gs-3919	472	23	for	for	ADP
gs-3919	472	24	drug	drug	NOUN
gs-3919	472	25	-	-	PUNCT
gs-3919	472	26	induced	induce	VERB
gs-3919	472	27	cases	case	NOUN
gs-3919	472	28	.	.	PUNCT
gs-3919	473	1	drug	drug	NOUN
gs-3919	473	2	rechallenge	rechallenge	NOUN
gs-3919	473	3	protocols	protocol	NOUN
gs-3919	473	4	:	:	PUNCT
gs-3919	473	5	desensitization	desensitization	NOUN
gs-3919	473	6	protocols	protocol	NOUN
gs-3919	473	7	incorporating	incorporate	VERB
gs-3919	473	8	omalizumab	omalizumab	NOUN
gs-3919	473	9	(	(	PUNCT
gs-3919	473	10	anti	anti	ADJ
gs-3919	473	11	-	-	ADJ
gs-3919	473	12	ige	ige	ADJ
gs-3919	473	13	)	)	PUNCT
gs-3919	473	14	successfully	successfully	ADV
gs-3919	473	15	permitted	permit	VERB
gs-3919	473	16	carboplatin	carboplatin	NOUN
gs-3919	473	17	rechallenge	rechallenge	NOUN
gs-3919	473	18	in	in	ADP
gs-3919	473	19	67	67	NUM
gs-3919	473	20	%	%	NOUN
gs-3919	473	21	of	of	ADP
gs-3919	473	22	eosinophilic	eosinophilic	ADJ
gs-3919	473	23	hypersensitivity	hypersensitivity	NOUN
gs-3919	473	24	cases	case	NOUN
gs-3919	473	25	,	,	PUNCT
gs-3919	473	26	per	per	ADP
gs-3919	473	27	the	the	DET
gs-3919	473	28	deskin	deskin	NOUN
gs-3919	473	29	study	study	NOUN
gs-3919	473	30	.	.	PUNCT
gs-3919	474	1	omics	omic	NOUN
gs-3919	474	2			VERB
gs-3919	474	3	proteomic	proteomic	ADJ
gs-3919	474	4	signatures	signature	NOUN
gs-3919	474	5	:	:	PUNCT
gs-3919	474	6	olink	olink	VERB
gs-3919	474	7	assays	assay	NOUN
gs-3919	474	8	identify	identify	VERB
gs-3919	474	9	a	a	DET
gs-3919	474	10	12	12	NUM
gs-3919	474	11	-	-	PUNCT
gs-3919	474	12	plex	plex	NOUN
gs-3919	474	13	protein	protein	NOUN
gs-3919	474	14	panel	panel	NOUN
gs-3919	474	15	(	(	PUNCT
gs-3919	474	16	including	include	VERB
gs-3919	474	17	ccl23	ccl23	NOUN
gs-3919	474	18	and	and	CCONJ
gs-3919	474	19	st2	st2	NOUN
gs-3919	474	20	)	)	PUNCT
gs-3919	474	21	predicting	predict	VERB
gs-3919	474	22	progression	progression	NOUN
gs-3919	474	23	to	to	PART
gs-3919	474	24	fibrosis	fibrosis	VERB
gs-3919	474	25	post	post	NOUN
gs-3919	474	26	-	-	NOUN
gs-3919	474	27	dress	dress	ADJ
gs-3919	474	28	.	.	PUNCT
gs-3919	475	1			VERB
gs-3919	475	2	ai	ai	VERB
gs-3919	475	3	-	-	PUNCT
gs-3919	475	4	augmented	augment	VERB
gs-3919	475	5	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	475	6	:	:	PUNCT
gs-3919	475	7	deep	deep	ADJ
gs-3919	475	8	learning	learning	NOUN
gs-3919	475	9	models	model	NOUN
gs-3919	475	10	analyzing	analyze	VERB
gs-3919	475	11	faers	faer	NOUN
gs-3919	475	12	data	datum	NOUN
gs-3919	475	13	flagged	flag	VERB
gs-3919	475	14	dabrafenib	dabrafenib	NOUN
gs-3919	475	15	-	-	PUNCT
gs-3919	475	16	trametinib	trametinib	NOUN
gs-3919	475	17	as	as	SCONJ
gs-3919	475	18	a	a	DET
gs-3919	475	19	new	new	ADJ
gs-3919	475	20	eosinophilia	eosinophilia	PROPN
gs-3919	475	21	risk	risk	NOUN
gs-3919	475	22	combo	combo	NOUN
gs-3919	475	23	18	18	NUM
gs-3919	475	24	months	month	NOUN
gs-3919	475	25	before	before	SCONJ
gs-3919	475	26	case	case	NOUN
gs-3919	475	27	reports	report	NOUN
gs-3919	475	28	emerged	emerge	VERB
gs-3919	475	29	.	.	PUNCT
gs-3919	476	1	the	the	DET
gs-3919	476	2	study	study	NOUN
gs-3919	476	3	found	find	VERB
gs-3919	476	4	unprecedented	unprecedented	ADJ
gs-3919	476	5	mechanistic	mechanistic	ADJ
gs-3919	476	6	depth	depth	NOUN
gs-3919	476	7	,	,	PUNCT
gs-3919	476	8	from	from	ADP
gs-3919	476	9	eosinophil	eosinophil	ADJ
gs-3919	476	10	subsets	subset	NOUN
gs-3919	476	11	to	to	ADP
gs-3919	476	12	haptenviral	haptenviral	ADJ
gs-3919	476	13	interplay	interplay	NOUN
gs-3919	476	14	,	,	PUNCT
gs-3919	476	15	while	while	SCONJ
gs-3919	476	16	translating	translate	VERB
gs-3919	476	17	findings	finding	NOUN
gs-3919	476	18	into	into	ADP
gs-3919	476	19	biomarkers	biomarker	NOUN
gs-3919	476	20	and	and	CCONJ
gs-3919	476	21	therapies	therapy	NOUN
gs-3919	476	22	.	.	PUNCT
gs-3919	477	1	the	the	DET
gs-3919	477	2	integration	integration	NOUN
gs-3919	477	3	of	of	ADP
gs-3919	477	4	multi	multi	NOUN
gs-3919	477	5	-	-	NOUN
gs-3919	477	6	omics	omic	NOUN
gs-3919	477	7	and	and	CCONJ
gs-3919	477	8	ai	ai	PROPN
gs-3919	477	9	heralds	herald	NOUN
gs-3919	477	10	a	a	DET
gs-3919	477	11	new	new	ADJ
gs-3919	477	12	era	era	NOUN
gs-3919	477	13	of	of	ADP
gs-3919	477	14	precision	precision	NOUN
gs-3919	477	15	management	management	NOUN
gs-3919	477	16	for	for	ADP
gs-3919	477	17	these	these	DET
gs-3919	477	18	reactions	reaction	NOUN
gs-3919	477	19	.	.	PUNCT
gs-3919	478	1	the	the	DET
gs-3919	478	2	scientific	scientific	ADJ
gs-3919	478	3	exploration	exploration	NOUN
gs-3919	478	4	of	of	ADP
gs-3919	478	5	drug	drug	NOUN
gs-3919	478	6	-	-	PUNCT
gs-3919	478	7	induced	induce	VERB
gs-3919	478	8	eosinophilia	eosinophilia	NOUN
gs-3919	478	9	and	and	CCONJ
gs-3919	478	10	systemic	systemic	ADJ
gs-3919	478	11	symptoms	symptom	NOUN
gs-3919	478	12	reveals	reveal	VERB
gs-3919	478	13	a	a	DET
gs-3919	478	14	complex	complex	ADJ
gs-3919	478	15	interplay	interplay	NOUN
gs-3919	478	16	between	between	ADP
gs-3919	478	17	pharmacological	pharmacological	ADJ
gs-3919	478	18	agents	agent	NOUN
gs-3919	478	19	,	,	PUNCT
gs-3919	478	20	host	host	NOUN
gs-3919	478	21	immune	immune	ADJ
gs-3919	478	22	responses	response	NOUN
gs-3919	478	23	,	,	PUNCT
gs-3919	478	24	and	and	CCONJ
gs-3919	478	25	environmental	environmental	ADJ
gs-3919	478	26	factors	factor	NOUN
gs-3919	478	27	that	that	PRON
gs-3919	478	28	collectively	collectively	ADV
gs-3919	478	29	shape	shape	VERB
gs-3919	478	30	the	the	DET
gs-3919	478	31	clinical	clinical	ADJ
gs-3919	478	32	manifestations	manifestation	NOUN
gs-3919	478	33	and	and	CCONJ
gs-3919	478	34	outcomes	outcome	NOUN
gs-3919	478	35	of	of	ADP
gs-3919	478	36	these	these	DET
gs-3919	478	37	adverse	adverse	ADJ
gs-3919	478	38	reactions	reaction	NOUN
gs-3919	478	39	.	.	PUNCT
gs-3919	479	1	this	this	DET
gs-3919	479	2	comprehensive	comprehensive	ADJ
gs-3919	479	3	examination	examination	NOUN
gs-3919	479	4	has	have	AUX
gs-3919	479	5	illuminated	illuminate	VERB
gs-3919	479	6	critical	critical	ADJ
gs-3919	479	7	aspects	aspect	NOUN
gs-3919	479	8	of	of	ADP
gs-3919	479	9	pathogenesis	pathogenesis	NOUN
gs-3919	479	10	while	while	SCONJ
gs-3919	479	11	identifying	identify	VERB
gs-3919	479	12	promising	promise	VERB
gs-3919	479	13	diagnostic	diagnostic	ADJ
gs-3919	479	14	and	and	CCONJ
gs-3919	479	15	therapeutic	therapeutic	ADJ
gs-3919	479	16	approaches	approach	NOUN
gs-3919	479	17	that	that	PRON
gs-3919	479	18	may	may	AUX
gs-3919	479	19	transform	transform	VERB
gs-3919	479	20	clinical	clinical	ADJ
gs-3919	479	21	management	management	NOUN
gs-3919	479	22	.	.	PUNCT
gs-3919	480	1	at	at	ADP
gs-3919	480	2	the	the	DET
gs-3919	480	3	core	core	NOUN
gs-3919	480	4	of	of	ADP
gs-3919	480	5	these	these	DET
gs-3919	480	6	reactions	reaction	NOUN
gs-3919	480	7	lies	lie	VERB
gs-3919	480	8	the	the	DET
gs-3919	480	9	intricate	intricate	ADJ
gs-3919	480	10	relationship	relationship	NOUN
gs-3919	480	11	between	between	ADP
gs-3919	480	12	drug	drug	NOUN
gs-3919	480	13	metabolism	metabolism	NOUN
gs-3919	480	14	and	and	CCONJ
gs-3919	480	15	immune	immune	ADJ
gs-3919	480	16	system	system	NOUN
gs-3919	480	17	activation	activation	NOUN
gs-3919	480	18	.	.	PUNCT
gs-3919	481	1	certain	certain	ADJ
gs-3919	481	2	pharmacological	pharmacological	ADJ
gs-3919	481	3	agents	agent	NOUN
gs-3919	481	4	,	,	PUNCT
gs-3919	481	5	through	through	ADP
gs-3919	481	6	their	their	PRON
gs-3919	481	7	structural	structural	ADJ
gs-3919	481	8	characteristics	characteristic	NOUN
gs-3919	481	9	and	and	CCONJ
gs-3919	481	10	metabolic	metabolic	NOUN
gs-3919	481	11	pathways	pathway	NOUN
gs-3919	481	12	,	,	PUNCT
gs-3919	481	13	generate	generate	VERB
gs-3919	481	14	reactive	reactive	ADJ
gs-3919	481	15	intermediates	intermediate	NOUN
gs-3919	481	16	capable	capable	ADJ
gs-3919	481	17	of	of	ADP
gs-3919	481	18	modifying	modify	VERB
gs-3919	481	19	host	host	NOUN
gs-3919	481	20	proteins	protein	NOUN
gs-3919	481	21	and	and	CCONJ
gs-3919	481	22	triggering	trigger	VERB
gs-3919	481	23	inappropriate	inappropriate	ADJ
gs-3919	481	24	immune	immune	ADJ
gs-3919	481	25	recognition	recognition	NOUN
gs-3919	481	26	.	.	PUNCT
gs-3919	482	1	the	the	DET
gs-3919	482	2	resulting	result	VERB
gs-3919	482	3	inflammatory	inflammatory	ADJ
gs-3919	482	4	cascade	cascade	NOUN
gs-3919	482	5	involves	involve	VERB
gs-3919	482	6	not	not	PART
gs-3919	482	7	only	only	ADV
gs-3919	482	8	classical	classical	ADJ
gs-3919	482	9	hypersensitivity	hypersensitivity	NOUN
gs-3919	482	10	mechanisms	mechanism	NOUN
gs-3919	482	11	but	but	CCONJ
gs-3919	482	12	also	also	ADV
gs-3919	482	13	novel	novel	ADJ
gs-3919	482	14	pathways	pathway	NOUN
gs-3919	482	15	of	of	ADP
gs-3919	482	16	eosinophil	eosinophil	ADJ
gs-3919	482	17	activation	activation	NOUN
gs-3919	482	18	and	and	CCONJ
gs-3919	482	19	tissue	tissue	NOUN
gs-3919	482	20	infiltration	infiltration	NOUN
gs-3919	482	21	that	that	PRON
gs-3919	482	22	extend	extend	VERB
gs-3919	482	23	beyond	beyond	ADP
gs-3919	482	24	traditional	traditional	ADJ
gs-3919	482	25	th2	th2	PROPN
gs-3919	482	26	-	-	PUNCT
gs-3919	482	27	mediated	mediate	VERB
gs-3919	482	28	responses	response	NOUN
gs-3919	482	29	.	.	PUNCT
gs-3919	483	1	recent	recent	ADJ
gs-3919	483	2	advances	advance	NOUN
gs-3919	483	3	in	in	ADP
gs-3919	483	4	genomic	genomic	ADJ
gs-3919	483	5	medicine	medicine	NOUN
gs-3919	483	6	have	have	AUX
gs-3919	483	7	substantially	substantially	ADV
gs-3919	483	8	enhanced	enhance	VERB
gs-3919	483	9	our	our	PRON
gs-3919	483	10	understanding	understanding	NOUN
gs-3919	483	11	of	of	ADP
gs-3919	483	12	individual	individual	ADJ
gs-3919	483	13	susceptibility	susceptibility	NOUN
gs-3919	483	14	patterns	pattern	NOUN
gs-3919	483	15	.	.	PUNCT
gs-3919	484	1	the	the	DET
gs-3919	484	2	identification	identification	NOUN
gs-3919	484	3	of	of	ADP
gs-3919	484	4	specific	specific	ADJ
gs-3919	484	5	genetic	genetic	ADJ
gs-3919	484	6	markers	marker	NOUN
gs-3919	484	7	associated	associate	VERB
gs-3919	484	8	with	with	ADP
gs-3919	484	9	severe	severe	ADJ
gs-3919	484	10	reactions	reaction	NOUN
gs-3919	484	11	provides	provide	VERB
gs-3919	484	12	opportunities	opportunity	NOUN
gs-3919	484	13	for	for	ADP
gs-3919	484	14	preemptive	preemptive	ADJ
gs-3919	484	15	risk	risk	NOUN
gs-3919	484	16	assessment	assessment	NOUN
gs-3919	484	17	and	and	CCONJ
gs-3919	484	18	personalized	personalize	VERB
gs-3919	484	19	therapeutic	therapeutic	ADJ
gs-3919	484	20	strategies	strategy	NOUN
gs-3919	484	21	.	.	PUNCT
gs-3919	485	1	furthermore	furthermore	ADV
gs-3919	485	2	,	,	PUNCT
gs-3919	485	3	emerging	emerge	VERB
gs-3919	485	4	evidence	evidence	NOUN
gs-3919	485	5	suggests	suggest	VERB
gs-3919	485	6	that	that	SCONJ
gs-3919	485	7	epigenetic	epigenetic	ADJ
gs-3919	485	8	modifications	modification	NOUN
gs-3919	485	9	and	and	CCONJ
gs-3919	485	10	post	post	ADJ
gs-3919	485	11	-	-	ADJ
gs-3919	485	12	transcriptional	transcriptional	ADJ
gs-3919	485	13	regulation	regulation	NOUN
gs-3919	485	14	may	may	AUX
gs-3919	485	15	play	play	VERB
gs-3919	485	16	georgian	georgian	ADJ
gs-3919	485	17	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	485	18	მეცნიერები	მეცნიერები	NOUN
gs-3919	485	19	ტ.	ტ.	VERB
gs-3919	485	20	7	7	NUM
gs-3919	485	21	n	n	PRON
gs-3919	485	22	3	3	NUM
gs-3919	485	23	,	,	PUNCT
gs-3919	485	24	2025	2025	NUM
gs-3919	485	25	171	171	NUM
gs-3919	485	26	previously	previously	ADV
gs-3919	485	27	underappreciated	underappreciate	VERB
gs-3919	485	28	roles	role	NOUN
gs-3919	485	29	in	in	ADP
gs-3919	485	30	determining	determine	VERB
gs-3919	485	31	both	both	CCONJ
gs-3919	485	32	the	the	DET
gs-3919	485	33	severity	severity	NOUN
gs-3919	485	34	and	and	CCONJ
gs-3919	485	35	duration	duration	NOUN
gs-3919	485	36	of	of	ADP
gs-3919	485	37	eosinophilic	eosinophilic	ADJ
gs-3919	485	38	responses	response	NOUN
gs-3919	485	39	to	to	ADP
gs-3919	485	40	pharmacological	pharmacological	ADJ
gs-3919	485	41	agents	agent	NOUN
gs-3919	485	42	.	.	PUNCT
gs-3919	486	1	the	the	DET
gs-3919	486	2	clinical	clinical	ADJ
gs-3919	486	3	spectrum	spectrum	NOUN
gs-3919	486	4	of	of	ADP
gs-3919	486	5	drug	drug	NOUN
gs-3919	486	6	-	-	PUNCT
gs-3919	486	7	induced	induce	VERB
gs-3919	486	8	eosinophilia	eosinophilia	NOUN
gs-3919	486	9	continues	continue	VERB
gs-3919	486	10	to	to	PART
gs-3919	486	11	expand	expand	VERB
gs-3919	486	12	as	as	SCONJ
gs-3919	486	13	new	new	ADJ
gs-3919	486	14	therapeutic	therapeutic	ADJ
gs-3919	486	15	classes	class	NOUN
gs-3919	486	16	enter	enter	VERB
gs-3919	486	17	clinical	clinical	ADJ
gs-3919	486	18	practice	practice	NOUN
gs-3919	486	19	.	.	PUNCT
gs-3919	487	1	contemporary	contemporary	ADJ
gs-3919	487	2	challenges	challenge	NOUN
gs-3919	487	3	include	include	VERB
gs-3919	487	4	the	the	DET
gs-3919	487	5	recognition	recognition	NOUN
gs-3919	487	6	of	of	ADP
gs-3919	487	7	atypical	atypical	ADJ
gs-3919	487	8	presentations	presentation	NOUN
gs-3919	487	9	and	and	CCONJ
gs-3919	487	10	the	the	DET
gs-3919	487	11	development	development	NOUN
gs-3919	487	12	of	of	ADP
gs-3919	487	13	reliable	reliable	ADJ
gs-3919	487	14	diagnostic	diagnostic	ADJ
gs-3919	487	15	criteria	criterion	NOUN
gs-3919	487	16	that	that	PRON
gs-3919	487	17	can	can	AUX
gs-3919	487	18	distinguish	distinguish	VERB
gs-3919	487	19	these	these	DET
gs-3919	487	20	reactions	reaction	NOUN
gs-3919	487	21	from	from	ADP
gs-3919	487	22	other	other	ADJ
gs-3919	487	23	inflammatory	inflammatory	ADJ
gs-3919	487	24	conditions	condition	NOUN
gs-3919	487	25	.	.	PUNCT
gs-3919	488	1	the	the	DET
gs-3919	488	2	integration	integration	NOUN
gs-3919	488	3	of	of	ADP
gs-3919	488	4	advanced	advanced	ADJ
gs-3919	488	5	imaging	imaging	NOUN
gs-3919	488	6	techniques	technique	NOUN
gs-3919	488	7	and	and	CCONJ
gs-3919	488	8	novel	novel	ADJ
gs-3919	488	9	biomarkers	biomarker	NOUN
gs-3919	488	10	into	into	ADP
gs-3919	488	11	clinical	clinical	ADJ
gs-3919	488	12	practice	practice	NOUN
gs-3919	488	13	offers	offer	VERB
gs-3919	488	14	potential	potential	ADJ
gs-3919	488	15	solutions	solution	NOUN
gs-3919	488	16	to	to	ADP
gs-3919	488	17	these	these	DET
gs-3919	488	18	diagnostic	diagnostic	ADJ
gs-3919	488	19	dilemmas	dilemma	NOUN
gs-3919	488	20	,	,	PUNCT
gs-3919	488	21	though	though	SCONJ
gs-3919	488	22	validation	validation	NOUN
gs-3919	488	23	in	in	ADP
gs-3919	488	24	diverse	diverse	ADJ
gs-3919	488	25	populations	population	NOUN
gs-3919	488	26	remains	remain	VERB
gs-3919	488	27	necessary	necessary	ADJ
gs-3919	488	28	.	.	PUNCT
gs-3919	489	1	therapeutic	therapeutic	ADJ
gs-3919	489	2	approaches	approach	NOUN
gs-3919	489	3	are	be	AUX
gs-3919	489	4	evolving	evolve	VERB
gs-3919	489	5	beyond	beyond	ADP
gs-3919	489	6	simple	simple	ADJ
gs-3919	489	7	drug	drug	NOUN
gs-3919	489	8	withdrawal	withdrawal	NOUN
gs-3919	489	9	and	and	CCONJ
gs-3919	489	10	corticosteroid	corticosteroid	ADJ
gs-3919	489	11	administration	administration	NOUN
gs-3919	489	12	.	.	PUNCT
gs-3919	490	1	targeted	target	VERB
gs-3919	490	2	biological	biological	ADJ
gs-3919	490	3	therapies	therapy	NOUN
gs-3919	490	4	that	that	PRON
gs-3919	490	5	specifically	specifically	ADV
gs-3919	490	6	interrupt	interrupt	VERB
gs-3919	490	7	key	key	ADJ
gs-3919	490	8	inflammatory	inflammatory	ADJ
gs-3919	490	9	pathways	pathway	NOUN
gs-3919	490	10	show	show	VERB
gs-3919	490	11	particular	particular	ADJ
gs-3919	490	12	promise	promise	NOUN
gs-3919	490	13	in	in	ADP
gs-3919	490	14	refractory	refractory	NOUN
gs-3919	490	15	cases	case	NOUN
gs-3919	490	16	,	,	PUNCT
gs-3919	490	17	while	while	SCONJ
gs-3919	490	18	advances	advance	NOUN
gs-3919	490	19	in	in	ADP
gs-3919	490	20	supportive	supportive	ADJ
gs-3919	490	21	care	care	NOUN
gs-3919	490	22	have	have	AUX
gs-3919	490	23	improved	improve	VERB
gs-3919	490	24	outcomes	outcome	NOUN
gs-3919	490	25	for	for	ADP
gs-3919	490	26	patients	patient	NOUN
gs-3919	490	27	with	with	ADP
gs-3919	490	28	organ	organ	NOUN
gs-3919	490	29	involvement	involvement	NOUN
gs-3919	490	30	.	.	PUNCT
gs-3919	491	1	nevertheless	nevertheless	ADV
gs-3919	491	2	,	,	PUNCT
gs-3919	491	3	important	important	ADJ
gs-3919	491	4	questions	question	NOUN
gs-3919	491	5	remain	remain	VERB
gs-3919	491	6	regarding	regard	VERB
gs-3919	491	7	optimal	optimal	ADJ
gs-3919	491	8	treatment	treatment	NOUN
gs-3919	491	9	duration	duration	NOUN
gs-3919	491	10	and	and	CCONJ
gs-3919	491	11	strategies	strategy	NOUN
gs-3919	491	12	for	for	ADP
gs-3919	491	13	preventing	prevent	VERB
gs-3919	491	14	long	long	ADJ
gs-3919	491	15	-	-	PUNCT
gs-3919	491	16	term	term	NOUN
gs-3919	491	17	sequelae	sequelae	NOUN
gs-3919	491	18	.	.	PUNCT
gs-3919	492	1	future	future	ADJ
gs-3919	492	2	progress	progress	NOUN
gs-3919	492	3	in	in	ADP
gs-3919	492	4	this	this	DET
gs-3919	492	5	field	field	NOUN
gs-3919	492	6	will	will	AUX
gs-3919	492	7	likely	likely	ADV
gs-3919	492	8	emerge	emerge	VERB
gs-3919	492	9	from	from	ADP
gs-3919	492	10	several	several	ADJ
gs-3919	492	11	key	key	ADJ
gs-3919	492	12	areas	area	NOUN
gs-3919	492	13	of	of	ADP
gs-3919	492	14	investigation	investigation	NOUN
gs-3919	492	15	.	.	PUNCT
gs-3919	493	1	first	first	ADV
gs-3919	493	2	,	,	PUNCT
gs-3919	493	3	the	the	DET
gs-3919	493	4	application	application	NOUN
gs-3919	493	5	of	of	ADP
gs-3919	493	6	single	single	ADJ
gs-3919	493	7	-	-	PUNCT
gs-3919	493	8	cell	cell	NOUN
gs-3919	493	9	technologies	technology	NOUN
gs-3919	493	10	may	may	AUX
gs-3919	493	11	reveal	reveal	VERB
gs-3919	493	12	previously	previously	ADV
gs-3919	493	13	unrecognized	unrecognize	VERB
gs-3919	493	14	heterogeneity	heterogeneity	NOUN
gs-3919	493	15	in	in	ADP
gs-3919	493	16	eosinophil	eosinophil	ADJ
gs-3919	493	17	populations	population	NOUN
gs-3919	493	18	and	and	CCONJ
gs-3919	493	19	their	their	PRON
gs-3919	493	20	respective	respective	ADJ
gs-3919	493	21	roles	role	NOUN
gs-3919	493	22	in	in	ADP
gs-3919	493	23	tissue	tissue	NOUN
gs-3919	493	24	damage	damage	NOUN
gs-3919	493	25	versus	versus	ADP
gs-3919	493	26	repair	repair	NOUN
gs-3919	493	27	.	.	PUNCT
gs-3919	494	1	second	second	ADJ
gs-3919	494	2	,	,	PUNCT
gs-3919	494	3	artificial	artificial	ADJ
gs-3919	494	4	intelligence	intelligence	NOUN
gs-3919	494	5	applications	application	NOUN
gs-3919	494	6	in	in	ADP
gs-3919	494	7	pharmacovigilance	pharmacovigilance	NOUN
gs-3919	494	8	systems	system	NOUN
gs-3919	494	9	could	could	AUX
gs-3919	494	10	enable	enable	VERB
gs-3919	494	11	earlier	early	ADJ
gs-3919	494	12	detection	detection	NOUN
gs-3919	494	13	of	of	ADP
gs-3919	494	14	at	at	ADP
gs-3919	494	15	-	-	PUNCT
gs-3919	494	16	risk	risk	NOUN
gs-3919	494	17	patients	patient	NOUN
gs-3919	494	18	and	and	CCONJ
gs-3919	494	19	medications	medication	NOUN
gs-3919	494	20	.	.	PUNCT
gs-3919	495	1	finally	finally	ADV
gs-3919	495	2	,	,	PUNCT
gs-3919	495	3	international	international	ADJ
gs-3919	495	4	collaborative	collaborative	ADJ
gs-3919	495	5	efforts	effort	NOUN
gs-3919	495	6	to	to	PART
gs-3919	495	7	standardize	standardize	VERB
gs-3919	495	8	diagnostic	diagnostic	ADJ
gs-3919	495	9	criteria	criterion	NOUN
gs-3919	495	10	and	and	CCONJ
gs-3919	495	11	treatment	treatment	NOUN
gs-3919	495	12	protocols	protocol	NOUN
gs-3919	495	13	will	will	AUX
gs-3919	495	14	be	be	AUX
gs-3919	495	15	essential	essential	ADJ
gs-3919	495	16	for	for	ADP
gs-3919	495	17	generating	generate	VERB
gs-3919	495	18	robust	robust	ADJ
gs-3919	495	19	evidence	evidence	NOUN
gs-3919	495	20	to	to	PART
gs-3919	495	21	guide	guide	VERB
gs-3919	495	22	clinical	clinical	ADJ
gs-3919	495	23	practice	practice	NOUN
gs-3919	495	24	.	.	PUNCT
gs-3919	496	1	the	the	DET
gs-3919	496	2	work	work	NOUN
gs-3919	496	3	underscores	underscore	VERB
gs-3919	496	4	the	the	DET
gs-3919	496	5	importance	importance	NOUN
gs-3919	496	6	of	of	ADP
gs-3919	496	7	maintaining	maintain	VERB
gs-3919	496	8	a	a	DET
gs-3919	496	9	high	high	ADJ
gs-3919	496	10	index	index	NOUN
gs-3919	496	11	of	of	ADP
gs-3919	496	12	suspicion	suspicion	NOUN
gs-3919	496	13	for	for	ADP
gs-3919	496	14	drug	drug	NOUN
gs-3919	496	15	-	-	PUNCT
gs-3919	496	16	induced	induce	VERB
gs-3919	496	17	eosinophilia	eosinophilia	NOUN
gs-3919	496	18	in	in	ADP
gs-3919	496	19	patients	patient	NOUN
gs-3919	496	20	receiving	receive	VERB
gs-3919	496	21	known	know	VERB
gs-3919	496	22	culprit	culprit	NOUN
gs-3919	496	23	medications	medication	NOUN
gs-3919	496	24	,	,	PUNCT
gs-3919	496	25	particularly	particularly	ADV
gs-3919	496	26	when	when	SCONJ
gs-3919	496	27	presenting	present	VERB
gs-3919	496	28	with	with	ADP
gs-3919	496	29	multiorgan	multiorgan	PROPN
gs-3919	496	30	involvement	involvement	NOUN
gs-3919	496	31	.	.	PUNCT
gs-3919	497	1	clinicians	clinician	NOUN
gs-3919	497	2	must	must	AUX
gs-3919	497	3	balance	balance	VERB
gs-3919	497	4	the	the	DET
gs-3919	497	5	therapeutic	therapeutic	ADJ
gs-3919	497	6	benefits	benefit	NOUN
gs-3919	497	7	of	of	ADP
gs-3919	497	8	essential	essential	ADJ
gs-3919	497	9	medications	medication	NOUN
gs-3919	497	10	against	against	ADP
gs-3919	497	11	the	the	DET
gs-3919	497	12	potential	potential	ADJ
gs-3919	497	13	risks	risk	NOUN
gs-3919	497	14	of	of	ADP
gs-3919	497	15	hypersensitivity	hypersensitivity	NOUN
gs-3919	497	16	reactions	reaction	NOUN
gs-3919	497	17	,	,	PUNCT
gs-3919	497	18	a	a	DET
gs-3919	497	19	decision	decision	NOUN
gs-3919	497	20	-	-	PUNCT
gs-3919	497	21	making	make	VERB
gs-3919	497	22	process	process	NOUN
gs-3919	497	23	that	that	PRON
gs-3919	497	24	will	will	AUX
gs-3919	497	25	be	be	AUX
gs-3919	497	26	increasingly	increasingly	ADV
gs-3919	497	27	informed	inform	VERB
gs-3919	497	28	by	by	ADP
gs-3919	497	29	pharmacogenetic	pharmacogenetic	ADJ
gs-3919	497	30	testing	testing	NOUN
gs-3919	497	31	and	and	CCONJ
gs-3919	497	32	personalized	personalized	ADJ
gs-3919	497	33	risk	risk	NOUN
gs-3919	497	34	assessment	assessment	NOUN
gs-3919	497	35	tools	tool	NOUN
gs-3919	497	36	.	.	PUNCT
gs-3919	498	1	the	the	DET
gs-3919	498	2	study	study	NOUN
gs-3919	498	3	of	of	ADP
gs-3919	498	4	drug	drug	NOUN
gs-3919	498	5	-	-	PUNCT
gs-3919	498	6	induced	induce	VERB
gs-3919	498	7	eosinophilia	eosinophilia	PROPN
gs-3919	498	8	serves	serve	VERB
gs-3919	498	9	as	as	ADP
gs-3919	498	10	a	a	DET
gs-3919	498	11	paradigm	paradigm	NOUN
gs-3919	498	12	for	for	ADP
gs-3919	498	13	understanding	understand	VERB
gs-3919	498	14	the	the	DET
gs-3919	498	15	broader	broad	ADJ
gs-3919	498	16	challenges	challenge	NOUN
gs-3919	498	17	of	of	ADP
gs-3919	498	18	adverse	adverse	ADJ
gs-3919	498	19	drug	drug	NOUN
gs-3919	498	20	reactions	reaction	NOUN
gs-3919	498	21	in	in	ADP
gs-3919	498	22	modern	modern	ADJ
gs-3919	498	23	medicine	medicine	NOUN
gs-3919	498	24	.	.	PUNCT
gs-3919	499	1	it	it	PRON
gs-3919	499	2	highlights	highlight	VERB
gs-3919	499	3	the	the	DET
gs-3919	499	4	need	need	NOUN
gs-3919	499	5	for	for	ADP
gs-3919	499	6	continued	continue	VERB
gs-3919	499	7	collaboration	collaboration	NOUN
gs-3919	499	8	between	between	ADP
gs-3919	499	9	basic	basic	ADJ
gs-3919	499	10	scientists	scientist	NOUN
gs-3919	499	11	,	,	PUNCT
gs-3919	499	12	clinical	clinical	ADJ
gs-3919	499	13	researchers	researcher	NOUN
gs-3919	499	14	,	,	PUNCT
gs-3919	499	15	and	and	CCONJ
gs-3919	499	16	practicing	practice	VERB
gs-3919	499	17	physicians	physician	NOUN
gs-3919	499	18	to	to	PART
gs-3919	499	19	translate	translate	VERB
gs-3919	499	20	mechanistic	mechanistic	ADJ
gs-3919	499	21	insights	insight	NOUN
gs-3919	499	22	into	into	ADP
gs-3919	499	23	improved	improved	ADJ
gs-3919	499	24	patient	patient	ADJ
gs-3919	499	25	outcomes	outcome	NOUN
gs-3919	499	26	.	.	PUNCT
gs-3919	500	1	as	as	SCONJ
gs-3919	500	2	therapeutic	therapeutic	ADJ
gs-3919	500	3	options	option	NOUN
gs-3919	500	4	expand	expand	VERB
gs-3919	500	5	and	and	CCONJ
gs-3919	500	6	diagnostic	diagnostic	ADJ
gs-3919	500	7	capabilities	capability	NOUN
gs-3919	500	8	advance	advance	NOUN
gs-3919	500	9	,	,	PUNCT
gs-3919	500	10	we	we	PRON
gs-3919	500	11	move	move	VERB
gs-3919	500	12	closer	close	ADV
gs-3919	500	13	to	to	ADP
gs-3919	500	14	an	an	DET
gs-3919	500	15	era	era	NOUN
gs-3919	500	16	of	of	ADP
gs-3919	500	17	precision	precision	NOUN
gs-3919	500	18	medicine	medicine	NOUN
gs-3919	500	19	where	where	SCONJ
gs-3919	500	20	these	these	DET
gs-3919	500	21	complex	complex	ADJ
gs-3919	500	22	reactions	reaction	NOUN
gs-3919	500	23	can	can	AUX
gs-3919	500	24	be	be	AUX
gs-3919	500	25	predicted	predict	VERB
gs-3919	500	26	,	,	PUNCT
gs-3919	500	27	prevented	prevent	VERB
gs-3919	500	28	,	,	PUNCT
gs-3919	500	29	or	or	CCONJ
gs-3919	500	30	effectively	effectively	ADV
gs-3919	500	31	managed	manage	VERB
gs-3919	500	32	with	with	ADP
gs-3919	500	33	minimal	minimal	ADJ
gs-3919	500	34	morbidity	morbidity	NOUN
gs-3919	500	35	.	.	PUNCT
gs-3919	501	1	conclusion	conclusion	NOUN
gs-3919	501	2			VERB
gs-3919	501	3	drug	drug	NOUN
gs-3919	501	4	reaction	reaction	NOUN
gs-3919	501	5	with	with	ADP
gs-3919	501	6	eosinophilia	eosinophilia	PROPN
gs-3919	501	7	and	and	CCONJ
gs-3919	501	8	systemic	systemic	ADJ
gs-3919	501	9	symptoms	symptom	NOUN
gs-3919	501	10	(	(	PUNCT
gs-3919	501	11	dress	dress	NOUN
gs-3919	501	12	)	)	PUNCT
gs-3919	501	13	is	be	AUX
gs-3919	501	14	one	one	NUM
gs-3919	501	15	of	of	ADP
gs-3919	501	16	the	the	DET
gs-3919	501	17	most	most	ADV
gs-3919	501	18	radical	radical	ADJ
gs-3919	501	19	and	and	CCONJ
gs-3919	501	20	more	more	ADV
gs-3919	501	21	complicated	complicated	ADJ
gs-3919	501	22	presentations	presentation	NOUN
gs-3919	501	23	of	of	ADP
gs-3919	501	24	adrs	adr	NOUN
gs-3919	501	25	.	.	PUNCT
gs-3919	502	1	this	this	DET
gs-3919	502	2	infrequent	infrequent	ADJ
gs-3919	502	3	but	but	CCONJ
gs-3919	502	4	fatal	fatal	ADJ
gs-3919	502	5	condition	condition	NOUN
gs-3919	502	6	still	still	ADV
gs-3919	502	7	underlines	underline	VERB
gs-3919	502	8	the	the	DET
gs-3919	502	9	difficulties	difficulty	NOUN
gs-3919	502	10	in	in	ADP
gs-3919	502	11	diagnosis	diagnosis	NOUN
gs-3919	502	12	,	,	PUNCT
gs-3919	502	13	management	management	NOUN
gs-3919	502	14	,	,	PUNCT
gs-3919	502	15	and	and	CCONJ
gs-3919	502	16	prognosis	prognosis	NOUN
gs-3919	502	17	in	in	ADP
gs-3919	502	18	georgian	georgian	ADJ
gs-3919	502	19	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	502	20	მეცნიერები	მეცნიერები	NOUN
gs-3919	502	21	ტ.	ტ.	VERB
gs-3919	502	22	7	7	NUM
gs-3919	502	23	n	n	DET
gs-3919	502	24	3	3	NUM
gs-3919	502	25	,	,	PUNCT
gs-3919	502	26	2025	2025	NUM
gs-3919	502	27	172	172	NUM
gs-3919	502	28	everyday	everyday	ADJ
gs-3919	502	29	practice	practice	NOUN
gs-3919	502	30	.	.	PUNCT
gs-3919	503	1	despite	despite	SCONJ
gs-3919	503	2	being	be	AUX
gs-3919	503	3	clinically	clinically	ADV
gs-3919	503	4	identified	identify	VERB
gs-3919	503	5	for	for	ADP
gs-3919	503	6	decades	decade	NOUN
gs-3919	503	7	,	,	PUNCT
gs-3919	503	8	dress	dress	NOUN
gs-3919	503	9	syndrome	syndrome	NOUN
gs-3919	503	10	is	be	AUX
gs-3919	503	11	underdiagnosed	underdiagnose	VERB
gs-3919	503	12	,	,	PUNCT
gs-3919	503	13	given	give	VERB
gs-3919	503	14	its	its	PRON
gs-3919	503	15	late	late	ADJ
gs-3919	503	16	onset	onset	NOUN
gs-3919	503	17	,	,	PUNCT
gs-3919	503	18	highly	highly	ADV
gs-3919	503	19	variable	variable	ADJ
gs-3919	503	20	clinical	clinical	ADJ
gs-3919	503	21	presentation	presentation	NOUN
gs-3919	503	22	,	,	PUNCT
gs-3919	503	23	and	and	CCONJ
gs-3919	503	24	the	the	DET
gs-3919	503	25	many	many	ADJ
gs-3919	503	26	overlapping	overlap	VERB
gs-3919	503	27	characteristics	characteristic	NOUN
gs-3919	503	28	with	with	ADP
gs-3919	503	29	other	other	ADJ
gs-3919	503	30	hypersensitivity	hypersensitivity	NOUN
gs-3919	503	31	syndromes	syndrome	NOUN
gs-3919	503	32	.	.	PUNCT
gs-3919	504	1	it	it	PRON
gs-3919	504	2	requires	require	VERB
gs-3919	504	3	a	a	DET
gs-3919	504	4	high	high	ADJ
gs-3919	504	5	index	index	NOUN
gs-3919	504	6	of	of	ADP
gs-3919	504	7	suspicion	suspicion	NOUN
gs-3919	504	8	and	and	CCONJ
gs-3919	504	9	multidisciplinary	multidisciplinary	ADJ
gs-3919	504	10	work	work	NOUN
gs-3919	504	11	-	-	PUNCT
gs-3919	504	12	up	up	NOUN
gs-3919	504	13	for	for	ADP
gs-3919	504	14	a	a	DET
gs-3919	504	15	prompt	prompt	ADJ
gs-3919	504	16	diagnosis	diagnosis	NOUN
gs-3919	504	17	and	and	CCONJ
gs-3919	504	18	a	a	DET
gs-3919	504	19	successful	successful	ADJ
gs-3919	504	20	management	management	NOUN
gs-3919	504	21	.	.	PUNCT
gs-3919	505	1			VERB
gs-3919	505	2	this	this	DET
gs-3919	505	3	thesis	thesis	NOUN
gs-3919	505	4	constitutes	constitute	VERB
gs-3919	505	5	a	a	DET
gs-3919	505	6	detailed	detailed	ADJ
gs-3919	505	7	overview	overview	NOUN
gs-3919	505	8	and	and	CCONJ
gs-3919	505	9	analysis	analysis	NOUN
gs-3919	505	10	of	of	ADP
gs-3919	505	11	research	research	NOUN
gs-3919	505	12	articles	article	NOUN
gs-3919	505	13	and	and	CCONJ
gs-3919	505	14	case	case	NOUN
gs-3919	505	15	reports	report	NOUN
gs-3919	505	16	on	on	ADP
gs-3919	505	17	dress	dress	NOUN
gs-3919	505	18	syndrome	syndrome	NOUN
gs-3919	505	19	from	from	ADP
gs-3919	505	20	2010	2010	NUM
gs-3919	505	21	to	to	ADP
gs-3919	505	22	2025	2025	NUM
gs-3919	505	23	.	.	PUNCT
gs-3919	506	1	this	this	DET
gs-3919	506	2	review	review	NOUN
gs-3919	506	3	has	have	AUX
gs-3919	506	4	systematically	systematically	ADV
gs-3919	506	5	examined	examine	VERB
gs-3919	506	6	more	more	ADJ
gs-3919	506	7	than	than	ADP
gs-3919	506	8	60	60	NUM
gs-3919	506	9	detailed	detailed	ADJ
gs-3919	506	10	case	case	NOUN
gs-3919	506	11	reports	report	NOUN
gs-3919	506	12	and	and	CCONJ
gs-3919	506	13	90	90	NUM
gs-3919	506	14	references	reference	NOUN
gs-3919	506	15	,	,	PUNCT
gs-3919	506	16	and	and	CCONJ
gs-3919	506	17	summarized	summarize	VERB
gs-3919	506	18	the	the	DET
gs-3919	506	19	profiles	profile	NOUN
gs-3919	506	20	of	of	ADP
gs-3919	506	21	drug	drug	NOUN
gs-3919	506	22	,	,	PUNCT
gs-3919	506	23	clinical	clinical	ADJ
gs-3919	506	24	presentation	presentation	NOUN
gs-3919	506	25	,	,	PUNCT
gs-3919	506	26	diagnostic	diagnostic	ADJ
gs-3919	506	27	workup	workup	NOUN
gs-3919	506	28	,	,	PUNCT
gs-3919	506	29	pathophysiologic	pathophysiologic	ADJ
gs-3919	506	30	mechanism	mechanism	NOUN
gs-3919	506	31	,	,	PUNCT
gs-3919	506	32	and	and	CCONJ
gs-3919	506	33	management	management	NOUN
gs-3919	506	34	of	of	ADP
gs-3919	506	35	dress	dress	NOUN
gs-3919	506	36	.	.	PUNCT
gs-3919	507	1	this	this	DET
gs-3919	507	2	pooled	pool	VERB
gs-3919	507	3	evidence	evidence	NOUN
gs-3919	507	4	from	from	ADP
gs-3919	507	5	real	real	ADJ
gs-3919	507	6	-	-	PUNCT
gs-3919	507	7	life	life	NOUN
gs-3919	507	8	cohorts	cohort	NOUN
gs-3919	507	9	has	have	AUX
gs-3919	507	10	contributed	contribute	VERB
gs-3919	507	11	to	to	ADP
gs-3919	507	12	a	a	DET
gs-3919	507	13	better	well	ADJ
gs-3919	507	14	characterization	characterization	NOUN
gs-3919	507	15	of	of	ADP
gs-3919	507	16	dress	dress	NOUN
gs-3919	507	17	epidemiology	epidemiology	NOUN
gs-3919	507	18	and	and	CCONJ
gs-3919	507	19	clinical	clinical	ADJ
gs-3919	507	20	course	course	NOUN
gs-3919	507	21	.	.	PUNCT
gs-3919	508	1			VERB
gs-3919	508	2	an	an	DET
gs-3919	508	3	important	important	ADJ
gs-3919	508	4	finding	finding	NOUN
gs-3919	508	5	from	from	ADP
gs-3919	508	6	this	this	DET
gs-3919	508	7	study	study	NOUN
gs-3919	508	8	is	be	AUX
gs-3919	508	9	the	the	DET
gs-3919	508	10	recognition	recognition	NOUN
gs-3919	508	11	and	and	CCONJ
gs-3919	508	12	classification	classification	NOUN
gs-3919	508	13	of	of	ADP
gs-3919	508	14	drugs	drug	NOUN
gs-3919	508	15	frequently	frequently	ADV
gs-3919	508	16	involved	involve	VERB
gs-3919	508	17	in	in	ADP
gs-3919	508	18	dress	dress	NOUN
gs-3919	508	19	syndrome	syndrome	NOUN
gs-3919	508	20	.	.	PUNCT
gs-3919	509	1	among	among	ADP
gs-3919	509	2	the	the	DET
gs-3919	509	3	anticonvulsants	anticonvulsant	NOUN
gs-3919	509	4	at	at	ADP
gs-3919	509	5	least	least	ADJ
gs-3919	509	6	the	the	DET
gs-3919	509	7	aromatic	aromatic	ADJ
gs-3919	509	8	compounds	compound	NOUN
gs-3919	509	9	(	(	PUNCT
gs-3919	509	10	e.g.	e.g.	ADV
gs-3919	509	11	,	,	PUNCT
gs-3919	509	12	carbamazepine	carbamazepine	NOUN
gs-3919	509	13	)	)	PUNCT
gs-3919	509	14	,	,	PUNCT
gs-3919	509	15	phenytoin	phenytoin	NOUN
gs-3919	509	16	,	,	PUNCT
gs-3919	509	17	and	and	CCONJ
gs-3919	509	18	lamotrigine	lamotrigine	PROPN
gs-3919	509	19	appear	appear	VERB
gs-3919	509	20	to	to	PART
gs-3919	509	21	be	be	AUX
gs-3919	509	22	the	the	DET
gs-3919	509	23	most	most	ADV
gs-3919	509	24	commonly	commonly	ADV
gs-3919	509	25	involved	involve	VERB
gs-3919	509	26	,	,	PUNCT
gs-3919	509	27	as	as	SCONJ
gs-3919	509	28	expected	expect	VERB
gs-3919	509	29	since	since	SCONJ
gs-3919	509	30	they	they	PRON
gs-3919	509	31	are	be	AUX
gs-3919	509	32	metabolically	metabolically	ADV
gs-3919	509	33	bioactivated	bioactivate	VERB
gs-3919	509	34	to	to	ADP
gs-3919	509	35	reactive	reactive	ADJ
gs-3919	509	36	intermediates	intermediate	NOUN
gs-3919	509	37	.	.	PUNCT
gs-3919	510	1	allopurinol	allopurinol	NOUN
gs-3919	510	2	,	,	PUNCT
gs-3919	510	3	a	a	DET
gs-3919	510	4	mainstay	mainstay	NOUN
gs-3919	510	5	drug	drug	NOUN
gs-3919	510	6	for	for	ADP
gs-3919	510	7	the	the	DET
gs-3919	510	8	treatment	treatment	NOUN
gs-3919	510	9	of	of	ADP
gs-3919	510	10	gout	gout	NOUN
gs-3919	510	11	,	,	PUNCT
gs-3919	510	12	was	be	AUX
gs-3919	510	13	also	also	ADV
gs-3919	510	14	identified	identify	VERB
gs-3919	510	15	as	as	ADP
gs-3919	510	16	a	a	DET
gs-3919	510	17	major	major	ADJ
gs-3919	510	18	trigger	trigger	NOUN
gs-3919	510	19	,	,	PUNCT
gs-3919	510	20	particularly	particularly	ADV
gs-3919	510	21	in	in	ADP
gs-3919	510	22	the	the	DET
gs-3919	510	23	asian	asian	ADJ
gs-3919	510	24	an	an	DET
gs-3919	510	25	african	african	ADJ
gs-3919	510	26	population	population	NOUN
gs-3919	510	27	,	,	PUNCT
gs-3919	510	28	where	where	SCONJ
gs-3919	510	29	there	there	PRON
gs-3919	510	30	exists	exist	VERB
gs-3919	510	31	a	a	DET
gs-3919	510	32	genetic	genetic	ADJ
gs-3919	510	33	predisposition	predisposition	NOUN
gs-3919	510	34	(	(	PUNCT
gs-3919	510	35	e.g.	e.g.	ADV
gs-3919	510	36	,	,	PUNCT
gs-3919	510	37	hla	hla	NOUN
gs-3919	510	38	-	-	PUNCT
gs-3919	510	39	b58:01	b58:01	NOUN
gs-3919	510	40	)	)	PUNCT
gs-3919	510	41	.	.	PUNCT
gs-3919	511	1	antibiotics	antibiotic	NOUN
gs-3919	511	2	including	include	VERB
gs-3919	511	3	vancomycin	vancomycin	PROPN
gs-3919	511	4	,	,	PUNCT
gs-3919	511	5	minocycline	minocycline	NOUN
gs-3919	511	6	and	and	CCONJ
gs-3919	511	7	penicillin	penicillin	NOUN
gs-3919	511	8	were	be	AUX
gs-3919	511	9	disproportionately	disproportionately	ADV
gs-3919	511	10	prevalent	prevalent	ADJ
gs-3919	511	11	alongside	alongside	ADP
gs-3919	511	12	nsaids	nsaid	NOUN
gs-3919	511	13	,	,	PUNCT
gs-3919	511	14	antiviral	antiviral	ADJ
gs-3919	511	15	therapies	therapy	NOUN
gs-3919	511	16	and	and	CCONJ
gs-3919	511	17	immunotherapeutics	immunotherapeutic	NOUN
gs-3919	511	18	including	include	VERB
gs-3919	511	19	checkpoint	checkpoint	NOUN
gs-3919	511	20	inhibitors	inhibitor	NOUN
gs-3919	511	21	.	.	PUNCT
gs-3919	512	1	this	this	DET
gs-3919	512	2	organized	organize	VERB
gs-3919	512	3	drug	drug	NOUN
gs-3919	512	4	-	-	PUNCT
gs-3919	512	5	wise	wise	ADJ
gs-3919	512	6	distribution	distribution	NOUN
gs-3919	512	7	of	of	ADP
gs-3919	512	8	information	information	NOUN
gs-3919	512	9	was	be	AUX
gs-3919	512	10	supplemented	supplement	VERB
gs-3919	512	11	with	with	ADP
gs-3919	512	12	references	reference	NOUN
gs-3919	512	13	from	from	ADP
gs-3919	512	14	case	case	NOUN
gs-3919	512	15	reports	report	NOUN
gs-3919	512	16	and	and	CCONJ
gs-3919	512	17	highlighted	highlight	VERB
gs-3919	512	18	the	the	DET
gs-3919	512	19	importance	importance	NOUN
gs-3919	512	20	of	of	ADP
gs-3919	512	21	cautious	cautious	ADJ
gs-3919	512	22	initiation	initiation	NOUN
gs-3919	512	23	and	and	CCONJ
gs-3919	512	24	observation	observation	NOUN
gs-3919	512	25	.	.	PUNCT
gs-3919	513	1			VERB
gs-3919	513	2	with	with	ADP
gs-3919	513	3	regard	regard	NOUN
gs-3919	513	4	to	to	ADP
gs-3919	513	5	clinical	clinical	ADJ
gs-3919	513	6	features	feature	NOUN
gs-3919	513	7	,	,	PUNCT
gs-3919	513	8	dress	dress	NOUN
gs-3919	513	9	is	be	AUX
gs-3919	513	10	characterized	characterize	VERB
gs-3919	513	11	by	by	ADP
gs-3919	513	12	characteristic	characteristic	ADJ
gs-3919	513	13	triad	triad	PROPN
gs-3919	513	14	(	(	PUNCT
gs-3919	513	15	fever	fever	NOUN
gs-3919	513	16	,	,	PUNCT
gs-3919	513	17	rash	rash	ADJ
gs-3919	513	18	,	,	PUNCT
gs-3919	513	19	and	and	CCONJ
gs-3919	513	20	eosinophilia	eosinophilia	PROPN
gs-3919	513	21	)	)	PUNCT
gs-3919	513	22	as	as	ADV
gs-3919	513	23	well	well	ADV
gs-3919	513	24	as	as	ADP
gs-3919	513	25	the	the	DET
gs-3919	513	26	involvement	involvement	NOUN
gs-3919	513	27	of	of	ADP
gs-3919	513	28	various	various	ADJ
gs-3919	513	29	internal	internal	ADJ
gs-3919	513	30	organs	organ	NOUN
gs-3919	513	31	.	.	PUNCT
gs-3919	514	1	liver	liver	NOUN
gs-3919	514	2	involvement	involvement	NOUN
gs-3919	514	3	was	be	AUX
gs-3919	514	4	predominant	predominant	ADJ
gs-3919	514	5	and	and	CCONJ
gs-3919	514	6	frequently	frequently	ADV
gs-3919	514	7	severe	severe	ADJ
gs-3919	514	8	,	,	PUNCT
gs-3919	514	9	occasionally	occasionally	ADV
gs-3919	514	10	leading	lead	VERB
gs-3919	514	11	to	to	ADP
gs-3919	514	12	a	a	DET
gs-3919	514	13	fulminant	fulminant	ADJ
gs-3919	514	14	hepatic	hepatic	ADJ
gs-3919	514	15	failure	failure	NOUN
gs-3919	514	16	.	.	PUNCT
gs-3919	515	1	associated	associate	VERB
gs-3919	515	2	with	with	ADP
gs-3919	515	3	systemic	systemic	ADJ
gs-3919	515	4	involvement	involvement	NOUN
gs-3919	515	5	,	,	PUNCT
gs-3919	515	6	renal	renal	ADJ
gs-3919	515	7	,	,	PUNCT
gs-3919	515	8	pulmonary	pulmonary	ADJ
gs-3919	515	9	,	,	PUNCT
gs-3919	515	10	and	and	CCONJ
gs-3919	515	11	hematologic	hematologic	NOUN
gs-3919	515	12	complications	complication	NOUN
gs-3919	515	13	were	be	AUX
gs-3919	515	14	frequently	frequently	ADV
gs-3919	515	15	published	publish	VERB
gs-3919	515	16	.	.	PUNCT
gs-3919	516	1	this	this	DET
gs-3919	516	2	abstract	abstract	NOUN
gs-3919	516	3	also	also	ADV
gs-3919	516	4	highlighted	highlight	VERB
gs-3919	516	5	the	the	DET
gs-3919	516	6	changing	change	VERB
gs-3919	516	7	concept	concept	NOUN
gs-3919	516	8	of	of	ADP
gs-3919	516	9	dress	dress	NOUN
gs-3919	516	10	being	be	AUX
gs-3919	516	11	an	an	DET
gs-3919	516	12	allergic	allergic	ADJ
gs-3919	516	13	phenomenon	phenomenon	NOUN
gs-3919	516	14	to	to	ADP
gs-3919	516	15	a	a	DET
gs-3919	516	16	medley	medley	NOUN
gs-3919	516	17	of	of	ADP
gs-3919	516	18	drug	drug	NOUN
gs-3919	516	19	metabolism	metabolism	NOUN
gs-3919	516	20	,	,	PUNCT
gs-3919	516	21	immune	immune	ADJ
gs-3919	516	22	dysregulation	dysregulation	NOUN
gs-3919	516	23	,	,	PUNCT
gs-3919	516	24	viral	viral	ADJ
gs-3919	516	25	reactivation	reactivation	NOUN
gs-3919	516	26	(	(	PUNCT
gs-3919	516	27	esply.hhv-6	esply.hhv-6	PROPN
gs-3919	516	28	reactivation	reactivation	NOUN
gs-3919	516	29	)	)	PUNCT
gs-3919	516	30	and	and	CCONJ
gs-3919	516	31	genetic	genetic	ADJ
gs-3919	516	32	predisposition	predisposition	NOUN
gs-3919	516	33	.	.	PUNCT
gs-3919	517	1	recommendations	recommendation	NOUN
gs-3919	517	2			VERB
gs-3919	517	3	facilitate	facilitate	ADJ
gs-3919	517	4	multidisciplinary	multidisciplinary	ADJ
gs-3919	517	5	teamwork	teamwork	NOUN
gs-3919	517	6	:	:	PUNCT
gs-3919	517	7	the	the	DET
gs-3919	517	8	optimal	optimal	ADJ
gs-3919	517	9	treatment	treatment	NOUN
gs-3919	517	10	of	of	ADP
gs-3919	517	11	dress	dress	NOUN
gs-3919	517	12	mandates	mandate	NOUN
gs-3919	517	13	cooperation	cooperation	NOUN
gs-3919	517	14	between	between	ADP
gs-3919	517	15	dermatology	dermatology	NOUN
gs-3919	517	16	,	,	PUNCT
gs-3919	517	17	immunology	immunology	NOUN
gs-3919	517	18	,	,	PUNCT
gs-3919	517	19	infectious	infectious	ADJ
gs-3919	517	20	disease	disease	NOUN
gs-3919	517	21	,	,	PUNCT
gs-3919	517	22	pharmacology	pharmacology	NOUN
gs-3919	517	23	,	,	PUNCT
gs-3919	517	24	and	and	CCONJ
gs-3919	517	25	other	other	ADJ
gs-3919	517	26	pertinent	pertinent	ADJ
gs-3919	517	27	subspecialties	subspecialtie	NOUN
gs-3919	517	28	.	.	PUNCT
gs-3919	518	1	multidisciplinary	multidisciplinary	ADJ
gs-3919	518	2	teams	team	NOUN
gs-3919	518	3	may	may	AUX
gs-3919	518	4	offer	offer	VERB
gs-3919	518	5	total	total	ADJ
gs-3919	518	6	evaluation	evaluation	NOUN
gs-3919	518	7	,	,	PUNCT
gs-3919	518	8	management	management	NOUN
gs-3919	518	9	,	,	PUNCT
gs-3919	518	10	and	and	CCONJ
gs-3919	518	11	follow	follow	VERB
gs-3919	518	12	-	-	PUNCT
gs-3919	518	13	up	up	NOUN
gs-3919	518	14	for	for	ADP
gs-3919	518	15	the	the	DET
gs-3919	518	16	syndrome	syndrome	NOUN
gs-3919	518	17	in	in	ADP
gs-3919	518	18	all	all	DET
gs-3919	518	19	its	its	PRON
gs-3919	518	20	aspects	aspect	NOUN
gs-3919	518	21	.	.	PUNCT
gs-3919	519	1	georgian	georgian	ADJ
gs-3919	519	2	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	519	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	519	4	ტ.	ტ.	VERB
gs-3919	519	5	7	7	NUM
gs-3919	519	6	n	n	PRON
gs-3919	519	7	3	3	NUM
gs-3919	519	8	,	,	PUNCT
gs-3919	519	9	2025	2025	NUM
gs-3919	519	10	173	173	NUM
gs-3919	519	11			ADJ
gs-3919	519	12	long	long	ADJ
gs-3919	519	13	term	term	NOUN
gs-3919	519	14	follow	follow	VERB
gs-3919	519	15	up	up	ADP
gs-3919	519	16	:	:	PUNCT
gs-3919	519	17	because	because	SCONJ
gs-3919	519	18	of	of	ADP
gs-3919	519	19	the	the	DET
gs-3919	519	20	potential	potential	NOUN
gs-3919	519	21	for	for	ADP
gs-3919	519	22	late	late	ADJ
gs-3919	519	23	autoimmune	autoimmune	ADJ
gs-3919	519	24	effects	effect	NOUN
gs-3919	519	25	or	or	CCONJ
gs-3919	519	26	organ	organ	NOUN
gs-3919	519	27	damage	damage	NOUN
gs-3919	519	28	,	,	PUNCT
gs-3919	519	29	patients	patient	NOUN
gs-3919	519	30	with	with	ADP
gs-3919	519	31	a	a	DET
gs-3919	519	32	diagnosis	diagnosis	NOUN
gs-3919	519	33	of	of	ADP
gs-3919	519	34	dress	dress	NOUN
gs-3919	519	35	should	should	AUX
gs-3919	519	36	have	have	VERB
gs-3919	519	37	regular	regular	ADJ
gs-3919	519	38	long	long	ADJ
gs-3919	519	39	-	-	PUNCT
gs-3919	519	40	term	term	NOUN
gs-3919	519	41	follow	follow	VERB
gs-3919	519	42	up	up	ADP
gs-3919	519	43	,	,	PUNCT
gs-3919	519	44	screening	screen	VERB
gs-3919	519	45	for	for	ADP
gs-3919	519	46	endocrine	endocrine	ADJ
gs-3919	519	47	abnormalities	abnormality	NOUN
gs-3919	519	48	and	and	CCONJ
gs-3919	519	49	autoimmune	autoimmune	ADJ
gs-3919	519	50	sequelae	sequelae	PROPN
gs-3919	519	51	.	.	PUNCT
gs-3919	520	1			VERB
gs-3919	520	2	provide	provide	VERB
gs-3919	520	3	patient	patient	ADJ
gs-3919	520	4	education	education	NOUN
gs-3919	520	5	:	:	PUNCT
gs-3919	520	6	teach	teach	VERB
gs-3919	520	7	patients	patient	NOUN
gs-3919	520	8	about	about	ADP
gs-3919	520	9	drug	drug	NOUN
gs-3919	520	10	allergies	allergy	NOUN
gs-3919	520	11	and	and	CCONJ
gs-3919	520	12	signs	sign	NOUN
gs-3919	520	13	of	of	ADP
gs-3919	520	14	hypersensitivity	hypersensitivity	NOUN
gs-3919	520	15	responses	response	NOUN
gs-3919	520	16	.	.	PUNCT
gs-3919	521	1	increased	increase	VERB
gs-3919	521	2	emphasis	emphasis	NOUN
gs-3919	521	3	of	of	ADP
gs-3919	521	4	having	having	AUX
gs-3919	521	5	available	available	ADJ
gs-3919	521	6	a	a	DET
gs-3919	521	7	documented	document	VERB
gs-3919	521	8	history	history	NOUN
gs-3919	521	9	of	of	ADP
gs-3919	521	10	drug	drug	NOUN
gs-3919	521	11	reactions	reaction	NOUN
gs-3919	521	12	can	can	AUX
gs-3919	521	13	enhance	enhance	VERB
gs-3919	521	14	safety	safety	NOUN
gs-3919	521	15	and	and	CCONJ
gs-3919	521	16	guide	guide	VERB
gs-3919	521	17	future	future	ADJ
gs-3919	521	18	prescribing	prescribing	NOUN
gs-3919	521	19	.	.	PUNCT
gs-3919	522	1	references	reference	NOUN
gs-3919	522	2	1	1	NUM
gs-3919	522	3	.	.	PUNCT
gs-3919	523	1	kong	kong	PROPN
gs-3919	523	2	,	,	PUNCT
gs-3919	523	3	d.	d.	PROPN
gs-3919	523	4	,	,	PUNCT
gs-3919	523	5	dixit	dixit	PROPN
gs-3919	523	6	,	,	PUNCT
gs-3919	523	7	k.	k.	PROPN
gs-3919	523	8	,	,	PUNCT
gs-3919	523	9	konje	konje	PROPN
gs-3919	523	10	,	,	PUNCT
gs-3919	523	11	s.	s.	PROPN
gs-3919	523	12	,	,	PUNCT
gs-3919	523	13	gandhi	gandhi	PROPN
gs-3919	523	14	,	,	PUNCT
gs-3919	523	15	k.	k.	PROPN
gs-3919	523	16	,	,	PUNCT
gs-3919	523	17	salman	salman	PROPN
gs-3919	523	18	,	,	PUNCT
gs-3919	523	19	s.	s.	PROPN
gs-3919	523	20	,	,	PUNCT
gs-3919	523	21	moras	moras	PROPN
gs-3919	523	22	,	,	PUNCT
gs-3919	523	23	e.	e.	PROPN
gs-3919	523	24	,	,	PUNCT
gs-3919	523	25	&	&	CCONJ
gs-3919	523	26	agarwal	agarwal	PROPN
gs-3919	523	27	,	,	PUNCT
gs-3919	523	28	v.	v.	PROPN
gs-3919	523	29	(	(	PUNCT
gs-3919	523	30	2023	2023	NUM
gs-3919	523	31	)	)	PUNCT
gs-3919	523	32	.	.	PUNCT
gs-3919	524	1	drug	drug	NOUN
gs-3919	524	2	reaction	reaction	NOUN
gs-3919	524	3	with	with	ADP
gs-3919	524	4	eosinophilia	eosinophilia	PROPN
gs-3919	524	5	and	and	CCONJ
gs-3919	524	6	systemic	systemic	ADJ
gs-3919	524	7	symptoms	symptom	NOUN
gs-3919	524	8	-	-	PUNCT
gs-3919	524	9	associated	associate	VERB
gs-3919	524	10	perimyocarditis	perimyocarditis	NOUN
gs-3919	524	11	after	after	ADP
gs-3919	524	12	initiation	initiation	NOUN
gs-3919	524	13	of	of	ADP
gs-3919	524	14	anti	anti	ADJ
gs-3919	524	15	-	-	ADJ
gs-3919	524	16	tuberculosis	tuberculosis	ADJ
gs-3919	524	17	therapy	therapy	NOUN
gs-3919	524	18	:	:	PUNCT
gs-3919	524	19	a	a	DET
gs-3919	524	20	case	case	NOUN
gs-3919	524	21	report	report	NOUN
gs-3919	524	22	.	.	PUNCT
gs-3919	525	1	cureus	cureus	NOUN
gs-3919	525	2	.	.	PUNCT
gs-3919	526	1	2	2	X
gs-3919	526	2	.	.	X
gs-3919	526	3	krantz	krantz	PROPN
gs-3919	526	4	,	,	PUNCT
gs-3919	526	5	m.	m.	NOUN
gs-3919	526	6	s.	s.	PROPN
gs-3919	526	7	,	,	PUNCT
gs-3919	526	8	&	&	CCONJ
gs-3919	526	9	phillips	phillips	PROPN
gs-3919	526	10	,	,	PUNCT
gs-3919	526	11	e.	e.	PROPN
gs-3919	526	12	j.	j.	PROPN
gs-3919	526	13	(	(	PUNCT
gs-3919	526	14	2023	2023	NUM
gs-3919	526	15	)	)	PUNCT
gs-3919	526	16	.	.	PUNCT
gs-3919	527	1	drug	drug	NOUN
gs-3919	527	2	reaction	reaction	NOUN
gs-3919	527	3	with	with	ADP
gs-3919	527	4	eosinophilia	eosinophilia	PROPN
gs-3919	527	5	and	and	CCONJ
gs-3919	527	6	systemic	systemic	ADJ
gs-3919	527	7	symptoms	symptom	NOUN
gs-3919	527	8	.	.	PUNCT
gs-3919	528	1	jama	jama	PROPN
gs-3919	528	2	dermatology	dermatology	PROPN
gs-3919	528	3	,	,	PUNCT
gs-3919	528	4	159(3	159(3	NUM
gs-3919	528	5	)	)	PUNCT
gs-3919	528	6	,	,	PUNCT
gs-3919	528	7	348	348	NUM
gs-3919	528	8	.	.	PUNCT
gs-3919	529	1	3	3	X
gs-3919	529	2	.	.	X
gs-3919	529	3	lee	lee	PROPN
gs-3919	529	4	,	,	PUNCT
gs-3919	529	5	s.	s.	PROPN
gs-3919	529	6	,	,	PUNCT
gs-3919	529	7	nam	nam	PROPN
gs-3919	529	8	,	,	PUNCT
gs-3919	529	9	y.	y.	PROPN
gs-3919	529	10	h.	h.	PROPN
gs-3919	529	11	,	,	PUNCT
gs-3919	529	12	koh	koh	PROPN
gs-3919	529	13	,	,	PUNCT
gs-3919	529	14	y.	y.	PROPN
gs-3919	529	15	,	,	PUNCT
gs-3919	529	16	kim	kim	PROPN
gs-3919	529	17	,	,	PUNCT
gs-3919	529	18	s.	s.	PROPN
gs-3919	529	19	h.	h.	PROPN
gs-3919	529	20	,	,	PUNCT
gs-3919	529	21	kim	kim	PROPN
gs-3919	529	22	,	,	PUNCT
gs-3919	529	23	s.	s.	PROPN
gs-3919	529	24	,	,	PUNCT
gs-3919	529	25	kang	kang	PROPN
gs-3919	529	26	,	,	PUNCT
gs-3919	529	27	h.	h.	PROPN
gs-3919	529	28	,	,	PUNCT
gs-3919	529	29	kim	kim	PROPN
gs-3919	529	30	,	,	PUNCT
gs-3919	529	31	m.	m.	NOUN
gs-3919	529	32	,	,	PUNCT
gs-3919	529	33	lee	lee	PROPN
gs-3919	529	34	,	,	PUNCT
gs-3919	529	35	j.	j.	PROPN
gs-3919	529	36	,	,	PUNCT
gs-3919	529	37	park	park	PROPN
gs-3919	529	38	,	,	PUNCT
gs-3919	529	39	j.	j.	PROPN
gs-3919	529	40	,	,	PUNCT
gs-3919	529	41	park	park	PROPN
gs-3919	529	42	,	,	PUNCT
gs-3919	529	43	h.	h.	PROPN
gs-3919	529	44	,	,	PUNCT
gs-3919	529	45	la	la	PROPN
gs-3919	529	46	,	,	PUNCT
gs-3919	529	47	h.	h.	PROPN
gs-3919	529	48	o.	o.	PROPN
gs-3919	529	49	,	,	PUNCT
gs-3919	529	50	kim	kim	PROPN
gs-3919	529	51	,	,	PUNCT
gs-3919	529	52	m.	m.	NOUN
gs-3919	529	53	,	,	PUNCT
gs-3919	529	54	park	park	NOUN
gs-3919	529	55	,	,	PUNCT
gs-3919	529	56	s.	s.	PROPN
gs-3919	529	57	j.	j.	PROPN
gs-3919	529	58	,	,	PUNCT
gs-3919	529	59	kwon	kwon	PROPN
gs-3919	529	60	,	,	PUNCT
gs-3919	529	61	y.	y.	PROPN
gs-3919	529	62	,	,	PUNCT
gs-3919	529	63	jung	jung	PROPN
gs-3919	529	64	,	,	PUNCT
gs-3919	529	65	j.	j.	PROPN
gs-3919	529	66	,	,	PUNCT
gs-3919	529	67	kim	kim	PROPN
gs-3919	529	68	,	,	PUNCT
gs-3919	529	69	s.	s.	PROPN
gs-3919	529	70	h.	h.	PROPN
gs-3919	529	71	,	,	PUNCT
gs-3919	529	72	kim	kim	PROPN
gs-3919	529	73	,	,	PUNCT
gs-3919	529	74	c.	c.	PROPN
gs-3919	529	75	,	,	PUNCT
gs-3919	529	76	yang	yang	PROPN
gs-3919	529	77	,	,	PUNCT
gs-3919	529	78	m.	m.	NOUN
gs-3919	529	79	,	,	PUNCT
gs-3919	529	80	kang	kang	PROPN
gs-3919	529	81	,	,	PUNCT
gs-3919	529	82	m.	m.	NOUN
gs-3919	529	83	,	,	PUNCT
gs-3919	529	84	...	...	PUNCT
gs-3919	530	1	ye	ye	X
gs-3919	530	2	,	,	PUNCT
gs-3919	530	3	y.	y.	NOUN
gs-3919	530	4	(	(	PUNCT
gs-3919	530	5	2019	2019	NUM
gs-3919	530	6	)	)	PUNCT
gs-3919	530	7	.	.	PUNCT
gs-3919	531	1	phenotypes	phenotype	NOUN
gs-3919	531	2	of	of	ADP
gs-3919	531	3	severe	severe	ADJ
gs-3919	531	4	cutaneous	cutaneous	ADJ
gs-3919	531	5	adverse	adverse	ADJ
gs-3919	531	6	reactions	reaction	NOUN
gs-3919	531	7	caused	cause	VERB
gs-3919	531	8	by	by	ADP
gs-3919	531	9	nonsteroidal	nonsteroidal	NOUN
gs-3919	531	10	anti	anti	ADJ
gs-3919	531	11	-	-	ADJ
gs-3919	531	12	inflammatory	inflammatory	ADJ
gs-3919	531	13	drugs	drug	NOUN
gs-3919	531	14	.	.	PUNCT
gs-3919	532	1	allergy	allergy	NOUN
gs-3919	532	2	asthma	asthma	NOUN
gs-3919	532	3	and	and	CCONJ
gs-3919	532	4	immunology	immunology	NOUN
gs-3919	532	5	research	research	NOUN
gs-3919	532	6	,	,	PUNCT
gs-3919	532	7	11(2	11(2	NOUN
gs-3919	532	8	)	)	PUNCT
gs-3919	532	9	,	,	PUNCT
gs-3919	532	10	212	212	NUM
gs-3919	532	11	.	.	PUNCT
gs-3919	533	1	4	4	NUM
gs-3919	533	2	.	.	X
gs-3919	533	3	li	li	PROPN
gs-3919	533	4	,	,	PUNCT
gs-3919	533	5	j.	j.	PROPN
gs-3919	533	6	c.	c.	PROPN
gs-3919	533	7	(	(	PUNCT
gs-3919	533	8	2022	2022	NUM
gs-3919	533	9	)	)	PUNCT
gs-3919	533	10	.	.	PUNCT
gs-3919	534	1	reactivation	reactivation	NOUN
gs-3919	534	2	of	of	ADP
gs-3919	534	3	human	human	ADJ
gs-3919	534	4	herpesvirus	herpesvirus	NOUN
gs-3919	534	5	(	(	PUNCT
gs-3919	534	6	hhv	hhv	NOUN
gs-3919	534	7	)	)	PUNCT
gs-3919	534	8	6	6	NUM
gs-3919	534	9	as	as	ADP
gs-3919	534	10	etiology	etiology	NOUN
gs-3919	534	11	of	of	ADP
gs-3919	534	12	acute	acute	ADJ
gs-3919	534	13	liver	liver	NOUN
gs-3919	534	14	injury	injury	NOUN
gs-3919	534	15	in	in	ADP
gs-3919	534	16	drug	drug	NOUN
gs-3919	534	17	reaction	reaction	NOUN
gs-3919	534	18	with	with	ADP
gs-3919	534	19	eosinophilia	eosinophilia	PROPN
gs-3919	534	20	and	and	CCONJ
gs-3919	534	21	systemic	systemic	ADJ
gs-3919	534	22	symptoms	symptom	NOUN
gs-3919	534	23	(	(	PUNCT
gs-3919	534	24	dress	dress	NOUN
gs-3919	534	25	)	)	PUNCT
gs-3919	534	26	syndrome	syndrome	NOUN
gs-3919	534	27	:	:	PUNCT
gs-3919	534	28	a	a	DET
gs-3919	534	29	case	case	NOUN
gs-3919	534	30	report	report	NOUN
gs-3919	534	31	.	.	PUNCT
gs-3919	535	1	cureus	cureus	NOUN
gs-3919	535	2	.	.	PUNCT
gs-3919	536	1	5	5	X
gs-3919	536	2	.	.	X
gs-3919	536	3	liang	liang	PROPN
gs-3919	536	4	,	,	PUNCT
gs-3919	536	5	c.	c.	PROPN
gs-3919	536	6	,	,	PUNCT
gs-3919	536	7	an	an	PRON
gs-3919	536	8	,	,	PUNCT
gs-3919	536	9	p.	p.	PROPN
gs-3919	536	10	,	,	PUNCT
gs-3919	536	11	zhang	zhang	PROPN
gs-3919	536	12	,	,	PUNCT
gs-3919	536	13	y.	y.	PROPN
gs-3919	536	14	,	,	PUNCT
gs-3919	536	15	liu	liu	PROPN
gs-3919	536	16	,	,	PUNCT
gs-3919	536	17	x.	x.	PROPN
gs-3919	536	18	,	,	PUNCT
gs-3919	536	19	&	&	CCONJ
gs-3919	536	20	zhang	zhang	PROPN
gs-3919	536	21	,	,	PUNCT
gs-3919	536	22	b.	b.	PROPN
gs-3919	536	23	(	(	PUNCT
gs-3919	536	24	2024	2024	NUM
gs-3919	536	25	)	)	PUNCT
gs-3919	536	26	.	.	PUNCT
gs-3919	537	1	fatal	fatal	ADJ
gs-3919	537	2	outcome	outcome	NOUN
gs-3919	537	3	related	relate	VERB
gs-3919	537	4	to	to	ADP
gs-3919	537	5	drug	drug	NOUN
gs-3919	537	6	reaction	reaction	NOUN
gs-3919	537	7	with	with	ADP
gs-3919	537	8	eosinophilia	eosinophilia	PROPN
gs-3919	537	9	and	and	CCONJ
gs-3919	537	10	systemic	systemic	ADJ
gs-3919	537	11	symptoms	symptom	NOUN
gs-3919	537	12	:	:	PUNCT
gs-3919	537	13	a	a	DET
gs-3919	537	14	disproportionality	disproportionality	NOUN
gs-3919	537	15	analysis	analysis	NOUN
gs-3919	537	16	of	of	ADP
gs-3919	537	17	faers	faer	NOUN
gs-3919	537	18	database	database	NOUN
gs-3919	537	19	and	and	CCONJ
gs-3919	537	20	a	a	DET
gs-3919	537	21	systematic	systematic	ADJ
gs-3919	537	22	review	review	NOUN
gs-3919	537	23	of	of	ADP
gs-3919	537	24	cases	case	NOUN
gs-3919	537	25	.	.	PUNCT
gs-3919	538	1	frontiers	frontier	NOUN
gs-3919	538	2	in	in	ADP
gs-3919	538	3	immunology	immunology	NOUN
gs-3919	538	4	,	,	PUNCT
gs-3919	538	5	15	15	NUM
gs-3919	538	6	.	.	NOUN
gs-3919	538	7	6	6	NUM
gs-3919	538	8	.	.	X
gs-3919	539	1	loranger	loranger	ADV
gs-3919	539	2	,	,	PUNCT
gs-3919	539	3	n.	n.	NOUN
gs-3919	539	4	,	,	PUNCT
gs-3919	539	5	karn	karn	PROPN
gs-3919	539	6	,	,	PUNCT
gs-3919	539	7	e.	e.	PROPN
gs-3919	539	8	,	,	PUNCT
gs-3919	539	9	anderson	anderson	PROPN
gs-3919	539	10	,	,	PUNCT
gs-3919	539	11	j.	j.	PROPN
gs-3919	539	12	,	,	PUNCT
gs-3919	539	13	groover	groover	PROPN
gs-3919	539	14	,	,	PUNCT
gs-3919	539	15	m.	m.	NOUN
gs-3919	539	16	,	,	PUNCT
gs-3919	539	17	wang	wang	PROPN
gs-3919	539	18	,	,	PUNCT
gs-3919	539	19	d.	d.	PROPN
gs-3919	539	20	,	,	PUNCT
gs-3919	539	21	schmults	schmult	NOUN
gs-3919	539	22	,	,	PUNCT
gs-3919	539	23	c.	c.	NOUN
gs-3919	539	24	,	,	PUNCT
gs-3919	539	25	ruiz	ruiz	NOUN
gs-3919	539	26	,	,	PUNCT
gs-3919	539	27	e.	e.	PROPN
gs-3919	539	28	,	,	PUNCT
gs-3919	539	29	&	&	CCONJ
gs-3919	539	30	waldman	waldman	PROPN
gs-3919	539	31	,	,	PUNCT
gs-3919	539	32	a.	a.	NOUN
gs-3919	539	33	(	(	PUNCT
gs-3919	539	34	2024	2024	NUM
gs-3919	539	35	)	)	PUNCT
gs-3919	539	36	.	.	PUNCT
gs-3919	540	1	subcutaneous	subcutaneous	ADJ
gs-3919	540	2	injection	injection	NOUN
gs-3919	540	3	of	of	ADP
gs-3919	540	4	tranexamic	tranexamic	ADJ
gs-3919	540	5	acid	acid	NOUN
gs-3919	540	6	reduces	reduce	VERB
gs-3919	540	7	postoperative	postoperative	ADJ
gs-3919	540	8	bleeding	bleeding	NOUN
gs-3919	540	9	following	follow	VERB
gs-3919	540	10	mohs	mohs	PROPN
gs-3919	540	11	micrographic	micrographic	ADJ
gs-3919	540	12	surgery	surgery	NOUN
gs-3919	540	13	:	:	PUNCT
gs-3919	540	14	a	a	DET
gs-3919	540	15	single	single	ADJ
gs-3919	540	16	-	-	PUNCT
gs-3919	540	17	institution	institution	NOUN
gs-3919	540	18	cohort	cohort	NOUN
gs-3919	540	19	study	study	NOUN
gs-3919	540	20	.	.	PUNCT
gs-3919	541	1	journal	journal	NOUN
gs-3919	541	2	of	of	ADP
gs-3919	541	3	the	the	DET
gs-3919	541	4	american	american	PROPN
gs-3919	541	5	academy	academy	PROPN
gs-3919	541	6	of	of	ADP
gs-3919	541	7	dermatology	dermatology	NOUN
gs-3919	541	8	,	,	PUNCT
gs-3919	541	9	91(3	91(3	NUM
gs-3919	541	10	)	)	PUNCT
gs-3919	541	11	,	,	PUNCT
gs-3919	541	12	542–544	542–544	NUM
gs-3919	541	13	.	.	PUNCT
gs-3919	542	1	7	7	X
gs-3919	542	2	.	.	X
gs-3919	542	3	maideen	maideen	PROPN
gs-3919	542	4	,	,	PUNCT
gs-3919	542	5	n.	n.	PROPN
gs-3919	542	6	m.	m.	PROPN
gs-3919	542	7	p.	p.	PROPN
gs-3919	542	8	,	,	PUNCT
gs-3919	542	9	barakat	barakat	PROPN
gs-3919	542	10	,	,	PUNCT
gs-3919	542	11	i.	i.	PROPN
gs-3919	542	12	r.	r.	PROPN
gs-3919	542	13	,	,	PUNCT
gs-3919	542	14	&	&	CCONJ
gs-3919	542	15	jumale	jumale	PROPN
gs-3919	542	16	,	,	PUNCT
gs-3919	542	17	a.	a.	PROPN
gs-3919	542	18	h.	h.	PROPN
gs-3919	542	19	(	(	PUNCT
gs-3919	542	20	2023	2023	NUM
gs-3919	542	21	)	)	PUNCT
gs-3919	542	22	.	.	PUNCT
gs-3919	543	1	paracetamol	paracetamol	NOUN
gs-3919	543	2	(	(	PUNCT
gs-3919	543	3	acetaminophen)-associated	acetaminophen)-associated	PROPN
gs-3919	543	4	sjs	sjs	PROPN
gs-3919	543	5	,	,	PUNCT
gs-3919	543	6	ten	ten	NUM
gs-3919	543	7	,	,	PUNCT
gs-3919	543	8	agep	agep	NOUN
gs-3919	543	9	,	,	PUNCT
gs-3919	543	10	and	and	CCONJ
gs-3919	543	11	dress	dress	NOUN
gs-3919	543	12	syndromes	syndrome	NOUN
gs-3919	543	13	a	a	DET
gs-3919	543	14	narrative	narrative	NOUN
gs-3919	543	15	review	review	NOUN
gs-3919	543	16	.	.	PUNCT
gs-3919	544	1	current	current	ADJ
gs-3919	544	2	drug	drug	NOUN
gs-3919	544	3	safety	safety	NOUN
gs-3919	544	4	,	,	PUNCT
gs-3919	544	5	19(2	19(2	NUM
gs-3919	544	6	)	)	PUNCT
gs-3919	544	7	,	,	PUNCT
gs-3919	544	8	218–223	218–223	NUM
gs-3919	544	9	.	.	PUNCT
gs-3919	544	10	8	8	NUM
gs-3919	544	11	.	.	X
gs-3919	544	12	manieri	manieri	PROPN
gs-3919	544	13	,	,	PUNCT
gs-3919	544	14	e.	e.	PROPN
gs-3919	544	15	,	,	PUNCT
gs-3919	544	16	dondi	dondi	PROPN
gs-3919	544	17	,	,	PUNCT
gs-3919	544	18	a.	a.	PROPN
gs-3919	544	19	,	,	PUNCT
gs-3919	544	20	neri	neri	PROPN
gs-3919	544	21	,	,	PUNCT
gs-3919	544	22	i.	i.	PROPN
gs-3919	544	23	,	,	PUNCT
gs-3919	544	24	&	&	CCONJ
gs-3919	544	25	lanari	lanari	PROPN
gs-3919	544	26	,	,	PUNCT
gs-3919	544	27	m.	m.	NOUN
gs-3919	544	28	(	(	PUNCT
gs-3919	544	29	2023	2023	NUM
gs-3919	544	30	)	)	PUNCT
gs-3919	544	31	.	.	PUNCT
gs-3919	545	1	drug	drug	NOUN
gs-3919	545	2	rash	rash	NOUN
gs-3919	545	3	with	with	ADP
gs-3919	545	4	eosinophilia	eosinophilia	PROPN
gs-3919	545	5	and	and	CCONJ
gs-3919	545	6	systemic	systemic	ADJ
gs-3919	545	7	symptoms	symptom	NOUN
gs-3919	545	8	(	(	PUNCT
gs-3919	545	9	dress	dress	NOUN
gs-3919	545	10	)	)	PUNCT
gs-3919	545	11	syndrome	syndrome	NOUN
gs-3919	545	12	in	in	ADP
gs-3919	545	13	childhood	childhood	NOUN
gs-3919	545	14	:	:	PUNCT
gs-3919	545	15	a	a	DET
gs-3919	545	16	narrative	narrative	NOUN
gs-3919	545	17	review	review	NOUN
gs-3919	545	18	.	.	PUNCT
gs-3919	546	1	frontiers	frontier	NOUN
gs-3919	546	2	in	in	ADP
gs-3919	546	3	medicine	medicine	NOUN
gs-3919	546	4	,	,	PUNCT
gs-3919	546	5	10	10	NUM
gs-3919	546	6	.	.	NOUN
gs-3919	546	7	9	9	NUM
gs-3919	546	8	.	.	X
gs-3919	547	1	maris	maris	PROPN
gs-3919	547	2	,	,	PUNCT
gs-3919	547	3	b.	b.	PROPN
gs-3919	547	4	r.	r.	PROPN
gs-3919	547	5	,	,	PUNCT
gs-3919	547	6	grama	grama	PROPN
gs-3919	547	7	,	,	PUNCT
gs-3919	547	8	a.	a.	PROPN
gs-3919	547	9	,	,	PUNCT
gs-3919	547	10	&	&	CCONJ
gs-3919	547	11	pop	pop	PROPN
gs-3919	547	12	,	,	PUNCT
gs-3919	547	13	t.	t.	PROPN
gs-3919	547	14	l.	l.	PROPN
gs-3919	547	15	(	(	PUNCT
gs-3919	547	16	2025	2025	NUM
gs-3919	547	17	)	)	PUNCT
gs-3919	547	18	.	.	PUNCT
gs-3919	548	1	drug	drug	NOUN
gs-3919	548	2	-	-	PUNCT
gs-3919	548	3	induced	induce	VERB
gs-3919	548	4	liver	liver	NOUN
gs-3919	548	5	injury	injury	NOUN
gs-3919	548	6	—	—	PUNCT
gs-3919	548	7	pharmacological	pharmacological	NOUN
gs-3919	548	8	spectrum	spectrum	NOUN
gs-3919	548	9	among	among	ADP
gs-3919	548	10	children	child	NOUN
gs-3919	548	11	.	.	PUNCT
gs-3919	549	1	international	international	ADJ
gs-3919	549	2	journal	journal	NOUN
gs-3919	549	3	of	of	ADP
gs-3919	549	4	molecular	molecular	ADJ
gs-3919	549	5	sciences	science	NOUN
gs-3919	549	6	,	,	PUNCT
gs-3919	549	7	26(5	26(5	NUM
gs-3919	549	8	)	)	PUNCT
gs-3919	549	9	,	,	PUNCT
gs-3919	549	10	2006	2006	NUM
gs-3919	549	11	.	.	PUNCT
gs-3919	550	1	10	10	NUM
gs-3919	550	2	.	.	PUNCT
gs-3919	551	1	martin	martin	PROPN
gs-3919	551	2	,	,	PUNCT
gs-3919	551	3	g.	g.	PROPN
gs-3919	551	4	,	,	PUNCT
gs-3919	551	5	lambert	lambert	PROPN
gs-3919	551	6	,	,	PUNCT
gs-3919	551	7	e.	e.	PROPN
gs-3919	551	8	,	,	PUNCT
gs-3919	551	9	&	&	CCONJ
gs-3919	551	10	wang	wang	PROPN
gs-3919	551	11	,	,	PUNCT
gs-3919	551	12	g.	g.	PROPN
gs-3919	551	13	k.	k.	PROPN
gs-3919	551	14	(	(	PUNCT
gs-3919	551	15	2023	2023	NUM
gs-3919	551	16	)	)	PUNCT
gs-3919	551	17	.	.	PUNCT
gs-3919	552	1	drug	drug	NOUN
gs-3919	552	2	reaction	reaction	NOUN
gs-3919	552	3	with	with	ADP
gs-3919	552	4	eosinophilia	eosinophilia	PROPN
gs-3919	552	5	and	and	CCONJ
gs-3919	552	6	systemic	systemic	ADJ
gs-3919	552	7	symptoms	symptom	NOUN
gs-3919	552	8	(	(	PUNCT
gs-3919	552	9	dress	dress	NOUN
gs-3919	552	10	)	)	PUNCT
gs-3919	552	11	syndrome	syndrome	NOUN
gs-3919	552	12	caused	cause	VERB
gs-3919	552	13	by	by	ADP
gs-3919	552	14	apalutamide	apalutamide	ADJ
gs-3919	552	15	:	:	PUNCT
gs-3919	552	16	a	a	DET
gs-3919	552	17	case	case	NOUN
gs-3919	552	18	presentation	presentation	NOUN
gs-3919	552	19	.	.	PUNCT
gs-3919	553	1	cureus	cureus	NOUN
gs-3919	553	2	.	.	PUNCT
gs-3919	554	1	georgian	georgian	ADJ
gs-3919	554	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	554	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	554	4	ტ.	ტ.	VERB
gs-3919	554	5	7	7	NUM
gs-3919	554	6	n	n	PRON
gs-3919	554	7	3	3	NUM
gs-3919	554	8	,	,	PUNCT
gs-3919	554	9	2025	2025	NUM
gs-3919	554	10	174	174	NUM
gs-3919	554	11	https://doi.org/10.7759/cureus.41687	https://doi.org/10.7759/cureus.41687	PROPN
gs-3919	554	12	martin	martin	PROPN
gs-3919	554	13	,	,	PUNCT
gs-3919	554	14	g.	g.	PROPN
gs-3919	554	15	,	,	PUNCT
gs-3919	554	16	lambert	lambert	PROPN
gs-3919	554	17	,	,	PUNCT
gs-3919	554	18	e.	e.	PROPN
gs-3919	554	19	,	,	PUNCT
gs-3919	554	20	&	&	CCONJ
gs-3919	554	21	wang	wang	PROPN
gs-3919	554	22	,	,	PUNCT
gs-3919	554	23	g.	g.	PROPN
gs-3919	554	24	k.	k.	PROPN
gs-3919	554	25	(	(	PUNCT
gs-3919	554	26	2023	2023	NUM
gs-3919	554	27	)	)	PUNCT
gs-3919	554	28	.	.	PUNCT
gs-3919	555	1	drug	drug	NOUN
gs-3919	555	2	reaction	reaction	NOUN
gs-3919	555	3	with	with	ADP
gs-3919	555	4	eosinophilia	eosinophilia	PROPN
gs-3919	555	5	and	and	CCONJ
gs-3919	555	6	systemic	systemic	ADJ
gs-3919	555	7	symptoms	symptom	NOUN
gs-3919	555	8	(	(	PUNCT
gs-3919	555	9	dress	dress	NOUN
gs-3919	555	10	)	)	PUNCT
gs-3919	555	11	syndrome	syndrome	NOUN
gs-3919	555	12	caused	cause	VERB
gs-3919	555	13	by	by	ADP
gs-3919	555	14	apalutamide	apalutamide	ADJ
gs-3919	555	15	:	:	PUNCT
gs-3919	555	16	a	a	DET
gs-3919	555	17	case	case	NOUN
gs-3919	555	18	presentation	presentation	NOUN
gs-3919	555	19	.	.	PUNCT
gs-3919	556	1	cureus	cureus	NOUN
gs-3919	556	2	.	.	PUNCT
gs-3919	557	1	11	11	NUM
gs-3919	557	2	.	.	PUNCT
gs-3919	558	1	martins	martin	NOUN
gs-3919	558	2	,	,	PUNCT
gs-3919	558	3	j.	j.	PROPN
gs-3919	558	4	c.	c.	PROPN
gs-3919	558	5	,	,	PUNCT
gs-3919	558	6	seque	seque	PROPN
gs-3919	558	7	,	,	PUNCT
gs-3919	558	8	c.	c.	PROPN
gs-3919	558	9	a.	a.	PROPN
gs-3919	558	10	,	,	PUNCT
gs-3919	558	11	&	&	CCONJ
gs-3919	558	12	porro	porro	PROPN
gs-3919	558	13	,	,	PUNCT
gs-3919	558	14	a.	a.	NOUN
gs-3919	558	15	m.	m.	NOUN
gs-3919	558	16	(	(	PUNCT
gs-3919	558	17	2022	2022	NUM
gs-3919	558	18	)	)	PUNCT
gs-3919	558	19	.	.	PUNCT
gs-3919	559	1	clinical	clinical	ADJ
gs-3919	559	2	aspects	aspect	NOUN
gs-3919	559	3	and	and	CCONJ
gs-3919	559	4	therapeutic	therapeutic	ADJ
gs-3919	559	5	approach	approach	NOUN
gs-3919	559	6	of	of	ADP
gs-3919	559	7	drug	drug	NOUN
gs-3919	559	8	-	-	PUNCT
gs-3919	559	9	induced	induce	VERB
gs-3919	559	10	adverse	adverse	ADJ
gs-3919	559	11	skin	skin	NOUN
gs-3919	559	12	reactions	reaction	NOUN
gs-3919	559	13	in	in	ADP
gs-3919	559	14	a	a	DET
gs-3919	559	15	quaternary	quaternary	ADJ
gs-3919	559	16	hospital	hospital	NOUN
gs-3919	559	17	:	:	PUNCT
gs-3919	559	18	a	a	DET
gs-3919	559	19	retrospective	retrospective	ADJ
gs-3919	559	20	study	study	NOUN
gs-3919	559	21	with	with	ADP
gs-3919	559	22	219	219	NUM
gs-3919	559	23	cases	case	NOUN
gs-3919	559	24	.	.	PUNCT
gs-3919	560	1	anais	anais	PROPN
gs-3919	560	2	brasileiros	brasileiros	PROPN
gs-3919	560	3	de	de	PROPN
gs-3919	560	4	dermatologia	dermatologia	PROPN
gs-3919	560	5	,	,	PUNCT
gs-3919	560	6	97(3	97(3	NUM
gs-3919	560	7	)	)	PUNCT
gs-3919	560	8	,	,	PUNCT
gs-3919	560	9	284–290	284–290	NUM
gs-3919	560	10	.	.	PUNCT
gs-3919	561	1	12	12	NUM
gs-3919	561	2	.	.	PUNCT
gs-3919	562	1	miyagawa	miyagawa	PROPN
gs-3919	562	2	,	,	PUNCT
gs-3919	562	3	f.	f.	PROPN
gs-3919	562	4	,	,	PUNCT
gs-3919	562	5	mizukawa	mizukawa	PROPN
gs-3919	562	6	,	,	PUNCT
gs-3919	562	7	y.	y.	PROPN
gs-3919	562	8	,	,	PUNCT
gs-3919	562	9	hayashino	hayashino	PROPN
gs-3919	562	10	,	,	PUNCT
gs-3919	562	11	y.	y.	PROPN
gs-3919	562	12	,	,	PUNCT
gs-3919	562	13	nakamura	nakamura	NOUN
gs-3919	562	14	-	-	PUNCT
gs-3919	562	15	nishimura	nishimura	PROPN
gs-3919	562	16	,	,	PUNCT
gs-3919	562	17	y.	y.	PROPN
gs-3919	562	18	,	,	PUNCT
gs-3919	562	19	&	&	CCONJ
gs-3919	562	20	asada	asada	PROPN
gs-3919	562	21	,	,	PUNCT
gs-3919	562	22	h.	h.	PROPN
gs-3919	562	23	(	(	PUNCT
gs-3919	562	24	2025	2025	NUM
gs-3919	562	25	)	)	PUNCT
gs-3919	562	26	.	.	PUNCT
gs-3919	563	1	risk	risk	NOUN
gs-3919	563	2	factors	factor	NOUN
gs-3919	563	3	associated	associate	VERB
gs-3919	563	4	with	with	ADP
gs-3919	563	5	cytomegalovirus	cytomegalovirus	NOUN
gs-3919	563	6	infection	infection	NOUN
gs-3919	563	7	in	in	ADP
gs-3919	563	8	patients	patient	NOUN
gs-3919	563	9	with	with	ADP
gs-3919	563	10	druginduced	druginduced	ADJ
gs-3919	563	11	hypersensitivity	hypersensitivity	NOUN
gs-3919	563	12	syndrome	syndrome	NOUN
gs-3919	563	13	/	/	SYM
gs-3919	563	14	drug	drug	NOUN
gs-3919	563	15	rash	rash	NOUN
gs-3919	563	16	with	with	ADP
gs-3919	563	17	eosinophilia	eosinophilia	PROPN
gs-3919	563	18	and	and	CCONJ
gs-3919	563	19	systemic	systemic	ADJ
gs-3919	563	20	symptoms	symptom	NOUN
gs-3919	563	21	(	(	PUNCT
gs-3919	563	22	dihs	dihs	NOUN
gs-3919	563	23	/	/	SYM
gs-3919	563	24	dress	dress	NOUN
gs-3919	563	25	):	):	PUNCT
gs-3919	563	26	comparison	comparison	NOUN
gs-3919	563	27	with	with	ADP
gs-3919	563	28	a	a	DET
gs-3919	563	29	population	population	NOUN
gs-3919	563	30	with	with	ADP
gs-3919	563	31	drug	drug	NOUN
gs-3919	563	32	eruptions	eruption	NOUN
gs-3919	563	33	.	.	PUNCT
gs-3919	564	1	jaad	jaad	PROPN
gs-3919	564	2	international	international	PROPN
gs-3919	564	3	.	.	PUNCT
gs-3919	565	1	13	13	NUM
gs-3919	565	2	.	.	PUNCT
gs-3919	565	3	moshayedi	moshayedi	PROPN
gs-3919	565	4	,	,	PUNCT
gs-3919	565	5	m.	m.	NOUN
gs-3919	565	6	a.	a.	PROPN
gs-3919	565	7	,	,	PUNCT
gs-3919	565	8	asilian	asilian	PROPN
gs-3919	565	9	,	,	PUNCT
gs-3919	565	10	a.	a.	NOUN
gs-3919	565	11	,	,	PUNCT
gs-3919	565	12	&	&	CCONJ
gs-3919	565	13	mokhtari	mokhtari	PROPN
gs-3919	565	14	,	,	PUNCT
gs-3919	565	15	f.	f.	PROPN
gs-3919	565	16	(	(	PUNCT
gs-3919	565	17	2024	2024	NUM
gs-3919	565	18	)	)	PUNCT
gs-3919	565	19	.	.	PUNCT
gs-3919	566	1	evaluation	evaluation	NOUN
gs-3919	566	2	of	of	ADP
gs-3919	566	3	severe	severe	ADJ
gs-3919	566	4	adverse	adverse	ADJ
gs-3919	566	5	cutaneous	cutaneous	ADJ
gs-3919	566	6	drug	drug	NOUN
gs-3919	566	7	reactions	reaction	NOUN
gs-3919	566	8	in	in	ADP
gs-3919	566	9	patients	patient	NOUN
gs-3919	566	10	admitted	admit	VERB
gs-3919	566	11	to	to	ADP
gs-3919	566	12	tertiary	tertiary	ADJ
gs-3919	566	13	care	care	NOUN
gs-3919	566	14	center	center	NOUN
gs-3919	566	15	:	:	PUNCT
gs-3919	566	16	a	a	DET
gs-3919	566	17	cross‐sectional	cross‐sectional	ADJ
gs-3919	566	18	study	study	NOUN
gs-3919	566	19	.	.	PUNCT
gs-3919	567	1	health	health	NOUN
gs-3919	567	2	science	science	PROPN
gs-3919	567	3	reports	report	NOUN
gs-3919	567	4	,	,	PUNCT
gs-3919	567	5	7(3	7(3	NUM
gs-3919	567	6	)	)	PUNCT
gs-3919	567	7	.	.	PUNCT
gs-3919	568	1	14	14	NUM
gs-3919	568	2	.	.	PUNCT
gs-3919	569	1	mustafa	mustafa	PROPN
gs-3919	569	2	,	,	PUNCT
gs-3919	569	3	s.	s.	PROPN
gs-3919	569	4	f.	f.	PROPN
gs-3919	569	5	,	,	PUNCT
gs-3919	569	6	zafar	zafar	PROPN
gs-3919	569	7	,	,	PUNCT
gs-3919	569	8	m.	m.	PROPN
gs-3919	569	9	r.	r.	PROPN
gs-3919	569	10	,	,	PUNCT
gs-3919	569	11	&	&	CCONJ
gs-3919	569	12	miller	miller	PROPN
gs-3919	569	13	,	,	PUNCT
gs-3919	569	14	t.	t.	PROPN
gs-3919	569	15	w.	w.	PROPN
gs-3919	569	16	(	(	PUNCT
gs-3919	569	17	2020	2020	NUM
gs-3919	569	18	)	)	PUNCT
gs-3919	569	19	.	.	PUNCT
gs-3919	570	1	rosuvastatin	rosuvastatin	ADJ
gs-3919	570	2	use	use	NOUN
gs-3919	570	3	implicated	implicate	VERB
gs-3919	570	4	in	in	ADP
gs-3919	570	5	the	the	DET
gs-3919	570	6	drug	drug	NOUN
gs-3919	570	7	reaction	reaction	NOUN
gs-3919	570	8	with	with	ADP
gs-3919	570	9	eosinophilia	eosinophilia	PROPN
gs-3919	570	10	and	and	CCONJ
gs-3919	570	11	systemic	systemic	ADJ
gs-3919	570	12	symptoms	symptom	NOUN
gs-3919	570	13	.	.	PUNCT
gs-3919	571	1	cureus	cureus	NOUN
gs-3919	571	2	.	.	PUNCT
gs-3919	572	1	15	15	NUM
gs-3919	572	2	.	.	PUNCT
gs-3919	573	1	nafil	nafil	PROPN
gs-3919	573	2	,	,	PUNCT
gs-3919	573	3	h.	h.	PROPN
gs-3919	573	4	,	,	PUNCT
gs-3919	573	5	tazi	tazi	NOUN
gs-3919	573	6	,	,	PUNCT
gs-3919	573	7	i.	i.	PROPN
gs-3919	573	8	,	,	PUNCT
gs-3919	573	9	sifessalam	sifessalam	PROPN
gs-3919	573	10	,	,	PUNCT
gs-3919	573	11	m.	m.	NOUN
gs-3919	573	12	,	,	PUNCT
gs-3919	573	13	bouchtia	bouchtia	PROPN
gs-3919	573	14	,	,	PUNCT
gs-3919	573	15	m.	m.	NOUN
gs-3919	573	16	,	,	PUNCT
gs-3919	573	17	&	&	CCONJ
gs-3919	573	18	mahmal	mahmal	PROPN
gs-3919	573	19	,	,	PUNCT
gs-3919	573	20	l.	l.	PROPN
gs-3919	573	21	(	(	PUNCT
gs-3919	573	22	2012	2012	NUM
gs-3919	573	23	)	)	PUNCT
gs-3919	573	24	.	.	PUNCT
gs-3919	574	1	dress	dress	NOUN
gs-3919	574	2	syndrome	syndrome	PROPN
gs-3919	574	3	induit	induit	PROPN
gs-3919	574	4	par	par	PROPN
gs-3919	574	5	l’ibuprofène	l’ibuprofène	PROPN
gs-3919	574	6	révélé	révélé	PROPN
gs-3919	574	7	par	par	PROPN
gs-3919	574	8	un	un	PROPN
gs-3919	574	9	ictère	ictère	PROPN
gs-3919	574	10	fébrile	fébrile	PROPN
gs-3919	574	11	.	.	PUNCT
gs-3919	575	1	journal	journal	PROPN
gs-3919	575	2	africain	africain	PROPN
gs-3919	575	3	d	d	PROPN
gs-3919	575	4	hépatogastroentérologie	hépatogastroentérologie	NOUN
gs-3919	575	5	,	,	PUNCT
gs-3919	575	6	6(2	6(2	NUM
gs-3919	575	7	)	)	PUNCT
gs-3919	575	8	,	,	PUNCT
gs-3919	575	9	85–86	85–86	NUM
gs-3919	575	10	.	.	PUNCT
gs-3919	575	11	16	16	NUM
gs-3919	575	12	.	.	PUNCT
gs-3919	576	1	nam	nam	PROPN
gs-3919	576	2	,	,	PUNCT
gs-3919	576	3	y.	y.	PROPN
gs-3919	576	4	,	,	PUNCT
gs-3919	576	5	park	park	NOUN
gs-3919	576	6	,	,	PUNCT
gs-3919	576	7	nam	nam	PROPN
gs-3919	576	8	,	,	PUNCT
gs-3919	576	9	h.	h.	PROPN
gs-3919	576	10	,	,	PUNCT
gs-3919	576	11	lee	lee	PROPN
gs-3919	576	12	,	,	PUNCT
gs-3919	576	13	s.	s.	PROPN
gs-3919	576	14	,	,	PUNCT
gs-3919	576	15	kim	kim	PROPN
gs-3919	576	16	,	,	PUNCT
gs-3919	576	17	k.	k.	PROPN
gs-3919	576	18	,	,	PUNCT
gs-3919	576	19	roh	roh	PROPN
gs-3919	576	20	,	,	PUNCT
gs-3919	576	21	um	um	INTJ
gs-3919	576	22	,	,	PUNCT
gs-3919	576	23	s.	s.	PROPN
gs-3919	576	24	,	,	PUNCT
gs-3919	576	25	&	&	CCONJ
gs-3919	576	26	son	son	PROPN
gs-3919	576	27	,	,	PUNCT
gs-3919	576	28	c.	c.	PROPN
gs-3919	576	29	(	(	PUNCT
gs-3919	576	30	2014	2014	NUM
gs-3919	576	31	)	)	PUNCT
gs-3919	576	32	.	.	PUNCT
gs-3919	577	1	drug	drug	NOUN
gs-3919	577	2	reaction	reaction	NOUN
gs-3919	577	3	with	with	ADP
gs-3919	577	4	eosinophilia	eosinophilia	PROPN
gs-3919	577	5	and	and	CCONJ
gs-3919	577	6	systemic	systemic	ADJ
gs-3919	577	7	symptoms	symptom	NOUN
gs-3919	577	8	syndrome	syndrome	NOUN
gs-3919	577	9	is	be	AUX
gs-3919	577	10	not	not	PART
gs-3919	577	11	uncommon	uncommon	ADJ
gs-3919	577	12	and	and	CCONJ
gs-3919	577	13	shows	show	VERB
gs-3919	577	14	better	well	ADJ
gs-3919	577	15	clinical	clinical	ADJ
gs-3919	577	16	outcome	outcome	NOUN
gs-3919	577	17	than	than	SCONJ
gs-3919	577	18	generally	generally	ADV
gs-3919	577	19	recognised	recognise	VERB
gs-3919	577	20	.	.	PUNCT
gs-3919	578	1	allergologia	allergologia	PROPN
gs-3919	578	2	et	et	PROPN
gs-3919	578	3	immunopathologia	immunopathologia	PROPN
gs-3919	578	4	,	,	PUNCT
gs-3919	578	5	43(1	43(1	NOUN
gs-3919	578	6	)	)	PUNCT
gs-3919	578	7	,	,	PUNCT
gs-3919	578	8	19–24	19–24	NUM
gs-3919	578	9	.	.	PUNCT
gs-3919	579	1	17	17	NUM
gs-3919	579	2	.	.	PUNCT
gs-3919	580	1	nguyen	nguyen	PROPN
gs-3919	580	2	,	,	PUNCT
gs-3919	580	3	k.	k.	PROPN
gs-3919	580	4	,	,	PUNCT
gs-3919	580	5	&	&	CCONJ
gs-3919	580	6	ahmed	ahmed	PROPN
gs-3919	580	7	,	,	PUNCT
gs-3919	580	8	m.	m.	NOUN
gs-3919	580	9	s.	s.	PROPN
gs-3919	580	10	(	(	PUNCT
gs-3919	580	11	2018	2018	NUM
gs-3919	580	12	)	)	PUNCT
gs-3919	580	13	.	.	PUNCT
gs-3919	581	1	drug	drug	NOUN
gs-3919	581	2	rash	rash	NOUN
gs-3919	581	3	with	with	ADP
gs-3919	581	4	eosinophilia	eosinophilia	PROPN
gs-3919	581	5	and	and	CCONJ
gs-3919	581	6	systemic	systemic	ADJ
gs-3919	581	7	symptoms	symptom	NOUN
gs-3919	581	8	syndrome	syndrome	VERB
gs-3919	581	9	presenting	present	VERB
gs-3919	581	10	after	after	ADP
gs-3919	581	11	the	the	DET
gs-3919	581	12	initiation	initiation	NOUN
gs-3919	581	13	of	of	ADP
gs-3919	581	14	staphylococcus	staphylococcus	NOUN
gs-3919	581	15	hominis	hominis	PROPN
gs-3919	581	16	infectious	infectious	ADJ
gs-3919	581	17	endocarditis	endocarditis	ADJ
gs-3919	581	18	treatment	treatment	NOUN
gs-3919	581	19	:	:	PUNCT
gs-3919	581	20	a	a	DET
gs-3919	581	21	18	18	NUM
gs-3919	581	22	.	.	PUNCT
gs-3919	582	1	nova	nova	PROPN
gs-3919	582	2	,	,	PUNCT
gs-3919	582	3	v.	v.	PROPN
gs-3919	582	4	v.	v.	ADJ
gs-3919	582	5	,	,	PUNCT
gs-3919	582	6	cotta	cotta	NOUN
gs-3919	582	7	,	,	PUNCT
gs-3919	582	8	c.	c.	NOUN
gs-3919	582	9	,	,	PUNCT
gs-3919	582	10	da	da	PROPN
gs-3919	582	11	ponte	ponte	PROPN
gs-3919	582	12	,	,	PUNCT
gs-3919	582	13	g.	g.	PROPN
gs-3919	582	14	,	,	PUNCT
gs-3919	582	15	&	&	CCONJ
gs-3919	582	16	mendes	mende	NOUN
gs-3919	582	17	,	,	PUNCT
gs-3919	582	18	s.	s.	PROPN
gs-3919	582	19	(	(	PUNCT
gs-3919	582	20	2013	2013	NUM
gs-3919	582	21	)	)	PUNCT
gs-3919	582	22	.	.	PUNCT
gs-3919	583	1	1738	1738	NUM
gs-3919	583	2	–	–	PUNCT
gs-3919	583	3	the	the	DET
gs-3919	583	4	lethal	lethal	ADJ
gs-3919	583	5	potential	potential	NOUN
gs-3919	583	6	of	of	ADP
gs-3919	583	7	lamotrigine	lamotrigine	ADJ
gs-3919	583	8	dress	dress	NOUN
gs-3919	583	9	syndrome	syndrome	NOUN
gs-3919	583	10	.	.	PUNCT
gs-3919	584	1	european	european	ADJ
gs-3919	584	2	psychiatry	psychiatry	PROPN
gs-3919	584	3	,	,	PUNCT
gs-3919	584	4	28	28	NUM
gs-3919	584	5	,	,	PUNCT
gs-3919	584	6	1	1	NUM
gs-3919	584	7	.	.	PUNCT
gs-3919	584	8	o’keefe	o’keefe	PROPN
gs-3919	584	9	,	,	PUNCT
gs-3919	584	10	l.	l.	PROPN
gs-3919	584	11	j.	j.	PROPN
gs-3919	584	12	,	,	PUNCT
gs-3919	584	13	&	&	CCONJ
gs-3919	584	14	burtson	burtson	PROPN
gs-3919	584	15	,	,	PUNCT
gs-3919	584	16	k.	k.	PROPN
gs-3919	584	17	m.	m.	PROPN
gs-3919	584	18	(	(	PUNCT
gs-3919	584	19	2023	2023	NUM
gs-3919	584	20	)	)	PUNCT
gs-3919	584	21	.	.	PUNCT
gs-3919	585	1	a	a	DET
gs-3919	585	2	case	case	NOUN
gs-3919	585	3	of	of	ADP
gs-3919	585	4	primary	primary	ADJ
gs-3919	585	5	epstein	epstein	PROPN
gs-3919	585	6	-	-	PUNCT
gs-3919	585	7	barr	barr	PROPN
gs-3919	585	8	virus	virus	PROPN
gs-3919	585	9	infection	infection	NOUN
gs-3919	585	10	masquerading	masquerade	VERB
gs-3919	585	11	as	as	ADP
gs-3919	585	12	drug	drug	NOUN
gs-3919	585	13	reaction	reaction	NOUN
gs-3919	585	14	with	with	ADP
gs-3919	585	15	eosinophilia	eosinophilia	PROPN
gs-3919	585	16	and	and	CCONJ
gs-3919	585	17	systemic	systemic	ADJ
gs-3919	585	18	symptoms	symptom	NOUN
gs-3919	585	19	.	.	PUNCT
gs-3919	586	1	cureus	cureus	NOUN
gs-3919	586	2	.	.	PUNCT
gs-3919	587	1	19	19	NUM
gs-3919	587	2	.	.	X
gs-3919	587	3	aphkhazava	aphkhazava	PROPN
gs-3919	587	4	,	,	PUNCT
gs-3919	587	5	david	david	PROPN
gs-3919	587	6	,	,	PUNCT
gs-3919	587	7	nodar	nodar	NOUN
gs-3919	587	8	sulashvili	sulashvili	NOUN
gs-3919	587	9	,	,	PUNCT
gs-3919	587	10	and	and	CCONJ
gs-3919	587	11	jaba	jaba	PROPN
gs-3919	587	12	tkemaladze	tkemaladze	PROPN
gs-3919	587	13	.	.	PUNCT
gs-3919	588	1	2025	2025	NUM
gs-3919	588	2	.	.	PUNCT
gs-3919	589	1	“	"	PUNCT
gs-3919	589	2	stem	stem	NOUN
gs-3919	589	3	cell	cell	NOUN
gs-3919	589	4	systems	system	NOUN
gs-3919	589	5	and	and	CCONJ
gs-3919	589	6	regeneration	regeneration	NOUN
gs-3919	589	7	”	"	PUNCT
gs-3919	589	8	.	.	PUNCT
gs-3919	590	1	georgian	georgian	PROPN
gs-3919	590	2	scientists	scientist	NOUN
gs-3919	590	3	7	7	NUM
gs-3919	590	4	(	(	PUNCT
gs-3919	590	5	1):271	1):271	NUM
gs-3919	590	6	-	-	SYM
gs-3919	590	7	319	319	NUM
gs-3919	590	8	.	.	PUNCT
gs-3919	591	1	https://doi.org/10.52340/gs.2025.07.01.26	https://doi.org/10.52340/gs.2025.07.01.26	NOUN
gs-3919	591	2	.	.	NOUN
gs-3919	591	3	20	20	NUM
gs-3919	591	4	.	.	X
gs-3919	591	5	aphkhazava	aphkhazava	PROPN
gs-3919	591	6	,	,	PUNCT
gs-3919	591	7	d.	d.	PROPN
gs-3919	591	8	,	,	PUNCT
gs-3919	591	9	sulashvili	sulashvili	NOUN
gs-3919	591	10	,	,	PUNCT
gs-3919	591	11	n.	n.	NOUN
gs-3919	591	12	,	,	PUNCT
gs-3919	591	13	tupinashvili	tupinashvili	NOUN
gs-3919	591	14	,	,	PUNCT
gs-3919	591	15	t.	t.	PROPN
gs-3919	591	16	,	,	PUNCT
gs-3919	591	17	&	&	CCONJ
gs-3919	591	18	nozadze	nozadze	NOUN
gs-3919	591	19	,	,	PUNCT
gs-3919	591	20	m.	m.	NOUN
gs-3919	591	21	(	(	PUNCT
gs-3919	591	22	2024	2024	NUM
gs-3919	591	23	)	)	PUNCT
gs-3919	591	24	.	.	PUNCT
gs-3919	592	1	dynamic	dynamic	ADJ
gs-3919	592	2	cellular	cellular	ADJ
gs-3919	592	3	equilibrium	equilibrium	NOUN
gs-3919	592	4	theory	theory	NOUN
gs-3919	592	5	of	of	ADP
gs-3919	592	6	aging	aging	NOUN
gs-3919	592	7	:	:	PUNCT
gs-3919	592	8	integrating	integrate	VERB
gs-3919	592	9	maintenance	maintenance	NOUN
gs-3919	592	10	and	and	CCONJ
gs-3919	592	11	accumulation	accumulation	NOUN
gs-3919	592	12	in	in	ADP
gs-3919	592	13	the	the	DET
gs-3919	592	14	aging	age	VERB
gs-3919	592	15	process	process	NOUN
gs-3919	592	16	.	.	PUNCT
gs-3919	593	1	scientific	scientific	ADJ
gs-3919	593	2	journal	journal	NOUN
gs-3919	593	3	„	„	PUNCT
gs-3919	593	4	spectri	spectri	NOUN
gs-3919	593	5	“	"	PUNCT
gs-3919	593	6	,	,	PUNCT
gs-3919	593	7	8(2	8(2	NUM
gs-3919	593	8	)	)	PUNCT
gs-3919	593	9	.	.	PUNCT
gs-3919	594	1	https://doi.org/10.52340/spectri.2023.08.02.03	https://doi.org/10.52340/spectri.2023.08.02.03	PROPN
gs-3919	594	2	21	21	NUM
gs-3919	594	3	.	.	PUNCT
gs-3919	595	1	aphkhazava	aphkhazava	PROPN
gs-3919	595	2	,	,	PUNCT
gs-3919	595	3	d.	d.	PROPN
gs-3919	595	4	,	,	PUNCT
gs-3919	595	5	tuphinashvili	tuphinashvili	NOUN
gs-3919	595	6	,	,	PUNCT
gs-3919	595	7	t.	t.	NOUN
gs-3919	595	8	,	,	PUNCT
gs-3919	595	9	sulashvili	sulashvili	NOUN
gs-3919	595	10	,	,	PUNCT
gs-3919	595	11	n.	n.	NOUN
gs-3919	595	12	,	,	PUNCT
gs-3919	595	13	&	&	CCONJ
gs-3919	595	14	nozadze	nozadze	NOUN
gs-3919	595	15	,	,	PUNCT
gs-3919	595	16	m.	m.	NOUN
gs-3919	595	17	(	(	PUNCT
gs-3919	595	18	2023	2023	NUM
gs-3919	595	19	)	)	PUNCT
gs-3919	595	20	.	.	PUNCT
gs-3919	596	1	the	the	DET
gs-3919	596	2	features	feature	NOUN
gs-3919	596	3	and	and	CCONJ
gs-3919	596	4	role	role	NOUN
gs-3919	596	5	of	of	ADP
gs-3919	596	6	shp2	shp2	ADJ
gs-3919	596	7	protein	protein	NOUN
gs-3919	596	8	in	in	ADP
gs-3919	596	9	postnatal	postnatal	ADJ
gs-3919	596	10	muscle	muscle	NOUN
gs-3919	596	11	development	development	NOUN
gs-3919	596	12	.	.	PUNCT
gs-3919	597	1	scientific	scientific	ADJ
gs-3919	597	2	journal	journal	NOUN
gs-3919	597	3	„	„	PUNCT
gs-3919	597	4	spectri	spectri	NOUN
gs-3919	597	5	“	"	PUNCT
gs-3919	597	6	,	,	PUNCT
gs-3919	597	7	1	1	X
gs-3919	597	8	.	.	PUNCT
gs-3919	598	1	https://doi.org/10.52340/spectri.2023.01	https://doi.org/10.52340/spectri.2023.01	DET
gs-3919	598	2	georgian	georgian	ADJ
gs-3919	598	3	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	598	4	მეცნიერები	მეცნიერები	NOUN
gs-3919	598	5	ტ.	ტ.	VERB
gs-3919	598	6	7	7	NUM
gs-3919	598	7	n	n	DET
gs-3919	598	8	3	3	NUM
gs-3919	598	9	,	,	PUNCT
gs-3919	598	10	2025	2025	NUM
gs-3919	598	11	175	175	NUM
gs-3919	598	12	22	22	NUM
gs-3919	598	13	.	.	PUNCT
gs-3919	599	1	sulashvili	sulashvili	NOUN
gs-3919	599	2	,	,	PUNCT
gs-3919	599	3	n.	n.	NOUN
gs-3919	599	4	,	,	PUNCT
gs-3919	599	5	beglaryan	beglaryan	ADJ
gs-3919	599	6	,	,	PUNCT
gs-3919	599	7	m.	m.	NOUN
gs-3919	599	8	,	,	PUNCT
gs-3919	599	9	gorgaslidze	gorgaslidze	PROPN
gs-3919	599	10	,	,	PUNCT
gs-3919	599	11	n.	n.	PROPN
gs-3919	599	12	,	,	PUNCT
gs-3919	599	13	kocharyan	kocharyan	PROPN
gs-3919	599	14	,	,	PUNCT
gs-3919	599	15	s.	s.	PROPN
gs-3919	599	16	,	,	PUNCT
gs-3919	599	17	chichoyan	chichoyan	PROPN
gs-3919	599	18	,	,	PUNCT
gs-3919	599	19	n.	n.	NOUN
gs-3919	599	20	,	,	PUNCT
gs-3919	599	21	gabunia	gabunia	NOUN
gs-3919	599	22	,	,	PUNCT
gs-3919	599	23	l.	l.	PROPN
gs-3919	599	24	,	,	PUNCT
gs-3919	599	25	zarnadze	zarnadze	PROPN
gs-3919	599	26	,	,	PUNCT
gs-3919	599	27	s.	s.	PROPN
gs-3919	599	28	(	(	PUNCT
gs-3919	599	29	davit	davit	PROPN
gs-3919	599	30	)	)	PUNCT
gs-3919	599	31	.	.	PUNCT
gs-3919	600	1	(	(	PUNCT
gs-3919	600	2	2023	2023	NUM
gs-3919	600	3	)	)	PUNCT
gs-3919	600	4	.	.	PUNCT
gs-3919	601	1	the	the	DET
gs-3919	601	2	disclosure	disclosure	NOUN
gs-3919	601	3	of	of	ADP
gs-3919	601	4	features	feature	NOUN
gs-3919	601	5	,	,	PUNCT
gs-3919	601	6	characteristics	characteristic	NOUN
gs-3919	601	7	,	,	PUNCT
gs-3919	601	8	possibilities	possibility	NOUN
gs-3919	601	9	and	and	CCONJ
gs-3919	601	10	specialties	specialty	NOUN
gs-3919	601	11	of	of	ADP
gs-3919	601	12	clinical	clinical	ADJ
gs-3919	601	13	pharmacists	pharmacist	NOUN
gs-3919	601	14	as	as	ADP
gs-3919	601	15	mediator	mediator	NOUN
gs-3919	601	16	among	among	ADP
gs-3919	601	17	doctors	doctor	NOUN
gs-3919	601	18	and	and	CCONJ
gs-3919	601	19	patients	patient	NOUN
gs-3919	601	20	for	for	ADP
gs-3919	601	21	enhancement	enhancement	NOUN
gs-3919	601	22	public	public	ADJ
gs-3919	601	23	health	health	NOUN
gs-3919	601	24	sector	sector	NOUN
gs-3919	601	25	in	in	ADP
gs-3919	601	26	a	a	DET
gs-3919	601	27	global	global	ADJ
gs-3919	601	28	world	world	NOUN
gs-3919	601	29	.	.	PUNCT
gs-3919	602	1	experimental	experimental	ADJ
gs-3919	602	2	and	and	CCONJ
gs-3919	602	3	clinical	clinical	ADJ
gs-3919	602	4	medicine	medicine	NOUN
gs-3919	602	5	georgia	georgia	PROPN
gs-3919	602	6	,	,	PUNCT
gs-3919	602	7	(	(	PUNCT
gs-3919	602	8	4	4	NUM
gs-3919	602	9	)	)	PUNCT
gs-3919	602	10	,	,	PUNCT
gs-3919	602	11	57–62	57–62	NUM
gs-3919	602	12	.	.	PUNCT
gs-3919	603	1	https://doi.org/10.52340/jecm.2023.04.15	https://doi.org/10.52340/jecm.2023.04.15	PROPN
gs-3919	603	2	23	23	NUM
gs-3919	603	3	.	.	PUNCT
gs-3919	604	1	sulashvili	sulashvili	NOUN
gs-3919	604	2	,	,	PUNCT
gs-3919	604	3	n.	n.	NOUN
gs-3919	604	4	,	,	PUNCT
gs-3919	604	5	gorgaslidze	gorgaslidze	PROPN
gs-3919	604	6	,	,	PUNCT
gs-3919	604	7	n.	n.	NOUN
gs-3919	604	8	,	,	PUNCT
gs-3919	604	9	gabunia	gabunia	NOUN
gs-3919	604	10	,	,	PUNCT
gs-3919	604	11	l.	l.	PROPN
gs-3919	604	12	,	,	PUNCT
gs-3919	604	13	giorgobiani	giorgobiani	PROPN
gs-3919	604	14	,	,	PUNCT
gs-3919	604	15	m.	m.	NOUN
gs-3919	604	16	,	,	PUNCT
gs-3919	604	17	&	&	CCONJ
gs-3919	604	18	ratiani	ratiani	PROPN
gs-3919	604	19	,	,	PUNCT
gs-3919	604	20	l.	l.	PROPN
gs-3919	604	21	(	(	PUNCT
gs-3919	604	22	2023	2023	NUM
gs-3919	604	23	)	)	PUNCT
gs-3919	604	24	.	.	PUNCT
gs-3919	605	1	manifestation	manifestation	NOUN
gs-3919	605	2	of	of	ADP
gs-3919	605	3	the	the	DET
gs-3919	605	4	particularities	particularity	NOUN
gs-3919	605	5	of	of	ADP
gs-3919	605	6	the	the	DET
gs-3919	605	7	usage	usage	NOUN
gs-3919	605	8	features	feature	NOUN
gs-3919	605	9	of	of	ADP
gs-3919	605	10	monoclonal	monoclonal	NOUN
gs-3919	605	11	antibodies	antibody	NOUN
gs-3919	605	12	in	in	ADP
gs-3919	605	13	various	various	ADJ
gs-3919	605	14	pharmacotherapeutic	pharmacotherapeutic	ADJ
gs-3919	605	15	applications	application	NOUN
gs-3919	605	16	.	.	PUNCT
gs-3919	606	1	experimental	experimental	ADJ
gs-3919	606	2	and	and	CCONJ
gs-3919	606	3	clinical	clinical	ADJ
gs-3919	606	4	medicine	medicine	NOUN
gs-3919	606	5	georgia	georgia	PROPN
gs-3919	606	6	,	,	PUNCT
gs-3919	606	7	(	(	PUNCT
gs-3919	606	8	4	4	NUM
gs-3919	606	9	)	)	PUNCT
gs-3919	606	10	,	,	PUNCT
gs-3919	606	11	52–57	52–57	NUM
gs-3919	606	12	.	.	PUNCT
gs-3919	607	1	24	24	NUM
gs-3919	607	2	.	.	PUNCT
gs-3919	607	3	sulashvili	sulashvili	NOUN
gs-3919	607	4	,	,	PUNCT
gs-3919	607	5	n.	n.	NOUN
gs-3919	607	6	,	,	PUNCT
gs-3919	607	7	davitashvili	davitashvili	ADJ
gs-3919	607	8	,	,	PUNCT
gs-3919	607	9	m.	m.	NOUN
gs-3919	607	10	,	,	PUNCT
gs-3919	607	11	gorgaslidze	gorgaslidze	PROPN
gs-3919	607	12	,	,	PUNCT
gs-3919	607	13	n.	n.	NOUN
gs-3919	607	14	,	,	PUNCT
gs-3919	607	15	gabunia	gabunia	NOUN
gs-3919	607	16	,	,	PUNCT
gs-3919	607	17	l.	l.	PROPN
gs-3919	607	18	,	,	PUNCT
gs-3919	607	19	beglaryan	beglaryan	ADJ
gs-3919	607	20	,	,	PUNCT
gs-3919	607	21	m.	m.	NOUN
gs-3919	607	22	,	,	PUNCT
gs-3919	607	23	alavidze	alavidze	NOUN
gs-3919	607	24	,	,	PUNCT
gs-3919	607	25	n.	n.	NOUN
gs-3919	607	26	,	,	PUNCT
gs-3919	607	27	…	…	PUNCT
gs-3919	607	28	sulashvili	sulashvili	NOUN
gs-3919	607	29	,	,	PUNCT
gs-3919	607	30	m.	m.	NOUN
gs-3919	607	31	(	(	PUNCT
gs-3919	607	32	2024	2024	NUM
gs-3919	607	33	)	)	PUNCT
gs-3919	607	34	.	.	PUNCT
gs-3919	608	1	the	the	DET
gs-3919	608	2	scientific	scientific	ADJ
gs-3919	608	3	discussion	discussion	NOUN
gs-3919	608	4	of	of	ADP
gs-3919	608	5	some	some	DET
gs-3919	608	6	issues	issue	NOUN
gs-3919	608	7	of	of	ADP
gs-3919	608	8	features	feature	NOUN
gs-3919	608	9	and	and	CCONJ
gs-3919	608	10	challenges	challenge	NOUN
gs-3919	608	11	of	of	ADP
gs-3919	608	12	using	use	VERB
gs-3919	608	13	of	of	ADP
gs-3919	608	14	car	car	NOUN
gs-3919	608	15	-	-	PUNCT
gs-3919	608	16	t	t	NOUN
gs-3919	608	17	cells	cell	NOUN
gs-3919	608	18	in	in	ADP
gs-3919	608	19	immunotherapy	immunotherapy	NOUN
gs-3919	608	20	.	.	PUNCT
gs-3919	609	1	georgian	georgian	ADJ
gs-3919	609	2	scientists	scientist	NOUN
gs-3919	609	3	,	,	PUNCT
gs-3919	609	4	6(4	6(4	NOUN
gs-3919	609	5	)	)	PUNCT
gs-3919	609	6	,	,	PUNCT
gs-3919	609	7	263–290	263–290	NUM
gs-3919	609	8	.	.	PUNCT
gs-3919	610	1	https://doi.org/10.52340/gs.2024.06.04.24	https://doi.org/10.52340/gs.2024.06.04.24	NUM
gs-3919	610	2	25	25	NUM
gs-3919	610	3	.	.	PUNCT
gs-3919	611	1	sulashvili	sulashvili	NOUN
gs-3919	611	2	,	,	PUNCT
gs-3919	611	3	n.	n.	NOUN
gs-3919	611	4	,	,	PUNCT
gs-3919	611	5	gorgaslidze	gorgaslidze	PROPN
gs-3919	611	6	,	,	PUNCT
gs-3919	611	7	n.	n.	NOUN
gs-3919	611	8	,	,	PUNCT
gs-3919	611	9	gabunia	gabunia	NOUN
gs-3919	611	10	,	,	PUNCT
gs-3919	611	11	l.	l.	PROPN
gs-3919	611	12	,	,	PUNCT
gs-3919	611	13	giorgobiani	giorgobiani	PROPN
gs-3919	611	14	,	,	PUNCT
gs-3919	611	15	m.	m.	NOUN
gs-3919	611	16	,	,	PUNCT
gs-3919	611	17	&	&	CCONJ
gs-3919	611	18	ratiani	ratiani	PROPN
gs-3919	611	19	,	,	PUNCT
gs-3919	611	20	l.	l.	PROPN
gs-3919	611	21	(	(	PUNCT
gs-3919	611	22	2023	2023	NUM
gs-3919	611	23	)	)	PUNCT
gs-3919	611	24	.	.	PUNCT
gs-3919	612	1	manifestation	manifestation	NOUN
gs-3919	612	2	of	of	ADP
gs-3919	612	3	the	the	DET
gs-3919	612	4	particularities	particularity	NOUN
gs-3919	612	5	of	of	ADP
gs-3919	612	6	the	the	DET
gs-3919	612	7	usage	usage	NOUN
gs-3919	612	8	features	feature	NOUN
gs-3919	612	9	of	of	ADP
gs-3919	612	10	monoclonal	monoclonal	NOUN
gs-3919	612	11	antibodies	antibody	NOUN
gs-3919	612	12	in	in	ADP
gs-3919	612	13	various	various	ADJ
gs-3919	612	14	pharmacotherapeutic	pharmacotherapeutic	ADJ
gs-3919	612	15	applications	application	NOUN
gs-3919	612	16	.	.	PUNCT
gs-3919	613	1	experimental	experimental	ADJ
gs-3919	613	2	and	and	CCONJ
gs-3919	613	3	clinical	clinical	ADJ
gs-3919	613	4	medicine	medicine	NOUN
gs-3919	613	5	georgia	georgia	PROPN
gs-3919	613	6	,	,	PUNCT
gs-3919	613	7	(	(	PUNCT
gs-3919	613	8	4	4	NUM
gs-3919	613	9	)	)	PUNCT
gs-3919	613	10	,	,	PUNCT
gs-3919	613	11	52–57	52–57	NUM
gs-3919	613	12	.	.	PUNCT
gs-3919	614	1	https://doi.org/10.52340/jecm.2023.04.14	https://doi.org/10.52340/jecm.2023.04.14	X
gs-3919	615	1	26	26	NUM
gs-3919	615	2	.	.	PUNCT
gs-3919	615	3	sulashvili	sulashvili	NOUN
gs-3919	615	4	,	,	PUNCT
gs-3919	615	5	n.	n.	NOUN
gs-3919	615	6	,	,	PUNCT
gs-3919	615	7	gorgaslidze	gorgaslidze	PROPN
gs-3919	615	8	,	,	PUNCT
gs-3919	615	9	n.	n.	NOUN
gs-3919	615	10	,	,	PUNCT
gs-3919	615	11	gabunia	gabunia	NOUN
gs-3919	615	12	,	,	PUNCT
gs-3919	615	13	l.	l.	PROPN
gs-3919	615	14	,	,	PUNCT
gs-3919	615	15	ratiani	ratiani	PROPN
gs-3919	615	16	,	,	PUNCT
gs-3919	615	17	l.	l.	PROPN
gs-3919	615	18	,	,	PUNCT
gs-3919	615	19	khetsuriani	khetsuriani	PROPN
gs-3919	615	20	,	,	PUNCT
gs-3919	615	21	s.	s.	PROPN
gs-3919	615	22	,	,	PUNCT
gs-3919	615	23	kravchenko	kravchenko	PROPN
gs-3919	615	24	,	,	PUNCT
gs-3919	615	25	v.	v.	NOUN
gs-3919	615	26	,	,	PUNCT
gs-3919	615	27	sulashvili	sulashvili	NOUN
gs-3919	615	28	,	,	PUNCT
gs-3919	615	29	m.	m.	NOUN
gs-3919	615	30	(	(	PUNCT
gs-3919	615	31	2024	2024	NUM
gs-3919	615	32	)	)	PUNCT
gs-3919	615	33	.	.	PUNCT
gs-3919	616	1	manifestation	manifestation	NOUN
gs-3919	616	2	of	of	ADP
gs-3919	616	3	the	the	DET
gs-3919	616	4	particularities	particularity	NOUN
gs-3919	616	5	of	of	ADP
gs-3919	616	6	some	some	DET
gs-3919	616	7	key	key	ADJ
gs-3919	616	8	issue	issue	NOUN
gs-3919	616	9	aspects	aspect	NOUN
gs-3919	616	10	of	of	ADP
gs-3919	616	11	new	new	ADJ
gs-3919	616	12	immunotherapy	immunotherapy	NOUN
gs-3919	616	13	challenges	challenge	NOUN
gs-3919	616	14	and	and	CCONJ
gs-3919	616	15	perspectives	perspective	NOUN
gs-3919	616	16	by	by	ADP
gs-3919	616	17	car	car	NOUN
gs-3919	616	18	-	-	PUNCT
gs-3919	616	19	t	t	NOUN
gs-3919	616	20	cell	cell	NOUN
gs-3919	616	21	therapy	therapy	NOUN
gs-3919	616	22	.	.	PUNCT
gs-3919	617	1	experimental	experimental	ADJ
gs-3919	617	2	and	and	CCONJ
gs-3919	617	3	clinical	clinical	ADJ
gs-3919	617	4	medicine	medicine	NOUN
gs-3919	617	5	georgia	georgia	PROPN
gs-3919	617	6	,	,	PUNCT
gs-3919	617	7	(	(	PUNCT
gs-3919	617	8	4	4	NUM
gs-3919	617	9	)	)	PUNCT
gs-3919	617	10	,	,	PUNCT
gs-3919	617	11	119–121	119–121	NUM
gs-3919	617	12	.	.	PUNCT
gs-3919	617	13	https://doi.org/10.52340/jecm.2024.04.32	https://doi.org/10.52340/jecm.2024.04.32	NUM
gs-3919	617	14	.	.	NOUN
gs-3919	617	15	27	27	NUM
gs-3919	617	16	.	.	PUNCT
gs-3919	617	17	sulashvili	sulashvili	NOUN
gs-3919	617	18	,	,	PUNCT
gs-3919	617	19	n	n	CCONJ
gs-3919	617	20	...	...	PUNCT
gs-3919	617	21	,	,	PUNCT
gs-3919	617	22	gorgaslidze	gorgaslidze	ADJ
gs-3919	617	23	,	,	PUNCT
gs-3919	617	24	n	n	CCONJ
gs-3919	617	25	..	..	PUNCT
gs-3919	617	26	,	,	PUNCT
gs-3919	617	27	beglaryan	beglaryan	ADJ
gs-3919	617	28	,	,	PUNCT
gs-3919	617	29	m	m	PROPN
gs-3919	617	30	..	..	PUNCT
gs-3919	617	31	,	,	PUNCT
gs-3919	617	32	gabunia	gabunia	NOUN
gs-3919	617	33	,	,	PUNCT
gs-3919	617	34	l	l	NOUN
gs-3919	617	35	..	..	PUNCT
gs-3919	617	36	,	,	PUNCT
gs-3919	617	37	chichoyan	chichoyan	PROPN
gs-3919	617	38	,	,	PUNCT
gs-3919	617	39	n	n	CCONJ
gs-3919	617	40	..	..	PUNCT
gs-3919	617	41	,	,	PUNCT
gs-3919	617	42	giorgobiani	giorgobiani	ADJ
gs-3919	617	43	,	,	PUNCT
gs-3919	617	44	m	m	PROPN
gs-3919	617	45	..	..	PUNCT
gs-3919	617	46	,	,	PUNCT
gs-3919	617	47	…	…	PUNCT
gs-3919	617	48	zarnadze	zarnadze	PROPN
gs-3919	617	49	,	,	PUNCT
gs-3919	617	50	s.	s.	PROPN
gs-3919	617	51	(	(	PUNCT
gs-3919	617	52	davit	davit	PROPN
gs-3919	617	53	)	)	PUNCT
gs-3919	617	54	.	.	PUNCT
gs-3919	618	1	(	(	PUNCT
gs-3919	618	2	2022	2022	NUM
gs-3919	618	3	)	)	PUNCT
gs-3919	618	4	.	.	PUNCT
gs-3919	619	1	the	the	DET
gs-3919	619	2	scientific	scientific	ADJ
gs-3919	619	3	talks	talk	NOUN
gs-3919	619	4	of	of	ADP
gs-3919	619	5	essential	essential	ADJ
gs-3919	619	6	issue	issue	NOUN
gs-3919	619	7	,	,	PUNCT
gs-3919	619	8	invocation	invocation	NOUN
gs-3919	619	9	,	,	PUNCT
gs-3919	619	10	perspectives	perspective	NOUN
gs-3919	619	11	,	,	PUNCT
gs-3919	619	12	inclinations	inclination	NOUN
gs-3919	619	13	and	and	CCONJ
gs-3919	619	14	features	feature	NOUN
gs-3919	619	15	of	of	ADP
gs-3919	619	16	the	the	DET
gs-3919	619	17	clinical	clinical	ADJ
gs-3919	619	18	pharmacists	pharmacist	NOUN
gs-3919	619	19	globally	globally	ADV
gs-3919	619	20	.	.	PUNCT
gs-3919	620	1	experimental	experimental	ADJ
gs-3919	620	2	and	and	CCONJ
gs-3919	620	3	clinical	clinical	ADJ
gs-3919	620	4	medicine	medicine	NOUN
gs-3919	620	5	georgia	georgia	PROPN
gs-3919	620	6	,	,	PUNCT
gs-3919	620	7	(	(	PUNCT
gs-3919	620	8	7	7	NUM
gs-3919	620	9	)	)	PUNCT
gs-3919	620	10	.	.	PUNCT
gs-3919	621	1	28	28	NUM
gs-3919	621	2	.	.	PUNCT
gs-3919	622	1	sulashvili	sulashvili	PROPN
gs-3919	622	2	n	n	CCONJ
gs-3919	622	3	,	,	PUNCT
gs-3919	622	4	nimangre	nimangre	PROPN
gs-3919	622	5	rr	rr	PROPN
gs-3919	622	6	.	.	PUNCT
gs-3919	623	1	manifestation	manifestation	NOUN
gs-3919	623	2	of	of	ADP
gs-3919	623	3	some	some	DET
gs-3919	623	4	aspects	aspect	NOUN
gs-3919	623	5	of	of	ADP
gs-3919	623	6	cardiovascular	cardiovascular	ADJ
gs-3919	623	7	diseases	disease	NOUN
gs-3919	623	8	,	,	PUNCT
gs-3919	623	9	implications	implication	NOUN
gs-3919	623	10	,	,	PUNCT
gs-3919	623	11	pharmacotherapeutic	pharmacotherapeutic	ADJ
gs-3919	623	12	strategies	strategy	NOUN
gs-3919	623	13	,	,	PUNCT
gs-3919	623	14	effects	effect	NOUN
gs-3919	623	15	,	,	PUNCT
gs-3919	623	16	impacts	impact	NOUN
gs-3919	623	17	and	and	CCONJ
gs-3919	623	18	potential	potential	ADJ
gs-3919	623	19	hazards	hazard	NOUN
gs-3919	623	20	in	in	ADP
gs-3919	623	21	general	general	ADJ
gs-3919	623	22	.	.	PUNCT
gs-3919	624	1	jr	jr	PROPN
gs-3919	625	1	[	[	X
gs-3919	625	2	internet	internet	NOUN
gs-3919	625	3	]	]	PUNCT
gs-3919	625	4	.	.	PUNCT
gs-3919	626	1	2025	2025	NUM
gs-3919	626	2	feb	feb	X
gs-3919	626	3	.	.	PROPN
gs-3919	626	4	7	7	NUM
gs-3919	626	5	[	[	X
gs-3919	626	6	cited	cite	VERB
gs-3919	626	7	2025	2025	NUM
gs-3919	626	8	may	may	PROPN
gs-3919	626	9	22];3(1):1	22];3(1):1	NUM
gs-3919	626	10	-	-	SYM
gs-3919	626	11	27	27	NUM
gs-3919	626	12	.	.	PUNCT
gs-3919	627	1	available	available	ADJ
gs-3919	627	2	from	from	ADP
gs-3919	627	3	:	:	PUNCT
gs-3919	627	4	https://journals.4science.ge/index.php/jr/article/view/3393	https://journals.4science.ge/index.php/jr/article/view/3393	PROPN
gs-3919	627	5	.	.	PUNCT
gs-3919	628	1	29	29	NUM
gs-3919	628	2	.	.	PUNCT
gs-3919	629	1	sulashvili	sulashvili	PROPN
gs-3919	629	2	n	n	CCONJ
gs-3919	629	3	,	,	PUNCT
gs-3919	629	4	yaduvanshi	yaduvanshi	NOUN
gs-3919	629	5	u	u	NOUN
gs-3919	629	6	,	,	PUNCT
gs-3919	629	7	yadav	yadav	PROPN
gs-3919	629	8	m	m	PROPN
gs-3919	629	9	,	,	PUNCT
gs-3919	629	10	gabunia	gabunia	NOUN
gs-3919	629	11	l	l	NOUN
gs-3919	629	12	,	,	PUNCT
gs-3919	629	13	ghambashidze	ghambashidze	PROPN
gs-3919	629	14	k	k	PROPN
gs-3919	629	15	,	,	PUNCT
gs-3919	629	16	gorgaslidze	gorgaslidze	ADJ
gs-3919	629	17	n	n	CCONJ
gs-3919	629	18	,	,	PUNCT
gs-3919	629	19	et	et	PROPN
gs-3919	629	20	al	al	PROPN
gs-3919	629	21	.	.	PUNCT
gs-3919	630	1	the	the	DET
gs-3919	630	2	scientific	scientific	ADJ
gs-3919	630	3	discourse	discourse	NOUN
gs-3919	630	4	of	of	ADP
gs-3919	630	5	features	feature	NOUN
gs-3919	630	6	of	of	ADP
gs-3919	630	7	clinical	clinical	ADJ
gs-3919	630	8	use	use	NOUN
gs-3919	630	9	and	and	CCONJ
gs-3919	630	10	pharmacology	pharmacology	NOUN
gs-3919	630	11	of	of	ADP
gs-3919	630	12	vasoconstrictors	vasoconstrictor	NOUN
gs-3919	630	13	and	and	CCONJ
gs-3919	630	14	their	their	PRON
gs-3919	630	15	impact	impact	NOUN
gs-3919	630	16	on	on	ADP
gs-3919	630	17	cardiac	cardiac	ADJ
gs-3919	630	18	georgian	georgian	ADJ
gs-3919	630	19	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3919	630	20	მეცნიერები	მეცნიერები	NOUN
gs-3919	630	21	ტ.	ტ.	VERB
gs-3919	630	22	7	7	NUM
gs-3919	630	23	n	n	PRON
gs-3919	630	24	3	3	NUM
gs-3919	630	25	,	,	PUNCT
gs-3919	630	26	2025	2025	NUM
gs-3919	630	27	176	176	NUM
gs-3919	630	28	function	function	NOUN
gs-3919	630	29	.	.	PUNCT
gs-3919	631	1	jr	jr	PROPN
gs-3919	632	1	[	[	X
gs-3919	632	2	internet	internet	NOUN
gs-3919	632	3	]	]	PUNCT
gs-3919	632	4	.	.	PUNCT
gs-3919	633	1	2025	2025	NUM
gs-3919	633	2	feb	feb	NOUN
gs-3919	633	3	.	.	PUNCT
gs-3919	634	1	[	[	X
gs-3919	634	2	cited	cite	VERB
gs-3919	634	3	2025	2025	NUM
gs-3919	634	4	may	may	PROPN
gs-3919	634	5	22];3(1):28	22];3(1):28	NUM
gs-3919	634	6	-	-	SYM
gs-3919	634	7	6	6	NUM
gs-3919	634	8	.	.	PUNCT
gs-3919	634	9	available	available	ADJ
gs-3919	634	10	from	from	ADP
gs-3919	634	11	:	:	PUNCT
gs-3919	634	12	https://journals.4science.ge/index.php/jr/article/view/3414	https://journals.4science.ge/index.php/jr/article/view/3414	NOUN
gs-3919	634	13	.	.	PUNCT
gs-3919	635	1	30	30	NUM
gs-3919	635	2	.	.	PUNCT
gs-3919	636	1	nodar	nodar	PROPN
gs-3919	636	2	sulashvili	sulashvili	NOUN
gs-3919	636	3	,	,	PUNCT
gs-3919	636	4	nana	nana	PROPN
gs-3919	636	5	gorgaslidze	gorgaslidze	PROPN
gs-3919	636	6	,	,	PUNCT
gs-3919	636	7	margarita	margarita	PROPN
gs-3919	636	8	beglaryan	beglaryan	PROPN
gs-3919	636	9	,	,	PUNCT
gs-3919	636	10	luiza	luiza	PROPN
gs-3919	636	11	gabunia	gabunia	PROPN
gs-3919	636	12	,	,	PUNCT
gs-3919	636	13	nato	nato	PROPN
gs-3919	636	14	alavidze	alavidze	PROPN
gs-3919	636	15	,	,	PUNCT
gs-3919	636	16	nino	nino	PROPN
gs-3919	636	17	abuladze	abuladze	PROPN
gs-3919	636	18	,	,	PUNCT
gs-3919	636	19	marina	marina	PROPN
gs-3919	636	20	giorgobiani	giorgobiani	PROPN
gs-3919	636	21	,	,	PUNCT
gs-3919	636	22	marika	marika	PROPN
gs-3919	636	23	sulashvili	sulashvili	PROPN
gs-3919	636	24	,	,	PUNCT
gs-3919	636	25	tamar	tamar	PROPN
gs-3919	636	26	okropiridze	okropiridze	PROPN
gs-3919	636	27	,	,	PUNCT
gs-3919	636	28	and	and	CCONJ
gs-3919	636	29	lali	lali	PROPN
gs-3919	636	30	patsia	patsia	PROPN
gs-3919	636	31	.	.	PUNCT
gs-3919	637	1	2025	2025	NUM
gs-3919	637	2	.	.	PUNCT
gs-3919	638	1	“	"	PUNCT
gs-3919	638	2	the	the	DET
gs-3919	638	3	scientific	scientific	ADJ
gs-3919	638	4	discourse	discourse	NOUN
gs-3919	638	5	of	of	ADP
gs-3919	638	6	key	key	ADJ
gs-3919	638	7	issue	issue	NOUN
gs-3919	638	8	aspects	aspect	NOUN
gs-3919	638	9	of	of	ADP
gs-3919	638	10	features	feature	NOUN
gs-3919	638	11	of	of	ADP
gs-3919	638	12	candida	candida	PROPN
gs-3919	638	13	problems	problem	NOUN
gs-3919	638	14	,	,	PUNCT
gs-3919	638	15	antifungal	antifungal	ADJ
gs-3919	638	16	drugs	drug	NOUN
gs-3919	638	17	resistance	resistance	NOUN
gs-3919	638	18	concerns	concern	NOUN
gs-3919	638	19	,	,	PUNCT
gs-3919	638	20	mycotoxicology	mycotoxicology	NOUN
gs-3919	638	21	issues	issue	NOUN
gs-3919	638	22	,	,	PUNCT
gs-3919	638	23	mycoecology	mycoecology	NOUN
gs-3919	638	24	,	,	PUNCT
gs-3919	638	25	biosafety	biosafety	NOUN
gs-3919	638	26	risks	risk	NOUN
gs-3919	638	27	and	and	CCONJ
gs-3919	638	28	emerging	emerge	VERB
gs-3919	638	29	solutions	solution	NOUN
gs-3919	638	30	”	"	PUNCT
gs-3919	638	31	.	.	PUNCT
gs-3919	639	1	modern	modern	ADJ
gs-3919	639	2	scientific	scientific	ADJ
gs-3919	639	3	method	method	NOUN
gs-3919	639	4	,	,	PUNCT
gs-3919	639	5	no	no	INTJ
gs-3919	639	6	.	.	NOUN
gs-3919	639	7	9	9	NUM
gs-3919	639	8	(	(	PUNCT
gs-3919	639	9	march	march	PROPN
gs-3919	639	10	)	)	PUNCT
gs-3919	639	11	.	.	PUNCT
gs-3919	640	1	https://ojs.scipub.de/index.php/msm/article/view/5423	https://ojs.scipub.de/index.php/msm/article/view/5423	NOUN
gs-3919	640	2	.	.	NOUN
gs-3919	641	1	31	31	NUM
gs-3919	641	2	.	.	PUNCT
gs-3919	642	1	paljärvi	paljärvi	PROPN
gs-3919	642	2	,	,	PUNCT
gs-3919	642	3	t.	t.	PROPN
gs-3919	642	4	,	,	PUNCT
gs-3919	642	5	mcpherson	mcpherson	PROPN
gs-3919	642	6	,	,	PUNCT
gs-3919	642	7	t.	t.	PROPN
gs-3919	642	8	,	,	PUNCT
gs-3919	642	9	thompson	thompson	PROPN
gs-3919	642	10	,	,	PUNCT
gs-3919	642	11	c.	c.	PROPN
gs-3919	642	12	,	,	PUNCT
gs-3919	642	13	luciano	luciano	PROPN
gs-3919	642	14	,	,	PUNCT
gs-3919	642	15	s.	s.	PROPN
gs-3919	642	16	,	,	PUNCT
gs-3919	642	17	herttua	herttua	PROPN
gs-3919	642	18	,	,	PUNCT
gs-3919	642	19	k.	k.	PROPN
gs-3919	642	20	,	,	PUNCT
gs-3919	642	21	&	&	CCONJ
gs-3919	642	22	fazel	fazel	PROPN
gs-3919	642	23	,	,	PUNCT
gs-3919	642	24	s.	s.	PROPN
gs-3919	642	25	(	(	PUNCT
gs-3919	642	26	2024	2024	NUM
gs-3919	642	27	)	)	PUNCT
gs-3919	642	28	.	.	PUNCT
gs-3919	643	1	neuropsychiatric	neuropsychiatric	ADJ
gs-3919	643	2	diagnoses	diagnosis	NOUN
gs-3919	643	3	after	after	ADP
gs-3919	643	4	isotretinoin	isotretinoin	PROPN
gs-3919	643	5	initiation	initiation	NOUN
gs-3919	643	6	in	in	ADP
gs-3919	643	7	pediatric	pediatric	ADJ
gs-3919	643	8	acne	acne	NOUN
gs-3919	643	9	patients	patient	NOUN
gs-3919	643	10	:	:	PUNCT
gs-3919	643	11	a	a	DET
gs-3919	643	12	retrospective	retrospective	ADJ
gs-3919	643	13	cohort	cohort	NOUN
gs-3919	643	14	study	study	NOUN
gs-3919	643	15	.	.	PUNCT
gs-3919	644	1	journal	journal	NOUN
gs-3919	644	2	of	of	ADP
gs-3919	644	3	the	the	DET
gs-3919	644	4	american	american	PROPN
gs-3919	644	5	academy	academy	PROPN
gs-3919	644	6	of	of	ADP
gs-3919	644	7	dermatology	dermatology	NOUN
gs-3919	644	8	,	,	PUNCT
gs-3919	644	9	91(3	91(3	NUM
gs-3919	644	10	)	)	PUNCT
gs-3919	644	11	,	,	PUNCT
gs-3919	644	12	571	571	NUM
gs-3919	644	13	–	–	PUNCT
gs-3919	644	14	573	573	NUM
gs-3919	644	15	.	.	NOUN
gs-3919	644	16	32	32	NUM
gs-3919	644	17	.	.	X
gs-3919	645	1	parsi	parsi	PROPN
gs-3919	645	2	,	,	PUNCT
gs-3919	645	3	m.	m.	NOUN
gs-3919	645	4	,	,	PUNCT
gs-3919	645	5	&	&	CCONJ
gs-3919	645	6	daniel	daniel	PROPN
gs-3919	645	7	,	,	PUNCT
gs-3919	645	8	c.	c.	PROPN
gs-3919	645	9	(	(	PUNCT
gs-3919	645	10	2020	2020	NUM
gs-3919	645	11	)	)	PUNCT
gs-3919	645	12	.	.	PUNCT
gs-3919	646	1	lamotrigine	lamotrigine	NOUN
gs-3919	646	2	-	-	PUNCT
gs-3919	646	3	induced	induce	VERB
gs-3919	646	4	dress	dress	NOUN
gs-3919	646	5	syndrome	syndrome	NOUN
gs-3919	646	6	manifesting	manifest	VERB
gs-3919	646	7	as	as	ADP
gs-3919	646	8	‘	'	PUNCT
gs-3919	646	9	eosinophilic	eosinophilic	ADJ
gs-3919	646	10	colitis	colitis	NOUN
gs-3919	646	11	’	'	PUNCT
gs-3919	646	12	:	:	PUNCT
gs-3919	646	13	an	an	DET
gs-3919	646	14	uncommon	uncommon	ADJ
gs-3919	646	15	presentation	presentation	NOUN
gs-3919	646	16	of	of	ADP
gs-3919	646	17	a	a	DET
gs-3919	646	18	very	very	ADV
gs-3919	646	19	uncommon	uncommon	ADJ
gs-3919	646	20	condition	condition	NOUN
gs-3919	646	21	.	.	PUNCT
gs-3919	647	1	cureus	cureus	NOUN
gs-3919	647	2	.	.	PUNCT
gs-3919	648	1	33	33	NUM
gs-3919	648	2	.	.	PUNCT
gs-3919	649	1	paul	paul	PROPN
gs-3919	649	2	,	,	PUNCT
gs-3919	649	3	p.	p.	PROPN
gs-3919	649	4	,	,	PUNCT
gs-3919	649	5	kamal	kamal	PROPN
gs-3919	649	6	,	,	PUNCT
gs-3919	649	7	r.	r.	PROPN
gs-3919	649	8	,	,	PUNCT
gs-3919	649	9	&	&	CCONJ
gs-3919	649	10	bhatia	bhatia	PROPN
gs-3919	649	11	,	,	PUNCT
gs-3919	649	12	r.	r.	PROPN
gs-3919	649	13	(	(	PUNCT
gs-3919	649	14	2024	2024	NUM
gs-3919	649	15	)	)	PUNCT
gs-3919	649	16	.	.	PUNCT
gs-3919	650	1	the	the	DET
gs-3919	650	2	hidden	hide	VERB
gs-3919	650	3	dangers	danger	NOUN
gs-3919	650	4	of	of	ADP
gs-3919	650	5	meftal	meftal	NOUN
gs-3919	650	6	:	:	PUNCT
gs-3919	650	7	a	a	DET
gs-3919	650	8	drug	drug	NOUN
gs-3919	650	9	safety	safety	NOUN
gs-3919	650	10	alert	alert	NOUN
gs-3919	650	11	for	for	ADP
gs-3919	650	12	a	a	DET
gs-3919	650	13	frequently	frequently	ADV
gs-3919	650	14	used	use	VERB
gs-3919	650	15	nsaid	nsaid	PROPN
gs-3919	650	16	.	.	PUNCT
gs-3919	651	1	current	current	ADJ
gs-3919	651	2	pharmaceutical	pharmaceutical	ADJ
gs-3919	651	3	design	design	NOUN
gs-3919	651	4	,	,	PUNCT
gs-3919	651	5	30(25	30(25	NUM
gs-3919	651	6	)	)	PUNCT
gs-3919	651	7	,	,	PUNCT
gs-3919	651	8	1949–1951	1949–1951	NUM
gs-3919	651	9	.	.	PUNCT
gs-3919	652	1	34	34	NUM
gs-3919	652	2	.	.	PUNCT
gs-3919	652	3	qadir	qadir	PROPN
gs-3919	652	4	,	,	PUNCT
gs-3919	652	5	n.	n.	PROPN
gs-3919	652	6	a.	a.	PROPN
gs-3919	652	7	,	,	PUNCT
gs-3919	652	8	marsalisi	marsalisi	PROPN
gs-3919	652	9	,	,	PUNCT
gs-3919	652	10	c.	c.	PROPN
gs-3919	652	11	,	,	PUNCT
gs-3919	652	12	reddy	reddy	PROPN
gs-3919	652	13	,	,	PUNCT
gs-3919	652	14	a.	a.	PROPN
gs-3919	652	15	d.	d.	PROPN
gs-3919	652	16	,	,	PUNCT
gs-3919	652	17	stachler	stachler	PROPN
gs-3919	652	18	,	,	PUNCT
gs-3919	652	19	l.	l.	PROPN
gs-3919	652	20	,	,	PUNCT
gs-3919	652	21	&	&	CCONJ
gs-3919	652	22	onteddu	onteddu	ADV
gs-3919	652	23	,	,	PUNCT
gs-3919	652	24	n.	n.	PROPN
gs-3919	652	25	(	(	PUNCT
gs-3919	652	26	2024	2024	NUM
gs-3919	652	27	)	)	PUNCT
gs-3919	652	28	.	.	PUNCT
gs-3919	653	1	a	a	DET
gs-3919	653	2	dermatological	dermatological	ADJ
gs-3919	653	3	dilemma	dilemma	NOUN
gs-3919	653	4	:	:	PUNCT
gs-3919	653	5	the	the	DET
gs-3919	653	6	importance	importance	NOUN
gs-3919	653	7	of	of	ADP
gs-3919	653	8	recognizing	recognize	VERB
gs-3919	653	9	dermatologic	dermatologic	ADJ
gs-3919	653	10	manifestations	manifestation	NOUN
gs-3919	653	11	of	of	ADP
gs-3919	653	12	drug	drug	NOUN
gs-3919	653	13	reaction	reaction	NOUN
gs-3919	653	14	with	with	ADP
gs-3919	653	15	eosinophilia	eosinophilia	PROPN
gs-3919	653	16	and	and	CCONJ
gs-3919	653	17	systemic	systemic	ADJ
gs-3919	653	18	symptoms	symptom	NOUN
gs-3919	653	19	(	(	PUNCT
gs-3919	653	20	dress	dress	NOUN
gs-3919	653	21	)	)	PUNCT
gs-3919	653	22	in	in	ADP
gs-3919	653	23	skin	skin	NOUN
gs-3919	653	24	of	of	ADP
gs-3919	653	25	color	color	NOUN
gs-3919	653	26	patients	patient	NOUN
gs-3919	653	27	.	.	PUNCT
gs-3919	654	1	cureus	cureus	NOUN
gs-3919	654	2	.	.	PUNCT
gs-3919	655	1	35	35	NUM
gs-3919	655	2	.	.	X
gs-3919	656	1	robinson	robinson	PROPN
gs-3919	656	2	,	,	PUNCT
gs-3919	656	3	f.	f.	PROPN
gs-3919	656	4	,	,	PUNCT
gs-3919	656	5	webber	webber	PROPN
gs-3919	656	6	,	,	PUNCT
gs-3919	656	7	l.	l.	PROPN
gs-3919	656	8	,	,	PUNCT
gs-3919	656	9	ormerod	ormerod	NOUN
gs-3919	656	10	,	,	PUNCT
gs-3919	656	11	e.	e.	PROPN
gs-3919	656	12	,	,	PUNCT
gs-3919	656	13	&	&	CCONJ
gs-3919	656	14	keith	keith	PROPN
gs-3919	656	15	,	,	PUNCT
gs-3919	656	16	d.	d.	PROPN
gs-3919	656	17	(	(	PUNCT
gs-3919	656	18	2025	2025	NUM
gs-3919	656	19	)	)	PUNCT
gs-3919	656	20	.	.	PUNCT
gs-3919	657	1	an	an	DET
gs-3919	657	2	extremely	extremely	ADV
gs-3919	657	3	prolonged	prolonged	ADJ
gs-3919	657	4	case	case	NOUN
gs-3919	657	5	of	of	ADP
gs-3919	657	6	drug	drug	NOUN
gs-3919	657	7	reaction	reaction	NOUN
gs-3919	657	8	with	with	ADP
gs-3919	657	9	eosinophilia	eosinophilia	PROPN
gs-3919	657	10	and	and	CCONJ
gs-3919	657	11	systemic	systemic	ADJ
gs-3919	657	12	symptoms	symptom	NOUN
gs-3919	657	13	(	(	PUNCT
gs-3919	657	14	dress	dress	NOUN
gs-3919	657	15	syndrome	syndrome	NOUN
gs-3919	657	16	)	)	PUNCT
gs-3919	657	17	secondary	secondary	ADJ
gs-3919	657	18	to	to	ADP
gs-3919	657	19	a	a	DET
gs-3919	657	20	penicillin	penicillin	NOUN
gs-3919	657	21	-	-	PUNCT
gs-3919	657	22	based	base	VERB
gs-3919	657	23	antibiotic	antibiotic	NOUN
gs-3919	657	24	.	.	PUNCT
gs-3919	658	1	anais	anais	PROPN
gs-3919	658	2	brasileiros	brasileiros	PROPN
gs-3919	658	3	de	de	PROPN
gs-3919	658	4	dermatologia	dermatologia	PROPN
gs-3919	658	5	.	.	PUNCT
gs-3919	659	1	36	36	NUM
gs-3919	659	2	.	.	PUNCT
gs-3919	660	1	sahukar	sahukar	PROPN
gs-3919	660	2	,	,	PUNCT
gs-3919	660	3	s.	s.	PROPN
gs-3919	660	4	,	,	PUNCT
gs-3919	660	5	&	&	CCONJ
gs-3919	660	6	byranahalli	byranahalli	PROPN
gs-3919	660	7	,	,	PUNCT
gs-3919	660	8	v.	v.	PROPN
gs-3919	660	9	c.	c.	PROPN
gs-3919	660	10	(	(	PUNCT
gs-3919	660	11	2024	2024	NUM
gs-3919	660	12	)	)	PUNCT
gs-3919	660	13	.	.	PUNCT
gs-3919	661	1	drug	drug	NOUN
gs-3919	661	2	reaction	reaction	NOUN
gs-3919	661	3	with	with	ADP
gs-3919	661	4	eosinophilia	eosinophilia	PROPN
gs-3919	661	5	and	and	CCONJ
gs-3919	661	6	systemic	systemic	ADJ
gs-3919	661	7	symptoms	symptom	NOUN
gs-3919	661	8	(	(	PUNCT
gs-3919	661	9	dress	dress	NOUN
gs-3919	661	10	)	)	PUNCT
gs-3919	661	11	syndrome	syndrome	NOUN
gs-3919	661	12	:	:	PUNCT
gs-3919	661	13	a	a	DET
gs-3919	661	14	case	case	NOUN
gs-3919	661	15	report	report	NOUN
gs-3919	661	16	from	from	ADP
gs-3919	661	17	south	south	PROPN
gs-3919	661	18	india	india	PROPN
gs-3919	661	19	.	.	PUNCT
gs-3919	662	1	cureus	cureus	NOUN
gs-3919	662	2	.	.	PUNCT
gs-3919	663	1	37	37	NUM
gs-3919	663	2	.	.	PUNCT
gs-3919	664	1	saleem	saleem	PROPN
gs-3919	664	2	,	,	PUNCT
gs-3919	664	3	a.	a.	PROPN
gs-3919	664	4	,	,	PUNCT
gs-3919	664	5	waheed	waheed	PROPN
gs-3919	664	6	,	,	PUNCT
gs-3919	664	7	h.	h.	PROPN
gs-3919	664	8	,	,	PUNCT
gs-3919	664	9	&	&	CCONJ
gs-3919	664	10	fatima	fatima	PROPN
gs-3919	664	11	,	,	PUNCT
gs-3919	664	12	s.	s.	PROPN
gs-3919	664	13	(	(	PUNCT
gs-3919	664	14	2025	2025	NUM
gs-3919	664	15	)	)	PUNCT
gs-3919	664	16	.	.	PUNCT
gs-3919	665	1	the	the	DET
gs-3919	665	2	rash	rash	NOUN
gs-3919	665	3	that	that	PRON
gs-3919	665	4	unraveled	unravel	VERB
gs-3919	665	5	:	:	PUNCT
gs-3919	665	6	a	a	DET
gs-3919	665	7	case	case	NOUN
gs-3919	665	8	report	report	NOUN
gs-3919	665	9	of	of	ADP
gs-3919	665	10	dress	dress	NOUN
gs-3919	665	11	syndrome	syndrome	NOUN
gs-3919	665	12	in	in	ADP
gs-3919	665	13	a	a	DET
gs-3919	665	14	45	45	NUM
gs-3919	665	15	-	-	PUNCT
gs-3919	665	16	year	year	NOUN
gs-3919	665	17	-	-	PUNCT
gs-3919	665	18	old	old	ADJ
gs-3919	665	19	woman	woman	NOUN
gs-3919	665	20	.	.	PUNCT
gs-3919	666	1	medical	medical	ADJ
gs-3919	666	2	reports	report	NOUN
gs-3919	666	3	,	,	PUNCT
gs-3919	666	4	100192	100192	NUM
gs-3919	666	5	.	.	PUNCT
gs-3919	667	1	38	38	NUM
gs-3919	667	2	.	.	PUNCT
gs-3919	667	3	saper	saper	NOUN
gs-3919	667	4	,	,	PUNCT
gs-3919	667	5	v.	v.	PROPN
gs-3919	667	6	e.	e.	PROPN
gs-3919	667	7	,	,	PUNCT
gs-3919	667	8	tian	tian	PROPN
gs-3919	667	9	,	,	PUNCT
gs-3919	667	10	l.	l.	PROPN
gs-3919	667	11	,	,	PUNCT
gs-3919	667	12	verstegen	verstegen	PROPN
gs-3919	667	13	,	,	PUNCT
gs-3919	667	14	r.	r.	PROPN
gs-3919	667	15	h.	h.	PROPN
gs-3919	667	16	j.	j.	PROPN
gs-3919	667	17	,	,	PUNCT
gs-3919	667	18	conrad	conrad	PROPN
gs-3919	667	19	,	,	PUNCT
gs-3919	667	20	c.	c.	PROPN
gs-3919	667	21	k.	k.	PROPN
gs-3919	667	22	,	,	PUNCT
gs-3919	667	23	cidon	cidon	PROPN
gs-3919	667	24	,	,	PUNCT
gs-3919	667	25	m.	m.	NOUN
gs-3919	667	26	,	,	PUNCT
gs-3919	667	27	hopper	hopper	NOUN
gs-3919	667	28	,	,	PUNCT
gs-3919	667	29	r.	r.	PROPN
gs-3919	667	30	k.	k.	PROPN
gs-3919	667	31	,	,	PUNCT
gs-3919	667	32	kuo	kuo	PROPN
gs-3919	667	33	,	,	PUNCT
gs-3919	667	34	c.	c.	PROPN
gs-3919	667	35	s.	s.	PROPN
gs-3919	667	36	,	,	PUNCT
gs-3919	667	37	osoegawa	osoegawa	PROPN
gs-3919	667	38	,	,	PUNCT
gs-3919	667	39	k.	k.	PROPN
gs-3919	667	40	,	,	PUNCT
gs-3919	667	41	baszis	baszi	NOUN
gs-3919	667	42	,	,	PUNCT
gs-3919	667	43	k.	k.	PROPN
gs-3919	667	44	,	,	PUNCT
gs-3919	667	45	bingham	bingham	PROPN
gs-3919	667	46	,	,	PUNCT
gs-3919	667	47	c.	c.	PROPN
gs-3919	667	48	a.	a.	PROPN
gs-3919	667	49	,	,	PUNCT
gs-3919	667	50	ferguson	ferguson	PROPN
gs-3919	667	51	,	,	PUNCT
gs-3919	667	52	i.	i.	PROPN
gs-3919	667	53	,	,	PUNCT
gs-3919	667	54	hahn	hahn	PROPN
gs-3919	667	55	,	,	PUNCT
gs-3919	667	56	t.	t.	PROPN
gs-3919	667	57	,	,	PUNCT
gs-3919	667	58	horne	horne	PROPN
gs-3919	667	59	,	,	PUNCT
gs-3919	667	60	a.	a.	PROPN
gs-3919	667	61	,	,	PUNCT
gs-3919	667	62	isupova	isupova	PROPN
gs-3919	667	63	,	,	PUNCT
gs-3919	667	64	e.	e.	PROPN
gs-3919	667	65	a.	a.	PROPN
gs-3919	667	66	,	,	PUNCT
gs-3919	667	67	jones	jones	PROPN
gs-3919	667	68	,	,	PUNCT
gs-3919	667	69	j.	j.	PROPN
gs-3919	667	70	t.	t.	PROPN
gs-3919	667	71	,	,	PUNCT
gs-3919	667	72	kasapcopur	kasapcopur	PROPN
gs-3919	667	73	,	,	PUNCT
gs-3919	667	74	ö.	ö.	PROPN
gs-3919	667	75	,	,	PUNCT
gs-3919	667	76	klein	klein	PROPN
gs-3919	667	77	-	-	PUNCT
gs-3919	667	78	gitelman	gitelman	PROPN
gs-3919	667	79	,	,	PUNCT
gs-3919	667	80	m.	m.	NOUN
gs-3919	667	81	s.	s.	PROPN
gs-3919	667	82	,	,	PUNCT
gs-3919	667	83	kostik	kostik	PROPN
gs-3919	667	84	,	,	PUNCT
gs-3919	667	85	m.	m.	NOUN
gs-3919	667	86	m.	m.	NOUN
gs-3919	667	87	,	,	PUNCT
gs-3919	667	88	ozen	ozen	PROPN
gs-3919	667	89	,	,	PUNCT
gs-3919	667	90	s.	s.	PROPN
gs-3919	667	91	,	,	PUNCT
gs-3919	667	92	...	...	PUNCT
gs-3919	667	93	mellins	mellin	NOUN
gs-3919	667	94	,	,	PUNCT
gs-3919	667	95	e.	e.	PROPN
gs-3919	667	96	d.	d.	PROPN
gs-3919	667	97	(	(	PUNCT
gs-3919	667	98	2024	2024	NUM
gs-3919	667	99	)	)	PUNCT
gs-3919	667	100	.	.	PUNCT
gs-3919	668	1	interleukin	interleukin	NOUN
gs-3919	668	2	(	(	PUNCT
gs-3919	668	3	il)-1	il)-1	NOUN
gs-3919	668	4	/	/	SYM
gs-3919	668	5	il-6	il-6	NOUN
gs-3919	668	6	-	-	PUNCT
gs-3919	668	7	inhibitor	inhibitor	NOUN
gs-3919	668	8	–	–	PUNCT
gs-3919	668	9	associated	associate	VERB
gs-3919	668	10	drug	drug	NOUN
gs-3919	668	11	reaction	reaction	NOUN
gs-3919	668	12	with	with	ADP
gs-3919	668	13	eosinophilia	eosinophilia	PROPN
gs-3919	668	14	and	and	CCONJ
gs-3919	668	15	systemic	systemic	ADJ
gs-3919	668	16	symptoms	symptom	NOUN
gs-3919	668	17	(	(	PUNCT
gs-3919	668	18	dress	dress	NOUN
gs-3919	668	19	)	)	PUNCT
gs-3919	668	20	in	in	ADP
gs-3919	668	21	systemic	systemic	ADJ
gs-3919	668	22	inflammatory	inflammatory	ADJ
gs-3919	668	23	illnesses	illness	NOUN
gs-3919	668	24	.	.	PUNCT
gs-3919	669	1	the	the	DET
gs-3919	669	2	journal	journal	PROPN
gs-3919	669	3	of	of	ADP
gs-3919	669	4	allergy	allergy	NOUN
gs-3919	669	5	and	and	CCONJ
gs-3919	669	6	clinical	clinical	ADJ
gs-3919	669	7	immunology	immunology	NOUN
gs-3919	669	8	in	in	ADP
gs-3919	669	9	practice	practice	NOUN
gs-3919	669	10	,	,	PUNCT
gs-3919	669	11	12(11	12(11	NUM
gs-3919	669	12	)	)	PUNCT
gs-3919	669	13	,	,	PUNCT
gs-3919	669	14	2996	2996	NUM
gs-3919	669	15	-	-	SYM
gs-3919	669	16	3013.e7	3013.e7	NOUN
gs-3919	669	17	.	.	PROPN
gs-3919	669	18	39	39	NUM
gs-3919	669	19	.	.	PUNCT
gs-3919	670	1	sasi	sasi	PROPN
gs-3919	670	2	,	,	PUNCT
gs-3919	670	3	s.	s.	PROPN
gs-3919	670	4	,	,	PUNCT
gs-3919	670	5	altarawneh	altarawneh	PROPN
gs-3919	670	6	,	,	PUNCT
gs-3919	670	7	h.	h.	PROPN
gs-3919	670	8	,	,	PUNCT
gs-3919	670	9	petkar	petkar	NOUN
gs-3919	670	10	,	,	PUNCT
gs-3919	670	11	m.	m.	NOUN
gs-3919	670	12	a.	a.	PROPN
gs-3919	670	13	,	,	PUNCT
gs-3919	670	14	&	&	CCONJ
gs-3919	670	15	nair	nair	PROPN
gs-3919	670	16	,	,	PUNCT
gs-3919	670	17	a.	a.	NOUN
gs-3919	670	18	p.	p.	NOUN
gs-3919	670	19	(	(	PUNCT
gs-3919	670	20	2020	2020	NUM
gs-3919	670	21	)	)	PUNCT
gs-3919	670	22	.	.	PUNCT
gs-3919	671	1	drug	drug	NOUN
gs-3919	671	2	reaction	reaction	NOUN
gs-3919	671	3	with	with	ADP
gs-3919	671	4	eosinophilia	eosinophilia	PROPN
gs-3919	671	5	and	and	CCONJ
gs-3919	671	6	systemic	systemic	ADJ
gs-3919	671	7	symptoms	symptom	NOUN
gs-3919	671	8	secondary	secondary	ADJ
gs-3919	671	9	to	to	ADP
gs-3919	671	10	naproxen	naproxen	PROPN
gs-3919	671	11	:	:	PUNCT
gs-3919	671	12	a	a	DET
gs-3919	671	13	case	case	NOUN
gs-3919	671	14	report	report	NOUN
gs-3919	671	15	and	and	CCONJ
gs-3919	671	16	systematic	systematic	ADJ
gs-3919	671	17	review	review	NOUN
gs-3919	671	18	.	.	PUNCT
gs-3919	672	1	case	case	NOUN
gs-3919	672	2	reports	report	VERB
gs-3919	672	3	in	in	ADP
gs-3919	672	4	acute	acute	ADJ
gs-3919	672	5	medicine	medicine	NOUN
gs-3919	672	6	,	,	PUNCT
gs-3919	672	7	3(2	3(2	NUM
gs-3919	672	8	)	)	PUNCT
gs-3919	672	9	,	,	PUNCT
gs-3919	672	10	63–72	63–72	NUM
gs-3919	672	11	.	.	PUNCT
gs-3919	673	1	40	40	NUM
gs-3919	673	2	.	.	PUNCT
gs-3919	674	1	saxena	saxena	PROPN
gs-3919	674	2	,	,	PUNCT
gs-3919	674	3	s.	s.	PROPN
gs-3919	674	4	,	,	PUNCT
gs-3919	674	5	&	&	CCONJ
gs-3919	674	6	singh	singh	PROPN
gs-3919	674	7	,	,	PUNCT
gs-3919	674	8	s.	s.	PROPN
gs-3919	674	9	(	(	PUNCT
gs-3919	674	10	2021	2021	NUM
gs-3919	674	11	)	)	PUNCT
gs-3919	674	12	.	.	PUNCT
gs-3919	675	1	efficacy	efficacy	NOUN
gs-3919	675	2	and	and	CCONJ
gs-3919	675	3	tolerability	tolerability	NOUN
gs-3919	675	4	of	of	ADP
gs-3919	675	5	eslicarbazepine	eslicarbazepine	NOUN
gs-3919	675	6	acetate	acetate	PROPN
gs-3919	675	7	as	as	ADP
gs-3919	675	8	monotherapy	monotherapy	NOUN
gs-3919	675	9	in	in	ADP
gs-3919	675	10	patients	patient	NOUN
gs-3919	675	11	of	of	ADP
gs-3919	675	12	newly	newly	ADV
gs-3919	675	13	diagnosed	diagnose	VERB
gs-3919	675	14	focal	focal	ADJ
gs-3919	675	15	epilepsy	epilepsy	NOUN
gs-3919	675	16	.	.	PUNCT
gs-3919	676	1	european	european	ADJ
gs-3919	676	2	psychiatry	psychiatry	PROPN
gs-3919	676	3	,	,	PUNCT
gs-3919	676	4	64(s1	64(s1	NUM
gs-3919	676	5	)	)	PUNCT
gs-3919	676	6	,	,	PUNCT
gs-3919	676	7	s774	s774	PROPN
gs-3919	676	8	–	–	PUNCT
gs-3919	676	9	s775	s775	PROPN
gs-3919	676	10	.	.	PUNCT
gs-3919	677	1	georgian	georgian	PROPN
gs-3919	677	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	677	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	677	4	ტ.	ტ.	VERB
gs-3919	677	5	7	7	NUM
gs-3919	677	6	n	n	DET
gs-3919	677	7	3	3	NUM
gs-3919	677	8	,	,	PUNCT
gs-3919	677	9	2025	2025	NUM
gs-3919	677	10	177	177	NUM
gs-3919	677	11	41	41	NUM
gs-3919	677	12	.	.	PUNCT
gs-3919	678	1	shakour	shakour	NOUN
gs-3919	678	2	,	,	PUNCT
gs-3919	678	3	h.	h.	PROPN
gs-3919	678	4	,	,	PUNCT
gs-3919	678	5	mumtaz	mumtaz	PROPN
gs-3919	678	6	,	,	PUNCT
gs-3919	678	7	r.	r.	PROPN
gs-3919	678	8	,	,	PUNCT
gs-3919	678	9	&	&	CCONJ
gs-3919	678	10	abu	abu	PROPN
gs-3919	678	11	-	-	PUNCT
gs-3919	678	12	samra	samra	NOUN
gs-3919	678	13	,	,	PUNCT
gs-3919	678	14	a.	a.	NOUN
gs-3919	678	15	(	(	PUNCT
gs-3919	678	16	2025	2025	NUM
gs-3919	678	17	)	)	PUNCT
gs-3919	678	18	.	.	PUNCT
gs-3919	679	1	a	a	DET
gs-3919	679	2	diagnostic	diagnostic	ADJ
gs-3919	679	3	dilemma	dilemma	NOUN
gs-3919	679	4	:	:	PUNCT
gs-3919	679	5	daptomycin	daptomycin	NOUN
gs-3919	679	6	-	-	PUNCT
gs-3919	679	7	induced	induce	VERB
gs-3919	679	8	drug	drug	NOUN
gs-3919	679	9	reaction	reaction	NOUN
gs-3919	679	10	with	with	ADP
gs-3919	679	11	eosinophilia	eosinophilia	PROPN
gs-3919	679	12	and	and	CCONJ
gs-3919	679	13	systemic	systemic	ADJ
gs-3919	679	14	symptoms	symptom	NOUN
gs-3919	679	15	(	(	PUNCT
gs-3919	679	16	dress	dress	NOUN
gs-3919	679	17	)	)	PUNCT
gs-3919	679	18	syndrome	syndrome	NOUN
gs-3919	679	19	and	and	CCONJ
gs-3919	679	20	eosinophilic	eosinophilic	ADJ
gs-3919	679	21	pneumonia	pneumonia	NOUN
gs-3919	679	22	with	with	ADP
gs-3919	679	23	concurrent	concurrent	ADJ
gs-3919	679	24	covid-19	covid-19	PROPN
gs-3919	679	25	.	.	PROPN
gs-3919	679	26	cureus	cureus	NOUN
gs-3919	679	27	.	.	PUNCT
gs-3919	680	1	42	42	NUM
gs-3919	680	2	.	.	PUNCT
gs-3919	681	1	shiohara	shiohara	ADJ
gs-3919	681	2	,	,	PUNCT
gs-3919	681	3	t.	t.	PROPN
gs-3919	681	4	,	,	PUNCT
gs-3919	681	5	&	&	CCONJ
gs-3919	681	6	mizukawa	mizukawa	PROPN
gs-3919	681	7	,	,	PUNCT
gs-3919	681	8	y.	y.	PROPN
gs-3919	681	9	(	(	PUNCT
gs-3919	681	10	2019	2019	NUM
gs-3919	681	11	)	)	PUNCT
gs-3919	681	12	.	.	PUNCT
gs-3919	682	1	drug	drug	NOUN
gs-3919	682	2	-	-	PUNCT
gs-3919	682	3	induced	induce	VERB
gs-3919	682	4	hypersensitivity	hypersensitivity	NOUN
gs-3919	682	5	syndrome	syndrome	NOUN
gs-3919	682	6	(	(	PUNCT
gs-3919	682	7	dihs)/drug	dihs)/drug	ADJ
gs-3919	682	8	reaction	reaction	NOUN
gs-3919	682	9	with	with	ADP
gs-3919	682	10	eosinophilia	eosinophilia	PROPN
gs-3919	682	11	and	and	CCONJ
gs-3919	682	12	systemic	systemic	ADJ
gs-3919	682	13	symptoms	symptom	NOUN
gs-3919	682	14	(	(	PUNCT
gs-3919	682	15	dress	dress	NOUN
gs-3919	682	16	):	):	PUNCT
gs-3919	682	17	an	an	DET
gs-3919	682	18	update	update	NOUN
gs-3919	682	19	in	in	ADP
gs-3919	682	20	2019	2019	NUM
gs-3919	682	21	.	.	PUNCT
gs-3919	683	1	allergology	allergology	NOUN
gs-3919	683	2	international	international	PROPN
gs-3919	683	3	,	,	PUNCT
gs-3919	683	4	68(3	68(3	PROPN
gs-3919	683	5	)	)	PUNCT
gs-3919	683	6	,	,	PUNCT
gs-3919	683	7	301–308	301–308	NUM
gs-3919	683	8	.	.	PUNCT
gs-3919	684	1	43	43	NUM
gs-3919	684	2	.	.	PUNCT
gs-3919	684	3	sqalli	sqalli	PROPN
gs-3919	684	4	-	-	PUNCT
gs-3919	684	5	houssini	houssini	PROPN
gs-3919	684	6	,	,	PUNCT
gs-3919	684	7	g.	g.	PROPN
gs-3919	684	8	,	,	PUNCT
gs-3919	684	9	douhi	douhi	PROPN
gs-3919	684	10	,	,	PUNCT
gs-3919	684	11	z.	z.	PROPN
gs-3919	684	12	,	,	PUNCT
gs-3919	684	13	soughi	soughi	PROPN
gs-3919	684	14	,	,	PUNCT
gs-3919	684	15	m.	m.	NOUN
gs-3919	684	16	,	,	PUNCT
gs-3919	684	17	elloudi	elloudi	PROPN
gs-3919	684	18	,	,	PUNCT
gs-3919	684	19	s.	s.	PROPN
gs-3919	684	20	,	,	PUNCT
gs-3919	684	21	baybay	baybay	VERB
gs-3919	684	22	,	,	PUNCT
gs-3919	684	23	h.	h.	PROPN
gs-3919	684	24	,	,	PUNCT
gs-3919	684	25	moukafih	moukafih	PROPN
gs-3919	684	26	,	,	PUNCT
gs-3919	684	27	b.	b.	PROPN
gs-3919	684	28	,	,	PUNCT
gs-3919	684	29	omari	omari	PROPN
gs-3919	684	30	,	,	PUNCT
gs-3919	684	31	m.	m.	NOUN
gs-3919	684	32	,	,	PUNCT
gs-3919	684	33	rhazi	rhazi	PROPN
gs-3919	684	34	,	,	PUNCT
gs-3919	684	35	k.	k.	PROPN
gs-3919	684	36	e.	e.	PROPN
gs-3919	684	37	,	,	PUNCT
gs-3919	684	38	&	&	CCONJ
gs-3919	684	39	mernissi	mernissi	PROPN
gs-3919	684	40	,	,	PUNCT
gs-3919	684	41	f.	f.	PROPN
gs-3919	684	42	(	(	PUNCT
gs-3919	684	43	2024	2024	NUM
gs-3919	684	44	)	)	PUNCT
gs-3919	684	45	.	.	PUNCT
gs-3919	685	1	drug	drug	NOUN
gs-3919	685	2	reaction	reaction	NOUN
gs-3919	685	3	with	with	ADP
gs-3919	685	4	eosinophilia	eosinophilia	PROPN
gs-3919	685	5	and	and	CCONJ
gs-3919	685	6	systemic	systemic	ADJ
gs-3919	685	7	symptoms	symptom	NOUN
gs-3919	685	8	:	:	PUNCT
gs-3919	685	9	analysis	analysis	NOUN
gs-3919	685	10	of	of	ADP
gs-3919	685	11	cutaneous	cutaneous	ADJ
gs-3919	685	12	phenotype	phenotype	NOUN
gs-3919	685	13	as	as	ADP
gs-3919	685	14	a	a	DET
gs-3919	685	15	prognosis	prognosis	NOUN
gs-3919	685	16	factor	factor	NOUN
gs-3919	685	17	.	.	PUNCT
gs-3919	686	1	revue	revue	PROPN
gs-3919	686	2	française	française	PROPN
gs-3919	686	3	d’allergologie	d’allergologie	PROPN
gs-3919	686	4	,	,	PUNCT
gs-3919	686	5	64(6	64(6	NUM
gs-3919	686	6	)	)	PUNCT
gs-3919	686	7	,	,	PUNCT
gs-3919	686	8	104161	104161	NUM
gs-3919	686	9	.	.	PUNCT
gs-3919	687	1	44	44	NUM
gs-3919	687	2	.	.	PUNCT
gs-3919	688	1	st	st	PROPN
gs-3919	688	2	george	george	PROPN
gs-3919	688	3	-	-	PUNCT
gs-3919	688	4	hyslop	hyslop	PROPN
gs-3919	688	5	,	,	PUNCT
gs-3919	688	6	f.	f.	PROPN
gs-3919	688	7	,	,	PUNCT
gs-3919	688	8	cherepacha	cherepacha	PROPN
gs-3919	688	9	,	,	PUNCT
gs-3919	688	10	n.	n.	NOUN
gs-3919	688	11	,	,	PUNCT
gs-3919	688	12	chugani	chugani	PROPN
gs-3919	688	13	,	,	PUNCT
gs-3919	688	14	b.	b.	PROPN
gs-3919	688	15	,	,	PUNCT
gs-3919	688	16	alabdeen	alabdeen	ADJ
gs-3919	688	17	,	,	PUNCT
gs-3919	688	18	y.	y.	PROPN
gs-3919	688	19	,	,	PUNCT
gs-3919	688	20	sanchez	sanchez	PROPN
gs-3919	688	21	-	-	PUNCT
gs-3919	688	22	espino	espino	PROPN
gs-3919	688	23	,	,	PUNCT
gs-3919	688	24	l.	l.	PROPN
gs-3919	688	25	f.	f.	PROPN
gs-3919	688	26	,	,	PUNCT
gs-3919	688	27	mahood	mahood	PROPN
gs-3919	688	28	,	,	PUNCT
gs-3919	688	29	q.	q.	NOUN
gs-3919	688	30	,	,	PUNCT
gs-3919	688	31	sibbald	sibbald	NOUN
gs-3919	688	32	,	,	PUNCT
gs-3919	688	33	c.	c.	PROPN
gs-3919	688	34	,	,	PUNCT
gs-3919	688	35	&	&	CCONJ
gs-3919	688	36	verstegen	verstegen	PROPN
gs-3919	688	37	,	,	PUNCT
gs-3919	688	38	r.	r.	PROPN
gs-3919	688	39	h.	h.	PROPN
gs-3919	688	40	j.	j.	PROPN
gs-3919	688	41	(	(	PUNCT
gs-3919	688	42	2024	2024	NUM
gs-3919	688	43	)	)	PUNCT
gs-3919	688	44	.	.	PUNCT
gs-3919	689	1	clinical	clinical	ADJ
gs-3919	689	2	presentation	presentation	NOUN
gs-3919	689	3	and	and	CCONJ
gs-3919	689	4	diagnosis	diagnosis	NOUN
gs-3919	689	5	of	of	ADP
gs-3919	689	6	drug	drug	NOUN
gs-3919	689	7	reaction	reaction	NOUN
gs-3919	689	8	with	with	ADP
gs-3919	689	9	eosinophilia	eosinophilia	PROPN
gs-3919	689	10	and	and	CCONJ
gs-3919	689	11	systemic	systemic	ADJ
gs-3919	689	12	symptoms	symptom	NOUN
gs-3919	689	13	(	(	PUNCT
gs-3919	689	14	dress	dress	NOUN
gs-3919	689	15	)	)	PUNCT
gs-3919	689	16	in	in	ADP
gs-3919	689	17	children	child	NOUN
gs-3919	689	18	:	:	PUNCT
gs-3919	689	19	a	a	DET
gs-3919	689	20	scoping	scope	VERB
gs-3919	689	21	review	review	NOUN
gs-3919	689	22	.	.	PUNCT
gs-3919	690	1	clinical	clinical	ADJ
gs-3919	690	2	reviews	review	NOUN
gs-3919	690	3	in	in	ADP
gs-3919	690	4	allergy	allergy	PROPN
gs-3919	690	5	&	&	CCONJ
gs-3919	690	6	immunology	immunology	NOUN
gs-3919	690	7	,	,	PUNCT
gs-3919	690	8	66(1	66(1	NOUN
gs-3919	690	9	)	)	PUNCT
gs-3919	690	10	,	,	PUNCT
gs-3919	690	11	112–123	112–123	NUM
gs-3919	690	12	.	.	PUNCT
gs-3919	691	1	45	45	NUM
gs-3919	691	2	.	.	PUNCT
gs-3919	691	3	taweesedt	taweesedt	PROPN
gs-3919	691	4	,	,	PUNCT
gs-3919	691	5	p.	p.	PROPN
gs-3919	691	6	t.	t.	PROPN
gs-3919	691	7	,	,	PUNCT
gs-3919	691	8	nordstrom	nordstrom	PROPN
gs-3919	691	9	,	,	PUNCT
gs-3919	691	10	c.	c.	PROPN
gs-3919	691	11	w.	w.	PROPN
gs-3919	691	12	,	,	PUNCT
gs-3919	691	13	stoeckel	stoeckel	PROPN
gs-3919	691	14	,	,	PUNCT
gs-3919	691	15	j.	j.	PROPN
gs-3919	691	16	,	,	PUNCT
gs-3919	691	17	&	&	CCONJ
gs-3919	691	18	dumic	dumic	PROPN
gs-3919	691	19	,	,	PUNCT
gs-3919	691	20	i.	i.	PROPN
gs-3919	691	21	(	(	PUNCT
gs-3919	691	22	2019	2019	NUM
gs-3919	691	23	)	)	PUNCT
gs-3919	691	24	.	.	PUNCT
gs-3919	692	1	pulmonary	pulmonary	ADJ
gs-3919	692	2	manifestations	manifestation	NOUN
gs-3919	692	3	of	of	ADP
gs-3919	692	4	drug	drug	NOUN
gs-3919	692	5	reaction	reaction	NOUN
gs-3919	692	6	with	with	ADP
gs-3919	692	7	eosinophilia	eosinophilia	PROPN
gs-3919	692	8	and	and	CCONJ
gs-3919	692	9	systemic	systemic	ADJ
gs-3919	692	10	symptoms	symptom	NOUN
gs-3919	692	11	(	(	PUNCT
gs-3919	692	12	dress	dress	NOUN
gs-3919	692	13	)	)	PUNCT
gs-3919	692	14	syndrome	syndrome	NOUN
gs-3919	692	15	:	:	PUNCT
gs-3919	692	16	a	a	DET
gs-3919	692	17	systematic	systematic	ADJ
gs-3919	692	18	review	review	NOUN
gs-3919	692	19	.	.	PUNCT
gs-3919	692	20	biomed	biome	VERB
gs-3919	692	21	research	research	NOUN
gs-3919	692	22	international	international	PROPN
gs-3919	692	23	,	,	PUNCT
gs-3919	692	24	2019	2019	NUM
gs-3919	692	25	,	,	PUNCT
gs-3919	692	26	1–10	1–10	NOUN
gs-3919	692	27	.	.	PUNCT
gs-3919	693	1	46	46	NUM
gs-3919	693	2	.	.	PUNCT
gs-3919	693	3	thaw	thaw	NOUN
gs-3919	693	4	,	,	PUNCT
gs-3919	693	5	k.	k.	PROPN
gs-3919	693	6	m.	m.	PROPN
gs-3919	693	7	,	,	PUNCT
gs-3919	693	8	ko	ko	PROPN
gs-3919	693	9	,	,	PUNCT
gs-3919	693	10	e.	e.	PROPN
gs-3919	693	11	k.	k.	PROPN
gs-3919	693	12	,	,	PUNCT
gs-3919	693	13	&	&	CCONJ
gs-3919	693	14	kazi	kazi	PROPN
gs-3919	693	15	,	,	PUNCT
gs-3919	694	1	a.	a.	PROPN
gs-3919	694	2	u.	u.	PROPN
gs-3919	694	3	(	(	PUNCT
gs-3919	694	4	2024	2024	NUM
gs-3919	694	5	)	)	PUNCT
gs-3919	694	6	.	.	PUNCT
gs-3919	695	1	atypical	atypical	ADJ
gs-3919	695	2	presentation	presentation	NOUN
gs-3919	695	3	of	of	ADP
gs-3919	695	4	drug	drug	NOUN
gs-3919	695	5	reaction	reaction	NOUN
gs-3919	695	6	with	with	ADP
gs-3919	695	7	eosinophilia	eosinophilia	PROPN
gs-3919	695	8	and	and	CCONJ
gs-3919	695	9	systemic	systemic	ADJ
gs-3919	695	10	symptoms	symptom	NOUN
gs-3919	695	11	(	(	PUNCT
gs-3919	695	12	dress	dress	NOUN
gs-3919	695	13	)	)	PUNCT
gs-3919	695	14	syndrome	syndrome	NOUN
gs-3919	695	15	:	:	PUNCT
gs-3919	695	16	when	when	SCONJ
gs-3919	695	17	gastrointestinal	gastrointestinal	ADJ
gs-3919	695	18	symptoms	symptom	NOUN
gs-3919	695	19	obscure	obscure	VERB
gs-3919	695	20	the	the	DET
gs-3919	695	21	diagnosis	diagnosis	NOUN
gs-3919	695	22	.	.	PUNCT
gs-3919	696	1	cureus	cureus	NOUN
gs-3919	696	2	.	.	PUNCT
gs-3919	697	1	47	47	NUM
gs-3919	697	2	.	.	PUNCT
gs-3919	698	1	thompson	thompson	PROPN
gs-3919	698	2	,	,	PUNCT
gs-3919	698	3	g.	g.	PROPN
gs-3919	698	4	,	,	PUNCT
gs-3919	698	5	ali	ali	PROPN
gs-3919	698	6	,	,	PUNCT
gs-3919	698	7	s.	s.	PROPN
gs-3919	698	8	,	,	PUNCT
gs-3919	698	9	trevenen	trevenen	NOUN
gs-3919	698	10	,	,	PUNCT
gs-3919	698	11	m.	m.	NOUN
gs-3919	698	12	,	,	PUNCT
gs-3919	698	13	vlaskovsky	vlaskovsky	NOUN
gs-3919	698	14	,	,	PUNCT
gs-3919	698	15	p.	p.	PROPN
gs-3919	698	16	,	,	PUNCT
gs-3919	698	17	murray	murray	PROPN
gs-3919	698	18	,	,	PUNCT
gs-3919	698	19	k.	k.	PROPN
gs-3919	698	20	,	,	PUNCT
gs-3919	698	21	&	&	CCONJ
gs-3919	698	22	lucas	lucas	PROPN
gs-3919	698	23	,	,	PUNCT
gs-3919	698	24	m.	m.	NOUN
gs-3919	698	25	(	(	PUNCT
gs-3919	698	26	2024	2024	NUM
gs-3919	698	27	)	)	PUNCT
gs-3919	698	28	.	.	PUNCT
gs-3919	699	1	distinguishing	distinguish	VERB
gs-3919	699	2	dress	dress	NOUN
gs-3919	699	3	syndrome	syndrome	NOUN
gs-3919	699	4	from	from	ADP
gs-3919	699	5	drug	drug	NOUN
gs-3919	699	6	rash	rash	NOUN
gs-3919	699	7	and	and	CCONJ
gs-3919	699	8	eosinophilia	eosinophilia	PROPN
gs-3919	699	9	:	:	PUNCT
gs-3919	699	10	beyond	beyond	ADP
gs-3919	699	11	the	the	DET
gs-3919	699	12	regiscar	regiscar	NOUN
gs-3919	699	13	criteria	criterion	NOUN
gs-3919	699	14	.	.	PUNCT
gs-3919	700	1	journal	journal	PROPN
gs-3919	700	2	of	of	ADP
gs-3919	700	3	allergy	allergy	PROPN
gs-3919	700	4	and	and	CCONJ
gs-3919	700	5	clinical	clinical	ADJ
gs-3919	700	6	immunology	immunology	NOUN
gs-3919	700	7	global	global	NOUN
gs-3919	700	8	,	,	PUNCT
gs-3919	700	9	3(4	3(4	NUM
gs-3919	700	10	)	)	PUNCT
gs-3919	700	11	,	,	PUNCT
gs-3919	700	12	100346	100346	NUM
gs-3919	700	13	.	.	PUNCT
gs-3919	701	1	48	48	NUM
gs-3919	701	2	.	.	PUNCT
gs-3919	702	1	tran	tran	PROPN
gs-3919	702	2	,	,	PUNCT
gs-3919	702	3	h.	h.	PROPN
gs-3919	702	4	,	,	PUNCT
gs-3919	702	5	&	&	CCONJ
gs-3919	702	6	bhatt	bhatt	PROPN
gs-3919	702	7	,	,	PUNCT
gs-3919	702	8	g.	g.	PROPN
gs-3919	702	9	(	(	PUNCT
gs-3919	702	10	2024	2024	NUM
gs-3919	702	11	)	)	PUNCT
gs-3919	702	12	.	.	PUNCT
gs-3919	703	1	atypical	atypical	ADJ
gs-3919	703	2	presentation	presentation	NOUN
gs-3919	703	3	of	of	ADP
gs-3919	703	4	drug	drug	NOUN
gs-3919	703	5	reaction	reaction	NOUN
gs-3919	703	6	with	with	ADP
gs-3919	703	7	eosinophilia	eosinophilia	PROPN
gs-3919	703	8	and	and	CCONJ
gs-3919	703	9	systemic	systemic	ADJ
gs-3919	703	10	symptoms	symptom	NOUN
gs-3919	703	11	(	(	PUNCT
gs-3919	703	12	dress	dress	NOUN
gs-3919	703	13	)	)	PUNCT
gs-3919	703	14	in	in	ADP
gs-3919	703	15	a	a	DET
gs-3919	703	16	patient	patient	NOUN
gs-3919	703	17	on	on	ADP
gs-3919	703	18	pembrolizumab	pembrolizumab	NOUN
gs-3919	703	19	:	:	PUNCT
gs-3919	703	20	a	a	DET
gs-3919	703	21	case	case	NOUN
gs-3919	703	22	report	report	NOUN
gs-3919	703	23	.	.	PUNCT
gs-3919	704	1	cureus	cureus	NOUN
gs-3919	704	2	.	.	PUNCT
gs-3919	705	1	49	49	NUM
gs-3919	705	2	.	.	PUNCT
gs-3919	706	1	tsevat	tsevat	PROPN
gs-3919	706	2	,	,	PUNCT
gs-3919	706	3	r.	r.	PROPN
gs-3919	706	4	k.	k.	PROPN
gs-3919	706	5	,	,	PUNCT
gs-3919	706	6	fisher	fisher	PROPN
gs-3919	706	7	,	,	PUNCT
gs-3919	706	8	o.	o.	PROPN
gs-3919	706	9	,	,	PUNCT
gs-3919	706	10	tsevat	tsevat	PROPN
gs-3919	706	11	,	,	PUNCT
gs-3919	706	12	d.	d.	PROPN
gs-3919	706	13	g.	g.	PROPN
gs-3919	706	14	,	,	PUNCT
gs-3919	706	15	brigmon	brigmon	PROPN
gs-3919	706	16	,	,	PUNCT
gs-3919	706	17	e.	e.	PROPN
gs-3919	706	18	,	,	PUNCT
gs-3919	706	19	crane	crane	NOUN
gs-3919	706	20	,	,	PUNCT
gs-3919	706	21	c.	c.	PROPN
gs-3919	706	22	,	,	PUNCT
gs-3919	706	23	hartzler	hartzler	NOUN
gs-3919	706	24	,	,	PUNCT
gs-3919	706	25	a.	a.	PROPN
gs-3919	706	26	,	,	PUNCT
gs-3919	706	27	becker	becker	PROPN
gs-3919	706	28	,	,	PUNCT
gs-3919	706	29	e.	e.	PROPN
gs-3919	706	30	m.	m.	PROPN
gs-3919	706	31	,	,	PUNCT
gs-3919	706	32	brooks	brooks	PROPN
gs-3919	706	33	,	,	PUNCT
gs-3919	706	34	e.	e.	PROPN
gs-3919	706	35	g.	g.	PROPN
gs-3919	706	36	,	,	PUNCT
gs-3919	706	37	kaur	kaur	PROPN
gs-3919	706	38	,	,	PUNCT
gs-3919	706	39	s.	s.	PROPN
gs-3919	706	40	,	,	PUNCT
gs-3919	706	41	&	&	CCONJ
gs-3919	706	42	tsevat	tsevat	PROPN
gs-3919	706	43	,	,	PUNCT
gs-3919	706	44	j.	j.	PROPN
gs-3919	706	45	(	(	PUNCT
gs-3919	706	46	2023	2023	NUM
gs-3919	706	47	)	)	PUNCT
gs-3919	706	48	.	.	PUNCT
gs-3919	707	1	drug	drug	NOUN
gs-3919	707	2	reaction	reaction	NOUN
gs-3919	707	3	with	with	ADP
gs-3919	707	4	eosinophilia	eosinophilia	PROPN
gs-3919	707	5	and	and	CCONJ
gs-3919	707	6	systemic	systemic	ADJ
gs-3919	707	7	symptoms	symptom	NOUN
gs-3919	707	8	(	(	PUNCT
gs-3919	707	9	dress	dress	NOUN
gs-3919	707	10	)	)	PUNCT
gs-3919	707	11	with	with	ADP
gs-3919	707	12	eosinophilic	eosinophilic	ADJ
gs-3919	707	13	cholecystitis	cholecystitis	NOUN
gs-3919	707	14	triggered	trigger	VERB
gs-3919	707	15	by	by	ADP
gs-3919	707	16	topical	topical	ADJ
gs-3919	707	17	diclofenac	diclofenac	NOUN
gs-3919	707	18	.	.	PUNCT
gs-3919	708	1	annals	annal	NOUN
gs-3919	708	2	of	of	ADP
gs-3919	708	3	internal	internal	ADJ
gs-3919	708	4	medicine	medicine	NOUN
gs-3919	708	5	clinical	clinical	ADJ
gs-3919	708	6	cases	case	NOUN
gs-3919	708	7	,	,	PUNCT
gs-3919	708	8	2(12	2(12	NUM
gs-3919	708	9	)	)	PUNCT
gs-3919	708	10	.	.	PUNCT
gs-3919	709	1	50	50	NUM
gs-3919	709	2	.	.	X
gs-3919	709	3	waseem	waseem	PROPN
gs-3919	709	4	,	,	PUNCT
gs-3919	709	5	h.	h.	PROPN
gs-3919	709	6	,	,	PUNCT
gs-3919	709	7	inayat	inayat	PROPN
gs-3919	709	8	,	,	PUNCT
gs-3919	709	9	f.	f.	PROPN
gs-3919	709	10	,	,	PUNCT
gs-3919	709	11	abduraimova	abduraimova	PROPN
gs-3919	709	12	,	,	PUNCT
gs-3919	709	13	m.	m.	NOUN
gs-3919	709	14	,	,	PUNCT
gs-3919	709	15	&	&	CCONJ
gs-3919	709	16	kamholz	kamholz	PROPN
gs-3919	709	17	,	,	PUNCT
gs-3919	709	18	s.	s.	PROPN
gs-3919	709	19	(	(	PUNCT
gs-3919	709	20	2017	2017	NUM
gs-3919	709	21	)	)	PUNCT
gs-3919	709	22	.	.	PUNCT
gs-3919	710	1	allopurinolinduced	allopurinolinduce	VERB
gs-3919	710	2	drug	drug	NOUN
gs-3919	710	3	reaction	reaction	NOUN
gs-3919	710	4	with	with	ADP
gs-3919	710	5	eosinophilia	eosinophilia	PROPN
gs-3919	710	6	and	and	CCONJ
gs-3919	710	7	systemic	systemic	ADJ
gs-3919	710	8	symptoms	symptom	NOUN
gs-3919	710	9	syndrome	syndrome	VERB
gs-3919	710	10	:	:	PUNCT
gs-3919	710	11	a	a	DET
gs-3919	710	12	cause	cause	NOUN
gs-3919	710	13	of	of	ADP
gs-3919	710	14	acalculous	acalculous	ADJ
gs-3919	710	15	cholecystitis	cholecystitis	NOUN
gs-3919	710	16	?	?	PUNCT
gs-3919	711	1	cureus	cureus	NOUN
gs-3919	711	2	.	.	PUNCT
gs-3919	712	1	51	51	NUM
gs-3919	712	2	.	.	PUNCT
gs-3919	712	3	watanabe	watanabe	PROPN
gs-3919	712	4	,	,	PUNCT
gs-3919	712	5	h.	h.	PROPN
gs-3919	712	6	(	(	PUNCT
gs-3919	712	7	2018	2018	NUM
gs-3919	712	8	)	)	PUNCT
gs-3919	712	9	.	.	PUNCT
gs-3919	713	1	recent	recent	ADJ
gs-3919	713	2	advances	advance	NOUN
gs-3919	713	3	in	in	ADP
gs-3919	713	4	drug	drug	NOUN
gs-3919	713	5	-	-	PUNCT
gs-3919	713	6	induced	induce	VERB
gs-3919	713	7	hypersensitivity	hypersensitivity	NOUN
gs-3919	713	8	syndrome	syndrome	NOUN
gs-3919	713	9	/	/	SYM
gs-3919	713	10	drug	drug	NOUN
gs-3919	713	11	reaction	reaction	NOUN
gs-3919	713	12	with	with	ADP
gs-3919	713	13	eosinophilia	eosinophilia	PROPN
gs-3919	713	14	and	and	CCONJ
gs-3919	713	15	systemic	systemic	ADJ
gs-3919	713	16	symptoms	symptom	NOUN
gs-3919	713	17	.	.	PUNCT
gs-3919	714	1	journal	journal	NOUN
gs-3919	714	2	of	of	ADP
gs-3919	714	3	immunology	immunology	NOUN
gs-3919	714	4	research	research	NOUN
gs-3919	714	5	,	,	PUNCT
gs-3919	714	6	2018	2018	NUM
gs-3919	714	7	,	,	PUNCT
gs-3919	714	8	1–10	1–10	NOUN
gs-3919	714	9	.	.	PUNCT
gs-3919	715	1	52	52	NUM
gs-3919	715	2	.	.	X
gs-3919	715	3	weaver	weaver	NOUN
gs-3919	715	4	,	,	PUNCT
gs-3919	715	5	m.	m.	NOUN
gs-3919	715	6	d.	d.	PROPN
gs-3919	715	7	,	,	PUNCT
gs-3919	715	8	glass	glass	PROPN
gs-3919	715	9	,	,	PUNCT
gs-3919	715	10	b.	b.	PROPN
gs-3919	715	11	,	,	PUNCT
gs-3919	715	12	aplanalp	aplanalp	PROPN
gs-3919	715	13	,	,	PUNCT
gs-3919	715	14	c.	c.	PROPN
gs-3919	715	15	,	,	PUNCT
gs-3919	715	16	patel	patel	PROPN
gs-3919	715	17	,	,	PUNCT
gs-3919	715	18	g.	g.	PROPN
gs-3919	715	19	,	,	PUNCT
gs-3919	715	20	mazhil	mazhil	PROPN
gs-3919	715	21	,	,	PUNCT
gs-3919	715	22	j.	j.	PROPN
gs-3919	715	23	,	,	PUNCT
gs-3919	715	24	wang	wang	PROPN
gs-3919	715	25	,	,	PUNCT
gs-3919	715	26	i.	i.	PROPN
gs-3919	715	27	,	,	PUNCT
gs-3919	715	28	&	&	CCONJ
gs-3919	715	29	dalia	dalia	PROPN
gs-3919	715	30	,	,	PUNCT
gs-3919	715	31	s.	s.	PROPN
gs-3919	715	32	(	(	PUNCT
gs-3919	715	33	2024	2024	NUM
gs-3919	715	34	)	)	PUNCT
gs-3919	715	35	.	.	PUNCT
gs-3919	716	1	review	review	NOUN
gs-3919	716	2	of	of	ADP
gs-3919	716	3	peripheral	peripheral	ADJ
gs-3919	716	4	blood	blood	NOUN
gs-3919	716	5	eosinophilia	eosinophilia	PROPN
gs-3919	716	6	:	:	PUNCT
gs-3919	716	7	workup	workup	NOUN
gs-3919	716	8	and	and	CCONJ
gs-3919	716	9	differential	differential	ADJ
gs-3919	716	10	diagnosis	diagnosis	NOUN
gs-3919	716	11	.	.	PUNCT
gs-3919	717	1	hemato	hemato	NOUN
gs-3919	717	2	,	,	PUNCT
gs-3919	717	3	5(1	5(1	NUM
gs-3919	717	4	)	)	PUNCT
gs-3919	717	5	,	,	PUNCT
gs-3919	717	6	81–108	81–108	NUM
gs-3919	717	7	.	.	PUNCT
gs-3919	718	1	georgian	georgian	ADJ
gs-3919	718	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	718	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	718	4	ტ.	ტ.	VERB
gs-3919	718	5	7	7	NUM
gs-3919	718	6	n	n	PRON
gs-3919	718	7	3	3	NUM
gs-3919	718	8	,	,	PUNCT
gs-3919	718	9	2025	2025	NUM
gs-3919	718	10	178	178	NUM
gs-3919	718	11	53	53	NUM
gs-3919	718	12	.	.	PUNCT
gs-3919	719	1	wei	wei	PROPN
gs-3919	719	2	,	,	PUNCT
gs-3919	719	3	b.	b.	PROPN
gs-3919	719	4	m.	m.	PROPN
gs-3919	719	5	,	,	PUNCT
gs-3919	719	6	fox	fox	PROPN
gs-3919	719	7	,	,	PUNCT
gs-3919	719	8	l.	l.	PROPN
gs-3919	719	9	p.	p.	PROPN
gs-3919	719	10	,	,	PUNCT
gs-3919	719	11	kaffenberger	kaffenberger	PROPN
gs-3919	719	12	,	,	PUNCT
gs-3919	719	13	b.	b.	PROPN
gs-3919	719	14	h.	h.	PROPN
gs-3919	719	15	,	,	PUNCT
gs-3919	719	16	korman	korman	PROPN
gs-3919	719	17	,	,	PUNCT
gs-3919	719	18	a.	a.	NOUN
gs-3919	719	19	m.	m.	NOUN
gs-3919	719	20	,	,	PUNCT
gs-3919	719	21	micheletti	micheletti	PROPN
gs-3919	719	22	,	,	PUNCT
gs-3919	719	23	r.	r.	PROPN
gs-3919	719	24	g.	g.	PROPN
gs-3919	719	25	,	,	PUNCT
gs-3919	719	26	mostaghimi	mostaghimi	PROPN
gs-3919	719	27	,	,	PUNCT
gs-3919	719	28	a.	a.	NOUN
gs-3919	719	29	,	,	PUNCT
gs-3919	719	30	noe	noe	PROPN
gs-3919	719	31	,	,	PUNCT
gs-3919	719	32	m.	m.	PROPN
gs-3919	719	33	h.	h.	PROPN
gs-3919	719	34	,	,	PUNCT
gs-3919	719	35	rosenbach	rosenbach	NOUN
gs-3919	719	36	,	,	PUNCT
gs-3919	719	37	m.	m.	NOUN
gs-3919	719	38	,	,	PUNCT
gs-3919	719	39	shinkai	shinkai	PROPN
gs-3919	719	40	,	,	PUNCT
gs-3919	719	41	k.	k.	PROPN
gs-3919	719	42	,	,	PUNCT
gs-3919	719	43	kwah	kwah	PROPN
gs-3919	719	44	,	,	PUNCT
gs-3919	719	45	j.	j.	PROPN
gs-3919	719	46	h.	h.	PROPN
gs-3919	719	47	,	,	PUNCT
gs-3919	719	48	phillips	phillips	PROPN
gs-3919	719	49	,	,	PUNCT
gs-3919	719	50	e.	e.	PROPN
gs-3919	719	51	j.	j.	PROPN
gs-3919	719	52	,	,	PUNCT
gs-3919	719	53	bolognia	bolognia	PROPN
gs-3919	719	54	,	,	PUNCT
gs-3919	719	55	j.	j.	PROPN
gs-3919	719	56	l.	l.	PROPN
gs-3919	719	57	,	,	PUNCT
gs-3919	719	58	damsky	damsky	PROPN
gs-3919	719	59	,	,	PUNCT
gs-3919	719	60	w.	w.	PROPN
gs-3919	719	61	,	,	PUNCT
gs-3919	719	62	&	&	CCONJ
gs-3919	719	63	nelson	nelson	PROPN
gs-3919	719	64	,	,	PUNCT
gs-3919	719	65	c.	c.	PROPN
gs-3919	719	66	a.	a.	PROPN
gs-3919	719	67	(	(	PUNCT
gs-3919	719	68	2023	2023	NUM
gs-3919	719	69	)	)	PUNCT
gs-3919	719	70	.	.	PUNCT
gs-3919	720	1	drug	drug	NOUN
gs-3919	720	2	-	-	PUNCT
gs-3919	720	3	induced	induce	VERB
gs-3919	720	4	hypersensitivity	hypersensitivity	NOUN
gs-3919	720	5	syndrome	syndrome	NOUN
gs-3919	720	6	/	/	SYM
gs-3919	720	7	drug	drug	NOUN
gs-3919	720	8	reaction	reaction	NOUN
gs-3919	720	9	with	with	ADP
gs-3919	720	10	eosinophilia	eosinophilia	PROPN
gs-3919	720	11	and	and	CCONJ
gs-3919	720	12	systemic	systemic	ADJ
gs-3919	720	13	symptoms	symptom	NOUN
gs-3919	720	14	.	.	PUNCT
gs-3919	721	1	part	part	NOUN
gs-3919	721	2	i.	i.	PROPN
gs-3919	721	3	epidemiology	epidemiology	PROPN
gs-3919	721	4	,	,	PUNCT
gs-3919	721	5	pathogenesis	pathogenesis	NOUN
gs-3919	721	6	,	,	PUNCT
gs-3919	721	7	clinicopathological	clinicopathological	ADJ
gs-3919	721	8	features	feature	NOUN
gs-3919	721	9	,	,	PUNCT
gs-3919	721	10	and	and	CCONJ
gs-3919	721	11	prognosis	prognosis	NOUN
gs-3919	721	12	.	.	PUNCT
gs-3919	722	1	journal	journal	NOUN
gs-3919	722	2	of	of	ADP
gs-3919	722	3	the	the	DET
gs-3919	722	4	american	american	PROPN
gs-3919	722	5	academy	academy	PROPN
gs-3919	722	6	of	of	ADP
gs-3919	722	7	dermatology	dermatology	NOUN
gs-3919	722	8	,	,	PUNCT
gs-3919	722	9	90(5	90(5	NUM
gs-3919	722	10	)	)	PUNCT
gs-3919	722	11	,	,	PUNCT
gs-3919	722	12	885–908	885–908	NUM
gs-3919	722	13	.	.	PUNCT
gs-3919	723	1	54	54	NUM
gs-3919	723	2	.	.	PUNCT
gs-3919	723	3	woessner	woessner	NOUN
gs-3919	723	4	,	,	PUNCT
gs-3919	723	5	k.	k.	PROPN
gs-3919	723	6	m.	m.	PROPN
gs-3919	723	7	,	,	PUNCT
gs-3919	723	8	&	&	CCONJ
gs-3919	723	9	castells	castells	PROPN
gs-3919	723	10	,	,	PUNCT
gs-3919	723	11	m.	m.	NOUN
gs-3919	723	12	(	(	PUNCT
gs-3919	723	13	2013	2013	NUM
gs-3919	723	14	)	)	PUNCT
gs-3919	723	15	.	.	PUNCT
gs-3919	724	1	nsaid	nsaid	PROPN
gs-3919	724	2	single	single	ADJ
gs-3919	724	3	-	-	PUNCT
gs-3919	724	4	drug	drug	NOUN
gs-3919	724	5	–	–	PUNCT
gs-3919	724	6	induced	induce	VERB
gs-3919	724	7	reactions	reaction	NOUN
gs-3919	724	8	.	.	PUNCT
gs-3919	725	1	immunology	immunology	NOUN
gs-3919	725	2	and	and	CCONJ
gs-3919	725	3	allergy	allergy	NOUN
gs-3919	725	4	clinics	clinic	NOUN
gs-3919	725	5	of	of	ADP
gs-3919	725	6	north	north	PROPN
gs-3919	725	7	america	america	PROPN
gs-3919	725	8	,	,	PUNCT
gs-3919	725	9	33(2	33(2	NUM
gs-3919	725	10	)	)	PUNCT
gs-3919	725	11	,	,	PUNCT
gs-3919	725	12	237–249	237–249	NUM
gs-3919	725	13	.	.	PUNCT
gs-3919	726	1	55	55	NUM
gs-3919	726	2	.	.	PUNCT
gs-3919	727	1	wolfson	wolfson	PROPN
gs-3919	727	2	,	,	PUNCT
gs-3919	727	3	a.	a.	PROPN
gs-3919	727	4	r.	r.	PROPN
gs-3919	727	5	,	,	PUNCT
gs-3919	727	6	zhou	zhou	PROPN
gs-3919	727	7	,	,	PUNCT
gs-3919	727	8	l.	l.	PROPN
gs-3919	727	9	,	,	PUNCT
gs-3919	727	10	li	li	PROPN
gs-3919	727	11	,	,	PUNCT
gs-3919	727	12	y.	y.	PROPN
gs-3919	727	13	,	,	PUNCT
gs-3919	727	14	phadke	phadke	NOUN
gs-3919	727	15	,	,	PUNCT
gs-3919	727	16	n.	n.	PROPN
gs-3919	727	17	a.	a.	PROPN
gs-3919	727	18	,	,	PUNCT
gs-3919	727	19	chow	chow	PROPN
gs-3919	727	20	,	,	PUNCT
gs-3919	727	21	o.	o.	PROPN
gs-3919	727	22	a.	a.	PROPN
gs-3919	727	23	,	,	PUNCT
gs-3919	727	24	&	&	CCONJ
gs-3919	727	25	blumenthal	blumenthal	PROPN
gs-3919	727	26	,	,	PUNCT
gs-3919	727	27	k.	k.	PROPN
gs-3919	727	28	g.	g.	PROPN
gs-3919	727	29	(	(	PUNCT
gs-3919	727	30	2018	2018	NUM
gs-3919	727	31	)	)	PUNCT
gs-3919	727	32	.	.	PUNCT
gs-3919	728	1	drug	drug	NOUN
gs-3919	728	2	reaction	reaction	NOUN
gs-3919	728	3	with	with	ADP
gs-3919	728	4	eosinophilia	eosinophilia	PROPN
gs-3919	728	5	and	and	CCONJ
gs-3919	728	6	systemic	systemic	ADJ
gs-3919	728	7	symptoms	symptom	NOUN
gs-3919	728	8	(	(	PUNCT
gs-3919	728	9	dress	dress	NOUN
gs-3919	728	10	)	)	PUNCT
gs-3919	728	11	syndrome	syndrome	NOUN
gs-3919	728	12	identified	identify	VERB
gs-3919	728	13	in	in	ADP
gs-3919	728	14	the	the	DET
gs-3919	728	15	electronic	electronic	ADJ
gs-3919	728	16	health	health	NOUN
gs-3919	728	17	record	record	NOUN
gs-3919	728	18	allergy	allergy	NOUN
gs-3919	728	19	module	module	NOUN
gs-3919	728	20	.	.	PUNCT
gs-3919	729	1	the	the	DET
gs-3919	729	2	journal	journal	PROPN
gs-3919	729	3	of	of	ADP
gs-3919	729	4	allergy	allergy	NOUN
gs-3919	729	5	and	and	CCONJ
gs-3919	729	6	clinical	clinical	ADJ
gs-3919	729	7	immunology	immunology	NOUN
gs-3919	729	8	in	in	ADP
gs-3919	729	9	practice	practice	NOUN
gs-3919	729	10	,	,	PUNCT
gs-3919	729	11	7(2	7(2	NUM
gs-3919	729	12	)	)	PUNCT
gs-3919	729	13	,	,	PUNCT
gs-3919	729	14	633–640	633–640	NUM
gs-3919	729	15	.	.	PUNCT
gs-3919	730	1	56	56	NUM
gs-3919	730	2	.	.	X
gs-3919	730	3	bocquet	bocquet	PROPN
gs-3919	730	4	,	,	PUNCT
gs-3919	730	5	hugues	hugue	NOUN
gs-3919	730	6	,	,	PUNCT
gs-3919	730	7	martine	martine	PROPN
gs-3919	730	8	bagot	bagot	PROPN
gs-3919	730	9	,	,	PUNCT
gs-3919	730	10	and	and	CCONJ
gs-3919	730	11	jean	jean	PROPN
gs-3919	730	12	-	-	PUNCT
gs-3919	730	13	claude	claude	PROPN
gs-3919	730	14	roujeau	roujeau	PROPN
gs-3919	730	15	.	.	PUNCT
gs-3919	731	1	"	"	PUNCT
gs-3919	731	2	drug	drug	NOUN
gs-3919	731	3	-	-	PUNCT
gs-3919	731	4	induced	induce	VERB
gs-3919	731	5	pseudolymphoma	pseudolymphoma	NOUN
gs-3919	731	6	and	and	CCONJ
gs-3919	731	7	drug	drug	NOUN
gs-3919	731	8	hypersensitivity	hypersensitivity	NOUN
gs-3919	731	9	syndrome	syndrome	NOUN
gs-3919	731	10	(	(	PUNCT
gs-3919	731	11	drug	drug	NOUN
gs-3919	731	12	rash	rash	NOUN
gs-3919	731	13	with	with	ADP
gs-3919	731	14	eosinophilia	eosinophilia	PROPN
gs-3919	731	15	and	and	CCONJ
gs-3919	731	16	systemic	systemic	ADJ
gs-3919	731	17	symptoms	symptom	NOUN
gs-3919	731	18	:	:	PUNCT
gs-3919	731	19	dress	dress	NOUN
gs-3919	731	20	)	)	PUNCT
gs-3919	731	21	.	.	PUNCT
gs-3919	731	22	"	"	PUNCT
gs-3919	732	1	seminars	seminar	NOUN
gs-3919	732	2	in	in	ADP
gs-3919	732	3	cutaneous	cutaneous	ADJ
gs-3919	732	4	medicine	medicine	NOUN
gs-3919	732	5	and	and	CCONJ
gs-3919	732	6	surgery	surgery	NOUN
gs-3919	732	7	15	15	NUM
gs-3919	732	8	,	,	PUNCT
gs-3919	732	9	no	no	INTJ
gs-3919	732	10	.	.	NOUN
gs-3919	732	11	4	4	NUM
gs-3919	732	12	(	(	PUNCT
gs-3919	732	13	1996	1996	NUM
gs-3919	732	14	):	):	PUNCT
gs-3919	732	15	250	250	NUM
gs-3919	732	16	-	-	SYM
gs-3919	732	17	257	257	NUM
gs-3919	732	18	.	.	NOUN
gs-3919	733	1	57	57	NUM
gs-3919	733	2	.	.	PUNCT
gs-3919	733	3	cacoub	cacoub	PROPN
gs-3919	733	4	,	,	PUNCT
gs-3919	733	5	patrice	patrice	PROPN
gs-3919	733	6	,	,	PUNCT
gs-3919	733	7	philippe	philippe	PROPN
gs-3919	733	8	musette	musette	PROPN
gs-3919	733	9	,	,	PUNCT
gs-3919	733	10	and	and	CCONJ
gs-3919	733	11	valérie	valérie	ADJ
gs-3919	733	12	descamps	descamp	NOUN
gs-3919	733	13	.	.	PUNCT
gs-3919	734	1	"	"	PUNCT
gs-3919	734	2	the	the	DET
gs-3919	734	3	dress	dress	NOUN
gs-3919	734	4	syndrome	syndrome	NOUN
gs-3919	734	5	:	:	PUNCT
gs-3919	734	6	a	a	DET
gs-3919	734	7	literature	literature	NOUN
gs-3919	734	8	review	review	NOUN
gs-3919	734	9	.	.	PUNCT
gs-3919	734	10	"	"	PUNCT
gs-3919	735	1	american	american	ADJ
gs-3919	735	2	journal	journal	PROPN
gs-3919	735	3	of	of	ADP
gs-3919	735	4	medicine	medicine	PROPN
gs-3919	735	5	124	124	NUM
gs-3919	735	6	,	,	PUNCT
gs-3919	735	7	no	no	INTJ
gs-3919	735	8	.	.	NOUN
gs-3919	735	9	7	7	NUM
gs-3919	735	10	(	(	PUNCT
gs-3919	735	11	2011	2011	NUM
gs-3919	735	12	):	):	PUNCT
gs-3919	735	13	588	588	NUM
gs-3919	735	14	-	-	SYM
gs-3919	735	15	597	597	NUM
gs-3919	735	16	.	.	PUNCT
gs-3919	735	17	58	58	NUM
gs-3919	735	18	.	.	PUNCT
gs-3919	736	1	chen	chen	PROPN
gs-3919	736	2	,	,	PUNCT
gs-3919	736	3	yin	yin	PROPN
gs-3919	736	4	-	-	PUNCT
gs-3919	736	5	chun	chun	PROPN
gs-3919	736	6	,	,	PUNCT
gs-3919	736	7	chuang	chuang	PROPN
gs-3919	736	8	-	-	PUNCT
gs-3919	736	9	wei	wei	PROPN
gs-3919	736	10	wang	wang	PROPN
gs-3919	736	11	,	,	PUNCT
gs-3919	736	12	and	and	CCONJ
gs-3919	736	13	chun	chun	PROPN
gs-3919	736	14	-	-	PUNCT
gs-3919	736	15	bing	bing	VERB
gs-3919	736	16	chen	chen	PROPN
gs-3919	736	17	.	.	PUNCT
gs-3919	737	1	"	"	PUNCT
gs-3919	737	2	drug	drug	NOUN
gs-3919	737	3	reaction	reaction	NOUN
gs-3919	737	4	with	with	ADP
gs-3919	737	5	eosinophilia	eosinophilia	PROPN
gs-3919	737	6	and	and	CCONJ
gs-3919	737	7	systemic	systemic	ADJ
gs-3919	737	8	symptoms	symptom	NOUN
gs-3919	737	9	(	(	PUNCT
gs-3919	737	10	dress	dress	NOUN
gs-3919	737	11	):	):	PUNCT
gs-3919	737	12	an	an	DET
gs-3919	737	13	update	update	NOUN
gs-3919	737	14	on	on	ADP
gs-3919	737	15	pathophysiology	pathophysiology	NOUN
gs-3919	737	16	and	and	CCONJ
gs-3919	737	17	management	management	NOUN
gs-3919	737	18	.	.	PUNCT
gs-3919	737	19	"	"	PUNCT
gs-3919	737	20	journal	journal	PROPN
gs-3919	737	21	of	of	ADP
gs-3919	737	22	allergy	allergy	NOUN
gs-3919	737	23	and	and	CCONJ
gs-3919	737	24	clinical	clinical	ADJ
gs-3919	737	25	immunology	immunology	NOUN
gs-3919	737	26	in	in	ADP
gs-3919	737	27	practice	practice	NOUN
gs-3919	737	28	9	9	NUM
gs-3919	737	29	,	,	PUNCT
gs-3919	737	30	no	no	INTJ
gs-3919	737	31	.	.	NOUN
gs-3919	737	32	4	4	NUM
gs-3919	737	33	(	(	PUNCT
gs-3919	737	34	2021	2021	NUM
gs-3919	737	35	):	):	PUNCT
gs-3919	737	36	14931501	14931501	NUM
gs-3919	737	37	.	.	PUNCT
gs-3919	738	1	59	59	NUM
gs-3919	738	2	.	.	PUNCT
gs-3919	739	1	cho	cho	PROPN
gs-3919	739	2	,	,	PUNCT
gs-3919	739	3	young	young	ADJ
gs-3919	739	4	-	-	PUNCT
gs-3919	739	5	tae	tae	ADJ
gs-3919	739	6	,	,	PUNCT
gs-3919	739	7	chia	chia	PROPN
gs-3919	739	8	-	-	PUNCT
gs-3919	739	9	yu	yu	PROPN
gs-3919	739	10	chu	chu	PROPN
gs-3919	739	11	,	,	PUNCT
gs-3919	739	12	and	and	CCONJ
gs-3919	739	13	wen	wen	PROPN
gs-3919	739	14	-	-	PROPN
gs-3919	739	15	hung	hung	ADJ
gs-3919	739	16	chung	chung	PROPN
gs-3919	739	17	.	.	PUNCT
gs-3919	740	1	"	"	PUNCT
gs-3919	740	2	the	the	DET
gs-3919	740	3	pathophysiology	pathophysiology	NOUN
gs-3919	740	4	of	of	ADP
gs-3919	740	5	dress	dress	NOUN
gs-3919	740	6	syndrome	syndrome	NOUN
gs-3919	740	7	:	:	PUNCT
gs-3919	740	8	the	the	DET
gs-3919	740	9	role	role	NOUN
gs-3919	740	10	of	of	ADP
gs-3919	740	11	herpesvirus	herpesvirus	NOUN
gs-3919	740	12	reactivation	reactivation	NOUN
gs-3919	740	13	.	.	PUNCT
gs-3919	740	14	"	"	PUNCT
gs-3919	741	1	journal	journal	NOUN
gs-3919	741	2	of	of	ADP
gs-3919	741	3	immunology	immunology	NOUN
gs-3919	741	4	research	research	NOUN
gs-3919	741	5	2015	2015	NUM
gs-3919	741	6	(	(	PUNCT
gs-3919	741	7	2015	2015	NUM
gs-3919	741	8	):	):	PUNCT
gs-3919	741	9	1	1	NUM
gs-3919	741	10	-	-	SYM
gs-3919	741	11	8	8	NUM
gs-3919	741	12	.	.	PUNCT
gs-3919	741	13	60	60	NUM
gs-3919	741	14	.	.	PUNCT
gs-3919	742	1	descamps	descamp	NOUN
gs-3919	742	2	,	,	PUNCT
gs-3919	742	3	valérie	valérie	NOUN
gs-3919	742	4	,	,	PUNCT
gs-3919	742	5	and	and	CCONJ
gs-3919	742	6	philippe	philippe	PROPN
gs-3919	742	7	musette	musette	PROPN
gs-3919	742	8	.	.	PUNCT
gs-3919	743	1	"	"	PUNCT
gs-3919	743	2	drug	drug	NOUN
gs-3919	743	3	reaction	reaction	NOUN
gs-3919	743	4	with	with	ADP
gs-3919	743	5	eosinophilia	eosinophilia	PROPN
gs-3919	743	6	and	and	CCONJ
gs-3919	743	7	systemic	systemic	ADJ
gs-3919	743	8	symptoms	symptom	NOUN
gs-3919	743	9	(	(	PUNCT
gs-3919	743	10	dress	dress	NOUN
gs-3919	743	11	)	)	PUNCT
gs-3919	743	12	.	.	PUNCT
gs-3919	743	13	"	"	PUNCT
gs-3919	744	1	clinics	clinic	NOUN
gs-3919	744	2	in	in	ADP
gs-3919	744	3	dermatology	dermatology	NOUN
gs-3919	744	4	38	38	NUM
gs-3919	744	5	,	,	PUNCT
gs-3919	744	6	no	no	INTJ
gs-3919	744	7	.	.	NOUN
gs-3919	744	8	6	6	NUM
gs-3919	744	9	(	(	PUNCT
gs-3919	744	10	2020	2020	NUM
gs-3919	744	11	):	):	PUNCT
gs-3919	744	12	702	702	NUM
gs-3919	744	13	-	-	SYM
gs-3919	744	14	711	711	NUM
gs-3919	744	15	.	.	NOUN
gs-3919	744	16	61	61	NUM
gs-3919	744	17	.	.	PUNCT
gs-3919	745	1	husain	husain	PROPN
gs-3919	745	2	,	,	PUNCT
gs-3919	745	3	zafar	zafar	PROPN
gs-3919	745	4	,	,	PUNCT
gs-3919	745	5	bryan	bryan	PROPN
gs-3919	745	6	e.	e.	PROPN
gs-3919	745	7	byrnes	byrnes	PROPN
gs-3919	745	8	,	,	PUNCT
gs-3919	745	9	and	and	CCONJ
gs-3919	745	10	luz	luz	PROPN
gs-3919	745	11	fonacier	fonacier	NOUN
gs-3919	745	12	.	.	PUNCT
gs-3919	746	1	"	"	PUNCT
gs-3919	746	2	severe	severe	ADJ
gs-3919	746	3	cutaneous	cutaneous	ADJ
gs-3919	746	4	adverse	adverse	ADJ
gs-3919	746	5	drug	drug	NOUN
gs-3919	746	6	reactions	reaction	NOUN
gs-3919	746	7	:	:	PUNCT
gs-3919	746	8	presentation	presentation	NOUN
gs-3919	746	9	,	,	PUNCT
gs-3919	746	10	risk	risk	NOUN
gs-3919	746	11	factors	factor	NOUN
gs-3919	746	12	,	,	PUNCT
gs-3919	746	13	and	and	CCONJ
gs-3919	746	14	management	management	NOUN
gs-3919	746	15	.	.	PUNCT
gs-3919	746	16	"	"	PUNCT
gs-3919	747	1	current	current	ADJ
gs-3919	747	2	allergy	allergy	NOUN
gs-3919	747	3	and	and	CCONJ
gs-3919	747	4	asthma	asthma	NOUN
gs-3919	747	5	reports	report	VERB
gs-3919	747	6	18	18	NUM
gs-3919	747	7	,	,	PUNCT
gs-3919	747	8	no	no	INTJ
gs-3919	747	9	.	.	NOUN
gs-3919	747	10	4	4	NUM
gs-3919	747	11	(	(	PUNCT
gs-3919	747	12	2018	2018	NUM
gs-3919	747	13	):	):	PUNCT
gs-3919	747	14	26	26	NUM
gs-3919	747	15	.	.	X
gs-3919	748	1	62	62	NUM
gs-3919	748	2	.	.	PUNCT
gs-3919	749	1	kardaun	kardaun	PROPN
gs-3919	749	2	,	,	PUNCT
gs-3919	749	3	sylvia	sylvia	PROPN
gs-3919	749	4	h.	h.	PROPN
gs-3919	749	5	,	,	PUNCT
gs-3919	749	6	and	and	CCONJ
gs-3919	749	7	maja	maja	PROPN
gs-3919	749	8	mockenhaupt	mockenhaupt	PROPN
gs-3919	749	9	.	.	PUNCT
gs-3919	750	1	"	"	PUNCT
gs-3919	750	2	drug	drug	NOUN
gs-3919	750	3	reaction	reaction	NOUN
gs-3919	750	4	with	with	ADP
gs-3919	750	5	eosinophilia	eosinophilia	PROPN
gs-3919	750	6	and	and	CCONJ
gs-3919	750	7	systemic	systemic	ADJ
gs-3919	750	8	symptoms	symptom	NOUN
gs-3919	750	9	(	(	PUNCT
gs-3919	750	10	dress	dress	NOUN
gs-3919	750	11	):	):	PUNCT
gs-3919	750	12	multiorgan	multiorgan	NOUN
gs-3919	750	13	disease	disease	NOUN
gs-3919	750	14	with	with	ADP
gs-3919	750	15	variable	variable	ADJ
gs-3919	750	16	clinical	clinical	ADJ
gs-3919	750	17	features	feature	NOUN
gs-3919	750	18	.	.	PUNCT
gs-3919	750	19	"	"	PUNCT
gs-3919	751	1	journal	journal	NOUN
gs-3919	751	2	of	of	ADP
gs-3919	751	3	the	the	DET
gs-3919	751	4	european	european	PROPN
gs-3919	751	5	academy	academy	PROPN
gs-3919	751	6	of	of	ADP
gs-3919	751	7	dermatology	dermatology	NOUN
gs-3919	751	8	and	and	CCONJ
gs-3919	751	9	venereology	venereology	NOUN
gs-3919	751	10	33	33	NUM
gs-3919	751	11	,	,	PUNCT
gs-3919	751	12	no	no	INTJ
gs-3919	751	13	.	.	NOUN
gs-3919	751	14	6	6	NUM
gs-3919	751	15	(	(	PUNCT
gs-3919	751	16	2019	2019	NUM
gs-3919	751	17	):	):	PUNCT
gs-3919	751	18	1001	1001	NUM
gs-3919	751	19	-	-	SYM
gs-3919	751	20	1013	1013	NUM
gs-3919	751	21	.	.	PUNCT
gs-3919	752	1	63	63	NUM
gs-3919	752	2	.	.	PUNCT
gs-3919	752	3	pichler	pichler	NOUN
gs-3919	752	4	,	,	PUNCT
gs-3919	752	5	werner	werner	PROPN
gs-3919	752	6	j.	j.	PROPN
gs-3919	752	7	,	,	PUNCT
gs-3919	752	8	andreas	andreas	PROPN
gs-3919	752	9	naisbitt	naisbitt	PROPN
gs-3919	752	10	,	,	PUNCT
gs-3919	752	11	and	and	CCONJ
gs-3919	752	12	daniel	daniel	PROPN
gs-3919	752	13	yerly	yerly	ADV
gs-3919	752	14	.	.	PUNCT
gs-3919	753	1	"	"	PUNCT
gs-3919	753	2	the	the	DET
gs-3919	753	3	changing	change	VERB
gs-3919	753	4	face	face	NOUN
gs-3919	753	5	of	of	ADP
gs-3919	753	6	drug	drug	NOUN
gs-3919	753	7	hypersensitivity	hypersensitivity	NOUN
gs-3919	753	8	.	.	PUNCT
gs-3919	753	9	"	"	PUNCT
gs-3919	754	1	journal	journal	PROPN
gs-3919	754	2	of	of	ADP
gs-3919	754	3	allergy	allergy	NOUN
gs-3919	754	4	and	and	CCONJ
gs-3919	754	5	clinical	clinical	ADJ
gs-3919	754	6	immunology	immunology	NOUN
gs-3919	754	7	143	143	NUM
gs-3919	754	8	,	,	PUNCT
gs-3919	754	9	no	no	INTJ
gs-3919	754	10	.	.	NOUN
gs-3919	754	11	1	1	NUM
gs-3919	754	12	(	(	PUNCT
gs-3919	754	13	2019	2019	NUM
gs-3919	754	14	):	):	PUNCT
gs-3919	754	15	50	50	NUM
gs-3919	754	16	-	-	SYM
gs-3919	754	17	57	57	NUM
gs-3919	754	18	.	.	PUNCT
gs-3919	754	19	64	64	NUM
gs-3919	754	20	.	.	PUNCT
gs-3919	755	1	roujeau	roujeau	PROPN
gs-3919	755	2	,	,	PUNCT
gs-3919	755	3	jean	jean	PROPN
gs-3919	755	4	-	-	PUNCT
gs-3919	755	5	claude	claude	PROPN
gs-3919	755	6	.	.	PUNCT
gs-3919	756	1	"	"	PUNCT
gs-3919	756	2	clinical	clinical	ADJ
gs-3919	756	3	heterogeneity	heterogeneity	NOUN
gs-3919	756	4	of	of	ADP
gs-3919	756	5	drug	drug	NOUN
gs-3919	756	6	hypersensitivity	hypersensitivity	NOUN
gs-3919	756	7	.	.	PUNCT
gs-3919	756	8	"	"	PUNCT
gs-3919	757	1	toxicology	toxicology	NOUN
gs-3919	757	2	209	209	NUM
gs-3919	757	3	,	,	PUNCT
gs-3919	757	4	no	no	INTJ
gs-3919	757	5	.	.	NOUN
gs-3919	757	6	2	2	NUM
gs-3919	757	7	(	(	PUNCT
gs-3919	757	8	2005	2005	NUM
gs-3919	757	9	):	):	PUNCT
gs-3919	757	10	123	123	NUM
gs-3919	757	11	-	-	SYM
gs-3919	757	12	129	129	NUM
gs-3919	757	13	.	.	PUNCT
gs-3919	758	1	65	65	NUM
gs-3919	758	2	.	.	PUNCT
gs-3919	758	3	shiohara	shiohara	PROPN
gs-3919	758	4	,	,	PUNCT
gs-3919	758	5	tetsuo	tetsuo	PROPN
gs-3919	758	6	,	,	PUNCT
gs-3919	758	7	and	and	CCONJ
gs-3919	758	8	yoko	yoko	PROPN
gs-3919	758	9	kano	kano	PROPN
gs-3919	758	10	.	.	PUNCT
gs-3919	759	1	"	"	PUNCT
gs-3919	759	2	drug	drug	NOUN
gs-3919	759	3	reaction	reaction	NOUN
gs-3919	759	4	with	with	ADP
gs-3919	759	5	eosinophilia	eosinophilia	PROPN
gs-3919	759	6	and	and	CCONJ
gs-3919	759	7	systemic	systemic	ADJ
gs-3919	759	8	symptoms	symptom	NOUN
gs-3919	759	9	(	(	PUNCT
gs-3919	759	10	dress	dress	NOUN
gs-3919	759	11	):	):	PUNCT
gs-3919	759	12	incidence	incidence	NOUN
gs-3919	759	13	,	,	PUNCT
gs-3919	759	14	pathogenesis	pathogenesis	NOUN
gs-3919	759	15	and	and	CCONJ
gs-3919	759	16	management	management	NOUN
gs-3919	759	17	.	.	PUNCT
gs-3919	759	18	"	"	PUNCT
gs-3919	760	1	expert	expert	ADJ
gs-3919	760	2	opinion	opinion	NOUN
gs-3919	760	3	on	on	ADP
gs-3919	760	4	drug	drug	NOUN
gs-3919	760	5	safety	safety	NOUN
gs-3919	760	6	16	16	NUM
gs-3919	760	7	,	,	PUNCT
gs-3919	760	8	no	no	INTJ
gs-3919	760	9	.	.	NOUN
gs-3919	760	10	2	2	NUM
gs-3919	760	11	(	(	PUNCT
gs-3919	760	12	2017	2017	NUM
gs-3919	760	13	):	):	PUNCT
gs-3919	760	14	139	139	NUM
gs-3919	760	15	-	-	SYM
gs-3919	760	16	147	147	NUM
gs-3919	760	17	.	.	PUNCT
gs-3919	761	1	georgian	georgian	ADJ
gs-3919	761	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3919	761	3	მეცნიერები	მეცნიერები	NOUN
gs-3919	761	4	ტ.	ტ.	VERB
gs-3919	761	5	7	7	NUM
gs-3919	761	6	n	n	PRON
gs-3919	761	7	3	3	NUM
gs-3919	761	8	,	,	PUNCT
gs-3919	761	9	2025	2025	NUM
gs-3919	761	10	179	179	NUM
gs-3919	761	11	66	66	NUM
gs-3919	761	12	.	.	PUNCT
gs-3919	762	1	sidoroff	sidoroff	PROPN
gs-3919	762	2	,	,	PUNCT
gs-3919	762	3	alexis	alexis	PROPN
gs-3919	762	4	,	,	PUNCT
gs-3919	762	5	and	and	CCONJ
gs-3919	762	6	jean	jean	PROPN
gs-3919	762	7	-	-	PUNCT
gs-3919	762	8	claude	claude	PROPN
gs-3919	762	9	roujeau	roujeau	PROPN
gs-3919	762	10	.	.	PUNCT
gs-3919	763	1	"	"	PUNCT
gs-3919	763	2	cutaneous	cutaneous	ADJ
gs-3919	763	3	adverse	adverse	ADJ
gs-3919	763	4	reactions	reaction	NOUN
gs-3919	763	5	to	to	ADP
gs-3919	763	6	drugs	drug	NOUN
gs-3919	763	7	.	.	PUNCT
gs-3919	763	8	"	"	PUNCT
gs-3919	764	1	clinical	clinical	ADJ
gs-3919	764	2	dermatology	dermatology	NOUN
gs-3919	764	3	26	26	NUM
gs-3919	764	4	,	,	PUNCT
gs-3919	764	5	no	no	INTJ
gs-3919	764	6	.	.	NOUN
gs-3919	764	7	1	1	NUM
gs-3919	764	8	(	(	PUNCT
gs-3919	764	9	2008	2008	NUM
gs-3919	764	10	):	):	PUNCT
gs-3919	764	11	11	11	NUM
gs-3919	764	12	-	-	SYM
gs-3919	764	13	18	18	NUM
gs-3919	764	14	.	.	NOUN
gs-3919	764	15	67	67	NUM
gs-3919	764	16	.	.	PUNCT
gs-3919	765	1	tohyama	tohyama	PROPN
gs-3919	765	2	,	,	PUNCT
gs-3919	765	3	mikiko	mikiko	NOUN
gs-3919	765	4	,	,	PUNCT
gs-3919	765	5	and	and	CCONJ
gs-3919	765	6	kazuhiko	kazuhiko	NOUN
gs-3919	765	7	hashimoto	hashimoto	NOUN
gs-3919	765	8	.	.	PUNCT
gs-3919	766	1	"	"	PUNCT
gs-3919	766	2	new	new	ADJ
gs-3919	766	3	aspects	aspect	NOUN
gs-3919	766	4	of	of	ADP
gs-3919	766	5	drug	drug	NOUN
gs-3919	766	6	-	-	PUNCT
gs-3919	766	7	induced	induce	VERB
gs-3919	766	8	hypersensitivity	hypersensitivity	NOUN
gs-3919	766	9	syndrome	syndrome	NOUN
gs-3919	766	10	.	.	PUNCT
gs-3919	766	11	"	"	PUNCT
gs-3919	767	1	journal	journal	NOUN
gs-3919	767	2	of	of	ADP
gs-3919	767	3	dermatology	dermatology	NOUN
gs-3919	767	4	38	38	NUM
gs-3919	767	5	,	,	PUNCT
gs-3919	767	6	no	no	INTJ
gs-3919	767	7	.	.	NOUN
gs-3919	767	8	3	3	NUM
gs-3919	767	9	(	(	PUNCT
gs-3919	767	10	2011	2011	NUM
gs-3919	767	11	):	):	PUNCT
gs-3919	767	12	222	222	NUM
gs-3919	767	13	-	-	SYM
gs-3919	767	14	228	228	NUM
gs-3919	767	15	.	.	PUNCT
gs-3919	767	16	68	68	NUM
gs-3919	767	17	.	.	PUNCT
gs-3919	768	1	walsh	walsh	PROPN
gs-3919	768	2	,	,	PUNCT
gs-3919	768	3	sarah	sarah	PROPN
gs-3919	768	4	a.	a.	PROPN
gs-3919	768	5	,	,	PUNCT
gs-3919	768	6	and	and	CCONJ
gs-3919	768	7	neil	neil	PROPN
gs-3919	768	8	h.	h.	PROPN
gs-3919	768	9	shear	shear	PROPN
gs-3919	768	10	.	.	PUNCT
gs-3919	769	1	"	"	PUNCT
gs-3919	769	2	drug	drug	NOUN
gs-3919	769	3	reaction	reaction	NOUN
gs-3919	769	4	with	with	ADP
gs-3919	769	5	eosinophilia	eosinophilia	PROPN
gs-3919	769	6	and	and	CCONJ
gs-3919	769	7	systemic	systemic	ADJ
gs-3919	769	8	symptoms	symptom	NOUN
gs-3919	769	9	:	:	PUNCT
gs-3919	769	10	is	be	AUX
gs-3919	769	11	cutaneous	cutaneous	ADJ
gs-3919	769	12	phenotype	phenotype	NOUN
gs-3919	769	13	a	a	DET
gs-3919	769	14	prognostic	prognostic	ADJ
gs-3919	769	15	marker	marker	NOUN
gs-3919	769	16	for	for	ADP
gs-3919	769	17	outcomes	outcome	NOUN
gs-3919	769	18	?	?	PUNCT
gs-3919	770	1	a	a	DET
gs-3919	770	2	review	review	NOUN
gs-3919	770	3	of	of	ADP
gs-3919	770	4	clinicopathological	clinicopathological	ADJ
gs-3919	770	5	features	feature	NOUN
gs-3919	770	6	of	of	ADP
gs-3919	770	7	27	27	NUM
gs-3919	770	8	cases	case	NOUN
gs-3919	770	9	.	.	PUNCT
gs-3919	770	10	"	"	PUNCT
gs-3919	771	1	journal	journal	NOUN
gs-3919	771	2	of	of	ADP
gs-3919	771	3	cutaneous	cutaneous	ADJ
gs-3919	771	4	medicine	medicine	NOUN
gs-3919	771	5	and	and	CCONJ
gs-3919	771	6	surgery	surgery	NOUN
gs-3919	771	7	17	17	NUM
gs-3919	771	8	,	,	PUNCT
gs-3919	771	9	no	no	INTJ
gs-3919	771	10	.	.	NOUN
gs-3919	771	11	4	4	NUM
gs-3919	771	12	(	(	PUNCT
gs-3919	771	13	2013	2013	NUM
gs-3919	771	14	):	):	PUNCT
gs-3919	771	15	245	245	NUM
gs-3919	771	16	-	-	SYM
gs-3919	771	17	251	251	NUM
gs-3919	771	18	.	.	PUNCT
gs-3919	772	1	69	69	NUM
gs-3919	772	2	.	.	PUNCT
gs-3919	773	1	wolfson	wolfson	PROPN
gs-3919	773	2	,	,	PUNCT
gs-3919	773	3	anna	anna	PROPN
gs-3919	773	4	r.	r.	PROPN
gs-3919	773	5	,	,	PUNCT
gs-3919	773	6	and	and	CCONJ
gs-3919	773	7	elizabeth	elizabeth	PROPN
gs-3919	773	8	j.	j.	PROPN
gs-3919	773	9	phillips	phillips	PROPN
gs-3919	773	10	.	.	PUNCT
gs-3919	774	1	"	"	PUNCT
gs-3919	774	2	advances	advance	VERB
gs-3919	774	3	in	in	ADP
gs-3919	774	4	the	the	DET
gs-3919	774	5	understanding	understanding	NOUN
gs-3919	774	6	of	of	ADP
gs-3919	774	7	drug	drug	NOUN
gs-3919	774	8	hypersensitivity	hypersensitivity	NOUN
gs-3919	774	9	:	:	PUNCT
gs-3919	774	10	2012	2012	NUM
gs-3919	774	11	through	through	ADP
gs-3919	774	12	2022	2022	NUM
gs-3919	774	13	.	.	PUNCT
gs-3919	775	1	journal	journal	PROPN
gs-3919	775	2	of	of	ADP
gs-3919	775	3	allergy	allergy	PROPN
gs-3919	775	4	and	and	CCONJ
gs-3919	775	5	clinical	clinical	ADJ
gs-3919	775	6	immunology	immunology	NOUN
gs-3919	775	7	151	151	NUM
gs-3919	775	8	,	,	PUNCT
gs-3919	775	9	no	no	INTJ
gs-3919	775	10	.	.	NOUN
gs-3919	775	11	3	3	NUM
gs-3919	775	12	(	(	PUNCT
gs-3919	775	13	2023	2023	NUM
gs-3919	775	14	):	):	PUNCT
gs-3919	775	15	689	689	NUM
gs-3919	775	16	-	-	SYM
gs-3919	775	17	702	702	NUM
gs-3919	775	18	.	.	NOUN
gs-3919	775	19	70	70	NUM
gs-3919	775	20	.	.	X
gs-3919	776	1	yang	yang	PROPN
gs-3919	776	2	,	,	PUNCT
gs-3919	776	3	chih	chih	PROPN
gs-3919	776	4	-	-	PUNCT
gs-3919	776	5	wan	wan	PROPN
gs-3919	776	6	,	,	PUNCT
gs-3919	776	7	and	and	CCONJ
gs-3919	776	8	wen	wen	PROPN
gs-3919	776	9	-	-	PROPN
gs-3919	776	10	hung	hung	ADJ
gs-3919	776	11	chung	chung	PROPN
gs-3919	776	12	.	.	PUNCT
gs-3919	777	1	"	"	PUNCT
gs-3919	777	2	genetic	genetic	ADJ
gs-3919	777	3	predisposition	predisposition	NOUN
gs-3919	777	4	to	to	ADP
gs-3919	777	5	drug	drug	NOUN
gs-3919	777	6	hypersensitivity	hypersensitivity	NOUN
gs-3919	777	7	.	.	PUNCT
gs-3919	777	8	"	"	PUNCT
gs-3919	778	1	pharmacogenomics	pharmacogenomic	NOUN
gs-3919	778	2	21	21	NUM
gs-3919	778	3	,	,	PUNCT
gs-3919	778	4	no	no	INTJ
gs-3919	778	5	.	.	NOUN
gs-3919	778	6	2	2	NUM
gs-3919	778	7	(	(	PUNCT
gs-3919	778	8	2020	2020	NUM
gs-3919	778	9	):	):	PUNCT
gs-3919	778	10	89	89	NUM
gs-3919	778	11	-	-	SYM
gs-3919	778	12	101	101	NUM
gs-3919	778	13	.	.	PUNCT
gs-3919	778	14	71	71	NUM
gs-3919	778	15	.	.	PUNCT
gs-3919	779	1	zvulunov	zvulunov	PROPN
gs-3919	779	2	,	,	PUNCT
gs-3919	779	3	a.	a.	NOUN
gs-3919	779	4	(	(	PUNCT
gs-3919	779	5	2013	2013	NUM
gs-3919	779	6	)	)	PUNCT
gs-3919	779	7	.	.	PUNCT
gs-3919	780	1	primum	primum	PROPN
gs-3919	780	2	non	non	X
gs-3919	780	3	nocere	nocere	PROPN
gs-3919	780	4	,	,	PUNCT
gs-3919	780	5	or	or	CCONJ
gs-3919	780	6	treat	treat	VERB
gs-3919	780	7	the	the	DET
gs-3919	780	8	patient	patient	NOUN
gs-3919	780	9	,	,	PUNCT
gs-3919	780	10	not	not	PART
gs-3919	780	11	the	the	DET
gs-3919	780	12	disease	disease	NOUN
gs-3919	780	13	.	.	PUNCT
gs-3919	781	1	journal	journal	NOUN
gs-3919	781	2	of	of	ADP
gs-3919	781	3	the	the	DET
gs-3919	781	4	american	american	PROPN
gs-3919	781	5	academy	academy	PROPN
gs-3919	781	6	of	of	ADP
gs-3919	781	7	dermatology	dermatology	NOUN
gs-3919	781	8	,	,	PUNCT
gs-3919	781	9	69(6	69(6	NUM
gs-3919	781	10	)	)	PUNCT
gs-3919	781	11	,	,	PUNCT
gs-3919	781	12	1055–1056	1055–1056	NUM
gs-3919	781	13	.	.	PUNCT